XXIII Congress of the International Society on Thrombosis and Haemostasis
57th Annual SSC Meeting
Venue: ICC Kyoto (Kyoto International Conference Center)
Dates: July 23-28, 2011

www.isth2011.com
We are Biogen Idec Hemophilia, and we're exploring ways to make clotting factors last longer.

Together with our development partner, Swedish Orphan Biovitrum, we welcome you to ISTH 2011. Start your experience with our special symposium, “Clinical Evaluation of Coagulation Factors With Prolonged Pharmacokinetic Activity,” on Sunday, July 24, from 12:30-14:30.

Visit us at booth #42 to:

- Discover our unique core technology, Fc fusion, which is being studied to determine its potential to prolong half-life.
- Learn about our hemophilia research.
- Test your knowledge with the Factor Forward Challenge and receive your booth giveaway.

Can't wait to learn more about Fc fusion technology?
Fast forward to our ad on the inside back cover.

Sign up for updates on our research at www.BiogenIdecHemophilia.com.
Table of Contents
Venue & Contacts

Venue
Kyoto International Conference Center (ICC Kyoto)
Takaragaike, Sakyo-ku, Kyoto 606-0001 Japan
Tel: +81-75-705-1234  Fax: +81-75-705-1100
The Kyoto International Conference Center is a compact and user-friendly facility which meets the global standard. It can be easily accessed from the main Kyoto Station. For the 2011 Exhibition two additional halls will be constructed temporarily next to the existing Event Hall. Meeting rooms for oral presentations and symposia are located in the Main Building and Annex Hall.
For further information on the ICC Kyoto, please visit http://www.icckyoto.or.jp/en/index.html

Contacts
For further information contact:

ISTH Headquarters
610 Jones Ferry road, Suite 205
Carrboro, NC 27510 USA
Tel: +1-919-929-3807
Fax: +1-919-929-3935
E-mail: headquarters@isth.org
Website: http://www.isth.org/

Scientific and Standardization Committee
Robert Cary Clark, SSC Coordinator
E-mail: headquarters@isth.org

Sharon Overcash, ISTH Membership Secretary
E-mail: membership@isth.org

Sponsorship & Exhibit Sales, Industry Relations
Requests about sales opportunities should be directed to:
Margo Price, ISTH Director of Corporate Relations
Direct Line: +1-919-929-2381
E-mail: margo_price@isth.org

General Society Information
Requests for information about ISTH and its mission may be directed to:

Cathy Cole, ISTH Executive Secretary
E-mail: ccole@med.unc.edu

Thomas Reiser, ISTH Executive Director
E-mail: tom_reiser@isth.org
The Japan Convention Services, the official 2011 Congress Organizer, will process registrations and abstracts. Information about the commercial exhibition as well as the organization and sponsorship of special events may also be obtained from the Organizing Secretariat.

**ISTH2011 Congress Secretariat**

Keiko Nishimoto
Kei Kunimoto
Emi Nishimura
Mayumi Inaba
c/o Japan Convention Services, Inc
Daido Seimei Kasumigaseki Bldg. 1-4-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013, Japan
Tel : +81-3-3508-1202
Fax : +81-3-3508-0820
E-mail : isth2011@convention.jp
Website : http://www.isth2011.com/

**ISTH2011 Registration Desk**

Ryoko Sanada
Meiko Matsuura
c/o Japan Convention Services, Inc
2-2 Kanda Nishiki-cho, Chiyoda-ku, Tokyo 101-0054, JAPAN
Tel : +81-3-3508-1250
Fax : +81-3-5283-5952
E-mail : isth2011reg@convention.co.jp

**ISTH2011 Abstract Desk**

Kaoru Fujimoto
Yuko Ninagawa
Tel : +81-3-3500-5935
Fax : +81-3-5283-5952
E-mail : isth2011ab@convention.co.jp

**Sponsorship & Exhibit Management**

Aya Okamoto
c/o Japan Convention Services, Inc
Daido Seimei Kasumigaseki Bldg. 1-4-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013, Japan
Tel : +81-3-3508-1202
Fax : +81-3-3508-0820
E-mail : isth2011sponsor@convention.co.jp

**Exhibition Planning & Logistics**

Takeshi Fukui / Keizo Yamamoto / Aya Fukumoto
Accost Corporation Kyoto Office
KRP4-111, 93 Chudojiawatacho, Shimogyo-ku, Kyoto 600-8815, Japan
Tel : +81-75-323-5856
Fax : +81-75-322-8025
E-mail : isth2011@accost.co.jp

**Hotel Accommodations**

JTB Global Marketing & Travel Inc.
JTB Bldg. 14F, 2-3-11, Higashishinagawa, Shinagawa-ku, Tokyo 140-8604, Japan
Tel : +81-3-5796-5445
Fax : +81-3-5495-0685
E-mail : isth2011@gmt.jtb.jp
Message from the Congress Presidents

Dear Colleagues and Friends,

On behalf of the Local Organizing Committee, it is our great pleasure to welcome you to Kyoto and the XXIII Congress of ISTH and 57th SSC Meeting.

Since Japan encountered the unprecedented earthquake and tsunami on March 11, followed by the nuclear power plant accident, we have conducted extensive surveys and discussions on every aspect which may affect the health and transportation safety of the Congress participants. After our council decided to hold the Congress in Kyoto as planned, Dr. Henri Bounameaux personally sent messages to not only ISTH members, but also registered non-member participants, sponsors and exhibitors, indicating that Kyoto and its vicinity were unaffected by the natural disasters and radioactivity, and people in Kyoto had been having their life as normally. As Congress President, I would like to thank you all who have supported us and come here to participate in the Congress; you not only contribute to the success of ISTH2011 but also encourage Japanese people to move forward to recovery and reconstruction.

We have worked hard to organize the congress during the past two years. We are proud of attractive scientific programs including Presidential Symposium, Plenary Lectures, SOA and Symposia, where you could find the most recent progress in basic and clinical research in the field of thrombosis and haemostasis. At the same time, we are very much honored to offer you exciting chances to hear 3,000 oral and poster presentations from 75 countries.

I am sure you could enjoy the highest quality of science but also taste different flavor of culture and atmosphere in Kyoto. Kyoto, the old capital of Japan, combines long-established tradition and modern convenience, bejeweled with over 2,000 temples and shrines. The Social programs include “World Cultural Heritage” tours, which take you to such popular places as the Golden Pavilion, Kiyomizu Temple, Nijo Castle, Heian Shrine, and etc. These architectures are not only splendid and gorgeous, but also have the souls of nobles and samurais in them. I also recommend that you try a ceremony, flower arrangement, kimono experience and zazen (zen meditation) during your stay in Kyoto. I’m confident that these experiences make your stay in Kyoto unforgettable.

Welcome to Kyoto!

Yasuo Ikeda, MD
President,
XXIII Congress of ISTH and 57th SSC Meeting
Message from the Secretary General of ISTH

Dear Colleagues and Friends,

For the first time since the Tokyo Congress in 1989, the ISTH returns to Japan - to Kyoto for our XXIII Congress and for the 57th SSC meeting. Congress President Yasuo Ikeda and his organizing committee have worked hard and have developed an outstanding program, including an educational component aimed at clinicians and basic scientists interested in our field. As always, the scientific program features invited speakers and the latest in our science and medicine. The convention center in Kyoto provides a beautiful site for the meeting. The social program showcases the remarkable history and culture of this very special city. Given the tragedy of March 2011 in northern Japan, with the earthquake, tsunami and nuclear accident, we are especially pleased that Kyoto was unaffected and that we are able to support the Japanese during this recovery phase.

Kyoto, the former capital of Japan, is a magnificent city. A little over two hours from Tokyo on the Shinkansen (high speed train), Kyoto is home to seventeen World Heritage Sites, including Nijo Castle, Kinkaku-ji (the Golden Pavilion) and Ginkaku-ji (the Silver Pavilion). Barbara and I have traveled extensively in Japan, and it is a truly remarkable country. People are extremely friendly and Westerners should have no difficulty exploring Japan now that most signage is in transliterated Japanese-English. Some of our most memorable activities outside of Kyoto include a visit to Mount Fuji, the castles in Kumamoto, Tokyo and Osaka, a couple of days at the Benesse House in Naoshima on the Inland Sea, and the Tokyo fish market-early in the morning. The Peace Parks in Hiroshima and Nagasaki are moving experiences. However, Kyoto itself has plenty to offer, from historic temples to gardens to the famous Philosopher’s Walk. The convention center, surrounded by gardens and ponds, is sited on the subway line in a lovely part of the city.

Welcome to Kyoto!

Bruce Furie, MD
Secretary General of ISTH
Message from the Council Chairman

Dear Colleagues and Friends,

It is my distinct privilege to extend to you a warm welcome to Kyoto. For the second time in its history, our Society will be convening in Japan—twenty-two years after the Tokyo Congress.

After the earthquake and the tsunami that devastated the region of Fukushima in North-Eastern Japan in early March, our overriding consideration was the safety of all congress participants, and based on all available objective evidence ISTH Council has firmly concluded that holding the congress in Kyoto does not present a health or transportation safety hazard. Indeed, given the reassurances that the situation is safe, this would have been the worst moment to abandon our Japanese colleagues.

Dr. Yasuo Ikeda and his colleagues on the Local Organizing Committee have set up a stellar program designed to attract and engage both basic and clinical scientists. Indeed, you will find a program tailored to reflect our biennial congresses’ goal to create educational experiences where bench meets bed for the best of our patients.

Certainly, the other characteristic of our meetings is their international flavor. Not only do participants come from all over the world, but we meet in such different places. In the past ten years, we visited Europe (Paris, Birmingham and Geneva), Australia (Sydney), and North America (Boston). Now we come to the revered old capital of Japan.

This extraordinary diversity blended with exemplary science is part of our wealth.

So at Kyoto, we invite you not only to attend the scientific sessions but also encourage you to explore the millenary Japanese culture. The “Historic Monuments of Ancient Kyoto” are listed by the UNESCO as a World Heritage Site. Visit the shrines scattered about Kyoto along with the Nijō Castle built by the Tokugawa shoguns a few centuries ago.

And by the way, do not miss out on the cuisine. Kyoto is renowned for its abundance of delicious Japanese foods.

In summary, I would simply like to welcome you to Kyoto and encourage you to benefit from the science and enjoy and experience the culture, and the friendship!

Henri Bounameaux, MD
ISTH, Chairman of Council
Message from the Scientific Program Committee Chairperson and Co-chairpersons

Dear Colleagues and Friends,

We are very pleased to show you the ISTH 2011 Scientific Program - an exciting roster of lectures and programmatic elements that address a wide variety of the articles on thrombosis and haemostasis from basic and clinical scientists.

In the invited lectures, we have 6 excellent Plenary Lectures, a memorial Presidential Symposium, 32 interesting State of the Art Lectures and 30 exciting Symposia including the Late Breaking Clinical Research.

We have kindly received presentation abstracts over 3,000 from 75 countries, nevertheless the unprecedented earthquake and tsunami followed by the nuclear plant accident in the east-north area of Japan in March. The abstracts were all reviewed and acceptance/rejection notifications have been decided by experts from Local and International Scientific Advisory Board members of the ISTH. Finally, for oral presentations, we have 8 Platelet (Basic) sessions, 6 Platelet (Clinical) sessions, 18 Coagulation Factors and Inhibitors sessions, 3 Fibrinolysis and Proteolysis sessions, 23 Thrombotic Disorders sessions, 5 VWF/VWD and ADAMTS13 sessions, 10 Hemorrhagic Disorders sessions, 5 Vascular Biology sessions, an Innovation and Technology session, and a session for Late Breaking Clinical Trials, which provides up-to-date findings. In addition, there are almost 2,500 poster presentations in total.

We are sincerely grateful to our Local Scientific Program Committee, International Scientific Advisory Board, Abstract Reviewers, and Congress Organizers, JCS, for all the hard work that went into making this excellent program.

We are truly pleased to welcome you to Kyoto to an interesting and stimulating Congress presenting the best work from across our field.

Koji Suzuki PhD
Congress Vice President and Chairperson, Scientific Program Committee

Toshiyuki Miyata PhD
Co-Chairperson, Scientific Program Committee (Basic Sciences)

Yoshiaki Tomiyama MD
Co-Chairperson, Scientific Program Committee (Clinical Sciences)
Committees

Congress Committees
Local Organizing Committee

Fumimaro Takaku
Special Adviser
Hidehiko Saito
Honorary President
Yasuo Ikeda
President
Akira Yoshioka
Vice President, SSC Chair
Koji Suzuki
Vice President, Scientific Program Committee Chair
Yukio Ozaki
Editor, “State of the Art Book”
Tetsuhiro Kojima
Co-Editor, “State of the Art Book”
Mitsuru Murata
Secretary General
Nobuhiro Yamada
Supervisor
Kazuyuki Shimada
Supervisor
Osamu Matsuo
Chairman, Financial Committee

Hajime Tsuji
Co-Chairman, Financial Committee
Yoichi Sakata
Chairman, Registration Committee
Katsuyuki Fukutake
Co-Chairman, Registration Committee
Akitada Ichinose
Chairman, Promotion Committee
Morio Arai
Co-Chairman, Promotion Committee
Katsuo Sueishi
Chairman, Liaison Committee
Shinichiro Uchiyama
Co-Chairman, Liaison Committee
Hiroshi Shigematsu
Chairman, Commemoration Committee
Yutaka Yatomi
Co-Chairman, Commemoration Committee
Masao Nakagawa
Chairman, Social Program Committee
Junki Takamatsu
Co-Chairman, Social Program Committee
Masao Nakabayashi
Chairman, Award Committee
Committees

International Members
Henri Bounameaux
Colin Chesterman
Anna Falanga
Barbara Furie
Bruce Furie
Ian Peake
Frits R. Rosendaal
Gilbert C. White II

Advisers
Nobuo Aoki
Kingo Fujimura
Saichi Hosoda
Sadaaki Iwanaga
Eizo Kakishita
Hisao Kato
Mutsuyoshi Kazama
Shoji Kume
Takefumi Matsuo
Yuji Matsuzawa
Hisashi Mihara
Masao Nakabayashi
Minoru Okuma
Nobuo Sakuragawa
Kenzo Tanaka
Toshihiko Terao
Kiyoaki Watanabe
Junichiro Yamamoto
Manabu Yamanaka
Hiroh Yamazaki

Scientific Program Committee

Koji Suzuki
Chairman,
Local Scientific Program Committee
Toshiyuki Miyata
Co-Chairman(Basic Medicine),
Local Scientific Program Committee
Yoshiaki Tomiyama
Co-Chairman(Clinical Medicine),
Local Scientific Program Committee

Platelets Basic
Atsushi Oda, Chair (JP)
Lawrence Brass (US)
Johannes L. Bos (NL)
Mark H. Ginsbarg (US)
Christian Gachet (FR)
Joseph E. Italiano, Jr (US)
Shaun P. Jackson (AU)
Sanford J. Shattil (US)
Yumiko Matsubara (JP)
Peter J. Newman (US)
Mortimer Poncz (US)
Steve P. Watson (UK)
Yutaka Yatomi (JP)

Platelets Clinical
Makoto Handa, Chair (JP)
Committees

Coagulation Factors and Inhibitors
Takashi Morita, Chair (JP)
Charles T. Esmon (US)
James A. Huntington (UK)
Takehiko Koide (JP)
R. Manjunatha Kini (SG)
Egon Persson (DK)
Wolfram Ruf (US)
Pieter H. Reitsma (NL)

Fibrinolysis and Proteolysis
Tetsuemi Urano, Chair (JP)
Nuala Ann Booth (UK)
Egbert K. O. Kruithof (CH)
Susan T. Lord (US)
Osamu Matsuo (JP)
Robert L. Medcalf (AU)
D. C. Rijken (NL)
Yoichi Sakata (JP)
Hua-Lin Wu (TW)
Johann Wojta (AT)

Thrombotic Disorders
Shinya Goto, Chair (JP)
Deepak L. Bhatt (US)
Francis K. L. Chan (HK)
James Douketis (CA)
Ajay Kakkar (UK)
Takao Kobayashi (JP)
Laiheng Lee (SG)
Gregory Y. H. Lip (UK)
Doyeum Oh (KR)
Ph. Gabriel Steg (FR)
Hideo Wada (JP)

VWF/VWD and ADAMTS13
Yoshihiro Fujimura, Chair (JP)
David Ginsburg (US)
Koichi Kokame (JP)
Bennhard Laemmle (CH)
Zaverio M. Ruggeri (US)
Changgeng Ruan (CN)
J. Evan Sadler (US)
Jan J. Voorberg (NL)

Haemorrhagic Disorders
Midori Shima, Chair (JP)
Kagehiro Amano (JP)
H. Marijke van den Berg (NL)
Donna M. DiMichele (US)
Philip J. Fay (US)
Nigel S. Key (US)
Committees

David Lillicrap (CA)
Jun Mimuro (JP)
Claude Negrier (FR)
Steven W. Pipe (US)
Alok Srivastava (IN)

Vascular Biology
Yujiro Asada, Chair (JP)
Masanori Aikawa (US)
Peter Carmeliet (BE)
Francoise Dignat-George (FR)
Satoshi Fujii (JP)
Goran K. Hansson (SE)
Nigel Mackman (US)
Shahin Rafii (US)
Roy L. Silverstein (US)
Denisa D. Wagner (US)
Yutaka Yatomi (JP)

Innovation and Technology
Koji Eto, Chair (JP)
Wolfgang Bergmeier (US)
Rodney M. Camire (US)
Tatsuhiko Kodama (JP)
Thierry VandenDriessche (BE)

Council of ISTH Officers

Chairman of Council (2010-2012)
Henri Bounameaux (Switzerland)

Secretary/Chairman-Elect (2010-2012/2012-2014)
Michael Berndt (Ireland)

Class of 2012
M. Berndt (Ireland)
H. Bounameaux (Switzerland)
A. Nurden (France)
B. Østerud (Norway)
P. Reitsma (The Netherlands)

Class of 2014
N.A. Booth (UK)
F. Dignat-George (France)
N. Key (USA)
R. Montgomery (USA)
H. ten Cate (The Netherlands)

Class of 2016
M. Cattaneo (Italy)
B. Dahlbäck (Sweden)
A. Greinacher (Germany)
P. Tracy (USA)
Y. Ozaki (Japan)

Secretary General
Bruce Furie (USA)

President of XXIII Congress
Yasuo Ikeda (Japan)

Vice President of XXIII Congress
Akira Yoshioka (Japan)

Editors-in-Chief, Journal of Thrombosis and Haemostasis
Mike Greaves and David Lane (UK)
Chairman, Scientific and Standardization Committee
Committees

Anna Falanga (Italy)

Special Assistant to the Chairman
Frits R. Rosendaal (The Netherlands)

Past Congress Presidents
Bruce and Barbara Furie (USA)

Secretary/Chairman-Elect, Scientific and Standardization Committee
David Lillicrap (Canada)

ISTH Officers of the Scientific and Standardization Committee

Chairman (2010-2012)
Anna Falanga (Italy)

Secretary/Chairman-Elect (2010-2012/2012-2014)
David Lillicrap (Canada)

Special Assistant to the Chairman (2010-2012)
Gerhard J. Johnson (USA)

Secretary General
Bruce Furie (USA)

Subcommittee Chairmen
Trevor Patrick Baglin (UK)
Marco Cattaneo (Italy)
Francoise Dignat-George (France)
James Douketis (Canada)
Sabine Eichinger (Austria)
Jeroen C. J. Eikenboom (The Netherlands)
Andreas Greinacher (Germany)
Johan W. M. Heemskerk (The Netherlands)
Anthony R. Hubbard (UK)
Hans P. Kohler (Switzerland)
Agnes Y. Y. Lee (Canada)
Colin Longstaff (UK)
Mary Ann McLane (USA)
Paul Monagle (Australia)
Timothy Charles Nichols (USA)
Thomas L. Ortel (USA)
Thomas Renne (Sweden)
Alok Srivastava (India)
Hideo Wada (Japan)
Herbert C. Whinna (USA)
Committees

Congress International Advisory Board

Walter Ageno (IT)
Giancarlo Agnelli (IT)
Masanori Aikawa (US)
Marie-Christine Alessi (FR)
Kagehiro Amano (JP)
Joji Ando (JP)
Pantep Angchaisuksiri (TH)
Anne Angelillo-Scherrer (CH)
Jack Ansell (US)
Morio Arai (JP)
Valder Arruda (US)
Yujiro Asada (JP)
Jan Astermark (SE)
Tatsuya Atsumi (JP)
Gunter Karl-Heinz Auerswald (DE)
Hellmut G. Augustin (DE)
Lina Badimon (ES)
Wadie Bahou (US)
Shannon Marie Bates (CA)
Angelika Batorova (SK)
Kenneth Alan Bauer (US)
Joel S. Bennett (US)
Wolfgang Bergmeier (US)
David Bergqvist (SE)
Michael C. Berndt (IE)
Erik Berntorp (SE)
Rogier Bertina (NL)
Paul E. Bock (US)
Nuala A. Booth (UK)
Lawrence Brass (US)
Benjamin Brenner (IL)
George Broze (US)
Francis J. Castellino (US)
Marco Cattaneo (IT)
Jean-Pierre Cazenave (FR)
Beng Chong (AU)
Douglas Cines (US)
Sergio Coccheri (IT)
Peter Collins (UK)
Ramon Corbalan (CL)
Benilde Cosmi (IT)
Mary Cushman (US)
Bjorn Dahlback (SE)
Alan Daugherty (US)
Raimondo De Cristofaro (IT)
Philippe de Moerloose (CH)
Valerio De Stefano (IT)
Najet Debili (FR)
Paul Declerck (BE)
Jay Degen (US)
Francesco Dentali (IT)
Francoise Dignat-George (FR)
Jing-Fei Dong (US)
Jonas Emsley (UK)
Miguel Escobar (US)
Naomi L. Esmon (US)
Philip J. Fay (US)
Augusto B. Federici (IT)
Garrett A. Fitzgerald (US)
Jonathan H. Foley (US)
Kathleen Freson (BE)
Committees

Satoshi Fujii (JP)
Barbara C. Furie (US)
Bruce Furie (US)
Christian Gachet (FR)
David Gailani (US)
Monica Galli (IT)
Alexander S. Gallus (AU)
Satoshi Gando (JP)
Sophie Gandrille (FR)
Jonathan Gibbins (UK)
David Ginsburg (US)
Samuel Z. Goldhaber (US)
Mike Greaves (UK)
John Griffin (US)
Alessandro Gringeri (IT)
Yves Gruel (FR)
John Hartwig (US)
Tatsuya Hayashi (JP)
John A. Heit (US)
Coen H. Hemker (NL)
Satoshi Higasa (JP)
Philip Hogg (AU)
Hisanori Horiuchi (JP)
Tom Eugene Howard (US)
Menno Huisman (NL)
Beverley J. Hunt (UK)
James A. Huntington (UK)
Akitada Ichinose (JP)
Masahiro Ieko (JP)
Aida Inbal (IL)
Toshiyuku Ishibashi (JP)
Masaru Ishii (JP)
Shaun P. Jackson (AU)
Gerhard Johnson (US)
Cecile Kaplan (FR)
Hirokazu Kashiwagi (JP)
Clive Kearrow (CA)
Gili Kenet (IL)
Craig M. Kessler (US)
Alok Anand Khorana (US)

R. Manjunatha Kini (SG)
Cornelis Kluft (NL)
Takao Kobayashi (JP)
Gou Young Koh (KR)
Takehiko Koide (JP)
Jun Koizumi (JP)
Hiroshi Kojima (JP)
Tetsuhiro Kojima (JP)
Koichi Kokame (JP)
Kimihiro Komori (JP)
Barbara Konkle (US)
Yukihiro Koretsune (JP)
Steve Krilis (AU)
Sriram Krishnaswamy (US)
Thomas Kuehne (CH)
Masataka Kuwana (JP)
Bernhard Laemmle (CH)
David A. Lane (UK)
Dan Lawrence (US)
Bernard Le Bonniec (FR)
Gregoire Le Gal (FR)
Agnes Lee (CA)
Marcel Levi (NL)
Howard Liebman (US)
H. Roger Lijnen (BE)
David Lillicrap (CA)
Shu-Wha Lin (TW)
Gregory Y. H. Lip (UK)
Colin Longstaff (UK)
Committees

Susan Lord (US)
Gordon Lowe (UK)
Nigel Mackman (US)
Asrar B. Malik (US)
Naveen Manchanda (US)
Marilyn Jean Manco-Johnson (US)
Ida Martinelli (IT)
Steffen Massberg (DE)
Yumiko Matsubara (JP)
Osamu Matsuo (JP)
Tadashi Matsushita (JP)
Robert Lindsay Medcalf (AU)
Leonid Medved (US)
Joost Meijers (NL)
Alan D. Michelson (US)
Saskia Middeldorp (NL)
Jonathan Miller (US)
Jun Mimuro (JP)
Tetsuro Miyata (JP)
Kohei Miyazono (JP)
Jun Mizuguchi (JP)
Stephan Moll (US)
Paul Monagle (AU)
Paul Edward Monahan (US)
Robert R. Montgomery (US)
Massimo Morfini (IT)
Eriko Morishita (JP)
Takashi Morita (JP)
Jim Morrissey (US)
Michael Mosesson (US)
Iris Felicitas Mueller (UK)
Laszlo Muszbek (HU)
Mashio Nakamura (JP)
Claude Negrier (FR)
Heyu Ni (CA)
Bernhard Nieswandt (DE)
Alan Nurden (FR)
Paquita Nurden (FR)
Tsukasa Ohmori (JP)
Johannes Oldenburg (DE)

Susanne Osanto (NL)
Bjarne Osterud (NO)
Paola Patrignani (IT)
Kathelijne Peerlinck (BE)
Vittorio Pengo (IT)
Egon Persson (DK)
Flora Peyvandi (IT)
Steven Pipe (US)
Mortimer Poncz (US)
Alastair William Poole (UK)
Paolo Prandoni (IT)
Kathleen Pratt (US)
Klaus T. Preissner (DE)
Martin H. Prins (NL)
A. Koneti Rao (US)
Peter Reitsma (NL)
Georges E. Rivard (CA)
Ljung Rolf (SE)
Frits R. Rosendaal (NL)
Jan Rosing (NL)
Changgeng Ruan (CN)
Wolfram Ruf (US)
Morten Sadset (NO)
Jean-Marie Robert Saint-Remy (BE)
Yoichi Sakata (JP)
Charles-Marc Samama (FR)
Elena Santagostino (IT)
Sentot Santoso (DE)
Alvin Schmaier (US)
Committees

Reinhard Schneppenheim (DE)  
Sam Schulman (CA)  
Uri Seligsohn (IL)  
Amy Shapiro (US)  
Midori Shima (JP)  
Kazuyuki Shimada (JP)  
Keiko Shinozawa (JP)  
Roy L. Silverstein (US)  
Radek C. Skoda (CH)  
Nicholas Smith (US)  
Kenji Soejima (JP)  
Henrik Sorensen (DK)  
Benny Sorensen (UK)  
Alok Srivastava (IN)  
Katsuo Sueishi (JP)  
Junichi Takagi (JP)  
Nobuyuki Takakura (JP)  
Hiroyuki Takeya (JP)  
Jerome Teitel (CA)  
Douglas Tollefsen (US)  
Mauro Torti (IT)  
Hiroko Tsuda (JP)  
Alexander G. G. Turpie (CA)  
Yoshio Uetsuka (JP)  
Tetsu Uruno (JP)  
Elizabeth Van Cott (US)  
Marijke van den Berg (NL)  
Karen Vanhoorelbeke (BE)  
David Varon (IL)  
Agnes Veyradier (FR)  
Vicente Vicente (ES)  
Jan Voorberg (NL)  
Hideo Wada (JP)  
Denisa D. Wagner (US)  
Hironao Wakabayashi (US)  
Theodore Warkentin (CA)  
Henry Watson (UK)  
Stephen Watson (UK)  
Phil Stephen Wells (CA)  
Andy Weyrich (US)  
Richard H. White (US)  
David Allen Wilcox (US)  
Takeshi Yamashita (JP)  
Renchi Yang (CN)  
Masahiro Yasaka (JP)  
Yutaka Yatomi (JP)  
Neil A. Zakai (US)  
Yongqiang Zhao (CN)  
Ariella Zivelin (IL)  
Jeffrey Zwicker (US)  

Society Partner

Japanese Society on Thrombosis and Hemostasis

Congress Supporters

Japan Tourism Agency - Ministry of Land, Infrastructure, Transport and Tourism  
City of Kyoto  
Kyoto Prefecture  
Ministry of Education, Culture, Sports, Science and Technology  
Ministry of Foreign Affairs  
Ministry of Health, Labour and Welfare

Japan Atherosclerosis Society  
Japan Medical Association  
Japan Society of Transfusion Medicine and Cell Therapy  
Japan Stroke Society  
Japanese Association of Medical Sciences  
Japanese Circulation Society  
Japanese College of Angiology  
Japanese Society of Hematology  
Japanese Society of Internal Medicine  
Japanese Vascular and Medicine Organization
Committees

Presidents of Past Congresses

I  1970  Fritz Koller  Montreux, Switzerland
II  1971  Paul A. Owren  Oslo, Norway
III 1972  Kenneth M. Brinkhous  Washington, DC, USA
IV 1973  Erwin Deutsch  Vienna, Austria
V  1975  Jean-Pierre Soulier  Paris, France
VI  1977  Sol Sherry  Philadelphia, PA, USA
VII  1979  Gustav V. R. Born  London, UK
VIII 1981  J. Fraser Mustard  Toronto, Canada
IX  1983  Birger Blomback  Stockholm, Sweden
X  1985  Russell F. Doolittle  San Diego, CA, USA
XI  1987  Marc Verstraete  Brussels, Belgium
XII  1989  Takeshi Abe  Tokyo, Japan
XIII 1991  Jan Sixma  Amsterdam, The Netherlands
XIV  1993  Yale Nemerson  New York, NY, USA
XV  1995  Uri Seligsohn  Jerusalem, Israel
XVI  1997  Pier M. Mannucci  Florence, Italy
XVII  1999  Victor J. Marder  Washington, DC, USA
XVIII 2001  Dominique Meyer  Paris, France
XIX  2003  Ian R. Peake  Birmingham, England
XX  2005  Colin N. Chesterman  Sydney, Australia
XXI 2007  Henri M. Bounameaux  Geneva, Switzerland
XXII 2009  Bruce and Barbara Furie  Boston, MA, USA

Presidents of Future Congresses

XXIV 2013  Frits R. Rosendaal  Amsterdam, The Netherlands
XXV  2015  Sam Schulman  Toronto, Canada
XXVI 2017  Johannes Oldenburg  Berlin, Germany
ISTH AWARDS 2011

Robert P. Grant Medal
The Robert P. Grant Medal is the highest award of the ISTH. Presented at each biennial Congress of the Society, it recognizes outstanding service or accomplishments which have promoted the goals of the Society: research achievement, organizational activities, important public recognition and support of research activities, facilitation of institutional cooperation and communications, unusual teaching or educational initiatives, or the development of concepts which result in a clearer understanding of the meaning of research data.

The ISTH Grant Medal will be presented at the XXIII Congress Opening Ceremony on Sunday, July 24 at 17:30.

Harold R. Roberts Award
The Harold R. Roberts Award recognizes meritorious service to the Scientific and Standardization Committee of the ISTH, beyond expectations and over a significant period of time.

This award will be presented at the Presidential Symposium on Wednesday, July 27 at 11:15.

Biennial Awards for Contributions to Hemostasis: Investigator Recognition
Initiated in 1982, the Biennial Awards for Contributions to Hemostasis (BACH) recognize individuals who have made significant contributions to research and education in blood coagulation. The awards are presented in two categories:

The Investigator Recognition Awards recognize ISTH members whose accomplishments are internationally regarded as exemplary models of excellence in research and teaching.

The Distinguished Career Awards recognize ISTH members whose career contributions have significantly advanced the scientific community's understanding of the diseases and disorders affecting hemostasis.

The ISTH BACH Awards will be presented during Presidential Dinner (invitation only) on Monday, July 25 at 19:00.

2010 Pier M. Mannucci Young Investigator Awards, Journal of Thrombosis and Haemostasis
The Pier M. Mannucci Young Investigator Awards recognize the best articles by investigators younger than 35 years of age published in ISTH journals. The prizes are made possible by a generous contribution from Bayer HealthCare, and recipients are selected by a jury of editors.

Megumi Takiguchi
Kim Marieke Baeten
Judith M.E.M. Cosemans, PhD
Dr. Stuart Michael Ellison
Hendrik B. Feys
Matteo Bonzini
Sofia Barbar
Congress Awards and Lectureships

XXIII ISTH CONGRESS SPECIAL LECTURESHIP 2011

Takeshi Abe Memorial Lecture
Katherine A. High
Monday, July 25 at 09:45

ISTH LECTURESHIPS 2011

ISTH Congress Plenary Lecture
Made possible by a grant from the Life Sciences Research Partners (formerly Désiré Collen Research Foundation)
Kari Alitalo
Monday, July 25 at 17:15

The Oscar Ratnoff Memorial Lecture
Kenji Kangawa
Tuesday, July 26 at 09:45

The Sol Sherry Memorial Lecture
Kenneth A. Bauer
Tuesday, July 26 at 17:15

Kenneth M. Brinkhous Memorial Lecture
Mark H. Ginsberg
Thursday, July 28 at 9:45

Wright-Schulte Memorial Lecture
James A. Huntington
Thursday, July 28 at 13:30
Congress Awards and Grants

Awards
These awards are part of the ISTH’s Reach the World initiative and have been made possible thanks to ISTH, the XXIII Congress of the ISTH, the Japanese Society on Thrombosis and Haemostasis and corporate sponsors.

Young Investigator Awards (YIA)
ISTH 2011 will provide travel grants (500USD) to medical trainees and young scientists (under 35 years of age as of July 23, 2011) who submit highly rated abstracts. The award helps subsidize travel to the Congress. The Young Investigator must be the presenter and first author of an abstract submitted to the Congress. To receive the award, a recipient must be present at the Congress, and a current passport showing date of birth is required to collect the award on site at ISTH 2011.

Developing World Scientists Awards (DWSA)
ISTH 2011 and the International Society on Thrombosis and Haemostasis will award travel grants (1,500 – 3,500USD) to scientists from developing countries to help to subsidize travel to the Congress. To be considered for a grant the scientist must be the presenter and first author of an abstract submitted to the Congress. A current passport showing country of residence is required to collect the grant exclusively available on site at ISTH 2011.

JSTH Asian-Pacific Scholarship (JSTH/APS)
This Scholarship is made possible by a generous contribution of the Japanese Society on Thrombosis and Haemostasis (JSTH) and is exclusive to the ISTH 2011 in Kyoto. JSTH will award scholarship (500 USD) to scientists who submitted highly rated abstracts. Scientists who are under 40 years of age and live in Asian countries, Australia, or New Zealand as of July 23, 2011 apply. The scholarship helps to subsidize travel to the Congress. The applicant must be the presenter and first author of an abstract submitted to the Congress. To receive the award, a recipient must be present at the Congress, and a current passport showing date of birth and country of residence is required to collect the scholarship on site at ISTH 2011.
# Congress Awards and Grants

## The Award Winners

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agar</td>
<td>Cetin</td>
<td>YIA</td>
</tr>
<tr>
<td>Ahlbrecht</td>
<td>Jonas</td>
<td>YIA</td>
</tr>
<tr>
<td>Ahmadinejad</td>
<td>Minoo</td>
<td>DWSA</td>
</tr>
<tr>
<td>Ahnstrom</td>
<td>Josefin</td>
<td>YIA</td>
</tr>
<tr>
<td>Asina</td>
<td>Roza</td>
<td>DWSA</td>
</tr>
<tr>
<td>Aladahalli Mallappa</td>
<td>Shanthala</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Albers</td>
<td>Cornelis</td>
<td>YIA</td>
</tr>
<tr>
<td>Alexander</td>
<td>Nicoleta</td>
<td>DWSA</td>
</tr>
<tr>
<td>Ali</td>
<td>Majid</td>
<td>YIA</td>
</tr>
<tr>
<td>Allan</td>
<td>Peter</td>
<td>YIA</td>
</tr>
<tr>
<td>Attard</td>
<td>Chantal</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Ay</td>
<td>Cihan</td>
<td>YIA</td>
</tr>
<tr>
<td>Bagoly</td>
<td>Zsuzsa</td>
<td>DWSA</td>
</tr>
<tr>
<td>Bai</td>
<td>Xia</td>
<td>DWSA</td>
</tr>
<tr>
<td>Bakchoul</td>
<td>Tamam</td>
<td>YIA</td>
</tr>
<tr>
<td>Balandina</td>
<td>Anna</td>
<td>DWSA</td>
</tr>
<tr>
<td>Banno</td>
<td>Fumiaki</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Benslimane-Ahmim</td>
<td>Zahia</td>
<td>YIA</td>
</tr>
<tr>
<td>Bermejo</td>
<td>Emilise</td>
<td>DWSA</td>
</tr>
<tr>
<td>Bertrand</td>
<td>Gerald</td>
<td>YIA</td>
</tr>
<tr>
<td>Bichan</td>
<td>Volha</td>
<td>DWSA</td>
</tr>
<tr>
<td>Bjorkqvist</td>
<td>Jenny</td>
<td>YIA</td>
</tr>
<tr>
<td>Blix</td>
<td>Kristine</td>
<td>YIA</td>
</tr>
<tr>
<td>Bloem</td>
<td>Esther</td>
<td>YIA</td>
</tr>
<tr>
<td>Boncela</td>
<td>Joanna</td>
<td>DWSA</td>
</tr>
<tr>
<td>Borgognone</td>
<td>Alessandra</td>
<td>YIA</td>
</tr>
<tr>
<td>Borhany</td>
<td>Munira</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Borissof</td>
<td>Julian</td>
<td>YIA</td>
</tr>
<tr>
<td>Boveda Ruiz</td>
<td>Daniel</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Branchford</td>
<td>Brian</td>
<td>YIA</td>
</tr>
<tr>
<td>Branchini</td>
<td>Alessio</td>
<td>YIA</td>
</tr>
<tr>
<td>Broos</td>
<td>Kateleen</td>
<td>YIA</td>
</tr>
<tr>
<td>Brophy</td>
<td>Teresa</td>
<td>YIA</td>
</tr>
<tr>
<td>Brzoska</td>
<td>Tomasz</td>
<td>YIA</td>
</tr>
<tr>
<td>Buitrago</td>
<td>Claudia</td>
<td>YIA</td>
</tr>
<tr>
<td>Burnier</td>
<td>Laurent</td>
<td>YIA</td>
</tr>
<tr>
<td>Calderazzo Pereyra</td>
<td>Julio</td>
<td>DWSA</td>
</tr>
<tr>
<td>Canault</td>
<td>Matthias</td>
<td>YIA</td>
</tr>
<tr>
<td>Caraballo</td>
<td>Deborah</td>
<td>YIA</td>
</tr>
<tr>
<td>Celinska-Lowenhoff</td>
<td>Magdalena</td>
<td>DWSA</td>
</tr>
<tr>
<td>Chakarova</td>
<td>Lidija</td>
<td>YIA</td>
</tr>
<tr>
<td>Chan</td>
<td>Mark</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Chantrathamacharti</td>
<td>Pichika</td>
<td>YIA</td>
</tr>
<tr>
<td>Chen</td>
<td>Younan</td>
<td>DWSA</td>
</tr>
<tr>
<td>Chen</td>
<td>Qiong</td>
<td>DWSA</td>
</tr>
<tr>
<td>Chen</td>
<td>Hai</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Chimeen</td>
<td>Punsaldulam</td>
<td>DWSA</td>
</tr>
<tr>
<td>Chudzinski-Tavassi</td>
<td>Ana Marisa</td>
<td>DWSA</td>
</tr>
<tr>
<td>Cleuren</td>
<td>Audrey</td>
<td>YIA</td>
</tr>
<tr>
<td>Cook</td>
<td>P. Michael</td>
<td>YIA</td>
</tr>
<tr>
<td>Corrigan</td>
<td>Claire</td>
<td>YIA</td>
</tr>
<tr>
<td>Cosemans</td>
<td>Judith</td>
<td>YIA</td>
</tr>
<tr>
<td>Dai</td>
<td>Jihong</td>
<td>DWSA</td>
</tr>
<tr>
<td>Dai</td>
<td>Jing</td>
<td>DWSA</td>
</tr>
<tr>
<td>Dashkevich</td>
<td>Natalia</td>
<td>DWSA</td>
</tr>
<tr>
<td>Davenport</td>
<td>Ross</td>
<td>YIA</td>
</tr>
<tr>
<td>De Boer</td>
<td>Johannes</td>
<td>YIA</td>
</tr>
<tr>
<td>De Ceunynck</td>
<td>Karen</td>
<td>YIA</td>
</tr>
<tr>
<td>de Groot</td>
<td>Rens</td>
<td>YIA</td>
</tr>
<tr>
<td>de Jong</td>
<td>Paulien</td>
<td>YIA</td>
</tr>
<tr>
<td>de Laat</td>
<td>Bas</td>
<td>YIA</td>
</tr>
<tr>
<td>de Paula</td>
<td>Erich</td>
<td>DWSA</td>
</tr>
<tr>
<td>De Wee</td>
<td>Eva</td>
<td>YIA</td>
</tr>
<tr>
<td>Debeij</td>
<td>Jan</td>
<td>YIA</td>
</tr>
<tr>
<td>Dickmann</td>
<td>Boris</td>
<td>YIA</td>
</tr>
<tr>
<td>Dimitrov</td>
<td>Jordan</td>
<td>YIA</td>
</tr>
<tr>
<td>Ding</td>
<td>Qulian</td>
<td>DWSA</td>
</tr>
<tr>
<td>Djordjevic</td>
<td>Valentina</td>
<td>DWSA</td>
</tr>
<tr>
<td>Djunic</td>
<td>Irena</td>
<td>DWSA</td>
</tr>
<tr>
<td>Dong</td>
<td>Jing-fei</td>
<td>YIA</td>
</tr>
<tr>
<td>Dong</td>
<td>Xiaoyuan</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Douma</td>
<td>Renee</td>
<td>YIA</td>
</tr>
<tr>
<td>Dovlatova</td>
<td>Natalia</td>
<td>YIA</td>
</tr>
<tr>
<td>Dropinski</td>
<td>Jerzy</td>
<td>DWSA</td>
</tr>
<tr>
<td>Drozd</td>
<td>Lizaveta</td>
<td>DWSA</td>
</tr>
<tr>
<td>Eickhardt</td>
<td>Corien</td>
<td>YIA</td>
</tr>
<tr>
<td>Erkens</td>
<td>Petra</td>
<td>YIA</td>
</tr>
<tr>
<td>Fang</td>
<td>Yi</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Faxalv</td>
<td>Lars</td>
<td>YIA</td>
</tr>
<tr>
<td>Feye</td>
<td>Hendrik</td>
<td>YIA</td>
</tr>
<tr>
<td>Finn</td>
<td>Jonathan</td>
<td>YIA</td>
</tr>
<tr>
<td>Fiore</td>
<td>Mathieu</td>
<td>YIA</td>
</tr>
</tbody>
</table>
# Congress Awards and Grants

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Awards</th>
<th>Last Name</th>
<th>First Name</th>
<th>Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fujieda</td>
<td>Yuichiro</td>
<td>YIA</td>
<td>Kager</td>
<td>Liesbeth</td>
<td>YIA</td>
</tr>
<tr>
<td>Fujii</td>
<td>Noriko</td>
<td>JSTH/APS</td>
<td>Kamada</td>
<td>Haruhiko</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Fujita</td>
<td>Junko</td>
<td>JSTH/APS</td>
<td>Kameda</td>
<td>Sachika</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Furukawa</td>
<td>Shoko</td>
<td>JSTH/APS</td>
<td>Kaplan</td>
<td>Zane</td>
<td>YIA</td>
</tr>
<tr>
<td>Gamzatov</td>
<td>Temirlan</td>
<td>DWSA</td>
<td>Kashiwaku</td>
<td>Yuji</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Gansler</td>
<td>Julia</td>
<td>YIA</td>
<td>Kawao</td>
<td>Naoyuki</td>
<td>YIA</td>
</tr>
<tr>
<td>Gebuis</td>
<td>Edward</td>
<td>YIA</td>
<td>Khan</td>
<td>Gausal</td>
<td>DWSA</td>
</tr>
<tr>
<td>Geersing</td>
<td>Geert-Jan</td>
<td>YIA</td>
<td>Khawaji</td>
<td>Mohammed</td>
<td>YIA</td>
</tr>
<tr>
<td>Gharini</td>
<td>Putrika</td>
<td>DWSA</td>
<td>Kim</td>
<td>Haein</td>
<td>YIA</td>
</tr>
<tr>
<td>Gil Bernabe</td>
<td>Paloma</td>
<td>YIA</td>
<td>Kim</td>
<td>Paul</td>
<td>YIA</td>
</tr>
<tr>
<td>Gleson</td>
<td>Eimear</td>
<td>YIA</td>
<td>Kim</td>
<td>Ji-Yoon</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Gorbacheva</td>
<td>Lyubov</td>
<td>DWSA</td>
<td>Kita</td>
<td>Toshiyuki</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Goubau</td>
<td>Christophe</td>
<td>YIA</td>
<td>Kiyomizu</td>
<td>Kazunobu</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Gouw</td>
<td>Samantha</td>
<td>YIA</td>
<td>Kleinjan</td>
<td>Ankje</td>
<td>YIA</td>
</tr>
<tr>
<td>Gribkova</td>
<td>Irina</td>
<td>DWSA</td>
<td>Klok</td>
<td>Frederikus</td>
<td>YIA</td>
</tr>
<tr>
<td>Guerrero</td>
<td>Jose</td>
<td>YIA</td>
<td>Kokabee</td>
<td>Leila</td>
<td>DWSA</td>
</tr>
<tr>
<td>gupta</td>
<td>Shuchi</td>
<td>YIA</td>
<td>Kolyadko</td>
<td>Vladimir</td>
<td>DWSA</td>
</tr>
<tr>
<td>Hagedorn</td>
<td>Ina</td>
<td>YIA</td>
<td>Konings</td>
<td>Joke</td>
<td>YIA</td>
</tr>
<tr>
<td>Hampshire</td>
<td>Daniel</td>
<td>YIA</td>
<td>Korzh</td>
<td>Oleksii</td>
<td>DWSA</td>
</tr>
<tr>
<td>Han</td>
<td>Yue</td>
<td>DWSA</td>
<td>Koizuma</td>
<td>Yukinori</td>
<td>YIA</td>
</tr>
<tr>
<td>Hansen-Krone</td>
<td>Ida</td>
<td>YIA</td>
<td>Laurance</td>
<td>Sandrine</td>
<td>YIA</td>
</tr>
<tr>
<td>Hanslik</td>
<td>Andreas</td>
<td>YIA</td>
<td>Lecut</td>
<td>Christelle</td>
<td>YIA</td>
</tr>
<tr>
<td>Hayakawa</td>
<td>Masaki</td>
<td>JSTH/APS</td>
<td>Li</td>
<td>Huiyuan</td>
<td>DWSA</td>
</tr>
<tr>
<td>HE</td>
<td>YANG</td>
<td>DWSA</td>
<td>Liao</td>
<td>Chien-Chang</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Hendrickx</td>
<td>Maarten</td>
<td>YIA</td>
<td>Lin</td>
<td>Jiangguo</td>
<td>YIA</td>
</tr>
<tr>
<td>Herzchenik</td>
<td>Eszter</td>
<td>YIA</td>
<td>Lin</td>
<td>Zhonghui</td>
<td>DWSA</td>
</tr>
<tr>
<td>Hess</td>
<td>Katharina</td>
<td>YIA</td>
<td>Liu</td>
<td>Xinguang</td>
<td>YIA</td>
</tr>
<tr>
<td>Hofbauer</td>
<td>Christoph</td>
<td>YIA</td>
<td>Lotta</td>
<td>Luca</td>
<td>YIA</td>
</tr>
<tr>
<td>Hu</td>
<td>Liang</td>
<td>YIA</td>
<td>Lowenberg</td>
<td>Ester</td>
<td>YIA</td>
</tr>
<tr>
<td>Hu</td>
<td>Yu</td>
<td>JSTH/APS</td>
<td>Lu</td>
<td>Bernardine</td>
<td>YIA</td>
</tr>
<tr>
<td>Huang</td>
<td>Chien-Ling</td>
<td>YIA</td>
<td>Lu</td>
<td>Yeling</td>
<td>DWSA</td>
</tr>
<tr>
<td>Huang</td>
<td>Jiansong</td>
<td>DWSA</td>
<td>Ma</td>
<td>Daoxin</td>
<td>DWSA</td>
</tr>
<tr>
<td>Huynh</td>
<td>Khon</td>
<td>JSTH/APS</td>
<td>Maas</td>
<td>Coen</td>
<td>YIA</td>
</tr>
<tr>
<td>Hwang</td>
<td>Sung ho</td>
<td>JSTH/APS</td>
<td>Maas</td>
<td>Coen</td>
<td>YIA</td>
</tr>
<tr>
<td>Iamsirinak</td>
<td>Poranchanok</td>
<td>JSTH/APS</td>
<td>Malato</td>
<td>Alessandra</td>
<td>YIA</td>
</tr>
<tr>
<td>Jadaon</td>
<td>Mehez</td>
<td>DWSA</td>
<td>Manukyan</td>
<td>Davit</td>
<td>YIA</td>
</tr>
<tr>
<td>Ji</td>
<td>Shundong</td>
<td>DWSA</td>
<td>Martinez-Martinez</td>
<td>Irene</td>
<td>YIA</td>
</tr>
<tr>
<td>Jiang</td>
<td>Miao</td>
<td>DWSA</td>
<td>Matsuda</td>
<td>Yasuyuki</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>jiang</td>
<td>Lin</td>
<td>JSTH/APS</td>
<td>Matsumoto</td>
<td>Tomoko</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Jin</td>
<td>Joseph</td>
<td>YIA</td>
<td>May</td>
<td>Frauke</td>
<td>YIA</td>
</tr>
<tr>
<td>Jones</td>
<td>Sophie</td>
<td>JSTH/APS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Awards</td>
<td>Last Name</td>
<td>First Name</td>
<td>Awards</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>------------</td>
<td>-----------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>McGrath</td>
<td>Rachel</td>
<td>YIA</td>
<td>Pierangel</td>
<td>Silvia</td>
<td>YIA</td>
</tr>
<tr>
<td>Meiring</td>
<td>Muslim</td>
<td>DWSA</td>
<td>Pinto</td>
<td>Patricia</td>
<td>DWSA</td>
</tr>
<tr>
<td>Mitsuguro</td>
<td>Mana</td>
<td>JSTH/APS</td>
<td>Pleines</td>
<td>Irina</td>
<td>YIA</td>
</tr>
<tr>
<td>Miyake</td>
<td>Yasushi</td>
<td>JSTH/APS</td>
<td>Popov</td>
<td>Viola Maria</td>
<td>DWSA</td>
</tr>
<tr>
<td>Mizurini</td>
<td>Daniella</td>
<td>DWSA</td>
<td>Qin</td>
<td>Huanhuan</td>
<td>DWSA</td>
</tr>
<tr>
<td>Mo</td>
<td>XI</td>
<td>DWSA</td>
<td>Queiroz</td>
<td>Karla</td>
<td>YIA</td>
</tr>
<tr>
<td>Moheimani</td>
<td>Fatemeh</td>
<td>JSTH/APS</td>
<td>Ratanawan</td>
<td>Chutima</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Mos</td>
<td>Inge</td>
<td>YIA</td>
<td>Ravanbod</td>
<td>Shrin</td>
<td>DWSA</td>
</tr>
<tr>
<td>Mueller</td>
<td>Felicitas</td>
<td>YIA</td>
<td>Reinhardt</td>
<td>Christoph</td>
<td>YIA</td>
</tr>
<tr>
<td>Nagasawa</td>
<td>Ayumi</td>
<td>JSTH/APS</td>
<td>Ren</td>
<td>Honggang</td>
<td>DWSA</td>
</tr>
<tr>
<td>Nakayama</td>
<td>Daisuke</td>
<td>JSTH/APS</td>
<td>Repesse</td>
<td>Yohann</td>
<td>YIA</td>
</tr>
<tr>
<td>Nakazawa</td>
<td>Tsuyoshi</td>
<td>JSTH/APS</td>
<td>Reshetnyak</td>
<td>Tatiana</td>
<td>DWSA</td>
</tr>
<tr>
<td>Nantakomol</td>
<td>Duangdao</td>
<td>DWSA</td>
<td>Rezende</td>
<td>Suely</td>
<td>DWSA</td>
</tr>
<tr>
<td>Natesirinikul</td>
<td>Rungrote</td>
<td>JSTH/APS</td>
<td>Ribeiro</td>
<td>Daniel</td>
<td>DWSA</td>
</tr>
<tr>
<td>Navarro-Fernandez</td>
<td>Jose</td>
<td>YIA</td>
<td>Riches</td>
<td>Jonathan</td>
<td>YIA</td>
</tr>
<tr>
<td>Navin</td>
<td>Pai</td>
<td>JSTH/APS</td>
<td>Romeo</td>
<td>Giuliana</td>
<td>YIA</td>
</tr>
<tr>
<td>Nazir</td>
<td>Mohamed</td>
<td>JSTH/APS</td>
<td>Rossetto</td>
<td>Valeria</td>
<td>YIA</td>
</tr>
<tr>
<td>Nergiz-Unal</td>
<td>Reyhan</td>
<td>JSTH/APS</td>
<td>Rourke</td>
<td>Claire</td>
<td>YIA</td>
</tr>
<tr>
<td>Ni</td>
<td>Ran</td>
<td>YIA</td>
<td>Ruchtrakool</td>
<td>Theera</td>
<td>DWSA</td>
</tr>
<tr>
<td>Ni Ainle</td>
<td>Fionnuala</td>
<td>YIA</td>
<td>Rydz</td>
<td>Natalia</td>
<td>YIA</td>
</tr>
<tr>
<td>Niewiarowska</td>
<td>Jolanta</td>
<td>DWSA</td>
<td>Sanchez-Luceros</td>
<td>Analia</td>
<td>DWSA</td>
</tr>
<tr>
<td>Ninivaggi</td>
<td>Marisa</td>
<td>YIA</td>
<td>Savage</td>
<td>Joshua</td>
<td>YIA</td>
</tr>
<tr>
<td>Nishimoto</td>
<td>Tetsuya</td>
<td>YIA</td>
<td>Schattner</td>
<td>Mirta</td>
<td>DWSA</td>
</tr>
<tr>
<td>Nowak</td>
<td>Agata</td>
<td>YIA</td>
<td>Schiviz</td>
<td>Alexandra</td>
<td>YIA</td>
</tr>
<tr>
<td>Nuchnoi</td>
<td>Fornlada</td>
<td>JSTH/APS</td>
<td>Segbefia</td>
<td>Catherine</td>
<td>DWSA</td>
</tr>
<tr>
<td>Ocak</td>
<td>Gurbey</td>
<td>YIA</td>
<td>Seifert</td>
<td>Stefanie</td>
<td>YIA</td>
</tr>
<tr>
<td>Ogiwara</td>
<td>Kenichi</td>
<td>JSTH/APS</td>
<td>Sharma</td>
<td>Anup</td>
<td>YIA</td>
</tr>
<tr>
<td>Olga</td>
<td>Panes</td>
<td>DWSA</td>
<td>Shi</td>
<td>Wei</td>
<td>DWSA</td>
</tr>
<tr>
<td>Oliveira</td>
<td>Andrea</td>
<td>YIA</td>
<td>Shi</td>
<td>yan</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Osborne</td>
<td>Simone</td>
<td>JSTH/APS</td>
<td>Shiltagh</td>
<td>Nuha</td>
<td>YIA</td>
</tr>
<tr>
<td>Oschatz</td>
<td>Chris</td>
<td>YIA</td>
<td>Shmeleva</td>
<td>Veronika</td>
<td>DWSA</td>
</tr>
<tr>
<td>Otgontaij</td>
<td>Sumiya</td>
<td>DWSA</td>
<td>Siigur</td>
<td>Ene</td>
<td>DWSA</td>
</tr>
<tr>
<td>OuYang</td>
<td>Qi</td>
<td>DWSA</td>
<td>Sinauridze</td>
<td>Elena</td>
<td>DWSA</td>
</tr>
<tr>
<td>Ovanesov</td>
<td>Mikhail</td>
<td>YIA</td>
<td>Sirotkina</td>
<td>Olga</td>
<td>DWSA</td>
</tr>
<tr>
<td>Oymak</td>
<td>Yesim</td>
<td>DWSA</td>
<td>Sluka</td>
<td>Susanna</td>
<td>YIA</td>
</tr>
<tr>
<td>Ozelo</td>
<td>Margareth</td>
<td>DWSA</td>
<td>Snoep</td>
<td>Jaapjan</td>
<td>YIA</td>
</tr>
<tr>
<td>P</td>
<td>Shenbagapriya</td>
<td>DWSA</td>
<td>Sorvillo</td>
<td>Nicoletta</td>
<td>YIA</td>
</tr>
<tr>
<td>Parunov</td>
<td>Leonid</td>
<td>DWSA</td>
<td>Stavik</td>
<td>Benedictie</td>
<td>YIA</td>
</tr>
<tr>
<td>Pasha</td>
<td>Sharif</td>
<td>YIA</td>
<td>Stegeman</td>
<td>Bernardine</td>
<td>YIA</td>
</tr>
<tr>
<td>Peng</td>
<td>Jun</td>
<td>DWSA</td>
<td>Steinitz</td>
<td>Katharina</td>
<td>YIA</td>
</tr>
<tr>
<td>Perez-Andreu</td>
<td>Virginia</td>
<td>YIA</td>
<td>Stevic</td>
<td>Ivan</td>
<td>YIA</td>
</tr>
</tbody>
</table>
### Congress Awards and Grants

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strukova</td>
<td>Svetlana</td>
<td>DWSA</td>
</tr>
<tr>
<td>Suzuki</td>
<td>Atsuo</td>
<td>YIA</td>
</tr>
<tr>
<td>Suzuki</td>
<td>Eriko</td>
<td>YIA</td>
</tr>
<tr>
<td>Swieringa</td>
<td>Frauke</td>
<td>YIA</td>
</tr>
<tr>
<td>Swystun</td>
<td>Laura</td>
<td>YIA</td>
</tr>
<tr>
<td>Takayama</td>
<td>Naoya</td>
<td>YIA</td>
</tr>
<tr>
<td>Talens</td>
<td>Simone</td>
<td>YIA</td>
</tr>
<tr>
<td>Tamura</td>
<td>Shogo</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Tang</td>
<td>Mariann</td>
<td>YIA</td>
</tr>
<tr>
<td>Tarandovskiy</td>
<td>Ivan</td>
<td>DWSA</td>
</tr>
<tr>
<td>Tatsumi</td>
<td>Kohei</td>
<td>YIA</td>
</tr>
<tr>
<td>Techavichit</td>
<td>Piti</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Teruel</td>
<td>Raul</td>
<td>YIA</td>
</tr>
<tr>
<td>Thaler</td>
<td>Johannes</td>
<td>YIA</td>
</tr>
<tr>
<td>Thomas</td>
<td>Mark</td>
<td>YIA</td>
</tr>
<tr>
<td>Tichelaar</td>
<td>Vladimir</td>
<td>YIA</td>
</tr>
<tr>
<td>Timp</td>
<td>Jasmijn</td>
<td>YIA</td>
</tr>
<tr>
<td>Topalov</td>
<td>Nikolay</td>
<td>DWSA</td>
</tr>
<tr>
<td>Traby</td>
<td>Ludwig</td>
<td>YIA</td>
</tr>
<tr>
<td>Tseng</td>
<td>Wei-Lien</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Tucker</td>
<td>Erik</td>
<td>YIA</td>
</tr>
<tr>
<td>Tuinenburg</td>
<td>Attie</td>
<td>YIA</td>
</tr>
<tr>
<td>Uaprasert</td>
<td>Noppacham</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Valizadeh</td>
<td>Nasim</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Valletiniteavide</td>
<td>Girish</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Valls-Seron</td>
<td>Mercedes</td>
<td>YIA</td>
</tr>
<tr>
<td>van Bladel</td>
<td>Esther</td>
<td>YIA</td>
</tr>
<tr>
<td>van den Boogaard</td>
<td>Floor</td>
<td>YIA</td>
</tr>
<tr>
<td>van den Hengel</td>
<td>Lisa</td>
<td>YIA</td>
</tr>
<tr>
<td>van der Pol</td>
<td>Edwin</td>
<td>YIA</td>
</tr>
<tr>
<td>van Geffen</td>
<td>Mark</td>
<td>YIA</td>
</tr>
<tr>
<td>van Kruchten</td>
<td>Roger</td>
<td>YIA</td>
</tr>
<tr>
<td>van Loon</td>
<td>Janine</td>
<td>YIA</td>
</tr>
<tr>
<td>van Os</td>
<td>Gwendolyn</td>
<td>YIA</td>
</tr>
<tr>
<td>van Schouwenburg</td>
<td>Inge</td>
<td>YIA</td>
</tr>
<tr>
<td>Vanassche</td>
<td>Thomas</td>
<td>YIA</td>
</tr>
<tr>
<td>Vorobyeva</td>
<td>Natalya</td>
<td>DWSA</td>
</tr>
<tr>
<td>Vu</td>
<td>Trang</td>
<td>YIA</td>
</tr>
<tr>
<td>Wahlmueller</td>
<td>Felix</td>
<td>YIA</td>
</tr>
<tr>
<td>Wajima</td>
<td>Daisuke</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Wang</td>
<td>Ying-Jie</td>
<td>YIA</td>
</tr>
<tr>
<td>Wang</td>
<td>Jiong-Wei</td>
<td>YIA</td>
</tr>
<tr>
<td>Wang</td>
<td>Xiaowei</td>
<td>YIA</td>
</tr>
<tr>
<td>Wang</td>
<td>Yiming</td>
<td>YIA</td>
</tr>
<tr>
<td>Wang</td>
<td>Zhaoyue</td>
<td>DWSA</td>
</tr>
<tr>
<td>Wang</td>
<td>Hong-mei</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Winckers</td>
<td>Kristien</td>
<td>YIA</td>
</tr>
<tr>
<td>Wohner</td>
<td>Nikolett</td>
<td>DWSA</td>
</tr>
<tr>
<td>Wroblewska</td>
<td>Aleksandra</td>
<td>YIA</td>
</tr>
<tr>
<td>Wu</td>
<td>Chengliang</td>
<td>YIA</td>
</tr>
<tr>
<td>Wu</td>
<td>Jianbo</td>
<td>DWSA</td>
</tr>
<tr>
<td>Xia</td>
<td>Yan</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Xiang</td>
<td>Yaozu</td>
<td>YIA</td>
</tr>
<tr>
<td>Xing</td>
<td>Zhifang</td>
<td>DWSA</td>
</tr>
<tr>
<td>Xiong</td>
<td>Shilong</td>
<td>DWSA</td>
</tr>
<tr>
<td>Yada</td>
<td>Koji</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Yamaguchi</td>
<td>Yusuke</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Yamamoto</td>
<td>Hitomi</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Yang</td>
<td>Azhen</td>
<td>YIA</td>
</tr>
<tr>
<td>Yang</td>
<td>Lei</td>
<td>DWSA</td>
</tr>
<tr>
<td>Yanrong</td>
<td>Lu</td>
<td>DWSA</td>
</tr>
<tr>
<td>Yeh</td>
<td>Calvin</td>
<td>YIA</td>
</tr>
<tr>
<td>Yoshida</td>
<td>Hideo</td>
<td>YIA</td>
</tr>
<tr>
<td>Yu</td>
<td>Tingting</td>
<td>DWSA</td>
</tr>
<tr>
<td>Yu</td>
<td>Ziqiang</td>
<td>DWSA</td>
</tr>
<tr>
<td>Yu</td>
<td>Yuan-Bin</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Yuki</td>
<td>Matsushima</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Zhang</td>
<td>Yan</td>
<td>YIA</td>
</tr>
<tr>
<td>Zhou</td>
<td>Hu</td>
<td>DWSA</td>
</tr>
<tr>
<td>Zhou</td>
<td>Jiawei</td>
<td>DWSA</td>
</tr>
<tr>
<td>Zhou</td>
<td>Junsong</td>
<td>JSTH/APS</td>
</tr>
<tr>
<td>Zhu</td>
<td>Mingqing</td>
<td>DWSA</td>
</tr>
</tbody>
</table>
## Other Meetings

**Friday, July 22, 2011**

<table>
<thead>
<tr>
<th>Meeting</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Relations and Communications</td>
<td>08:00–09:00</td>
<td>160</td>
</tr>
<tr>
<td>ISTH Membership Taskforce</td>
<td>09:00–10:00</td>
<td>160</td>
</tr>
<tr>
<td>ISTH Congress Presidents Committee</td>
<td>10:00–11:00</td>
<td>K</td>
</tr>
<tr>
<td>SSC Executive/Nominating Committee</td>
<td>11:00–12:00</td>
<td>J</td>
</tr>
<tr>
<td>ISTH Executive Committee</td>
<td>12:00–14:00</td>
<td>K</td>
</tr>
<tr>
<td>Ethics Committee</td>
<td>13:00–14:00</td>
<td>159</td>
</tr>
<tr>
<td>ISTH Finance Committee</td>
<td>14:00–15:00</td>
<td>J</td>
</tr>
<tr>
<td>ISTH Awards Committee</td>
<td>14:00–15:00</td>
<td>159</td>
</tr>
<tr>
<td>ISTH Education Committee</td>
<td>15:00–16:00</td>
<td>K</td>
</tr>
<tr>
<td>ISTH Publications Committee</td>
<td>16:00–17:00</td>
<td>J</td>
</tr>
<tr>
<td>JTH Editor Search Committee</td>
<td>17:00–20:00</td>
<td>158</td>
</tr>
</tbody>
</table>

**Saturday, July 23, 2011**

<table>
<thead>
<tr>
<th>Meeting</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>JTH Editor Search Committee—Debriefing</td>
<td>07:00–08:00</td>
<td>158</td>
</tr>
<tr>
<td>Nominating Committee</td>
<td>08:00–09:00</td>
<td>158</td>
</tr>
<tr>
<td>EQATH</td>
<td>08:00–09:30</td>
<td>K</td>
</tr>
<tr>
<td>Predictive Variables Special Meeting</td>
<td>14:00–17:00</td>
<td>K</td>
</tr>
<tr>
<td>Outreach Forum Dinner</td>
<td>18:00–21:00</td>
<td>K</td>
</tr>
<tr>
<td>SSC Members Meeting</td>
<td>18:30–21:30</td>
<td>Kisen Room</td>
</tr>
</tbody>
</table>
## Other Meetings

### Sunday, July 24, 2011

- **EU VWD Meeting**
  - Room I
  - 12:00 – 14:00
- **WG on Coagulation Standards**
  - Room C-2
  - 12:30 – 14:30
- **RESIST-ITI and SIPPET Investigator Meeting**
  - Room C-1
  - 12:30 – 16:30
- **JTH Editorial Board Luncheon**
  - Room K
  - 13:00 – 14:00
- **Bleeding Score SSC Standing Committee**
  - Room K
  - 15:00 – 16:00
- **ISFP**
  - Room J
  - 15:00 – 17:30
- **WHO-ISTH Joint Standards Liaison Group**
  - Room 160
  - 15:30 – 17:00

### Monday, July 25, 2011

- **APSTH Council Board Meeting**
  - Room I
  - 12:00 – 13:00
- **Seminars in Thrombosis and Hemostasis**
  - Room I
  - 17:15 – 19:15

### Tuesday, July 26, 2011

- **Multicenter Hemophilia Study**
  - Room I
  - 7:30 – 09:00
- **EUHASS Meeting**
  - Room C-2
  - 11:45 – 13:15
- **GTC-Bio Investigator Meeting**
  - Room K
  - 12:00 – 13:30
- **Schattauer Editorial Board Meeting**
  - Room I
  - 16:30 – 19:00
- **ISTH Council**
  - Grand Prince Hotel Kyoto,
  - Room Kurama (council reception/dinner)
  - Room Hiei (council meeting)
  - 18:30 – 23:00
**Other Meetings**

**Wednesday, July 27**

**Industry Liaison Meeting**

Rose Room

7:30 – 9:30

ISTH General Membership Assembly

Main Hall

11:00 – 11:15

Haemophilia Board Meeting

Room I

12:00 – 14:00

ISFP-General Meeting

Room C-1

13:15 – 14:00

SSC Annual Business Meeting

Room E

14:30 – 17:00

Individual Subcommittee Chairman Meetings

TBA

TBA

Clinical Guidelines Committee

TBA

TBA
The International Society on Thrombosis & Haemostasis (ISTH) is the leading worldwide organization dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

ISTH is an international professional individual membership organization with over 3,000 members in more than 80 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and conferences, peer-reviewed publications and expert committees.

**Membership benefits include:**
- A network of over 3,000 members in more than 80 countries
- Priority registration and discounted fees for ISTH meetings and congresses
- Complimentary print (for regular members only) and online subscription to ISTH’s *Journal of Thrombosis and Haemostasis*
- Access to the ISTH members-only online resources, including educational materials, e-learning and membership directory
- Exclusive access and/or reduced fees for other educational activities, programs and publications
- The quarterly ISTH Newsletter and regular e-updates
- The right to nominate, elect and serve on ISTH committees

**ISTH Membership Categories are:**
- **Regular:** for active researchers, educators and clinicians in the field
- **Associate:** for students, trainees, research staff, post-doctoral fellows as well as allied health professionals
- **Reach-the-World:** for researchers, educators and clinicians in non-industrialized countries

For more information or to join the society, please contact:

International Society on Thrombosis & Haemostasis (ISTH)
Headquarters Office
610 Jones Ferry Road, Suite 205
Carrboro, NC 27510, USA
Tel: +1 919 929-3807
Fax: +1 919 929-3935
General Inquiries: headquarters@isth.org
Membership: membership@isth.org
Industry opportunities: margo_price@isth.org

or visit us at Booth # 5 in the Exhibition Area
www.isth.org
Benefits of membership in ISTH include:

- An international network of over 3,000 members in more than 80 countries
- Priority registration and discounted fees for ISTH meetings and congresses
- Complimentary print subscription for regular members and online subscription for all membership categories to ISTH's *Journal of Thrombosis and Haemostasis*
- Access to the ISTH members-only online resources, including educational materials, e-learning and membership directory
- Exclusive access and/or reduced fees for other educational activities, programs and publications
- The quarterly ISTH Newsletter and regular e-updates
- The right to nominate, elect and serve on ISTH committees

The International Society on Thrombosis and Haemostasis is the leading worldwide organization dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

ISTH provides a forum for discussion, encourages research and fosters the dissemination and exchange of ideas through scientific meetings and publications, education initiatives, research activities, expert committees and standardization of nomenclature and methods.
58th

Annual Meeting of the Scientific and Standardization Committee of the ISTH

LIVERPOOL
UNITED KINGDOM

EDUCATIONAL FORMAT
27-30 JUNE 2012

www.ssc2012.org
Program Overview
### Program at a Glance (Saturday, July 23, 2011)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 13:00</td>
<td>SSC Sessions, Educational Sessions, Nursing Forum</td>
</tr>
<tr>
<td>14:00 - 18:00</td>
<td>Special Symposia</td>
</tr>
</tbody>
</table>

### Sunday, July 24, 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 12:00</td>
<td>Symposia, Oral Communications</td>
</tr>
<tr>
<td>9:45 - 10:30</td>
<td>Plenary Lecture</td>
</tr>
<tr>
<td>10:00 - 11:00</td>
<td>Coffee Break / Booth Visit</td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>State-of-the-Art</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>Lunch / Poster Discussion</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Oral Communications</td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td>Coffee Break / Booth Visit</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>Oral Communications</td>
</tr>
</tbody>
</table>

### Monday, July 25, 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:30</td>
<td>Oral Communications</td>
</tr>
<tr>
<td>9:45 - 10:30</td>
<td>Plenary Lecture</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>Lunch / Poster Discussion</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Oral Communications</td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td>Coffee Break / Booth Visit</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>Oral Communications</td>
</tr>
<tr>
<td>17:15 - 18:00</td>
<td>Plenary Lecture</td>
</tr>
<tr>
<td>18:15 - 20:15</td>
<td>Special Symposia</td>
</tr>
</tbody>
</table>
July 23, 2011 ~ Thursday, July 28, 2011

**Tuesday**
*July 26, 2011*
- 8:00 - 9:30 Symposia
- 9:45 - 10:30 Plenary Lecture
- 10:30 - 11:00 Coffee Break / Booth Visit
- 11:00 - 12:00 State-of-the-Art
- 12:15 - 13:15 Lunch / Poster Discussion
- 13:30 - 15:00 Sympoisas
- 15:00 - 15:30 Coffee Break / Booth Visit
- 15:30 - 17:00 Symposia
- 17:15 - 18:00 Plenary Lecture
- 18:15 - 19:45 Satellite Symposia

**Wednesday**
*July 27, 2011*
- 8:00 - 9:30 Symposia
- 9:45 - 10:45 State-of-the-Art
- 10:45 - 11:15 Coffee Break / Booth Visit
- 11:15 - 12:15 Presidential Symposium
- 12:15 - 13:15 Lunch / Poster Discussion
- 13:30 - 14:00 Sympoisas
- 13:45 - 14:15 Oral Communications
- 14:15 - 15:45 Satellite Symposia
- 15:45 - 16:00 Coffee Break / Booth Visit
- 16:00 - 17:00 Technical Sessions
- 17:15 - 18:00 Plenary Lecture
- 18:00 - 20:30 All Congress Party

**Thursday**
*July 28, 2011*
- 8:00 - 9:30 Symposia
- 9:45 - 10:30 Plenary Lecture
- 10:30 - 11:00 Coffee Break / Booth Visit
- 11:00 - 12:00 State-of-the-Art
- 12:15 - 13:15 Lunch / Poster Discussion
- 13:30 - 14:00 Sympoisas
- 14:30 - 15:30 Oral Communications
- 14:30 - 16:00 Symposium
- 16:15 - 17:45 Oral Communications
- 16:30 - 17:15 Technical Sessions
- 17:15 - 18:00 Plenary Lecture
- 18:00 - 20:30 Meeting Adjourn
<table>
<thead>
<tr>
<th>Time</th>
<th>Room C-2</th>
<th>Room D</th>
<th>Room E</th>
<th>Annex Hall 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 10:00</td>
<td><strong>Predictive Variables in Cardiovascular Disease</strong></td>
<td>9:00 - 10:00</td>
<td>9:00 - 10:30</td>
<td><strong>Platelet Immunology</strong></td>
</tr>
<tr>
<td></td>
<td>Nursing Forum</td>
<td>10:00 - 13:00</td>
<td>10:00 - 13:00</td>
<td><strong>Platelet Immunology</strong></td>
</tr>
<tr>
<td>9:00 - 10:30</td>
<td><strong>Vascular Biology</strong></td>
<td>9:00 - 10:30</td>
<td>9:00 - 10:05</td>
<td></td>
</tr>
<tr>
<td>10:00 - 13:00</td>
<td>Predictive Variables in Cardiovascular Disease</td>
<td>10:30 - 13:00</td>
<td>10:05 - 13:00</td>
<td></td>
</tr>
<tr>
<td>14:00 - 18:00</td>
<td>Nursing Forum</td>
<td>14:00 - 15:05</td>
<td>14:00 - 18:00</td>
<td><strong>Animal, Cellular, and Molecular Models of Thrombosis</strong></td>
</tr>
<tr>
<td>14:00 - 15:05</td>
<td><strong>Factor XIII and Fibrinogen</strong></td>
<td>15:05 - 18:00</td>
<td>14:05 - 15:45</td>
<td><strong>Animal, Cellular, and Molecular Models of Thrombosis</strong></td>
</tr>
<tr>
<td>14:00 - 15:45</td>
<td><strong>Biorheology</strong></td>
<td></td>
<td>15:45 - 18:00</td>
<td></td>
</tr>
</tbody>
</table>
| * Coffee will be available from 10:30 to 11:00 and from 15:30 to 16:00, but coffee breaks will not be set. *
Saturday, July 23, 2011

**Sakura**

9:00 - 10:15  
Lupus Anticoagulant/Phospholipid-Dependent Antibodies

10:15 - 13:00  
Lupus Anticoagulant/Phospholipid-Dependent Antibodies

14:00 - 16:00  
Hemostasis and Malignancy

16:00 - 18:00  
Hemostasis and Malignancy

**Room A**

9:00 - 10:50  
Factor VIII and Factor IX

10:50 - 13:00  
Factor VIII and Factor IX

14:00 - 18:00  
Factor VIII and Factor IX

15:30 - 18:00  
Perinatal / Pediatric Hemostasis

16:00 - 18:00  
Perinatal / Pediatric Hemostasis

**Room B-1**

9:00 - 11:15  
Women’s Health Issue in Thrombosis and Hemostasis

11:15 - 13:00  
Women’s Health Issue in Thrombosis and Hemostasis

14:00 - 15:30  
Perinatal / Pediatric Hemostasis

15:30 - 18:00  
Perinatal / Pediatric Hemostasis

16:00 - 18:00  
Perinatal / Pediatric Hemostasis

**Room B-2**

9:00 - 10:15  
Lupus Anticoagulant/Phospholipid-Dependent Antibodies

10:15 - 13:00  
Lupus Anticoagulant/Phospholipid-Dependent Antibodies

14:00 - 16:00  
Plasma Coagulation Inhibitors

16:00 - 18:00  
Plasma Coagulation Inhibitors

**Nursing Forum**

**Educational Sessions**

**SSC Sessions**
Sunday, July 24, 2011

Main Hall

8:00 - 12:00
Nursing Forum

8:00 - 9:00
Fibrinolysis

9:00 - 12:00
Fibrinolysis

Room C-2

8:00 - 9:00
Factor XI and the Contact System

9:00 - 12:00
Factor XI and the Contact System

Room D

8:00 - 9:30
Fibrinolysis

9:30 - 12:00
Fibrinolysis

Room E

8:00 - 9:00
Factor XI and the Contact System

9:00 - 12:00
Factor XI and the Contact System

Annex Hall 1

12:30 - 14:30
** Antiplatelet Therapy: Improving the Care of Patients with Acute Coronary Syndromes through Evidence-based Approaches

15:00 - 17:00
** Prophylaxis: Current and Future Trends, Insights and Controversies

17:30 - 20:30
Opening Ceremony
Welcome Reception

17:30 - 18:30
Opening Ceremony Live

** Made possible by generous support from cooperate partners.

* Coffee will be available from 10:30 to 11:00, but coffee breaks will not be set.
<table>
<thead>
<tr>
<th>Time</th>
<th>Annex Hall 2</th>
<th>Sakura</th>
<th>Room A</th>
<th>Room B-1</th>
<th>Room B-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:30</td>
<td>Platelet Physiology</td>
<td></td>
<td></td>
<td></td>
<td>Registry of Exogenous Hemostatic Factors</td>
</tr>
<tr>
<td>9:30 - 12:00</td>
<td>Platelet Physiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 14:30</td>
<td><strong>Clinical Evaluation of Coagulation Factors with Prolonged Pharmacokinetic Activity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 17:00</td>
<td><strong>Toward Better Anticoagulation Management: Experience and Evidence with Enoxaparin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>Opening Ceremony Live</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 9:10</td>
<td>Disseminated Intravascular Coagulation</td>
<td>von Willebrand Factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:10 - 12:00</td>
<td>Disseminated Intravascular Coagulation</td>
<td>von Willebrand Factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 14:30</td>
<td><strong>Future Directions in the Prediction and Prevention of FVIII Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 17:00</td>
<td><strong>Bypass Therapy Prophylaxis for Inhibitor Management in Hemophilia A</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 9:20</td>
<td>von Willebrand Factor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:20 - 12:00</td>
<td>von Willebrand Factor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 12:00</td>
<td>Control of Anticoagulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 9:45</td>
<td>Registry of Exogenous Hemostatic Factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45 - 12:00</td>
<td>Registry of Exogenous Hemostatic Factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sessions**
- **SSC Sessions**
- **SSC & Educational Sessions**
- **Educational Sessions**
- **Nursing Forum**
- **Social Event**
- **Special Symposia**
<table>
<thead>
<tr>
<th>Time</th>
<th>Main Hall</th>
<th>Annex Hall 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:30</td>
<td>Hemorrhagic Disorders: Prediction of Inhibitor Development in Hemophilia</td>
<td>Platelet (Basic &amp; Clinical): Megakaryocytes and Thrombopoiesis</td>
</tr>
<tr>
<td>9:45 - 10:30</td>
<td>Plenary Lecture Live</td>
<td>Gene therapy for hemophilia: A long and winding road K.</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>COFFEE BREAK at Event Hall</td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>Thrombotic Disorders: Epidemiology</td>
<td>Platelet Biology</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LUNCH / POSTER DISCUSSION at Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Platelet (Basic &amp; Clinical): Emerging Antiplatelet Drugs</td>
<td>Innovation &amp; Technology: Innovative Imaging</td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>Thrombotic Disorders: Pharmacotherapy Update for Periferal Arterial Disease: From TASC II to TASC III</td>
<td>Platelet (Basic &amp; Clinical): Congenital Thrombocytopenia</td>
</tr>
<tr>
<td>17:15 - 18:00</td>
<td>Biological functions and therapeutics of vascular endothelial growth factors K. Alitalo</td>
<td>Plenary Lecture Live</td>
</tr>
</tbody>
</table>

** Made possible by generous support from cooperate partners.
Monday, July 25, 2011

**Annex Hall 2**

8:00 - 9:30
Coagulation Factors and Inhibitors: Contact Phase Activation

9:45 - 10:30
Plenary Lecture Live

12:15 - 13:15
LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 15:00
VWF/VWD and ADAMTS13: Structure and Function of ADAMTS13 and von Willebrand Factor

15:30 - 17:00
Hemorrhagic Disorders: FV/FVIII Synthesis and Regulation

18:15 - 20:15
** Factors for Life – Advances in Treatment of Congenital and Coagulopathic Bleeding Disorders

**Room A**

8:00 - 9:45
Late Breaking Clinical Trials

11:00 - 12:00
Coagulation and Inflammation

13:30 - 15:00
Malignancy and Thrombosis II

15:00 - 15:30
COFFEE BREAK at Event Hall

15:30 - 17:00
Malignancy and Thrombosis I

15:30 - 17:00
COFFEE BREAK at Event Hall
Monday, July 25, 2011

Room B-1

8:00 - 9:30
VTE: Risk Factors I

10:30 - 11:00
COFFEE BREAK at Event Hall

12:15 - 13:15
LUNCH / POSTER DISCUSSION at Exhibition Hall

Room B-2

8:00 - 9:30
Thrombotic Thrombocytopenic Purpura

13:30 - 15:00
VTE: Epidemiology

Room C-1

8:00 - 9:30
Platelet Signaling

13:30 - 15:00
Inflammatory Cells and Cytokines

Room C-2

8:00 - 9:30
Fibrinolysis

13:30 - 15:00
Structures of Coagulation Factors

15:00 - 15:30
COFFEE BREAK at Event Hall

15:30 - 17:00
Laboratory Tests for Coagulopathy

18:15 - 20:15
** Burdens on Anti-thrombotic Therapy ~ How Do You Select Anti-platelet Agents? ~

10:30 - 11:00
COFFEE BREAK at Event Hall

13:30 - 15:00
von Willebrand Disease

15:30 - 17:00
Thrombotic Disorders: Experimental Models

15:30 - 17:00
Platelet Receptors
### Monday, July 25, 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Room D</th>
<th>Room E</th>
<th>Sakura</th>
<th>Exhibition Hall</th>
<th>Event Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:30</td>
<td>Protein S and GAS6</td>
<td>Antiplatelet Therapy</td>
<td>Inherited Coagulation Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>COFFEE BREAK at Event Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Pathway of Coagulation Factor VIII</td>
<td>Megakaryopoiesis and Platelet Production</td>
<td>Hemophilia: Clinical Aspects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:15 - 20:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Special Symposia**

- **Protein S and GAS6**
- **Antiplatelet Therapy**
- **Inherited Coagulation Disorders**
- **Pathway of Coagulation Factor VIII**
- **Megakaryopoiesis and Platelet Production**
- **Hemophilia: Clinical Aspects**
- **Tissue Factor and Tissue Factor Pathway Inhibitor**
- **P2Y₁₂ Antagonists**
- **Acquired Coagulation Disorders**
- **Chronic Anticoagulation in AF: Optimization of Treatment**
- **Long-term Oral Anticoagulation: Debating the Future**

---

**Exhibition Hall**

- **Poster Set-up**
- **Poster Set-up**
- **Poster Dismantle**

---

**Event Hall**

- **COFFEE BREAK at Event Hall**
- **LUNCH / POSTER DISCUSSION at Exhibition Hall**
- **Poster Dismantle**
Tuesday, July 26, 2011

Main Hall

8:00 - 9:30
Platelet (Basic & Clinical): Immune Thrombocytopenia

9:45 - 10:30
Challenge to novel bioactive peptides K. Kangawa

11:00 - 12:00
von Willebrand Factor and von Willebrand Disease

12:15 - 13:15
LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 15:00
Thrombotic Disorders: Acute Cerebrovascular Syndrome

15:30 - 17:00
Recent progress in anticoagulant therapy: Oral direct inhibitors of thrombin and factor X K. Bauer

Annex Hall 1

8:00 - 9:30
VWF/VWD and ADAMTS13: Pathogenesis of Thrombotic Microangiopathy

9:45 - 10:30
Plenary Lecture Live

11:00 - 12:00
APSTH-Genome: Genomes in Asian and Caucasian

15:30 - 17:00
Platelet (Basic & Clinical): Platelet Proteomics and Gene Expression

17:15 - 18:00
Plenary Lecture Live

18:15 - 19:45
Join the Revolution: Advances in Oral Anticoagulation (Boehringer Ingelheim)
<table>
<thead>
<tr>
<th>Time</th>
<th>Annex Hall 2</th>
<th>Room A</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:30</td>
<td>Vascular Biology: Inflammation and Atherothrombosis</td>
<td>Pregnancy and Thrombosis I</td>
</tr>
<tr>
<td>9:45 - 10:30</td>
<td>Plenary Lecture Live</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>COFFEE BREAK at Event Hall</td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>Vascular biology</td>
<td>Cancer thrombosis</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LUNCH / POSTER DISCUSSION at Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Platelet (Basic &amp; Clinical): Lysophospholipids in Platelets and Vasculature</td>
<td>Anticoagulation Therapy</td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td>COFFEE BREAK at Event Hall</td>
<td></td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>Fibrinolysis and Proteolysis: t-PA Mediated Brain Injury</td>
<td>Thrombotic Disorders: Clinical Trials I</td>
</tr>
<tr>
<td>17:15 - 18:00</td>
<td>Plenary Lecture Live</td>
<td></td>
</tr>
<tr>
<td>18:15 - 19:45</td>
<td>Progress in Haemophilia Care: New Molecules on the Horizon (Novo Nordisk)</td>
<td></td>
</tr>
</tbody>
</table>
Tuesday, July 26, 2011

Room B-1
8:00 - 9:30
VTE: Basic

Room B-2
8:00 - 9:30
Hemostatic Abnormalities in Thrombosis

Room C-1
8:00 - 9:30
Integrin αIIbβ3

Room C-2
8:00 - 9:30
Fibrinogen and Other Factors I

10:30 - 11:00
COFFEE BREAK at Event Hall

12:15 - 13:15
LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 15:00
- Diagnosis and Treatment for VWD and TTP
- Antiphospholipid Syndrome: Basic
- Progenitor Cells and Stem Cells
- Serine Protease Inhibitors I

15:00 - 15:30
COFFEE BREAK at Event Hall

15:30 - 17:00
- VTE: Laboratory Tests I
- ADAMTS13
- Platelets: Experimental Models
- Plasminogen Activation System: Basic

18:15 - 19:45
Atypical Hemolytic Uremic Syndrome (aHUS): New Insights and Emerging Treatment Options (Alexion Pharmaceuticals)
Tuesday, July 26, 2011

8:00 - 9:30
Regulators of Coagulation
Room D

8:00 - 9:30
Heparin-induced Thrombocytopenia
Room E

8:00 - 9:30
Hemophilia: Treatment
Sakura

8:00 - 9:30
Heparin-induced Thrombocytopenia
Room E

13:30 - 15:00
Coagulation Factors: Experimental Models I
Room D

13:30 - 15:00
Immune Thrombocytopenia
Room E

13:30 - 15:00
Hemophilia: Innovative Therapy I
Sakura

15:30 - 17:00
Tissue Factor and Factor VII
Room D

15:30 - 17:00
Endothelial Cells
Room E

15:30 - 17:00
Hemophilia: Inhibitor Development
Sakura

18:15 - 19:45
Chronic Anticoagulation in Prevention and Treatment of VTE
Event Hall (Daiichi Sankyo)

18:15 - 19:45
Can We Predict Interventions in Haemostasis and Thrombosis? (Stago)

10:30 - 11:00
COFFEE BREAK at Event Hall

11:00 - 15:00
Exhibition

12:15 - 13:15
LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 15:00
Hemophilia: Innovative Therapy I
Sakura

15:00 - 15:30
COFFEE BREAK at Event Hall

15:30 - 18:00
Exhibition

17:00 - 18:30
Poster Dismantle

Oral Communication
Technical Sessions
Satellite Symposia
Wednesday, July 27, 2011

Main Hall

8:00 - 9:30  
**Thrombotic Disorders: Venous Thromboembolism Prophylaxis**

9:45 - 10:45  
**Atherothrombosis**

11:00 - 11:15  
ISTH General Membership Assembly

11:15 - 12:45  
**Historical Perspective and Future Direction in Platelet, Coagulation, and Fibrinolysis Research**

Annex Hall 1

8:00 - 9:30  
**Platelet (Basic & Clinical): Platelets beyond Hemostasis**

9:45 - 10:45  
**Platelet activation**

11:15 - 12:45  
**Presidential Symposium Live**

13:00 - 14:00  
**LUNCH / POSTER DISCUSSION at Exhibition Hall**

18:00 - 20:30  
**All Congress Party at the Grand Prince Hotel**
Wednesday, July 27, 2011

**Annex Hall 2**

- **8:00 - 9:30**
  - Coagulation Factors and Inhibitors: Coagulation Initiation and Amplification

**Room A**

- **8:00 - 9:30**
  - Antiphospholipid Syndrome: Clinical

- **9:45 - 10:45**
  - Genetics in Thrombosis

- **9:45 - 10:45**
  - Hemorrhagic and Thrombotic Disorders in Women

- **10:45 - 11:15**
  - COFFEE BREAK at Event Hall

- **11:15 - 12:45**
  - Presidential Symposium Live

- **13:00 - 14:00**
  - LUNCH / POSTER DISCUSSION at Exhibition Hall

- **18:00 - 20:30**
  - All Congress Party at the Grand Prince Hotel
Wednesday, July 27, 2011

Room B-1
8:00 - 9:30
Microparticles

Room B-2
8:00 - 9:30
Plasminogen Activation System: Tissue Remodeling

Room C-1
8:00 - 9:30
Innovation and Technology

Room C-2
8:00 - 9:30
Fibrinogen and Other Factors II

10:45 - 11:15
COFFEE BREAK at Event Hall

13:00 - 14:00
LUNCH / POSTER DISCUSSION at Exhibition Hall

14:15 - 15:45
Development of New Anticoagulant Drugs! Are Unmet Needs Met? (Loyola University)

16:00 - 17:00
Prevention of Stroke—What Can We Learn from the Recent Clinical Trials? (Pfizer Japan)

18:00 - 20:30
All Congress Party at the Grand Prince Hotel
Wednesday, July 27, 2011

Room D
8:00 - 9:30
Coagulation Factors: Experimental Models II

Room E
8:00 - 9:30
Atherosclerosis and Atherothrombosis

Sakura
8:00 - 9:30
Hemophilia: Inhibitor Treatment

Exhibition Hall
9:00 - 10:00
Poster Set-up

Event Hall
9:25 - 14:00

10:45 - 11:15
COFFEE BREAK at Event Hall

13:00 - 14:00
LUNCH / POSTER DISCUSSION at Exhibition Hall

14:15 - 15:45
Challenges in VTE Management in East and West (GlaxoSmithKline)

14:15 - 15:45
Managing Haemophilia for Life: Treatment Trends in Haemophilia B (Pfizer)

14:30 - 17:00
SSC Annual Business Meeting

16:00 - 17:00
Inhibitors of Factor VIII: Use of a Recombinant Porcine FVIII as a Future Treatment Option (Inspiration Biopharmaceuticals)

18:00 - 20:30
All Congress Party at the Grand Prince Hotel
<table>
<thead>
<tr>
<th>Time</th>
<th>Main Hall</th>
<th>Annex Hall 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:30</td>
<td>Thrombotic Disorders: Pathogenesis, Diagnosis and Treatment of Septic DIC</td>
<td>Platelet (Basic &amp; Clinical): Mechanisms of Platelet Adhesive Function</td>
</tr>
<tr>
<td>9:45 - 10:30</td>
<td>Molecular Mechanism of Inside-out Integrin Regulation M. H. Ginsberg</td>
<td>9:45 - 10:30 Plenary Lecture Live</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>COFFEE BREAK at Event Hall</td>
<td></td>
</tr>
<tr>
<td>11:00 - 12:00</td>
<td>Hemophilia</td>
<td>11:00 - 12:00 Platelet and Vascular Wall</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>LUNCH / POSTER DISCUSSION at Exhibition Hall</td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:15</td>
<td>Serpin structure, function and dysfunction J. A. Huntington</td>
<td>13:30 - 14:15 Plenary Lecture Live</td>
</tr>
<tr>
<td>14:30 - 16:00</td>
<td>VWF/VWD and ADAMTS13: Function and Dysfunction of von Willebrand Factor</td>
<td>14:30 - 16:00 Hemorrhagic Disorders: Molecular Mechanisms of Coagulation Disorders</td>
</tr>
<tr>
<td>16:15 - 17:45</td>
<td>Coagulation Factors and Inhibitors: Protein C System</td>
<td>16:15 - 17:45 Fibrinolysis and Proteolysis: Plasminogen Activation and Its Modulation</td>
</tr>
</tbody>
</table>
Thursday, July 28, 2011

Annex Hall 2

8:00 - 9:30
Coagulation Factors and Inhibitors: Structural Biology in Thrombosis

9:45 - 10:30
Plenary Lecture Live

11:00 - 12:00
Congenital and Acquired Thrombotic Disorders

12:15 - 13:15
LUNCH / POSTER DISCUSSION at Exhibition Hall

13:30 - 14:15
Plenary Lecture Live

14:30 - 16:00
Thrombotic Disorders: Clinical II

16:15 - 17:45
Late Breaking Clinical Research

Room A

8:00 - 9:30
Thrombotic Disorders: Clinical Trials II

10:30 - 11:00
COFFEE BREAK at Event Hall

11:00 - 12:00
Coagulation Activation

14:30 - 16:00
Vascular Biology: Angiogenesis and Vasculogenesis

16:15 - 17:45
VTE: Risk Factors III
Thursday, July 28, 2011

Room B-1
8:00 - 9:30
VTE: Laboratory Tests II

Room B-2
8:00 - 9:30
von Willebrand Factor

Room C-1
8:00 - 9:30
Inherited Platelet Disorders

Room C-2
8:00 - 9:30
Serine Protease Inhibitors II

10:30 - 11:00
COFFEE BREAK at Event Hall

12:15 - 13:15
LUNCH / POSTER DISCUSSION at Exhibition Hall

Room C-1
14:30 - 16:00
Platelet Signaling

Room C-2
14:30 - 16:00
Platelet Granules

16:15 - 17:45
Thrombin Generation Test

Room B-1
14:30 - 16:00
Contact Phase Activation

16:15 - 17:45
Thrombotic Disorders: Genetic Determinations and Epidemiology

Room B-2
16:15 - 17:45
Thromboprophylaxis in Children
Thursday, July 28, 2011

Room D
8:00 - 9:30
Coagulation Factors I

Room E
8:00 - 9:30
Platelets as Drug Targets

Sakura
8:00 - 9:30
Hemophilia: Pathophysiology

Exhibition Hall
9:00 - 10:30
Poster Set-up

Event Hall
9:30 - 10:30

10:30 - 11:00
COFFEE BREAK at Event Hall

12:15 - 13:15
LUNCH / POSTER DISCUSSION at Exhibition Hall

Exhibition Hall
8:00 - 9:30
Coagulation Factors I
14:30 - 16:00
Protein C
16:15 - 17:45
Coagulation Factors II

Event Hall
8:00 - 9:30
Platelets as Drug Targets
14:30 - 16:00
Laboratory Tests in Platelet Function
16:15 - 17:45
Angiogenesis and Lymphangiogenesis

Event Hall
8:00 - 9:30
Hemophilia: Pathophysiology
14:30 - 16:00
Hemophilia: Clinical Study
16:15 - 17:45
Hemophilia: Innovative Therapy II

17:00 - 17:45
Poster Dismantle

Oral Communication
SSC SH
57th Annual Meeting of the Scientific and Standardization Committee and Educational Program

The SSC Annual Meeting will be held on Saturday July 23 from 9:00 - 18:00 and on Sunday July 24 from 8:00 - 12:00.

Education Sessions, sponsored jointly by the Congress and the SSC, will be a part of individual SSC scientific subcommittee sessions, and will supplement topics not addressed in the main ISTH program. Speakers will provide attendees with an introduction to, and fundamentals of, a given subject.

Coffee Breaks
Coffee will be served near the SSC Meeting Rooms. It will be possible to purchase coffee at the main lounge of the ICC Kyoto.

Name Badges
Name Badges are not required at SSC and Educational Session.

SSC Speakers Preview Room
SSC and Education Session Speakers are asked to bring their formatted PowerPoint presentations to the Speaker's Preview Room (Room 104) at least two hours before their session. Files from key drives or CD-ROMs can be transferred to the Congress servers at that time. All conference rooms contain state-of-the-art technical equipment.

Speaker Preview Room Hours:
Friday, July 22, 2011  15:00 - 18:00
Saturday, July 23, 2011  07:30 - 19:00
Sunday, July 24, 2011  07:30 - 19:00

Scientific and Standardization Committee
See page XXX for committee list. (No.12-page)
Message from the SSC Chairman

Dear Colleagues and Friends,

Welcome to Kyoto to the 57th Annual SSC meeting!

As the Chairman of the SSC, it is my honor to invite you to participate in the SSC Subcommittee meetings on Saturday July 23rd and Sunday July 24th. This is important because, although our understanding of the mechanisms of hemostasis and its disorders has reached significant levels, however, new challenges are constantly emerging and new tools and standards are necessary for measuring and calibrate the hemostatic process. The continuous commitment of the SSC and its components is to respond quickly to these challenges, and to render a useful service to the entire scientific community. The main goals of SSC, among the broad spectrum of activities, are to constantly improve our ability to diagnose more precociously and treat more accurately the various disorders of hemostasis, and to this purpose, to prepare simple risk models, to evaluate the reliability and relevance of new laboratory tests, to improve the quality of reagents, to carefully evaluate the new anti-thrombotic and anti-hemorrhagic strategies, to understand the real impact of some rare clinical conditions, to go deeper into pathogenetic mechanisms up to the level of individual genetic mutations.

As started in 2009 in Boston, the scientific programs of the SSC subcommittees will begin with an Educational Session, followed by the update of the ongoing scientific activities and the proposal of new ones. The Educational sessions will give an overview and information on the recent advances in each specific field, and also will better frame the work of the subcommittees. This is of particular value to the younger colleagues that face these topics for the first time.

This year program looks very exciting, and indeed all chairs and co-chairs of SSC made a great work in assembling their part of the program. Therefore, I’m confident that all of you will enjoy the SSC meetings, and that all this will be the perfect introduction to a great XXIII ISTH congress!

With all my best wishes for a successful meeting.

Anna Falanga, M.D.
Chairman
Scientific and Standardization Committees of the ISTH
Saturday, 23 July, 2011

**Factor VIII and IX**

*Chairperson: Flora Peyvandi (IT)*

*Co-Chairpersons: C. Alok Srivastava (IN); Jan Astermark (SE); Kathelijn Fischer (NL); Charles Hay (UK); Claude Negrier (FR); Johannes Oldenburg (DE); Midori Shima (JP); Edward Tuddenham (UK); Leonard Valentino (US)*

---

**Educational Session** 9:00 – 10:50  Room A

**Welcome and introduction to the program**  
*Flora Peyvandi (IT) and Alok Srivastava (IN)*  
9:00 – 9:20

**New Era of Treatment in Hemophilia**  
*Chairpersons: Claude Negrier (FR) and Kathelijn Fischer (NL)*

**New products for treatment of haemophilia- changing options**  
*Jerry Powell (US)*  
9:20 – 9:40

**Evaluation of safety and efficacy of new products (clinical and laboratory problems)**  
*Elena Santagostino (IT)*  
9:40 – 10:00

**FDA and EMEA regulators: Clinical trials requirements**  
- *FDA – Nisha Jain (US)*  
- *EMEA – Anneliese Hilger (DE)*  
10:00 – 10:30

**General discussion**  
10:30 – 10:40

**Break**  
10:40 – 10:50

---

**SSC Session** 10:50 – 13:00  Room A

**Rare Bleeding Disorders (RBDs)**  
*Chairpersons: Flora Peyvandi (IT) and Alok Srivastava (IN)*

**European network on RBDs (EN-RBD): What has been obtained and next steps**  
*Flora Peyvandi (IT)*  
10:50 – 11:05

**Nijmegen thrombin and plasmin generation assay in RBDs**  
*Mark van Geffen (NL)*  
11:05 – 11:15
Saturday, 23 July, 2011

Clinical trials in RBDs: 11:15 – 11:55

- Clinical development plan of a double-virus inactivated fibrinogen concentrate in patients with hereditary fibrinogen deficiency – EU and US requirements
  Sigurd Knaub, Octapharma (CH)
- Congenital FXIII deficiency, clinical and regulatory challenges
  Ramin Tehranchi, Novonordisk (SE)
- Challenges in clinical development of novel coagulation factors
  Charmaine Gittleson, CSL Behring (AU)
- Ligneous conjunctivitis and plasminogen deficiency: An experience of an orphan drug development for an extremely rare disease
  Bruno Fiorentino, Kedrion (IT)

General discussion 11:55 – 12:05

Project Reports - 1
Chairpersons: Edward Tuddenham (UK) and Midori Shima (JP)

Report of project on thrombin generation – standardization of the method
Claude Negrier (FR) 12:05 – 12:20

Report of TEG/ROTEM project – future strategies
Meera Chitlur (US) 12:20 – 12:35

Report of project on clot wave form analysis: Application to currently available clot detection instruments
Midori Shima (JP) 12:35 – 12:50

General discussion 12:50 – 13:00
**Lupus Anticoagulant / Phospholipid-Dependent Antibodies**

*Chairperson: Thomas L. Ortel (US)*

*Co-Chairpersons: Tatsuya Atsumi (JP); Ph de Groot (NL); Bas de Laat (NL); Vittorio Pengo (IT); Jacob Rand (US); Guido Reber (CH); Armando Tripodi (IT)*

---

### Educational Session 9:00 – 10:15 Room Sakura

**Antiphospholipid antibody testing in the real world of the diagnostic pathology laboratory**
Emmanuel Favaloro (AU)  
9:00 – 9:25

**How should we diagnose/classify APS?**
Tatsuya Atsumi (JP)  
9:25 – 9:50

**Catastrophic APS**
Thomas L. Ortel (US)  
9:50 – 10:15

---

### SSC Session 10:15 – 13:00 Room Sakura

**Lupus Anticoagulant Testing**

**Compliance with the lupus anticoagulant SSC guidelines.**
Ian Jennings (UK)  
10:15 – 10:35

**ECAT Data: Compliance with the lupus anticoagulant SSC guidelines.**
Piet Meijer (NL)  
10:35 – 10:55

**Integrated test systems and the role of mixing studies.**
Katrien Devreese (BE)  
10:55 – 11:15

**CLSI report on lupus anticoagulant testing.**
Thomas L. Ortel (US)  
11:15 – 11:30

**Anticardiolipin and Anti-β₂-glycoprotein I Antibody Standards**

**Anticardiolipin antibody standards.**
Silvia Pierangeli (US)  
11:30 – 11:55

**Anti-β₂-glycoprotein I antibody standards.**
Bas de Laat (NL)  
11:55 – 12:20
Saturday, 23 July, 2011

Diagnostic Strategies for APS

Antiphospholipid score
Kotaro Otomo (JP) 12:20 – 12:45

Updates

Antibodies to domain I of $\beta_2$-glycoprotein I
Bas de Laat (NL) 12:45 – 13:00
Platelet Immunology

Chairperson: Andreas Greinacher (DE)
Co-Chairpersons: Beng Chong (AU); Yves Gruel (FR); Donald Arnold (CA); Hartmut Kroll (DE); Yoshiaki Tomiyama (JP)

Educational Session 9:00 – 10:05  Annex Hall 2

Welcome
A. Greinacher (DE) 9:00 – 9:05
Chairpersons: Yoshiaki Tomiyama (JP) and Andreas Greinacher (DE)

Animal models for immune thrombocytopenia
John Semple (CA) 9:05 – 9:35

Mechanisms of IVIgG in immune thrombocytopenia lessons learned from in-vitro studies and animal studies
Alan Lazarus (CA) 9:35 – 10:05

SSC Session 10:05 – 13:00  Annex Hall 2

Autoimmune and Alloimmune Thrombocytopenia
Chairperson: Beng Chong (AU)

Role of complement in the pathomechanism of ITP
Ulrich Sachs (DE) 10:05 – 10:20

Platelet immunology SSC statement on the antibody testing in trials on immune thrombocytopenia (ITP)
Andreas Greinacher (DE) 10:20 – 10:35

Predictive parameters for the fetal status in anti-HPA-1a managed pregnancies
Gerard Bertrand, Cecile Kaplan (FR) 10:35 – 10:50

Break 10:50 – 11:00

Heparin-induced Thrombocytopenia
Chairpersons: Yves Gruel (FR) and Theodore Warkentin (CA)

IL10 gene polymorphisms and the risk of HIT
Yves Gruel (FR) 11:00 – 11:15

Evaluation of the platelet microparticle assay for the diagnosis of HIT
Francois Mullier (BE) 11:15 – 11:30
Saturday, 23 July, 2011

Which "gold standard" for the diagnosis of HIT: A clinical score, an expert opinion or SRA?
Brigitte Tardy (FR) 11:30 – 11:45

Heterogeneity of the heparin dependent antigen in some atypical patients with clinically characterized HIT, and incidence in immunoassay reactivity
Jean Amiral (FR) 11:40 – 12:00

Whole blood aggregometry using the Multiplate analyzer for the diagnosis of HIT
Marie-Christine Morel-Kopp (AU) 12:00 – 12:15

Multiplate and HIT: Opportunities and limits
Ismail Elalamy (FR) 12:15 – 12:30

Interassay variability of the high heparin step
Andreas Greinacher (DE) 12:30 – 12:40

Standardization of quality control of functional HIT assays
Theodore Warkentin, Jane C. Moore (CA) 12:40 – 12:55

Concluding remarks
Andreas Greinacher (DE) 12:55 – 13:00
Predictive Variables in Cardiovascular Disease

Chairperson: James Douketis (CA)
Co-Chairpersons: Gordon Lowe (UK); Karel Moons (NL); Frederick Spencer (CA); Alberto Tosetto (IT); Richard White (US)

Educational Session 9:00 – 10:00 Room D

CV and Thrombotic Disease Around the World
Co-Chairpersons: James Douketis (CA) and Richard White (US)

VTE and race/ethnicity: Linked database studies
Richard White (US) 9:00 – 9:15

VTE and race/ethnicity: Observational cohort studies
Neil Zakai (US) 9:15 – 9:30

CVD in Asians
Shinya Goto (JP) 9:30 – 9:45

Panel discussion 9:45 – 10:00

SSC Session 10:00 – 13:00 Room D

Update of SSC-related Activities

Predictors of arterial disease
Olivia Wu (UK) 10:00 – 10:15

Epidemiology of D-dimer in venous/arterial disease
Mary Cushman (US) 10:15 – 10:30

D-dimer to predict stroke risk in atrial fibrillation
John Eikelboom (CA) 10:30 – 10:45

Panel discussion 10:45 – 11:00

Break 11:00 – 11:20

New studies (predicting recurrent VTE) – VISTA
Geert-Jan Geersing (NL) 11:20 – 11:32

New studies (predicting recurrent VTE) – REVERSE-2
Marc Rodger (CA) 11:32 – 11:44

New studies (predicting recurrent VTE) – MORGAGNI
James Douketis (CA) 11:44 – 11:56
Saturday, 23 July, 2011

Panel discussion 11:56 – 12:10

Debate: Thrombophilia testing should be done routinely in patients with idiopathic first VTE: Yes
Mary Cushman (US) 12:10 – 12:30

Debate: Thrombophilia testing should be done routinely in patients with idiopathic first VTE: No
Richard White (US) 12:30 – 12:50

Rebuttals and adjournment 12:50 – 13:00
Vascular Biology

Chairperson: Françoise Dignat George (FR)
Co-Chairpersons: Michael Berndt (IE); John Griffin (US); Nigel Key (US); Peter Newman (US); Florence Toti (FR)

Educational Session 9:00 – 10:30 Room E

Microparticles: Generation and Function

Cellular mechanisms underlying the formation of circulating microparticles.
Florence Toti (FR) 9:00 – 9:25

Multifaceted endothelial derived microparticles.
Françoise Dignat-George (FR) 9:25 – 9:50

Microvesicles in cancer
Janus Rak (CA) 9:50 – 10:15

Break 10:15 – 10:30

SSC Session 10:30 – 13:00 Room E

Determination and Characterization of (Circulating) Microparticles

Part A : Standardized Strategies 10:30 – 11:00

– Results from the multicentric study on standardization of preanalytical variables
Nigel Key (US); On behalf of the ISTH SSC Workshop participating groups

– Standardized microparticle enumeration using latest generation of flow cytometers.
R Lacroix (FR)

Part B : Functional Assays 11:00 – 11:30

– Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability
Alisa Wolberg (US)

– A novel assay for measuring plasmin generation capacity of microparticles.
Philippe Poncelet (FR)
Saturday, 23 July, 2011

Break  
11:30 – 11:45

Part C : Novel Methodologies  
11:45 – 13:00

- An update on the ISADE technique  
  Don Gabriel (US)

- Novel methods to detect microparticles  
  Edwin van der Pol (NL)

- Update on nanoparticle tracking analysis.  
  Chris Gardiner (UK)

- Towards the use of microfluidics in combination with atomic force microscopy for the direct detection and quantification of microparticles from blood plasma.  
  Yuana Yuana (NL)

  François Mullier (BE)
Saturday, 23 July, 2011

Women’s Health Issues in Thrombosis and Haemostasis

Chairperson: Sabine Eichinger (AT)
Co-Chairpersons: Benjamin Brenner (IL); Jacqueline Conard (FR); Andra James (US); Takao Kobayashi (JP); Barbara Konkle (US); Peter Kouides (US); Claire McLintock (NZ); Claire Philipp (US)

Educational Session 9:00 – 11:15 Room B-1

Welcome and Introduction of Co-Chairpersons
Sabine Eichinger (AT)  9:00 – 9:05
Chairperson: Sabine Eichinger (AT)

Management of thrombocytopenia during pregnancy
Andra James (US)

Diagnosis of VTE during pregnancy
Menno V. Huisman (NL)

Management of obstetric haemorrhage
Claire McLintock (NZ)

Education Activities
10:20 – 10:30
Chairperson: Sabine Eichinger (AT)

Menorrhagia Working Group
10:30 – 11:00
Chairperson: Claire Philipp (US)

Standardized bleeding scores
Claire Philipp (US)

US prospective data collection of women with bleeding disorders...prospects for harmonizing data worldwide"
Roshni Kulkarni (US)

Menorrhagia management from the Canadian perspective
Rochelle Winikoff (CA)

Update on prenatal diagnosis of haemophilia
Rezan Kadir (UK)

Break
11:00 – 11:15
### Symposium in Honour of Margareta Blombäck

**Chairperson:** Jacqueline Conard (FR)

11:15 – 12:15

**“Something should be done”: A SSC working group on women’s health.**

**Hormonal influences on the coagulation system**  
Jacqueline Conard (FR)

**An attenuated fibrinolytic profile measured with a global assay haemostasis assay is associated with risk of a first myocardial infarction in the different gender populations**  
Margareta Blombäck (SE)

**Fibrinogen deficiency in pregnancy**  
Takao Kobayashi (JP)

### SSC Projects

**Chairperson:** Sabine Eichinger (AT)

12:15 – 12:55

**Prospective study using VQ scan in pregnant women with a suspected acute pulmonary embolism**  
Menno V. Huisman (NL)

**CT scan for suspected PE in pregnancy – the PEP study** –  
Menno V. Huisman (NL)

**Development of a clinical decision rule for suspected PE in pregnant patients**  
Menno V. Huisman (NL)

**Heparanase procoagulant activity in oral contraceptives users and pregnancy**  
Yona Nadir (IL)

**Highlow study - optimal dose of LMWH prophylaxis in pregnancy and postpartum period**  
Saskia Middeldorp (NL)

**Update on Registries**  
Andra James (US)

### Closing Remarks

**Chairperson and Co-Chairpersons**

12:55 – 13:00
Animal, Cellular, and Molecular Models of Thrombosis

Chairperson: Timothy Charles Nichols (US)

Co-Chairpersons: Edward M. Conway (CA); Shaun R. Coughlin (US); Jay L. Degen (US); Cecile Denis (FR); Nigel Mackman (US); Toshiyuki Miyata (JP); Eva-Maria Muchitsch (AT); Susan S. Smyth (US); Hugo ten Cate (NL); Hartmut Weiler (US)

Participants: Tom Knudsen, Fumiaki Banno, Jianglin Fan, David Motto

---

Educational Session 14:05 – 15:45  
Annex Hall 2

Chairpersons: Cecile Denis (FR) and Timothy C. Nichols (US)

Rapid in vivo evaluation of haemostatic agents using hydrodynamic injection  
Cecil Denis (FR) 14:05 – 14:30

Models of vascular inflammation  
Susan Smyth (US) 14:30 – 14:55

Scanning electron microscopy studies of endothelial injury and thrombus formation in mouse models of thrombosis  
David Motto (US) 14:55 – 15:15

Break  
15:15 – 15:45

---

SSC Session 15:45 – 18:00  
Annex Hall 2

Focused Talks

Chairpersons: Hartmut Weiler and Timothy C. Nichols (US)

Characterization of canine coagulation factor VII and its complex formation with tissue factor: Canine–human cross-species compatibility  
Tom Knudsen (DK) 15:45 – 16:00

Mouse models of FVIII immunogenicity  
David Lillicrap (CA) 16:00 – 16:15

Measurement of a procoagulant state in mice  
Nigel Mackman (US) 16:15 – 16:30

Thrombin and atherosclerosis: Effects on plaque morphology  
Hugo ten Cate (NL) 16:30 – 16:45
Saturday, 23 July, 2011

Genetic mouse models for evaluating pathophysiological roles of ADAMTS13
Fumiaki Banno (JP) 16:45 – 17:00

Development of a mouse model of TTP for preclinical efficacy testing of rADAMT S13
Eva-Maria Muchitsch (AT) 17:00 – 17:15

Transgenic rabbit models for the study of atherosclerosis
Jianglin Fang (JP) 17:15 – 17:30

In vivo function of human aPC in mouse models of thrombosis and inflammation
Hartmut Weiler (US) 17:30 – 17:45

Animal models committee business meeting
Timothy C. Nichols (US) 17:45 – 18:00
Biorheology

Chairperson: Michael R. King (US)
Co-Chairpersons: Lawrence Brass (US); Thomas Diacovo (US); Johan Heemskerk (NL); Shaun Jackson (AU); Armin Reininger (DE); J. Zwaginga (NL)

SSC Session 14:00 – 18:00 Room E

Welcome and Opening Comments
Michael King (US) 14:00 – 14:10

In Vitro Thrombosis Assays and Standardization
Chairpersons: T. Diacovo and M. King (US)

Standardization of the use of flow devices to measure thrombus formation
Judith Cosemans (NL) 14:10 – 14:30

Clinical evaluation of microfluidic flow assays
Keith Neeves (US) 14:30 – 14:50

Development of an in vitro model of occlusive thrombus formation
Owen McCarty (US) 14:50 – 15:10

Perfusion chamber with static mixer: New possibilities to study the interplay between platelets and coagulation under conditions of flow
Attie Tuinenburg (NL) 15:10 – 15:30

Questionnaires and literature review on mouse models and genes in arterial thrombus formation in vivo and in vitro
Johan Heemskerk (NL) and Peter Lenting (FR) 15:30 – 15:50

Break 15:50 – 16:00

In Vivo Thrombosis Models
Chairpersons: K. Neeves (US) and J. Heemskerk (NL)

New approaches to investigate biomechanical platelet activation
Shaun Jackson (AU) 16:00 – 16:20

Using intravital confocal fluorescence microscopy to probe the microheterogeneity and permeability of the platelet response to laser and mechanical injury
Lawrence Brass (US) 16:20 – 16:40
The utility of a humanized mouse system for multiscale analysis of thrombus growth, platelet convection, and drug efficacy
Tom Diacovo (US) and Michael King (US) 16:40 – 17:00

Disturbed blood flow induces plaque erosion and thrombus formation
Atsushi Yamashita (JP) 17:00 – 17:20

In vivo imaging of cerebral circulation in mouse models of polycythemia vera and essential thrombocythemia
William Olbricht (US) 17:20 – 18:00
Factor VIII and IX

Chairperson: Flora Peyvandi (IT)
Co-Chairpersons: C. Alok Srivastava (IN); Jan Astermark (SE); Kathelijn Fischer (NL); Charles Hay (UK); Claude Negrier (FR); Johannes Oldenburg (DE); Midori Shima (JP); Edward Tuddenham (UK); Leonard Valentino (US)

SSC Session 14:00 – 18:00 Room A

Clinical Issues (Inhibitors, Prophylaxis, Novel Therapies)
Chairpersons: Kathelijn Fischer (NL) and Charles Hay (UK)

Considerations for optimal clinical trial design for new clotting factor concentrates
Donna DiMichele (US) 14:00 – 14:15

ITI study: Results
Donna DiMichele (US) or Charles Hay (UK) 14:15 – 14:30

Prophylaxis in patients with inhibitor
Manuel Carcao (CA) or Claude Negrier (FR) 14:30 – 14:45

On going clinical studies on inhibitor development:
  – SIPPET
    Pier Mannuccio Mannucci (IT)
  – RODIN (intensity of treatment and prophylaxis)
    Marijke van den Berg (NL)

European haemophilia safety surveillance system (EUHASS): Update
Mike Makris (UK) 15:05 – 15:20

General discussion
15:20 – 15:30

Break
15:30 – 15:40

Project Reports - 2
Chairpersons: Flora Peyvandi (IT) and Alok Srivastava (IN)

Report of project on RBDs – Update
Paula Bolton-Maggs (UK) 15:40 – 15:55

Report of project on definitions in hemophilia
Victor Blanchette (CA) and Alok Srivastava (IN) 15:55 – 16:10

Report of project on potency labelling of clotting factor concentrates
Anthony Hubbard (UK) 16:10 – 16:25
Saturday, 23 July, 2011

Report of project on PK of FVIII/FIX
Sven Bjorkman (SE) 16:25 – 16:40

General discussion 16:40 – 16:50

**Standardization Issues**
Chairpersons: Leonard Valentino (US) and Johannes Oldenburg (DE)

Monitoring recombinant FVIII concentrates and role of ReFacto AF laboratory standard
Steven Kitchen (UK) 16:50 – 17:05

Standardization of low TF and TF+tPA assays for TEG/ROTEM
Benny Sorensen (UK) 17:05 – 17:20

New approaches in FVIII inhibitor measurement and standardization
Sanj Raut (UK) 17:20 – 17:35

Standarisation of assays for rare bleeding disorders: Data from UK NEQAS
Steven Kitchen (UK) 17:35 – 17:50

General discussion 17:50 – 18:00
Saturday, 23 July, 2011

Factor XIII and Fibrinogen

Chairperson: Hans P. Kohler (CH)
Co-Chairpersons: Moniek P. M. de Maat (NL); Aida Inbal (IL); Muriel Maurer (US); Leonid Medved (US); Marguerite Neerman-Arbez (CH); John W Weisel (US); Sanj Raut (UK)

Educational Session 14:00 – 15:05 Room D

Welcome and introduction to the program
Hans P. Kohler (CH) 14:00 – 14:05
Chairperson: Hans P. Kohler (CH)

Effects of common genetic variation in fibrinogen genes
Moniek P.M. de Maat (NL) 14:05 – 14:35

Congenital and acquired FXIII deficiency
Hans P. Kohler (CH) 14:35 – 15:05

SSC Session 15:05 – 18:00 Room D

International collaborative study for the value assignment of the 3rd International Standard for fibrinogen, plasma
Sanj Raut (UK) 15:05 – 15:15

International collaborative study for the value assignment of the 2nd International Standard for fibrinogen, concentrate
Sanj Raut (UK) 15:15 – 15:25

Novel aspects of fibrinogen gamma prime
Shirley Uitte de Willige (NL) 15:25 – 15:40

Origin of the nonadhesive properties of fibrinogen matrices: Implications for hemostasis and biomaterial science
Tatiana Ugarova (US) 15:40 – 16:00

Characterizing the kinetics of activation of zymogen FXIII: The role of fibrinogen and thrombin exosite I
Barbara Cardinali, Brian A. Holliday, Susan T. Lord (US) 16:00 – 16:15

Break 16:15 – 16:30

Recombinant factor XIII. Safe and novel treatment for congenital factor XIII deficiency
Aida Inbal (IL) 16:30 – 16:45
Saturday, 23 July, 2011

Characterization and quantitation of rFXIII (N13)
Lene Hørligck (DK) 16:45 – 17:00

Proposal for measurement of FXIII B-subunit (free and total) in the
WHO 1st International Standard (02/206)
Hans P. Kohler (CH) & Sanj Raut (UK) 17:00 – 17:20

International collaborative study to calibrate the ISTH/SSC secondary
couagulation plasma standard lot 4: Value assignment for analyte FXIII
Sanj Raut (UK) 17:20 – 17:30

Interaction of factor XIII subunits in plasma and other body fluids
Muszbek L., Katona É., Bagoly Z., Pénzes K., Orosz Z.Z., Csapó A. (HU) 17:30 – 17:45

Update of the nation-wide campaign/study on acquired hemophilia XIII
(13) and proposal for international collaboration
Akitada Ichinose (JP) 17:45 – 18:00
**Saturday, 23 July, 2011**

**Haemostasis and Malignancy**

*Chairperson: Agnes Y. Y. Lee (CA)*

*Co-Chairpersons: Giancarlo Agnelli (IT); Marc Carrier (CA); Dominique Farge (FR); Alok Khorana (US); Marina Marchetti (IT); Wolfram Ruf (US); Jeffrey Zwicker (US)*

<table>
<thead>
<tr>
<th>Educational Session</th>
<th>14:00 – 16:00</th>
<th>Room Sakura</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Chairpersons: Wolfram Ruf (US) and Agnes Lee (CA)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Mechanism of coagulation in tumour progression and metastasis**  
  **Janus Rak (CA)** | 14:00 – 14:30 |
| **Role of tissue factor and biomarkers: is it ready for prime time?**  
  **Jeff Zwicker (US)** | 14:30 – 15:00 |
| **Targeted thromboprophylaxis using clinical prediction models**  
  **Alok Khorana (US)** | 15:00 – 15:30 |
| **Break** | 15:30 – 16:00 |

<table>
<thead>
<tr>
<th>SSC Session</th>
<th>16:00 – 18:00</th>
<th>Room Sakura</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Chairpersons: Wolfram Ruf and Alok Khorana (US)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Subcommittee Activity Updates</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Tissue factor assay standardization**  
  **Marina Marchetti (IT)** | 16:00 – 16:15 |
| **Incidental VTE: Definition, prognosis, treatment**  
  **Casey O’Connell (US)** | 16:15 – 16:30 |
| **Role of D-dimer in prognosis and diagnosis**  
  **Cihan Ay (AT)** | 16:30 – 16:45 |
| **Standardizing VTE outcomes in oncology trials**  
  **Marc Carrier (CA)** | 16:45 – 17:00 |
| **Ongoing Studies and New Proposals**  
  *Chairpersons: Giancarlo Agnelli and Dominique Farge* |
| **Tissue factor as a therapeutic target for cancer**  
  **Alok Khorana (US)** | 17:00 – 17:15 |
| **International working group on guidelines for VTE management in cancer: Progress report**  
  **Dominique Farge (FR)** | 17:15 – 17:30 |
Saturday, 23 July, 2011

New oral anticoagulants: Celebration and cautions
Giancarlo Agnelli (IT) 17:30 – 17:45

Updates on CATCH, TILT, SAVEONC, SOME, and others
Agnes Lee (CA) 17:45 – 18:00

SSC Subcommittee Meeting
Perinatal / Paediatric Haemostasis

Chairperson: Paul Monagle (AU)
Co-Chairpersons: Anthony Chan (CA); Janna Journeycake (US); Christoph Male (AT); Ulrike Nowak Gottl (DE); Paolo Simioni (IT); Guy Young (US)

Educational Session 14:00 – 15:30 Room B-1

Welcome and Introduction
Paul Monagle 14:00 – 14:05
Chairperson: Guy Young (US)

Intracerebral bleeding in neonates, current concepts of causes, management and prognosis
Elizabeth Chalmers (UK) 14:05 – 14:30

Haemostatic replacement therapy in non haemophiliac children
Tom Abshire (US) 14:30 – 14:55

DIC in children. Common precipitants, presentations, management and outcome
Christoph Male (AT) 14:55 – 15:20

Break 15:20 – 15:30

SSC Session 15:30 – 18:00 Room B-1

Chairpersons: Anthony Chan (CA) and Christoph Male (AT)

PTS as an outcome measure of paediatric thrombosis therapy: Can we develop standardised criteria
Neil Goldenberg (US) 15:30 – 15:55

Quality of life as outcome measure for anticoagulant trials in children: Developing a standardised tool
Aisha Bruce (CA) 15:55 – 16:20

Laboratory monitoring of anticoagulants in children: Developing a uniform approach 16:20 – 16:45

a) Heparin monitoring
Fiona Newall (AU)

b) Cardiac surgery and heparin monitoring in neonates
Simon Davidson (UK)
Diagnostic criteria for thrombosis in children: Which Radiological techniques are validated?  16:45 – 17:10
   a) diagnosis of venous thrombosis
      Leo Brandau (CA)
   b) diagnosis of intracardiac thrombosis and pulmonary embolism
      Leo Brandau (CA)

Developmental haemostasis: Recommendations for laboratories reporting paediatric samples
Paul Monagle (CA)  17:10 – 17:30

Role of thrombophilia testing in children: Development of standard indications for testing, and assay methodologies
Ulrike Nowak Gottl (DE)  17:30 – 17:50

Conclusion and planning for next years work
Paul Monagle (CA)  17:50 – 18:00
Saturday, 23 July, 2011

**Plasma Coagulation Inhibitors**

*Chairperson: Steve Kitchen (UK)*

*Co-Chairpersons: Elisabetta Castoldi (NL); Elaine Gray (UK); Tilman Hackeng (NL); Richard Marlar (US); Piet Meijer (NL); Laurent Mosnier (US)*

**Educational Session 14:00 – 16:00 Room B-2**

*Chairpersons: Steve Kitchen and Elaine Gray (UK)*

- **Welcome and introduction** 14:00 – 14:05
- **Thrombophilia: Who should be tested?** 14:05 – 14:35  
  *Trevor Baglin (UK)*
- **APC resistance: Biological basis and acquired influences** 14:35 – 15:05  
  *Elisabetta Castoldi (NL)*
- **Problems with laboratory assays for PC, PS and AT** 15:05 – 15:35  
  *Richard Marlar (US)*
- **Break** 15:35 – 16:00

**SSC Session 16:00 – 18:00 Room B-2**

*Chairpersons: Richard Marlar (US) and Piet Meijer (NL)*

- **Standardisation of Protein S Assays**
  - **Instability of protein S in blood samples** 16.00 – 16:25  
    *Kieron Hickey (UK)*
  - **Calibration of SSC plasma standard lot 4 for PC, PS and AT** 16:25 – 16:45  
    *Elaine Gray (UK)*
  - **Protein S assays: Need for standardisation** 16:45 – 17:05  
    *Ian Jennings (UK)*
  - **Biological variation for antithrombin, protein C and protein S: Their relation to analytical quality** 17:05 – 17:25  
    *Piet Meijer (NL)*

**Mutation Databases**

*Chairpersons: Tilman Hackeng and Elisabetta Castoldi (NL)*

- **Mutation databases for PC, PS and AT** 17:25 – 18:00  
  *Carolina Pintao (NL)*
Sunday, 24 July 2011

Control of Anticoagulation

Chairperson: Trevor Patrick Baglin (UK)
Co-Chairpersons: Walter Ageno (IT); Job Harenberg (DE); Clive Kearon (CA); John Olson (US); Gualtiero Palareti (IT); Sam Schulman (CA)

SSC Session 8:00 – 12:00 Room B-1

Update of SSC activities
Trevor Baglin (UK) 08:00 – 08:05

SSC registry report: Splanchnic vein thrombosis
Walter Ageno (IT) 08:05 – 08:15

Quality of anticoagulation control during VKA therapy: Effects on risk of bleeding and treatment failure
Gualtiero Palareti (IT) 08:15 – 08:35

Interpretation and management of INR results from patients taking VKA antagonists, a study among clinicians from 14 countries
Ann-Helen Kristoffersen (NO) 08:35 – 08:55

How should INR calibrants be used?
John Olson (US); Steve Kitchen (UK); Armando Tripodi (IT) 08:55 – 09:35

Update on novel non-oral anticoagulants - Including idraparinux, idrabiotoparinux
Harry Buller (NL) 09:35 – 10:00

SSC project report: Determination of anticoagulant effects of rivaroxaban: Towards a recommendation for assays
Job Harenberg (DE) 10:00 – 10:15

SSC project report: Determination of anticoagulant effects of dabigatran: Towards a recommendation for assays
Elaine Gray (UK) 10:15 – 10:30

Effects of the oral, direct thrombin inhibitor dabigatran on commonly used coagulation assays
Tomas Lindahl (SE) 10:30 – 10:45

Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
Andreas Hillarp (SE) 10:45 – 11:00
Systematic review of perioperative heparin bridging therapy: Implications of harmonization of outcome definitions and bivariate endpoints
Alex Spyropoulos (CA) 11:00 – 11:15

An outline for an SSC recommendation on new oral anticoagulants
Open discussion 11:15 – 12:00

Issues for Inclusion:
- Which patients should be treated with the new anticoagulants first?
- What to do in case of bleeding?
- How to try to assess/improve compliance.
- Follow up during treatment - when and by whom?
- Instructions and documents to be given to patients.
- Pharmacokinetics/dynamics / implications for bridging
- Influence of renal function and practical considerations
- Information (efficacy/safety) to be collected during treatment (for phase IV studies)
- Recommendations for the national regulatory agencies regarding the introduction of the NOAC in clinical practice and observational phase IV studies -
- Interactions with drugs/diet
- Different doses for different patients
- Side-effects
Sunday, 24 July 2011

Disseminated Intravascular Coagulation

Chairperson: Hideo Wada (JP)
Co-Chairpersons: Satoshi Gando (JP); Hyun Kyung Kim (KR); Jorn Nielsen (DK); Jecko Thachil (UK); Cheng-Hock Toh (UK)

Educational Session 8:00 – 9:10 Room Sakura

Disseminated intravascular coagulation due to anthrax : A pre-clinical in vivo study
Shinichiro Kurosawa (JP)

Pathogenesis of septic DIC
Marcel Levi (NL) 8:00 – 9:10

SSC Session 9:10 – 12:00 Room Sakura

DIC due to Sepsis or Trauma Part I
Chairperson’s report
Hideo Wada (JP)

Mimics of DIC in the intensive care unit
Jecko Thachil (UK)

DIC due to trauma
Satoshi Gando (JP) 9:10 – 9:55

Break 9:55 – 10:20

DIC due to Sepsis or Trauma Part II

AT
Toshiaki Iba (JP)

Therapeutic effects of recombinant thrombomodulin in DIC patient with hematologic malignancy
Shousaku Nomura (JP) 10:20 – 11:00

Diagnosis of DIC, TF

Microparticle assays in human endotoxemia
Nigel Key (US)

Controversies in DIC scoring
Jorn Nielsen (DK)
Involvement of tissue factor and annexin II in pathoclinical profiles of acute promyelocytic leukemia

Zhaoyue Wang (CN) 11:00 – 12:00
Factor XI and the Contact System

Chairperson: Thomas Renne (SE)
Co-Chairpersons: David Gailani (US); Keith McCrae (US)

Educational Session 8:00 – 9:30 Room E

Putting the Contact into Contact Activation

Historical overview
Hidehiko Saito (JP) 8:00 – 8:25

Roles and functions of polyphosphates
James H. Morrissey (US) 8:25 – 8:50

Roles of polysaccharides as contact activators
Thomas Renne (SE) 8:50 – 9:15

Break
9:15 – 9:30

SSC Session 9:30 – 12:00 Room E

Targeting factor XI
Joost Meijers (NL) 9:30 – 9:50

Role of factor XI in septic disease
Erik Tucker (US) 9:50 – 10:10

Factor XII in angiogenesis and inflammation
Alvin Schmaier (US) 10:10 – 10:30

Effect of factor XII on fibrin structure
José Govers (NL) 10:30 – 10:50

Break
10:50 – 11:15

Characterization of factor XI-blood cell interactions
Owen McCarty (US) 11:15 – 11:20

The role of factor XI in bleeding and thrombotic disorders in humans
Uri Seligsohn (IL) 11:20 – 11:40

Factor XII in angiogenesis and inflammation
Alvin Schmaier (US) 11:40 – 12:00
Sunday, 24 July 2011

Fibrinolysis

Chairperson: Ann Gils (BE)
Co-Chairpersons: Jonathan Foley (US); Dirk Hendriks (BE); Colin Longstaff (UK); Osamu Matsuo (JP); Nicola Mutch (UK); Michael Nesheim (CA); Craig Thelwell (UK); Tetsumei Urano (JP)

Educational Session 8:00 – 9:00 Room D

PAI-1: Clinical significance and therapeutic opportunities
Ann Gils (BE) 8:00 – 8:20

Is TAFI a target?
John Morser (US) 8:20 – 8:40

α2-antiplasmin: Clinical significance and therapeutic opportunities
Yosuke Kanno (JP) 8:40 – 9:00

SSC Session 9:00 – 12:00 Room D

EQA for point of care D-Dimer measurement
Ian Jennings (UK) 9:00 – 9:15

Update on WHO Internationals Standards: Urokinase, PAI-1 and D-dimer
Colin Longstaff (UK) 9:15 – 9:30

PAI-1 deficiency-Euglobin clot lysis assay
Tetsu Urano (JP) 9:30 – 9:45

Break 9:45 – 10:00

Microplasmin degrades fibrinogen like plasmin but fibrin degradation is impaired
Paul Kim (CA) 10:00 – 10:15

The kinetics of TAFIa-catalyzed cleavage of C-terminal lysine residues from fibrin degradation products and removal of plasminogen binding sites
Jonathan Foley (CA) 10:15 – 10:30

In vitro evaluation of profibrinolytic properties of TAFI and PAI-1 inhibitors
Tine Wyseure, Ann Gils, Paul Declerck (BE) 10:30 – 10:45
The role of TAFI in the regulation of growth and apoptosis in the hepatocyte
Taiichiro Seki (JP) 10:54 – 11:00

Fibrinolysis in whole blood model thrombi formed under flow
Nuala Booth (UK) 11:00 – 11:15

In vivo evaluation of TAFI inhibitors
Ellen Vercauteren, Paul Declerck, Ann Gils (BE) 11:15 – 11:30

Alternative pathway for fibrinolysis: Clinical significance and therapeutic opportunities, leukocyte elastase
Seiji Madoiwa (JP) 11:30 – 11:45

Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction
Shirley Uitte de Willige (NL), Megan Miedzak, Angela M. Carter (UK), Ton Lisman (NL), Frits R. Rosendaal (NL), Peter J. Grant (UK), Helen Philippou, Robert A.S. Ariëns (UK) 11:45 – 12:00
Sunday, 24 July 2011

Platelet Physiology

Chairperson: Marco Cattaneo (IT)
Co-Chairpersons: Christian Gachet (FR); Paolo Gresele (IT); Paul Harrison (UK); Catherine Hayward (CA); Dermot Kenny (IE); Diego Mezzano (CL); Andrew David Mumford (UK); Diane Nugent (US); Alan T. Nurden (FR)

Educational Session 8:00 – 9:30  Annex Hall 2

Physiology and pharmacology of platelet activation by ADP
Christian Gachet (FR) 8:00 – 8:30

Platelets, von Willebrand factor and deep vein thrombosis
Denisa Wagner (US) 8:30 – 9:00

Genetic determinants of platelet function
Paul Bray (US) 9:00 – 9:30

SSC Session 9:30 – 12:00  Annex Hall 2

Update on the project: Guidelines for the diagnosis of platelet function disorders
Paolo Gresele (IT) 9:30 – 10:00

Break 10:00 – 10:30

Could platelet function testing be of use to the internist?
Dermot Kenny (IE) 10:30 – 10:55

How to measure platelet secretion in patients with platelet function disorders
Diego Mezzano (CL) and Cathy Hayward (CA) 10:55 – 11:35

96 well plate LTA assay
Tim Warner (UK) 11:35 – 12:00
Sunday, 24 July 2011

Registry of Exogenous Hemostatic Factors
Chairperson: Mary Ann McLane (US)
Co-Chairperson: Kenneth Clemetson (CH); Manjunatha Kini (SG); Francis Markland Jr (US); Takashi Morita (JP); Jan Rosing (NL)

Educational Session 8:00 – 9:45 Room B-2

Sialomics and functional characterization of novel proteins
Ivo Francischetti (US) 8:00 – 8:25

Snaclecs and platelet receptor signaling
Kenneth J. Clemetson (CH) 8:25 – 8:50

Design of potent, tunable thrombin inhibitors
R. Manjunatha Kini (SG) 8:50 – 9:15

Break 9:15 – 9:45

SSC Session 9:45 – 12:00 Room B-2

Welcome 9:45 – 9:50

Introduction of new members 9:50 – 9:55

Minutes of the last meeting 9:55 – 10:05

Publications of subcommittee 10:05 – 10:20

Annual report 10:20 – 10:30

New inventories/activities 10:30 – 10:40

Any other business (Review on exogenous factors)

  A. Novel exogenous factors

  B. Next international meeting on exogenous factors to be held in Amsterdam 2013

Next meeting 11:10 – 12:00
Sunday, 24 July 2011

von Willebrand Factor

Chairperson: Jeroen Eikenboom (NL)
Co-Chairpersons: Thomas Abshire (US); Imre Bodo (HU); Jorge DiPaola (US); Emmanuel J. Favaloro (AU); Yoshihiro Fujimura (JP); Paula D. James (CA); Bernhard Lämmle (CH); Reinhard Schneppenheim (DE)

Educational Session 8:00 – 9:20 Room A

Chairperson: Jeroen Eikenboom (NL)

The clinical and laboratory diagnosis of VWD
Tom Abshire (US) 8:00 – 8:25

Replacement therapy in von Willebrand disease: What is the choice?
Jenny Goudemand (FR) 8:25 – 8:50

VWF: Glycosylation and function
Mike Laffan (UK) 8:50 – 9:20

SSC Session 9:20 – 12:00 Room A

Bleeding Scores and Bleeding Assessment Tool
Chairperson: Paula James (CA)

Update on activities of bleeding score working group
TBA 9:20 – 9:35

Online bleeding assessment tool
Barry Coller (US) 9:35 – 9:50

Standardization of Assays
Chairperson: Bernhard Lämmle (CH)

Working party on standardization of VWFpp assays
Tony Hubbard (UK) 9:50 – 9:57

Variation in ADAMTS13 activity assays and the need for standardization
Ian Mackie (UK) 9:57 – 10:04

A 10 min-assay for ADAMTS13 activity with an automated biochemistry analyzer

ADAMTS13 activity assays: Comparison of different methods
Johanna Kremer Hovinga (CH) 10:11 – 10:18
Sunday, 24 July 2011

Collagen binding assay, current status
Emmanuel Favaloro (AU) 10:18 – 10:25

Performance data of a particle enhanced VWF activity assay with no need of ristocetin
Jürgen Patzke (DE) 10:25 – 10:30

VWF and VWD Registries
Chairperson: Imre Bodo (HU)

Platelet Type–VWD registry/database (www.pt-vwd.org/)
Maha Othman (CA) 10:30 – 10:40

VWF database (www.vwf.group.shef.ac.uk/), activities of steering committee, publication/report on database
Dan Hampshire (UK) 10:40 – 10:50

International registry on acquired von Willebrand syndrome (www.intreavws.com)
Augusto Federici (IT) 10:50 – 11:00

Multicenter Studies on VWD
Chairpersons: Reinhard Schneppenheim (DE) and Jorge DiPaola (US)

European Project on type 3 VWD
Augusto Federici (IT) 11:00 – 11:10

EUVWD Cooperative Group
Ian Peake (UK) 11:10 – 11:20

Zimmerman Project (ZPMCB-VWD)
Bob Montgomery (US) 11:20 – 11:30

Potential importance of the CHARGE loci in VWD patients
David Lillicrap (CA) 11:30 – 11:40

VWD International Prophylaxis (VIP) Study
Tom Abshire (US) 11:40 – 11:50

WIN (Willebrand in Netherlands)
Frank Leebeek (NL) 11:50 – 12:00
Opening Ceremony

You are cordially invited to attend the XXIII Congress' Opening Ceremony on **Sunday, July 24, 2011 at 17:30** at the Main Hall in ICC Kyoto, followed by the Welcome Reception, which will take place at the beautiful Japanese-style garden.

- **Welcome by Yasuo Ikeda**  
  President of the XXIII Congress of the ISTH

- **Remarks by Hiroshi Mizohata**  
  Commissioner, Japan Tourism Agency

- **Remarks and Presentation of the Grant Medal by Henri Bounamaux**  
  Chairman of the ISTH Council

- **Closing Remarks by Yasuo Ikeda**  
  President of the XXIII Congress of the ISTH
ISTH Nursing Forum

The ISTH mission statement is clear in its broad intent and implies that a mechanism exists for extraction of patient-related and laboratory data, and for dissemination and implementation of scientific advances. Nurses play a primary role in this mechanism because of their direct involvement in information flow, and by virtue of their direct contact with patients and the source documents that are the raw materials of scientific progress. Nursing involvement ranges from protocol design and implementation to extraction and transmission of basic quantitative data.

The purpose of the Nursing Program is to provide a forum for nurses worldwide to identify issues that directly impact their role in advancing the objectives of the organization pertaining to disorders of hemostasis and thrombosis in both pediatric and adult populations. The goal is to provide free exchange of knowledge, experience, and practice patterns to standardize and improve the quality of hands-on participation in the art and science of medicine focused on disorders of hemostasis and thrombosis. Models of care exist for patients with hemophilia (treatment protocols, practice guidelines, educational materials, etc), but do not exist for many other coagulation disorders.

The forum provides an opportunity for nurses to communicate and share protocols, strategies, and knowledge. Nurses identify similar clinical challenges and develop interventions and strategies to address the challenge, yet nurses are often isolated within their institutions making duplication of strategy development widespread. The ISTH nursing forum facilitates knowledge transfer within the profession of nursing and both reduces duplication of strategy development, and facilitates knowledge based sharing of information and strategies resulting in improved efficacy.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room C-2</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 9:15</td>
<td>Welcome and Introductions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15 – 9:30</td>
<td>A model of nursing practice in Japan</td>
<td>Orie Ono (JP)</td>
<td></td>
</tr>
<tr>
<td>9:30 – 10:00</td>
<td>Nursing Research Session</td>
<td></td>
<td>Moderator: Fiona Newall (AU), Mary Bauman (CA)</td>
</tr>
<tr>
<td>10:00 – 10:20</td>
<td>Nurse led research: “Raising the ‘voice’ of nursing”.</td>
<td>Fiona Newall (AU)</td>
<td></td>
</tr>
<tr>
<td>10:20 – 10:40</td>
<td>Selected oral communications</td>
<td></td>
<td>Examining the education needs of parents learning to use an infusaport in their child with hemophilia</td>
</tr>
<tr>
<td>10:40 – 11:00</td>
<td>The learning process of self infusion in haemophilia: Finally some numbers we could give to our patients</td>
<td>Liesbeth Helene Schrijvers (NL), Marlene Beijlevelt-Van der Zande (NL), Marjolein Peters (NL), Kathelijn Fischer (NL)</td>
<td></td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>An innovative clinic approach to increase patient participation in their health care</td>
<td>Mary Elisabeth Bauman (CA), M. Patricia Massicotte (CA), Aisha Bruce (CA)</td>
<td></td>
</tr>
<tr>
<td>11:15 – 12:20</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 – 12:20</td>
<td>Invited research papers</td>
<td></td>
<td>Survey on the role and challenges of nurses in education of home infusion for hemophilia patients and family</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lower than expected clot rates in the absence of effective thromboprophylaxis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Initiation of warfarin therapy for patients with atrial fibrillation comparison 5mg vs. 3mg</td>
</tr>
</tbody>
</table>
Saturday, July 23, 2011 14:00 – 18:00

Concept paper: 12:20 – 13:00
- Do we need a nursing scientific subcommittee-style approach to advancing nursing practice in the area of thrombosis and haemostasis?
  Fiona Newall (AU), Mary Bauman (CA)

Session 2 Room C-2

Women’s Health Issues in Hemostasis and Thrombosis
Moderators: Maura Dumas (US), Caroline Baglin (UK)
- Treatment options for managing menorrhagia for woman with bleeding and clotting disorders 14:00 – 14:40
  Andi James (US)
- Question and answer discussion period 14:40 – 15:00

Obstetrical issues
- The management of pregnancy, labour and delivery in severe haemophilia 15:00 – 15:20
  Ann O’Sullivan (IE)
- Guidelines for labor and delivery for carrier of neonate with hemophilia 15:20 – 15:40
  Regina Butler (US)

Pearls on the new anticoagulants 15:40 – 16:00
Karen Baker (US)

Abstract poster presentation set up in reception room. 16:00 – 16:30

Discrepant one-stage versus chromogenic FVIII:C assays in the management of haemophilia a carriers
Claire Bell (AU), Ross I. Baker (AU), Jim Thom (AU)

The ongoing impact of 25 years of hepatitis C (HCV) infection in people with inherited bleeding disorders (IBD)
Allison L. Greig (UK), Steve Austin (UK)

CVADs in children with haemophilia, a multi centre study
Karin Lindvall (SE), Kate Khair (UK), James Porter

Social networking in haemophilia: Adolescents’ views
Kate Khair (UK), Mike Holland (UK), Shawn Carrington (UK)
Functional health status assessment in haemophilia patients with the International classification of functioning, disability and health (ICF, ICF-CY)
Silvia Riva (IT), Gringeri Alessandro (IT), Monika Bullinger (DE), Sylvia von Mackensen (DE)

The nurse and thrombosis center in a developing country
Eliane Partite Nobre Sandoval (BR), Paula Ribeiro Villaca (BR), Erica Okazaki (BR), Audrey Kruse Zeinad Valim (BR), Dalton de Alencar Fischer Chamone (BR), Elbio Antonio D’Amico (BR)

Development of a pediatric thrombosis educational tool (flash cards) for children receiving oral anticoagulation
Leonardo Rodrigues Brandao (CA), Elbio D’Amico (BR), Jorge D.A. Carneiro (BR), Frederica Cassis (BR)

Nurses’ network meeting/ catered reception with concomitant abstract poster presentations
Sunday, July 24, 2011  
8:00 – 10:30

Session 3  
Room C-2

Optimizing Health
Moderators: Maura Dumas (US), Debi Smith (NZ)

Health issues  
8:00 – 9:00

- Obesity and thrombosis risk  
  Caroline Baglin (UK)
- General aging health issues: The impact on hemophilia population  
  Jennifer Maahs (US)

Sports: What’s your game plan: Risk vs. benefit?  
9:00 – 9:30

- In the pediatric bleeding population  
  James Munn (US)
- Applying this model to a pediatric thrombosis population  
  Mary Bauman (CA)

Education, adherence, and quality of life  
9:30 – 10:30

- Developing university accredited degree module in anticoagulation and VTE prevention  
  Bunis Packham (UK)
- Review of adherence in health care: Is patient education always enough?  
  Regina Butler (US)
- Outcomes of clinical practice: The role of quality of life assessments in pediatric anticoagulation management  
  Sophie Jones (AU)
Sunday, July 24, 2011

Session 4  Room C-2

Case Studies/Discussions
Moderators: Jen Maahs (US), Fiona Newall (AU)

Invited case studies, projects, protocols selected from nursing community.

- **Teaching aids through images: A comparison between hemoaction and P-TET educational tools**
  Frederica Cassis (BR)

- **Identical twins with severe vWD: Medical and psychosocial challenges**
  Ann O’Sullivan (IE)

- **Coping with a new diagnosis - striking a healthy balance: Case study**
  Maura Dumas (US)
### Monday, July 25, 2011

#### Plenary Lecture 9:45-10:30

**Takeshi Abe Memorial Lecture**

*Chairpersons: Gilbert White (US) and Akira Yoshioka (JP)*

**Gene therapy for hemophilia: A long and winding road**

*Katherine A. High (US)*

#### Plenary Lecture 17:15-18:00

**Life Sciences Research Partners Lecture**

*Chairpersons: J. Evan Sadler (US) and Katsuo Sueishi (JP)*

**Biological functions and therapeutic potential of vascular endothelial growth factors**

*Kari Kustaa Alitalo (FI), Collaborators*

#### State-of-the-Art Lecture 11:00-12:00

**Thrombotic Disorders: Epidemiology**

*Chairpersons: Daniel Myers Jr. (US) and Kazuyuki Shimada (JP)*

**Stroke in atrial fibrillation: Epidemiology and thromboprophylaxis**

*Gregory Y.H. Lip (UK)*

**Anticoagulant therapy in venous thromboembolism**

*Harry R. Büller (NL)*

#### Platelet Biology Annex Hall 1

*Chairpersons: Zaverio M. Ruggeri (US) and Yukio Ozaki (JP)*

**The role of lectins and glycans in platelet clearance**

*Karin Hoffmeister (US)*

**Regulating thrombus growth and stability to achieve an optimal response to injury**

*Lawrence Fisher Brass (US), Kenneth M. Wannemacher, Peisong Ma, Timothy J. Stalker*
Monday, July 25, 2011

Plasminogen Activation System  Annex Hall 2
Chairpersons: Robert Medcalf (AU) and Junichiro Yamamoto (JP)

Exploration of the host hemostatic system by group a streptococcus: Implications in searching for novel antimicrobial therapies  SA-MO-005
Hongmin Sun (US)  11:00 – 11:30

tPA-mediated plasminogen activation and contact activation, implications in and beyond haemostasis  SA-MO-006
Martijn F.B.G. Gebbink (NL)  11:30 – 12:00

Coagulation and Inflammation  Room A
Chairpersons: John Griffin (US) and Paula Tracy (US)

Crosstalk between hemostasis and inflammation  SA-MO-007
Charles T. Esmon (US)  11:00 – 11:30

Recombinant thrombomodulin: As a therapeutic regulator in coagulation and inflammation  SA-MO-008
Ikuro Maruyama (JP), Takashi Ito  11:30 – 12:00

Symposia  8:00-9:30

Hemorrhagic Disorders  Main Hall
Prediction of Inhibitor Development in Hemophilia
Chairpersons: H. Marijke van den Berg (NL) and Midori Shima (JP)

Factor VIII gene haplotype and inhibitor development  SY-MO-001
Tom E. Howard (US)  08:00 – 08:30

Genotype and inhibitor development  SY-MO-002
Johannes Oldenburg (DE)  08:30 – 09:00

Immunological aspects of inhibitor development  SY-MO-003
Jan Astermark (SE)  09:00 – 09:30
Monday, July 25, 2011

Platelet (Basic and Clinical)  
Annex Hall 1

Megakaryocytes and Thrombopoiesis  
Chairpersons: David J. Kuter (US) and Takashi Kato (JP)

Apoptotic processes in megakaryocytes and platelets  SY-MO-004  
Benjamin Thomas Kile (AU) 08:00 – 08:30

Mechanistic insights into how platelets are produced and how they regulate angiogenesis  SY-MO-005  
Joseph E Italiano Jr (US) 08:30 – 09:00

Towards making platelets from ex vivo grown cells  SY-MO-006  
Mortimer Poncz (US), Yuhuan Wang, Rudy Fuentes, Michele Puszkarczuk Lambert 09:00 – 09:30

Coagulation Factors and Inhibitors  
Annex Hall 2

Contact Phase Activation  
Chairpersons: Klaus T. Preissner (DE) and Hiroko Tsuda (JP)

Thrombosis risk of protein deficiencies of the plasma kallikrein/kinin system  SY-MO-007  
Alvin Harold Schmaier (US), Gregory N. Adams 08:00 – 08:30

Factor XI: Structure, activation and target for therapy  SY-MO-008  
Joost C. M. Meijers (NL) 08:30 – 09:00

Initiation of coagulation by polyphosphates in vivo  SY-MO-009  
Thomas Renne (SE) 09:00 – 09:30

Symposia  13:30-15:00

Platelet (Basic and Clinical)  
Main Hall

Emerging Antiplatelet Drugs  
Chairpersons: Alan D. Michelson (US) and Hisanori Horiuchi (JP)

New P2Y12 inhibitors for the treatment of coronary artery disease  SY-MO-010  
Paul Alfred Gurbel (US) 13:30 – 14:00

PAR-1 antagonists in cardiovascular disease  SY-MO-011  
David A. Morrow (US) 14:00 – 14:30
Monday, July 25, 2011

**Perspective of new PDE-3 inhibitor as anti-thrombotic drug** SY-MO-012
Masakatsu Nishikawa (JP), Hiroyoshi Hidaka
14:30 – 15:00

**Innovation and Technology** Annex Hall 1

**Innovative Imaging**
Chairpersons: Owen McCarty (US) and Junichi Takagi (JP)

*In vivo molecular imaging reveals multi-cellular kinetics and pro-inflammatory cytokine involvement in developing thrombus* SY-MO-013
Satoshi Nishimura (JP), Mika Nagasaki, Ichiro Manabe, Koji Eto, Ryozo Nagai
13:30 – 14:00

**Dynamics of adhesion molecules studied using single-molecule mechanical experiments and molecular dynamics simulations** SY-MO-014
Cheng Zhu (US), Wei Jack Chen, Fang Kong, Wei Chen
14:00 – 14:30

**Imaging leukocyte-thrombus interactions in vivo** SY-MO-015
Shaun Jackson (AU)
14:30 – 15:00

**VWF/VWD and ADAMTS13** Annex Hall 2

**Structure and Function of ADAMTS13 and von Willebrand Factor**
Chairpersons: Jose Lopez (US) and X. Long Zheng (US)

**Findings from ADAMTS13 activity assay** SY-MO-016
Koichi Kokame (JP)
13:30 – 14:00

**How ADAMTS13 recognises and cleaves the VWF scissile bond** SY-MO-017
David A. Lane (UK)
14:00 – 14:30

**Characterization of anti-ADAMTS13 antibodies that develop in patients with acquired thrombotic thrombocytopenic purpura** SY-MO-018
Jan Voorberg (NL), Wouter Pos, Nicoletta Sorvillo
14:30 – 15:00
### Monday, July 25, 2011

**Symposia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30-17:00</td>
<td><strong>Thrombotic Disorders</strong></td>
<td><strong>Main Hall</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Pharmacotherapy Update for Peripheral Arterial Disease: From Tasc II to Tasc III</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Lars Norgren (SE) and Hiroshi Shigematsu (JP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Management of peripheral artery disease and claudication</strong></td>
<td>SY-MO-019</td>
</tr>
<tr>
<td></td>
<td>William R. Hiatt (US)</td>
<td>15:30 – 16:00</td>
</tr>
<tr>
<td></td>
<td><strong>Stem cell therapy for peripheral arterial occlusive disease</strong></td>
<td>SY-MO-020</td>
</tr>
<tr>
<td></td>
<td>Dong-Ik Kim (KR)</td>
<td>16:00 – 16:30</td>
</tr>
<tr>
<td></td>
<td><strong>Role of pharmacotherapy in peripheral intervention</strong></td>
<td>SY-MO-021</td>
</tr>
<tr>
<td></td>
<td>Hiroyoshi Yokoi (JP)</td>
<td>16:30 – 17:00</td>
</tr>
<tr>
<td></td>
<td><strong>Platelet (Basic and Clinical)</strong></td>
<td><strong>Annex Hall 1</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Congenital Thrombocytopenia</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Paquita Nurden (FR) and Taisuke Kanaji (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Diagnosis of congenital macrothrombocytopenia</strong></td>
<td>SY-MO-022</td>
</tr>
<tr>
<td></td>
<td>Shinji Kunishima (JP)</td>
<td>15:30 – 16:00</td>
</tr>
<tr>
<td></td>
<td><strong>Mouse models of macrothrombocytopenia</strong></td>
<td>SY-MO-023</td>
</tr>
<tr>
<td></td>
<td>Christian Gachet (FR), Catherine Leon, Catherine Strassel, Francois Lanza</td>
<td>16:00 – 16:30</td>
</tr>
<tr>
<td></td>
<td><strong>Gray platelet syndrome: Clinical features and genetic analysis (TBD)</strong></td>
<td>SY-MO-024</td>
</tr>
<tr>
<td></td>
<td>Tzipora C. Falik-Zaccai (IL)</td>
<td>16:30 – 17:00</td>
</tr>
<tr>
<td></td>
<td><strong>Hemorrhagic Disorders</strong></td>
<td><strong>Annex Hall 2</strong></td>
</tr>
<tr>
<td></td>
<td><strong>FV/FVIII Synthesis and Regulation</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Rodney Camire (US) and Tadashi Matsushita (JP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Endothelial synthesis of factor VIII</strong></td>
<td>SY-MO-025</td>
</tr>
<tr>
<td></td>
<td>Claire L. Shovlin (UK)</td>
<td>15:30 – 16:00</td>
</tr>
<tr>
<td></td>
<td><strong>Combined deficiency of FV and FVIII</strong></td>
<td>SY-MO-026</td>
</tr>
<tr>
<td></td>
<td>Bin Zhang (US)</td>
<td>16:00 – 16:30</td>
</tr>
</tbody>
</table>
Monday, July 25, 2011

A role and mechanism of plasmin-catalyzed FVIII activation in blood coagulation and fibrinolysis

Keiji Nogami (JP)

SY-MO-027
16:30 – 17:00
ORAL COMMUNICATIONS

Monday, July 25, 2011  8:00 - 9:30

Platelet Signaling I  Room C-1

Chairpersons: Bernhard Nieswandt (DE) and Mauro Torti (IT)

O-MO-001  08:00 - 08:15
DISCOVERY OF A NEW SIGNALING COMPLEX BASED ON SPINOPHILIN THAT REGULATES PLATELET ACTIVATION IN VITRO AND IN VIVO
Peisong Ma* (US), Aleksandra Cierniewska, Rachel Signarvic, Andrew Sinnamon, Marcin Cieslak, Timothy Stalker, Richard Neubig, Lawrence Brass

O-MO-002  08:15 - 08:30
CLP36 IS A NEGATIVE REGULATOR OF GPVI SIGNALING IN PLATELETS
shuchi gupta* (DE), Attila Braun, Martina Morowski, Zoltan Nagy, Bernhard Nieswandt

O-MO-003  08:30 - 08:45
SEVERE GPVI DEFICIENCY AND MACROTROMBOCYTOPENIA IN MICE LACKING G6B-B
Ying-Jie Wang* (UK), Alexandra Mazharian, Jun Mori, Danai Bem, Brenda Finney, Silke Heising, Paul Gissen, Michael Douglas, James G White, Neel G Benjamin, R Duncan Campbell, Steve P Watson, Yotis A Senis

O-MO-004  08:45 - 09:00
THE PLATELET SURFACE THIOL ISOMERASE ERP57 IS REQUIRED FOR PLATELET FUNCTION
Ronald Geoffrey Stanley* (UK), Lisa-Marie Holbrook, Parvathy Sasikumar, Jonathan Gibbins

O-MO-005  09:00 - 09:15
ELUCIDATING THE ROLE OF THE INTRINSIC APOPTOSIS PATHWAY IN PLATELET FUNCTION
Emma Charlotte Josefsson* (AU), Michael J White, Simone M Schoenwaelder, Kate Jarman, Katya J Henley, Rachael M Lane, Shaun P Jackson, Benjamin T Kile

O-MO-006  09:15 - 09:30
PAR1, PAR4 AND GPIB FORM FUNCTIONAL INTERDEPENDENT UNITS IN A RECEPTOR COMPLEX MEDIATING PLATELET ACTIVATION BY THROMBIN
Lars Faxalv* (SE), Niklas Boknas, Tomas L Lindahl

Fibrinolysis  Room C-2

Chairpersons: Paul Declerck (BE) and Koji Yamamoto (JP)

O-MO-007  08:00 - 08:15
RED BLOOD CELLS CONFER LYTIC RESISTANCE TO FIBRIN
Nikolett Wohner* (HU), Laszlo Szabo, Raymund Machovich, Marta Silva, Colin Longstaff, Krasimir Kolev

O-MO-008  08:15 - 08:30
THE INVOLVEMENT OF FACTOR XIII IN THE IMPAIRED FIBRINOLYSIS OF PATIENTS WITH FACTOR V LEIDEN MUTATION
Zsuzsa Bagoly* (HU), Zsuzsa Koncz, Zoltán Andras Mezei, Zsolt Olah, Robert A. S. Ariens, Laszlo Muszbek
ORAL COMMUNICATIONS

Monday, July 25, 2011 8:00 - 9:30

O-MO-009  08:30 - 08:45
FIBRIN CLOTS CONTAIN FUNCTIONALLY ACTIVE ALPHA-1-ANTITRYPSIN
Dick C Rijken* (NL), Simone Talens, Joyce J.M.C. Malfliet, Frank W.G. Leebeek

O-MO-010  08:45 - 09:00
DNA STABILISES FIBRIN CLOTS AND MODULATES THE ACTIVITY OF STREPTOKINASE
Colin Longstaff* (UK), Craig Thelwell

O-MO-011  09:00 - 09:15
ALTERATIONS OF COAGULATION AND FIBRINOLYSIS IN PATIENTS WITH ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY: THE INVOLVEMENT OF THROMBOMODULIN
Mark van Geffen* (NL), Massimo Cugno, Paul Lap, Arnoud Loof, Marco Cicardi, Waander van Heerde

O-MO-012  09:15 - 09:30
A NEW APPROACH FOR MEASUREMENT OF MP-ASSOCIATED PLASMIN GENERATION.
Romaric Lacroix* (FR), Philippe Poncelet, Tarik Bouriche, Coralie Judicone, Karim Harl Souab, Sebastien Bordon, Genevieve Contant, Florence Sabatier, Jose Sampol, Eduardo Angles-Cano, Francoise Dignat-George

Protein S and GAS6 Room D

Chairpersons: Brian and Tatsuya Hayashi (JP)

O-MO-013  08:00 - 08:15
HDL FRESHLY ISOLATED BY ULTRACENTRIFUGATION FROM PLASMA IS A COFACTOR FOR ACTIVATED PROTEIN C(APC)/PROTEIN S ANTICOAGULANT ACTIVITY: CONTROVERSY AND REEVALUATION
John H Griffin* (US), Jose A Fernandez, Natalie Pecheniuk, Subramanian Yegneswaran, Carole L Banka, Hiroshi Deguchi

O-MO-014  08:15 - 08:30
ACTIVATED PROTEIN S COFACTOR FUNCTION OF PROTEIN S: A NOVEL FUNCTION FOR A γ-CARBOXYGLUTAMIC ACID RESIDUE
Josefin Ahnstrom* (UK), Helena M Andersson, Kevin Canis, Eva Norstrom, Yao Yu, Bjorn Dahlback, Maria Panico, Howard R Morris, James TB Crawley, David A Lane

O-MO-015  08:30 - 08:45
GROWTH ARREST-SPECIFIC GENE 6 (GAS6) AS AN INTRA-HOSPITAL MORTALITY PREDICTOR FOR PATIENTS IN SEPTIC SHOCK
Anne Angelillo-Scherrer (CH), Gregoire Stalder*, Christophe Kosinski, Frederik Delodder, Beatrice Ternon, Thierry Roger, Thierry Calandra, Michel A. Duchosal, Philippe Eggimann, Anne Angelillo-Scherrer, Lausanne The Lausanne Sepsis Study Group

O-MO-016  08:45 - 09:00
COMPOUND HETEROZYGOUS PROTEIN S DEFICIENCY IN A HEALTHY WOMAN
Carolina Pintao* (NL), Kristien Winckers, Herm-Jan M Brinkman, Elisabetta Castoldi, Tilman M Hackeng, Pieter H Reitsma
ORAL COMMUNICATIONS

Monday, July 25, 2011 8:00 - 9:30

O-MO-017  09:00 - 09:15
DOWNREGULATION OF PROTEIN S BY MICRO-RIBONUCLEIC ACID 494 (MIR-494)
Giuliana Romeo (AU), Quintin Hughes, Ross Baker*

O-MO-018  09:15 - 09:30
PHOSPHORYLATION OF PROTEIN S (PS) BY PLATELET KINASES ENHANCES ITS DIRECT ANTICOAGULANT ACTIVITY
Fabian Stavenhuler* (US), Mary-Jo Heeb

Antiplatelet Therapy  Room E

Chairpersons: Christopher Ward (AU) and Tsukasa Ohmori (JP)

O-MO-019  08:00 - 08:15
DEVELOPMENT OF REFERENCE METHODS FOR EVALUATING THE EFFECT OF ASPIRIN AND FOR COMPARISON WITH ROUTINELY USED METHODS; THE LACK OF ASPIRIN RESISTANCE IN HEALTHY VOLUNTEERS
Eva Katora* (HU), Emese Gyongyver Kovacs, Zsuzsanna Bereczyky, Laszlo Balogh, Nora Homorodi, Gizella Hamamura, Eszter Toth, Judit Csapo, Istvan Edes, Laszlo Muszbek

O-MO-020  08:15 - 08:30
PLATELET REACTIVITY AND RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE USING ASPIRIN: A HEAD-TO-HEAD COMPARISON OF DIFFERENT TESTS
Jaapjan D. Snoep* (NL), Jeroen CJ Eikenboom, Jaap Jan Zwaginga, Mark Roest, Carlo Patrono, Bianca Rocca, Giovanna Petrucci, Frits R Rosendaal, Johanna G van der Bom

O-MO-021  08:30 - 08:45
ACETYLSALICYLIC ACID INHIBITS THROMBOXANE A2 PRODUCTION AND THROMBOXANE A2-DEPENDENT PLATELET FUNCTION EQUALLY WELL IN DIABETIC AND NON-DIABETIC SUBJECTS
Marco Cattaneo* (IT), Eti Alessandra Femia, Mariateresa Pugliano, Gian Marco Podda, Klodiana Dosti, Cristina Razzari

O-MO-022  08:45 - 09:00
HIGH ON-TREATMENT PLATELET REACTIVITY BY VARIOUS PLATELET FUNCTION TESTS: IS THE CURRENTLY REPORTED VASP PRI CUTOFF TOO LOW?
Paul Alfred Gurbel* (US), Jeong Young-Hoon, Kevin P Bilden, Mark J Antonino, Udaya S Tantry, Udaya S Tantry

O-MO-023  09:00 - 09:15
EV-077-3201-2TB, A TP ANTAGONIST AND TS INHIBITOR, REDUCES PLATELET AGGREGATION IN WHOLE BLOOD OF TYPE 2 DIABETICS WITH CORONARY ARTERY DISEASE ON CHRONIC ASPIRIN THERAPY

O-MO-024  09:15 - 09:30
ARC15105 A POTENT ANTAGONIST OF VON WILLEBRAND FACTOR (VWF) PLATELET ACTIVATION AND ADHESION
Bernd Jilma* (AT), Jolanta M Siller-Matula, Yahye Merhi, Jean-Francois Tanguay, Daniel Duerschmied, Kathleen E. McGinness,
ORAL COMMUNICATIONS

Monday, July 25, 2011  8:00 - 9:30

Shannon P. Pendergrast, Denisa D. Wagner, Robert G. Schaub, Bernd Jilma

Inherited Coagulation Disorders  Sakura

Chairpersons: Eriko Morishita (JP) and Kathelijn Fischer (NL)

O-MO-025  08:00 - 08:15
A ZEBRAFISH MODEL FOR HUMAN FIBRINOGEN DISORDERS
Richard J Fish* (CH), Silja Vorjohann, Alexandre Fort, Corinne DiSanza, Franck Bontems, Frederique Bena, Roland Dosch, Marguerite Neerman-Arbez

O-MO-026  08:15 - 08:30
THE FVII R402X NONSENSE MUTATION, ASSOCIATED WITH AN ASYMPTOMATIC PHENOTYPE, IS RESPONSIBLE FOR SMALL AMOUNTS OF CIRCULATING PROTEIN WITH IMPROVED COAGULANT ACTIVITY
Alessio Branchini* (IT), Lara Rizzotto, Alessandro Canella, Rosella Mari, Mario Lapecorella, Marisanta Napolitano, Guglielmo Mariani, Mirko Pinotti, Francesco Bernardi

O-MO-027  08:30 - 08:45
“COMPENSATORY” ABERRANT SPLICING SUPPORTS RESIDUAL EXPRESSION LEVELS IN SEVERE COAGULATION FACTOR VII DEFICIENCY
Nicola Cavallari (IT), Dario Balestra, Lara Rizzotto, Alessio Branchini, Iva Maestri, Ampaiwan Chuansumrit, Werasak Sasanaakul, Guglielmo Mariani, Franco Pagani, Francesco Bernardi, Mirko Pinotti*

O-MO-028  08:45 - 09:00
EFFICACY OF PROPHYLAXIS AND GENOTYPE-PHENOTYPE CORRELATION IN PATIENTS WITH SEVERE FACTOR X DEFICIENCY IN IRAN
Mehran Karimi* (IR), Armaghan Vafafar, Sezaneh Haghpanah, Mehrdad Payandeh, Peyman Eshghi, Hamid Hoofar, Abdorreza Afraisiabi, Javad Gerdabi, Rezvan Ardeshiri, Marzia Menegatti, Flora Peyvandi

O-MO-029  09:00 - 09:15
A RECURRENT P.GLY43ASP SUBSTITUTION OF COAGULATION FACTOR X (FX) IMPAIRS INTRACELLULAR TRAFFICKING AND FUNCTIONAL ACTIVITY CAUSING A SEVERE FX DEFICIENCY IN FOUR PATIENTS
Marzia Menegatti* (IT), Roberta Palla, Mehran Karimi, Rossella Bader, Raimondo De Cristofaro, Flora Peyvandi

O-MO-030  09:15 - 09:30
PHENOTYPE-GENOTYPE CORRELATION OF 181 PATIENTS WITH HEREDITARY COAGULATION FACTOR XII DEFICIENCY
Vytautas Ivasevicius* (DE), Arijit Biswas, Anne Thomas, Rainer Seitz, Selfried Erhard, Johannes Oldenburg
ORAL COMMUNICATIONS

Monday, July 25, 2011  8:00 - 9:45

Late Breaking Clinical Trials  Room A

Chairpersons: Takenori Yamaguchi (JP) and Kenneth Bauer (US)

O-MO-031  08:00 - 08:15
APIXABAN FOR PREVENTION OF ACUTE ISCHEMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES
Stefan Karl James* (SE), John H Alexander, Puneet Mohan, Lars Wallentin, Robert A Harrington

O-MO-032  08:15 - 08:30
J-ROCKET AF: THE SAFETY AND EFFICACY OF RIVAROXABAN FOR PREVENTION OF STROKE IN JAPANESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Masatsugu Hori* (JP), Masayasu Matsumoto, Norio Tanahashi, Shin-ichi Momomura, Shinichiro Uchiyama, Shinya Goto, Tohru Izumi, Yukihiro Koresutane, the J-ROCKET AF Study Investigators on behalf of

O-MO-033  08:30 - 08:45
IDRABITAPARINUX FOR ACUTE SYMPTOMATIC PULMONARY EMBOLISM
Harry R Buller* (NL), Alex S Gallus, Gerard Pillion, Martin H Prins, Gary E Raskob

O-MO-034  08:45 - 09:00
RIVAROXABAN VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS: MAGELLAN SUBGROUP ANALYSES
Alexander T Cohen* (UK), Theodore E. Spiro, Harry R. Buller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex Spyropoulos, Victor Tapson

O-MO-035  09:00 - 09:15
TREATMENT-RELATED RISK FACTORS OF INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A: THE RODIN STUDY
Samantha C Gouw* (NL), H Marijke van den Berg, Johanna G van der Bom, On behalf of the PedNet Study group, and the RODIN Study group

O-MO-036  09:15 - 09:30
THE IMPACT OF LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) PROPHYLAXIS ON MORTALITY IN ACUTELY ILL MEDICAL PATIENTS: THE LIFENOX STUDY
Ajay Kakkar* (UK), Claudio Cimminiello, Samuel Z Goldhaber, Rajiv Parakh, Chen Wang, Jean-Francois Bergmann

O-MO-037  09:30 - 09:45
DABIGATRAN VERSUS PLACEBO FOR EXTENDED MAINTENANCE THERAPY OF VENOUS THROMBOEMBOLISM
Sam Schulman* (CA), D Baanstra, H Eriksson, S Goldhaber, A Kakkar, C Kearon, P Mismetti, S Schellong, J Schnee, the RE-SONATE Study Group
ORAL COMMUNICATIONS
Monday, July 25, 2011 8:00 - 9:30

VTE: Risk Factors I
Room B-1

Chairpersons: Masataka Ikeda (JP) and Richard White (US)

O-MO-038
THE OPTIMAL DURATION OF ANTICOAGULANT THERAPY IN PATIENTS WITH CANCER-RELATED DEEP VEIN THROMBOSIS: THE ADVANTAGE OF USING RESIDUAL VEIN THROMBOSIS (THE CANCER-DACUS STUDY)
ALESSANDRA MALATO* (IT), Sergio Siragusa

O-MO-039
MELISSE, A LARGE MULTICENTRIC OBSERVATIONAL STUDY TO DETERMINE RISK FACTORS OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMMUNOMODULATOR DRUGS
Xavier Leleu* (FR), L Daley, P Rodon, C Hulin, C Daureiac, M Hacini, O Decaux, JC Eisemann, O Fitoussi, B Liouët, L Voillat, B Slama, A Al Jijakli, C Chaleteix, R Costello, A Lamblin, P Natta, JP Fermand, P Moreau

O-MO-040
A SIMPLE NON-INVASIVE DIAGNOSTIC ALGORITHM FOR RULING OUT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN PATIENTS AFTER ACUTE PULMONARY EMBOLISM
Frederikus A Klok* (NL), Sulaiman Surie, Tibor Kempf, Jeroen Eikenboom, Jan van Stralen, Klaas van Kralingen, Arie van Dijk, Hubert Vliegen, Paul Bresser, Kai Wolpert, Menno Huisman

O-MO-041
INSULIN RESISTANCE AND RISK OF VENOUS THROMBOEMBOLISM
Inge M van Schouwenburg* (NL), Bakhtawar K Mahmoodi, Nic JGM Veeger, Karina Meijer, Stephan JL Bakker, Hanneke C Kuin-Nelemans, Ron T Gansevoort

O-MO-042
Ida Johanne Hansen-Krone* (NO), Ida Johanne Hansen-Krone, John-Bjarne Hansen, Kristin Enga, Sigrid Braekkan

O-MO-043
INCIDENCE AND RISK FACTORS FOR POST-DISCHARGE VTE AMONG MEDICALLY ILL PATIENTS HOSPITALIZED IN THE UNITED STATES: 2005-2009
Alex C Spyropoulos* (CA), Maxine Fisher, Charles Mahan, Larry E Fields, Roger Mills, Judith J Stephenson, Tom Wasser, An-Chen Fu, Winslow Klaskala

Thrombotic Thrombocytopenic Purpura
Room B-2

Chairpersons: Paul COPPO (FR) and Masanori Matsumoto (JP)

O-MO-044
STRAIN-SPECIFIC MODIFIER GENE(S) FOR THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) SUSCEPTIBILITY IN THE MOUSE
Yosef Y Kalish* (US), David Siemieniak, Karl Desch, David Ginsburg
ORAL COMMUNICATIONS

Monday, July 25, 2011 8:00 - 9:30

O-MO-045  08:15 - 08:30
SPLEEN-DERIVED ANTI-ADAMTS13 B-CELLS IN RELAPSING TTP PATIENTS USE THE SAME RESTRICTED GENES BUT DIFFERENT IGG SUBCLASS DISTRIBUTION WHEN TREATED WITH OR WITHOUT RITUXIMAB
Monica Maria Schaller* (CH), Karin Sprecher, Irmela Sulzer, Monique Vogel, Beda Stadler, Kent Kentouche, Bernhard Laemmle, Johanna Anna Kremer Hovinga

O-MO-046  08:30 - 08:45
PRECLINICAL EFFICACY TESTING OF BAXTER'S RECOMBINANT ADAMTS13 IN A MOUSE MODEL OF TTP
Alexandra Schiviz* (AT), John Philip Lawo, Kuno Wuersch, Hartmut Ehrlich, Friedrich Schellinger, Hans-Peter Schwarz, Werner Hoellriegl, Eva-Maria Muchitsch

O-MO-047  08:45 - 09:00
AAV LIVER-SPECIFIC EXPRESSION OF A C-TERMINAL TRUNCATED ADAMTS13 VARIANT CORRECTS THROMBOTIC THROMBOCYTOPENIC PURPURA IN A MURINE MODEL
Sheng-Yu Jin* (US), Juan (Jenny) Xiao, Fraser J Wright, X. Long Zheng

O-MO-048  09:00 - 09:15
RESIDUAL PLASMATIC ACTIVITY OF ADAMTS13 IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA AND ITS CORRELATION WITH DISEASE PHENOTYPE
Luca A Lotta* (IT), Haifeng M Wu, Ian J Mackie, Marina Noris, Agnes Veyradier, Samuel J Machin, Giuseppe Remuzzi, Paul Coppo, Marie A Scully, Roberta Donadelli, Chantal Loirat, Richard A Gibbs, April Horne, Shangbin Yang, Roberta Palla, Flora Peyvandi

O-MO-049  09:15 - 09:30
PLASMA MODIFIERS OF VWF CLEAVAGE BY ADAMTS13
Han-Mou Tsai* (US), Wenhua Zhou

Inflammatory Cells and Cytokines

Room C-1

O-MO-050  13:30 - 13:45
SURFACE PROTEIN DISULFIDE ISOMERASE PLAYS AN IMPORTANT ROLE IN BET2 INTEGRIN-MEDIATED NEUTROPHIL ADHESION TO THE ACTIVATED ENDOTHELUM UNDER VASCULAR INFLAMMATION.
Jaehyung Cho* (US), Eunsil Hahm, Stella Huh, Melissa Geyer, Snezna Rogelj

O-MO-051  13:45 - 14:00
COMPLEMENT MBL-ASSOCIATED SERINE PROTEASE-1 (MASP-1) INTERACTS WITH PLASMA CLOT FORMATION - A NOVEL LINK BETWEEN INFLAMMATION AND THROMBOSIS?
Verena Schroeder* (CH), Katharina Hess, Jozsef Dobo, Peter Gal, Ramzi Ajjan

O-MO-052  14:00 - 14:15
PLATELETS REGULATE CD4+ T CELL DIFFERENTIATION VIA MULTIPLE CHEMOKINES
Linjing Zhu* (SE), Zhu Linjing, Norbert Gerdes, Maria Ersoy, Andreas Hermansson, Maud Dalesskog, Ragnhild Stalesen, Paul Hjemdahl, Hu Hu, Goran Hansson, Nailin Li
ORAL COMMUNICATIONS

Monday, July 25, 2011  13:30 - 15:00

**O-MO-053**  14:15 - 14:30
PLASMIN AND CPB CLEAVAGE OF CHEMERIN IS NECESSARY FOR ACTIVATION TO THE ACTIVE FORM, CHEM157S, THAT FUNCTIONS AS A SIGNALING MOLECULE IN GLIOBLASTOMA.
Yasuto Yamaguchi* (US), Xiao-yan Du, Zhao Lei, John Morser, Lawrence L. K. Leung

**O-MO-054**  14:30 - 14:45
LACK OF P2X1 ION CHANNELS INCREASES ENDOTOXEMIA-ASSOCIATED COAGULATION AND ORGAN DAMAGE THROUGH NEUTROPHIL HYPERRESPONSIVENESS
Christelle Lecut* (BE), Celine Facchinetto, Richard J Evans, Vincent Bours, Cecile Oury

**O-MO-055**  14:45 - 15:00
MICROPARTICLES’ APOPTOSIS, ANGIOGENESIS AND MIGRATION EFFECTS IN HEALTHY AND PATHOLOGICAL PREGNANCIES
Anat Aharon* (IL), Einat Shomer, Sarah Katzenell, Yaniv Zipori, Rami Sammour, Benjamin Brenner

**Structures of Coagulation Factors**

*Chairpersons: Weikai Li and James Huntington (UK)*

**O-MO-056**  13:30 - 13:45
STRUCTURAL CHARACTERIZATION OF THE THROMBIN ACTIVATION OF COAGULATION FACTOR VIII STUDIED BY HYDROGEN-DEUTERIUM EXCHANGE MASS SPECTROMETRY
Johan Henrik Faber* (DK), Anders Svensson, Mette Dahl Andersen, Ole Hvilsted Olsen, Henning Stennicke

**O-MO-057**  13:45 - 14:00
PEPTIDES BINDING TO KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR INHIBIT THE INTERACTION WITH FACTOR XA

**O-MO-058**  14:00 - 14:15
THROMBIN ALLOSTERY: EFFECT OF EXOSITE-1 AND EXOSITE-2 BINDERS ON THE ENZYME MOLECULAR RECOGNITION AND CATALYSIS
Vincenzo De Filippis* (IT), Nicola Pozzi, Roberta Frasson, Laura Acquasaliente, Davide Zaramella

**O-MO-059**  14:15 - 14:30
A DYNAMICAL, ATOMIC-DETAILED VIEW OF COMPLEX FORMATION BETWEEN FACTOR VIIA, TISSUE FACTOR, AND FACTOR X ON THE SURFACE OF THE MEMBRANE
Y Zenmei Ohkubo* (US), Emad Tajkhoshid

**O-MO-060**  14:30 - 14:45
Esther Bloem* (NL), Henriet Meems, Maartje van den Biggelaar, Carmen van der Zwaan, Koen Mertens, Alexander B Meijer
ORAL COMMUNICATIONS

Monday, July 25, 2011 13:30 - 15:00

O-MO-061  14:45 - 15:00
IDENTIFICATION OF THE FACTOR XII SEQUENCE THAT MEDIATES CONTACT ACTIVATION IN VITRO AND IN VIVO
Felicitas E Mueller* (SE), Daniela Urlaub, Christoph Kleinschnitz, Thomas Renne

Pathway of Coagulation Factor VIII  Room D

Chairpersons: KAGEHIRO AMANO (JP) and Peter Collins

O-MO-062  13:30 - 13:45
PROLONGED OSCILLATORY SHEAR STRESS INDUCES FVIII EXPRESSION IN ENDOTHELIAL PROGENITOR CELLS
Jonathan Jacob Riches* (CA), Barbara Vidal, Christine Brown, Colleen Noltey, Christine Hough, David Lillicrap

O-MO-063  13:45 - 14:00
INCREASED FACTOR VIII LEVELS IN PATIENTS TREATED FOR VENOUS THROMBOSIS
Vladimir Tichelaar* (NL), Andre B. Mulder, Hanneke C. Kluin-Nelemans, Karina Meijer

O-MO-064  14:00 - 14:15
C1 DOMAIN RESIDUES LYS 2092 AND PHE 2093 ARE OF MAJOR IMPORTANCE FOR THE ENDOCYTIC UPTAKE OF COAGULATION FACTOR VIII
Alexander B Meijer* (NL), Henriet Meems, Maartje van den Biggelaar, Mariska Rondaij, Carmen van der Zwaan, Koen Mertens

O-MO-065  14:15 - 14:30
THE ROLE OF PROTEOLYSIS AT INDIVIDUAL CLEAVAGE SITES IN THE EXPRESSION OF FVIIIA COFACTOR ACTIVITY
Mettine H.A. Bos* (US), Lacramioara Ivanciu, Raffaella Toso, Hua Zhu, Rodney M. Camire

O-MO-066  14:30 - 14:45
MUTATION OF ALA108ILE IN THE FACTOR VIII A1 DOMAIN ENHANCES AFFINITY FOR LIGHT CHAIN VIA INTERACTION WITH THE C2 DOMAIN AND CONTRIBUTES TO INCREASED FACTOR VIII STABILITY
Hironao Wakabayashi* (US), Amy E Griffiths, Masahiro Takeyama, Philip J Fay

O-MO-067  14:45 - 15:00
THE GAP JUNCTION PROTEIN CONNEXIN37 REGULATES FVIII PLASMATIC ACTIVITY
Laurent Burnier* (CH), Pierre Fontana, Brenda R. Kwak, Anne Angelillo-Scherrer

Megakaryopoiesis and Platelet Production  Room E

Chairpersons: Benjamin Kile (AU) and Mortimer Poncz (US)

O-MO-068  13:30 - 13:45
REGULATOR OF G PROTEIN SIGNALING 18 REGULATES MEGAKARYOPOIESIS AND THE CILIA-MEDIATED VERTEBRATE MECHANOSENSORY SYSTEM
Kathleen - Freson* (BE), Sophie Louwette, Chantal Thys, Chantal Wittevrongel, Veerle Labarque, Rik Gijsbers, Zeger Debyser, Jef Arnout, Chris Van Geet, Kathleen Freson
ORAL COMMUNICATIONS

Monday, July 25, 2011 13:30 - 15:00

O-MO-069  13:45 - 14:00
EXPRESSION AND FUNCTION OF LINE-1 DURING MEGAKARYOPOIESIS AND ITS ROLE IN HUMAN PLATELET PROGENY FORMATION
Hansjorg Schwertz* (US), Larry W Kraiss, Andrew S Weyrich

O-MO-070  14:00 - 14:15
SEVERE MACROTROMBOCYTOPENIA AND ABNORMAL MEGAKARYOCYTE DEVELOPMENT IN MICE LACKING SHP1 AND SHP2
Yotis A Senis* (UK), Alexandra Mazharian, Ying-Jie Wang, Jun Mori, Silke Heising, Benjamin G. Neel, Steve P. Watson, Yotis A. Senis

O-MO-071  14:15 - 14:30
SILENCING OF RHOA NUCLEOTIDE EXCHANGE FACTOR, ARHGEF3, REVEALS ITS ROLE IN THROMBOPOIESIS AND IRON UPTAKE
Kathleen - Freson* (BE), Jovana Serbanovic-Canic, Ana Cvejic, Nicole Soranzo, Derek Stemple, Kathleen Freson, Willem Ouwehand

O-MO-072  14:30 - 14:45
GENETIC TARGETING IN MICE REVEALS THE IMPORTANCE OF RHOA FOR PLATELET FUNCTION IN VITRO AND IN VIVO
Irina Pleines* (DE), Ina Hagedorn, Shuchi Gupta, Frauke May, Lidija Chakarova, Jolanda van Hengel, Georg Krohne, Cord Brakebusch, Bernhard Nieswandt

O-MO-073  14:45 - 15:00
REDUNDANT FUNCTIONS OF RHOA AND CDC42 IN PLATELET BIOGENESIS AND ACTIVATION
Lidija Chakarova* (DE), Irina Pleines, Johanna Andersson, Xunwei Wu, Jolanda van Hengel, Georg Krohne, Cord Brakebusch, Bernhard Nieswandt

Hemophilia: Clinical Aspects

Chairpersons: Renchi Yang (CN) and Amy Shapiro (US)

O-MO-074  13:30 - 13:45
IS THERE A NEED FOR A NEW STRATEGY IN GENOTYPING HAEMOPHILIA A FAMILIES?
Shirin Ravanbod* (IR), Maryam Rassoulzadegan, Farzaneh Nassirinejad, Ghasem Rastegar Lari, Said Enayat, Fereydoun Ala

O-MO-075  13:45 - 14:00
XQ28 LARGE DELETIONS DETECTED BY OLIGONUCLEOTIDE ARRAY CGH IN PATIENTS WITH HAEMOPHILIA B AND MENTAL RETARDATION
Christine Vinciguerra* (FR), Marie-Laure Carage, Audrey Labalme, Dorothee Pellecchia, Mathilde Freiligny, Christophe Zawadzki, Claude Negrier, Damien Sanlaville

O-MO-076  14:00 - 14:15
OUTCOME IN MODERATE HAEMOPHILIA
Ingrid den Uijl* (NL), Douwe Biesma, Diederick Grobbee, Kathelijn Fischer
NOT MILD AT ALL: VIRAL INFECTIONS (HIV, HBV, HCV) ARE PRESENT IN OVER ONE THIRD OF 2600 MILD AND MODERATE HEMOPHILIA A PATIENTS AND CAUSE 24% OF THE OBSERVED 30-YEAR MORTALITY
Corien Eckhardt* (NL), Alice S. van Velzen, Marjolein Peters, Kathelijne Peerlinck, Jan Astermark, Rainer Schweab, Charles R.M. Hay, Pieter-Willem Kamphuisen, Maria Elisa Mancuso, Johanna G. van der Bom, Karin Fijnvandraat

HEALTH-RELATED QUALITY OF LIFE IN RELATION TO BONE MINERAL DENSITY IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA
Sylvia von Mackensen* (DE), Mohammed Khawaji, Jan Astermark, Kristina Axesson, Erik Berntorp

OBESITY-RELATED HEMOSTATIC CHANGES IN HEMOPHILIA PATIENTS

SURVIVAL IN CANCER PATIENTS WITH AND WITHOUT VTE IN A PROSPECTIVE CASE-CONTROL STUDY: THE MASTER-ONCOLOGY PROJECT
Giancarlo Agnelli* (IT), Roberto LaBianca, Claudio Cimminiello, Giovanni Di Minno, Paolo Prandoni, Melina Verso

Kristine Blix* (NO), Sigrid K. Braekkan, Finn E. Skjeldestad, John-Bjarne Hansen

OCURRENCE OF MYOCARDIAL INFARCTION, ISCHEMIC STROKE AND PULMONARY EMBOLISM IN LUNG CANCER PATIENTS
PW Kamphuisen* (NL), Myrthe Van Herk-Sukel, Sumitra Shantakumar, Christof Majoor, Lucy Overbeek, Fennie Penning-van Beest, Ron Herings

INCIDENCE AND RISK FACTORS FOR DEVELOPING VENOUS THROMBOEMBOLISM (VTE) IN JAPANESE PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Kenji Yokoyama* (JP), Mitsuru Murata, Yasuo Ikeda, Shinichiro Okamoto

A WORLDWIDE SURVEY TO ASSESS THE CURRENT APPROACH TO THE TREATMENT OF PATIENTS WITH CANCER AND VENOUS THROMBOEMBOLISM
Ankie Kleinjan* (NL), Pieter W. Kamphuisen, Frederick R. Rickles, Charles Faselis, Dalia Mobarek, Harry R. Buller
**ORAL COMMUNICATIONS**

**Monday, July 25, 2011 13:30 - 15:00**

**O-MO-085**  
14:45 - 15:00  
**TUMOR GRADE IS ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: RESULTS FROM THE VIENNA CANCER AND THROMBOSIS STUDY (CATS)**
Jonas Ahlbrecht* (AT), Boris Dickmann, Cihan Ay, Daniela Dunkler, Johannes Thaler, Manuela Schmidinger, Peter Quehenberger, Andrea Haitel, Christoph Zielinski, Ingrid Pabinger

**Thrombotic Disorders: Clinical I  Room B-1**

Chairpersons: Valder Arruda (US) and Mashio Nakamura (JP)

**O-MO-086**  
13:30 - 13:45  
**DABIGATRAN DOES NOT INTERACT WITH PF4 OR PF4 BINDING TO PLATELETS AND MIGHT BE USED AS AN ALTERNATIVE ANTICOAGULANT IN HEPARIN-INDUCED THROMBOCYTOPENIA**
Krystin Krauel* (DE), Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher

**O-MO-087**  
13:45 - 14:00  
**COMPLEMENT INHIBITION ATTENUATES COAGULATION, INFLAMMATION AND FIBROSIS IN THE LUNG OF SEPTIC BABOONS**
Florea Lupu* (US), Hua Zhu, Robert Silasi-Mansat, Narcis Popescu, Glenn Peer, Cristina Lupu, Fetcher B. Taylor, Gary T. Kinasewitz, John D. Lambris

**O-MO-088**  
14:00 - 14:15  
**RIVAROXABAN AS A POTENTIAL ALTERNATIVE ANTICOAGULANT IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA**
Krystin Krauel* (DE), Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher

**O-MO-089**  
14:15 - 14:30  
**VISUALIZING THE ENDOTHELIAL INVOLVEMENT IN THE PATHOGENESIS OF HEPARIN INDUCED THROMBOCYTOPENIA**
Lubica Rauova* (US), Vincent M. Hayes, Douglas B. Cines, Mortimer Poncz

**O-MO-090**  
14:30 - 14:45  
**EXTENDED FOLLOW-UP OF THE MULTI-CENTER PROSPECTIVE COHORT THAT DERIVED THE “MEN CONTINUE AND HERDOO2” CLINICAL DECISION RULE IDENTIFYING LOW RISK UNPROVOKED PATIENTS**
Marc Alan Rodger* (CA), Marc Rodger, Mike Kovacs, Gregoire Le Gal, Susan Kahn, David Anderson, Isabelle Chagnon, Philip Wells, Marc Carrier, Mark Crowther, Richard White, Susan Solymoss, Arnaud Perrier

**O-MO-091**  
14:45 - 15:00  
**EXTRACELLULAR CHROMATIN IS AN IMPORTANT MEDIATOR OF ISCHEMIC STROKE**
Simon F De Meyer* (US), Tobias A Fuchs, Georgette L Suidan, Alex Brill, Daphne Schatzberg, Marc Monestier, Markus Napierei, Hans G Mannherz, Denisa D Wagner
## ORAL COMMUNICATIONS

**Monday, July 25, 2011**  
13:30 - 15:00

### VTE: Epidemiology

**Room B-2**

**O-MO-092**  
13:30 - 13:45  
PREVALENCE OF CHRONIC THROMBO-EMBOLIC PULMONARY HYPERTENSION AFTER ACUTE PULMONARY EMBOLISM: A PROSPECTIVE MULTICENTER STUDY  
Olivier Sanchez* (FR), Laurent Guerin, Francis Couturaud, Florence Parent, Florence Gilliazeau, Gerald Simonneau, Guy Meyer

**O-MO-093**  
13:45 - 14:00  
SEASONAL VARIATION IN THE OCCURRENCE OF VENOUS THROMBOEMBOLISM IN CANADA  
Vicky Tagalakis* (CA), Dimple Kondal, Antonio Ciampi, Susan Rebecca Kahn

**O-MO-094**  
14:00 - 14:15  
YEAR-LONG, REAL-TIME AUDIT OF HOSPITAL ACQUIRED (HAT) VENOUS THROMBOEMBOLIC EVENTS (VTE), FROM RADIOLOGICAL INVESTIGATIONS IN AN EXEMPLAR CENTRE  
Huw Raymond Rowswell* (UK), Timothy Nokes, Kathy Clarke

**O-MO-095**  
14:15 - 14:30  
INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN THE GENERAL POPULATION - VTE EPIDEMIOLOGY GROUP (VEG) STUDY  

**O-MO-096**  
14:30 - 14:45  
INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN THE MEDICALLY-ILL POPULATION - VTE EPIDEMIOLOGY GROUP (VEG) STUDY  
Alexander T Cohen* (UK), Stephen Rietbrock, Carlos Martinez

**O-MO-097**  
14:45 - 15:00  
RECURRENT VENOUS THROMBOSIS: INCIDENCE AND CHARACTERISTICS IN A LARGE COHORT OF VT PATIENTS (MEGA)  
Linda E Flinterman* (NL), Astrid Hylckama Vlieg, Suzanne C Cannegieter, Frits R Rosendaal

### Platelet Receptors

**Room C-1**

**O-MO-098**  
15:30 - 15:45  
COMPARISON OF GENETIC AND ANTIBODY-INDUCED GPVI DEFICIENCY IN DIFFERENT MURINE ARTERIAL THROMBOSIS MODELS  
Ina Hagedorn (DE), Markus Bender*, Bernhard Nieswandt

**O-MO-099**  
15:45 - 16:00  
SEVERELY DEFECTIVE HEMOSTASIS AND ARTERIAL THROMBUS FORMATION IN GPVI/CLEC-2 DOUBLE-DEPLETED MICE  
Frauke May* (DE), Markus Bender, Ina Hagedorn, Attila Braun, Bernhard Nieswandt
ORAL COMMUNICATIONS

Monday, July 25, 2011 15:30 - 17:00

O-MO-100

A ROLE OF PLATELET C-TYPE LECTIN LIKE RECEPTOR-2 (CLEC-2) IN THROMBUS FORMATION IN VIVO.
Osamu Inoue* (JP), Hokamura Kazuo, Umemura Kazuo, Hatakeyama Kinta, Asada Yuiro, Ozaki Yukio, Suzuki-Inoue Katsue

O-MO-101

CLEC-2 REGULATES LYMPHANGIOGENESIS BY INHIBITING PROLIFERATION, MIGRATION, AND TUBE FORMATION OF LYMPHATIC ENDOTHELIAL CELLS.
Makoto Osada* (JP), Osamu Inoue, Guo Ding, Masanori Hirashima, Yukio Ozaki, Katsue Suzuki-Inoue

O-MO-102

A NOVEL SPLICE VARIANT OF THE MER RECEPTOR TYROSINE KINASE FUNCTIONS AS AN INHIBITOR OF THE GAS6/TAM SIGNALING PATHWAY AND DECREASES PLATELET ACTIVATION RESPONSES
Brian R Branchford* (US), Susan Sather, Gary Brodsky, Tara White-Adams, Deborah DeRyckere, Keith Neves, Douglas Graham, Jorge Di Paola

O-MO-103

PLATELET NMDA RECEPTORS AS MEDIATORS OF GLUTAMATE EFFECTS ON PLATELET FUNCTION
Maggie L Kalev-Zylinska* (NZ), Marie-Christine Morel-Kopp, Paul Sun, Deborah Young, Matthew J During, Christopher M Ward

Laboratory Tests for Coagulopathy Room C-2

Chairpersons: Masashi Taki (JP) and Anne Angelillo-Scherrer (CH)

O-MO-104

SEVERITY OF CLINICAL PHENOTYPE IN PEDIATRIC HEMOPHILIA A SUBJECTS IS INVERSELY CORRELATED WITH TISSUE FACTOR-BEARING MICROPARTICLE LEVELS AND ACTIVITY
Mona D Shah* (US), Angela L Bergeron, Molly Behymer, Noha Eyada, Swapan K Dasgupta, Perumal Thiagarajan, Jing-fei Dong

O-MO-105

FVIII-SPECIFIC CD4+ T CELLS ARE IMPORTANT REGULATORS OF FVIII INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A
Christoph Hofbauer* (AT), Eva Altinger, Peter Allacher, Johannes Oldenburg, Jerzy Windyga, Hans Peter Schwarz, Birgit Maria Reipert

O-MO-106

ENOXAPARIN DOWN REGULATES INFLAMMATORY AND THROMBOTIC MEDIATORS IN CANCER PATIENTS AS STUDIED USING PROTEIN AND BIOCHIP ARRAY APPROACHES
Debra A Hoppensteadt* (US), Evangelos Litinas, Hussein Khan, Josephine Cunanan, Indermohan Thethi, Jawed Fareed

O-MO-107

PROCDOAGULANT AND INFLAMMATORY MEDIATORS IN SMALL CELL LUNG CARCINOMA: POTENTIAL ROLE IN THROMBOEMBOLIC COMPLICATIONS
Indermohan Thethi* (US), Debra Hoppensteadt, Husseinf Khan, Muzzafer Demir, Cafer Adiguzel, Evangelos Litinas, Jawed Fareed
ORAL COMMUNICATIONS

Monday, July 25, 2011 15:30 - 17:00

O-MO-108  16:30 - 16:45
ADAPTATION OF THE CALIBRATED AUTOMATED THROMBOGRAPHY ASSAY FOR ACCURATE PK/PD MEASUREMENT OF BAY 86-6150 FVIIA THERAPY IN CLINICAL TESTING FOR HEMOPHILIA A
Timothy Myles* (US), Ji-Yun Kim, Claus Bornaes, Juliang Pan, John E. Murphy, Jesper Haaning

O-MO-109  16:45 - 17:00
SIGNIFICANT IMPROVEMENT OF THE BETWEEN-LABORATORY VARIATION OF FVIII INHIBITOR TESTING: RESULTS OF A WORKSHOP
H W Verbruggen* (NL), Bert Verbruggen, Myriam Dardikh, Clint van Duren, Robert Polenewen, Piet Meijer

Tissue Factor and Tissue Factor Pathway Inhibitor
Chairpersons: ESTEBAN GABAZZA (JP) and

O-MO-110  15:30 - 15:45
TISSUE FACTOR-DEPENDENT CHEMOKINE PRODUCTION AGGRAVATES EXPERIMENTAL COLITIS
Karla CS Queiroz* (NL), Cornelis van t Veer, Yascha van den Berg, Jan Willems Duitman, Henri H Versteeg, Hella L Aberson, Angelique P Groot, Marlen I Verstege, Joris J.T.H. Roelofs, Anje A te Velde, C Arnold Spek

O-MO-111  15:45 - 16:00
TISSUE FACTOR DEENCRYPTION IS REQUIRED FOR NORMAL DEVELOPMENT AND HEMOSTASIS
Susanna HM Sluka* (CH), Alexander Akhmedov, Giovanni G Camici, Thomas F Luscher, Felix C Tanner

O-MO-112  16:00 - 16:15
INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) BY SMALL PEPTIDES PROTECTS FXA AND ENHANCES FXA AND THROMBIN FORMATION IN MODEL SYSTEMS AND IN PLASMA
Michael Dockal* (AT), M. C.L.G.D. Thomassen, A. C.A. Heinzmann, C. Duckers, R. Hartmann, F. Scheiflinger, J. Rosing

O-MO-113  16:15 - 16:30
INHIBITION OF TISSUE FACTOR ATTENUATES COAGULATION AND INFLAMMATION IN A MOUSE MODEL OF SICKLE CELL DISEASE
Pichika Chantrathammachat* (US), Nigel S. Key, Daniel Kirchhofer, Nigel Mackman, Rafal Pawlinski

O-MO-114  16:30 - 16:45
TISSUE FACTOR PATHWAY INHIBITOR APTAMER AS A POTENTIAL DRUG FOR HEMOPHILIA TREATMENT
Saulius Butenas* (US), Matthew Gissel, Thomas Orfeo, Kenneth G. Mann

O-MO-115  16:45 - 17:00
TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AND TISSUE FACTOR (TF) CO-LOCALIZE IN LIPID RAFTS OF PLATELET MEMBRANES: MECHANISM TO INHIBIT PLATELET PROCOAGULANT (PCA) ACTIVITY?
Panes Olga* (CL), Cesar Gonzalez, Valeria Matus, Jaime Pereira, Diego Mezzano
ORAL COMMUNICATIONS

Monday, July 25, 2011 15:30 - 17:00

P2Y₁₂ Antagonists  Room E

Chairpersons: Christian Gachet (FR) and Stan Heptinstall (UK)

O-MO-116  15:30 - 15:45
DETECTION OF CLOPIDOGREL RESISTANCE: COMPARISON OF A NEW, P2Y₁₂ RECEPTOR SPECIFIC PLATELET AGGREGATION TEST AND OTHER LABORATORY METHODS IN PATIENTS ON CLOPIDOGREL MONOTHERAPY
Zsuzsa Bagoly* (HU), Ferenc Sarkady, Tunde Magyar, Endre Pongracz, Janos Kappelmayer, Laszlo Csiba, Laszlo Muszbek

O-MO-117  15:45 - 16:00
BENEFIT OF TAILORED THERAPY WITH HIGH CLOPIDOGREL MAINTENANCE DOSE ACCORDING TO CYP2C19 GENOTYPES IN CLOPIDOGREL NON RESPONDERS UNDERGOING CORONARY STENTING FOR ACS
Marie-Christine Alessi* (FR), Thomas Cuisset, Jacques Quilici, William Cohen, Laurent Foucard, Charlotte Grosdidier, Noemie Saut, Benedicte Gaborit, Mathieu Pankert, Laurent Molines, Pierre-Emmanuel Morange, Jean Louis Bonnet

O-MO-118  16:00 - 16:15
PLATELET INHIBITION BY ADJUNCTIVE CILOSTAZOL VERSUS HIGH MAINTENANCE-DOSE CLOPIDOGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO CYTOCHROME P450 2C19 GENOTYPE
Young-Hoon Jeong* (US), In-Suk Kim, Yongwhi Park, Seong-Eun Yun

O-MO-119  16:15 - 16:30
IS THERE A “REBOUND” AFTER CESSION OF ANTIPLATELET THERAPY? FIRST COMPARISON OF IRREVERSIBLE VERSUS REVERSIBLE P2Y₁₂ RECEPTOR BLOCKER
Paul Alfred Gurbel* (US), Kevin P Bliden, Mark J Antonino, Martin Geshelf, Young-Hoon Jeong, Udaya S Tantry

O-MO-120  16:30 - 16:45
ROLE OF NEWLY FORMED PLATELETS IN THROMBUS FORMATION AFTER CLOPIDOGREL TREATMENT: COMPARISON TO THE REVERSIBLY BINDING P2Y₁₂ ANTAGONIST TICAGRELOR
Marijke J.E. Kuijpers (NL), Remco T.A. Megens, Elham Nikookhesal, Marion A.H. Feige, Mirjam G.A. oude Egbrink, Jo G.R. De Mey, J. J.J. van Giezen, Johan W.M. Heemskerk*

O-MO-121  16:45 - 17:00
BF061, A NOVEL ANTIPLATELET AND ANTITHROMBOTIC AGENT TARGETING P2Y₁₂ AND PDE
Liang Hu* (CN), Zhichao Fan, Hongguang Du, Ran Ni, Si Zhang, Kanhuai Yin, Jianqin Ye, Yan Zhang, Xunbing Wei, Xiaohui Zhang, Peter Gross, Satya P. Kunapul, Zhongren Ding

Acquired Coagulation Disorders  Sakura

Chairpersons: Paul Edward Monahan

O-MO-122  15:30 - 15:45
BIOCHEMICAL CHARACTERIZATION OF ANTI-FACTOR XIII AUTOANTIBODIES IN PATIENTS WITH HEMORRHAGIC ACQUIRED FACTOR XIII DEFICIENCY
Masayoshi Soun* (JP), Hiroki Iwata, Wei Guang Zhang, Akitada Ichinose
ORAL COMMUNICATIONS

Monday, July 25, 2011 15:30 - 17:00

O-MO-123  15:45 - 16:00
ROTATIONAL THROMBOELASTOMETRY IN CIRRHOSIS: HYPERCOAGULABLE AND HYPERFIBRINOLYTIC
Paul Harrison* (UK), Vipil Jairath, Simon Stanworth, Amber Raja, Jane Collier, Mike Murphy, Ellie Barnes

O-MO-124  16:45 - 17:00
LEFT VENTRICULAR ASSIST DEVICES CAUSE LOSS OF VON WILLEBRAND FACTOR ACTIVITY BY PROMOTING ITS PROTEOLYTIC CLEAVAGE
Han-Mou Tsai* (US), William J Weiss, Evan Leibner, Branka Lukic, Wenhua Zhou, Gerson Rosenberg

O-MO-125  16:15 - 16:30
FACTOR SEVEN ACTIVATING PROTEASE (FSAP) IS ACTIVATED MASSIVELY IN MULTIPLE TRAUMA PATIENTS AND IN TURN ACTIVATES COMPLEMENT FACTORS.
Sandip M Kanse* (DE), Andrea Gallenmueller, Marcus Krueger, Markus Huber-Lang

O-MO-126  16:30 - 16:45
POST CARDIAC COAGULOPATHY; A 48 HOURS LONGITUDINAL DESCRIPTIVE STUDY BASED ON WHOLE BLOOD CLOT FORMATION AND THROMBIN GENERATION
Mariann Tang* (UK), Per Wierup, Kirsten Christiansen, Jacob Greisen, Benny Soerensen

O-MO-127  16:00 - 16:15
ACTIVATED PROTEIN C IS A PRINCIPLE MEDIATOR OF ACUTE TRAUMATIC COAGULOPATHY
Ross Davenport* (UK), Claire Rourke, Joanna Manson, Henry De’Ath, Sean Platton, Amy Coates, Daniel Hart, Pasi Pears, John Pasi, Simon Stanworth, Karim Brohi

Malignancy and Thrombosis II  Room A

Chairpersons: Sigrid Braekkan (NO) and Roberto Labianca

O-MO-128  15:30 - 15:45
VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: REGIONAL LYMPH NODE METASTASIS AS A RISK FACTOR
Boris Dickmann* (AT), Jonas Ahlbrecht, Cihan Ay, Daniela Dunkler, Johannes Thaler, Roman Kanz, Werner Scheithauer, Peter Quehenberger, Christoph Zielinski, Ingrid Pabinger

O-MO-129  15:45 - 16:00
INCIDENTAL AND SYMPTOMATIC VENOUS THROMBOEMBOLIC EVENTS ARE ASSOCIATED WITH INCREASED MORTALITY IN LUNG CANCER PATIENTS.
Gregory Clayton Connolly* (US), Laurel Menapace, Tarek Sousou, Saman Safadjou, Khorana Alok

O-MO-130  16:00 - 16:15
MALIGNANCIES AND RISK OF RECURRENT VENOUS THROMBOSIS
Jasmijn F Timp* (NL), Linda E Flinterman, Astrid van Hylckama Vlieg, Frits R Rosendaal, Suzanne C Cannegieter
## ORAL COMMUNICATIONS

**Monday, July 25, 2011**  
**15:30 - 17:00**

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-MO-131</td>
<td>VENOUS THROMBOEMBOLISM (VTE) IN THE CANCER OUTPATIENT SETTING: CONTEMPORARY RATES AND PREDICTORS IN THE U.S.</td>
<td>Alok A Khorana* (US), Mehul Dalal, Jay Lin, Gregory Connolly</td>
</tr>
<tr>
<td>O-MO-132</td>
<td>CELL FREE DNA AS A NOVEL PROCOAGULANT STIMULUS IN BREAST CANCER CHEMOTHERAPY</td>
<td>Laura Swystun* (CA), Patricia C Liaw</td>
</tr>
<tr>
<td>O-MO-133</td>
<td>MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY AND OCCURRENCE OF VENOUS THROMBOEMBOLISM IN BRAIN, GASTROINTESTINAL AND PANCREATIC CANCER</td>
<td>Cihan Ay* (AT), Nigel Mackman, Nigel S Key, Alexandra Kaider, Johannes Thaler, Christine Marosi, Christoph Zielinski, Ingrid Pabinger</td>
</tr>
</tbody>
</table>

**Von Willebrand Disease**  
Room B-1  
Chairpersons: Ulrich Budde (DE) and

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-MO-134</td>
<td>CHARACTERIZATION OF BLOOD OUTGROWTH ENDOTHELIAL CELLS DERIVED FROM VON WILLEBRAND DISEASE PATIENTS</td>
<td>Jiong-Wei Wang* (NL), Eveline Bouwene, Carolina Pintao, Jan Voorberg, Karine M Valentiijn, Hetty C de Boer, Pieter H Reitsma, Jeroen Eikenboom</td>
</tr>
<tr>
<td>O-MO-135</td>
<td>GENETIC VARIATIONS IN SNARE PROTEIN GENES DETERMINE VON WILLEBRAND FACTOR PLASMA LEVELS IN PATIENTS WITH TYPE I VON WILLEBRAND DISEASE</td>
<td>Janine E. van Loon* (NL), Eva M. de Wee, Yvonne V. Sanders, Moniek P.M. de Maat, Frank W.G. Leebeek</td>
</tr>
<tr>
<td>O-MO-136</td>
<td>AN L1278P VON WILLEBRAND FACTOR (VWF) MUTATION IDENTIFIED IN A TYPE 1 VWD PATIENT CAUSES REDUCED VWF SECRETION AND INCREASED VWF CLEARANCE</td>
<td>Sandra Haberichter* (US), Jocelyn A. Schroeder, Paula M. Jacobi, Ashley L. Gehrand, Kenneth D. Friedman, Donna DiMichele, Robert R Montgomery</td>
</tr>
<tr>
<td>O-MO-137</td>
<td>GENETIC VARIABILITY OF THE CLEC4M ENDOTHELIAL LECTIN RECEPTOR IN TYPE 1 VON WILLEBRAND DISEASE</td>
<td>Natalia Rydz* (CA), B. Boonyawat, J. J. Riches, W. Hopman, A. Paterson, R. Montgomery, D. Lillicrap, P. D. James, For the ZPMCB-VWD Study Group</td>
</tr>
<tr>
<td>O-MO-138</td>
<td>COPY NUMBER VARIATION IS A SIGNIFICANT CONTRIBUTOR TO TYPE 1 VWD PATHOGENESIS IN THE EU MCMDM-1VWD COHORT</td>
<td>Daniel J Hampshire* (UK), Ashley Cartwright, Lisa D Bloomer, Ahlam M Al-Buhairan, Raymon N C P Vizelaar, David Habart, Frank G H Hill, Francesco Rodeghiero, Ulrich Budde, Jeroen C J Eikenboom, Ian R Peake, Anne C Goodeve, on behalf of the EU-VWD and ZPMCB-VWD study groups</td>
</tr>
</tbody>
</table>
ORAL COMMUNICATIONS

Monday, July 25, 2011 15:30 - 17:00

O-MO-139  16:45 - 17:00
CLASSIFICATION OF A LARGE COHORT OF PATIENTS WITH VON WILLEBRAND DISEASE BETWEEN 2004 AND 2010
Ulrich Budde* (DE), Sonja Schneppenheim, Rita Dittmer, Reinhard Schneppenheim

Chairpersons: Nobuo Nagai (JP) and Alvin Schmaier (US)

O-MO-140  15:30 - 15:45
NON-HUMAN PRIMATE MODEL OF HEMOLYTIC UREMIC SYNDROME AND THERAPEUTIC TESTING
Shinichiro Kurosawa* (US), Deborah J. Stearns-Kurosawa

O-MO-141  15:45 - 16:00
CD36 PARTICIPATES IN A SIGNALING PATHWAY THAT REGULATES ROS FORMATION AND CONTRIBUTES TO THROMBOSIS AND NEOINTIMAL HYPERPLASIA
Wei Li* (US), Roy L Silverstein

O-MO-142  16:00 - 16:15
IDENTIFICATION OF ENU-INDUCED AND STRAIN MODIFIER GENES FOR FACTOR V LEIDEN DEPENDENT THROMBOSIS IN THE MOUSE
Randal J Westrick* (US), Guojing Zhu, Sara L Manning, Angela Y Yang, Audrey C.A. Cleuren, David R Siemieniak, David Ginsburg

O-MO-143  16:15 - 16:30
EARLY DEATH OF FACTOR V LEIDEN HEMIZYGOUS MICE: A FATAL ABSENCE OF WILD TYPE FV ANTICOAGULANT FUNCTION
Audrey CA Cleuren* (NL), Hongmin Sun, Guojing Zhu, Bart JM van Vlijmen, Pieter H Reitsma, David Ginsburg, Randal J Westrick

O-MO-144  16:30 - 16:45
REGULATION OF VKORC1 EXPRESSION BY MICRORNAS AND ITS POTENTIAL EFFECT ON ACENOCOUMAROL REQUIREMENTS.
Virginia Perez-Andreu* (ES), Raul Teruel, Rocio Gonzalez-Conejero, Javier Corral, Vanessa Roldan, Nuria Garcia-Barbera, Maria Jose Gomez-Lechon, Vicente Vicente-Garcia, Constantino Martinez

O-MO-145  16:45 - 17:00
ADMINISTRATION OF THE ANTI-FXI ANTIBODY, 14E11, IMPROVES NEUROLOGICAL FUNCTION IN A MOUSE MODEL OF STROKE
Owen J McCarty* (US), Sawan Hurst, Norah Verbout, Erik I Tucker, David Gailani, Michelle A. Berny-Lang, Andras Gruber
POSTER PRESENTATIONS

Monday, July 25, 2011

P-LB-001  **HEPARIN-INDUCED THROMBOCYTOPENIA (HIT); RETROSPECTIVE ANALYSIS OF DATA ON INCIDENCE AND OUTCOMES (HIT-RADIO STUDY)**
David J Kuter* (US), E Gerstenberger, Barbara A Konkle, L Uhl, S F Assmann, T L Ortel

P-LB-002  **EFFECTS OF TANSHINONEIA ON INFLAMMATORY CYTOKINES AND GMP-140 IN THE PATIENT WITH KAWASAKI DISEASES**
Qing Zhang* (CN)

P-LB-003  **PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) WITH THE ULTRA-LOW-MOLECULAR-WEIGHT HEPARIN (ULMWH) SEMULOPARIN IN CANCER PATIENTS INITIATING CHEMOTHERAPY: THE SAVE ONCO STUDY**
Giancarlo Agnelli† (IT), Daniel George, William Fisher, Ajay Kakkar, Michael R. Lassen, Patrick Mismetti, Patrick Mouret, Umesh Chaudhari, Alexander G.G. Turpie

P-LB-004  **MULTI-CENTER TRIAL OF DESIRUDIN FOR THE PROPHYLAXIS OF THROMBOSIS: AN ALTERNATIVE TO HEPARIN-BASED ANTICOAGULATION: RESULTS FROM THE DESIRABLE TRIAL**
Jerrold H Levy* (US), Sergio D Bergese, Amir Jaffer, Harold S Minkowitz, Michael A Kurz, David C Sane

P-LB-006  **RIVAROXABAN VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS: ANALYSIS OF FACTORS CONTRIBUTING TO BENEFIT AND RISK IN MAGELLAN**
Alexander T Cohen* (UK), Theodore E. Spiro, Harry R. Buller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex Spyropoulos, Victor Tapson

P-LB-007  **XAMOS: A NON-INTERVENTIONAL STUDY OF RIVAROXABAN IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AFTER HIP OR KNEE SURGERY**
Sylvia Haas* (DE), Alexander G.G. Turpie, Michael Lassen, Lorenzo Mantovani, Reinhold Kreutz, Waheed Jamal, Andre Schmidt

P-LB-008  **THE ROLE OF HLA-ANTIGENS AS PREDISPOSING AND/OR PROTECTIVE FACTORS IN PATIENTS WITH IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA**
Marie-Luise John* (DE), Inge Scharrer

P-LB-009  **METHOD COMPARISON BETWEEN RISTOCETIN-INDEPENDENT AND RISTOCETIN-DEPENDENT VWF ACTIVITY ASSAYS**
Michelle Ann Stapleton* (US), Marcy Lloyd, Allison Kremers

P-LB-011  **PROTEIN S ALTERS DIFFERENTIATION, MATURATION AND ANTIGEN PRESENTATION OF MURINE DENDRITIC CELLS IN VITRO**
Yuki Matsushima* (JP), Masaaki Toda, Yasushi Miyake, Atsushi Yasukawa, Corina N Gabazza, Takehiro Takagi, Masahiro Naito, Daniel Boveda Ruiz, Paloma Gil Bernabe, Osamu Taguchi, John Morser, Esteban C Gabazza

P-LB-012  **MOLECULAR BASIS OF HEREDITARY FACTOR VII DEFICIENCY IN SEVEN UNRELATED TUNISIAN PATIENTS**
Hejer Elmahmoudi* (TN), Rim Sassi, Asma Jlizi, Kaouther Zahra, Belkis Meddeb, Amel Elgaaied Ben Ammar, Emna Gouider

P-LB-013  **RE-CANALIZATION OF CHRONIC DEEP VEIN THROMBOSIS WITH COMBINATION OF HERBAL MEDICINES DESCRIBED IN AYURVEDA**
Abhay Narayan Kulkarni* (IN)
POSTER PRESENTATIONS

Monday, July 25, 2011

Signal transduction of platelet activation

P-MO-001  REGULATION OF RAP1B LOCALIZATION AND FUNCTION BY PROSTAGLANDIN E1 (PGE1)
Jaclyn A Porath* (US), Jenny H Petkova, Gilbert C White, II

P-MO-002  PLATELET REACTIVITY INCREASED BY ADVANCE GLYCATED HEMOGLOBIN
Bahram Alamdary Badlou* (IR), M. Bakhti, M. Habibi-Rezaei, A.A. Moosavi-Movahedi, SMR. Tabatabai, M. Asadifar, M. Ahmadinejad

P-MO-003  PLATELET ACTIVATORS (VWF, THROMBIN, COLLAGEN) INITIATE NOVEL INHIBITORY PATHWAYS INVOLVING NO-INDEPENDENT ACTIVATION OF PKG AND CAMP-DEPENDENT ACTIVATION OF PKA
Stepan Gambaryan* (DE), Anna Kobsar, Sabine Herterich, Suzanne M Lohmann, Ulrich Walter

P-MO-004  PEAR1 PROMOTES STABILIZATION OF PLATELET AGGREGATES VIA A PI3K PATHWAY
Alexandre Kauskot* (BE), Serena Loyen, Chantal Thys, Peter Verhamme, Marc Florimond Hoylaerts

P-MO-005  THE ALZHEIMER’S DISEASE ASSOCIATED AMYLOID β-PEPTIDE SUPPORTS PLATELET ADHESION AND ACTIVATION.
Ilaria Canobbio* (IT), Silvia Catricala, Gianni Guidetti, Lina Cipolla, Alessandra Consonni, Cesare Baldiunu, Mauro Torti

P-MO-006  SYNAPTOTAGMIN-LIKE PROTEIN 4 REGULATES PLATELET GRANULE SECRETION
Ashling Hampson* (IE), Olga Neumuller, Kristina Gegenbauer, Albert Smolenski

P-MO-007  12-LIPOOXYGENASE MEDIATES PRO- AND ANTI-THROMBOTIC EFFECTS IN HUMAN PLATELETS VIA METABOLISM OF ARACHIDONIC ACID AND DGLA TO 12(S)-HETE AND 12(S)-HETRE, RESPECTIVELY
Michael Holinstat* (US), Jennifer Yeung, Patrick L. Apopa, Joanne Vesci, Theodore R. Holman

P-MO-008  REGULATOR OF G-PROTEIN SIGNALLING PROTEIN 18 (RGS18) IS A TARGET OF CYCLIC NUCLEOTIDE MEDIATED PLATELET INHIBITION
Kristina Gegenbauer* (IE), Giuliano Elia, Alfonso Blanco, Albert Smolenski

P-MO-009  PHOSPHOLIPASE D1, BUT NOT PLD2, IS ESSENTIAL FOR EFFICIENT GPIB-DEPENDENT αIIβ3 ACTIVATION
David Stegner* (DE), Ina Thielmann, Ina Hagedorn, Christoph Kleinschnitz, Attila Braun, Johan W.M. Heemskerk, Guido Stoll, Bernhard Nieswandt

P-MO-010  AGONIST INDUCED αIIBβ3 ACTIVATION IN GENETICALLY ENGINEERED HUMAN MEGAKARYOBLASTIC CELL LINE, CMK.
Tsuyoshi Nakazawa* (JP), Tsuyoshi Kamas, Kazunobu Kiyomizu, Seiji Tadokoro, Shigenori Honda, Hirokazu Kashiwagi, Yuzuru Kanakura, Yoshiaki Tomiyama

Biology of platelets

P-MO-011  VWF MORPHOLOGY ON FIBRILLAR AND NON-FIBRILLAR COLLAGEN CONTROLS PLATELET DEPOSITION AT ARTERIAL AND PATHOLOGICAL SHEAR: SIPA IN MICROFLUIDIC CHAMBERS IS SENSITIVE TO αIIB3.
Thomas Colace* (US), Scott L Diamond

P-MO-012  DIFFERENTIAL REGULATION OF PLATELET CONTACT AND SPREADING MONITORED BY REFLECTION INTERFERENCE CONTRAST MICROSCOPY
Dooyoung Lee* (US), Karen P. Fong, Lawrence F. Brass, Daniel A. Hammer
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-013  PLATELET REACTIVITY IS A STABLE AND GLOBAL PHENOMENON IN ASPIRIN-TREATED CARDIOVASCULAR PATIENTS
Anne Zufferey* (CH), Jean-Luc Reny, Christophe Combescure, Philippe de Moerloose, Jean-Charles Sanchez, Pierre Fontana

P-MO-014  THE RESTRICTED DELETION OF THE PODOCALYXIN GENE IN MEGAKARYOCYTES PERTURBS THE CONTROL OF HEMOSTASIA
Matilde S. Ayuso* (ES), Miguel Pericacho, Sonia Alonso-Martin, Susana Larrueca, Consuelo Gonzalez-Manchon, Dario Fernandez, Roberto Parrilla

P-MO-015  MEASUREMENT OF PROCOAGULANT MICROVESICLES GENERATED WITHIN AGEING PLATELET CONCENTRATES
Abdulmajeed Abdullah Albanyan* (SA), Abdulmajeed Albanyan, B Curry, R Dragovic, C Gardiner, J Biggenstaff, M Murphy, P Harrison

P-MO-016  BCL-X\_ INHIBITORY BH3 MIMETICS CAN INDUCE A TRANSIENT THROMBOCYTOPATHY THAT UNDERMINES THE HEMOSTATIC FUNCTION OF PLATELETS
Simone Marianne Schoenwalder* (AU), Kate Jarman, Elizabeth Gardiner, JianLin Qiao, Michael J White, Emma C Josefsson, Imalia Alwis, Robert K Andrews, Kylie D Mason, Hatem H Salem, David C.S. Huang, Benjamin T Kile, Andrew W Roberts, Shaun P Jackson

P-MO-017  DETECTION OF THE AMINOPHOSPHOLIPID TRANSLOCASE ATP8A1 IN HUMAN PLATELETS AND ITS CLEAVAGE WHEN CALPAIN IS ACTIVATED
Hong Wang (CA), Adam M Gwozdz, KW Annie Bang, Marian A Packham, Margaret L Rand* (AUS)

Integrins and other glycoproteins

P-MO-020  MOLECULAR BASIS FOR FIBRIN BINDING BY PLATELET INTEGRIN \(\alpha_{\text{IIb}}\beta_{3}\)
Nataly Podolnikova* (US), Valentin P. Yakubenko, Tatiana P. Ugarova

P-MO-021  THE PDZ PROTEIN SYNTENIN-1 ASSOCIATES WITH TETRASPANINS CD63 AND CD9 IN ACTIVATED PLATELETS
Sara J Israels* (CA), Eileen M. McMillan-Ward

P-MO-022  STAPHYLOCOCCUS AUREUS IRON REGULATED SURFACE PROTEIN (ISDB) DIRECTLY BINDS TO PLATELET INTEGRIN GPIIB/IIIA
Marta Anna Zapotoczna* (IE), Timothy J. Foster

P-MO-023  COATED PLATELETS FORM AGGREGATES WITH NON-COATED ONES, BUT DO NOT AGGREGATE WITH EACH OTHER
Alena O Yakimenko (RU), Yana N Kotova, Fazoil I Ataullakhanov, Mikhail A Panteleev*

P-MO-024  GLANZMANN’S THROMBASTHENIA: IDENTIFICATION OF 25 NEW MUTATIONS IN 25 PATIENTS
qingya cui* (CN), qingya cui, ziqiang yu, jian su, xia bai, wei zhang, mingqing zhu, wenhong shen, li chen, changgeng ruan
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-025  APPLICATION OF αIIBβ3 NANODISCS TO DIRECTLY ASSESS EXTENSION OF αIIBβ3 INDUCED BY αIIBβ3 ANTAGONISTS BY ELECTRON MICROSCOPY.
Won-Seok Choi* (US), Barry S. Coller

P-MO-026  GPIIBIIIA-MEDIATED PLATELET APOPTOSIS
Asuman Mutlu (CA), Armen V Gyuikhandanyan, Sergiy Mykhaylov, David J Allen, Elena Lyubimov, Anna Chavlovski, Alan Lazarus, John Freedman, Valery Leytin*

P-MO-027  THROMBIN-INDUCED INTERACTION BETWEEN HUMAN PLATELETS AND FIBRINOGEN γ-CHAIN DODECAPEPTIDE-MODIFIED LIPOSOMES AS A SYNTHETIC PLATELET SUBSTITUTE.
Hidenori Suzuki* (JP), Yosuke Okamura, Yasuo Ikeda, Shinji Takeoka, Makoto Handa

P-MO-028  A MUTATION IN THE β3 CYTOPLASMIC TAIL WHICH CAUSES VARIANT GLANZMANN THROMBASTENIA ABROGATES THE TRANSITION OF αIIBβ3 TO THE ACTIVE STATE
Hagit Hauschner* (IL), Ronit Mor-Cohen, Uri Seligsohn, Nurit Rosenberg

P-MO-029  DIFFERENT STRUCTURAL AND FUNCTIONAL ROLES FOR INTEGRIN UNIQUE DISULFIDE BONDS IN THE β3 SUBUNIT OF αIIBβ3 AND αVβ3
Ronit Mor-Cohen* (IL), Nurit Rosenberg, Yulia Einav, Ehud Zelzion, Wissam Mansour, Yulia Averbukh, Uri Seligsohn

P-MO-030  GPVI, WHICH RECOGNIZES A HIGHER ORDER STRUCTURE IN COLLAGEN, IS MARKEDLY INCREASED UPON PLATELET ACTIVATION
Stephanie May Jung* (UK), Masaaki Moroi, Kenji Soejima, Tomohiro Nakagaki, Michael Berndt, Elizabeth Gardiner, Steve P Watson, Richard W Farndale

Platelet receptors

P-MO-031  LXR AS AN ANTI-THROMBOTIC TARGET
Michael Spyridon* (UK), Leonardo A Moraes, Chris I Jones, Tanya Sage, Parvathy Sasikumar, Jonathan M Gibbins

P-MO-032  THE INTRACELLULAR COLLAGEN CHAPERONE HSP47 IS A COLLAGEN ADHESION PROTEIN ON THE SURFACE OF PLATELETS REQUIRED FOR NORMAL THROMBOSIS AND HAEOMOSTASIS
Jonathan Gibbins* (UK), William J Kaiser, Parvathy Sasikumar, Tanya Sage, Laura Dobson, Nicholas Pugh, Lisa Holbrook

P-MO-033  RECIPROCAL REGULATION OF PLATELET FUNCTION BY ENDOGENOUS PROSTAGLANDINS - EXPERIMENTAL DATA AND MATHEMATICAL MODELING
Jorg Goiger* (DE), Katharina Hubertus, Maxime Moulard, Marcel Mischnik, Jens Timmer, Ulrich Walter

P-MO-034  PECAM-1 CLUSTERING REDUCES SURFACE EXPRESSION OF GPIB ON PLATELETS WHICH IMPAIRS THE BINDING OF THROMBIN AND DIMINISHES PLATELET ACTIVATION
Chris Ian Jones* (UK), Leonardo A Moraes, Kirk Taylor, Emily Knight, Jonathan M Gibbins

P-MO-035  SIGNALING ROLE OF CD36 IN PLATELET ADHESION AND SPREADING
Reyhane Nergiz-Unal* (NL), Moniek M.E. Lamers, Roger van Kruchten, Judith M.E.M. Cosemans, Joost Luiken, Jan F.C. Glatz, Marijke J.E. Kuijpers, Johan W.M. Heemskerk

P-MO-036  TRANSMEMBRANE DOMAINS ARE CRITICAL TO THE INTERACTION BETWEEN PLATELET GLYCOPROTEIN V AND GLYCOPROTEIN IB-IX COMPLEX
Xi Mo* (CN), Jose A Lopez, Renhao Li
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-037  KAINATE RECEPTOR INHIBITOR UBP-302 REDUCES HOMOCYSTEINE-ENHANCED PLATELET AGGREGATION
Cezary W Watala* (PL), Kamil Karolczak

P-MO-038  PAR4 MEDIATES THROMBIN-INDUCED PRO-COAGULANT ACTIVITY IN HUMAN PLATELETS
Hannah Lee* (AU), Cheryl Berndt, Elizabeth E Gardiner, Robert K Andrews, Shaun P Jackson, Justin R Hamilton

P-MO-039  PAI-1 SECRETION, RE-SYNTHESIZING & THE ROLE OF THROMBIN RECEPTORS IN PLATELETS
Martina Nylander* (SE), Emma Lofgren, Anders Larsson, Tomas L Lindahl

Megakaryocytes and thrombopoiesis

P-MO-040  PITUITARY ADENYLYATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) IMPAIRS APOPTOSIS DURING MEGAKARYOPOIESIS BY ACTIVATING NF-κB: A PROTEOMIC STUDY
Michela Di Michele* (BE), Karen Peeters, Serena Loyen, Etienne Waelkens, Lutgart Overbergh, Marc Hoylaerts, Chris Van Geet, Kathleen Freson

P-MO-041  DIFFERENTIATION OF OP9 BONE MARROW STROMA CELLS INTO MEGAKARYOCYTES AND PLATELETS VIA A P45NF-E2-MEDIATED MECHANISM
Yumiko Matsubara* (JP), Yukako Ono, Hidenori Suzuki, Fumio Arai, Toshio Suda, Mitsuru Murata, Yasuo Ikeda

P-MO-042  SILK FIBROIN ENGINEERED 3D SYSTEM FOR THE STUDY OF MEGAKARYOCYTES AND FUNCTIONAL PLATELET PRODUCTION
Isabella Pallotta (IT), Alessandra Balduini, Michael Lovett, David L. Kaplan, Alessandra Balduini*

P-MO-043  STUDY OF MEGAKARYOPOIESIS AND PROPLATELET FORMATION IN MYELOPROLIFERATIVE DISORDERS
Stefania Badalucco* (IT), Mariateresa Pugliano, Vittorio Rosti, Marco Cattaneo, Giovanni Barosi, Alessandra Balduini

P-MO-044  EXPRESSION OF TYPE I INTERFERON RECEPTOR IN MEGAKARYOPOIESIS
Soledad Negrotto* (AR), Carolina Jaquenod de Giusti, Maria J Laponi, Julia Etulain, Agostina Carestia, Ricardo M Gomez, Mirta Schattner

P-MO-045  ULTRASTRUCTURAL INDICATIONS FOR AN ENDOGENOUS ORIGIN OF THE DEMARCATION MEMBRANE SYSTEM IN MURINE MEGAKARYOCYTES
Anita Eckly* (FR), Fabienne Proamer, Jean-Yves Rinckel, Francois Lanza, Christian Gachet

P-MO-046  FACTOR V SUGAR MOIETIES ARE ESSENTIAL FOR BINDING TO THE SURFACE OF MEGAKARYOCYTES
Claudia Zappelli* (NL), Carmen van der Zwaan, Koen Mertens, Alexander B. Meijer

P-MO-047  THE ABNORMAL PROPLATELET FORMATION OBSERVED IN PATIENTS WITH MYH9-RELATED SYNDROME RESULTS FROM AN INCREASE OF PMLC2
Yolande Chen (FR), Sham Boukour, Paquita Nurden, Ababakar Seye, Olivier Bluteau, Yinhua Chang, Larissa Lordier, Remi Favier, Beatrice Sapoznik, Nicole Schlegel, Anne Galy, Alan Nurden, Hana Raslova, William Vainchenker, Najet Debili*

P-MO-048  CRUCIAL ROLE FOR ENDOPLASMIC RETICULUM STRESS DURING THROMBOPOIESIS
Jose Javier Lopez (FR), Najet Debili, Chiraz Chaabane, Evelyne Poldiano, Saoussen Dally, Elisabeth Corvazier, Paquita Nurden, Jocelyne Enouf, Regis Bobe*
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-049  THE INTERACTION OF ADENOSINE DIPHOSPHATE WITH P2Y13 REGULATES IN VITRO PROPLATELET FORMATION FROM HUMAN MEGAKARYOCYTES
Christian Di Buduo* (IT), Alessandro Malara, Isabella Pallotta, Anna Lecchi, Alessandra Balduini, Marco Cattaneo

Platelets as drug targets

P-MO-050  EVALUATION OF PLATELET AGONISTS AND ANTAGONISTS BY A NOVEL ELISA-BASED VASP ASSAY AND Compatibility WITH WHOLE BLOOD SAMPLES FROM SEVERAL ANIMAL SPECIES
Daniele Boulay-Moine (FR), Nicolas Bourguet, Sylvie Miet, Maxime Moulard*

P-MO-051  THE EFFECT OF THE ORAL DIRECT FACTOR XA INHIBITOR RIVAROXaban ON TISSUE FACTOR MEDIATED IN VITRO PLATELET AGGREGATION IS ENHANCED BY A P2Y12 RECEPTOR BLOCKER
Elisabeth Perzborn* (DE), M Harwardt, S Heitmeier, V Laux

P-MO-052  PROTEIN KINASE C REGULATES AGONIST-MEDIATED PLATELET ACTIVATION DOWNSTREAM OF 12-LIPÖXGENASE IN HUMAN PLATELETS
Patrick L Apopa* (US), Joanne Vesci, Jennifer Yeung, Michael Holinstat

P-MO-053  ASPIRIN IS LESS EFFICIENT FOR THROMBOXANE A2 INHIBITION IN ACTIVATED PLATELETS.
Juana Valles (ES), Antonio Moscardo, Isabel Madrid, Maria Angeles Dasi, Belen Cortina, Ana Maria Larrota, Maria Teresa Santos*

P-MO-054  ASPIRIN TREATMENT IS RESPONSIBLE FOR AN MRP4 OVER-EXPRESSION IN HUMAN PLATELETS
Fabio M Pulcinelli* (IT), Isabella Massimi, Elisabetta Trifiro’, Lavinia Vittoria Lotti

P-MO-055  INCREASED VASCULAR NO & PROSTACYCLIN PROTECTS B2R KO MICE FROM THROMBOSIS BY AN ACQUIRED PLATELET GLYCOPROTEIN VI ACTIVATION AND SPREADING DEFECT
Chao Fang* (US), Evi Stavrou, Alec Schmaier, Andrew Chen, Marvin Nieman, Gregory Adams, Gretchen LaRusch, Yihua Zhou, Matthew Bilodeau, Fakhri Mahdi, Mark Warnock, Douglas Tollefsen, Alvin Schmaier

P-MO-056  THE INFLUENCE OF GENETIC POLYMORPHISM AND DRUG-DRUG INTERACTION ON ANTIPLATELET EFFECT IN PATIENTS TREATED WITH LONG-TERM DUAL ANTIPLATELET THERAPY
Young-Hoon Jeong* (US), Park Yongwhi, Kim In-Suk, Jung Kwon Tae, Hwang Jin-Yong

P-MO-057  FIRST VALIDATION OF ADJUNCTIVE CILOSTAZOL LOADING EFFECT AND DOSAGE ON PLATELET INHIBITION: RESULTS OF THE ACCEL-LOADING STUDY
Young-Hoon Jeong* (US), Kim In-Suk, Yun Seong-Eun, Park Yongwhi, Jung Kwon Tae

P-MO-058  FIRST COMPARISON OF PLATELET INHIBITION BY CILOSTAZOL VERSUS CLOPIDOGREL IN PATIENTS WITH CYTOCHROME 2C19 LOSS-OF-FUNCTION ALLELE: RESULTS OF THE ACCEL-SWITCH STUDY
Young-Hoon Jeong* (US), Yongwhi Park, In-Suk Kim, Seong-Eun Yun, Kwon Tae Jung

P-MO-059  CONSENSUS DEFINITION-BASED CUTOFFS OF HIGH ON-TREATMENT PLATELET REACTIVITY: VALIDATION BETWEEN LIGHT TRANSMITTANCE AND MULTIPLE ELECTRODE AGGREGOMETRIES
Young-Hoon Jeong* (US), Yongwhi Park, In-Suk Kim, Seong-Eun Yun
POSTER PRESENTATIONS

Monday, July 25, 2011

Molecular basis of inherited or acquired platelet disorders

P-MO-060  MUTATION SCREENING IN GLANZMANN THROMBASTHENIA: IDENTIFICATION OF FOUR NOVEL MUTATIONS IN THE ITGA2B AND ITGB3 GENES
Bimal D M Theophilus* (UK), Andrea M Guilliatt, Lesley M Baugh, Jayashree Motwani, Michael D Williams

P-MO-061  IDENTIFICATION OF TWO NOVEL TMEM16F MUTATIONS IN A PATIENT WITH SCOTT SYNDROME
Elisabetta Castoldi* (NL), Peter W. Collins, Patrick L. Williamson, Edouard M. Bevers

P-MO-062  PLATELET FUNCTION ABNORMALITIES IN GAUCHER DISEASE: ETIOLOGY AND EFFECT OF ENZYME REPLACEMENT THERAPY
Mirjana Miroslav Mitrovic* (RS), Darko A Antic, Ivo I Elezovic, Dragana D Janic, Predrag P Milijic, Sumarac Z Zorica, Tanja T Nikolic, Nada N Suvajdizc

P-MO-063  BLEEDING PHENOTYPE IN A PATIENT WITH MDS IN THE ABSENCE OF THROMBOCYTOPENIA IS CAUSED BY A PROFOUND DYSREGULATION OF THE SIGNALING PROTEIN, SYK
Elizabeth E Gardiner* (AU), Jian L Qiao, Jane F Arthur, Amanda K Davis, Margaret Collecutt, Yang Shen, Fi-Tjen Mu, Robert K Andrews

P-MO-064  THROMBOCYTOPENIA IN MICE LACKING SPHINGOMYELIN SYNTHASE 1
Takahiro Fujii* (JP), Akira Hayashi, Yuwina Yakura, Makoto Taniguchi, Ken Watanabe, Kazuyuki Kitatani, Toshiro Okazaki, Hiroyuki Takeya

P-MO-065  PLATELET MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH SEPTIC SHOCK
Andrea Artoni* (IT), Anna Lecchi, Alessandro Protti, Giovanna Motta, Giovanni Mistaletti, Francesca Pagan, Sergio De Chiara, Luciano Gattinoni

HIT

P-MO-066  EVALUATION OF A FAST ELISA ASSAY FOR MEASURING HIT IGG ANTIBODIES
Lieselotte Wagner* (AT), Sabine Geiter, Markus Graf, Helga Vetr, Annelie Siegemund

P-MO-067  USEFULLNESS OF 4TS SCORING SYSTEM FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IN THE FIELD OF HEMODIALYSIS
Keiko Wanaka* (JP), Miyashita Kumiko, Kaneko Chieko, Walenga M Jeanine, Prechel Margaret, Escalante Vicki, Matsuo Miyako, Asada Reiko

P-MO-068  GERMAN REGISTRY FOR THE USE OF FONDAPARINUX IN HIT OR SUSPECTED HIT
Marc Schindewolf* (DE), Julia Scheuermann, Jan Beyer-Westendorf, Sebastian Schellong, Pascal Dohmen, Johannes Brachmann, Katharina Madiener, Bernd Poetzsch, Robert Klarmroth, Johannes Hankowitz, Stefan Kropff, Norbert Banik, Sabine Eberle, Markus Michael Mueller, Edelgard Lindhoff-Last

P-MO-069  DEVELOPMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IN SIX PATIENTS WITH HEPARIN LOCK (OR FLUSH) IN THE EARLY PHASE OF HEMODIALYSIS
Kumiko Miyashita* (JP), Keiko Wanaka, Chieko Kaneko, Yoshikico Nakajima, Jeanine Walenga, Vicki Escalante, Miyako Matsuo

P-MO-070  HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS WITH MULTIPLE ELECTRODE AGGREGOMETRY
Ludek Slavik* (CZ), Jana Ulievlova, Vera Krcova, Antonin Hlusi, Jana Prochazkova
## POSTER PRESENTATIONS

### Monday, July 25, 2011

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-MO-071</td>
<td>COMPARISON OF DIAGNOSTIC PERFORMANCE OF HEPARIN EXPERT PROBABILITY (HEP) AND 4T’S SCORES IN SCREENING FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)</td>
<td>Noppacharn Uaprasert*, Ponlapat Rojnuckarin, Benjaporn Akkawat</td>
</tr>
<tr>
<td>P-MO-072</td>
<td>COMPARISON OF CLINICAL PERFORMANCES OF TWO ELISA ASSAYS: ASSERACHROM HP1A-IGG AND PF4 IGG FOR HEPARIN INDUCED THROMBOCYTOPENIA DIAGNOSIS</td>
<td>Sylvie Langlet*, Christine Bahuon, Claire Maurel, Stephane Le Floc’h, Ismael Elalamy, Pierre Emmanuel Morange, William Cohen</td>
</tr>
<tr>
<td>P-MO-073</td>
<td>SIMPLE SCORING SYSTEM FOR EARLY MANAGEMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA</td>
<td>Harry Messmore*, Nanacy Fabbrini, Mary Bird, Abdul Choudhury, Miguel Cerejo, Margaret Prechel, Walter Jeske, Anshea Siddiqui, Theethi Indermohan, William Wehrmacher, Jeanine Walenga</td>
</tr>
<tr>
<td>P-MO-074</td>
<td>IMMUNOLOGIC DIFFERENTIATION OF GENERIC LOW MOLECULAR WEIGHT HEPARINS</td>
<td>Jeanine Walenga*, Margaret Prechel, Vicki Escalante, Walter Jeske, Mamdouh Bakhos</td>
</tr>
<tr>
<td>P-MO-075</td>
<td>NON-PATHOGENIC ANTI-HEPARIN/PF4 ANTIBODIES GENERATED BY LOW MOLECULAR WEIGHT HEPARINS MEDIATE PROCOAGULANT EFFECTS</td>
<td>Jeanine Walenga*, Debra Hoppensteadt, Evangelos Litinas, Harry Messmore, Bruce Lewis, Gundu Rao, Russell Hull, Jawed Fareed, Mamdouh Bakhos</td>
</tr>
</tbody>
</table>

### Antiplatelet therapy

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-MO-077</td>
<td>ANTIPLATELET THERAPY EFFECTIVELY REDUCES PLASMA PLASMINOGEN ACTIVATOR INHIBITOR-1 LEVELS</td>
<td>Toshiyuki Sakata* (JP), Kazuomi Kario</td>
</tr>
<tr>
<td>P-MO-078</td>
<td>VASODILATOR-STIMULATED PHOSPHOPROTEIN (VASP) PHOSPHORYLATION ASSAY FOR PLATELET RESPONSE TO CILOSTAZOL</td>
<td>Jun Yamanouchi* (JP), Takaaki Hato, Toshiyuki Niriya, Masaki Yasukawa</td>
</tr>
<tr>
<td>P-MO-079</td>
<td>GLYCOPROTEIN IIB-IIIA CONTENT, MEAN PLATELET VOLUME AND PLATELET AGGREGATION IN PATIENTS WITH ACUTE CORONARY SYNDROME</td>
<td>Alexey V Mazurov* (RU), Iliia T Zyuryaev, Vladimir V Yakushkin, Svetlana G Khaspekov, Mikhail Ya Ruda</td>
</tr>
<tr>
<td>P-MO-080</td>
<td>IMPAIRED CLOPIDOGREL RESPONSIVENESS IN STEMI PATIENTS PREDISPOSES FOR CARDIOVASCULAR EVENTS</td>
<td>Andreas Schaefer* (DE), Uliker Flierl, Nora Seydelmann, Johann Bauersachs</td>
</tr>
<tr>
<td>P-MO-081</td>
<td>PLATELET HYPERCOAGULANT ACTIVITY DUE TO REDUCED AMINOPHOSPHOLIPI D TRANSLOCASE ACTIVITY IN T2DM IS AMELIORATED BY GPIIb/IIIa BLOCKADE</td>
<td>Wei Zhang* (SE), Zhangsen Huang, Paul Hjemdahl, Nalin Li</td>
</tr>
<tr>
<td>P-MO-082</td>
<td>ESSENTIAL THROMBOCYTHAEMIA TREATMENT OF A PATIENT UNDER 12 MONTHS- A CASE REPORT</td>
<td>Pawel Laguna* (PL), Michal Romiszewski, Anna Klukowska, Michal Matysiak</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-083 CLINICAL OUTCOME AND PLATELET FUNCTION OF ACUTE STROKE BY GLOBAL THROMBOSIS TEST (GTT) AFTER T-PA THERAPY
Katsushi Taomoto* (JP), Hideyuki Ohnishi, Yoshihiro Kuga, Kazuya Nakashima, Yuji Kodama, Hisashi Kubota, Takashi Tominaga, Makoto Hayashi, Shiro Miyata, Junichiro Yamamoto

P-MO-084 CILOSTAZOL, A PLATELET INHIBITOR, IN TREATING INTERMITTENT CLAUDICATION. A SYSTEMATIC REVIEW.
David Bergqvist* (SE), Olov Rolandsson, Juliette Sawe

P-MO-085 FEATURES OF TREATMENT AND PROGNOSIS OF NON-ST ELEVATION ACUTE CORONARY SYNDROME IN PATIENTS WITH IRON DEFICIENCY ANEMIA
Anton Skolnikov* (RU), Arcady Verklin, Fedor Vilkovskii

P-MO-086 CHARACTERIZATION OF THE ANTIPLATELET EFFECT OF ASPIRIN AT ENROLLMENT AND AFTER A 2-YEAR FOLLOW-UP IN THE REAL CLINICAL SETTING IN JAPAN
Keiichiro Yamane* (JP), Tormoyuki Ikeda, Ryoji Taniguchi, Toru Kita, Takeshi Kimura, Hisanori Horiiuchi

P-MO-087 100 MG OF ASPIRIN IS SUFFICIENT TO SUPPRESS PLATELET ACTIVITY IN TYPE 2 DIABETES, IRRESPECTIVE OF GLYCEMIC CONTROL

P-MO-088 CLOPIDOGREL AND ASPIRIN PHARMACODYNAMIC RESPONSE IN ELDERLY INPATIENTS: A PILOT STUDY

P-MO-089 EFFECTS OF TANSHINONEIIA ON INFLAMMATORY CYTOKINES AND GMP-140 IN THE PATIENT WITH KAWASAKI DISEASES.
Xiaojing Li* (CN), Qing Zhang, Ming Zhou

P-MO-090 MORE RAPID AND GREATER PHARMACODYNAMIC EFFECTS OF PRASUGREL IN JAPANESE PATIENTS WITH STABLE CORONARY ARTERY DISEASE (CAD) UNDERGOING ELECTIVE PCI
Hisanori Horiiuchi* (JP), Hiroyoshi Yokoi, Takeshi Kimura, Takaaki Ishishi, Hisao Ogawa, Yasuo Ikeda

Inherited and acquired platelet disorders

P-MO-091 FEATURES OF PLATELET FUNCTION IN PATIENTS WITH PORTAL HYPERTENSION SECONDARY CHRONIC MYELOPROLIFERATIVE NEOPLASMS
Viola Maria I Popov (RO), Ana Maria Vladareanu, Horia Buruea, Eugenia Kovacs, Tudor Savopol, Adrian Tase, Minodora Onisai, Marilena Miulescu, Anca Maria Ilea, Camelia Dobrea

P-MO-092 PLATELET DYSFUNCTION IN PATIENTS WITH PULMONARY HYPERTENSION ON SILDENAFIL
Edmond S K Ma* (HK), Elaine M C Chau, Katherine Fan

P-MO-093 CAUSES OF PLATELETS DISFUNCTION IN MULTIPLE MYELOMA
Irena Djunic* (RS), Ivo Elezovic, Vesna Ilic, Dragica Tomin, Nada Svajdziej-Vukovic, Jelena Bila, Darko Antic, Ana Vidovic, Nadeza Milosevic-Jovicic
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-094  FOUNDER EFFECT AND PHENOTYPIC SEVERITY OF THE FRENCH GYPSY MUTATION IN GLANZMANN THROMBASTHENIA
Mathieu Fiore* (FR), Frederic Austerlitz, Xavier Pillois, Nadia Firah, Paquita Nurden, Alan T Nurden

P-MO-095  A CASE OF ESSENTIAL THROMBOCYTHEMIA AND VERSION OF HEREDITARY THROMBOPHILIA - MTHFR MUTATION
Sandra Lejniece* (LV), Viktorija Dunska-Petersone, Anna Toma, Alivars Lejnieks

P-MO-096  MACROTROMBOCYTOPENIA AND HEMOLYSIS ASSOCIATED WITH PHYTOSTEROLEMIA: A POTENTIAL NEW PLATELET DISORDER
Zhaoyue Wang* (CN), Gaifeng Wang, Lijuan Cao, Minghua Jiang, Xia Bai, Changgeng Ruan

P-MO-097  THROMBOTIC THROMBOCYTOPENIC PURPURA CONCOMITANT WITH AUTOIMMUNE THYROIDITIS
Ali Bay* (TR), ali seckin yalcin, Goksel Leblebisatan, Enes Coskun, hatice uygun, Mehmet Yilmaz

P-MO-098  PLATELET TRANSFUSION REQUIREMENTS INVERSELY CORRELATE WITH ENDOGENOUS PF4 LEVELS IN PATIENTS WITH STANDARD RISK ACUTE LYMPHOBlastic LEUKEMIA.
Michele Puszkarczuk Lambert* (US), Alisa Reznikov, Liqing Xiao, Yvonne Nguyen, Lubica Rauova, Mortimer Poncz

P-MO-099  ADOLESCENTS WITH DIABETES MELLITUS HAVE EVIDENCE OF IN VIVO PLATELET ACTIVATION
Sara J Israels* (CA), Heather J. Dean, Elizabeth A.C. Sellers, Fabrice Cognasse, Archie McNicol

P-MO-100  RFVIIA IS AS EFFECTIVE AS PLATELETS IN GLANZMANN THROMBASTHENIA (GT) WITH OR WITHOUT PLATELET ANTIBODIES AND/OR REFRACTORINESS (PA/PR): DATA FROM GT REGISTRY (GTR)
Man-Chiu Poon* (CA), Giovanni di Minno, Rainer Zott, Roseline d’Oiron

Laboratory tests

P-MO-101  INCREASED PLATELET AND LEUKOCYTE ACTIVATION AS CONTRIBUTING MECHANISMS FOR THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA AND CORRELATION WITH THE JAK2 MUTATION STATUS
Elena - Tothova* (SK), Adriana Kafkova, Marek Sarisky, Beata Benova, Natalia Stolecova, Monika Hlebaskova

P-MO-102  DETECTION OF AUTOANTIBODIES AGAINST PLATELET GLYCOPROTEINS IN PATIENTS WITH ITP BY FLOW CYTOMETRY
YANG HE* (CN), Ming Qing Zhu, Yi Ming Zhao, Chang Geng Ruan

P-MO-103  ASSOCIATION OF PLATELET REACTIVITY WITH LIPID AND PAI-1 LEVELS IN A JAPANESE GENERAL POPULATION, THE SUITA STUDY
Sachika Kameda* (JP), Toshiyuki Sakata, Yoshhiro Kokubo, Mana Mitsuguro, Akira Okamoto, Mchitaaka Sano, Toshiyuki Miyata

P-MO-104  WIDE TEMPERATURE RANGE TESTING WITH SONOCLOT PLATELET FUNCTION AND ROTEM EXTEM/FIBTEM/APTEM TESTS
Ulf Stellan Schott* (SE), Jens Brokopp, Attila Frigyesi, Jon Martinsson, Hans Friberg

P-MO-105  COMPARISON STUDY BETWEEN TWO BLOOD COUNTER INSTRUMENTS: ADVIA 2120 AND LH 780
Selime Ayaz* (TR), Gulshak Kacur Fidan
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-106  ASPIRIN RESISTANCE IN PATIENTS WITH SAPPHENOUS VEIN CORONARY BYPASS GRAFT OCCLUSION
Selime Ayaz* (TR), Goksel Cagirci, Yilmaz Sevinc, Ozcan Ozdemir, Dursun Aras

P-MO-107  TRANSPLACENTAL TRANSMISSION OF EDTA DEPENDENT PSEUDO-TROMBOCYTOPENIA IN A NEONATE
Ali Bay* (TR), Safak Tavil, Goksel Leblebisatan, Ercan Sivasli, Enes Coskun

P-MO-108  A SIMPLE PORTABLE MICROSYSTEM TO MONITOR PLATELET AGGREGATION
Francine Rendu* (FR), Thibault Donnet, Daniel Fruman

P-MO-109  DIFFERENTIAL PREVALENCE OF ANTI-HEPARIN PLATELET FACTOR 4 ANTIBODIES IN ELDERLY PATIENTS UNDERGOING ORTHOPAEDIC SURGERY AND ANTICOAGULATED WITH HEPARIN.
Christopher Song* (US), Josephine Cunanan, Debra Hoppensteadt, Hussein Kahn, Indermohan Thethi, Jawed Fareed

P-MO-110  NEW MULTIPLATE AGGREGATION TEST TO SCREEN FOR GSα DYSFUNCTION: SCREENING OF PATIENTS WITH UNEXPLAINED MENTAL RETARDATION FOR GSα DYSFUNCTION.
Irene MLW Korver-Keularts* (NL), Estela M Rubio-Gozalbo, Connie TRM Schrander-Stumpel, Paul WM Verhezen, Dionne Maessen, Monique GM Willems, Paola EJ Meijden, van der, Johan WM Heemskerk, Yvonne MC Henskens, Karly Hamulyak

Extrinsic pathway of coagulation

P-MO-111  THE EXTENSIVE EPITOPE OVERLAP OF THE HUMANIZED MONOCLONAL ANTIBODY MAB 2021 WITH THE FXA BINDING SITE ON K2 EXPLAINS ITS NEUTRALIZING EFFECT ON TFPI

P-MO-112  EFFICIENT PROCEDURE FOR PURIFICATION OF HUMAN TISSUE FACTOR PATHWAY INHIBITOR (TFPI) EXPRESSED FROM A BABY HAMSTER KIDNEY (BHK) CELL LINE
Christina Jespersgaard* (DK), Jorn Meidahl Petersen, Ida Hilden

P-MO-113  PROTEOMIC ANALYSIS OF ANGIOTENSIN II- INDUCED PROTEIN EXPRESSIONS IN U937 CELLS
Shilin He* (CN), Li Bangtao, Wen ZHIBin, He Xiaofan

P-MO-114  AN INFANT WITH PROLONGED CIRCUMCISION BLEEDING AND UNEXPLAINED COAGULOPATHY
Ali Bay* (TR), Ozlem Karaoglu, Goksel Leblebisatan, Enes Coskun, Ali Seckin Yalcin, Mehmet Keskin

P-MO-115  EXPRESSION OF TF IN MONOCYTES AND PLASMA TF DURING ACUTE PHASE AND RECOVERY STAGE IN PATIENTS WITH MYOCARDIAL INFARCTION
Rui WANG* (CN), Shulu ZHANG, Yitong MA, De CHEN, Jing MA, Yimeng ZHOU, Bingzhao WEN

P-MO-116  ACUTE HAEMOSTATIC EFFECT OF A POLYCLONAL RABBIT ANTI-MOUSE TFPI ANTIBODY IN A MURINE JOINT BLEEDING MODEL
Kirstine Ovlisen* (DK), Mette Brunsgaard Hermit, Jes Thorn Clausen, Lars Christian Petersen, Mikael Tranholm, Brit Binow Sorensen, Ida Hilden

P-MO-117  A POLYCLONAL ANTI-MOUSE TFPI ANTIBODY DOSE-DEPENDENTLY REDUCES BLOOD LOSS IN HAEMOPHILIA A MICE
Peter B Johansen* (DK), Mette B Hermit, Jes T Clausen, Ida Hilden
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-118 SELECTION AND CHARACTERISATION OF A MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI) BLOCKING THE INTERACTION BETWEEN TFPI KUNITZ 2 DOMAIN AND FACTOR XA
Jes Thorn Clausen* (DK), Bent Olsen Krogh, Andrew Neil Bowler, Christina Jespersgaard, Thomas Egebjerg, Birgitte Friedrichsen, Ida Hilden

P-MO-119 THROMBINURIA AS A USEFUL MARKER FOR SCREENING AND MONITORING OF CRESCENTIC GLOMERULONEPHRITIS
Yasunori Kitamoto* (JP), Kenji Arizono, Yoshihisa Taguma, Takahisa Imamura

P-MO-120 A MONOCLONAL ANTI-TFPI-ANTIBODY, MAB 2021, REDUCES BLEEDING IN HAEMOPHILIC RABBITS AFTER INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION
Brian Lauritzen* (DK), Mette Brunsgaard Hermit, Kristoffer W Balling, Henrik Agersoe, Brit Binow Sorensen, Ida Hilden

P-MO-121 A MONOCLONAL ANTI-TFPI-ANTIBODY, MAB 2021, IS EFFICACIOUS AGAINST BLEEDING IN HAEMOPHILIC RABBITS FOR AT LEAST 7 DAYS
Brian Lauritzen* (DK), Lene Hansen, Henrik Agersoe, Kristoffer W Balling, Mette Brunsgaard Hermit, Jes Thorn Clausen, Ida Hilden, Brit Binow Sorensen

P-MO-122 PLATELET UPTAKE OF RECOMBINANT FACTOR VIIA
Agon Hyseni* (NL), Philip G. de Groot, Ton Lisman, Mark Roest

P-MO-123 A MONOCLONAL ANTIBODY MAB 2021 BLOCKING TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ENHANCES HAEMOSTASIS UNDER HAEMOPHILIA A LIKE CONDITIONS
Brit Binow Sorensen* (DK), Ida Hilden, Lars Chr. Petersen, Mette Brunsgaard Hermit, Helle Heibroch Petersen, Kristoffer W. Balling

P-MO-124 PHARMACOLOGICAL EVALUATION OF FVIIA/FX MIXTURE (MC710) IN ANIMAL MODELS OF HEMOPHILIA
Yasushi Nakatomi* (JP), Teruhisa Nakashima, Manami Tsuji, Eisuke Takami, Hiroki Miyazaki, Emiko Kusumoto, Ai Takaki-Kakisaka, Asami Shindome, Kauhiko Tomokyo, Takayoshi Hamamoto, Tomohiro Nakagaki

P-MO-125 DISCORDANT CLEARANCE PATHWAYS FOR FACTOR X AND ITS N-DEGLYCOSYLATED DERIVATIVE
Mohamad KURDI* (FR), Ghislaine CHEREL, Peter J. LENTING, Cecile V. DENIS, Olivier D. CHRISTOPHE

P-MO-126 TISSUE FACTOR PROCOAGULANT ACTIVITY IN SICKLE CELL DISEASE: NOVEL FINDINGS
B.N.Yamaja Setty* (US), Nigel S Key, A. Koneti Rao, Suba Krishnan, Suhita Gayen-Betal, Marie J Stuart

P-MO-127 STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF NON-ANTICOAGULANT SULFATED POLYSACCHARIDES FOR THE TREATMENT OF HEMOPHILIA
Michael Dockal* (AT), Sabine Knappe, Susanne Till, Michael Palige, Christina Miki Szabo, Zhenqing Zhang, Klara Michalkova, Hartmut Ehrlich, Friedrich Schefflinger

P-MO-128 ENDOGENOUS BLOOD BORNE TISSUE FACTOR CONTRIBUTES TO CLOT FORMATION IN HAEMOPHILIA-LIKE WHOLE BLOOD ASSESSED BY KAOLIN-INITIATED THROMBOELASTOGRAPHY (TEG) ANALYSIS
Brit Binow Sorensen* (DK), Marie Louise Schougaard Christiansen, Mirella Ezban, Soeren Bjoern, Stefan Lethagen
### POSTER PRESENTATIONS

**Monday, July 25, 2011**

#### Intrinsic pathway of coagulation

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-MO-129</td>
<td>SIMULATION AND MEASUREMENT OF THROMBIN PRODUCTION IN RESTING AND CONVULXIN-TREATED WHOLE BLOOD IN VITRO: XIIA BYPASS OF CORN TRYP SIN INHIBITOR</td>
<td>Scott L Diamond* (US), Manash Chatterjee</td>
</tr>
<tr>
<td>P-MO-130</td>
<td>MILD HEMOPHILIA B IN A CASE OF SHEEHAN SYNDROME</td>
<td>Valizadeh Nasim* (IR), Neda Valizadeh</td>
</tr>
<tr>
<td>P-MO-131</td>
<td>FUNCTIONAL CHARACTERIZATION OF IMMOBILIZED FACTOR VIII IN INTRA-THROMBUS FIBRIN NETWORK FORMATION UNDER WHOLE BLOOD FLOW CONDITIONS WITH HIGH SHEAR RATES</td>
<td>Masaaki Doi* (JP), Mitsuhiko Sugimoto, Hideto Matsui, Tomoko Matsumoto, Midori Shima</td>
</tr>
<tr>
<td>P-MO-132</td>
<td>MOLECULAR PATHOLOGY OF HAEMOPHILIA B IN CHINA PATIENTS: IDENTIFICATION OF 20 NOVEL MUTATIONS.</td>
<td>Jing Dai* (CN), Qiong Chen, Ting Ying Wu, Ling Ye Lu, Lan Qiu Ding, Li Hong Wang, Fang Xue Wang</td>
</tr>
<tr>
<td>P-MO-133</td>
<td>METABOLIC REGULATION OF MOUSE LIVER F11 GENE TRANSCRIPTION AND ITS RELATION TO KLKB1 AND CYP4V3 CONTROL</td>
<td>Huma Safdar* (NL), Audery C.A. Cleuren, Ka Lei Cheung, Pieter H. Reitsma, Bart J.M. van Vlijmen</td>
</tr>
<tr>
<td>P-MO-134</td>
<td>FACTOR IX ARG327ILE MUTATION RESULTING IMPAIRED AFFINITY TO FVIIIA AS WELL AS CATALYTIC EFFICIENCY LEADS TO SEVERE HAEMOPHILIA B</td>
<td>Jiawei Zhou* (CN), Jing Dai, Xuefeng Wang, Tingting Yu, yeling Lu, Qiulan Ding, Hongli Wang</td>
</tr>
<tr>
<td>P-MO-135</td>
<td>AN EPIDEMIOLOGIC CLINICAL STUDY ON HEMOPHILIA IN THE PATIENTS FROM THE REGION OF OLTENIA, ROMANIA</td>
<td>Polixenia Stancu* (RO), Cristina Singer, Alina Botu, Simona Cosoveanu, Diana-Maria Trasca, Emil Tiberius Trasca</td>
</tr>
<tr>
<td>P-MO-136</td>
<td>FACTOR VIII INHIBITORS IN HEMOPHILIA A PATIENTS WITH DIFFERENT TREATMENT MODALITIES</td>
<td>Ola Abdel-Halim Afifi* (EG), Salah Abdul-Azeem Argoon, Yousreyia Abdel-Rahman Ahmad, Nabila Mohamed Thabet, Reffat Fathi Abdul-All, Gamal Ghanem Mohamed, Ahmad Farrag Thabet</td>
</tr>
<tr>
<td>P-MO-137</td>
<td>AVALABILITY OF CYCLOSPORINE A IN COMBINATION WITH CORTICOSTEROIDS FOR ACQUIRED HAEMOPHILIA A - A REVIEW OF CLINICAL COURSE IN 13 PATIENTS</td>
<td>Seiji Saito* (JP), Teruhisa Fujii, Noboru Takata</td>
</tr>
<tr>
<td>P-MO-138</td>
<td>POLYMORPHISM 4G/5G IN PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 AS A FACTOR FOR EARLY RECURRENT PREGNANCY LOSS DEVELOPMENT</td>
<td>Petar D Ivanov* (BG), Regina Komsa-Penkovka, Emiliana Konova, Tsvetomira Tsvyatkovska, Ivan Ivanov, Katya Kovacheva, Maria Simeonova, Stoyan Tanchev</td>
</tr>
<tr>
<td>P-MO-139</td>
<td>EXPRESSION OF RECOMBINANT HUMAN FACTOR IX PROTEIN IN MOUSE ERYTHROCYTES BY USING A TRANSGENIC RODENT MALARIA PARASITE, PLASMODIUM BEGHEI AS AN EXPRESSION VECTOR.</td>
<td>Teruko Sugo* (JP), Hiroyuki Matsuoka, Makoto Hirai, Darrel Stafford, Paul Monahan</td>
</tr>
<tr>
<td>P-MO-140</td>
<td>FACTOR VIII LIGHT CHAIN CONTAINS A BINDING SITE FOR FACTOR X</td>
<td>Masahiro Takeyama* (US), Hironao Wakabayashi, Phillip J Fay</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-141  SUITABILITY OF INSECT CELLS FOR THE EXPRESSION OF HUMAN COAGULATION FACTOR VIII
Svetlana A Shestopal (US), Daniel J Makover, Timothy K Lee, Andrey G Sarafanov

P-MO-142  INHIBITION OF FACTOR XI IMPROVES SEPSIS SURVIVAL IN MICE
Erik Ian Tucker* (US), Melani Helm, Norah Verbout, Owen JT McCarty, Sawan Hurst, David Gailani, Andras Gruber

P-MO-143  THE USE OF A VWF-CONTAINING PLASMA-DERIVED FVIII PRODUCT IN INHIBITOR PATIENTS LIKELY TO FAIL IMMUNE TOLERANCE INDUCTION
Margaret Heisel Kurth* (US), J Puetz, P Koudes, J Sanders, C Sexauer, J Berstein, R Gruppo, M Manco-Johnson, E Neufeld, D Quon, N Rodriguez, B Wicklund, L Aledort

P-MO-144  ANTI-FACTOR VIII INHIBITOR IN SEVERE HAEMOPHILA A CAUSED BY SER470ASN BINDS TO A2 AND C2 DOMAINS
Qiong Chen* (CN), Jiawei Zhou, Xuefeng Wang, Quilan Ding, Jing Dai, Yeling Lu, Hongli Wang

P-MO-145  GENETIC DIAGNOSIS OF TWO PEDIGREES WITH INHERITED COAGULATION FACTOR XII DEFICIENCY
Zhou Rong-Fu* (CN), Jian Ouyang, Lu Chen, Xiao-yan Shao, Jing-Yan Xu

Anticoagulant pathway

P-MO-146  GENERIC VERSIONS OF LOW MOLECULAR WEIGHT HEPARIN MAY NOT HAVE THE SAME SAFETY-EFFICACY PROFILE AS THE BRANDED LOW MOLECULAR WEIGHT HEPARINS IN ACUTE CORONARY SYNDROME
Debra A Hoppensteadt* (US), Walter Jeske, Evangelos Litinas, Omer Iqbal, Jeanine Walenga, Bruce Lewis, Hussein Kahn, Fareed Jawed

P-MO-147  TESTSTRIP-BASED GENOTYPING TO ASSIST IN THE PREDICTION OF ANTICOAGULANT DOSE REQUIREMENT
Christian Oberkanins* (AT), Helene Puehringer, Gudrun Klose, Brigitte Schreyer, Walter Krugluger, Ralph M. Loreth

P-MO-148  INTER-INDIVIDUAL DIFFERENCES IN BASELINE COAGULATION ACTIVITIES AND THEIR CLINICAL IMPLICATIONS FOR WARFARIN THERAPY
Harumi Takahashi* (JP), Mari Shiomi, Kiyoshi Mihara, Takashi Morita, Yuan-Tsong Chen, Hirotohshi Echizen

P-MO-149  DEVELOPMENTAL EFFECTS ON THE GLYCOSYLATION OF ANTICOAGULANT PROTEIN C
Maria C Van Walderveen* (CA), Leslie R Berry, Anthony K C Chan

P-MO-150  PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF PROTEIN C DEFICIENCY CASES FROM INDIA
PAI P NAVIN* (IN), RONIT MOR-COHEN, SHRIMATI S SHETTY, BIPIN P KULKARNI, KANJAKSHA GHOSH

P-MO-151  CIRCULATING NUCLEOSOMES AS PROGNOSTIC MARKER AND TARGET OF PROTEIN C IN CHILDREN WITH MENINGOCOCCAL SEPSIS
Sacha Zeerleder* (NL), Femke Stephan, Marijke Ermonts, Ester de Kleijn, Charles Esmon, Katalin Varadi, Erik Hack, Jan Hazelzet

P-MO-153  PROTEIN Z LEVELS IN PREGNANT OMANI WOMEN: CORRELATION WITH PREGNANCY OUTCOMES
Anil Pathare* (OM), Vaidyanathan Gowri, Mariam Mathew, Karima AlFalahi, David Gravell, Ibrahim Zakwani
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-154  CHANGE OF BEHAVIOR IN C4B BINDING PROTEIN AND PROTEIN S IN THE PATIENT WITH INFLAMMATORY DISEASE.
Makoto Ikejiri* (JP), Junji Nishioka, Yuko Sakamoto, Yuji Shimokariya, Katsura Noma, Yasunori Abe, Kaname Nakatani, Hideo Wada, Tatsuya Hayashi, Koji Suzuki, Tsutomu Nobori

P-MO-155  WHAT IS THE ORIGIN OF FACTOR V LEIDEN MUTATION IN ARABS? THE FIRST MOLECULAR PROOF
Mehrez M Jadaon* (KW), Ali A Dashti, Hend L Lewis

P-MO-156  NEUTRALIZABLE PARENTERAL ANTICOAGULATION: EP217609 AND ITS SPECIFIC ANTIDOTE, AVIDIN, IN HEALTHY SUBJECTS. A NEW PARADIGM?
ERIC NEUHART* (FR), Pierre Gueret, Chantal Krezel, Eliane Fuseau, Maurice Petitou

P-MO-157  REVERSION OF VITAMIN K ANTAGONISTS (VKA) EFFECT IN PATIENTS WITH BLEEDING COMPLICATIONS: AN OBSERVATIONAL STUDY FOR MONITORING PCC USE.
Marc C Samama* (FR), Claudine Heccquard, Roland Jaussaud, Christian Guillaudin, Thibaut Desmettre, Flavie Lefebvre, Jean-Charles Crave, Pierre Clerion

P-MO-158  COMPARISON OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-442, A NOVEL FACTOR XA INHIBITOR, BETWEEN JAPANESE ACUTE CORONARY SYNDROME PATIENTS AND HEALTHY JAPANESE MALES
Koki Nakamura* (JP), Hiroyuki Okamoto, Fran Stringer, Masashi Hirayama, Emi Nakata, Yuki Minamide, Masaki Kawamura, Hisao Ogawa

P-MO-159  EVALUATION OF INTERETHNIC DIFFERENCES IN THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TAK-442, A NOVEL FACTOR XA INHIBITOR, IN HEALTHY MALE JAPANESE AND EUROPEAN SUBJECTS
Hiroyuki Okamoto* (JP), Fran Stringer, Masashi Hirayama, Koki Nakamura, Emi Nakata, Yuki Minamide, Masaki Kawamura

Serine protease inhibitors

P-MO-160  DEVELOPMENT OF A NEW IMMUNO-ACTIVITY ASSAY FOR QUANTIFICATION OF ALPHA-2-MACROGLOBULIN COMPLEXES
Helen M. Atkinson* (CA), Nagina Parmar, Leslie R. Berry, Anthony K. C. Chan

P-MO-161  INCREASED MARGIN OF PATHOGEN SAFETY OF A HIGHLY-PURIFIED, PLASMA-DERIVED C1 ESTERASE INHIBITOR FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA
Albrecht Groener* (DE), Thomas Nowak, Birgit Popp, Wolfram Schaefer

P-MO-162  NOVEL THROMBIN BINDING DNA APTAMER EXHIBITS HIGH INHIBITORY POTENTIAL FOR BLOOD COAGULATION
Elena Zavyalova* (RU), Roman Reshetnikov, Andrey Golovin, Nikolay Mudrik, Dmitriy Panteleev, Galina Pavlova, Alexey Kopylov

P-MO-163  EFFICACY AND SAFETY OF EDOXABAN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE OR HIP ARTHROPLASTY: A POOLED ANALYSIS OF TWO PIVOTAL STUDIES VERSUS ENOXAPARIN
Takeshi Fuji* (JP), Ching-Jen Wang, Satoru Fujita, Shintaro Tachibana, Yohko Kawai, Yukihiro Koretsune, Takeshi Yamashita, Maschio Nakamura

P-MO-164  CALCULATION OF A SENSITIVITY INDEX USING THE WHO RBT/90 THROMBOPLASTIN ELIMINATES THE VARIABILITY OF THROMBOPLASTIN REAGENTS FOR PLASMA SAMPLES SPIKED WITH RIVAROXABAN
Job Harenberg* (DE), Christina Giese, Christel Weiss, Svetlana Marx, Roland Kraemer
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-165  WHICH PATIENTS WOULD BE WILLING TO CHANGE ANTICOAGULATION WITH VITAMIN-K ANTAGONISTS TO A NEW ORAL ANTICOAGULANT
Job Harenberg* (DE), Nadja Abou-Ayash, Svetlana Marx, Vera Hoeing, Kathrin Schirk, Christel Weiss, Lutz Froelich

P-MO-166  AN ANTIBODY SELECTIVE TO DABIGATRAN SAFELY NEUTRALIZES BOTH DABIGATRAN-INDUCED ANTICOAGULANT AND BLEEDING ACTIVITY IN IN VITRO AND IN VIVO MODELS
Joanne Van Ryn* (US), Tobias Litzenburger, Alisa Waterman, Keith Canada, Norbert Hauel, Chris Sarko, Rachel Kroee-Barrett, Sanjaya Singh, John Park

P-MO-167  COMPARISON OF DIRECT FACTOR XA INHIBITOR YM150 WITH OTHER ORAL FXA INHIBITORS ON PROTHROMBIN TIME CLOTTING TESTS USING COMMERCIAL THROMBOPLASTIN REAGENTS
Toshiyuki Funatsu* (JP), Yoshiyuki Iwatsuki, Seiji Kaku

P-MO-168  EFFECTS OF YM150 AND ENOXAPARIN IN RABBIT MODELS OF VENOUS THROMBOSIS AND SURGICAL BLEEDING
Toshio Uemura* (JP), Seiji Kaku

P-MO-169  THE ANTICOAGULANT EFFECT OF YM150 CAN BE REVERSED BY ADMINISTERING COAGULATION FACTORS IN VITRO AND IN VIVO
Seiji Kaku* (JP), Toshio Uemura, Ken-ichi Suzuki

P-MO-170  COMPARISON OF YM150 WITH WARFARIN IN A MOUSE MODEL OF PULMONARY EMBOLISM
Yoshiyuki Iwatsuki* (JP), Mami Suzuki, Tomihisa Kawasaki

Structural biology and drug design

P-MO-171  DISSOCIATION OF THE HOMODIMER RFXIII MOLECULE UPON CALCIUM INDUCED ACTIVATION AND REASSOCIATION DUE TO ELIMINATION OF CALCIUM
Lene Hoerlyck* (DK), Gunhild Klarskov Kristiansen, Mette Dahl Andersen

P-MO-172  CHARACTERIZATION OF TYROSINE SULFATION IN RFVIII (N8) EXPRESSED IN CHO AND HEK-293 CELLS
Per Franklin Nielsen* (DK), Brian Vandahl, Steffen Bak

P-MO-173  ANALYSIS AND CHARACTERIZATION OF A GLYCOPEGLYLATED RECOMBINANT HUMAN FACTOR VIII
Henrik Rahbek-Nielsen* (DK), Jytte Pedersen, Helle Hassan, Jensen Skyt Peter, Anne Kroil Kristensen, Niels Kristian Klausen

P-MO-174  METHYL CHLORIDE AS AN IMPURITY IN GENERIC CLOPIDOGREL PREPARATIONS
Indermohan Thethi* (US), Alain Duguet, Helene Belva-Besnet, Christine Conocar, Marc Daurnas, Rakesh Wahi, Gundu Rao, Lekha Pathak, Jawed Fareed

P-MO-175  DISTINCT STRUCTURE FOR Mg(II)-PROTHROMBIN FRAGMENT 1
Whyte G Owen* (US), Franklyn G Prendergast, Joel Schrock, Jack Hedstrom

P-MO-176  RESULTS OF A PATIENT SURVEY OF HEMOPHILIA PATIENTS WITH INHIBITORS IN THE US AND EU
Sangeeta Krishnan* (US), Yan Xiong, Diane Ito
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-177  A DISCRETE CHOICE EXPERIMENT TO ELICIT PHYSICIAN PREFERENCES FOR MEDICATION ATTRIBUTES IN THE TREATMENT OF PATIENTS WITH SEVERE HEMOPHILIA A AND INHIBITORS TO FACTOR VIII
Sangeeta Krishnan* (US), Heather Gelhorn, Elizabeth Merikle, Josephine Li-McLeod, Leonard A. Valentino

P-MO-178  CAPTURING MEMBRANE BINDING OF COAGULATION FACTORS AT ATOMIC RESOLUTION USING A NOVEL MEMBRANE MIMETIC MODEL
Emadi Takhorshtid* (US), Y. Zenmei Ohkubo

P-MO-179  HEREDITARY THROMBOFILIA IN VENEZUELAN WOMEN WITH RECURRENT FETAL LOSS
Aixa J Muller Soyano* (VE), Aixa Elena Soyano, juan Aller, Anibal Pulido, Andres L Soyano, Ana Ferreira, Gustavo Salazar, Gisela Mendez, Rafael Cortes

Exogenous hemostatic factors

P-MO-180  USE OF RECOMBINANT FACTOR IX (BENEFIX) IN HIP REPLACEMENT IN A PATIENT WITH SEVERE HAEMOPHILIA B
Kai Severin* (DE), Michael Heyl, Markus Compes, H. Tilman Steinmetz, Stephan Schmitz

P-MO-181  PROLONGED EFFECT OF N8-GP IN HAEMOPHILIA A DOGS SUPPORTS LESS FREQUENT DOSING
Henrik Agersoe* (DK), Henning Stennicke, Hermann Pelzer, Eva Norling Olsen, Tim Nichols, Mirella Ezban

P-MO-182  THE USE OF RFVIIA AND APCC IN THERAPY OF BLEEDINGS OF DIFFERENT ORIGIN - THREE YEARS EXPERIENCE OF LODZ HEMOPHILIA TREATMENT CENTER.
Jacek Trelinski* (PL), Michal Zamolski, Krzysztof Choynowski

P-MO-183  CONTINUOUS INFUSION FOR THE MANAGEMENT OF MAJOR POST-TRAUMATIC, LONG-LASTING MUSCULOSKELETAL BLEEDINGS IN HAEMOPHILIA A CHILDREN AND ADOLESCENTS
Brigitte A Pautard Muchemble* (FR), Valerie Li Thiao Te, Christine Vinciguerra, Julie Notheaux-Micheli, Annelutun, Marie Anne Guersing, Bertrand Roussell, Claude Negrier

P-MO-184  ADDITIONAL IMPACT OF MORNING HEMOSTATIC RISK FACTORS AND MORNING BLOOD PRESSURE SURGE ON STROKE RISK IN OLDER JAPANESE HYPERTENSIVE PATIENTS
Yuichiro Yano* (JP), Takefumi Matsuo, Satoshi Hoshide, Kazuo Eguchi, Kazuyuki Shimada, Kazuomi Kario

P-MO-185  GLYCOPEGULATED RFVIII (N8-GP) HAS PROLONGED HAEMOSTATIC EFFECT IN HAEMOPHILIA A MICE.
Torben Elm* (DK), Mirella Ezban, Mikael Tranholm, Henning Stennicke, Heidi Holmberg

P-MO-186  ADVATE HAEMOPHILIA A OUTOME DATABASE (AHEAD): A LONG-TERM REGISTRY FOCUSING ON JOINT OUTCOMES AND QUALITY OF LIFE
Clara K Song* (US), Johannes Oldenburg, Gerald D Spotts, Ingo Abraham, Manfred Pirck, Werner Engi, Armin J Reininger

P-MO-187  APCC (FEIBA) PROPHYLAXIS: LONG TERM EXPERIENCE (1998-2011) IN A SEVERE HAEMOPHILIA A PATIENT WITH FVIII INHIBITOR
michele schino* (IT), pierosandro sbrighti, Massimo Morfini
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-188  PLASMA DERIVED FACTOR VIII IN THE TREATMENT OF PATIENTS WITH HEMOPHILIA A: UPDATE OF A LONG-TERM PHARMACOVIGILANCE
Robert Klamroth (DE), Rainer Zimmermann, Susanne Holzhauer, Mathias Juers*, Claudia Zacharias, Karin Kurnik

P-MO-189  IMPACT OF THE 2500 U VIAL SIZE FOR APCC ON DOSE AND VIAL BURDEN IN A US SPECIALTY PHARMACY DATABASE
Sangeeta Krishnan* (US), Yan Xiong

P-MO-190  P.I.S.A. POST-MARKETING ITALIAN SURVEILLANCE STUDY ON ADVATE TREATMENT OF HAEMOPHILIA A PATIENTS IN ORDER TO EVALUATE ITS EFFICACY, SAFETY AND IMMUNOGENICITY.
michele schino* (IT), angiola rocino, Elena Santagostino, Maria Gabriella Mazzucchoni

P-MO-191  PRECLINICAL SAFETY PHARMACOLOGY OF BAXTER’S RECOMBINANT FACTOR IX
Barbara Dietrich* (AT), Susan Kubik, Hartmut Ehrlich, Friedrich Schefflinger, Hans Peter Schwarz, Eva Maria Muchitsch

P-MO-192  REPEATED APPLICATION OF BAXTER’S RECOMBINANT FACTOR IX IN RATS AND CYNOMOLGUS MONKEYS
Barbara Dietrich* (AT), Wilfried Auer, Kuno Wuersch, Martin Wolfsegger, Hartmut Ehrlich, Friedrich Schefflinger, Hans Peter Schwarz, Eva Maria Muchitsch

P-MO-193  IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS WITH INHIBITORS BY TREATMENT WITH RECOMBINANT FACTOR VIII (IN FACT): A RETROSPECTIVE NON-INTERVENTIONAL STUDY
Georges E. Rivard* (CA), Chantal Rothschild, Teresa Toll

P-MO-194  A COMPARISON OF HEALTH-RELATED QUALITY OF LIFE AND JOINT HEALTH OUTCOMES BETWEEN HEMOPHILIA A PATIENTS WITH INHIBITORS AND NON-INHIBITOR PATIENTS
Diane Ito* (US), Yan Xiong, Sangeeta Krishnan

Fibrinogen and other factors

P-MO-195  COMPARISON OF BRANDED ENOXAPARIN (LOVENOX) AND A BIOSIMILAR VERSION OF ENOXAPARIN (FIBRINOX)
Walter Jeske* (US), Elizabeth McGeehan, Omer Iqbal, Debra Hoppensteadt, Jeanine Walenga, Jawed Fareed

P-MO-196  MOLECULAR MECHANISMS THAT CONTROL CLOT STRUCTURE: EXPLORING THE αC REGION WITH A HUMAN/CHICKEN HYBRID FIBRINOGEN
Susan T Lord* (US), Lifang Ping, Nathan E Hudson, Michael R. Falvo

P-MO-197  FACTOR X DEFICIENCY CAUSED BY DOUBLE NOVEL HETEROZYGOUS MUTATIONS ((IVS5+1G>A AND ASP368DEL)
Jiawei Zhou* (CN), Qiong Chen, Xuefeng Wang, Qiulan Ding, Hongli Wang

P-MO-198  ABDOMINAL AORTIC CALCIFICATION IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: PREVALENCE AND COAGULATION ABNORMALITY.
Vladimir A Zelinsky* (RU), Vladimir V Andreev

P-MO-200  “SNAPSHOTS” OF FIBRIN POLYMERIZATION: ANALYSIS OF FORMALDEHYDE-FIXED PRODUCTS
Susan T Lord* (US), Lihong Huang
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-201 THE INTERIORS OF THE FIBERS IN A FIBRIN CLOT ARE ACCESSIBLE TO LARGE PROTEINS LIKE ACTIVATED FACTOR XIII.
Susan T Lord* (US), Shelby L Allen, Oleg V Gorkun

P-MO-202 RESTORATION OF IMPAIRED HEMOSTASIS BY PLATELETS AND COAGULATION FACTORS IN PATIENTS UNDERGOING CARDIOTHORACIC SURGERY
Marisa Ninivaggi* (NL), Marcus D. Lance, Gerhardus J. Kuiper, Saskia E. Schols, Marion A. Feijge, Marco Marcus, Hugo ten Cate, Johan W. Heemskerk

P-MO-203 CHARACTERIZATION OF FIBRINOGEN DEPLETION AND RESPONSE TO REPLACEMENT THERAPY IN BLEEDING TRAUMA PATIENTS
Claire Rourke* (UK), Nicola S Curry, Sirat Khan, Simon Stanworth, Karim Brohi

P-MO-204 DISCREPANCY BETWEEN ACTIVITY AND ANTIGEN LEVELS OF FACTOR(F) XIII AFTER ADMINISTRATION OF FXIII CONCENTRATES IN HEMORRHAGIC ACQUIRED FXIII DEFICIENCY DUE TO ITS AUTOANTIBODY
Fumihiro Ishida* (JP), Kentaro Okubo, Toshiro Ito, Nobuo Okumura, Masayoshi Souri, Akita T Ichinose

P-MO-205 IDENTIFICATION OF FIBRIN CLOT-BOUND PLASMA PROTEINS
Simone Talens* (NL), Frank W.G. Leebeek, Jeroen A.A. Demmers, Dick C. Rijken

P-MO-206 ANALYSIS AND CHARACTERIZATION OF GLYCOPEGULATED RECOMBINANT HUMAN FIX
Lisbeth C Palm* (DK), Karen Hansen, Anders Dybdal Nielsen, Finn Stausholm Nielsen, Anette Skammelsn Schmidt

Laboratory tests

P-MO-207 ABSENCE OF LOW-DOSE TISSUE FACTOR INDUCED-THROMBIN GENERATION IN SOME SEPTIC SHOCK PATIENTS.
Jean-Christophe Raymond Gris* (FR), Eva Cochery-Nouvellon, Erik Mercier, Marie Bozon, Geraldine Lissalde-Lavigne, Christian Bengler, Guillaume Louart, Jean-Yves Lefrant

P-MO-208 DETERMINING THE ACTIVITY OF RIVAROXABAN TREATMENT: THE NEW PROTHROMBIN TIME REAGENT TECHNOCLOT PT PLUS
Lieselotte Wagner* (AT), Jutta Mager, Viktoria Kaufmann, Nikolaus Binder

P-MO-209 THE EVALUATION OF THE ISI AND MNPT USING FRESH PATIENT SAMPLES AND AK-CALIBRANT: A COMPARISON.
Lieselotte Wagner* (AT), Viktoria Kaufmann, Jutta Mager, Nikolaus Binder

P-MO-210 EVALUATION OF ASSAY PERFORMANCE MONITORING XA INHIBITORS WITH TECHNOCHROM ANTI-XA (AT+) AND TECHNOCHROM ANTI-XA
Lieselotte Wagner* (AT), Sabine Geiter, Stephan Stranz, Viktoria Kaufmann, Jutta Mager, Markus Graf

P-MO-211 ABNORMAL APTT SECOND DERIVATIVE CLOT CURVES ON THE ACL TOP ANALYSER AND THEIR DIAGNOSTIC UTILITY.
Simon J Davidson* (UK), Cristina Valenciano, Stephen Fox, Farah Kamani, Louise Tillyer

P-MO-212 FACTOR XII LEVELS IN CHILDREN WITH CYANOTIC AND ACYANOTIC CONGENITAL HEART DEFECTS: THE IMPACT OF CARDIOPULMONARY BYPASS
Leo A. Bockeria (RU), Natalia N. Samsonova, Ivan A. Yurlov, Ludmila G. Klimovitch, Elena F. Kozar, Iya Tsagareli, Nikolay N. Eliseev, Eva HN. Olsen, Sergey B. Zaets*

P-MO-213 THE STATUS OF CARRIER AND PRENATAL DIAGNOSIS OF HEMOPHILIA IN CHINA
Jing Dai* (CN), Ling Ye Lu, Lan Qiu Ding, Li Hong Wang, Feng Xue Wang
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-214  HAEMOLYSIS DURING SAMPLE COLLECTION CAUSES VARIABLE BUT SOMETIMES CLINICALLY IMPORTANT ERRORS
Anita Woolley* (UK), Kevin Horner, Steve Kitchen

P-MO-215  EFFECT OF MATRINE ON THE EXPRESSION OF TISSUE FACTOR INDUCED BY LIPOPOLYSACCHARIDE IN MONOCYTES
Zhbin Wen* (CN), Xudong Tang, Xiaofan He, Shinlin He

P-MO-216  A NEW APTT REAGENT WITH SYNTHETIC PHOSPHOLIPIDS
Virginia Montanini* (ES), Maite Munoz, Albert Huisman, Ana Chiva

P-MO-217  HIGH ANTI-FACTOR V (AFV) ACTIVITY AND NO-SPONTANEOUS BLEEDING: A CASE REPORT
Silvia Grosso* (AR), Marcelo Ingratti, Graciela Alfonso, Analia Sanchez Luceros, Susana Meschengieser, Alicia Blanco, Maria Lazzari

P-MO-218  UPRREGULATION OF INFLAMMATORY MEDIATORS IN END STAGE RENAL DISEASE AS MEASURED VIA BIOCHIP ARRAY TECHNOLOGY
Vinod Bansal* (US), Rachel Davis, Evangelos Litinas, Debra Hoppensteadt, Jawed Fareed

P-MO-219  THE INHIBITORY EFFECT OF SERUM ALBUMINS ON THE HYDROLYSIS OF ZGGR-AMC BY THROMBIN AND α2M-THROMBIN AND ITS CONSEQUENCES FOR FLUOROREGENIC THROMBIN GENERATION METHODS.
Erik De Smedt* (NL), Rob Wagenvoord, C. H. Hemker

P-MO-220  EVALUATION OF THE Q HEMOSTASIS ANALYSER (GRIFOLS) FOR ROUTINE TESTS OF HAEMOSTASIS
Anita Woolley* (UK), Steve Kitchen

P-MO-221  COAGULATION TESTING: INFLUENCE OF BLOOD COLLECTION TUBE AND PRE-ANALYTICAL STORAGE TEMPERATURE
Marie-Claire F Kleinegris* (NL), M.C.F. Kleinegris, R. Loeffen, F.J.M. van der Meer, P.H. Reitsma, S.T.B.G. Loubele, H.M.H. Spronk, H. ten Cate

P-MO-222  COMPARISON OF SYSMEX CS AND CA SERIES ANALYSERS FOR ROUTINE TESTS OF HAEMOSTASIS
Julie M Smith* (UK), Jackie Deeming, Kevin Horner, Anne Sermon, Jackie Storr, Anita Woolley, Steve Kitchen

P-MO-223  SCALING UP Q HEMOSTASIS ANALYZER TO HIGH THROUGHPUT LABORATORIES
Josep Pages* (ES), Ramon Cases, Susanna Torres

P-MO-224  IMPORTANCE OF THROMBIN GENERATION ASSAY IN MONITORING OF HEMOSTASIS IN PATIENTS WITH HEMOPHILIA
Kaan Kavakli* (TR), Yilmaz Ay, Can Balkan, Deniz Yilmaz, Basri Bilenoglu, Kaan Kavakli

P-MO-225  DECREASED PROCOAGULANT PHOSPHOLIPIDS IN PATIENTS WITH VITAMIN K ANTAGONISTS
Barry J Woodhams* (FR), Aurelie Rousseau, Barry Woodhams, Bernard Lenormand, Marc Vasse

P-MO-226  ATYPICAL VARIANTS OF THE F8 INTRON 22 INVERSION IDENTIFIED USING INVERSE SHIFTING-PCR
Felicity Catherine Edwards* (UK), Jacky Cutler, Steve Austin, Savita Rangarajan, Mike Mitchell

P-MO-227  COMPARISON OF INHIBITION OF THROMBIN GENERATION BY DIFFERENT CLASSES OF ANTICOAGULANTS
Yiming Xu* (US), KehDih Lai, Barry Antonacci, Madhu Chintala
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-228  POLYBRENE CAN NEUTRALISE ENOXAPARIN IN PLASMA BEING TESTED FOR THROMBIN GENERATION, HOWEVER THIS EFFECT IS CONCENTRATION DEPENDENT
Jignesh P Patel* (UK), Lara N Roberts, Raj K Patel, Michael S Marsh, Bruce Green, John G Davies, Roopen Arya

P-MO-229  ACCURACY AND RELIABILITY OF INTERNATIONAL NORMALIZED RATIO (INR) IN MONITORING OF WARFARIN ON QUICK-PT (INR) AND OWREN-TT (INR) REAGENTS
Masahiro Okuda* (JP), Tasuku Sakayori, Sumiyoshi Naito, Mika Yoshida, Noriyoshi Kato, Nobuhiro Takahashi, Masahiro Ieko

P-MO-230  PASTEURIZATION EFFECTIVELY INACTIVATES CLOTTING ACTIVITIES DURING MANUFACTURING OF TWO LIQUID READY TO USE DIFFERENT INTRAVENOUS IMMUNOGLOBULIN (IVIG) PRODUCTS
Marta Jose* (ES), Marzo Nuria, Lopez Laura, Lopez Maite, Ristol Pere, Jorquera I. Juan

P-MO-231  THROMBIN GENERATION (TG) ASSAYS IN HAEMOPHILICS WITH INHIBITORS TREATED WITH BY-PASSING AGENTS: THE UTILITY OF ADDING CORN TRYSIN INHIBITOR (CTI).
Veena Chantarangkul* (IT), Maria Elisa Mancuso, Laura Lemma, Marigrazia Clerici, Elena Santagostino, Armando Tripodi

P-MO-232  COMPARISON BETWEEN ACT+ AND ACT-LR RESULTS USING THE HEMOCHRON SIGNATURE ELITE
Tarek Owaidah* (SA), Merlito De Torres

P-MO-233  COAGULATION TESTING BEFORE EPIDURAL ANALGESIA AT DELIVERY: COST-ANALYSIS
Eugenia Biguzzi* (IT), Franca Franchi, Buthaina Ibrahim, Federica Rossi, Maria Luisa Maspero, Oronzo Morabito, Daniela Asti, Paolo Bucciarelli

P-MO-234  CORRECTION OF INR DISCREPANCY BETWEEN LABORATORIES USING VARIOUS PT SYSTEMS
Felix J.M Van Der Meer* (NL), Anton M. Van den Besselaar, Anton P. Van Zanten, Helen M. Brandjes, Mark G. Elisen, Dennis C. Poland, August Sturk, Anja Leyte, Ad Castel

P-MO-235  EVALUATION AND PERFORMANCE CHARACTERISTICS OF THE Q HEMOSTASIS ANALYZER.
Pierre A Toulon* (FR), Florence Fischer, Anny Appert-Flory, Didier Jambou

P-MO-236  A LOW MAGNESIUM EVACUATED BLOOD COLLECTION TUBE MINIMIZES INR DISCREPANCIES AMONGST DISPARATE PROTHROMBIN TIME SYSTEMS
Keith Moskowitz* (US), Evelina Witteveen, Karen Byron, Amy Mouser, David Warunek, A.M.H.P. van den Besselaar

P-MO-237  ANTITHROMBIN-INDEPENDENT IMPAIRED THROMBIN INACTIVATION IS NOT A FREQUENT FINDING AMONG THROMBOPHILIC PATIENTS
Heiko Ruehl* (DE), Jens Mueller, Ursula Harbrecht, Johannes Oldenburg, Bernd Poetzsch

Experimental models

P-MO-238  PROLONGED HAEMOSTATIC EFFECT OF N8-GP ON JOINT BLEEDS IN HAEMOPHILIA A MICE
Kirstine Ovlisen* (DK), Mirella Ezban, Mikael Tranholm
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-239  EXPERIMENTAL USE OF RECOMBINANT FACTOR XIII (RFXIII) IN CRITICAL CONDITIONS: COMPARISON OF EFFECTIVENESS IN DIFFERENT ANIMAL MODELS
Sergey B. Zaets* (US), Da-Zhong Xu, Qi Lu, Eleonora Feketova, Tamara Berezina, Inga Malinina, Edwin Deitch, Eva Olsen

P-MO-240  THE EFFECT OF COMMON BETA2-RECEPTOR HAPLOTYPES ON CATECHOLAMINE LEVELS AND HEMOSTASIS AFTER STANDING UP
Olav R De Peuter* (NL), Joost C Meijers, Bas Van den Bogaard, Yu-Sok Kim, Marianna C Schaap, Rienk Nieuwland, Wouter E Kok, Harry R Buller, Pieter W Kamphuisen

P-MO-241  DEVELOPMENT OF AN EX VIVO MODEL OF OCCLUSIVE THROMBUS FORMATION
Ishan A Patel* (US), Garth Tormoen, Hrebesh Subhash, Erik I Tucker, Andras Gruber, Owen J McCarty

P-MO-242  EFFICACY OF BAXTER’S RECOMBINANT FACTOR VIA IN ANIMAL MODELS OF HEMOPHILIA
Alexandra Schiviz* (AT), John Philip Lawo, Marlene Resch, Peter Leidenmuerler, Bettina Bischetsrieder, Hartmut Ehrlich, Friedrich Scheiffinger, Hans-Peter Schwarz, Werner Hoellriegl, Eva-Maria Muchitsch

P-MO-243  EFFICACY OF BAXTER’S RECOMBINANT FACTOR IX IN MOUSE MODELS OF HEMOPHILIA B
Werner Hoellriegl* (AT), Alexandra Schiviz, Barbara Eder, John Philip Lawo, Martin Wolfsegger, Hartmut Ehrlich, Friedrich Scheiffinger, Hans-Peter Schwarz, Eva-Maria Muchitsch

P-MO-244  PHARMACOKINETICS OF BAXTER’S RECOMBINANT FIX IN FACTOR IX KO MICE, RATS AND CYNOMOLGUS MONKEYS
Gerald Hoebarth* (AT), Susan Kubik, John Philip Lawo, Alfred Weber, Herbert Gritsch, Alexandra Schiviz, Hartmut Ehrlich, Friedrich Scheiffinger, Hans-Peter Schwarz, Eva-Maria Muchitsch

P-MO-245  PHARMACOKINETICS OF BAXTER’S RECOMBINANT FVIIA IN FACTOR VIII KO MICE, RATS AND CYNOMOLGUS MONKEYS
Gerald Hoebarth* (AT), Susan Kubik, Martin Wolfsegger, John Philip Lawo, Alfred Weber, Herbert Gritsch, Alexandra Schiviz, Hartmut Ehrlich, Friedrich Scheiffinger, Hans-Peter Schwarz, Eva-Maria Muchitsch

P-MO-246  REVERSAL AGENTS FOR EDOXABAN, A FACTOR XA INHIBITOR: EFFECTS OF FACTOR VIIA, ANTI-INHIBITOR COAGULANT COMPLEX, PROTHROMBIN COMPLEX CONCENTRATE, FRESH PLASMA, AND VITAMIN K
Yoshiyuki Morishima* (JP), Yuko Honda, Chikako Kamisato, Taketoshi Furugohri, Toshiro Shibano

P-MO-247  IMPAIRED CARBOXYLATION OF OSTEOCALCIN BY WARFARIN, BUT NOT BY EDOXABAN, AN ORAL DIRECT FACTOR XA INHIBITOR, IN RATS
Yoshiyuki Morishima* (JP), Chikako Kamisato, Taketoshi Furugohri, Toshiro Shibano

P-MO-248  CHARACTERIZATION OF A NOVEL VITAMIN K EPOXIDE REDUCTASE INHIBITOR
Yoshiyuki Morishima* (JP), Toshiyuki Sato, Naoki Tsuji, Mina Delawary, Yuko Honda, Chikako Kamisato, Toshiro Shibano

P-MO-249  PROGRESSION OF THE HYPERCOAGULABLE STATE IN AGEING BMAL1 DEFICIENT MICE
Bianca Hemmeryckx* (BE), Cor E Van Hove, Paul Fransen, Jan Emmerechts, Alexandre Kauskot, Hidde Bult, Henri Roger Lijnen, Marc Hoyaerts
POSTER PRESENTATIONS

Monday, July 25, 2011

Plasminogen activator inhibitors

P-MO-250  EFFECT OF INSULIN ON THE PRODUCTION OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 IN HEPG2 CELLS: INDUCTION THROUGH 3’-UNTRANSLATED REGION
Satoshi Fujii* (JP), Ryu Miyagawa, Takefumi Asakura, Tomomi Nakamura, Hiromi Okada, Soichiro Iwaki, Burton E Sobel

P-MO-251  EFFECT OF FIBRINOGEN AND FACTOR XIII ON CLOT FORMATION AND THROMBIN GENERATION IN GLANZMANN THROMbasthenia BLOOD
Boris Shenkman* (IL), Tami Livnat, Mudi Misgav, Ivan Budnik, Uri Martinowitz

P-MO-252  PLASMINOGEN ACTIVATOR INHIBITOR -1 4G/5G POLYMORPHISM AND RISK OF ACUTE ONSET ISCHEMIC STROKE IN YOUNG ASIAN INDIANS
Mohd S Akhter* (IN), Arijit Biswas, Ravi Ranjan, Amit Sharma, Sunil Kumar, Madhuri Behari, Renu Saxena

P-MO-253  AGE- AND GENDER-RELATED DIFFERENCES IN PAI-1 ANTIGEN LEVELS IN A JAPANESE GENERAL POPULATION, THE SUITA STUDY
Okamoto Akira* (JP), Toshiyuki Sakata, Yoshihiro Kokubo, Michitaka Sano, Toshiyuki Miyata

P-MO-254  PAI-1 DEFICIENCY IN HUMANS AND MICE
Takayuki Iwaki* (JP), Takao Kobayashi, Kazuo Umemura, Tetsumi Urano, Tetsuhiro Kojima, Naohiro Kanayama

P-MO-255  XANTHOANGELOLS ISOLATED FROM ANGELICA KEISKEI INHIBIT INFLAMMATORY-INDUCED PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) PRODUCTION
Naoki Ohkura* (JP), Yoshitaka Nakakuki, Masahiko Taniguchi, Shiho Kanai, Katsunori Ohnishi, Toshiyuki Sakata, Tomoyoshi Nohira, Juzo Matsuda, Kimiye Baba, Gen-ichi Atsumi

P-MO-256  INCREASED FIBRINOLYTIC POTENTIAL IN PATIENTS WITH TYPE 1 DIABETES
Anna Agren* (SE), Gun Jorneskog, Per-Eric Lins, Graciela Elgue, Hakan Wallen, Bjorn Wiman

Fibrinogen and fibrin

P-MO-258  EFFECTS OF MONOMERIC C-REACTIVE PROTEIN ON CLOT DYNAMICS AND FIBRIN STRUCTURE FROM ENDOTHELIAL CELLS: A POSSIBLE MECHANISM OF THE INCREASED THROMBOTIC RISK
Jianbo Wu* (CN), Tammy L Strawn, William P Fay

P-MO-259  FIBRINOGEN MINTO: CONGENITAL HYPOFIBRINOGENAEMIA DUE TO HETEROZYGOSITY FOR A NOVEL MUTATION IN THE FIBRINOGEN GAMMA CHAIN CORRESPONDING TO A γ346GLY TO VAL SUBSTITUTION
Diane Zebeljan* (AU), Lye Lin HO, Penelope MOTUM, Stephen LANG, Stephen BRENNAN, Sarah JUST

P-MO-260  A NOVEL MECHANISM FOR HYPOFIBRINOLYSIS IN DIABETES: THE ROLE OF COMPLEMENT C3
Katharina Hess* (DE), Verena Schroeder, Saad Alzahrani, Mathew Mathai, Gareth Howell, Kerrie Smith, Angela M Carter, Nikolaus Marx, Peter J Grant, Ramzi Ajjan
P-MO-261  MATURITY ONSET DIABETES OF THE YOUNG IS CHARACTERISED BY LESS THROMBOTIC FIBRIN NETWORK STRUCTURE COMPARED WITH PHENOTYPICALLY SIMILAR TYPE 2 DIABETES SUBJECTS
Ramzi A Ajjan* (UK), Matthew J Bottomley, Gaya Thanabalasingham, Saad H Alzahrani, Katharina Hess, Katharine R Owen

P-MO-262  THE PREDICTIVE ABILITY OF D-DIMER FOR THE EFFECT OF THROMBOLYTIC THERAPY AT DEEP VEIN THROMBOSIS
SATOSHI OTA* (JP), NORIKAZU YAMADA, YOSHIITO OGIHARA, AKIHIRO TSUJI, KEN ISHIKURA, MASHIO NAKAMURA, MASAAMI ITO

P-MO-263  EFFECTS OF BARG448LYS POLYMORPHISM ON FIBRIN CLOT STRUCTURE/ FIBRINOLYSIS AND CARDIOVASCULAR COMPLICATIONS IN SUBJECTS WITH TYPE 2 DIABETES.
Katie Amy Greenhalgh* (UK), Saad Alzahrani, J Price, M Strachan, P Baxter, Kristina Standeven, Z Kurdee, Peter Alajian, Robert SA Ariens

P-MO-264  A HIGH DOSE OF ASPIRIN IS REQUIRED FOR POSITIVE INFLUENCE ON PLASMA FIBRIN NETWORK IN PATIENTS WITH TYPE 1 DIABETES.
Sara Tehrani* (SE), Aleksandra Antovic, Fariborz Mobarrez, Koteiba Mageed, Per-Eric Lins, Ulf Adamson, Hakan Jorneskog

P-MO-265  PULMONARY COAGULATION IS INCREASED DEPENDENT ON MAST CELLS IN A MURINE ASTHMA MODEL USING INTRANASAL INOCULATION OF HOUSE DUST MITE EXTRACT.
Johannes Daan De Boer* (NL), C Van t Veer, TJ Hommes, AF De Vos, JJTH Roelofs, JS Van der Zee, T Van der Poll

P-MO-266  COMPLEMENT C3 IS SUBSTRATE FOR PLASMIN AND IMPAIRS TPA-MEDIATED PLASMIN GENERATION RESULTING IN IMPAIRED FIBRINOLYSIS
Victoria R Richardson* (UK), Kristina F Standeven, Peter J Grant, Angela M Carter

P-MO-267  IN VIVO N-HOMOCYSTEINYLATION OF FIBRINOGEN AND ITS ROLE IN THROMBOSIS
Amy L Cilia La Cortel* (UK), Majid Ali, Rafal Glowacki, Hieronim Jakubowski, Victoria Ridger, Richard Pease, Julian Scott, Robert A Ariens, Helen Philippou

P-MO-268  THE ANTIFIBRINOLYTIC FUNCTION OF FACTOR XIII IS EXCLUSIVELY EXPRESSED THROUGH a2ANTIPLASMIN CROSS-LINKING
Nicola J Mutch* (UK), Steven R Fraser, Nuala A Booth

P-MO-269  FIBRIN CLOT FORMATION IS A REVERSIBLE PROCESS
Irina N Chernysh* (US), John W Weisel, Chandrasekaran Nagaswami, Prashant K Purohit

P-MO-270  POSSIBILITY OF FIBRIN MONOMER AS A EARLY MARKER FOR DISSEMINATED INTRAVASCULAR COAGULATION
Hyoeun Shim* (KR), Seongsoo Jang, Boraee G. Park, Chan-Jeoung Park, Hyun-Sook Chi, Sang-Bum Hong

Laboratory tests

P-MO-271  MEASUREMENT OF IMPAIRMENT OF SPONTANEOUS THROMBOLYTIC ACTIVITY IN HABITUAL SMOKERS BY THE GLOBAL THROMBOSIS TEST
Akira Suehiro* (JP), Ichiro Wakabayashi, Tsutomu Yamashita, Junichiro Yamamoto
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-272 ACETYLSALICYLIC ACID THERAPY IN TYPE 2 DIABETIC PATIENTS AND ASSOCIATION WITH URINARY 11-DEHYDRO THROMBOXANE B2 LEVELS
Marinez Oliveira Sousa* (BR), Lillian Harboe Goncalves, Karina Braga Gomes, Ana Paula Fernandes, Luci Maria Sant’Ana Dusse, Adriana Aparecida Bosco, Fernanda Rocha Freitas, Gerson Antonio Planetti, Maria das Gracas Carvalho

P-MO-273 FISH INGREDIENT TAURINE MIGHT RAISE ENDOGENOUS THROMBOLYTIC ACTIVITY IN HEALTHY MIDDLE-AGED JAPANESE, ASSESSED BY A GLOBAL THROMBOSIS TEST (GTT)
Yoshinobu Ijiri* (JP), Hideo Ikurugi, Yukinori Tamura, Mayumi Ura, Mari Morishita, Mari Mori, Hiromitsu Ishii, Yukio Yamori, Junichiro Yamamoto

P-MO-274 IS THERE AN ASSOCIATION BETWEEN APOLIPOPROTEIN A5 -1131T>C POLYMORPHISM AND HEMOSTATIC VARIABLES?
Marinez Oliveira Sousa* (BR), Claudia Natalia Ferreira, Ana Paula Fernandes, Karina Braga Gomes, Isabela Ribeiro Santos, Fernanda Fonseca Coelho, Poliana Silva Pinheiro, Kathryn Fontana Rodrigues, Nathalia Gomide Cruz, Maria das Gracas Carvalho

P-MO-275 HEMOSTATIC AND LIPIDIC VARIABLES IN NORMOLIPIDEMIC AND DYSLIPIDEMIC SUBJECTS
Marinez Oliveira Sousa* (BR), Claudia Natalia Ferreira, Luciana Moreira Lima, Karina Braga Gomes, Poliana Silva Pinheiro, Gerald Fatima Guerra Lages, Maria das Gracas Carvalho

P-MO-276 HYPERFIBRINOLYSIS - TIME REQUIRED TO REACH THE DIAGNOSIS USING STANDARD THROMBOELASTOMETRY ASSAYS
Ole Halfdan Larsen* (DK), Christian Fenger-Eriksen, Kirsten Christiansen, Jorgen Ingerslev, Benny Sorensen

P-MO-277 HIGHLY SENSITIVE ELISA METHOD FOR THE DETERMINATION OF α2-PLASMIN INHIBITOR ANTIGEN LEVEL IN PLASMA AND OTHER BODY FLUIDS
Eva Katona* (HU), Adrienn Orosz, Andrea Csapo, Laszlo Muszbek

P-MO-278 DEVELOPMENT OF AN IMMUNOASSAY FOR THROMBOMODULIN ON STACIA SYSTEM
Shuhei Matsushita* (JP), Tomoko Ono

Deep vein thrombosis and pulmonary embolism

P-MO-279 TWO TEST-SYSTEMS FOR QUANTIFICATION OF SOLUBLE FIBRIN AND D-DIMER. APPROBATION IN CLINICS.
Eduard Vitalievich Lugovskoy* (UA), Serhiy Vasilievich Komisarenko, Irina Nikolaevna Kolesnikova, Tetyana Anatoliivna Koshe, Ievgen Oleksandrovich Koliesnik, Nataliya Eduardovna Lugovskaya, Lesya Petrinvna Urvant, Olena Petrinvna Koistyuchenko

P-MO-280 CAUSAL RELATIONSHIP BETWEEN HYPERFIBRINOGENEMIA, THROMBOSIS, AND RESISTANCE TO THROMBOLYSIS
Kellie Rae Machlus (US), Jessica Cardenas, Frank Church, Alisa S Wolberg*

P-MO-281 STRESS-INDUCED HYPERGLYCEMIA AND VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR TOTAL KNEE ARTHROPLASTY: ANALYSIS FROM THE RECORD TRIALS
Danny Michael Cohn* (NL), Jeroen Hermanides, J. Hans Devries, Pieter-Willem Kamphuisen, Sylvia Kuhls, Martijn Homering, Joost B.L. Hoekstra, Anthonie W.A. Lensing, Harry R. Bulter

P-MO-282 ‘RISING LEUKOCYTE COUNT’ COULD MAKE A GOOD MARKER FOR VENOUS THROMBOEMBOLISM!
Raghavendra R Allareddy* (US)
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-283  RESIDUAL VEIN OBSTRUCTION TO PREDICT THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH DEEP VEIN THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Marc Carrier* (CA), Marc A Rodger, Phil S Wells, M Righini, Gregoire Le Gal

P-MO-284  ENDOVENOUS HEAT INDUCED THROMBOSIS: A NEW CLINICAL ENTITY.
Markiyon Soloviy* (UA)

P-MO-285  VENOUS THROMBOEMBOLIC EVENTS AT A SPECIALIST HEART AND LUNG CENTRE
M Louise Tillyer* (UK)

P-MO-286  HIGH LEVELS OF GLUCOSE AT TIME OF DIAGNOSING VENOUS THROMBOSIS: A CASE-CONTROL STUDY
Vladimir Tichelaar* (NL), Willem M. Liljering, Jan C. ter Maaten, Hanneke C. Kluij-Nellemans, Karina Meijer

P-MO-287  EVALUATION OF DIAGNOSTIC PROCEDURES FOR DIAGNOSIS OF HEPARIN-INDUCED DELAYED-TYPE HYPERSENSITIVITY REACTIONS (DTH)
Marc Schindewolf* (DE), Katja Hardt, Manfred Wolter, Roland Kaufmann, Birgit Kahle, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig

P-MO-288  DEEP VEIN THROMBOSIS AFTER TOTAL KNEE OR HIP ARTHROPLASTY IS ASSOCIATED WITH INCREASED CALF MUSCLE DEOXGENATION BEFORE SURGERY
Takashi Yamaki* (JP), Atsumori Hamahata, Daisuke Fujisawa, Hisato Konoeda, Kazuyuki Kubo, Taro Kono, Mitohiro Nazaki, Hiroyuki Sakurai

P-MO-289  INCREASING OF ISCHEMIC STROKE IN RESIDENTS WITH DVT AFTER MID NIIGATA PREFECTURE EARTHQUAKE
Kazuhiko Hanzawa* (JP), Maiko Ikura, Takeshi Okamoto, Kohichi Sato, Kyoko Shinada, Takashi Nakajima

P-MO-290  HYPERTENSION IS A RISK FACTOR FOR DVT IN JAPANESE QUAKE RESIDENTS.
Kazuhiko Hanzawa* (JP), Maiko Ikura, Takeshi Okamoto, Kohichi Sato, Kyoko Shinada, Takashi Nakajima

P-MO-291  RELEVANCE OF THROMBOPHILIA IN DEEP VEIN THROMBOSIS FOLLOWING A MAJOR EARTHQUAKE
Mana Mitsuguro* (JP), Toshiyuki Sakata, Akira Okamoto, Kazuhiko Hanzawa, Kyoko Shinada, Takashi Nakajima, Sachika Kameda, Michitaka Sano, Toshiyuki Miyata

P-MO-292  QUALITY AND SAFETY LABORATORY MONITORING OF INDIRECT ANTICOAGULANTS THERAPY
Alyona I. Vorobyeva (RU), Ludmila A. Isaeva, Alexsandra S. Rogozina, Petr A. Lavrinov, Nadezda A. Vorobyeva*

P-MO-293  HEREDITARY PROTEIN C DEFICIENCY CAUSED BY COMPOUND HETEROZYGOUS MUTANTS IN TWO UNRELATED CHINESE FAMILIES
Yingting Wu* (CN), Xuefeng Wang, Hongli Wang, Qiulan Ding, Jing Dai, Yeling Lu

P-MO-294  LOW INCIDENCE OF POSTOPERATIVE DEEP VEIN THROMBOSIS IN PATIENTS UNDERGOING COLORECTAL CANCER SURGERY SEEN IN TAIWAN
Ching-Yeh Lin* (TW), Ming Ching Shen, Hungh Chang Chen, Ting Ming Huang, Tsang Chi Lin, Jau Jie You, Shyuann Yuh Lin, Han Ni Hsieh

P-MO-295  THROMBIN GENERATION IS INCREASED IN AFRICAN-CARIBBEANS COMPARED TO CAUCASIANS WITH DEEP VEIN THROMBOSIS.
Lara N Roberts* (UK), Raj K Patel, Roopen Arya
Monday, July 25, 2011

**P-MO-296**  PROGNOSTIC VALUE OF THE GENEVA PREDICTION RULE IN PATIENTS WITH PULMONARY EMBOLISM.
Laurent Bertoletti* (FR), Gregoire Le Gal, Drahomir Aujesky, Olivier Sanchez, Pierre-Marie Roy, Franck Verschuren, Henri Bounaumeau, Arnaud Perrier, Marc Righini

**P-MO-297**  PROGNOSTIC VALUE OF THE GENEVA PREDICTION RULE IN PATIENTS IN WHOM PULMONARY EMBOLISM IS RULED OUT.
Laurent Bertoletti* (FR), Gregoire Le Gal, Drahomir Aujesky, Olivier Sanchez, Pierre-Marie Roy, Franck Verschuren, Henri Bounaumeau, Arnaud Perrier, Marc Righini

**P-MO-298**  HEMATOCRIT AND THE RISK OF RECURRENT VENOUS THROMBOSIS: A PROSPECTIVE COHORT STUDY
Lisbeth Eischer* (AT), Verena Tscholl, Georg Heinze, Ludwig Traby, Paul Alexander Kyrle, Sabine Eichinger

**P-MO-299**  PAST PROVOKING VENOUS THROMBOSIS RISK SITUATIONS ON THE RISK OF A RECURRENT THROMBOTIC EVENT: A COHORT STUDY
Daniel Dias Ribeiro* (BR), Willem Lifering, Sandhi Barreto, Izabella Silva, Mariana Chalup, Frits Rosendaal, Suely Rezende

**P-MO-300**  IS DEEP-VEIN THROMBOSIS ALWAYS THE ORIGIN OF PULMONARY EMBOLISM? IMAGING OF VEINS WITH A TOTAL-BODY DIRECT THROMBUS MRI TECHNIQUE.
Kirsten van Langevelde* (NL), A. Sramek, P. W.J. Vincken, C.J. van Rooden, F. R. Rosendaal, S. C. Cannegieter

**P-MO-301**  HOMOZYGOUS FACTOR V LEIDEN AND COMPOUND HETEROZYGOSITY FOR FACTOR V LEIDEN AND PROTHROMBIN MUTATION
Ymir Saemundsson* (SE), Signy Vala Sveinsdottir, Henrik Svantesson, Peter J. Svensson

**P-MO-302**  SOCIOECONOMIC FACTORS AND CONCOMITANT DISEASES ARE RELATED TO THE RISK FOR VENOUS THROMBOEMBOLISM DURING 13 YEARS OF PROSPECTIVE FOLLOW-UP.
Nazim Isma* (SE), Peter J Svensson, Bengt Lindblad, Juan Merlo, Henrik Ohlsson, Anders Gottsater

**P-MO-303**  SAFETY AND EFFICACY OF FONDAPARINUX FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) IN JAPANESE PATIENTS UNDERGOING COLORECTAL CANCER SURGERY.

**P-MO-304**  DOES RESIDUAL VEIN OBSTRUCTION PREDICT RECURRENT THROMBOEMBOLISM AFTER DEEP VEIN THROMBOSIS? A PATIENT-LEVEL META-ANALYSIS
MARCO P DONADINI* (IT), WALTER AGENO, BENILDE COSMI, DANIELA POLI, PAOLO FRANDONI, SERGIO SIRAGUSA, LAURA YOUNG, FRANCESCO DENTALI, MONICA CAPRIOLI, JAMES DOUKETIS

**P-MO-305**  ACTIVATION OF COAGULATION BY A THALIDOMIDE-BASED REGIMEN
Yu Isozumi* (JP), Aya Matsumoto, Asuka Hoshi, Jihwa Chung, Takatoshi Koyama

**P-MO-306**  BENCHMARK OF THE INTERNATIONAL NORMALIZED RATIO DURING VITAMIN K TREATMENT IN VENOUS THROMBOEMBOLISM: A SYSTEMATIC REVIEW
Petra MG Erkens* (NL), Hugo ten Cate, Martin H Prins

**P-MO-307**  THROMBOSIS RISK IN MEDICAL INPATIENTS: ASSESSMENT OF TWO THROMBOSIS RISK SCORES
Neil Adrian Zakai* (US), Peter W Callas, Allen B Repp, Mary Cushman
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-308  THE MANAGEMENT OF SUB-SEGMENTAL PULMONARY EMBOLISM: A CROSS-SECTIONAL SURVEY OF CANADIAN THROMBOSIS PHYSICIANS
Marc Carrier* (CA), Gregoire Le Gal, Susan Kahn, Michael Kovacs, Philip Wells, David Anderson, Marc Rodger

P-MO-309  DEVELOPMENT AND APPLICATION OF AN AUTOMATED THROMBIN GENERATION ASSAY WHICH IS SENSITIVE TO DEFECTS OF PROTEIN C PATHWAY
Laura Green* (UK), Andrew S Lawrie, Ian J Mackie, Kim Ryland, Hannah Cohen, Ri Liesner, Samuel J Machin

P-MO-310  EVALUATION OF A NEW D-DIMER TEST IN COMBINATION WITH PRETEST CLINICAL PROBABILITY SCORE FOR DIAGNOSIS OF PULMONARY EMBOLISM AND DEEP VENOUS THROMBOSIS
Tarek M Owaidah (SA), Nahla Al.Ghasham, Khalid Magrabi

P-MO-311  BLEEDING-THE MOST FREQUENT UNEXPECTED EFFECT OF THE THERAPY WITH ORAL ANTICOAGULANT DRUGS
Deniza Donco Stambolieva* (MK), Tanja Timova, Jani Angelovski, Meri Sorova, Laura Gorcaj, Lence Maseva, Mirjana Trenceva, Ivanka Nikoloska

P-MO-312  ANTICOAGULANT PROTOCOL FOR TREATING CEREBRAL VEIN THROMBOSIS: A PROSPECTIVE SINGLE-CENTER STUDY
Maria Teresa Sartori* (IT), Sofia Barbar, Paolo Zampieri, Marina Munari, Carla Carollo, Chiara Brian, Gianluigi Ricchieri, Laura Pasetto, Grazziella Saggiorato, Paolo Prandoni

P-MO-313  INCREASED INCIDENCE OF PULMONARY EMBOLISM IN PATIENTS WITH SEVERE ASTHMA.
Christof J Majoor* (NL), Aelko H Zwinderman, Harry B Buller, Pieter W Kamphuisen

P-MO-314  PROGNOSTIC MARKERS FOR RESIDUAL PERFUSION DEFECTS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM
Roger EG Schutgens* (NL), Mariette Agterof, Roger Schutgens, Fred Verzijlbergen, Monique van Buul, Repke Snijder, Rene Eijkemans, Douwe Biesma

P-MO-316  ASSESSMENT OF THROMBIN GENERATION IN PRIMARY THROMBOPHILIA AND ACQUIRED RISK FACTORS FOR VENOUS THROMBOEMBOLISM
Antonin Hlusi* (CZ), Ludek Slavik, Jana Ulehlova, Jana Prochazkova, Vera Krcova

P-MO-317  PROC GLOBAL ASSAY IN PATIENTS WITH VENOUS THROMBOEMBOLISM AND PREGNANCY COMPLICATIONS
Pablo Alberto Martinez* (AR), Maria Luciana Roumeque, Romina Valeria Suarez, Solange Alejandra Rodriguez

P-MO-318  EFFICACY OF RIVAROXABAN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER KNEE ARTHROSCOPY: A RANDOMIZED DOUBLE-BLIND TRIAL (ERIKA STUDY)
Giuseppe Camporese* (IT), Enrico Bernardi, Franco Noventa

P-MO-319  EMERGENCY DEPARTMENT ACCESS RATE FOR VENOUS THROMBOEMBOLISM, CARDIOVASCULAR AND PULMONARY DISEASES IN RELATIONSHIP WITH THE COARSE AND FINE PARTICULATE MATTER AIR POLLUTION.
Nicola Martinelli* (IT), Davide Cigolini, Marco Sandri, Domenico Girelli, Giorgio Ricci, Giampaolo Rocca, Olivier Olivieri

P-MO-320  ANTICOAGULANT UTILIZATION IN CANCER ASSOCIATED THROMBOSIS (CAT) PATIENTS
Elham Rahme* (CA), Guillaume Feugere, Elodie Ramos, Myriam Antoun
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-321  AIR POLLUTION-INDUCED PROCOAGULANT CHANGES ARE TRIGGERED BY CIRCULATING MICROVESICLES
Jan Emmerechts* (BE), Lotte Jacobs, Soetkin Van kerckhoven, Serena Loyen, Chantal Mathieu, Frans Fierens, Ben Nemery, Tim Nawrot, Marc Hoylaerts

P-MO-322  A COMMON STANDARD IS INAPPROPRIATE FOR DETERMINING THE POTENCY OF SEMULOPARIN AND BEMIPARIN
Walter Jeske* (US), Debra Hoppensteadt, Angel Gray, Jeanine Walenga, Josephine Cunanan, Lauren Meyer, Jawed Fareed, Alain Bayol, Helene Rigal, Christian Viskov

P-MO-323  CYSTATIN C IS ASSOCIATED WITH RISK OF VENOUS THROMBOEMBOLISM IN SUBJECTS WITH NORMAL KIDNEY FUNCTION - THE TROMSO STUDY
Ellen E Brodin* (NO), Sigrid Braekkan, Anders Vik, Jan Brox, John-Bjarne Hansen

P-MO-324  EMOTIONAL STATES AND FUTURE RISK OF VENOUS THROMBOEMBOLISM: THE TROMSO STUDY
Kristin F Enga* (NO), Sigrid K Braekkan, Ida J Hansen-Krone, John-Bjarne Hansen

P-MO-325  INPATIENT RISKS OF VENOUS THROMBOEMBOLISM AND BLEEDING FOLLOWING HIP AND KNEE REPLACEMENT SURGERY
Elham Rahme* (CA), Kaberi Dasgupta, Susan R Kahn, Sasha Bernatsky, Greg K Berry, Alain Cirkovic, Yves Laflamme, Ronald A Dimentberg, Mark Burman, Youssef Habel, Celine Khodr

P-MO-326  OUTPATIENT RISKS OF VENOUS THROMBOEMBOLISM AND BLEEDING FOLLOWING HIP AND KNEE REPLACEMENT SURGERY
Elham Rahme* (CA), Kaberi Dasgupta, Susan R Kahn, Sasha Bernatsky, Greg K Berry, Mark Burman, Alain Cirkovic, Yves Laflamme, Ronald A Dimentberg, Youssef Habel, Celine Khodr

P-MO-327  EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN TRAUMA PATIENTS WITH LOWER EXTREMITY INJURIES
Kerry Hitos* (AU), Patrick Chu, John P Fletcher

P-MO-328  CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND THE RISK OF PE AND DVT
Linda E Flintorman* (NL), Astrid Hylckama Vlieg, Suzanne C Cannegieter, Frits R Rosendaal

P-MO-329  INFLUENCE OF PUBLIC AWARENESS OF SYMPTOMS OF DEEP VEIN THROMBOSIS AND BURDEN OF THE DISEASE ON THE RATE OF CONFIRMED THROMBOTIC EVENTS
Malgorzata Dybowska (PL), Witold Z Tomkowski*, Renata Gralec, Janusz Burakowski, Adam Jozwik, Pawel Kuca

P-MO-330  SEASONAL RATE OF DEEP VENOUS THROMBOSIS
Pawel Kuca (PL), Malgorzata Dybowska, Renata Gralec, Janusz Burakowski, Adam Jozwik, Witold Z Tomkowski*

Genetic determinants and epidemiology

P-MO-331  INTERACTION BETWEEN HYPERHOMOCYSTEINEMIA AND SEVERAL DNA POLYMORPHISMS INVOLVED IN ENDOTHELIAL DYSFUNCTION IN VENOUS THROMBOEMBOLISM
Veronika Shmeleva* (RU), Sergei Kapustin, Anastasia Polyakova, Mikhail Blinov

P-MO-332  PROTHROMBIN G20210A MUTATION IS ASSOCIATED WITH HIGHER DILUTE RUSSELL VIPER VENOM TIME, WHICH HAS MODERATE POWER TO PREDICT CARRIER STATUS
Kristi Johnson Smock* (US), George M Rodgers, Brian H Shirts
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-333  PREVALENCE OF GENETIC RISK FACTORS FOR CARDIOVASCULAR DISEASE IN THE IRANIAN POPULATION
Christian Oberkanins* (AT), Helene Puehringer, Valeh Hadavi, Kimia Kahrizi, Hossein Najmabadi

P-MO-334  ROLE OF GENE ENVIRONMENTAL INTERACTIONS IN DEVELOPMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN NORTH WEST RUSSIA.
Veronika Shmeleva* (RU), Sergei Kapustin, Mikhail Blinov, Ludmila Papayan

P-MO-335  SUPERFICIAL VEIN THROMBOSIS AS A PRECURSOR FOR VENOUS THROMBOSIS IN THE MEGA STUDY.
Kirsten van Langevelde* (NL), Willem M. Lijfering, Frits R. Rosendaal

P-MO-336  R147W MUTATION OF PROTEIN C GENE IS COMMON IN THAI POPULATION
Amphawan Chuansumrit* (TH), Werasak Sasanaakul, Duanrundee Wattanasirichaigoon, Nongnuch Sirachainan, Natjava Yudhasompop, Arjit Tiraganjana, Praguywan Kadegasem

P-MO-337  A NOVEL PROTHROMBIN GENE MUTATION LEADS TO AN AT-RESISTANT THROMBIN IN A FAMILY WITH INHERITED THROMBOPHILIA.
Yuhi Miyawaki* (JP), Alsuou Suzuki, Yuhta Fujimori, Junko Fujita, Asuka Maki, Akira Takagi, Takashi Murate, Michio Sakai, Kohji Okamoto, Tadashi Matsushita, Tetsuhiro Kojima

P-MO-338  STUDY ON THE DEFICIENCY OF ANTICOAGULANT PROTEINS IN PATIENTS OF THROMBOTIC EVENTS WITH NO EVIDENT ACQUIRED FACTORS: CLINICAL PREVALENCE, RISKS, AND GENETIC ANALYSIS
Changcheng Zheng* (CN), Jingsheng Wu, Kaiyang Ding, Jie Li, Xin Liu, Xiaoyan Cai, WeiBo Zhu

P-MO-339  PON2 SER311CYS POLYMORPHISM IS A PREDICTOR OF TOTAL AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH ANGIOGRAPHICALLY CONFIRMED CORONARY ARTERY DISEASE.
Nicola Martinelli* (IT), Domenico Girelli, Elisa Grison, Letizia Consoli, Roberta Micaglio, Elisabetta Trabetti, Giovanni Malerba, Simonetta Friso, Francesca Pizzolo, Pier Franco Pignatti, Roberto Corrocher, Olivieri Oliviero

P-MO-340  RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH DIFFERENT PLASMA LEVELS OF ANTITHROMBIN, PROTEIN C AND PROTEIN S
Ida Martinelli* (IT), Paolo Bucciarelli, Francesca Gianniello, Serena M Passamonti, Franca Franchi, Eugenia Biguzzi, Pier Mannuccio Mannucci

P-MO-341  STUDY ON THE PATHOGENESIS OF PROC P275S MUTATION IN PROTEIN C DEFICIENCY AND THE ROLE OF ITS CORRESPONDING LOOP
Tingting Yu (CN), Jing Dai*, Jian Wang, Xuefeng Wang, Qihua Fu

P-MO-342  PHYSICAL ACTIVITY AND RISK OF FIRST VENOUS THROMBOSIS: A SUBGROUP ANALYSIS WITHIN THE MEGA CASE-CONTROL STUDY
Willem M Lijfering* (NL), Frits Rosendaal, Suzanne Cannegeiter

P-MO-343  OVER FIFTY PERCENT OF DUTCH VTE FAMILIES WITH PROTEIN C DEFICIENCY SHARE A FOUNDERS R272C MUTATION.
Jorine S Koenderman* (NL), Rogier M Bertina, Pieter H Reitsma, Marieke CH de Visser

P-MO-344  MULTIVARIATE ANALYSIS OF GENETIC, BEHAVIOURAL AND SOCIO-PSYCHOLOGICAL DETERMINANTS OF VITAMIN K-ANTAGONIST DOSE
Jane Skov* (DK), Else-Marie Bladbjerg, Morten Arendt Rasmussen, Johannes Sidelmann, Anja Leppin, Joergen Jespersen
Monday, July 25, 2011

**Antiphospholipid syndrome**

**P-MO-345** LATE ONSET WARFARIN INDUCED SKIN NECROSIS IN A YOUNG FEMALE WITH ANTIPHOSPHOLIPID ANTIBODY SYNDROME
Valizadeh Nasim* (IR), Mir Amir Aghdash, Sona Nori Vahed, Kamran Keyvan Pazhuh, Fathollah Moradi

**P-MO-346** PLATELET ACTIVATION AND PARADOXICAL INHIBITION OF ADP INDUCED AGGREGATION BY ANTIPHOSPHOLIPID ANTIBODIES IN VITRO
Kenji Oku* (JP), Tatsuya Atsumi, Olga Amengual, Yuuichirou Fujieda, Kotaro Otomo, Masaru Kato, Shin Furukawa, Hirohiko Kitakawa, Shinsuke Yasuda, Tetsuya Horita, Yuuji Hori, Tetsuhiro Nishikawa, Kazuyoshi Nihei, Masahiro Ieko, Takao Koike

**P-MO-347** ARTERIAL THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME
Nuria Bermejo* (ES), M.J Garcia Blanco, C. Martin Aguilera, M.L Bengochea, F. Carnicero, J. Bergua

**P-MO-348** HAEMOSTATIC CHANGES IN CORONARY ARTERY DISEASE PATIENTS WITH HYPERHOMOCYSTEINEMIA AND ANTI-BETA2 GLYCOPROTEIN-I AND/OR ANTI-PROTHROMBIN ANTIBODIES
Veronika Shmeleva* (RU), Olga Smirnova, Vera Kobilyanskaya, Ludmila Papayan

**P-MO-349** FIBRINOLYSIS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
Karen A Breen* (UK), Kiran Parmar, Beverley J Hunt

**P-MO-350** COMPLEMENT ACTIVATION IN PATIENTS WITH ISOLATED ANTIPHOSPHOLIPID ANTIBODIES (APL) AND PRIMARY ANTIPHOSPHOLIPID SYNDROME (PAPS)
Karen A Breen* (UK), Paul Seed, Kiran Parmar, Beverley J Hunt

**P-MO-351** USEFULNESS OF THROMBOELASTOGRAPHY IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES OR PRIMARY ANTIPHOSPHOLIPID SYNDROME
Karen A Breen* (UK), Beverley J Hunt

**P-MO-352** MESENTERIC VASCULAR THROMBOEMBOLISM IN ASSOCIATION WITH ANTIPHOSPHOLIPID ANTIBODIES: A CASE SERIES
Karen A Breen* (UK), Beverley J Hunt

**P-MO-353** THE PROBLEM OF INTER-ASSAY VARIABILITY IN ANTIPHOSPHOLIPID ANTIBODY ASSAYS PERSISTS
Katrien M.J. Devreese* (BE)

**P-MO-354** AUTOANTIBODIES AGAINST PROTHROMBIN AND PROTHROMBIN-PHOSPHATIDYLSERIN COMPLEX: A DIAGNOSTIC TOOL FOR THE ANTIPHOSPHOLIPID SYNDROME?
Katrien M.J. Devreese* (BE), Marc F Hoylaerts

**P-MO-355** THE RISK OF MISSING LUPUS ANTIICOAGULANT: VALIDATION OF ISTH GUIDELINES 2009
Jun Teruya* (US), Ozlem Bilen, Barry Myones

**P-MO-356** FOLLOW-UP OF 148 PATIENT WITH ANTIPHOSPHOLIPID SYNDROME (APS) DURING A 18-YEAR PERIOD.
Tatiana M Reshetnyak* (RU), Tatiana M Reshetnyak, Inna B Shitivelband, Natalia V Seredavkina, Elena N Aleksandrova, Lubov V Kondratyeva, Evgenii L Nassonov

**P-MO-357** RENAL TRANSPLANTATION IN A PATIENT WITH CATASTROPHIC APLS AND HIT AND DOUBLE TRANSPLANTATION (LIVER AND RENAL) IN A PATIENT WITH TTP.
Dorit Blickstein* (IL), Eytan Mor, Ruth Rahamimov, Aida Inbal
POSTER PRESENTATIONS

Monday, July 25, 2011

Pregnancy, hormones, women’s issues

P-MO-358  MONITORING ANTI-XA ACTIVITY OF TINZAPARIN AND BEMIPARIN [LOW MOLECULAR WEIGHT HEPARINS(LMWHS)] AT THERAPEUTIC DOSAGES DURING PREGNANCY.
Amparo Santamaria* (ES), Adriana Sierra, Laura Hernandez, Marina Carrasco, Montse Borrell, Dolors Llobet, Jordi Fontcuberta

P-MO-359  INCREASED LEVELS OF TISSUE FACTOR ACTIVITY ON SYNCYTIOBLAST MICROVESICLES RELEASED INTO THE MATERNAL CIRCULATION DURING PRE-ECLAMPSIA.
Chris Gardiner* (UK), Dionne S Tannetta, Paul Harrison, Christopher WG Redman, Ian L Sargent

P-MO-360  A “NEW” THROMBOPHILIA MARKER IN THE PROTEIN C PATHWAY - A LIKELY CAUSE FOR UNEXPLAINED RECURRENT PREGNANCY LOSS IN YOUNG MALAYSIAN WOMEN!
Thiruchelvam Ayadurai* (BN), Faraizah Abdul Karim, Sekaran Muiniand

P-MO-361  PREGNANCY IS A HIGH RISK FACTOR FOR HEPARIN-INDUCED ALLERGIC SKIN REACTIONS - RESULTS OF A PROSPECTIVE STUDY
Marc Schindewolf* (DE), Corinna Gobst, Hartmut Kroll, Andreas Recke, Frank Louwen, Manfred Wolter, Roland Kaufmann, Wolf-Henning Boehncke, Edelgard Lindhoff-Last, Ralf J. Ludwig

P-MO-362  STUDY OF VARIABILITY IN THE MANAGEMENT OF THROMBOEMBOLIC DISEASE (TD) IN WOMEN IN SPAIN: NATIONAL MULTICENTER STUDY.
Amparo Santamaria* (ES), Dolors Tassies, Oscar Martinez, F Javier Rodriguez-Martorell, R. Lecumberri, M. Casellas, M. Jose Gutierrez-Pimentel, IM Ramirez

P-MO-363  INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CUSHING’S SYNDROME: A MULTICENTER COHORT STUDY
Danka J Stuijver* (NL), Birgie van Zaane, Richard A Feelders, Jan Debeij, Suzanne C Cannegieter, Ad R Herrum, Gerrit van den Berg, Alberto M Pereira, Wouter W de Herder, Margreet A Wagenmakers, Michiel N Kerstens, Pierre M Zelissen, Eric Fliers, Nicolaas Schaper, Madeleine L Drent, Olaf M Dekkers, Victor E Gerdes

P-MO-364  THROMBOPHILIC STATUS OF WOMEN WITH COMPLICATED OBSTETRIC HISTORY
Nadezda A. Vorobyeva* (RU), Nadezda A. Vorobyeva, Diana R. Garnyakra, Yana A. Dremova Ya

P-MO-365  POSTPARTUM LIFE-THREATENING THROMBOEMBOLIC COMPLICATIONS IN A PATIENT WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA: A ‘RESCUER’ ROLE FOR ECULIZUMAB?
Kristin Jochmans* (BE), Frederik Vandenbroucke, Marc De Waele, Fabienne Trullemans

P-MO-366  OCCURRENCE OF OBSTETRIC AND THROMBOEMBOLIC COMPLICATIONS IN FAMILY MEMBERS OF WOMEN WITH COMMON INHERITED THROMBOPHILIAS AND PREVIOUS OBSTETRIC COMPLICATIONS.
Elvira Grandone* (IT), Michela Villani, Donatella Colaizzo, Giovanni Tiscia, Elena Chinni, Filomena Cappucci, Patrizia Vergura, Gennaro Vecchione, Lucia Fischetti, Maurizio Margaglione

P-MO-367  THE THROMBIN GENERATION PROFILES OF WOMEN ON PROPHYLACTIC ENOXAPARIN DURING PREGNANCY AND THE Puerperium
Jignesh P Patel* (UK), Raj K Patel, Michael S Marsh, Bruce Green, John Graham Davies, Roopen Arya

P-MO-368  WOMEN’S VIEWS AND ADHERENCE TO ENOXAPARIN THERAPY DURING PREGNANCY AND THE Puerperium
Jignesh P Patel* (UK), Vivian Auyeung, Raj K Patel, Michael S Marsh, Bruce Green, Roopen Arya, John Graham Davies
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-369  PREGNANCY COMPLICATIONS AND ANTIPHOSPHOLIPID ANTIBODIES
Katia M Taouli* (DZ), Riad Benhabib, Nabilah Baba Ahmed, Sara Ayad

P-MO-370  THE RISK OF RECURRENT VENOUS THROMBOSIS ASSOCIATED WITH ORAL CONTRACEPTIVE USE
Astrid van Hylckama Vlieg* (NL), Linda E. Flinterman, Suzanna C. Cannegieter, Frits R. Rosendaal

P-MO-371  CAN ANTI COAGULANT THERAPY IMPROVE THE OUTCOME OF PREGNANCY IN THROMBOPHILIC WOMEN?
Mirjana K Kovac* (RS), Zeljko Mikovic, Gorana Mitic, Valentina Djordjevic, Ivana Jaglicic, Vesna Mandic, Dragica Radojkovic

P-MO-372  RESULTS OF THROMBOPHILIA SCREENING IN ORAL CONTRACEPTIVE USERS WITH VENOUS THROMBOTIC COMPLICATIONS IN NORTH WEST RUSSIA.
Veronika Shmeleva* (RU), Natalia Saltikova, Ludmila Papayan, Natalia Aganezova

P-MO-373  RISK OF PPH IN WOMEN USING THERAPEUTIC DOSAGE OF LMWH DURING PREGNANCY AND PUERPERIUM
H. Marieke Knot* (NL), Lejan Schultinge, Jan Jaap H.M. Erwich, Nic J.G.M. Veeger, Hanneke C. Kluin-Nelemans, Karina Meijer

Cancer and thrombosis

P-MO-375  CIRCULATING BLASTS, PLATELET COUNT AND D-DIMER IN ACUTE LEUKEMIA: IS THERE ANY CORRELATION?
Amaylia Oehadian* (ID), Anggun Mekar, Rachmat Sumantri, Nadjwa Zamalek

P-MO-376  SPLANCHNIC VENOUS THROMBOEMBOLISM IN AMBULATORY CANCER PATIENTS RECEIVING CHEMOTHERAPY.
Rita Carlotta Santoro* (IT), Simona Prejano’, Piergiorgio Iannaccaro

P-MO-377  CLINICOHEMATOLOGICAL RESPONSE AND RESISTANCE/INTOLERANCE TO HYDROXYCARBAMIDE IN ESSENTIAL THROMBOCYTHAEMIA.
Rita Carlotta Santoro* (IT), Simona Prejano’, Piergiorgio Iannaccaro

P-MO-378  PROTEIN C PATHWAY AND ANTITHROMBIN IN THROMBOSIS-RELATED GASTROINTESTINAL DISORDERS
Selime Ayaz* (TR), Huseyin Alkim, Canan Alkim, Nurgul Sasmaz

P-MO-379  HYPERHOMOCYSTEINEMIA AS PREDICTOR OF THROMBIC COMPLICATIONS IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISEASES AND MULTIPLE MYELOMA
Veronika Shmeleva* (RU), Ludmila Papayan, Kudrat Abdulkadyrov, Stanislav Bessmeltsev, Ekaterina Chait, Tatyana Zamotina

P-MO-380  INCIDENTAL PULMONARY EMBOLISM IN CANCER PATIENTS IS ASSOCIATED WITH SIGNIFICANT MORBIDITY AND MORTALITY. A COMPREHENSIVE CANCER CENTER EXPERIENCE
Hikmat N. Abdel-Razeq* (JO), Asem H Mansour, Yousef M Ismael
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-381  THE RISK OF STROKE AND MYOCARDIAL INFARCTION IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS. A STUDY OF THE IMPORTANCE OF PLATELET AGGREGATION.
Viola Maria I Popov* (RO), Ana Maria Vladarean, Horia Bumbea, Eugenia Kovacs, Tudor Savopol, Adrian Tase, Minodora Onisai, Mihaela Camelia Stancu, Anca Maria Ilea, Camelia Marioara Dobrea, Staniciu Marian

P-MO-382  RECOMBINANT THROMBOMODULIN MAY PLAY A PREVENTIVE ROLE FOR VENO-OCCCLUSIVE DISEASE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
Shosaku Nomura* (JP), Shinya Fujita, Ryotaro Ozasa, Takahisa Nakanishi, Michihiko Miyaji, Shinichiro Mori, Tomoki Ito, Kazuyoshi Ishii

P-MO-383  CURRENT USE OF PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN COLORECTAL CANCER SURGERY PATIENTS: THE SCALA STUDY
Walter Ageno* (IT), Charles M Samama, Fred A Anderson

P-MO-384  LONG-TERM USE OF CURATIVE DOSES OF TINzaparin VERSUS VITAMIN K ANTAGONISTS IN THE TREATMENT OF VENOUS THROMBOEMBOLISM (VTE): META-ANALYSIS OF 5 RANDOMIZED TRIALS
Silvy Laporte* (FR), Laurent Bertoletti, Patrick Mismetti

P-MO-385  IDENTIFICATION OF GLYCOPROTEIN IB (GPIB), LRP1 AND ANNEXIN II MRNA IN DIFFERENT HUMAN AND MOUSE TUMOR CELL LINES
Yanina P Powazniak* (AR), Ana C Kempfer, Julio C Calderazzo Pereyra, Daniel F Alonso, Maria A Lazzari, Analia Sanchez-Luceros

P-MO-386  CANCER-CELL EPCR CONTRIBUTES TO CELL-SURVIVAL, TUMOR-PROGRESSION AND PROMOTES HYPERCOAGULABILITY.
Elodie Ducros (FR), Shahsoltan Mirshahi, Pezhman Mirshahi, Anne Marie Faussat, Francoise Dagonnet, Dalel Azzazene, Sophie Camilleri-Brouet, Eliane Mery, Amu Therwath, Eric Pujade-Lauraine, Jeannette Soria, Massoud Mirshahi*

P-MO-387  EXPRESSION OF ENDOTHELIAL PROTEIN C RECEPTOR BY HUMAN HEMATOLOGIC MALIGNANCIES: IMPLICATION IN CANCER-ASSOCIATED HYPERCOAGULABILITY.
Elodie Ducros (FR), Shahsoltan Mirshahi, Anne Marie Faussat, Pezhman Mirshahi, Sophie Dimicoli, Ruoping Tang, Nadia Benabbou, Julia Pardo, Fanny Fava, Amu Therwath, Jean Pierre Marie, Jeannette Soria, Massoud Mirshahi*

P-MO-388  LONG-TERM THERAPY WITH LOW-MOLECULAR-WEIGHT HEPARIN IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM. FINDINGS FROM THE RIETE REGISTRY.
Pablo Javier Marchena Yglesias* (ES), Jose Antonio Nieto Rodriguez, Maria Guil, Ferran Garcia-Bragado, Ramon Rabunal, Henri Boccalon, Manel Monreal

Pediatric thrombosis

P-MO-389  BILATERAL CAROTID ARTERY THROMBOSIS IN A NEWBORN
Monika Hannelore Girisch* (DE), Michael Alber, Gesa Wiegand, Michael Hofbeck

Peter Bradbeer* (NZ), Nyree Cole, Lochie Teague

P-MO-391  INFLUENCE OF GENETIC THROMBOPHILIC DISORDERS IN EXTRAHEPATIC PORTAL VEIN THROMBOSIS IN CHILDREN AND ADOLESCENTS
Matteo Luciani* (IT), Andrea Pietrobattista, Juan G Abrailes, Manila Candusso, Simona Pancotti, Massimo Soldati, Lidia Monti, Giuliano Torre, Valerio Nobile
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-392  NORMALIZED COAGULATION MARKERS AND ANTIMOAGULATION PROTEINS IN CHILDREN WITH SEVERE $\beta$-THALASSEMA DISEASE AFTER STEM CELL TRANSPLANTATION
Nongnuich Sirachainan* (TH), Jaruwan Thongsad, Samart Pakakasama, Suradej Hongeng, Ampaiwan Chaunsamrit, Praguywan Kadegasem, Arjit Tirakanjana, Napaporn Archararit, Somtawin Sirireung

P-MO-393  THROMBIN AND PLASMIN GENERATION IN CHILDREN FOLLOWING PERINATAL ARTERIAL ISCHEMIC STROKE

P-MO-394  ATYPIC HEPARIN THROMBOCYTOPENIA: ABOUT A PAEDIATRIC CASE
Dominique Desprez* (FR), Julien Exinger, Annie Heidt, Monique Gladin, Pauline Vernay, Francois Depasse*, Laurent Mauvieux, Leila Grunebaum, Harry Magnani

P-MO-395  A COMPARISON OF CAT AND A MANUAL SUB-SAMPLING THROMBIN GENERATION ASSAYS IN HEALTHY CHILDREN.
Robyn G Summerhayes* (AU), Paul Monagle, Vera Ignjatovic

P-MO-396  THE INFLUENCE OF PLASMA ALPHA 2-MACROGLOBULIN LEVELS AND COMPLEXION TO THROMBIN DURING THROMBIN GENERATION IN HEALTHY CHILDREN.
Robyn G Summerhayes* (AU), Paul Monagle, Vera Ignjatovic

P-MO-397  AGE-RELATED DIFFERENCES IN HEPARIN COFACTOR ANTIGEN AND ACTIVITY IN HEALTHY CHILDREN: EVIDENCE FOR STRUCTURAL DIFFERENCES IN HEPARIN COFACTOR II IN NEONATES.
Robyn G Summerhayes* (AU), Paul Monagle, Vera Ignjatovic

P-MO-398  PROGNOSTIC FACTORS FOR PERSISTENT VENOUS OCCLUSION IN CHILDREN WITH VENOUS THROMBOEMBOLISM
Courtney A Lyle* (US), Amy E Lovejoy, Neil A Goldenberg

P-MO-399  RISK FACTORS FOR ELEVATED INR VALUES DURING WARFARIN THERAPY AT A PEDIATRIC HOSPITAL
Lisa Bombara* (US), Meng Ung, Brady Moffett

P-MO-400  A THAI BOY WITH SEVERE PROTEIN C DEFICIENCY; CLINICAL PRESENTATIONS, GENETIC MUTATION ANALYSIS AND TREATMENT OUTCOMES
Bunchoo Pontianakut* (TH), Kleebsabai Sanpakit, Jassada Buaboonnam, Nongnuich Sirachainan

P-MO-401  TRENDS OF THE COAGULATION INHIBITOR PROTEINS: PROTEIN C, PROTEIN S AND ANTITHROMBIN (AT) IN CHILDREN FOLLOWING LIVER TRANSPLANT
Patricia Massicotte* (CA), Mary Bauman, Aisha Bruce, Jessica Tan, Ketan Kulkarni, Jason Yap, Norm Kneteman

P-MO-402  EVALUATION OF UPPER VENOUS THROMBOSIS AND ITS ASSOCIATION WITH CHYLOTHORAX IN POST SURGICAL CHILDREN WITH CONGENITAL HEART DISEASE
Patricia Massicotte* (CA), Satvinder Kaur, Mary Bauman, Luis Quinonez, Aisha Bruce

Microparticles

P-MO-403  NOVEL METHODOLOGY IN THE CHARACTERIZATION OF PLATELET-DERIVED MICROVESICLES
Pia R-M Siljander* (FI), Maria T. Aatonen, Mikaela Gronholm
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-404 DETECTION OF 100 NM BEADS WITH OPTICAL PROPERTIES CLOSE TO MICROPARTICLES AND EXOSOMES USING A REGULAR FLOW CYTOMETER
Edwin van der Pol* (NL), A Sturk, T G van Leeuwen, R Nieuwland

P-MO-405 SIZE DISTRIBUTION AND CONCENTRATION OF MICROPARTICLES AND EXOSOMES DETERMINED BY ADVANCED OPTICAL AND NON-OPTICAL DETECTION METHODS
Edwin van der Pol* (NL), C Gardiner, P Harrison, A E Grootemaat, A Sturk, T G van Leeuwen, R Nieuwland

P-MO-406 PLATELET-DERIVED MICROPARTICLES AND TISSUE FACTOR ACTIVITY ARE ENHANCED IN BEHCET'S DISEASE

P-MO-407 INCREASED NUMBERS OF MICROPARTICLES AND INCREASED MICROPARTICLE SPECIFIC THROMBIN GENERATION IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE
Muriel van Schilfgaarde* (NL), Muriel van Schilfgaarde, Marijke C. Trappenburg, Michiel C. van Aalderen, Pascal J. Molenaar, Hugo ten Cate, Anja Leyte, Wim E. Terpstra

P-MO-408 PLACENTA-SPECIFIC RNA IS PRESENT IN VESICLES ISOLATED FROM MATERNAL BLOOD
Guus Sturk* (NL), Anita Boing, Elke de Grouw, Chi Hau, Wessel Ganzvoort, Carrie Ris-Stalpers, Rienk Nieuwland

P-MO-409 PLATELET MICROPARTICLES PARTICIPATE TO IMMUNE COMPLEXE FORMATION IN RHEUMATOID ARTHRITIS.
Nathalie Cloutier* (CA), Ruslan Shnayder, William Robinson, Richard Farndale, David M Lee, Eric Boilard

P-MO-410 TISSUE-FACTOR BEARING MICROPARTICLES ARE INCREASED IN NON-HODGKIN'S LYMPHOMA, AND MAINLY DERIVED FROM B-LYMPHOCYTES
Brandon James McMahon* (US), Hau C. Kwaan, Ivy Weiss, James Marvin

P-MO-411 ACTIVATED FACTOR X-BASED ASSAY FOR THE DETECTION OF PROCOAGULANT PHOSPHOLIPID ACTIVITY IN PATIENTS WITH CANCER AND/OR VENOUS THROMBOEMBOLISM
Claudia Maria Radu (IT), Luca Spiezia, Elena Campello, Sabrina Gavasso, Sara Carraro, Valeria Ferri, Barry Woodhams*, Paolo Simioni

P-MO-412 MICROPARTICLE ANALYSIS BY FLOWCYTOMETRY DEPENDS ON WELL DEFINED PRE-ANALYTICAL CONDITIONS.
Muriel van Schilfgaarde* (NL), Saskia V Oussoren, Anja Leyte

P-MO-413 ELEVATION OF TOTAL CELL-DERIVED MICROPARTICLE IN THE PATEINT WITH ESSENTIAL HYPERTENSION
Pornlada Nuchnoi* (TH), Duangdao Nantakomol, Chartchalerm Isarankura-Na-Ayudhya, Virapong Prachayasittikul

Clinical trials and registries

P-MO-414 LOW ALLERGENICITY OF FONDAPARINUX - RESULTS OF A PROSPECTIVE INVESTIGATION
### POSTER PRESENTATIONS

**Monday, July 25, 2011**

**P-MO-415**

INCIDENCE AND CAUSES OF HEPARIN-INDUCED SKIN LESIONS - RESULTS OF A PROSPECTIVE INVESTIGATION  
Marc Schindewolf* (DE), Svantje Schwaner, Manfred Wolter, Hartmut Kroll, Andreas Recke, Roland Kaufmann, Wolf-Henning Boehnicke, Edelgard Lindhoff-Last, RaJ L. Ludwig

**P-MO-416**

THE EFFECT OF POLYMORPHISMS OF CYP2C9 AND VKORC1 ON STABILITY OF THE INR WHEN SUPPLEMENTED WITH VITAMIN K1  
Edward P.A. Gebuis* (NL), Frits R Rosendaal, Erik van Meegen, Felix J.M. van der Meer

**P-MO-417**

VENOUS THROMBOEMBOLISM (VTE) AFTER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA (BPH). A SYSTEMATIC REVIEW ON THROMBOPROPHYLAXIS.  
David Bergqvist* (SE)

**P-MO-418**

SAFETY OF LOW MOLECULAR WEIGHT HEPARINS IN SWEDEN AS REFLECTED BY ADVERSE EVENTS REPORTED TO NATIONAL AUTHORITIES.  
David Bergqvist* (SE), Nils Feltelius

**P-MO-419**

ORAL FACTOR XA INHIBITORS VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER JOINT REPLACEMENT SURGERY: A META-ANALYSIS  
Simon Mantha* (US)

**P-MO-420**

HEMOSTASIS IN THE PRIMARY MULTIPLE MYELOMA PATIENTS  
Evdokiya S Urnova* (RU), Larissa P Mendeleeva, Olga S Pokrovskaya, Elena I Sinauridze, Anna N Balandina, Elena N Lipets, Irina V Gribkova, Sergey A Vasiliev, Valery G Savchenko

**P-MO-421**

CLINICAL OUTCOME IN PATIENTS WITH PULMONARY EMBOLISM SELECTED FOR OUTPATIENT OR HOSPITAL TREATMENT WITH THE HESTIA CRITERIA  
Wendy Zondag* (NL), Inge Mos, Dina Creemers-Schild, Lidia Hoogerbrugge, Olaf Dekkers, Anneke Dolsma, Michiel Eijsvogel, Laura Faber, Herman Hofstee, Marcel Hovens, Ge Jonkers, Klaas van Kralingen, Marieke Krup, Tom Vlasveld, Marielle de Vreede, Menno Huisman

**P-MO-422**

NATURAL HISTORY OF PATIENTS DEVELOPING THROMBOCYTOPENIA WHILE RECEIVING ANTIKOAGULANT THERAPY FOR VENOUS THROMBOEMBOLISM.  
Adriana Visorina* (IT), Pierpaolo Di Micco, Nicolas Falvo, Justo Ruiz, Jose M. Pedrajas, Mariano Valdes, Manuel Monreal, and the RIETE INVESTIGATORS

**P-MO-423**

DESIRUDIN-REACTIVE IGG ANTIBODIES IN THE DESIR-ABLE THROMBOSIS PREVENTION CLINICAL TRIAL: LOW PREVALENCE OF ANTIGENICITY IN DESIRUDIN-TREATED SUBJECTS  
Robert G Hamilton* (US), Jerrold H. Levy

---

**Intravascular devices and thrombosis**

**P-MO-424**

VENOUS THROMBOSIS AS A COMPLICATION OF PACEMAKER IMPLANTATION - IN OWN OBSERVATIONS  
Teresa Barbara Domagala* (PL), Jacek Lelakowski, Anna Rydlewksa, Justyna Piekarz, Rafal Januszek, Grzegorz Karkowski, Katarzyna Kotula-Horowitz, Jacek Musial

**P-MO-425**

DESIGN OF THE CATHETER DIRECTED THROMBOLYSIS AND ANTICOAGULATION THERAPY VS ANTICOAGULATION ALONE; THE DUTCH CAVA-STUDY; MULTICENTER RANDOMIZED CONTROLLED TRIAL.  
Rob H.W. Strijkers* (NL), Anna J. ten Cate - Hoek, Martin H Prins, Hugo ten Cate, Cees H.A. Wittens

**P-MO-426**

POLYURETHANE IMMOBILIZED WITH A COVALENT ANTITHROMBIN-HEPARI COMPLEX FOR REDUCING THROMBOSIS ON BLOOD CONTACTING DEVICES  
Kyla N Sask* (CA), Leslie R Berry, Anthony KC Chan, John L Brash
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-427  ROLE OF LOW MOLECULAR WEIGHT HEPARINS IN PROPHYLAXIS OF THROMBOEMBOLIC EVENTS IN ONCOLOGICAL PATIENTS RECEIVING ANTITUMOR THERAPIES
Oksana Vasilievna Somonova* (RU), Albina Vasilievna Madzhuga, Anna Lyvovna Elizarova

P-MO-428  REASONS FOR FAILURE TO REMOVE INFERIOR VENA CAVA FILTERS (IVCF): 2 YEAR RETROSPECTIVE STUDY IN A TERTIARY CARE AND TRAUMA CENTRE
Erica Ann Peterson* (CA), Paul Richard Yenson, Dave Liu, Andy Lee, Agnes Yuei Ying Lee

P-MO-429  IN VITRO AND IN VIVO COMPARISON OF VKORC1 MUTATIONS
Katrin Jeannette Czogalla* (DE), Matthias Watzka, Philipp Westhofen, Ann-Christin Wendeln, Johannes Oldenburg

P-MO-430  LOW SULFATED HEPARIN (ODSH) INTERFERES WITH ANTI-PF4/HEPARIN ANTIBODY INDUCED PLATELET ACTIVATION BY DISRUPTING PF4/HEPARIN COMPLEXES
Krystin Krauel* (DE), Christine Hackbarth, Birgitt Fuerll, Andreas Greinacher

P-MO-431  IN VITRO AND IN VIVO COMPARISON OF VKORC1 MUTATIONS
Katrin Jeannette Czogalla* (DE), Matthias Watzka, Philipp Westhofen, Ann-Christin Wendeln, Johannes Oldenburg

P-MO-432  DISORDERS OF MORPHOLOGY AND FUNCTION OF LIVING PLATELETS IN PATIENTS TREATED WITH HEMODIALYSIS
Elizaveta Vlasova* (RU), Irina Vasilenko, Vladimir Suslov

P-MO-433  TWO CASES OF THROMBOTIC COMPLICATIONS IN INFANTS ON ECMO: HETEROZYGOUS FACTOR V LEIDEN AND COCCIDIOIDOMYCOSIS
Fong W Lam* (US), Ozlem Bilen, Trung C Nguyen, Jun Teruya

Health service and outcomes

P-MO-434  THE IMPACT OF ANTICOAGULANT MONITORING AND CONTROL ON RECURRENT VENOUS THROMBOEMBOLISM AND BLEEDING IN ROUTINE CLINICAL PRACTICE
Neil S Roskell (UK), Sorrel E Wolowacz, Ryan Ziemecki, Arlene M Gallagher, Martin Feuring, Mandy Fraessdorf, Bastian Hass*

P-MO-435  INTERPLAY BETWEEN DIET AND VITAMIN K-ANTAGONISTS: DISCLOSED BY VISUALIZATION OF A MULTIVARIATE MODEL
Jane Skov* (DK), Else-Marie Bladbjerg, Morten Arendt Rasmussen, Johannes Sidelmann, Marianne Vamosi, Joergen Jespersen

P-MO-436  A COLLABORATIVE STUDY OF OUTCOMES FROM ROOT CAUSE ANALYSIS OF HOSPITAL-ASSOCIATED THROMBOSIS
Lara N Roberts* (UK), Kim Carter, Huw Rowswell, Christopher James, Lorraine Albon, Tim Nokes, Raj K Patel, Roopen Arya

P-MO-437  ANTICOAGULATED PATIENTS: HOW THE POPULATION IS CHANGING
Sophie Testa* (IT), Oriana Paololetti, Laura Bassi, Emilia Cancellieri, Silvia Zambelli, Anke Zimmermann

P-MO-438  COST-EFFECTIVENESS OF APIXABAN PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM (VTE) IN TOTAL KNEE AND HIP REPLACEMENT (TKR/THR)
Dale Rublee* (US), Teresa Simon, Kristen Migliaccio-Walle, Elizabeth Merkle, Jarmie Caro, Nick Marchant, Pieter Drost
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-439 PROTAMINE DRUG UTILIZATION EVALUATION TO DETERMINE POSSIBLE FUTURE ROLES FOR THE HEPATOGONIST REVERSAL AGENT PMX-60056
Charles Mahan* (US)

P-MO-440 REDUCTION IN HOSPITAL ACQUIRED VTE BY IMPROVED COMPLIANCE WITH VTE RISK ASSESSMENT
Jamie M Maddox* (UK), Anthony P Roberts

P-MO-441 USE OF NATIONAL PATIENT SAFETY AGENCY / BRITISH SOCIETY OF HAEMATOLOGY SAFETY INDICATORS FOR ORAL ANTICOAGULANTS IN HOSPITALISED PATIENTS
Jamie M Maddox* (UK)

P-MO-442 REDUCTION OF EMERGENCY DEPARTMENT (ED) UTILIZATION FOR COMPLICATIONS OF WARFARIN THERAPY USING ORGANIZED ANTICOAGULATION CLINICS IN AN ACADEMIC MEDICAL INSTITUTION
Patrick Michael Klem* (US), Tiffany Brown, William Pace, Gina Woodhouse, Kathryn Hassell, Christiana Thienelt, Shardul Poydal, Julie Cantlon, Gregory Misky, William LeBlanc, Kristen Nordenholz, Carolee Whitehill

von Willebrand factor

P-MO-443 INTERACTION BETWEEN A1, A2 AND A3 DOMAINS REGULATES THE BINDING OF VWF TO PLATELET GPIIBα IN SOLUTION.
Miguel A. Cruz* (US), Matthew Auton, Katie E. Sowa

P-MO-444 INCREASED VON WILLEBRAND FACTOR LEVELS IN LATER LIFE ARE ASSOCIATED WITH EVIDENCE OF BOTH ENHANCED BIOSYNTHESIS AND REDUCED CLEARANCE
Silvia Albanez* (CA), Julie Grabell, Erin Burnett, Kate Sponagle, Paula D James, David Lillicrap

P-MO-445 STABILIZATION OF FVIII BY VWF FRAGMENTS
Andrew Yee* (US), Beth M McGee, David Ginsburg

P-MO-446 EPITOPE MAPPING OF HUMAN VWF A3 RECOGNIZED BY MONOCLONAL ANTIBODY SZ-123 USING MALDI MASS SPECTROMETRY
Miao Jiang* (CN), Yiming Zhao, Yang He, Fei Shen, Changgeng Ruan

P-MO-447 VON WILLEBRAND FACTOR PLASMA LEVELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA
Jerzy Windyga* (PL), Ksenia Bykowska, Ewa Czajkowska, Bozena Sokolowska, Krzysztof Warzocha, Edyta Odnoczoło, Jerzy Windyga

P-MO-448 PHARMACOKINETIC (PK) EVALUATION OF A NEWLY INTRODUCED VON WILLEBRAND FACTOR (VWF) CONCENTRATE AT TWO LONDON HAEMOPHILIA CENTRES.
Natasha M Wiles* (UK), Anne Wareing, Bella Madan, Steven K Austin

P-MO-449 AFFINITY AND KINETICS OF VWF PROPEPTIDE BINDING TO MATURE VWF
Sriram Neelamegham* (US), Sri R. Madabhushi, Chengwei Shang, Kannayakanahalli M. Dayananda, Thomas E. Ryan

P-MO-450 THE INTERACTION OF VON WILLEBRAND FACTOR WITH ANGIOPOIETINS-1 & 2
Thomas McKinnon* (UK), Agata Nowak, Kushani Ediriwickrema, Mike Laffan

P-MO-451 THE DISCOVERY AND CHARACTERIZATION OF A SECOND GENERATION VON WILLEBRAND FACTOR (VWF) A-1 DOMAIN INHIBITORY APTAMER
Robert G Schaub* (US), P Shannon Pendergrast, Kathleen E McGinness, Xianbin Tian
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-452 IN VITRO AND IN VIVO CHARACTERIZATION OF VON WILLEBRAND FACTOR COLLAGEN BINDING VARIANTS USING A MOUSE MODEL SYSTEM
Yasuaki Shida* (CA), Christine Ann Brown, Jeff Mewburn, Kate Sponagle, Carol Anne Hegadorn, David Lillicrap

von Willebrand disease

P-MO-453 ESTABLISHMENT OF A VON WILLEBRAND FACTOR RISTOCETIN CO-FACTOR ACTIVITY ELISA AND ITS APPLICATION IN THE DIAGNOSIS AND CLASSIFICATION OF VWD
Yiming Zhao* (CN), Ying Gu, Jianfeng Yang, Changgeng Ruan

P-MO-454 MUTATION SPECTRUM AND CHARACTERIZATION OF TWO NOVEL LARGE DELETIONS CAUSING SEVERE TYPE 3 VON WILLEBRAND DISEASE
Firdos Ahmad* (US), Reinhard Schneppenheim, Florian Oyen, Tobias Obser, Meganathan Kannan, Renu Saxena

P-MO-455 -1 TO +4 VS. 0 TO +3?: COMPARING SCORING SYSTEMS FOR BLEEDING SYMPTOMS IN THE CONDENSED MCMDM-1 VWD AND THE PEDIATRIC BLEEDING QUESTIONNAIRES
Paula D James* (CA), Tina T Biss, Dewi S Clark, Julie Grabell, Jim Riddell, Mariana Silva, Dilya Rapson, Margaret L Rand

P-MO-456 EFFECT OF FIBRINOLYSIS ON BLEEDING PHENOTYPE IN MILD AND SEVERE
Eva M De Wee (NL), Jeroen Eikema, Johanna van der Bom, Manon Degenaar-Dujardin, Karin Fijnvandraat, Arja Goede-Bolder, Britta Laros-van Gorkom, Eveline Mauser-Bunschoten, Karina Meijer, Gerard Goverde, Peter-Willem van der Linden, Dingeman Rijken, Frank Leebeek

P-MO-457 WILATE® 500 AND WILATE® 1000 - ADVANCED CONTENT OF VWF AND FVIII: A COMPARISON OF ACTIVE INGREDIENTS AND EXCIPIENTS DRUG RATIOS
Gerhard Gruber* (AT), Monika Stadler, Manfred Karlovits, Josef Weinberger, Juergen Roland Roemisch

P-MO-458 DETERMINANTS OF BLEEDING PHENOTYPE IN PATIENTS WITH MODERATE OR SEVERE VON WILLEBRAND DISEASE
Eva M De Wee (NL), Manon Degenaar-Dujardin, Jeroen Eikema, Arja Goede-Bolder, Britta Laros-van Gorkom, Karina Meijer, Karly Hamulyak, Marten Nijziel, Karin Fijnvandraat, Frank Leebeek

P-MO-459 UNUSUAL FINDING IN LABORATORY TESTS IN A PREGNANT PATIENT WITH VON WILLEBRAND DISEASE TYPE 2B
Adriana I Woods* (AR), Analia Sanchez-Luceros, Maria Fabiana Alberto, Ana Catalina Kempfer, Alicia Noemi Blanco, Maria Angela Lazzari

P-MO-460 THE P.CYS1060TYR MUTATION IS RESPONSIBLE FOR VON WILLEBRAND DISEASE TYPE 2N
Bas J.T. van Haren* (NL), Selene C.M. Schoormans, Tom G.J. Hofste, Britta A.P. Laros-van Gorkom, Paul F.T. Brons, Lies H. Hoefsloot, Waander L. van Heerde

P-MO-461 COLLAGEN BINDING ASSAY AND GENOTYPIC ANALYSIS HAVE AN ADDITIONAL VALUE IN THE SUBCLASSIFICATION OF VON WILLEBRAND DISEASE TYPE 2M
Bas J.T. van Haren* (NL), Selene C.M. Schoormans, Tom G.J. Hofste, Britta A.P. Laros-van Gorkom, Paul F.T. Brons, Lies H. Hoefsloot, Waander L. van Heerde

P-MO-462 ASSESSMENT OF THE BURDEN OF VON WILLEBRAND DISEASE IN A US COMMERCIAL POPULATION
Diane Ito* (US), Yan Xiong, Josephine Li-McLeod
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-463 DEVELOPMENT OF A HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR VON WILLEBRAND DISEASE
Diane Ito* (US), Kathy Lasch, Kristina Fitzgerald, Andrea Zeytoonjian, Steve Hwang, Josephine Li-McLeod

P-MO-464 DIAGNOSIS OF TYPE 2N VON WILLEBRAND DISEASE IN A JAPANESE PATIENT BY PHARMACOKINETICS, FACTOR VIII BINDING ASSAY AND GENE ANALYSIS
Yushi Chikasawa* (JP), Kagehiro Amano, Keiko Shinozawa, Tomoko Matsumoto, Hiroshi Inaba, Midori Shima, Katsuysuji Fukutake

P-MO-465 A GLY1609ARG MISSENSE MUTATION IN THE VWF GENE IN A KOREAN PATIENT WITH VON WILLEBRAND DISEASE TYPE 2A
Duck Jin Hong (KR), Seung Jun Choi*, Jonghyeon Choi, Sue Jung Kim, Hee-Jin Kim, Kyung-A Lee, Jaewoo Song, Jong-Rak Choi, Jong-Ha Yoo

P-MO-466 A FAMILY WITH TYPE 2M VWD WITH NORMAL VWF:RCO BUT REDUCED VWF:CB DUE TO A M1761K MUTATION IN THE A3 DOMAIN
David M Keeling* (UK), James Beavis, Rhiannon Marr, Kampta Sukhu, Patricia Bignell

Acquired von Willebrand syndrome

P-MO-467 TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) AND THE EFFECTS ON VON WILLEBRAND FACTOR (VWF) AND ADAMTS-13 CONCENTRATIONS
Simon J Davidson* (UK), Jayenthay Karunanantham, Kaltun Farah, Sarah Barker, Simon W Davies, Moat Neil

P-MO-468 MITRAL VALVE PROSTHESIS LEAK AND ACQUIRED VON WILLEBRAND SYNDROME (AVWS)
Javier Batlle* (ES), Almudena Perez-Rodriguez, Joana Costa Pinto, Esther Loures, Angela Rodriguez-Trillo, Jose Joaquin Cuenc, Javier Batlle, Maria Fernanda Lopez-Fernandez

P-MO-469 VWF & PROPEPTIDE ASSAY (GTI DIAGNOSTICS) EVALUATION IN ACQUIRED VON WILLEBRAND SYNDROME
Claudine Caron* (FR), Jacqueline Tapon-Bretaudiere, Sylvia Bellucci, Philippe Cauchie, Isabelle Martin Toutain, Brigitte Pan Petesch, Catherine Ternisien, Jenny Goudemand

P-MO-470 A RARE CASE OF ACQUIRED VON WILLEBRAND SYNDROME IN THE SETTING OF NEW DIAGNOSIS POLYMYOSITIS
Adrienne Lee* (CA), Gary D Sinclair, Karen Valentine, Man-Chiu Poon

P-MO-471 EXCESS PROTEOLYSIS OF VON WILLEBRAND FACTOR IN AORTIC STENOSIS DOES NOT ENHANCE THE RISK OF BLEEDING AFTER AORTIC VALVE REPLACEMENT
Sophie Susen* (FR), Andre Vincentelli, Thierry Le Tourneau, Claudine Caron, Annie Borel-Derlon, Massimo Massetti, Jeanne-Yvonne Borg, Helene Eltchaninoff, Fabrice Bauer, Eric Van Belle, Jenny Goudemand, Brigitte Jude

P-MO-472 THERAPEUTIC ALGORITHM FOR PATIENTS WITH ACQUIRED VON WILLEBRAND SYNDROME AND MONOCLONAL GAMMOPATHY
Peter Staritz* (DE), Peter Lages, Manuela Krause, Rainer Zimmermann, Angela Huth-Kuehne

P-MO-473 ACQUIRED LOSS OF THE LARGEST VON WILLEBRAND FACTOR MULTIMERS IN SEVERE TETRALOGY OF FALLOT: A CASE REPORT
Sofia Barbaten* (IT), Alessandra Casonato, Emiliano De Bon, Elena Pontara, Antonella Bertomoro
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-474  A NEGATIVE FEEDBACK MECHANISM OF REGULATING VWF PROTEOLYSIS BY ADAMTS-13
Trung Chanh Nguyen* (US), Chalmette Ball, Miguel A Cruz, Xiaowen Liang, Zhou Zhou, Jing-fei Dong

P-MO-475  ACQUIRED VON WILLEBRAND DISEASE (AVWD) SECONDARY TO ACUTE MYELOPATHY
Erica Okazaki* (BR), Audrey Kruse Zeinad Valim, Paula Ribeiro Villaca, Patricia Lima Junqueira, Dalton de Alencar Fischer Chamone, Elbio Antonio DAmico

P-MO-476  UPREGULATION OF VON WILLEBRAND FACTOR, VON WILLEBRAND FACTOR PROPEPTIDE AND ADAMTS-13 IN END STAGE RENAL DISEASE
Vinod Bansal* (US), Rachel Davis, Evangelos Litinas, Debra Hoppensteadt, Indermohan Thethi, Jawed Fareed

P-MO-477  DETERMINATION OF ADAMTS13 AND ITS CLINICAL SIGNIFICANCE RELATED TO ENDOTOXEMIA IN PATIENTS WITH HEPATIC FAILURE
Hiroaki Takaya* (JP), Masahito Uemura, Masao Fujimoto, Tomomi Matsuyama, Chie Morioka, Masatoshi Ishikawa, Tatsuhiro Tsujimoto, Hideto Kawaratani, Shinya Takeyama, Masanori Matsumoto, Yoshihiro Fujimura, Hiroshi Fukui

P-MO-478  CILOSTAZOL DOWN-REGULATES THE HEIGHT OF MURAL PLATELET THROMBI FORMED UNDER A HIGH SHEAR RATE FLOW IN THE ABSENCE OF ADAMTS13 ACTIVITY
Hideo Yagi* (JP), Naoko Yamaguchi, Yasuaki Shida, Masanori Matsumoto, Mitsuhiko Sugimoto, Kazuo Tsubaki, Yoshihiro Fujimura

P-MO-479  ISOELECTRIC FOCUSING ANALYSIS WITH A LARGE-PORE AGAROSE-ACRYLAMIDE COMPOSITE GEL IDENTIFIED TWO FORMS OF ADAMTS13, UNBOUND AND BOUND TO VON WILLEBRAND FACTOR, IN PLASMA MILIEU
Yuji Hori* (JP), Ayami Isonishi, Kenji Soejima, Masanori Matsumoto, Midori Shima, Yoshihiro Fujimura

P-MO-480  ESTIMATION OF THE NUMBER OF INDIVIDUALS WITH A CONGENITAL ADAMTS13 DEFICIENCY IN JAPAN
Koichi Kokame* (JP), Yoshihiro Kokubo, Toshiyuki Miyata

P-MO-481  POTENTIAL ROLE OF ADAMTS13 ASSOCIATED WITH POST ERCP PANCREATITIS
Chie Morioka* (JP), Masahito Uemura, Hiroaki Takaya, Masayoshi Sawai, Motoyuki Yoshida, Akira Mitoro, Jyunichi Yamao, Masanori Matsumoto, Yoshihiro Fujimura, Hiroshi Fukui

P-MO-482  THE ADAMTS13 ACTIVITY REFLECTS THE CUMULATIVE SURVIVAL OF PATIENTS WITH LIVER CIRRHOSIS
Masahito Uemura* (JP), Yoshihiro Fujimura, Masanori Matsumoto, Hiromichi Ishizashi, Tomomi Matsuyama, Seiji Kato, Yuji Hori, Chie Morioka, Hiroaki Takaya, Masao Fujimoto, Tatsuhiro Tsujimoto, Hideto Kawaratani, Hiroshi Fukui

P-MO-483  VWF AND ADAMTS13 LEVELS AND THE RISK OF MYOCARDIAL INFARCTION AND ISCHAEMIC STROKE IN YOUNG WOMEN: RESULTS FROM THE RATIO CASE-CONTROL STUDY
Bob Siegerink* (NL), Helena M Andersson, Brenda M Luken, James TB Crawley, Ale Algra, David A Lane, Frits R Rosendaal

P-MO-484  EVALUATION OF A NEW ADAMTS13 ELISA BASED ACTIVITY ASSAY AND COMPARISON TO AN IN-HOUSE COLLAGEN BINDING ASSAY
Wahbi Hammouda* (CA), Jacqueline Ongteco, Nellie Ku
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-485  CHARACTERIZATION OF TWO CASES OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH PREGNANCY
Xia Bai* (CN), Jian Su, Minghua Jiang, Changgeng Ruan

P-MO-486  DISCREPANCIES BETWEEN DIFFERENT TYPES OF ADAMTS13 ASSAYS IN PATIENTS WITH THROMBOTIC MICROANGIOPATHIES
Ian J Mackie* (UK), Katy Langley, Andrew Chitolie, Rl Leisner, Marie Scully, Sam Machin, Flora Peyvandi

P-MO-487  NOVEL ADAMTS13 MUTATIONS IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA
Ziqiang Yu* (CN), Yunwen Bu, Jian Su, Qingya Cui, Xia Bai, Changgeng Ruan

Hemophilia

P-MO-488  PROFILING OF F8 GENE MUTATIONS IN 262 CHINESE HAEMOPHILIA A PATIENTS
Yeling Lu* (CN), Xuefeng Wang, Qiulan Ding, Jing Dai, Hongli Wang, Xiaodong Xi

P-MO-489  SPORADIC HAEMOPHILIA A PEDIGREE WITH Mosaicism of the F8 GENE Mutation in the Index’s Maternal Grandmother
Yeling Lu* (CN), Xuefeng Wang, Qiulan Ding, Jing Dai, Hongli Wang, Xiaodong Xi

P-MO-490  IMPROVEMENTS OF HEMOPHILIA CARES IN 30 YEARS SEEN IN TAIWAN
Ming Ching Shen* (TW), Wei Tsay, Young Li Yang, Shyuann Yuh Lin, Ching Yeh Lin, Po Kuang Chen, In Ling Chang, Ta Sen Wei, Chin Ming Jeng, Chao Yu Hsu, Ruei Pung Lin, Cheng Hsiung Chang

P-MO-491  CHARACTERIZATION AND VALIDATION OF A NOVEL PANEL OF 6 SHORT TANDEM REPEATS FOR CARRIER AND PRENATAL DIAGNOSIS OF HAEMOPHILIA A
Qiulan Ding* (CN), Yeling Lu, Jing Dai, Xiaodong Xi, Xuefeng Wang, Hongli Wang

P-MO-492  F8 LOCUS ITSELF SEEMS TO EXPLAIN ALL CASES OF HEMOPHILIA A PATIENTS WITHOUT MUTATIONS IN THE F8 CDNA
Osman El-Maarri* (DE), Behnaz Pezeshkpoor, Natascha Vidocich, Nicole Nuesgen, Indrajit Nanda, Thomas Haaf, Ulrich Budde, Johannes Oldenburg, Osman El-Maarri

P-MO-493  CARRIER AND PRENATAL DIAGNOSIS IN A HAEMOPHILIA A FAMILY WITH LARGE F8 GENE DELETION BY FLUORESCENT QUANTITATION PCR METHOD
Yeling Lu* (CN), Xuefeng Wang, Qiulan Ding, Jing Dai, Xiaodong Xi, Xuefeng Wang, Hongli Wang

P-MO-494  INCREASED PREVALENCE OF HYPERTENSION IN HAEMOPHILIA PATIENTS
Roger EG Schutgens* (NL), Dietje Fransen van de Putte, Kathelijn Fischer, Mike Makris, Campbell Tait, Pratima Chowdary, Peter Collins, Karina Meijer, Goris Roosendaal, Eveline Mauser-Bunschoten

P-MO-495  INCREASED QRISK2 CARDIOVASCULAR DISEASE RISK SCORE IN HAEMOPHILIA PATIENTS
Roger EG Schutgens* (NL), Dietje Fransen van de Putte, Kathelijn Fischer, Mike Makris, Campbell Tait, Pratima Chowdary, Peter Collins, Karina Meijer, Goris Roosendaal, Eveline Mauser-Bunschoten

P-MO-496  DECREASED OCCURRENCE OF CARDIOVASCULAR DISEASE IN HAEMOPHILIA PATIENTS
Roger EG Schutgens* (NL), Dietje Fransen van de Putte, Kathelijn Fischer, Astrid Pulles, Goris Roosendaal, Eveline Mauser-Bunschoten
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-497  MALIGNANCIES IN HAEMOPHILIA PATIENTS
Roger EG Schutgens* (NL), Diele Fransen van de Putte, Kathelijn Fischer, Astrid Pulles, Goris Roosendaal, Eveline Mauser-Bunschoten

P-MO-498  THE PROVISION OF GENETIC TESTING FOR BLEEDING DISORDERS IN THE UK - AN OVERVIEW AND AUDIT OF UKHCDO GENETIC NETWORK LABORATORIES
Marian Hill* (UK), Jacky Cutler, Mike Mitchell

P-MO-499  A COST-EFFECTIVE PROVINCIAL REDISTRIBUTION SYSTEM TO PREVENT WASTAGE OF CLOTTING FACTOR CONCENTRATES
Jerome Teitel* (CA), Sarah Crymble, Monique Anderson, Antonette Travas, Georgia Floros

P-MO-500  DISTINCT X-CHROMOSOMAL REARRANGEMENTS WITH F8-INTRON22 INVERSION IN THREE UNRELATED JAPANESE SEVERE HEMOPHILIA A PATIENTS WITH HIGH TITER INHIBITOR
Junko Fujita* (JP), Atsuo Suzuki, Yuhri Miyawaki, Asuka Maki, Yuhita Fujimori, Akira Takagi, Takashi Murute, Tadashi Matsushita, Nobufumi Suzuki, Hidehiko Saito, Tetsuhito Koijima

P-MO-501  HELICOBACTER PYLORI INFECTION IN PATIENTS WITH HEREDITARY HEMORRHAGIC DISORDERS: A COMPARISON OF STOOL ANTIGEN TEST AND SEROLOGY TESTS
Dolatkhah Roya* (IR), Khoshbaten Manouchehr, Asvadi Kermani Iraj, Bonyadi Mohammad Reza, Ghojazadeh Morteza, Sanaat Zohreh

P-MO-502  SAFETY AND EFFICACY OF RALTEGRAVIR IN PATIENTS WITH HAEMOPHILIA AND ANTI-HIV MULTIDRUG RESISTANCE
Alessandro Gringeri* (IT), Lucia Mangiafico, Myrvete Muca-Perja, Silvia Riva, Francesco Fusco, Debora Mago

P-MO-503  MUTATION ANALYSIS OF HEMOPHILIA A IN THE JAPANESE POPULATION: INCREASED PREVALENCE OF TYR473CYS CAUSED BY FOUNDERR EFFECT
Hiroshi Inaba* (JP), Keiko Shinozawa, Takashi Suzuki, Manabu Otaki, Ikuko Saita, Kyouchi Ogata, Mihoko Yotsumoto, Takashi Muramatsu, Yushi Chikasawa, Takeshi Hagiwara, Yasuyuki Yamamoto, Kagehiro Arano, Katsuyuki Fukutake

P-MO-504  PSEUDOTUMOR SURGERY IN HAEMOPHILIA A PATIENTS: COMPARATIVE RESULTS BETWEEN INHIBITOR AND NON-INHIBITOR PATIENTS
Caviglia Horacio* (AR), Alejandra Baques, Ana Laura Douglas Price, Daniela Neme, Guillermo Arbesu, Raul Perez Blanco

P-MO-505  IMAGING EVALUATION OF ARTHROPATHY AT THE BEGINNING OF PROPHYLAXIC THERAPY FOR SEvere HEMOPHILIA CHILDREN
Kazoru Katsukawa* (JP), Hideyuki Takedani, Midori Shima, Masashi Taki

P-MO-506  IDENTIFICATION AND CHARACTERIZATION OF AN ANCIENT HAEMOPHILIA A FOUNDER MUTATION
Sylvia Elisabeth Reitter* (AT), Arndt von Haeseler, Birgit Horvath, Rautre Sunder-Plassmann, Vera Tiedje, Ingrid Pabinger-Fasching, Christine Mannhalter

P-MO-507  THE EFFECT OF CRYOPRECIPITATE ON THE SEROPREVALENCE OF VARICELLA ZOSTER VIRUS IN PATIENTS WITH SEVERE HEMOPHILIA
Thomas W van der Vaart* (NL), Jan TM van der Meer, Caroline Valk, Hans L Zaaljier, Pieter Wille Kamphuisen

P-MO-508  WIDE VARIATION IN FACTOR VIII PLASMA LEVELS IN MILD AND MODERATE HEMOPHILIA A PATIENTS WITH THE SAME MISSENSE MUTATION IS PRESENTLY UNEXPLAINED
Corien Eckhardt* (NL), Alice S. van Velzen, Marjolein Peters, Elena Santagostino, Kathelijne Peerlinck, Jan Astermark, Johannes Oldenburg, Charles R.M. Hay, Pieter-Wille Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat
**POSTER PRESENTATIONS**

**Monday, July 25, 2011**

**Hemophilia therapy**

<table>
<thead>
<tr>
<th>poster number</th>
<th>title</th>
<th>authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-MO-509</td>
<td>EFFECTIVE PATHOGEN REDUCTION OF A PLASMA-DERIVED FACTOR VIII</td>
<td>Albrecht Groener*, Thomas Nowak, Birgit Popp, Wolfram Schaefer</td>
</tr>
<tr>
<td></td>
<td>CONCENTRATE THROUGH MULTIPLE DEDICATED MEASURES</td>
<td></td>
</tr>
<tr>
<td>P-MO-510</td>
<td>POST MARKETING SURVEILLANCE OF BLOOD PRODUCTS IN JAPAN</td>
<td>Teruyo Arato*, Kaori Nomura, Madoka Hiraki, Jun Matsumoto, Atsushi Yoshimura, Toyotaka Iguchi, Masanari Takayama</td>
</tr>
<tr>
<td>P-MO-511</td>
<td>CURRENT SITUATION OF CLINICAL TRIALS OF BLOOD COAGULATION FACTORS FOR</td>
<td>Atsushi Yoshimura*, Masayuki Nagasaki, Jun Matsumoto, Madoka Hiraki, Yasuhiro Kishioka, Masanari Takayama, Teruyo Arato, Toyotaka Iguchi, Masanari Takayama</td>
</tr>
<tr>
<td></td>
<td>HAEMOPHILIA PATIENTS IN JAPAN</td>
<td></td>
</tr>
<tr>
<td>P-MO-512</td>
<td>THE COMBINED TREATMENT OF APCC AND TRANEXAMIC ACID IN PATIENTS WITH</td>
<td>Hoa Thi Tuyet Tran*, Margareta Holmstrom, Paal Andre Holme</td>
</tr>
<tr>
<td></td>
<td>HAEMOPHILIA A WITH INHIBITORS AND IN PATIENTS WITH ACQUIRED HAEMOPHILIA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A - A TWO-CENTRE EXPERIENCE</td>
<td></td>
</tr>
<tr>
<td>P-MO-513</td>
<td>SUCCESSFUL TREATMENT OF PROSTATE CANCER IN A CASE OF SEVERE HAEMOPHILIA A PATIENT</td>
<td>Sandra Lejniece*, Gunta Kluce, Armands Balins, Peteris Tomins, Aivars Lejnieks</td>
</tr>
<tr>
<td>P-MO-514</td>
<td>IMPROVED KINETICS OF RIX-FP, A RECOMBINANT FUSION PROTEIN LINKING</td>
<td>Marc W Nolte*, Timothy Nichols, Jochen Mueller-Cohrs, Ingo Pragst, Gerhard Dickneite*</td>
</tr>
<tr>
<td></td>
<td>COAGULATION FACTOR IX WITH ALBUMIN, IN CYNOMOLGUS MONKEYS AND</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HEMOPHILIA B DOGS</td>
<td></td>
</tr>
<tr>
<td>P-MO-515</td>
<td>FINE (FEIBA INHIBITOR ENTRY) POST-AUTHORIZATION SAFETY SURVEILLANCE</td>
<td>Satoshi Higasa*, Kagehiro Amano, Hideji Hanabusa, Shinji Muto, Tadashi Matsushita, Midori Shima, Teruhisa Fujii, Michio Sakai, Study Group FINE</td>
</tr>
<tr>
<td></td>
<td>(PASS) : CAPTURING LONG-TERM EXPERIENCE IN JAPANESE INHIBITOR SUBJECTS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>UNDER ROUTINE CLINICAL MANAGEMENT</td>
<td></td>
</tr>
<tr>
<td>P-MO-516</td>
<td>CLINICAL AND LABORATORY DATA OF SAFETY, EFFICACY OF A RECOMBINANT</td>
<td>Katalin KoehlerVajta*, Gerhard Froesner, Reinhard Zachoval</td>
</tr>
<tr>
<td></td>
<td>FACTOR VIII CONCENTRATE IN PATIENTS WITH SEVERE HAEMOPHILIA A IN A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PRIVATE PRACTICE CCC</td>
<td></td>
</tr>
<tr>
<td>P-MO-517</td>
<td>GASTROINTESTINAL BLEEDING FROM UPPER GASTROINTESTINAL TRACT IN</td>
<td>Sergey Shutov*, S R Karagyulyan, V Y Zorenko, A V Grzhimolovsky, K I Danishyan, E E Karpov, T Y Polyansky, G M Galstyan</td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH HEMOPHILIA</td>
<td></td>
</tr>
<tr>
<td>P-MO-518</td>
<td>FINAL PHARMACOKINETIC, EFFICACY AND SAFETY DATA OF THE FIRST STUDY</td>
<td>Sigurd Knaub*, Nadezhda Zozulya, Olga Plyushch, Martina Jansen</td>
</tr>
<tr>
<td></td>
<td>WITH A RECOMBINANT FACTOR VIII FROM A HUMAN CELL LINE</td>
<td></td>
</tr>
<tr>
<td>P-MO-519</td>
<td>ANTI-FIBRINOLYTIC EFFECTS OF RECOMBINANT FACTOR VIII IN PLASMA FROM</td>
<td>Kamran Bakhtiar*, Maria Elisa Mancuso, Karly Hamulyak, Elena Santagostino, Roger E.G. Schutgens, Pieter W. Kamphuisen, Joost C.M. Meijers</td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH HEMOPHILIA A WITH INHIBITORS</td>
<td></td>
</tr>
</tbody>
</table>
**POSTER PRESENTATIONS**

**Monday, July 25, 2011**

### Inherited coagulation disorders (except for von Willebrand disease)

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-MO-521</td>
<td>Survival among 5118 patients with bleeding disorders compared to matched controls in Sweden: results from a cohort register study</td>
<td>Karin M Henriksen* (SE), Jan Astermark, Jan-Ake Nilsson, Fariba Baghaei, Margareta Holmstrom, Erik Berntorp</td>
</tr>
<tr>
<td>P-MO-522</td>
<td>A plasma-derived FXIII concentrate with a very high margin of virus safety for the treatment of congenital FXIII deficiency</td>
<td>Albrecht Groener* (DE), Thomas Nowak, Birgit Popp, Wolfram Schaefer</td>
</tr>
<tr>
<td>P-MO-523</td>
<td>A first Taiwanese patient of severe prekallikrein deficiency with novel mutations seen in Taiwan</td>
<td>Jiaan-Der Wang* (TW), Ming Ching Shen, Kuo Shu Hua, Chuan Cheng Wang, Ching Ye Lin, Bo Do Lin, Su Feng Kuo, Jen Shiou Lin, Shyuann Yuh Lin, Kuan Ju Lai, Cheng Shyong Chang, Chih-Yuan Chong</td>
</tr>
<tr>
<td>P-MO-524</td>
<td>Point mutations regarded as missense mutations cause splicing defects in the factor XI gene</td>
<td>Michal Zucker* (IL), Nirit Rosenberg, Hava Peretz, David Green, Frederic Bauduer, Ariella Zivelin, Uri Seligsohn</td>
</tr>
<tr>
<td>P-MO-525</td>
<td>Prevention of bleeding and haemorrhagic complications in perioperative period in patients with inherited factor VII deficiency</td>
<td>Adam Wiszniewski* (PL), Ksenia Bykowska, Piotr Szopinski, Alfred Jerzy Meissner</td>
</tr>
<tr>
<td>P-MO-526</td>
<td>Novel L13Q mutation of endoglin gene in hereditary hemorrhagic telangiectasia caused impaired cotranslational processing and cell-surface expression</td>
<td>Atsuo Suzuki* (JP), Yuhri Miyawaki, Junko Fujita, Asuka Maki, Yuta Fujimori, Akira Takagi, Takashi Murate, Masaaki Teranishi, Tadashi Matsushita, Hidetaka Saito, Tetsuhiro Kojima</td>
</tr>
<tr>
<td>P-MO-527</td>
<td>A novel hereditary bleeding disorder characterized by low thrombin generation caused by factor V inhibition</td>
<td>Yesim Dargaud* (FR), Theo Lindhout, Rob J Wagenvoord, Elisabetta Castoldi, Tilman Hackeng, Christine M Trzeziak, Coenraad H Hemker</td>
</tr>
<tr>
<td>P-MO-528</td>
<td>Molecular characterization of a new combined factor V and factor VII deficiency and review of the literature</td>
<td>Michael Daskalakis* (DE), Julia Driesen, Anna Pavlova, Johannes Oldenburg, Meike Burger, Ulrich Geisen, Juergen Heinz</td>
</tr>
<tr>
<td>P-MO-529</td>
<td>First report of a patient with severe factor X deficiency resulting from two homozygous factor X mutations and low bleeding tendency</td>
<td>Michael Daskalakis* (DE), Winnie Schroeder, Juliane Najm, Ute Felbor, Barbara Zieger, Meike Burger, Juergen Heinz, Ulrich Geisen</td>
</tr>
</tbody>
</table>

### Acquired coagulation disorders

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-MO-530</td>
<td>Patients with severe aortic valve stenosis and impaired platelet function benefit from pre-operative desmopressin infusion</td>
<td>Barbara Steinlechner (AT), Michael Spannagl, Peter Quehenberger, Petra Zeidler, Bernd Jilma*</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-531  SUCCESSFUL RITUXIMAB-TREATMENT OF TWO PATIENTS WITH ACQUIRED HEMORRHAPHILIA 13 (HEMORRHAGIC ACQUIRED FACTOR 13 DEFICIENCY DUE TO ITS AUTOANTIBODIES)
Yasuhiro Nagate* (JP), Satoru Kosugi, Soichi Nakata, Takeshi Kotake, Toru Kida, Hironori Take, Masayoshi Souri, Shuichi Katagiri, Akitada Ichinose

P-MO-532  CORRELATION BETWEEN PLATELET ACTIVATION MARKERS AND HMGB1 IN DIC PATIENTS WITH HEMATOLOGIC MALIGNANCY
Shinya Fujita* (JP), Ryotaro Otsasa, Takahisa Nakanishi, Michihiko Miyaji, Shinichihi Mori, Kazyuoshi Ishii, Tomoki Ito, Shosaku Nomura

P-MO-534  WARFARIN TREATED PATIENTS HAVE INCREASED MORTALITY FOLLOWING CHRONIC SUBDURAL HEMATOMA
Israel Gavish* (IL), Lion Levi, Anatoly Rikier, Daniel Kirshner, Ali Hatib, Menashe Zaaroor, Benjamin Brenner

P-MO-535  DELAYED DIAGNOSIS OF ACQUIRED HAEMOPHILIA A IN SUBJECTS WITH BLEEDING SYMPTOMS
Gabriella Gamba* (IT), Nadia Montani, Alice Trinchero, Fabio Lodo, Nicola Ghidelli

P-MO-536  ACQUIRED HAEMOPHILIA A (AHA) IN THREE PATIENTS ON ANTICOAGULANT THERAPY AND PROFUSE BLEEDING: DIAGNOSTIC AND THERAPEUTIC PROBLEMS
Gabriella Gamba* (IT), Nadia Montani, Alice Trinchero, Fabio Lodo, Nicola Ghidelli

P-MO-537  A CASE OF ACQUIRED HEMOPHILIA WITH SPURIOUSLY ELEVATED ALP MAY BE ASSOCIATED WITH DRUGS
Yutaka Komiyama* (JP), Tomoki Ito, Shosaku Nomura, Yukiie Sato, Yoshika Masamichi, Masaki Hiroya, Hakuo Takahashi

P-MO-538  THE SURVEY OF SUPPORTIVE THERAPY FOR COAGULATION DISORDER DURING L-ASPARAGINASE-(L-ASP) THERAPY IN JAPAN
Chitose Ogawa* (JP), Atsushi Manabe, Akira Ohara, Akira Ishiguro

P-MO-539  DIVERSITY OF UNDERLYING DISORDERS AND VARIETY OF FIRST VISIT CLINICS FOR PATIENTS WITH ACQUIRED HEMOPHILIA: RESULTS FROM SHIZUOKA REGISTRY
Chiho Otani* (JP), Sadahiro Tamashima, Michiaki Koike, Jun Taguchi, Kensei Naito, Nobuharu Kosugi, Kentarou Misawa, Toshihide Tanaka, Juichi Tanabe, Hiroshi Mouri

P-MO-540  RECOMBINANT FACTOR VIIA (RFVIIA) USE FOR SURGERY IN ACQUIRED HEMOPHILIA (AH): ANALYSIS FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY
Alice Ma* (US), Craig M. Kessler, Robert Z. Gut, David L. Cooper

Innovative therapies for hemorrhagic disorders

P-MO-541  RFVIIA ADMINISTERED AS CONTINUOUS INFUSION DURING SURGERY IN PATIENTS WITH CONGENITAL SEVERE FVII DEFICIENCY
Hoa Thi Tuyet Tran* (NO), Geir Tjonneland, Albert Paus, Paal Andre Holme

P-MO-542  SUCCESSFUL TREATMENT OF HEMOTHORAX AND INTRACRANIAL HEMORRHAGE IN A TAIWANESE HEMOPHILIAC WITH INHIBITORS BY ACTIVATED RECOMBINANT FACTOR VII AND POSITIVE PRESSURE VENTILATION
Chia-Yau Chang* (TW), Ming-Ching Shen, Chung-Che Wu, Chen-Hua Tsai, Jia-Ruey Tsai, Shi-Yi Lin, Ing-Jy Tseng
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-543  DEVELOPMENT AND USE OF A SURGICAL DATABASE TO STANDARDIZE CARE, ASSESS EFFICACY AND OUTCOMES IN BLEEDING DISORDER PATIENTS: REPORT OF 1184 PROCEDURES FROM A SINGLE CENTER
Charles Nakar* (US), Craig Haddix, Nina Meschino, Jeanne Sagar, Elaine Menshouse, Ivonne Fuentes, Anne Greist, Amy Shapiro

P-MO-544  PARTIAL PROHEMOSTATIC EFFECT OF TRANSFUSION OF FIBRINOGEN CONCENTRATE REPLACING FRESH FROZEN PLASMA IN MASSIVE HEMORRHAGE
Marcus D. Lance* (NL), M. Ninivaggi, M.A.E. Marcus, K. Hamulyak, E.C.M. van Pampus, H. ten Cate, J.W.M. Heemskerk

P-MO-545  TREATING ANTICOAGULATION RESISTANCE IN THROMBOTIC HYPODYSFIBRINOGENAEMIA
Catherine J Rea* (UK), Julia Mitchell, Beverley J Hunt

P-MO-546  IMPROVEMENT OF SPATIAL FIBRIN FORMATION BY THE ANTI-TFPI APTAMER BAX499: CHANGING CLOT SIZE BY TARGETING EXTRINSIC PATHWAY INITIATION

P-MO-547  LONGATE, A LONG-ACTING LIPOSOMAL FORMULATION OF PLASMA-DERIVED FACTOR VIII - RESULTS OF AN OPEN LABEL PHASE IIIIB CLINICAL TRIAL IN ADULT HEMOPHILIA A PATIENTS
Moshe Baru* (IL), Jack Spira, Olga Plyushch, Tatiana Andreeva, Vladimir Zorenko, Nadezhdza Zozulya, Irena Velichkol, Rivka Yatuv

P-MO-548  HAEMOSTASTIC POTENTIAL OF COAGULATION FACTOR CONCENTRATES VS ALLOGENEIC BLOOD PRODUCTS FOLLOWING CARDIAC SURGERY
Mariann Tang* (UK), Per Wierup, Jacob Greisen, Joergen Ingerslev, Benny Soerensen

P-MO-549  USE OF PROTHROMBIN COMPLEX CONCENTRATE IN PATIENTS WITH ACUTE OR CHRONIC LIVER DISEASE - A SINGLE CENTRE RETROSPECTIVE AUDIT
Anja B Drebes* (UK), Andrew Burroughs, Alex Gatt, Susan Mallett, Edward G. D. Tuddenham, Pratima Chowday

P-MO-550  AN ANALOGUE OF FACTOR VIlla IMPROVES WOUND HEALING IN HEMOPHILIA B MICE
Maureane Hoffman* (US), Jacqueline Brock, Mirella Ezban, Dougald M Monroe

P-MO-551  NEUTRALIZING ANTIBODIES AGAINST ADENO-ASSOCIATED VIRUS EXAMINED PROSPECTIVELY IN PEDIATRIC PATIENTS WITH HEMOPHILIA
Paul E Monahan* (US), Chengwen Li, Nattee Narkdunnam, R. Jude Samulski, Genlin Hu, Aravind Asokan, Marilyn J. Manco-Johnson, Joint Outcome Study Investigators

P-MO-552  BONE MARROW TRANSPLANTATION CURES HEMOPHILIA A
Antonia Follenzi* (IT), Sanj Raut, Simone Merlin, Rita Sarkar, Sanjeev Gupta

P-MO-553  THROMBIN ACTIVATION OF PAR-1 ON BOECS RESULTS IN RELEASE OF CYTOKINES THAT LIKEWY contribute to the IMMUNE RESPONSE IN A CANINE HEMOPHILIA GENE TRANSFER STRATEGY
Christine A. Hough* (CA), Colleen Notley, Nathalie LeBlanc, Margareth C Ozelo, Christine Brown, Carol Hegadorn, Andrea Labelle, David Lillicrap

P-MO-554  INTRA-ARTICULAR INJECTION OF AUTOLOGOUS MESENCHYMAL STEM CELLS AMELIORATES HEMOPHILIC ARTHROPATHY IN FACTOR VIII-DEFICIENT MICE
Yuji Kashiwakura* (JP), Tsukasa Ohmori, Jun Mimuro, Atsushi Yasumoto, Akira Ishiwata, Asuka Sakata, Seiji Madoiwa, Mokoto Inoue, Momoru Hasegawa, Natsumi Watanabe, Kohki Tatsumi, Kazuo Ohashi, Teruo Okano, Yoichi Sakata
**POSTER PRESENTATIONS**

Monday, July 25, 2011

### Atherosclerosis

**P-MO-555**  
**SILENCING THE F11R GENE CONFIRMS THE CRITICAL ROLE OF THE F11 RECEPTOR (F11R/JAM-A) IN PLATELET ADHESION TO INFLAMED ENDOTHELIUM AND IN ATHEROSCLEROSIS.**  
Bani Mekisha Azari* (US), Jonathan D. Marmur, Moro O. Salifu, Yigal H. Ehrlich, Elizabeth Kornecki, Anna Babinska

**P-MO-556**  
**THE LONG PENTRAXIN 3 (PTX3), A BIOMARKER OF INFLAMMATION, PREDICTS LONG-TERM MORTALITY IN PATIENTS HOSPITALIZED WITH SUSPECTED ACUTE CORONARY SYNDROME**  
Trygve Brugger-Andersen* (NO), Volker Poentner, Frederic Kontny, Harry Staines, Oistein Mjelva, Heidi Grundt, Dennis WT Nilssen

**P-MO-557**  
**ACTIVATED PROTEIN C THERAPY PREVENTS AGAINST COMPLEX ATHEROSCLEROSIS PROGRESSION IN MICE WITH GENETICALLY IMPAIRED ANTICOAGULANT RESPONSE**  
Julian I. Borissoff* (NL), Sarah T.B.G. Loubele, Sylvia Heeneman, Peter Leenders, Rene van Oerle, Oliver Soehnlein, Karly Hamulyak, Erik A. Biessen, Hartmut Weiler, Charles T. Esmon, Tilman M. Hackeng, Mat J.A.P. Daemen, Henri M.H. Spronk, Hugo ten Cate

**P-MO-558**  
**VITAMIN K-ANTAGONISTS INDUCE A VULNERABLE ATHEROSCLEROTIC PLACQUE PHENOTYPE**  
Leon J Schurgers* (NL), Martijn Chatrou, Jagat Narula, Leonard Hofstra, Cees Vermeer, Chris P Reutelingsperger

**P-MO-559**  
**SECRETION OF SALUSIN-β FROM HUMAN MONOCYTE-DERIVED CELLS AND DEVELOPMENT OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR MEASUREMENT OF SALUSIN-β IN HUMAN PLASMA**  
Kazumi Fujimoto* (JP), Kengo Sato, Masayoshi Shichiri, Takatoshi Koyama

**P-MO-560**  
**THE FACTOR VII-ACTIVATING PROTEASE (FSAP) ENHANCES THE ACTIVITY OF TRANSFORMING GROWTH FACTOR-β (TGF-β) FAMILY MEMBERS**  
Elfie Roedel* (DE), Frank Ploeger, Elisabeth Schwarz, Sandip Kanse

**P-MO-561**  
**CAROTID INTIMA-MEDIA THICKNESS IN PSORIATIC ARTHRITIS: THE EFFECT OF TNF-α BLOCKERS**  
Matteo Nicola Dario Di Minno* (IT), Anna Russolillo, Salvatore Iervolino, Antonella Tufano, Rosario Peluso, Raffaele Scarpa, Giovanni Di Minno

**P-MO-562**  
**MMP-9 SERUM LEVELS ARE ASSOCIATED WITH CAROTID ATHEROSCLEROSIS PROGRESSION**  
Walter S Speidi* (AT), Matthias Hoke, Jasmin Amighi, Wolfgang Mieksch, Alexander Niessner, Gerald Maurer, Renate Koppensteiner, Erich Minar, Johann Wojta, Martin Schillinger

**P-MO-563**  
**PLASMATIC LEUKOCYTE-DERIVED MICROPARTICLES : NEW BIOMARKER FOR PREDICTION OF PLAQUE UNSTABILITY IN ASYMPTOMATIC PATIENTS WITH HIGH-GRAGE CAROTID STENOsis**  

**P-MO-564**  
**CD39 IN ATHEROSCLEROTIC LESION CONTRIBUTES TO THE VASCULAR PLEIOTROPIC EFFECTS OF STATIN**  
Tsunei+Soeda* (JP), Hiroyuki Kawata, Ji-Hee Sung, Satoshi Somekawa, Masanori Matsumoto, Yoshihiro Fujimura, Shiro Uemura, Yoshihiko Satoh
POSTER PRESENTATIONS

Monday, July 25, 2011

Endothelial cells

P-MO-565  SIGNIFICANCE OF ENDOTHELIAL CELL-DERIVED MICROPARTICLES IN TYPE 2 DIABETES MELLITUS
Oleksii M. Korzh* (UA), Elena A. Pavlova, Sergiy V. Krasnokutskiy

P-MO-566  VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)-ENHANCED VASCULAR PERMEABILITY VIA VEGF RECEPTOR-2 SELECTIVELY FORM FENESTRAE ULTRASTRUCTURE IN ENDOTHELIUM
Yukiko Matsunaga* (JP), Yasuo Yamazaki, Hidenori Suzuki, Takashi Morita

P-MO-567  THE PREDICTIVE VALUE OF THE LONG PENTRAxin 3 (PTX3) FOR HEART FAILURE DEVELOPMENT IN ACUTE CHEST PAIN PATIENTS
Trygve Bruggier-Andersen* (NO), Volker Ponitz, Frederic Kontry, Harry Staines, Oistein Mjelva, Heidi Grundt, Dennis Nilsen

P-MO-568  THE EFFECT OF RADICAL SCAVENGER TO NO RELEASE IN MICROVESSELS
Tsutomu Yamashita* (JP), Kumi Sakamoto, Hiroshi Yamanishi, Junichiro Yamamoto

P-MO-569  THE EFFECT OF RADICAL SCAVENGER TO LEUKOCYTE ROLLING IN MICROVESSELS
Kumi Sakamoto* (JP), Tsutomu Yamashita, Hiroshi Yamanishi, Junichiro Yamamoto

P-MO-570  ALTERATIONS OF MARKERS OF INFLAMMATION AND ENDOTHELIAL CELL DAMAGE AFTER CAROTID ENDOARTERECTOMY
Masako Yamazaki* (JP), Yoshikazu Okada, Akitsugu Kawashima, Koji Yamaguchi, Taku Yoneyama, Shinichiro Uchiyama

P-MO-571  VON WILLEBRAND FACTOR (VWF) ANTIGEN AND VWF PRO-PEPTIDE AS BIOMARKERS OF ACUTE LUNG INJURY IN H1N1
Simon J Davidson* (UK), Anne Riddell, Louise Tillyer, Simon J Finney, Jeremy J Cordingley, Mark J Griffiths

P-MO-572  THE VITAMIN K-DEPENDENT ANTI-COAUGULANT FACTOR, PROTEIN S, REGULATES ANGIogenesis IN VITRO AND IN VIVO
Sylvain Fraineau* (FR), Michel Philippe, Julie Talbot, Sandip M Kanse, Arnaud Monvoisin, Omar Benzakour

P-MO-573  PROTEIN KINASE C ISOFORMS IN THE DIVERGENT ENDOTHELIAL SIGNALLING EXERTED BY THROMBIN- AND ACTIVATED PROTEIN C-DEPENDENT ACTIVATION OF PAR-1
Yao Yu* (UK), James TB Crawley, Justin C Mason, David A Lane

P-MO-574  UREMIC TOXINS ENHANCE ENDOTHELIAL TISSUE FACTOR PRODUCTION

P-MO-575  CIRCULATING ENDOTHELIAL CELLS AND ITS POTENTIAL AS A MARKER OF THE VASCULAR CONDITION
Manuel Cesar Campos* (PT), Claudia Torres, Mafalda Fonseca, Ana Santos, Marlene Santos, Marta Goncalves, Sonia Fonseca, Luis Queiroz, Catarina Lau, Marika Antunes, Anjos Teixeira, Rui Matos, Sara Morais, Margarida Lima
### POSTER PRESENTATIONS

**Monday, July 25, 2011**

#### Inflammatory cells and cytokines

<table>
<thead>
<tr>
<th>POSTER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-MO-576</td>
<td><strong>THE EFFECT OF PLATELET DERIVED MICROPARTICLES ON GENES IN CELLS OF WHOLE BLOOD AND THP-1 CELLS</strong>&lt;br&gt;Bjarne Osterud* (NO), Trine Lund, Hege Devold</td>
</tr>
<tr>
<td>P-MO-577</td>
<td><strong>THROMBOMODULIN TREATMENT OF DENDRITIC CELLS ALTERS GENE EXPRESSION</strong>&lt;br&gt;John Morser* (US), Masaaki Toda, Daniel Boveda Ruiz, Paloma Gil Bernabe, Corina N. D’Alessandro-Gabazza, Yasushi Miyake, Esteban C. Gabazza</td>
</tr>
<tr>
<td>P-MO-578</td>
<td><strong>RELATIONSHIP BETWEEN ENDOTHELIAL HAEMOSTATIC MARKERS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE</strong>&lt;br&gt;Oleksii M. Korzh* (UA), Elizaveta Lavrova, Elena Pavlova</td>
</tr>
<tr>
<td>P-MO-579</td>
<td><strong>PLASMIN-CLEAVED CHEMERIN, CHEM158K, IS THE DOMINANT CHEMERIN ISOFORM IN INFLAMMATORY CEREBROSPINAL FLUIDS</strong>&lt;br&gt;Lei Zhao* (US), Yasuto Yamaguchi, Shadi Sharif, Xiaoyan Du, Lawrence D. Recht, John M. Morser, Lawrence L.K. Leung</td>
</tr>
<tr>
<td>P-MO-580</td>
<td><strong>EXOGENOUS GLUCOCORTICOIDS ATTENUATES HYPERCOAGULABLE STATE AND SYSTEMIC INFLAMMATION IN EXPERIMENTAL HEATSTROKE</strong>&lt;br&gt;Chia-Chyuan Liu* (TW), Yi-Szu Wen, Wen-Yueh Ho, Kuen-Lin Leu, Tsai-Hsiu Yang</td>
</tr>
<tr>
<td>P-MO-581</td>
<td><strong>HIGH PLASMA LEVELS OF S-ADENOSYLHOMOCYSTEINE HAVE INCREASED THE RISK OF HEATSTROKE IN A RAT MODEL</strong>&lt;br&gt;Tsai-Hsiu Yang* (TW), Chau-Chen Yang, Mei-Lin Tsai, Mei-Ying Wang, Chia-Chyuan Liu</td>
</tr>
<tr>
<td>P-MO-582</td>
<td><strong>TWO-SITE PHOSPHORYLATION OF A TRNA SYNTHETASE LINKS CDK5-MTOR-S6K TRIO TO CONTROL OF INFLAMMATORY GENE EXPRESSION</strong>&lt;br&gt;Abul Arif* (US), Paul Fox</td>
</tr>
<tr>
<td>P-MO-583</td>
<td><strong>UROKINASE RECEPTOR (CD87) IS DECREASED AT THE SURFACE OF MONOCYTES OF PATIENTS TREATED BY STATINS AND CORRELATES WITH PLATELET MICROPARTICLES</strong>&lt;br&gt;Marc Vasse* (FR), Dany Bigot, Sylviane Leclerc, Bernard Lenormand</td>
</tr>
<tr>
<td>P-MO-584</td>
<td><strong>EVIDENCE THAT THE THIOL ISOMERASE-BINDING PEPTIDE, MASTOPARAN, INHIBITS SHEAR-INDUCED TGF-β1 ACTIVATION</strong>&lt;br&gt;Teresa Brophy* (US), Jasimuddin Ahamed, Barry S Collier</td>
</tr>
</tbody>
</table>

#### Angiogenesis and lymphangiogenesis

<table>
<thead>
<tr>
<th>POSTER</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-MO-586</td>
<td><strong>PLATELETS TRANSPORT THE TUMOR SECRETOME DURING CANCER PROGRESSION AND METASTASIS</strong>&lt;br&gt;Bethany A Kerr* (US), Weiyi Feng, Maria Madajka, N. Patrick McCabe, Tatiana V. Byzova</td>
</tr>
<tr>
<td>P-MO-587</td>
<td><strong>PROANGIOGENIC ACTIVITY OF RECOMBINANT THROMBOMODULIN PROTEINS</strong>&lt;br&gt;Guey-Yueh Shi* (TW), Yu-Ming Cheng, Bi-Ing Chang, Cheng-Hsiang Kuo, Hua-Lin Wu</td>
</tr>
<tr>
<td>P-MO-588</td>
<td><strong>CONDITIONAL ABLATION OF ALPHA6 INTEGRIN SUBUNIT IN MOUSE ENDOTHELIUM REDUCES ANGIGENESIS</strong>&lt;br&gt;Claire Bouvard* (FR), Adele De Arcangelis, Blandine Dizier, Isabelle Galy-Fauroux, Anne-Marie Fischer, Elisabeth Georges-Labouesse, Dominique Helley</td>
</tr>
<tr>
<td>P-MO-589</td>
<td><strong>THE ROLE OF THROMBOMODULIN AND LEWIS Y ANTIGEN ON VASCULAR ENDOTHELIAL TUBE FORMATION</strong>&lt;br&gt;Cheng-Hsiang Kuo* (TW), Po-Ku Chen, Hua-Lin Wu, Guey-Yueh Shi</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Monday, July 25, 2011

P-MO-590  THE CARCINOEMBRYONIC ANTIGEN (CEA) INDUCES ANGIOGENESIS VIA INTEGRIN B3-DEPENDENT ACTIVATION OF ENDOTHELIAL CELLS
Gerald W Prager* (AT), Kira H Bramswig, Marina Poettler, Fritz Wrba, Christoph C Zielinksi

P-MO-591  PRESERVATION OF RENAL MICROVASCULATURE IN VASCULAR ENDOTHELIAL ENDOThELIN-1 KNOCK OUT (VEETKO) MICE AFTER KIDNEY FIBROSIS

P-MO-592  EVALUATION THE ANTIANGIOGENIC EFFECT OF A NOVEL ENDOGENOUS ANTIANGIOGENIC FACTOR
Ching-Hu Chung* (TW)

P-MO-593  ANALYSIS OF THE CELLULAR RESPONSE AND THE PROTEASE ACTIVITIES IN THE PROCESS OF RECOVERY FROM SCRATCH WOUNDING USING A PERFUSION CELL CULTURE SYSTEM
Moyuru Hayashi* (JP), Motoyuki Shimonaka

P-MO-594  INTRAMYOCARDIAL INJECTION OF ANGF-1 IMPROVES CARDIAC FUNCTION AFTER MYOCARDIAL INFARCTION IN PIGS
Kuan-Chieh Wang* (TW), Hsieh C.H. Patrick, Shi Guey-Yueh, Lee Fang-Tzu, Chu Ting-Yu, Shih Ya-Yun, Wu Hua-Lin

P-MO-595  INHIBITORY EFFECTS OF THAN42 ON ANGIOGENESIS INDUCED BY VASCULAR ENDOTHELIAL GROWTH FACTOR
Oh-hu Yuan Tan* (TW), Tur-Fu Huang

P-MO-596  BP5250 INHIBITS THE VASCULAR ENDOTHELIAL GROWTH FACTOR INDUCED ANGIOGENESIS AND HIF-1α EXPRESSION ON ENDOTHELIAL CELLS
Kuan-Ting Lin* (TW), Tur-Fu Huang

P-MO-597  SIGNIFICANCE OF HRT FAMILY OF TRANSCRIPTION FACTORS IN POSTNATAL ANGIOGENESIS
Hisaki Hayashi* (JP), Masahide Sakabe, Tomoki Ioka, Takashi Morioka, Genki Sato, Ken Inada, Osamu Nakagawa

P-MO-598  THE ANTHOCYANIN DELPHINIDIN-3-GLUCOSIDE, CONTAINED IN WILD BLUEBERRIES, PROTECTS ENDOTHELIAL CELLS FROM PROANGIOGENIC AND PROTHROMBOTIC STIMULI
Marina Marchetti* (IT), Gaia Bonacina, Erika Diani, Alfonso Vignoli, Patrizia Riso, Marisa Porrini, Anna Falanga

P-MO-599  TARGETING TUMOR VASCULATURE WITH SRNA AGAINST BETA 1 INTEGRIN SUBUNIT AND MMP-7
Jolanta M. Niewiarowska* (PL), Tomasz - Wysocki, Magdalena - Wiktorska, Izabela - Sacewicz-Hofman, Olga - Stasiakowska, Czeslaw S. Cierniewski

Structural biology and drug design

P-MO-600  NEW GENERATION OF ANTITHROMBOTIC COMPOUNDS WITH DUAL - THROMBIN INHIBITORY AND GPIIB/IIIA RECEPTOR ANTAGONISTIC ACTIVITY
Janez Ilas* (SI), Danijel Kikelj

P-MO-601  TARGETING OF THE TENASE COMPLEX BY RATIONAL DESIGN OF FACTOR VIII-MEMBRANE INTERACTION INHIBITORS
Gerry A F Nicolaes* (NL), Mahesh Kulharia, Olivier Sperandio, Jan Voorberg, Simone Wielders, Bruno O. Villoutreix
Monday, July 25, 2011

**POSTER PRESENTATIONS**

**P-MO-602**  
**DISCOVERY OF BIOLOGICALLY ACTIVE MOLECULES THAT INHIBIT THE FUNCTIONS OF ANTICOAGULANT ACTIVATED PROTEIN C**  
Gerry A F Nicolaes* (NL), Karin C.A.A. Wildhagen, Olivier Sperandio, Roy Schrijver, Bruno O. Villoutreix

**P-MO-603**  
**THE PERFORMANCES OF MULTI-WAVELENGTH COAGULOMETER ON HEMOLYZED, ICTERIC, AND LIPEMIC SAMPLES. A COMPARATIVE STUDY WITH A MECHANICAL COAGULOMETER**  
Rahajuningsih Dharma Setiabudy* (ID), Agus Kosasih, Lyana Setiawan

**P-MO-604**  
**PREVENTION OF VENOUS THROMBUS FORMATION IN RABBITS AFTER SINGLE ORAL AND INTRAVENOUS DOSES OF DERMATAN SULPHATE EXTRACTED FROM BOVINE HIDE PROCESSING WASTE**  
Simone Angeliique Osborne* (AU), Paul Masci, Sharon Qianyun Du, Robyn Daniel, Wei Chen, Peter Stockwell, Kerri Tyrrell, Gregory Harper, Kirthi Desilva, Robert Seymour

**P-MO-605**  
**IDENTIFICATION OF FACTOR IX LIGHT CHAIN VARIANTS WITH INCREASED ACTIVITY; V86 SATURATION MUTAGENESIS AND ANALYSIS OF A D85X-V86A-T87X FOCUSED LIBRARY**  
Chandra Patel* (US), Uwe Gritzan, Xiaqiao Jiang, Ulrich Haupts, Jesper Haarning, John E Murphy, Alan R Brooks

**P-MO-606**  
**CREATION OF TNFR1-SELECTIVE MUTANT TNF WITH ANTAGONISTIC ACTIVITY**  
Haruhiko Kamada* (JP), Yasuhiro Abe, Kazuya Nagano, Yasuo Tsutsumi, Shin-ichi Tsunoda

**P-MO-607**  
**TISSUE FACTOR TRIGGERED BLOOD THROMBOELASTOMETRY AND THROMBIN GENERATION ASSAY IDENTIFY INTER-INDIVIDUAL VARIABILITY OF ANTICOAGULANT RESPONSE TO TREATMENT WITH LMWH.**  
Grigoris Thomas Gerotziafas* (FR), Mourad Chaari, Mouna Sassi, Vassiliki Galea, Chrysoula Papageorgiou, Hatmi Mohamed, Elalamy Ismail, Meyer Michel Samama

**P-MO-608**  
**1-6 ANHYDRO RING OF ENOXAPARIN IS ESSENTIAL FOR THE DOWN-REGULATION OF FACTOR VIIA GENERATION DURING CLOTTING OF HUMAN PLASMA.**  
Grigoris Thomas Gerotziafas* (FR), Tahar Chakroun, Andre Uzan, Meyer Michel Samama, Ismail Elalamy

**P-MO-609**  
**COMPARISON OF METHODS FOR THROMBOEMBOLIC RISK ASSESSMENT WITH CLINICAL PERCEPTIONS AND AWARENESS IN REAL LIFE MEDICAL PATIENTS. COMPASS-MED STUDY**  
Grigoris Thomas Gerotziafas* (FR), Asterios Katsamouis, Athanasios Liopoulos, Dimitris Kiskinis, John Tsolakis, Evagelos Tsimogiannis, Anastasios Koukos, Alex Spyropoulos, Vassiliki Galea, Isabelle Debrux, Hela Bacouche, Ismail Elalamy

**P-MO-610**  
**LOVENOX AND ITS GENERICS EXERT DIFFERENT DEGREE OF INHIBITION OF THROMBIN GENERATION IN PLATELET RICH PLASMA. AN ADDITIONAL CRITERION FOR THE EVALUATION OF LMWH BIOSIMILARITY.**  
Grigoris Thomas Gerotziafas* (FR), Mouna Sassi, Vassiliki Galea, Jawed Fareed, Jeanine Walenga, Ismail Elalamy

**P-MO-611**  
**IN VITRO INHIBITORY EFFECT OF Tinzaparin and Enoxaparin on Thrombin Generation Triggered by Ovarian Adenocarcinoma Cells IGROV1**  
Vassiliki Galea* (FR), Mouna Sassi, Grigoris T. Gerotziafas, Elisabeth Mbemba, Mohamed Hatmi, Jean Francois Bernaudin, Ismail Elalamy

**P-MO-612**  
**LOW MOLECULAR WEIGHT HEPARINS Tinzaparin and Enoxaparin Equally Inhibited In Vitro Thrombin Generation Triggered by Prostate Cancer Cell Line PC3**  
Vassiliki Galea* (FR), Grigoris T. Gerotziafas, Mohamed Hatmi, Ismail Elalamy
POSTER PRESENTATIONS

Monday, July 25, 2011
Scientific Program
Tuesday, July 26, 2011
Tuesday, July 26, 2011

**Plenary Lecture** 9:45-10:30

**Oscar Ratnoff Memorial Lecture** Main Hall

*Chairpersons: P. M. Mannucci (IT) and Koji Suzuki (JP)*

**Challenge to novel bioactive peptides**  
*Kenji Kangawa (JP)*

**Plenary Lecture** 17:15-18:00

**Sol Sherry Memorial Lecture** Main Hall

*Chairpersons: Henri Bounameaux (CH) and Yoichi Sakata (JP)*

**Recent progress in anticoagulant therapy: Oral direct inhibitors of thrombin and factor Xa**  
*Kenneth A. Bauer (US)*

**State-of-the-Art Lecture** 11:00-12:00

**Platelet Clinical** Main Hall

*Chairpersons: Marco Cattaneo (IT) and Andreas Greinacher (DE)*

**Advances in our understanding of the molecular basis of disorders of platelet function**  
*Alan T. Nurden (FR), Paquita Nurden*  
SA-TU-001  
11:00 – 11:30

**HIT paradigms and paradoxes**  
*Theodore Earl Warkentin (CA)*  
SA-TU-002  
11:30 – 12:00

**von Willebrand Factor and von Willebrand Disease** Annex Hall 1

*Chairpersons: Robert R. Montgomery (US) and Yohko Kawai (JP)*

**Von Willebrand factor: The complex molecular genetics of a multidomain and multifunctional protein**  
*Reinhard Schneppenheim (DE), Ulrich Budde*  
SA-TU-003  
11:00 – 11:30

**Biology and physics of von Willebrand factor concatamers**  
*Timothy A. Springer (US)*  
SA-TU-004  
11:30 – 12:00
Tuesday, July 26, 2011

**Vascular Biology**

*Chairpersons: Francoise Dignat-George (FR) and Ikuo Morita (JP)*

**Molecular analysis of blood vessel maturation**  
Nobuyuki Takakura (JP)  
11:00 – 11:30  
SA-TU-005

**Tissue specific adult stem cells**  
Piero Anversa (US)  
11:30 – 12:00  
SA-TU-006

---

**Cancer Thrombosis**

*Chairpersons: Michael Greaves (UK) and Yujiro Asada (JP)*

**Tissue factor and cell signaling in cancer progression and thrombosis**  
Wolfram Ruf (US), Jennifer Disse, Tatiana Correa Carneiro-Lobo, Naho Yokota, Florence Schaffner  
11:00 – 11:30  
SA-TU-007

**Management of thrombosis in patients with cancer**  
Giancarlo Agnelli (IT)  
11:30 – 12:00  
SA-TU-008

---

**Symposia**  
8:00-9:30

**Platelet (Basic and Clinical)**

*Main Hall*

**Immune Thrombocytopenia**

*Chairpersons: Cecile Kaplan (FR) and Diane Nugent (US)*

**Pathophysiology of primary immune thrombocytopenia**  
Roberto Stasi (UK)  
08:00 – 08:30  
SY-TU-001

**Loss of tolerance and tolerance regain in ITP**  
Ming Hou (CN)  
08:30 – 09:00  
SY-TU-002

**TPO mimetics in ITP**  
David J. Kuter (US)  
09:00 – 09:30  
SY-TU-003
VWF/VWD and ADAMTS13  
Annex Hall 1

Pathogenesis of Thrombotic Microangiopathy  
Chairpersons: Jeroen Eikenboom (NL) and Changgeng Ruan (CN)

Von Willebrand factor, ADAMTS13, and thrombotic microangiopathy  
J. Evan Sadler (US) 08:00 – 08:30  
SY-TU-004

Baboon model of acquired thrombotic thrombocytopenic purpura  
Karen Vanhoorelbeke (BE) 08:30 – 09:00  
SY-TU-005

Atypical hemolytic uremic syndrome, complement and coagulation  
Edward M. Conway (CA) 09:00 – 09:30  
SY-TU-006

Inflammation and Atherothrombosis  
Annex Hall 2

New triggering mechanisms of macrophage activation  
Masanori Aikawa (US) 08:00 – 08:30  
SY-TU-007

Thrombus formation on disrupted plaques  
Atsushi Yamashita (JP) 08:30 – 09:00  
SY-TU-008

Hematopoietic and non-hematopoietic cell tissue factor  
Nigel Mackman (US) 09:00 – 09:30  
SY-TU-009

Symposia  
13:30-15:00

Thrombotic Disorders  
Main Hall

Acute Cerebrovascular Syndrome  
Chairpersons: K.S. Lawrence Wong (HK) and Shinichiro Uchiyama (JP)

Epidemiology and registry of TIA in acute setting  
Pierre Amarenco (FR) 13:30 – 14:00  
SY-TU-010

Microembolic signals and MRI findings in acute TIA patients  
K.S. Lawrence Wong (HK) 14:00 – 14:30  
SY-TU-011
Tuesday, July 26, 2011

Acute cerebrovascular syndrome (ACVS)  
J. Donald Easton (US)  
14:30 – 15:00

APSTH Genome  
Annex Hall 1

Genomes in Asian and Caucasian  
Chairpersons: Uri Seligsohn (IL) and Hatem Salem (AU)

Genome-wide association study identifies three new susceptibility loci for coronary artery disease in East Asian populations  
SY-TU-013
Jong-Young Lee (KR), Young-Ah Shin, Kwang Joong Kim, Dong-Jik Shin, Kyung Woo Park, Bok-So Lee, Mitsuhiro Yokota, Hiroyuki Asano, Masahiro Nakatoh, Tatsuaki Matubara, Hitotoshi Kitajima, Ken Yamamoto, Bok-Ghe Han, Yangsoo Jang, Hyo-Soo Kim, Jeong Euy Park, Lee Jong-Young  
13:30 – 14:00

Genome-wide association studies (GWAS) for hematological phenotypes, and possible application of the results to medicine and pharmacology  
SY-TU-014
Naoyuki Kamatani (JP)  
14:00 – 14:30

The genetic architecture of the pharmacological response to vitamin K antagonists  
SY-TU-015
Pieter H. Reitsma (NL)  
14:30 – 15:00

Platelet (Basic and Clinical)  
Annex Hall 2

Lysophospholipids in Platelets and Vasculature  
Chairpersons: Jonathan Gibbins (UK) and Heyu Ni (CA)

Metabolism of lysophospholipids in the blood  
SY-TU-016
Yutaka Yatomi (JP)  
13:30 – 14:00

Lysophospholipids in platelets and the vasculature  
SY-TU-017
Susan S. Smyth (US)  
14:00 – 14:30

Sphingosine - 1 - phosphate at the vascular/immune nexus  
SY-TU-018
Timothy Hla (US)  
14:30 – 15:00
Symposia 15:30-17:00

Thrombotic Disorders Main Hall

Atherothrombosis and Antithrombotic Therapy
Chairpersons: Philippe G. Steg (FR) and Hisao Ogawa (JP)

**Thrombosis or bleeding in patients with ventricle assist devices and impact on therapy**
*Barbara Zieger (DE)*
SY-TU-019 15:30 – 16:00

**Antiplatelet therapy in ACS: Will new therapeutic agents translate into better outcomes?**
*Ingo Ahrens (DE)*
SY-TU-020 16:00 – 16:30

**Clinical impact of aspirin "resistance" on the secondary prevention of atherothrombosis**
*Shigeki Miyata (JP), Akiko Kada, and Kazuyuki Nagatsuka, on behalf of the Study on Profile and GEnetic factors of Aspirin Resistance (ProGEAR study)*
SY-TU-021 16:30 – 17:00

Platelet (Basic and Clinical) Annex Hall 1

Platelet Proteomics and Gene Expression
Chairpersons: Yotis A. Senis (UK) and Mitsuru Murata (JP)

**Novel YxxL containing proteins in platelets**
*Steve P. Watson (UK), Yotis A. Senis*
SY-TU-022 15:30 – 16:00

**New functions of the dynamic platelet proteome**
*Andrew S. Weyrich (US)*
SY-TU-023 16:00 – 16:30

**Platelet microRNAs**
*Patrick Provost (CA)*
SY-TU-024 16:30 – 17:00

Fibrinolysis and Proteolysis Annex Hall 2

**t-PA Mediated Brain Injury**
Chairpersons: H. Roger Lijnen (BE) and Osamu Matsuo (JP)

**t-PA mediated brain injury: MMP-dependent and -independent mechanisms**
*Nobuo Nagai (JP), Yasuhiro Suzuki, Kazuo Umemura, Lijnen H. Roger*
SY-TU-025 15:30 – 16:00
Tuesday, July 26, 2011

Denatured proteins substitute for fibrin to promote t-PA activity in the brain
Robert L. Medcalf (AU), Maithili Sashindranath, Amanda Au, Rachael Jane Borg, Anja Knaupp, Stephen Bottomley, Andre Laval Samson 16:00 – 16:30

PDGF-dependent injury in the CNS
Daniel A. Lawrence (US) 16:30 – 17:00
<table>
<thead>
<tr>
<th>Session ID</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-TU-001</td>
<td>08:00 - 08:15</td>
<td>APOPIPOTEIN A-IV IS A NOVEL LIGAND OF PLATELET β3 INTEGRINS AND AN ENDOGENOUS INHIBITOR OF THROMBOSIS</td>
<td>Joseph W Jin* (CA), Christopher M Spring, Hong Yang, Adili Reheman, Yiming Wang, Sean Lang, Jina Song, Yan Yang, Marc Andrews, Guangheng Zhu, Pingguo Chen, Phil Connelly, W Sean Davidson, Patrick Tso, Yi-Min She, Terry Cyr, John Freedman, Heyu Ni</td>
</tr>
<tr>
<td>O-TU-002</td>
<td>08:15 - 08:30</td>
<td>APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) REGULATES IN VIVO THROMBOSIS BY REGULATING BOTH INSIDE-OUT AND OUTSIDE-IN SIGNALING THROUGH PLATELET INTEGRIN αIIβ3.</td>
<td>Meghna U Naik* (US), Hidinori Ichijo, Ulhas P Naik</td>
</tr>
<tr>
<td>O-TU-003</td>
<td>08:30 - 08:45</td>
<td>ANTITHROMBOTIC EFFECTS OF SELECTIVELY MODULATING TALIN-INTEGRIN INTERACTIONS IN PLATELETS</td>
<td>Brian G Petrich* (US), Jacob R. Haling, Susan J. Monkley, David R. Critchley</td>
</tr>
<tr>
<td>O-TU-004</td>
<td>08:45 - 09:00</td>
<td>α-ACTININ STABILIZES INTEGRINS TO A LOW-AFFINITY LIGAND-BINDING STATE IN RESTING PLATELETS.</td>
<td>Seiji Tadokoro* (JP), Tsuyoshi Nakazawa, Tsuyoshi Kamae, Kazunobu Kiyomizu, Hirokazu Kashihagi, Shigenori Honda, Yuzuru Kanakura, Yoshiaki Tomiyama</td>
</tr>
<tr>
<td>O-TU-005</td>
<td>09:00 - 09:15</td>
<td>INTEGRIN αIIβ3 ACTIVATION AND INTERNALIZATION IN PLATELETS OF SITOSTEROLEMIC MICE.</td>
<td>Taisuke Kanaji* (US), Sachiko Kanaji, Robert R Montgomery, Shalendira B Patel, Peter J Newman</td>
</tr>
<tr>
<td>O-TU-006</td>
<td>09:15 - 09:30</td>
<td>MITOCHONDRIALLY-MEDIATED PLATELET INTEGRIN αmβ3 INACTIVATION LIMITS PLATELET RECRUITMENT AND THROMBUS GROWTH</td>
<td>Fang Liu* (US), Graciela Gamez, Wayne Clemmons, Shawn M Jobe</td>
</tr>
</tbody>
</table>

**Fibrinogen and Other Factors I**

<table>
<thead>
<tr>
<th>Session ID</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-TU-007</td>
<td>08:00 - 08:15</td>
<td>THROMBIN GENERATION, WALL SHEAR RATE, AND GEOMETRY REGULATE FIBRIN ASSEMBLY UNDER FLOW</td>
<td>Keith Benjamin Neeves* (US), Damian A.R. Illing, Scott L Diamond</td>
</tr>
<tr>
<td>O-TU-008</td>
<td>08:15 - 08:30</td>
<td>EFFECTS OF TOTAL FIBRINOGEN AND FIBRINOGEN γ ON THROMBIN GENERATION AND ACTIVITY IN PLASMA</td>
<td>Elisabetta Castoldi* (NL), Shirley Uitte de Willige, Richard J. Dirven, Robert A.S. Ariens, Jan Rosing, Rogier M. Bertina</td>
</tr>
</tbody>
</table>
FIBRINOGEN γ' MODULATES CLOT STRUCTURE AND STIFFNESS THROUGH IMPAIRED PROTOFIBRIL FORMATION
Peter Allan* (UK), Shirley Uitte de Willige, Simon Connell, Robert Ariens

NOVEL REGULATORY SEQUENCES IN THE HUMAN FIBRINOGEN GENE CLUSTER
Richard J Fish* (CH), Alexandre Fort, Silja Vorjohann, Marguerite Neerman-Arbez

THE ASSOCIATION BETWEEN PLASMA FIBRINOGEN AND CORONARY HEART DISEASE IN A JAPANESE URBAN COHORT: THE SUITA STUDY
Yoshihiro Kokubo* (JP), Toshiyuki Miyata, Toshiyuki Sakata, Akira Okamoto, Makoto Watanabe, Yuu Ono, Mariko Banno, Yoshihiro Miyamoto

THE GENE MUTATIONS AND MECHANISMS OF FACTOR X DEFICIENCY IN THREE CHINESE FAMILIES
Qiong Chen* (CN), Jiawei Zhou, Qiutan Ding, Jing Dai, Xuefeng Wang, Hongli Wang

ENDOTHELIAL PROTEIN C RECEPTOR OVEREXPRESSION PROTECTS MICE AGAINST ALLERGIC LUNG INFLAMMATION IN AN ASTHMA MODEL WITH INTRANASAL INOCULATION OF HOUSE DUST MITE EXTRACT.
Johannes Daan De Boer* (NL), C Van t Veer, FE Van den Boogaard, LM Kager, JUTH Roelofs, JS Van der Zee, CT Esmon, T Van der Poll

P-SELECTIN INHIBITION WITH AN ANTI P-SELECTIN APTAMER, ARCS692, THERAPEUTICALLY PROMOTES THROMBUS RESOLUTION
Jose Antonio Diaz* (US), Christine M Alvarado, Shirley K Wrobleski, Angela E Hawley, Nichole Baker, Patrick Lester, Frank J Londy, Peter K Henke, Robert G Schaub, Thomas W Wakefield, Daniel D Myers

FACTOR-VII ACTIVATING PROTEASE (FSAP) ACTIVATION IN HUMAN INFLAMMATION: A SENSOR FOR CELL DEATH
Femke Steffan* (NL), Ingrid Bulder, Jan Hazelzet, Marja Boermeester, Olivier van Till, Tom van der Poll, Walter Wullemien, Lucien Aarden, Sacha Zeerleder

PROTECTIVE ROLE OF ANTITHROMBIN IN MOUSE MODELS OF LIVER INJURY: POSSIBLE IMPLICATION OF THIS SERPIN IN APOPTOSIS
Jose Antonio Guerrero* (ES), Raul Teruel, Javier Corral, Isabel Arcas, Antonia Minano, Nuria Garcia-Barbera, Irene Martinez-Martinez, Vicente Vicente, Constantino Martinez
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-017  09:00 - 09:15
TICK SALIVARY PROTEIN P23 INHIBITS COAGULATION BY POSTPONING FACTOR V ACTIVATION AND PLAYS A CRUCIAL ROLE IN TICK FEEDING
Cornelis van ’t Veer* (NL), Kamran Bakhtiari, Erol Fikrig, Sirlei Daffre, Tom van der Poll, Kathleen DePonte, Sukanya Narasimhan, Joost Meijers, Tim Schuijt

O-TU-018  09:15 - 09:30
ROLE OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY
Masahiro Naito* (JP), Osamu Taguchi, Takehiro Takagi, Masaaki Toda, Tetsu Kobayashi, Yasushi Miyake, Daniell Boveda Ruiz, Corina N. D’Alessandro-Gabazza, John Morser, Yoshiyuki Takei, Esteban C. Gabazza

Heparin-induced Thrombocytopenia  Room E

Chairpersons: Yves Gruel (FR) and Beng Chong (AU)

O-TU-019  08:00 - 08:15
INDUCTION OF TISSUE FACTOR EXPRESSION IN MONOCYTES BY THE PLATELET FACTOR 4/HEPARIN ANTIBODY COMPLEX IS MEDIATED BY MEK1 AND PERK1/2
Raj S Kasthuri* (US), Sam L Glover, Jonas William, Rafal Pawlinski, Gowthami M Arepally, Nigel S Key, Nigel Mackman

O-TU-020  08:15 - 08:30
ASSOCIATION OF NATURAL ANTI-PLATELET FACTOR 4/HEPARIN ANTIBODIES WITH PERIODONTAL DISEASE
Andreas Greinacher* (DE), Birte Holtfreter, Krystin Krauel, Daniela Gaetke, Claudia Weber, Till Ittermann, Sven Hammerschmidt, Thomas Kocher

O-TU-021  08:30 - 08:45
FLUCTUATIONS IN THE PREVALENCE OF HIT ANTIBODIES DURING THE PERIOD 2004-2011. RELEVANCE TO HEPARIN CONTAMINANTS.
Jawed Fareed* (US), Cafer Adiguzel, Debra Hoppensteadt, Walter Jeske, Jeanine Walenga, Vinod Bansal

O-TU-022  08:45 - 09:00
ANTI-PROTAMINE SULPHATE/PF4 ANTIBODIES CAN ACTIVATE PLATELETS AND MAY CAUSE THROMBOCYTOPENIA IN PATIENTS UNDERGOING CARDIAC SURGERY
Tamam Bakchoul* (DE), Astrid Giptner, Annika Krautwurst, Gregor Bein, Sentot Santos, Jean Amiral, Ulrich J Sachs

O-TU-023  09:00 - 09:15
SEROCONVERSION OF ANTI-PF4/HEPARIN ANTIBODIES AND ITS ASSOCIATION WITH DEEP VEIN THROMBOSIS IN ORTHOPEDIC SURGERY PATIENTS RECEIVING VARIOUS THROMBOPROPHYLAXIS METHODS
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-024  09:15 - 09:30
FONDAPARINUX TREATMENT OF ACUTE HEPARIN-INDUCED
THROMBOCYTOPENIA (HIT) CONFIRMED BY A POSITIVE
SEROTONIN-RELEASE ASSAY (SRA+).
Theodore Earl Warkentin* (CA), Menaka Pai, Sam Schulman,
Alex C. Spyropoulos, John W. Eikelboom

Hemophilia: Treatment
Chairpersons: Georges E Rivard and Steven Pipe (US)

O-TU-025  08:00 - 08:15
RECOMBINANT FVIIIFC FUSION PROTEIN RETAINS NORMAL
BIOCHEMICAL PROCOAGULANT ATTRIBUTES.
Garabet G. Toby* (US), Stacie Seidel, Robert T. Peters

O-TU-026  08:15 - 08:30
ENHANCED PHARMACOKINETICS OF FACTOR VIIA AS A
MONOMERIC FC FUSION
Joe Salas* (US), Tongyao Liu, Elena Kistanova, Tamera Ashworth,
Mark Stein, Ruchita Patel, George Kamphaus, Amy Correia, Alan Bitonti,
Susan Dallabrida, Haiyan Jiang, Robert Peters

O-TU-027  08:30 - 08:45
STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A
RECOMBINANT FVIIA DRUG CANDIDATE
Peter L Turecek* (AT), Katalin Varadi, Susanne Vejda, Ernst Boehm,
Hanspeter Rottensteiner, Hans Peter Schwarz, Manfred Reiter,
Artur Mitterer, Wolfgang Mundt, Hartmut J Ehrlich, Friedrich Schellinger

O-TU-028  08:45 - 09:00
INHIBITION OF TISSUE FACTOR INHIBITOR BY ARC19499 (BAX499)
IMPROVES EX VIVO CLOTTING IN HEMOPHILIA PATIENTS
Monika Gorczyca (AT), Christoph Maile, Ingrid Pabinger, Sylvia Reitter,
Paul Knoebel, Kathleen E McGinness, Robert G Schaub, Bernd Jilma*

O-TU-029  09:00 - 09:15
MHC CLASS II-PRESENTED PEPTIDE REPERTOIRES DERIVED
FROM HUMAN ANTIGEN-PRESENTING CELLS PULSED WITH BLOOD
COAGULATION FACTOR VIII.
Simon Daniel van Haren* (NL), Eszter Herczenik, Anja ten Brinke,
Koen Mertens, Alexander Meijer, Jan Voorberg

O-TU-030  09:15 - 09:30
RED CELL DERIVED MICROPARTICLES (RMP) AS HEMOSTATIC
AGENT TO TREAT BLEEDING DISORDERS: THE MODE OF ACTION OF
RMP
Yeon S Ahn* (US), Wenche Jy, Max Johansen, Laurence L Horstman
## ORAL COMMUNICATIONS

### Pregnancy and Thrombosis I

**Room A**

**Chairpersons: Ariella Zivelin and Howard Liebman (US)**

**O-TU-031 08:00 - 08:15**

**COMPARATIVE OBSERVATIONAL STUDY OF THE THROMBOTIC RISK IN WOMEN WITH AN OBSTETRICAL ANTIPHOSPHOLIPID SYNDROME REVEALED BY PREGNANCY LOSS. THE NOH-APS STUDY.**

Jean-Christophe Raymond Gris* (FR), Erick Mercier, Eva Cochery-Nouvellon, Jean-Pierre Balducchi, Pierre Mares, Isabelle Quere, Michel Dauzat

**O-TU-032 08:15 - 08:30**

**LOW-DOSE ASPIRIN FOR IN VITRO FERTILIZATION: A SYSTEMATIC**

Francesco Dentali* (IT), Walter Ageno, Emanuele Rezzaogli, Elena Rancan, Alessandro Squizzato, Maurizio Margaglione, Elvira Grandone

**O-TU-033 08:30 - 08:45**

**MENORRHAGIA AND HEALTH-RELATED QUALITY OF LIFE IN WOMEN TREATED WITH ORAL ANTICOAGULANTS**

Emma Stromdahl (SE), Petra Elvinge, Eva Johansson, Mans Edlund, Margareta Holmstrom*

**O-TU-034 08:45 - 09:00**

**LONG-TERM QUALITY OF LIFE AFTER PREGNANCY RELATED DEEP VEIN THROMBOSIS AND INFLUENCE OF SOCIOECONOMIC FACTORS AND COMORBIDITY**

Hilde Skuterud Wik* (NO), Tone Enden, Anne Flem Jacobsen, Per Morten Sandset

**O-TU-035 09:00 - 09:15**

**HEPARANASE PROCOAGULANT ACTIVITY IS ELEVATED IN WOMEN TAKING ORAL CONTRACEPTIVES**

Matan Moshe (IL), Elena Axelman, Benjamin Brenner, Yona Nadir*

**O-TU-036 09:15 - 09:30**

**THROMBOPHILIA, FAMILY HISTORY OF VTE, AND PROGNOSIS OF LIVE BIRTH IN WOMEN WITH RECURRENT MISCARRIAGE**

Paulien G de Jong* (NL), Stef P Kaandorp, Mariette Goddijn, Barbara A Hutten, Saskia Middeldorp

### VTE: Basic

**Room B-1**

**Chairpersons: Iris Mueller (UK) and Naveen Manchanda**

**O-TU-037 08:00 - 08:15**

**RETROSPECTIVE SURVEY OF HEMOSTATIC COMPLICATIONS IN 478 PATIENTS UNDERGOING HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)**

Yue Han* (CN), Depei Wu, Luping Hu, Xia Bai, Wei Zhang, Lili Zhou, Aining Sun, Zhaoyue Wang, Changgeng Ruan

**O-TU-038 08:15 - 08:30**

**POTENTIAL ROLE FOR LEPTIN AND OTHER INFLAMMATORY CYTOKINES IN BEVACIZUMAB-INDUCED HYPERCOAGULABILITY.**

Gregory Clayton Connolly* (US), Charles W Francis, Brian H Smith, Nigel Mackman, Mark B Taubman, Alok A Khorana
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-039 08:30 - 08:45
ASSOCIATION OF FACTOR XIA WITH INTRAVENOUS IMMUNE GLOBULIN PRODUCTS IMPLICATED IN THROMBOTIC ADVERSE EVENTS: BIOCHEMICAL ROOT CAUSE INVESTIGATION
Mikhail V Ovanesov* (US), Alexey M Shibeko, Samuel A Woodle, Christine M Anderson, John Hogwood, Helen Barson, Elaine Gray, Dorothy Scott

O-TU-040 08:45 - 09:00
CIRCULATING MICROPARTICLES IN CARRIERS OF FACTOR V LEIDEN MUTATION.
Elena Campello (IT), Luca Spiezia, Claudia Radu, Andrea Ballin, Patrizia Zerbinati, Sabrina Gavasso, Barry Woodhams*, Daniela Tormene, Paolo Simioni

O-TU-041 09:00 - 09:15
AN IMPAIRED PROTEIN S/TFPI PATHWAY IS A STRONG AND INDEPENDENT RISK FACTOR FOR RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH FIRST UNPROVOKED DEEP VEIN THROMBOSIS
Kristien Winckers* (NL), Arina J ten Cate-Hoek, Kim C.M.M. Beekers, Petra Erkens, Karly Hamulyak, Hugo ten Cate, Tilman M Hackeng

O-TU-042 09:15 - 09:30
GENETIC VARIANTS OF F11, STATIN USE AND VENOUS THROMBOSIS IN MEGA
Lance A Bare* (US), Andre R Arrellano, Carmen H Tong, Irene D Bezemer, Willem M Lijfering, James J Devlin, Pieter H Reitsma, Frits R Rosendaal

Hemostatic Abnormalities in Thrombosis Room B-2
Chairpersons: Flora Peyvandi (IT) and YOSHIO UETSUKA (JP)

O-TU-043 08:00 - 08:15
THE EFFECT OF THERAPEUTIC ANTICOAGULATION ON THE RISK OF TRAUMATIC LUMBAR PUNCTURES IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Leonardo Rodrigues Brandao* (CA), Laura M. Avila, Furqan Shaik, McCartney Christine, Suzan Williams

O-TU-044 08:15 - 08:30
DEEP VEIN THROMBOSIS: A UNITED STATES COST MODEL FOR A PREVENTABLE AND COSTLY ADVERSE EVENT
Charles Mahan* (US), Mark T Holdsworth, Shawn M Welch, Matt E Borrego, Alex C Spyropoulos

O-TU-045 08:30 - 08:45
IS MAINTENANCE OF ORAL ANTICOAGULANT THERAPY FOR CATHETER ABLATION OF TYPICAL ATRIAL FLUTTER ASSOCIATED WITH LESS BLEEDING AND THROMBOEMBOLIC COMPLICATIONS?
Romain Didier (FR), Gregoire Le Gal*, Jean-Christophe Cornily, Yves Etienne, Marjaneh Fatemi

O-TU-046 08:45 - 09:00
PEDIATRIC INFECTIVE ENDOCARDITIS OVER THE LAST 30 YEARS: THROMBOEMBOLIC COMPLICATIONS AND ASSOCIATIONS OF VEGETATION AND HEART FAILURE WITH MORTALITY
Katharina Ellen Thom* (AT), Ponny Sivaprakasam, Jennifer L. Russel, Suzan Williams, Upton Allen, Leonardo R. Brandao
SHIGA TOXIN UPREGULATES TISSUE FACTOR GENE EXPRESSION IN ENDOTHELUM WHILE REDUCING SECRETION AND CELL-SURFACE ASSOCIATION OF TISSUE FACTOR PATHWAY INHIBITOR
Eric Franklin Grabowski* (US), Ming Cheung, Amy Skaria, Rafail I. Kushak, Julie R. Ingelfinger

HEPARIN-INDUCED-THROMBOCYTOPENIA IN CHILDREN: A SYSTEMATIC REVIEW IDENTIFYING LITERATURE GAPS AND PITFALLS
Leonardo Rodrigues Brandao* (CA), Vibhuti Shah, Maria L. Avila

METHODOLOGICAL DEVELOPMENT OF A CLONOGENIC ASSAY TO DETERMINE ENDOTHELIAL PROGENITOR CELL POTENTIAL
Haruchika Masuda* (JP), Tomoko Shizuno, Toshiya Ishihara, Shunichi Kato, Takayuki Asahara

CLEAVED HIGH MOLECULAR WEIGHT KININOGEN ACCELERATES THE ONSET OF ENDOTHELIAL PROGENITOR CELL SENESCENCE IN VITRO AND IN VIVO
Jihong Dai* (CN), Xuemei Zhu, Mervin C. Yoder, Robert W. Colman, Yi Wu

ABSENCE OF CIRCULATING CD34+ ANGIogenic MONOCYTE PROGENITORS AFTER ALLOGeneIC AORTic TRANSPLANTATION STRONGLY CORRELATES WITH VASCULAR REPAIR OF ALLOimmune DAMAGE.
Daxin Chen* (UK), Li El Tham, John H McVey, Anthony Dorling

AUGMENTING THE HOMING OF PROGENITOR CELLS WITH BISPECIFIC SINGLE CHAIN ANTIBODIES TARGETING SCA-1 AND THE ACTIVATED GPIIb/IIIa RECEPTOR ON PLATELETS.
Ingo Ahrens* (DE), Christoph Hagemeyer, Franco Klingberg, Ephraem Leitner, Kati Viitaniemi, Fu Jia, Nicole Bassler, Christoph Bode, Karlheinz Peter

TWO DISTINCT SUBPOPULATIONS OF ADULT HUMAN CARDIAC STEM CELLS CONTRIBUTE TO THE THERAPEUTIC REGENERATION OF THE FAILING HEART
Toru Hosoda* (US)

MESENCHYMAL STEM CELLS POTENTIATE ANGIogenic ACTIVITY OF ENDOTHELIAL PROGENITOR CELLS THROUGH UP-REGULATION OF SPHK-1/S1P PATHWAY
Florence Sabatier* (FR), Stephane Poitevin, Gabrielle Sarlon-Bartoli, Virginie Albinet, Nathalie Andrieu-Abadie, Daniel Cussac, Angelo Parini, Francoise Dignat-George
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

Serine Protease Inhibitors I

Chairpersons: J. O. and Hiroyuki Takeya

O-TU-055  13:30 - 13:45
HUMAN ANTIPLASMIN-PLASMIN INTERACTION: A COMPREHENSIVE STUDY OF THE ANTIPLASMIN C-TERMINUS REGION USING SURFACE PLASMON RESONANCE
Bernadine G C Lu* (AU), Trifina Sofian, Ruby H P Law, Paul B Coughlin, Anila J Horvath

O-TU-056  13:45 - 14:00
MECHANISM OF INHIBITION OF THE PROTHROMBINASE COMPLEX BY A COVALENT ANTITHROMBIN-HEPARIN CONJUGATE
Ivan Stevic* (CA), Leslie R Berry, Anthony K.C. Chan

O-TU-057  14:00 - 14:15
WHEN ASSEMBLED INTO THEIR RESPECTIVE ACTIVATION COMPLEXES, FACTORS XA, IXA, AND VIIA ARE DIFFERENTIALLY PROTECTED FROM INHIBITION BY THE ANTITHROMBIN/HEPARIN COMPLEX.
Calvin H Yeh* (CA), Hashem Alshurafa, James C Fredenburgh, Alan R Stafford, Paul Y Kim, Jeffrey I Weitz

O-TU-058  14:15 - 14:30
INDIVIDUAL ANTICOAGULANT APTAMERS UNIQUELY IMPAIR THROMBIN GENERATION AND HAVE A SYNERGISTIC EFFECT WHEN USED IN COMBINATION
Kristin Marie Bompiani* (US), Jens Lorhmann, James Frederiksen, Bruce A. Sullenger

O-TU-059  14:30 - 14:45
PROTEIN C INHIBITOR (PCI) INTERACTS WITH PHOSPHOINOSITIDES AND MIGHT AFFECT LIPID SIGNALING.
Felix Wahlmueller* (AT), Barbora Sokolikova, Daniela Rieger, Margarethe Geiger

O-TU-060  14:45 - 15:00
β-ISOFORM OF ANTITHROMBIN COMPENSATES THE EFFECT OF THE MUTATION IN TYPE II DEFICIENCIES WITH HEPARIN BINDING DEFECT.
Irene Martinez-Martinez* (ES), Jose Navarro-Fernandez, Alice Ostergaard, Ricardo Gutierrez-Gallego, Jose Padilla, Nataliya Bohdan, Antonia Minano, Cristina Pascual, Constantino Martinez, Maria Eugenia de la Morena-Barrio, Sonia Aguila, Shonia Pedersen, Soren Risom Kristensen, Vicente Vicente, Javier Corral

Coagulation Factors: Experimental Models I

Chairpersons: Katherine High (US) and Ming Shen (TW)

O-TU-061  13:30 - 13:45
MEASURING THROMBIN GENERATION IN A HETEROGENEOUS SYSTEM AS A FUNCTION OF SPACE AND TIME: A NOVEL APPROACH FOR BASIC AND APPLIED COAGULATION RESEARCH
Natalia M Dashkevich* (RU), Mikhail V Ovanesov, Mikhail A Panteleev, Fazoil I Ataullakhanov
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-062  13:45 - 14:00
SPATIAL AND TEMPORAL LOCALIZATION OF SITE-SPECIFICALLY LABELED COAGULATION FACTORS IN THE DEVELOPING THROMBUS IN VIVO
Lacramioara Ivanciu* (US), Sriram Krishnaswamy, Rodney M Camire

O-TU-063  14:00 - 14:15
EFFICACY AND POTENTIAL SYSTEMIC COAGULATION BIOMARKERS IN A JOINT INJURY MODEL OF HEMA MICE COMPARING BAY 86-6150 (A MODIFIED HUMAN RFVIIA) TO EPTACOG ALFA [ACTIVATED] OR APCC
Maria Koellnberger* (US), Cristina Loomis, Perry Liu, Jian-Ming Gu, Ji-Yun Kim, Inge A. Ivens, Corneli Mallari, Derek S. Sim, John E. Murphy, Jesper Haaning

O-TU-064  14:15 - 14:30
EFFECTS OF RECOMBINANT FVIII IN A VENOUS BLEEDING MODEL IN HAEMOPHILIA A MICE
Brian Lauritzen* (DK), Anne Engedahl Pastoft, Mirella Ezban, Mikael Tranholm, Jens Lykkefeldt

O-TU-065  14:30 - 14:45
IL2/IL2 MAB COMPLEXES INDUCE IN VIVO EXPANSION OF TREG CELLS AND PREVENT ANTI-FVIII ANTIBODY PRODUCTION FOLLOWING FVIII PROTEIN REPLACEMENT THERAPY IN HEMOPHILIA A MICE
Chao-Lien Liu* (US), Peiqing Ye, Jacqueline Lin, Carol H. Miao

O-TU-066  14:45 - 15:00
IMMUNE RESPONSE VERSUS TOLERANCE TO FVIII - A NEW APPROACH TO ANSWER BURNING QUESTIONS IN HEMOPHILIA A
Katharina Nora Steinitz* (AT), Paula Maria van Helden, Brigitte Binder, Ahmad Uddin Rafi, Markus Weiller, Maurus de la Rosa, Hans-Peter Schwarz, Birgit Maria Reipert

Immune Thrombocytopenia
Room E

Chairpersons: Yoshitaka Miyakawa (JP) and

O-TU-067  13:30 - 13:45
MESENCHYMAL STEM CELL-MODULATED DENDRITIC CELLS INDUCE PLATELET-SPECIFIC T CELLS ANERGY IN A KLF10-DEPENDENT MANNER IN PRIMARY THROMBOCYTOPENIC PURPURA
Xinguang Liu* (CN), Ji Ma, Lin Sun, Ming Hou, Jun Peng

O-TU-068  13:45 - 14:00
EMERGENCE OF POLYCLONAL AUTOANTIBODY RESPONSES TO MULTIPLE PLATELET SURFACE GLYCOPROTEINS IN REGULATORY T CELL-DIFFICIENT MICE WITH IMMUNE THROMBOCYTOPENIA
Tetsuya Nishimoto* (JP), Takashi Satoh, Elisa Simpson, Heyu Ni, Tsutomu Takeuchi, Masataka Kuwana

O-TU-069  14:00 - 14:15
GP IIb/IIIa-DEPENDENT COMPLEMENT ACTIVATION IS A COMMON FINDING IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA AND DEPENDENS ON ANTIBODY-GLYCOSYLATION STATUS
Tamam Bakchoul* (DE), Abdullrahim Najaoui, Annika Krautwurst, Katrin Walek, Gregor Bein, Sentot Santoso, Ulrich Sachs
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-070  14:15 - 14:30
MICRO RNA ANALYSIS IN IMMUNE THROMBOCYTOPENIC PURPURA
Huiyuan Li* (CN), Haifeng Zhao, Weiting Du, Renchi Yang

O-TU-071  14:30 - 14:45
LOW-AVIDITY ANTI-HPA-1A ALLOANTIBODIES ARE CAPABLE OF
ANTIGEN-POSITIVE PLATELET DESTRUCTION IN THE NOD/SCID
MOUSE MODEL OF ALLOIMMUNE THROMBOCYTOPENIA
Tamam Bakchoul* (DE), Sebastian Kubrak, Annika Krauthwurz,
Gregor Bein, Ulrich Sachs, Sentol Santoso

O-TU-072  14:45 - 15:00
ANTI HPA-1A ALLOIMMUNIZATION AND PREGNANCY: PREDICTION
OF THE FETAL STATUS AND RESPONSE TO IVIG THERAPY
Gerald Bertrand* (FR), Corinne Martageix, Moustapha Drame,
Cecile Kaplan

Hemophilia: Innovative Therapy I  Sakura

O-TU-073  13:30 - 13:45
PHARMACOKINETICS AND SAFETY OF RECOMBINANT FACTOR
VIII FC FUSION PROTEIN (RFVIIIIFC) IN A PHASE 1/2A TRIAL IN
PREVIOUSLY TREATED PATIENTS (PTPS) WITH SEVERE HEMOPHILIA
A
Jerry Powell* (US), N C Josephson, D Quon, M V Ragni, G Cheng,
B McKinney, Haiyan Jiang, Lian Li, Jennifer Dumont, Jaya Goyal,
Jurg Sommer, Alvin Luk, Glenn F Pierce

O-TU-074  13:45 - 14:00
SAFETY AND PHARMACOKINETIC PROPERTIES OF
GLYCOPEGYLATED RECOMBINANT FACTOR IX: A FIRST HUMAN
DOSE TRIAL IN PATIENTS WITH HAEMOPHILIA B
Claude Negrier* (FR), Karin Knobe, Andreas Tiede, Paul Giangrande,
Judi Moss

O-TU-075  14:00 - 14:15
SYNTHETIC PEPTIDES DISCOVERED BY PHAGE DISPLAY ENHANCE
THE ACTIVITY OF HFIXA IN FUNCTIONAL COAGULATION ASSAYS.
Karina Thorn* (US), Garo Toby, Ku-chuan Hsiao, Stacie Seidel,
Ryan Donnelly, Swapnil Rakhe, Cara Fraley, Alan Bitonti, Robert Peters,
Adam Mezo

O-TU-076  14:15 - 14:30
APTAMER BAX499, A POTENT AND SPECIFIC INHIBITOR OF TFPI,
CORRECTS HEMOSTASIS PARAMETERS OF HEMOPHILIC BLOOD
Shenbagapriya P* (IN), Nair Sukesh Chandran, Devadarshini Mercy,
Abraham Aby, Mathews Vikram, Srivastava Alok

O-TU-077  14:30 - 14:45
SOLULIN INCREASES CLOT STABILITY IN WHOLE BLOOD FROM
INDIVIDUALS WITH HEMOPHILIA A OR B
Jonathan H Foley* (US), Catherine J Rea, Karl Uwe Petersen,
Michael E Nesheim, Benny Sorensen
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-078  TARGETING FACTOR VIIA TO PLATELET RECEPTORS RESULTS IN ENHANCED ACTIVITY
Joe Salas* (US), Tamera Ashworth, Elena Kistanova, Ruchita Patel, Paul Sakorafas, Bob Pape, Adam Mezo, Susan Dallabrida, Haiyan Jiang, Robert Peters

Anticoagulation Therapy  Room A

Chairpersons: Masahiro Yasaka (JP) and Nicholas Smith (US)

O-TU-079  ADHERENCE TO 2008 ACCP GUIDELINES FOR PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION RESULTS IN DECREASED BLEEDING COMPLICATIONS: A SINGLE CENTER EXPERIENCE
Maria T DeSancho* (US), John Chapin, Svetoslava Bardarova

O-TU-080  MAJOR BLEEDING DURING VITAMIN K ANTAGONIST TREATMENT: THE INFLUENCE OF THYROID HORMONE
Jan Debeij* (NL), Suzanne C Cannegieter, Bregje van Zaane, Anton PS van Zanten, Frits R Rosendaal, Victor EA Gerdes, Pieter H Reitsma, Olaf M Dekkers

O-TU-081  VITAMIN K ANTAGONIST THERAPY (VKA): EMPOWERMENT; EDMONTON PEDIATRIC WARFARIN SELF-MANAGEMENT
Mary Elisabeth Bauman* (CA), Aisha Bruce, Satvinder Kaur, Michelle Bauman, M Patricia Massicotte

O-TU-082  INTER-INDIVIDUAL VARIABILITY IN WARFARIN DOSE REQUIREMENT IN CHILDREN CAN BE EXPLAINED BY VKORC1 AND CYP2C9 GENOTYPE AND PATIENT CHARACTERISTICS
Tina T Biss* (UK), Peter J Avery, Leonardo R Brandao, Elizabeth A Chalmers, Michael D Williams, John D Grainger, Julian BS Leathart, John P Hanley, Ann K Daly, Farhad Kamali

O-TU-083  PATIENT SELF MANAGEMENT OF WARFARIN: MEASUREMENT OF QUALITY OF LIFE IN CHILDREN/FAMILIES
Aiko MD Bruce* (CA), M Patricia Massicotte, Mary Bauman

O-TU-084  PHARMACOGENETIC EXPERT DOSING STRATEGIES (PEDS) FOR WARFARIN
Lisa Bomgaard* (US), M P Massicotte, Courtney Thornburg, Leslie Raffini, Shannon Saldana, Eve Surcobe, Mary Bauman, Emma Jones, Alexander Vinks, Brian Gage
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

Diagnosis and Treatment for VWD and TTP Room B-1

Chairpersons: \( \ddagger \) \( \ddagger \) and Johanna Kremer Hovinga (CH)

O-TU-085  13:30 - 13:45
IN VIVO CHARACTERIZATION OF THE ANTI-THROMBOTIC EFFECT OF ANTIBODIES INHIBITING BINDING OF VON WILLEBRAND FACTOR TO COLLAGENS OR TO PLATELET GLYCOPEPTIDE IIBIIIA
Cecile V Denis* (FR), Ana-Maria Navarrete, Isabelle Marx, Peter J Lenting, Olivier D Christophe, Cecile V Denis

O-TU-086  13:45 - 14:00
RECOMBINANT HUMAN VON WILLEBRAND FACTOR-PLASMA FREE MANUFACTURED: FIRST-IN-HUMAN STUDY EVALUATING PHARMACOKINETICS, DEMONSTRATING SAFETY AND TOLERABILITY IN SEVERE VWD
Piero M Mannucci (IT), Christine L Kempton, Michael A Laffan, Edward H Romond, Amy Shapiro, Ingvild Birschmann, Margaret V Ragni, Joan C Gill, Thynn Thynn Yee, Robert Klamroth, Sandor Fritsch, Peter L Turecek, Bruce M Ewenstein, Tobias M Suter*, Baxter BioScience rVWF Study Team

O-TU-087  14:00 - 14:15
FIRST ASSAY TO ACCURATELY DETERMINE ADAMTS13-VWF COMPLEXES IN PLASMA
Hendrik B Feys* (BE), Aaron Peace, Emanuele Barbato, Hans Deckmyn, Jozef Bartunek, Karen Vanhoorelbeke

O-TU-088  14:15 - 14:30
A NOVEL ASSAY SPECIFICALLY DETECTING VON WILLEBRAND FACTOR (VWF) CLEAVED IN THE A2 DOMAIN - INCREASED CLEAVED VWF IN RESPONSE TO ENDOTHELIAL PERTURBATION IN HEALTH AND DISEASE
Ester C Lowenberg* (NL), Bert-Jan H van den Born, Marcel Levi, Philip G de Groot, J A Lisman, Frank W Leebeek, Jeroen Eikenboom, Rob Fijnheer, Rosemarijn Renckens, Eva de Wee, Joost CM Meijers

O-TU-089  14:30 - 14:45
IDENTIFICATION OF A SMALL MOLECULE THAT MODULATES THE VON WILLEBRAND FACTOR - PLATELET GLYCOPEPTIDE IB INTERACTION
Katleen Broos* (BE), Mieke Treckels, Jonas Demeulemeester, Rani A Jose, Wim De Borggraeve, Marc De Maeyer, Karen Vanhoorelbeke, Hans Deckmyn

O-TU-090  14:45 - 15:00
THE ANTITHROMBOTIC EFFECT OF THE FUCOIDAN OF LESSONIA VADOVA: A STRONG INHIBITOR OF THE PLATELET GLYCOPEPTIDE IB RECEPTOR - VON WILLEBRAND FACTOR INTERACTION
Katleen Broos* (BE), Wim De Borggraeve, Aline Vandenbulcke, Nele Vandeputte, Karen De Ceunynck, Nancy P Chandra, Betty Y Matsuhiro, Karen Vanhoorelbeke, Hans Deckmyn
## ORAL COMMUNICATIONS

### Tuesday, July 26, 2011

### Antiphospholipid Syndrome: Basic  
**Room B-2**

**Chairpersons:** Vittorio Peng and Eiji Matsuura (JP)

**O-TU-091  13:30 - 13:45**

*C5 INHIBITOR REV576 AMELIORATES IN VIVO EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES.*

Ana Laura Carrera-Marin (US), Ana Laura Carrera-Marin, Zurina Romay-Penabad, Wynne Weston-Davis, Samuel Machin, Hannah Cohen, Silvia S Pierangeli*

**O-TU-092  13:45 - 14:00**

*C6-DEFICIENT MICE ARE PROTECTED FROM THE PATHOGENIC EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES.*

Ana Laura Carrera-Marin (US), Zurina Romay-Penabad, Renan Aguilar-Valenzuela, Silvia S Pierangeli*

**O-TU-093  14:00 - 14:15**

*ANTI-DOMAIN I ANTIBODIES HAVE A PROTHROMBOTIC CHARACTER ON COAGULATION BY INHIBITING THE ANTICOAGULANT EFFECT OF BETA2GPI*

Bas de Laat* (NL), Gwen van Os, Marisa Ninivaggi, Cetin Agar, Philip de Groot, Coen Hemker, Theo Lindhout, Joost Meijers

**O-TU-094  14:15 - 14:30**

*MIR-19B AND MIR-20A AS REGULATORS OF TISSUE FACTOR EXPRESSION IN MONOCYTES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME*

Raul Teruel* (ES), Carlos Perez-Sanchez, Javier Corral, Maria Teresa Herranz, Virginia Perez-Andreu, Encarnacion Saiz, Nuria Garcia-Barbera, Jesus Lozano, Irene Martinez-Martinez, Vesna Roldan, Vicente Vicente, Chari Lopez-Pedrera, Constantino Martinez

**O-TU-095  14:30 - 14:45**

*ROLE FOR TOLL-LIKE RECEPTOR 2 AND CD14 IN THE ACTIVATION OF HUMAN MONOCYTES AND ENDOTHELIAL CELLS BY ANTIPHOSPHOLIPID ANTIBODIES*

Nathalie Satta (CH), Egbert KO Kruithof*, Celine Fickentscher, Sylvie Dunoyer-Geindre, Francoise Boehlen, Guido Reber, Daniellle Burger, Philippe de Moerloose

**O-TU-096  14:45 - 15:00**

*CD39 OVER EXPRESSION PROTECTS IN A MURINE MODEL OF ANTIPHOSPHOLIPID ANTIBODY-INDUCED MISCARRIAGES*

Harshal Nandurkar* (AU), Anushka Samudra, Anup Sharma, Xiang-Ming Zhang, Carly Selan, Karen Dwyer, Anthony d’Apice, Peter Cowan

### Platelets: Experimental Models  
**Room C-1**

**Chairpersons:** S. Massberg and Lawrence Brass (US)

**O-TU-097  15:30 - 15:45**

*CALDAG-GEFII IN THROMBOSIS AND HEMOSTASIS*

Stolla Moritz* (US), Lucia Stefanini, R. Claire Roden, Massiel Chavez, Jessica Hirsch, Tesheli Greene, Timothy D. Ouellette, Michael P. Reilly, Steven E. McKenzie, Mortimer Poncz, Donna S. Wouffe, Wolfgang Bergmeier
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-098  15:45 - 16:00
SELECTIVE BLOCKADE OF THE A1 DOMAIN OF VON WILLEBRAND FACTOR (VWF), PREVENTS ISCHEMIC STROKE IN THE GUINEA PIG: COMPARISON WITH THE THROMBOLYTIC RTPA.
Stefania Momi* (IT), Michela Tantucci, Maarten Van Roy, Hans Ulrichts, Josephin Holz, Paolo Gresele

O-TU-099  16:00 - 16:15
ACTIVATED FACTOR XII ENHANCES THROMBUS FORMATION INDEPENDENT OF ITS ROLE IN COAGULATION
Coen Maas* (NL), Rolf T Urbanus, Sabine C den Hartogh, Cees Weeterings, S AE Sebastian, Philip G de Groot

O-TU-100  16:15 - 16:30
IMPORTANCE OF THROMBIN-ACTIVATION OF PLATELETS IN REGULATING LEUKOCYTE RECRUITMENT TO SITES OF VASCULAR INJURY
Zane Kaplan* (AU), Mehran Ghasemzadeh, Imala Alwis, Yuping Yuan, Erik Westein, Shaun P. Jackson

O-TU-101  16:30 - 16:45
ENOS INDEPENDENT PLATELET INHIBITION BY ATORVASTATIN
Ran Ni* (CA), Tal Peleg, Peter L Gross

O-TU-102  16:45 - 17:00
INVERSE ROLE OF PULSATILE BLOOD FLOW ON THROMBUS GROWTH UNDER PHYSIOLOGICAL AND DISTURBED RHEOLOGICAL CONDITIONS
Pierre Mangin* (FR), Eric Maurer, Mathieu Schaff, Jean-Pierre Cazenave, Christian Gachet, Francois Lanza, Pierre H Mangin

Plasminogen Activation System: Basic  Room C-2

Chairpersons: Taiichiro Seki (JP) and Colin Longstaff (UK)

O-TU-103  15:30 - 15:45
A NEW PAI-1 INHIBITOR AND ITS CRYSTAL STRUCTURE IN COMPLEX WITH PAI-1
Zhonghui Lin* (CN), Zebin Hong, Lihong Hu, Mingdong Huang

O-TU-104  15:45 - 16:00
THE EFFECTS OF MUTATIONS OF RESIDUES LYS42, LYS43, AND LYS44 OF TAFI ON ITS ACTIVATION BY THROMBIN-THROMBOMODULIN
Chengliang Wu* (CA), Ann Gils, Paul Declerck, Michael E Nesheim

O-TU-105  16:00 - 16:15
SPECIFIC TAFIA INHIBITING NANOBODIES AS PROFIBRINOLYTIC TOOLS AND DISCOVERY OF A NEW TAFIA CONFORMATION
Maarten Hendrickx* (BE), Anais De Winter, Karlien Buelens, Griet Compernolle, Gholamreza Hassanzadeh-Ghassabeh, Serge Muyldermans, Ann Gils, Paul J. Declerck

O-TU-106  16:15 - 16:30
EPIGENETIC CONTROL OF TISSUE-TYPE PLASMINOGEN ACTIVATOR SYNTHESIS IN HUMAN ENDOTHELIAL CELLS
Egbert KO Kruithof* (CH), Sylvie Dunoyer-Geindre
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-107  16:30 - 16:45
SUSCEPTIBILITY OF HUMAN TAFI-TRANSGENIC MICE TO STREPTOCOCCUS PYOGENES
Mercedes Valls-Seron* (NL), Stefan R Havik, Heiko Herwald, Philip G de Groot, Joost CM Meijers

O-TU-108  16:45 - 17:00
PLASMINOGEN ACTIVATOR INHIBITOR TYPE I CONTRIBUTES TO PROTECTIVE IMMUNITY DURING EXPERIMENTAL GRAM-NEGATIVE SEPSIS (MELIOIDOSIS)
Liesbeth M Kager* (NL), W. Joost Wiersinga, Joris J Roelofs, Joost C Meijers, Cornelis Van ‘t Veer, Tom Van der Poll

Tissue Factor and Factor VII  Room D
Chairpersons: Philip Hogg (AU) and Wolfram Ruf (US)

O-TU-109  15:30 - 15:45
MURINE ALTERNATIVELY SPliced TISSUE FACTOR IS NOT SUFFICIENT FOR EMBRYONIC DEVELOPMENT AND DOES NOT TRIGGER COAGULATION
Susanna HM Sluka* (CH), Alexander Akhmedov, Johannes Vogel, Thomas F Luscher, Felix C Tanner

O-TU-110  15:45 - 16:00
CRITICAL LENGTH OF THE LINKER BETWEEN THE EGF-LIKE DOMAINS IN FACTOR VIIA ESSENTIAL FOR PRODUCTIVE, HIGH-AFFINITY INTERACTION WITH TISSUE FACTOR
Egon Persson* (DK), Ole Hvilsted Olsen

O-TU-111  16:00 - 16:15
COAGULATION FACTOR VII EXPRESSION CORRELATES WITH TUMOR MIGRATION AND INVASIVENESS IN HUMAN HEPATOCELLULAR CARCINOMA
Chih Che Lin* (TW), Hsiang-Jen Yang, Li-Yu Chen, Chih-Chi Wang, Toshiaki Nakano, Shigeru Goto, Kuang-Den Chen, Chao-Long Chen

O-TU-112  16:15 - 16:30
FACTOR VII ACTIVATING PROTEASE (FSAP) PROMOTES PROTEOLYSIS AND INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
Sandip M Kanse* (DE), Paul J Declerck, Wolfram Ruf, George Broze, Michael Etscheid

O-TU-113  16:30 - 16:45
A MONOCLONAL ANTI-TFPI-ANTIBODY, MAB 2021, REDUCES AN ONGOING BLEEDING IN HAEMOPHILIC RABBITS WITH A SIMILAR EFFECT AS RFVIIA
Brian Lauritzen* (DK), Ida Hilden, Brit Binow Sorensen

O-TU-114  16:45 - 17:00
BAY 86-6150, A NOVEL RECOMBINANT FACTOR VIIA VARIANT, HAS A SIGNIFICANTLY HIGHER THERAPEUTIC INDEX THAN EPTACOG ALFA (ACTIVATED) IN RABBIT BLEEDING AND THROMBOSIS MODELS
Derek S. Sim* (US), Maria Koellnberger, Jian-Ming Gu, Claus Bornaes, Michael Kragh, Susanne K Clausen, John E. Murphy, Jesper Haaning
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

Endothelial Cells

Chairpersons: Asrar B Malik and Joji Ando

O-TU-115  15:30 - 15:45

UROKINASE PLASMINOGEN ACTIVATOR INDUCES PULMONARY MICROVASCULAR ENDOTHELIAL PERMEABILITY THROUGH LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN - DEPENDENT ENOS ACTIVATION

Anastasia M. Makarova* (US), Tatiana V Lebedeva, Abd Al-Roof Higazi, Douglas B Cines, Victoria V Stepanova

O-TU-116  15:45 - 16:00

TARGETING ENA/VASP ACTIVITY IN ENDOTHELIAL CELLS AND IN VESSELS IN VIVO

Stefanie Seifert* (SE), Renne Thomas

O-TU-117  16:00 - 16:15

THIOREDOXIN RESTORES EXOCYTOSIS BY DENITROSYLATING N-ETHYLMALEIMIDE SENSITIVE FACTOR.

Takashi Ito* (JP), Ikuro Maruyama, Charles J Lowenstein

O-TU-118  16:15 - 16:30

GAP JUNCTION PROTEIN, CONNEXIN32 REGULATES EXPRESSION OF TISSUE FACTOR AND INFLAMMATORY CYTOKINES IN THE ENDOTHELIAL CELLS

Okamoto Takayuki* (JP), Tatsuya Hayashi, Koji Suzuki

O-TU-119  16:30 - 16:45

OSTEOPROTEGERIN, A NEW ACTOR IN VASCULOGENESIS, STIMULATES ENDOTHELIAL COLONY-FORMING CELLS PROPERTIES

Zahia Benslimane-Ahmar (FR), Dominique Heymann, Blandine Dizier, Anna Lokajczyk, Regis Brion, Francoise Grelac, David M Smadja, Isabelle Galy-Fauroux, Sylvia Colliec-Jouault, Anne Marie Fischer, Catherine Boisson-Vidal*

O-TU-120  16:45 - 17:00

PARADOXICAL INVOLVEMENT OF THE ENDOTHELIAL MINERALOCORTICOID RECEPTOR IN PLATELET ACTIVATION AND VASCULAR THROMBOSIS IN MOUSE

Jeremy Lagrange* (FR), Celine Fassot-Lucht, Aurelie Nguyen Dinh Cat, Patrick Lalolilay, Frederic Jaisser, Veronique Regnault

Hemophilia: Inhibitor Development

Chairpersons: Seiji Madoiwa (JP) and

O-TU-121  15:30 - 15:45

THE DEVELOPMENT OF INHIBITORY ANTIBODY TO THERAPEUTIC FACTOR VIII IN SEVERE HEMOPHILIA A IS ASSOCIATED WITH MICROSATELLITE POLYMORPHISM IN HMOX1 PROMOTER

Yohann Repesse* (FR), Jordan Dimitrov, Surya Dasgupta, Elika Farrokhli, Catherine Costa, Anna Pavlova, Annie Borel Derlon, Roselyne D'Oiron, Johannes Oldenburg, Srinivas Kaveri, Sebastien Lacroix-Desmazes
## ORAL COMMUNICATIONS

### Tuesday, July 26, 2011

<table>
<thead>
<tr>
<th>O-TU-122</th>
<th>15:45 - 16:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLOCKAGE OF FACTOR VIII UPTAKE BY DENDRITIC CELLS RESULTS IN REDUCED ANTIBODY RESPONSES IN A MOUSE MODEL OF HAEMOPHILIA A</td>
<td></td>
</tr>
<tr>
<td>Aleksandra Wroblewska* (NL), Simon D. van Haren, Eszter Herczenik, Alexander B. Meijer, Anja ten Brinke, Jan Voorberg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-TU-123</th>
<th>16:00 - 16:15</th>
</tr>
</thead>
<tbody>
<tr>
<td>F8 GENE MUTATION TYPE AND INHIBITOR DEVELOPMENT IN PATIENTS WITH SEVERE HEMOPHILIA A: PRELIMINARY RESULTS OF A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
<td></td>
</tr>
<tr>
<td>Samantha C Gouw* (NL), H Marijke van den Berg, Jan Astermark, Johannes Oldenburg, Maurizio Margaglione, Arthur R Thompson, Jorien Boekhorst, Connie H Miller, Philip G de Groot, Johanna G van der Bom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-TU-124</th>
<th>16:15 - 16:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEVENFOLD RISK FOR INHIBITORS IN MILD/MODERATE HEMOPHILIA A WITH FACTOR VIII MISSENSE MUTATIONS IN TWO DISTINCT REGIONS</td>
<td></td>
</tr>
<tr>
<td>Corien Eckhardt* (NL), Alice S. van Velzen, Marjolein Peters, Nina Streelfkerk, Jan Astermark, Johannes Oldenburg, Kathelijne Peerlinck, Charles R.M. Hay, Pieter-Willem Kamphuisen, Elena Santagostino, Johanna G. van der Bom, Karin Fijnvandraat</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-TU-125</th>
<th>16:30 - 16:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>MONITORING INHIBITOR DEVELOPMENT IN HAEMOPHILIA: 2-YEAR RESULTS OF EUHASS.</td>
<td></td>
</tr>
<tr>
<td>Kathelijn Fischer* (NL), Mike Makris, Gabriele Calizzani, Charles Hay, Christopher Ludlam, Thierry Lambert, Riitta Lassila, Piero Mannucci</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-TU-126</th>
<th>16:45 - 17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>INHIBITOR DEVELOPMENT IN MILD AND MODERATE HEMOPHILIA A SEEMS TO BE ASSOCIATED WITH AN INCREASED MORTALITY RISK</td>
<td></td>
</tr>
<tr>
<td>Corien Eckhardt* (NL), Alice S. van Velzen, Marjolein Peters, Jan Astermark, Rainer Schwaab, Kathelijne Peerlinck, Charles R.M. Hay, Pieter-Willem Kamphuisen, Maria Elisa Mancuso, Johanna G. van der Bom, Karin Fijnvandraat</td>
<td></td>
</tr>
</tbody>
</table>

### Thrombotic Disorders: Clinical Trials I

#### Room A

**Chairpersons:** Ramon Corbalan and Alok Khorana (US)

<table>
<thead>
<tr>
<th>O-TU-127</th>
<th>15:30 - 15:45</th>
</tr>
</thead>
<tbody>
<tr>
<td>RANDOMIZED COMPARISON OF THE DAWN AC COMPUTER PROGRAM AND A SIMPLE MANUAL NOMOGRAM FOR QUALITY OF WARFARIN DOSING</td>
<td></td>
</tr>
<tr>
<td>Robby Nieuwlaat* (CA), Alex C Spyropoulos, Lowiek Hubers, Alexander Stehouwer, Harriette G Van Spall, John W Eikelboom, Sam Schulman, Stuart J Connolly</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-TU-128</th>
<th>15:45 - 16:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>THE EFFECT OF POLYMORPHISMS OF VKORC1 C1173T ON THE PERCENTAGE OF TIME THE INR IS WITHIN THE THERAPEUTIC RANGE IN PATIENTS USING VITAMIN K ANTAGONISTS</td>
<td></td>
</tr>
<tr>
<td>Edward P.A. Gebuis* (NL), Frits R. Rosendaal, Erik van Meegen, Felix J.M. van der Meer</td>
<td></td>
</tr>
</tbody>
</table>
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-129
16:00 - 16:15
INTERMITTENT PNEUMATIC COMPRESSION TO PREVENT VENOUS THROMBOEMBOLISM IN PATIENTS HOSPITALIZED IN INTENSIVE MEDICAL CARE UNITS WITH HIGH RISK OF BLEEDING: A RANDOMIZED TRIAL

O-TU-130
16:15 - 16:30
A RANDOMIZED CONTROLLED TRIAL COMPARING ASPIRIN WITH DALTEPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP ARTHROPLASTY
David Robert Anderson* (CA), Michael Dunbar, Pascal-Andre Venotoli, Susan Kahn, Etienne Belzile, Eric Bohm, William Fisher, Peter Gross, Paul Kim, Wade Gofton, Stephen MacDonald, Stephane Pelet, Mark Crowther, Susan Pleasance, Marc Rodger, Philip Wells, Michael Kovacs, Pantelis Andreou

O-TU-131
16:30 - 16:45
THE IMPACT OF RENAL FUNCTION ON OPTIONS FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS FOLLOWING MAJOR ORTHOPEDIC SURGERY: INSIGHTS FROM A RANDOMIZED TRIAL
Amir K Jaffer* (US), Andrew Shorr, Bengt I Eriksson, Michael Kurz

O-TU-132
16:45 - 17:00
INTERNATIONAL REGISTRY ON SPLANCHNIC VEIN THROMBOSIS: DESCRIPTION OF THE STUDY POPULATION
Walter Ageno* (IT), Sam Schulman, Nicoletta Riva, Soo-Mee Bang, Maria Teresa Sartori, Jan Beyer, Giovanni Barillari, Elvira Grandone, Alessandra Malato, Rita Santoro, Rita Duce, Ida Martinelli, Daniela Poli, Adriano Alatri, Peter Verhamme, Peter W Kamphuisen, Doyeun Oh, Cecilia Becattini, Eugenio Bucherini, Francesco Dentali, Study Investigators IRSVT

VTE: Laboratory Tests I
Room B-1
Chairpersons: Alexander Gallus (AU) and Henry Watson

O-TU-133
15:30 - 15:45
DIAGNOSTIC SAFETY OF A STRUCTURED ALGORITHM WITH USE OF CLINICAL DECISION RULE, D-DIMER AND CT SCAN FOR CLINICALLY SUSPECTED RECURRENT PULMONARY EMBOLISM
Inge C.M. Mos* (NL), Renee A. Douma, Petra M.G. Erkens, Tessa A.C. Nizet, Marc F. Durian, Marcel M.M. Hovens, Anja A. van Houten, Herman M.A. Hofstee, Judith Kooiman, Frederikus A. Klok, Hugo ten Cate, Erik F. Ullmann, Harry R. Buller, Pieter W. Kamphuisen, Menno V. Huisman

O-TU-134
15:45 - 16:00
AGE-ADJUSTED D-DIMER CUT-OFF VALUE INCREASES THE NUMBER OF OLDER PATIENTS IN WHOM DEEP VEIN THROMBOSIS CAN BE SAFELY EXCLUDED
Renee A Douma* (NL), Nadine S Gibson, Roger E.G. Schutgens, Shannon M Bates, Arnaud Perrier, Cristina Legnani, Douwe H Bleiema, Jeffrey S Ginsberg, Henri Bounamaux, Gianluigi Pialaret, Marc Carrier, Gregoire le Gal, Pieter W Kamphuisen, Marc Righini
ORAL COMMUNICATIONS

Tuesday, July 26, 2011

O-TU-135  16:00 - 16:15
DIAGNOSTIC ACCURACY OF UNENHANCED AND GADOLINIUM-ENHANCED MAGNETIC RESONANCE IMAGING FOR ACUTE PULMONARY EMBOLISM DIAGNOSIS: RESULTS OF THE “IRM-EP” STUDY
Olivier Sanchez* (FR), Marie-Pierre Revel, Sophie Couchon, Benjamin Planquette, Anne Hernigou, Raphael Niarra, Catherine Lefort, Gilles Chatellier, Guy Meyer

O-TU-136  16:15 - 16:30
MAJOR ILLNESSES AND RISK OF VENOUS THROMBOSIS: RELATION WITH ESTABLISHED ACQUIRED CAUSES OF THROMBOSIS AND CHANGES IN THE COAGULATION SYSTEM
Gurbey Ocak* (NL), Carla Y. Vossen, Marion Verduijn, Karlijn J. van Stralen, Friedo W. Dekker, Frits R. Rosendaal, Willem M. Lijfering

O-TU-137  16:30 - 16:45
A PROGNOSTIC MODEL FOR SHORT TERM ADVERSE EVENTS IN NORMOTENSIVE PATIENTS WITH PULMONARY EMBOLISM
Mariette Agterof (NL), Roger EG Schutgens*, Noureddine Mounti, Rene Ejikemans, Rene van der Griend, Ellen Tromp, Douwe Biesma

O-TU-138  16:45 - 17:00
IN PATIENTS WITH INHERITED THROMBOPHILIA THE ABO GROUP AND VWF LEVELS CONTRIBUTE BOTH INDEPENDENTLY TO THE RISK OF VENOUS THROMBOSIS: A RETROSPECTIVE STUDY OF 1774 SUBJECTS
William Cohen (FR), Christel Castelli, Sophie Bouvet, Dominique Brunet, Marie-Christine Barthet, Marie-Francoise Aillaud, Marie-Christine Alessi, Geraldine Lavigne-Lissalde, Pierre Emmanuel Morange*

ADAMTS 13
Room B-2

Chairpersons: Jing-fei Dong (US) and Agnes Veyradier

O-TU-139  15:30 - 15:45
ADAMTS-13 BOUND TO GPIB CLEAVES A1A2A3 DOMAIN OF VWF
Andrea Artoni* (IT), Rossana Lombardi, Immaculada Garcia-Oya, Luciano Baronciani, Flora Peyvandi

O-TU-140  15:45 - 16:00
VWF PROTEOLYSIS BY ADAMTS13 IS DEPENDENT ON COOPERATION BETWEEN THE ADAMTS13 CYSTEINE-RICH DOMAIN LOOP Q456-Q478 AND THE SPACER DOMAIN.
Rens de Groot* (UK), Joon-Yeol Ryu, Matthew Jaring, Brenda Marianne Luken, David Anthony Lane, James Thomas Blick Crawley

O-TU-141  16:00 - 16:15
C-TYPE LECTIN RECEPTORS PROMOTE THE UPTAKE OF ADAMTS13 BY DENDRITIC CELLS
Nicoleta Sorvillo* (NL), Wouter Pos, Rob Fijnheer, Eszter Herczenik, Jan Voorberg

O-TU-142  16:15 - 16:30
ADAMTS13 CONTAINS TWO BINDING SITES FOR VWF THAT COORDINATE ENZYME-SUBSTRATE INTERACTION: AN ATOMIC FORCE MICROSCOPY STUDY
Jiangguo Lin* (US), Tao Wu, Miguel A. Cruz, Jing-fei Dong, Cheng Zhu
O-TU-143  16:30 - 16:45
ADAMTS13 BINDS TO VON WILLEBRAND FACTOR MULTIMERS IN SOLUTION VIA THE EIGHTH THROMBOSPONDIN-1 REPEAT

O-TU-144  16:45 - 17:00
LOCAL STRETCHING OF VWF STRINGS IS A TRIGGER FOR ADAMTS13 MEDIATED PROTEOLYSIS
Karen E De Ceunynck* (BE), Susana Rocha, Hendrik B Feys, Simon F De Meyer, Hans Deckmyn, Hiroshi Uji-i, Johan Hofkens, Karen Vanhoorelbeke
POSTER PRESENTATIONS

Tuesday, July 26, 2011

Signal transduction of platelet activation

P-TU-001  TRANSLOCATION OF FIBRIN AND MYOSIN INTO PLATELET MEMBRANE RAFTS IS AN IMPORTANT PROCESS FOR CLOT RETRACTION VIA A FUNCTIONAL PROPERTY OF GPIIb/IIIa

P-TU-002  EVIDENCE FOR A ROLE FOR THE OPEN CANALICULAR SYSTEM IN GENERATING PERICELLULAR CA²⁺ SIGNALS IN HUMAN PLATELETS.
Alan George Scott Harper* (UK), Nicholas Pugh, Richard W. Farndale, Stewart O. Sage

P-TU-003  CALCIUM ACTS UPSTREAM OF MITOCHONDRIAL EVENTS TO REGULATE PLATELET PS EXPOSURE
Choo Hyojung* (US), Talib Saafir, Mary Wagner, Shawn Jobe

P-TU-004  QUANTITATIVE AND TIME RESOLVED HIGH-THROUGHPUT ANALYSIS OF ADP INDUCED TYROSINE PHOSPHORYLATION IN PLATELETS
Jorg Geiger* (DE), Ulrich Walter, Hardy Schweigel, Peter Nollau, Rene Zahedi, Albert Sickmann

P-TU-005  IN VITRO PHARMACOKINETICS OF DIETARY FLAVONOIDS ON PLATELET FUNCTION
Jonathan Gibbins* (UK), Bernice Wright, Julie A Lovegrove

P-TU-006  MOLECULAR MECHANISMS INVOLVED IN PLATELET ACTIVATION MEDIATED BY GALECTIN-1
Mirta Ana Schattner* (AR), M A Romaniuk, M J Lapponi, A Carestia, S Negrotto, R Benzadon, M V Tribulatti, G A Rabinovich

P-TU-007  MTOR AND S6K1 DRIVE RAC1-MEDIATED PLATELET SPREADING AND PLATELET AGGREGATION
Joseph E Aslan* (US), Garth W Tormoen, Cassandra P. Loren, Jiaqing Pang, Owen JT McCarty

P-TU-008  ROLE OF THE CALDAG-GEFI/RAP1 SIGNALING MODULE IN ITAM-DEPENDENT PLATELET ACTIVATION
Lucia Stefanini (US), Yacine Boulaftali, Timothy D. Ouellette, Michael Holinstat, Laurent Desire, Bertrand Leblond, Patrick Andre, Pamela B. Conley, Wolfgang Bergmeier

P-TU-009  INCREASED PLATELET ACTIVATION AND THROMBOSIS IN TRANSGENIC MICE OVEREXPRESSING CONSTITUTIVELY ACTIVE P2Y12 RECEPTOR
Yan Zhang* (CN), Jianzhin Ye, Liang Hu, Zhichao Fan, Si Zhang, Yan Yan, Xunbin Wei, Satya P. Kunapuli, Zhongren Ding

P-TU-010  THE ROLE OF 14-3-3ζ IN PLATELET GLYCOPROTEIN Iβ/α-VON WILLEBRAND FACTOR INTERACTION-INDUCED SIGNALING
Kesheng Dai* (CN), Zhang Weilin, Liu Jun, Zhao Lili, Du Juan, Sun Ruichen, Yan Rong, Ruan Changgeng

Biology of platelets

P-TU-011  PLATELET CYCLIC AMP REGULATION - MATHEMATICAL MODELING AND EXPERIMENTAL VERIFICATION
Jorg Geiger* (DE), Gaby Wangorsch, Marcus Dittrich, Thomas Dandekar, Katharina Hubertus, Ulrich Walter
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-012  GALECTINS DIFFERENTIALLY REGULATE THE RELEASE OF PLATELET-DERIVED ANGIOGENIC MOLECULES
Mirta Ana Schattner* (AR), J Etulain, S Negrotto, M A Romaniuk, D O Croci, V Cattaneo, O Campetella, G A Rabinovich

P-TU-013  REQUIREMENTS FOR MEMBRANE ATTACK COMPLEX FORMATION AND ANAPHYLATOXINS BINDING ON COLLAGEN-ACTIVATED PLATELETS
Arnaud Bonnefoy* (CA), Catherine Martel, Sylvie Cointe, Pascal Maurice, Said Matar, Marta Ghilescu, Pierre Theroux

P-TU-014  PYK2 DOWNSTREAM OF Go13 IS AN IMPORTANT FUNCTIONAL TYROSINE KINASE IN REGULATION OF PLATELET FUNCTIONAL RESPONSES
Soochong Kim* (US), Jianguo Jin, Lina Cipolla, Gianni Guidetti, Mitsuhiko Okigaki, Mauro Torti, Satya P. Kunapuli

P-TU-015  ROLE OF ENDOGENOUS GALECTIN-1 IN REGULATION OF THE HEMOSTATIC PROCESSES
Mirta Ana Schattner* (AR), M A Romaniuk, M J Lapponi, J Etulain, A Carestia, D O Croci, G A Rabinovich

P-TU-016  CONTACT- AND AGONIST-REGULATED PLATELET MICROVESICULATION
Yanjun Zhang (CN), Xi Yang, Xiao Liu, Li Liu, Zhou Zhou, Jing-fei Dong*, Jianning Zhang

P-TU-017  PLATELETS PARTICIPATION IN HOST DEFENSE: THE ROLE OF PLATELET MEMBRANE RECEPTORS IN PLATELET INTERACTION WITH FOREIGN PARTICLES
Elena M Gupalo* (RU), Cynthia Kuk, Mohammad Qadura, Liudmilia I Buryachkovskaya, Maha Othman

P-TU-018  SER559 OF GLYCOPROTEIN Iβ IS PHOSPHORYLATED BY PROTEIN KINASE A WHICH REPRESENTS A MECHANISM FOR REGULATING VWF-GLYCOPROTEIN IB-IX INTERACTION
Kesheng Dai* (CN), Zhang Weilin, Liu Guanglei, Yuan Yanhong, Zhao Lili, Yan Rong, Liao Yi, Ruan Changgeng

P-TU-019  DIFFERENTIAL EFFECTS OF PLATELET-DERIVED MATRIX METALLOPROTEINASES ON THROMBUS FORMATION AND COLLAGEN MATRIX DEGRADATION
Judith M.E.M. Cosemans* (NL), Marion A.H. Feijge, Romy M.W. Kremers, Paola E.J. van der Meijden, Jason L. Johnson, Johan W.M. Heemskerk

P-TU-020  INCREASED CONCENTRATIONS OF PLATELET DERIVED MICROPARTICLES WITH A CIRCADIAN RHYTHM IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Christina Christersson* (SE), Bertil Lindahl, Agneta Siegbahn

Integrins and other glycoproteins

P-TU-021  THROMBOXANE A2 GENERATED BY INTERACTION OF PLATELETS WITH IMMOBILIZED FIBRINOGEN REGULATES EARLY PLATELET SPREADING AND LAMELLIPODIA FORMATION
Jianguo Jin* (US), Madalina Tuluc, Satya P. Kunapuli

P-TU-022  HYDROGEN SULPHIDE (H2S) INHIBITS HUMAN PLATELET ACTIVATION THROUGH AN INSIDE-OUT INTEGRIN αIIbβ3 SIGNALING PATHWAY.
Emilse Bermejo* (AR), Daniel Alberto Saenz, Maria Fabiana Alberto, Maria Angela Lazzari, Ruth Estela Rosenstei
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-023  LENTIVIRAL GENE RESCUE OF GPIbβ IN A BERNARD-SOULIER MOUSE MODEL TO EVALUATE ITS FUNCTION IN CIRCULATING PLATELETS.
Francois Lanza* (FR), Catherine Strassel, Anne Bull, Sylvie Moog, Monique Freund, Anita Eckly, Anne Dubart-Kupperschmitt, Catherine Leon, Christian Gachet, Francois Lanza

P-TU-024  A MACROMOLECULAR MACHINE CONTROLS INTEGRIN ACTIVATION
Yan-Qing Ma* (US), Jun Yang, Kamila Bledzka, Dhanuja Perera, Jun Qin, Edward F Plow

P-TU-025  DISSOCIATION BETWEEN CLOT RETRACTION AND FIBRIN BINDING BY ALPHAIIBET3: DEPENDENCE ON ACTIVE CONFORMATION OR PRESENCE OF FREE THIOLS
Ronit Mor-Cohen (IL), Nurit Rosenberg*, Olga Romanenko, Uri Seligsohn, Judith Lahav

P-TU-026  PLATELET RECEPTORS IN THROMBUS FORMATION ON SPOTTED MICROARRAY SURFACES
Susanne Maria de Witt* (NL), Moniek M.E Lamers, Reyhan Nergiz, Frauke Swieringa, Erik Westein, Judith M.E.M Cosemans, Johan W.M Heemskerk

P-TU-027  HYDROPHOBIC INTERACTIONS REGULATE INTEGRIN ALPHA 2 I DOMAIN
Samir W Hamaia* (UK), D G Bihan, R Stone, S Farrow, V Bolanos-Garcia, R W Farnsdale

P-TU-028  ROLE OF ILK-PINCH-PARVIN COMPLEX IN SUPPORTING FUNCTIONAL EXPRESSION OF INTEGRIN
Shigenori Honda* (JP), Hiroko Shirotani-Ikejima, Yasuyuki Matsuda, Seiji Tadokoro, Yoshiaki Tomiyama, Toshiyuki Miyata

P-TU-029  MUTATIONAL INHIBITION OF TALIN ROD BINDING TO INTEGRIN β3 IDENTIFIES FOCAL ADHESIONS IN WHICH MUTANT β3 IS LINKED TO THE ACTIN CYTOSKELETON VIA α-ACTININ.
Nelly Kieffer* (CN), Xiao Dong Xi, Yue Zhang, Yong Kui Kong, Ming Hui Lin

P-TU-030  PLATELET AGGREGATION MEDIATED VIA EITHER dIIbβ3 OR GPIb LEADS TO CYTOSKELETON ASSOCIATION OF BOTH OF THE RECEPTORS
Naphtali Savion* (IL), Ivan Budnik, Boris Shenkman

P-TU-031  REGULATION OF INTEGRIN CLOSURE IN PROCOAGULANT PLATELETS
Nadine J.A. Mattheij* (NL), Karen Gilio, Roger van Kruchten, Marion A.H. Feijge, Edouard M. Bevers, Shawn M. Jobe, Judith M.E.M Cosemans, Johan W.M. Heemskerk

Platelet receptors

P-TU-032  CROSSTALK BETWEEN P2X1 AND P2Y1 RECEPTORS STIMULATES SYNERGISTIC CALCIUM RESPONSES AND PROMOTES ADP-MEDIATED PLATELET AGGREGATION.
Sarah Jones* (UK), Christopher Moore, Michael Emerson, Catherine Leon, Christian Gachet, Richard Evans, Martyn Mahaut-Smith

P-TU-033  ESCHERICHIA COLI-INDUCED PLATELET AGGREGATION
Dermot Cox* (IE), Rosin Moriarty, Alysia Cox, Niamh Farrelly, Michael King, Stephen Smith

P-TU-034  COOPERATIVE CALCIUM SIGNALING MEDIATED BY GLICOPROTEINS (GP)IB-IX-V, GPVI AND INTEGRIN α2β1 DURING PLATELET ADHESION TO COLLAGEN UNDER FLOW
Maria Rita Cozzi* (IT), Monica Battiston, Mario Mazzucato, Martine Jandrot-Perrus, Zaverio M. Ruggeri, Luis De Marco

P-TU-035  CLONING OF PLATELET GLYCOPROTEIN IB-IX OF RHESUS MONKEY (MACACA MULATTA) AND COMPARISON WITH HUMAN GLYCOPROTEIN IB-IX
Youan Chen* (CN), Jianlin Qiao, Yang Shen, Yanrong Lu, Jingqiu Cheng
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-036  PLATELET GLYCOPROTEIN VI ACTIVITY IN RHESUS MONKEY MODELS OF INSULIN-CONTROLLED OR UNCONTROLLED DIABETES MELLITUS
Lu Yanrong* (CN), Yang Shen, Jane Arthur, Younan Chen, Elizabeth Gardiner, Robert Andrews, Jingqiu Cheng

P-TU-037  TWO-SITE MECHANISM OF α-THROMBIN BINDING TO PLATELET GLYCOPROTEIN Ibα
Alessandro Zarpellon* (US), Antonella Zampolli, James Roberts, Richard McClintock, Grazia Loredana Mendolicchio, Zaverio Ruggeri

P-TU-038  MODE OF ACTION OF P2Y12 ANTAGONISTS AS INHIBITORS OF PLATELET FUNCTION
Jacqueline Glenn* (UK), David Espinosa Iyu, Ann E White, Susan C Fox, Hans van Giezen, Sven Nylander, Stan Heptinstall

P-TU-039  MEASUREMENT OF HUMAN PLATELET GLYCOPROTEIN VI (GPVI) BY FLOW CYTOMETRY AND EFFECTS OF PATHOLOGICAL SHEAR ON GPVI LEVELS
Chee W Tan* (AU), Marie-Christine Morel-Kopp, Mohammad Al-Tamimi, Jing Jing, Elizabeth Gardiner, Christopher Ward, Robert Andrews

P-TU-040  LARGE-SCALE SCREENING FOR EXTRACELLULAR PROTEIN INTERACTIONS INVOLVED IN PLATELET AGGREGATION
Yi Sun* (UK), Gavin Wright

Megakaryocytes and thrombopoiesis

P-TU-041  ALPHA-LINOLENIC ACID INCREASES PLATELET SURVIVAL BY REDUCING PLATELET ACTIVATION AND INHIBITS P38 AND ERK PHOSPHORYLATION
Simona Stivala* (CH), Christine Lohmann, Eric Holy, Christian Matter, Thomas Luescher, Juerg Beer

P-TU-042  TRANSIENT ACTIVATION OF C-MYC EXPRESSION IS CRITICAL FOR EFFICIENT PLATELET GENERATION FROM HUMAN INDUCED PLURIPOTENT STEM CELLS
Naoya Takayama* (JP), Satoshi Nishimura, Sou Nakamura, Takaumi Shimizu, Ryoko Ohnishi, Hiroshi Endo, Tomoyuki Yamaguchi, Makoto Otsu, Ken Nishimura, Mahito Nakanishi, Akira Sawaguchi, Ryozo Nagai, Kazutoshi Takahashi, Shinya Yamanaka, Hiromitsu Nakauchi, Koji Eto

P-TU-043  ANGIOGENIC GROWTH FACTOR 1 (AGGF1) IS EXPRESSED IN HUMAN BONE MARROW MEGAKARYOCYTES
Victoria S Hahn-Stromberg* (SE), Alia Shamikh, Maria Aström

P-TU-044  DEFECTIVE MEGAKARYOCYTEPOIESIS AND PRO-PLATELET FORMATION IN A NOVEL GLANZMANN VARIANT MACROTHROMBOCYTOPENIA
Loredana Bury* (IT), Alessandro Malara, Paolo Gresele, Alessandra Baldunni

P-TU-045  RHOA DEFICIENCY RESULTS IN MISLOCALIZATION OF MEGAKARYOCYTES AND REDUCED PLATELET PRODUCTION IN VIVO
Irina Pleines* (DE), Ina Hagedorn, Jolanda van Hengel, Georg Krahne, Cord Brakebusch, Bernhard Nieswandt

P-TU-046  MEGAKARYOCYTES POSSESS FUNCTIONAL APOPTOTIC PATHWAYS THAT MUST BE RESTRAINED IN ORDER TO SURVIVE AND PRODUCE PLATELETS
Emma Charlotte Josefsson* (AU), Chloe James, Deborah Burnett, Marlyse A Debrincat, Katya J Henley, Rachael Lane, Kelly L Rogers, Mark R Dowling, Michael J White, Elizabeth A Kruse, Sarah Ellis, Cassandra J Vandenberge, Kylie D Mason, Lorraine A O’Reilly, Paquita Nurden, Donald Metcalf, Andrew W Roberts, Andreas Strasser, David CS Huang, Benjamin T Kile
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-047  EFFECTS OF WARFARIN AND VITAMIN K IN PS SYNTHESIS BY MEGAKARYOCYTE CULTURES
Claudia Maria Radu* (IT), Cristiana Bulato, Sabrina Gavasso, Luca Spiezia, Paolo Simioni

P-TU-048  QUININE-INDUCED THROMBOCYTOPENIA: DRUG-DEPENDENT ANTIBODIES INHIBIT MEGAKARYOCYTE AND PROPLATELET PRODUCTION
Jose S Perdomo* (AU), Feng Yan, Zohra Ahmadi, Xing-Mai Jiang, Beng H Chong

Rheology of platelets

P-TU-049  ANTITHROMBOTIC PROPERTIES OF PRAVASTATIN REDUCING INTRA-THROMBUS FIBRIN DEPOSITION UNDER HIGH SHEAR BLOOD FLOW CONDITIONS
Mitsuhiko Sugimoto* (JP), Masaaki Hamada, Hideto Matsui, Masaaki Doi, Yasunori Matsunari, Hidetada Fukushima, Kenji Nishio, Akira Yoshioka, Midori Shima

P-TU-050  EFFECTS OF PATHOGEN REDUCTION TECHNOLOGY TREATMENT ON PLATELET FUNCTIONS
Chikahiro Terada* (JP), Hitoshi Okazaki, Masahiro Satake, Kenji Tadokoro

P-TU-051  MATRIX METALLOPROTEINASE (MMP)-2 ENHANCES PLATELET DEPOSITION UNDER FLOW CONDITIONS
Paolo Gresele* (IT), Viviana Appolloni, Giuseppe Guglielmimi, Emanuela Falconelli, Philip De Groot, Luigi De Marco, Paolo Gresele

P-TU-052  PATIENTS WITH SICKLE CELL DISEASE HAVE INCREASED PLASMA LEVELS OF TOTAL AND ACTIVE TGF-β1
Jasimuddin Ahamed* (US), Patricia Shi, Andreas Mauer, Barry S Collier

Experimental models

P-TU-053  LC231306, A NOVEL ANTIPLATELET AGENT, INHIBITS ARTERIAL THROMBOSIS THROUGH SELECTIVE BLOCKADE OF PLATELET P2Y12 RECEPTORS
Hee Dong Park* (KR), Jung Gyu Park, Tae Hun Kim, Ahn Young Ha

P-TU-054  COMPARISON OF PLATELET AGGREGATION DURING HIBERNATION AND NON-HIBERNATION IN SCANDINAVIAN BROWN BEARS (URSUS ARCTOS)
Karin A H Arinell (SE), Kjeld Christensen*, Johan Josefsson, Jon M Arnemo, Alina Evans, Ole Frobert

P-TU-055  PROGRESSION OF DIABETES AND ALTERED HAEMOSTATIC VARIABLES IN A NEW TYPE 2 DIABETIC RAT MODEL
Fumitoshi Asai* (JP), Norihiko Hirai, Noriyuki Kaji, Mitsuyuki Shirai, Ito Katsusaki

P-TU-056  EFFECT OF HEPARIN: PMX60056 COMPLEXES ON PLATELET AGGREGATION INDUCED BY ADP OF HIT ANTIBODY
Walter Jeske* (US), Eric McAllister, Jeanine Walenga, Michelle Paulus, Jawed Fareed

P-TU-057  Efficacy of cilostazol for preventing the occurrences of cerebral infarction due to the disturbance of cerebral venous circulation in rat two-vein occlusion (2VO) model
Daisuke Wajima* (JP), Ichiro Nakagawa, Yusuhiko Takeshima, Hirokazu Nakase

P-TU-058  The direct factor Xa inhibitor rivaroxaban reduces platelet activation in congestive heart failure by attenuating secondary ADP-mediated aggregation
Andreas Schaefer* (DE), Ulrike Flierl, Jan Micka, Daniela Fracarollo, Johann Bauersachs
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-059 DETECTION OF THROMBOEMBOLISM WITH 99M-T-LABELLED F(AB) 2 FRAGMENT OF ANTI-GPIIIA CHIMERIC MONOCLONAL ANTIBODY IN DOGS
Shundong Ji* (CN), Wei Fang, Ningzheng Dong, Zuoxiang He, Changpeng Ruan

P-TU-060 PRODUCTION AND APPLICATION OF MONOCLONAL ANTIBODY TO THROMBIN-ACTIVATED PLATELETS
Sawitree Chiampanichayakul* (TH), Nungruthai Nimnuch, Patsara Lekawipat

P-TU-061 PHOSPHOLIPASE A2 AND PLATELET AGGREGATION INHIBITOR FROM AGKISTRODON BLOMHOFFI USURIENSIS VENOM
Nataliia Burlova-Vasilieva* (UA), Olexiy Savchuk, Ludmila Ostapchenko

P-TU-062 DEVELOPMENT OF PLATELET CELL SIMULATOR IMPLEMENTING THE FUNCTION OF RELEASE REACTION
Yohei Nanazawa* (JP), Noriko Tamura, Shinya Goto, Yasuhiro Sunaga, Takashi Koyama, Hideo Yokota

P-TU-063 THROMBOCYTOPENIA IMPAIRS HOST DEFENSE AND SURVIVAL DURING MURINE STREPTOCOCCUS PNEUMONIAE PNEUMONIA
Floor E. van den Boogaard* (NL), Marcel Schouten, Cornelis van ’t Veer, Tom van der Poll

P-TU-064 DEVELOPMENT OF A MOUSE MODEL TO STUDY HUMAN PLATELET FUNCTION IN VIVO.
Lisa-Marie Holbrook* (UK), Christopher Moore, Michael Emerson

P-TU-065 THE COMPLEX RELATION OF THROMBUS GROWTH TO WALL SHEAR RATES UP TO 100,000 1/S
David N KU* (US), David L. Bark, Andrea Para

ITP

P-TU-066 RISKS OF POSTOPERATIVE MORTALITY AND COMPlications AMONG SURGICAL PATIENTS WITH PURPURA: A POPULATION-BASED STUDY
Chien-Chang Liao* (TW), Ta-Liang Chen

P-TU-067 CTLA-4-IG CORRECTS ABNORMAL INDOLEAMINE 2,3-DIOXYGENASE-MEDIATED Tryptophan catabolism in dendritic cells from immune thrombocytopenia
yan shi* (CN), chunyan wang, xiaojuan zhu, xiaoyuan dong, jun peng, heyu ni, ming hou

P-TU-068 DEXAMETHASONE VS STANDARD PREDNISONE IN PATIENTS WITH CHRONIC ITP: RESULTS AND PREFERENCES
Maria E Mingot* (ES), Dana Diaz-Canales, Laura Gonzalez-Diaz, Anabel Heiniger-Mazo

P-TU-069 CD72 GENE EXPRESSION IN IMMUNE THROMBOCYTOPENIA
Hu ZHOU* (CN), Aiping Qi, Huiyuan LI, Li MA, Jianhui XU, Feng XUE, Shihong LU, Qinjun ZHAO, Zeping ZHOU, Renchii YANG

P-TU-070 SPLENECTOMY, RITUXIMAB AND ROMIPLOSTIM IN CHRONIC ITP: EFFICACY AND SAFETY PROFILE.
Maria E Mingot* (ES), Dana Diaz-Canales, Maria Rosario Prieto-Bonilla, Alejandro Contento, Alicia Bailen-Garcia, Anabel Heiniger-Mazo
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-071  IDENTIFICATION OF EPITOPES AND CRITICAL RESIDUES FOR BINDING OF PLATELET-ASSOCIATED ANTI-GPIIBIIIA AUTOANTIBODIES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA
Kazunobu Kiyomizu* (JP), Hirokazu Kashiwagi, Tsuyoshi Nakazawa, Tsuyoshi Kamae, Seiji Tadokoro, Shigenori Honda, Yuzuru Kanakura, Yoshiaki Tomiyama

P-TU-072  PERCENTAGE OF CD56+ LYMPHOCYTES THAT PREDICTS THE RESPONSE TO STEROID TREATMENT IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIA PURPURA
YI-FENG WU* (TW), Tso-Fu Wang, Sung-Chiao Chu, Kuan-Po Huang, Michael R. Loken, Ruey-Ho Kao

P-TU-073  LOW-DOSE RITUXIMAB TREATMENT IN CHINESE PATIENTS WITH IMMUNE THROMBOCYTOPENIA
Hong-mei Wang* (CN), Tao Sui, Yanhui Yang, Zeping Zhou, Xiaofan Liu, Yongze Liu, Lei Zhang, Renchi Yang

P-TU-074  CONTRIBUTIONS OF TRAIL MEDIATED MEGAKARYOCYTE APOPTOSIS TO IMPAIRED MEGAKARYOCYTE AND PLATELET PRODUCTION IN IMMUNE THROMBOCYTOPENIA
Lei Yang* (CN), Lin Wang, Chunhong Zhao, Xiaojuan Zhu, Yu Hou, Jun Peng, Ming Hou

HIT

P-TU-075  ORDERING OF HEPARIN-PF4 ANTIBODY TESTS AND TREATMENT OF HEPARIN INDUCED THROMBOCYTOPENIA IN THE INTENSIVE CARE UNIT
Matthew A Wanat* (US), Kalliopi Fitousis, Jeffrey Hall, Lawrence Rice

P-TU-076  PROFILING OF HEPARIN-INDUCED THROMBOCYTOPENIA ANTIBODY TITER IN PATIENTS WITH AND WITHOUT DIABETES
M. Margaret Prechel* (US), Josefina L. Diaz, Mary Ann Emanuele, Nicholas V. Emanuele, Jeanine M. Walenga

P-TU-077  PREVALENCE OF ANTI-HEPARIN PLATELET FACTOR 4 ANTIBODIES IN PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION
Jawed Fareed* (US), Josephine Cunanan, Walter Jeske, Debra Hoppensteadt, Harry Messmore

P-TU-078  PREVALENCE OF HIT ANTIBODIES IN HIP FRACTURE PATIENTS UNDERGOING ORTHOPAEDIC SURGERY AND THEIR RELEVANCE TO SERUM AMYLOID A
Jawed Fareed* (US), Justin Griffin, Evangelos Litinas, Indermohan Thethi, Debra Hoppensteadt, Michael Lassen, William Hopkinsson, Rakesh Wahi

P-TU-079  PLATELET WASHING BY BSA-SEPHAROSE GEL FILTRATION IS A PRACTICAL METHOD TO ISOLATE PLATELETS FOR THE SEROTONIN RELEASE ASSAY
Nana Kwasi Sono-Koree* (US), Ronda A Crist, George M Rodgers, Kristi J Smock

P-TU-080  HIGH-PRESSURE LIQUID CHROMATOGRAPHY IS A ROBUST METHOD FOR PERFORMING THE SEROTONIN RELEASE ASSAY AND CORRELATES WELL WITH THE RADIOACTIVITY METHOD
Nana Kwasi Sono-Koree* (US), Ronda A Crist, Elizabeth A Frank, George M Rodgers, Kristi J Smock

P-TU-081  DIFFERENTIAL IMMUNOGENIC RESPONSE OF BRANDED AND GENERIC VERSIONS OF LMWH
Eduardo Ramacciotti* (US), Marise Gomes, Jeanine Walenga, Debra Hoppensteadt, Gundu Rao, Helena Nader, Walter Jeske, Jawed Fareed
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-082  PERIOPERATIVE VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): THE DESIRUDIN EXPERIENCE
Jerrold H Levy* (US), Michael A Kurz, Andreas Koster

P-TU-083  VALIDATION OF MONOSPECIFIC ELISA TEST AS A SCREENING TEST FOR HEPARIN INDUCED THROMBOCYTOPENIA COMPARE TO OTHER IMMUNOLOGICAL AND FUNCTIONAL ASSAYS
Tarek Owaidah* (SA), Rasheed Nasr, Tarek Owaidah

P-TU-084  THE FREQUENCY OF RENAL IMPAIRMENT IN PATIENTS SUSPECTED OF HEPARIN INDUCED THROMBOCYTOPENIA SYNDROME (HIT)
Philip Young-III Choi* (AU), Beng Hock Chong, Max Fu, Rosalie Gemmell

P-TU-085  ARTERIAL THROMBOEMBOLECTOMY AND INTRAOPERATIVE ANTICOAGULATION IN THE SETTING OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT).
Theodore Earl Warkentin* (CA), Menaka Pai

P-TU-086  RISKS OF IVC FILTERS IN THE SETTING OF HEPARIN-INDUCED THROMBOCYTOPENIA
Moonjung Jung (US), John J McCarthy, Keity R Baker, Lawrence Rice*

Antiplatelet therapy

P-TU-087  ASPIRIN AM OR PM? : A RANDOMIZED CROSS-OVER TRIAL
Tobias Bonten* (NL), JD Snoep, WJ Assendelft, V van der Meer, JJ Zwaginga, FR Rosendaal, HCJ Eikenboom, JG van der Bom

P-TU-088  ACETYLSALICYLIC ACID THERAPY: INFLUENCE OF METFORMIN USE ON URINARY 11-DEHYDRO THROMBOXANE B2 LEVELS.
Maria das Gracas Carvalho* (BR), Lillian Harboe Goncalves, Luci Maria Sant’Ana Dusse, Ana Paula Fernandes, Karina Braga Gomes, Marcos Vinicius Ferreira Silva, Geralda de Fatima Guerra Lages, Flavia Komatsuzaki, Marinez Oliveira Sousa, Adriana Aparecida Bosco

P-TU-089  HEAD-TO-HEAD COMPARISON OF CLOPIDOGREL EFFICACY IN STENTED PATIENTS WITH DIABETES MELLITUS, METABOLIC SYNDROME, OR NONE
Nadine Ajzenberg* (FR), Florence Tubach, Gregory Ducrocq, Helene Abergel, Marina Esposito Farese, Marie-Genevieve Huisse, Gabriel Philippe Steg, Laurent Feldman

P-TU-090  IN VITRO THIENOPYRIDINES’ EFFECTS ON PLATELET PROCOAGULANT ACTIVITY:RFVIIA ALONE OR WITH ADP OFFSETS THROMBIN GENERATION INHIBITION MEDIATED BY PRASUGREL’S ACTIVE METABOLITE
Jerrold H Levy* (US), Fania Szlam, Heezoo Kim, Satoru Ogawa, Joseph A Jakubowski, Atsuhiro Sugidachi, Kenichi A Tanaka

P-TU-091  CONSISTENT AND POTENT PLATELET INHIBITION OF PRASUGREL IRRESPECTIVE OF CYP2C19 POLYMORPHISM IN JAPANESE PATIENTS WITH CORONARY ARTERY DISEASE

P-TU-092  DIFFERENTIAL PREVALENCE AND PHARMACODYNAMIC IMPACT OF CYP2C19 POLYMORPHISMS IN 3 MAJOR ASIAN ETHNICITIES
Mark Y Chan* (SG), Karen Tan, Qian Hui Phua, Huay Cheem Tan, Arthur Mark Richards, Pei Tee Huan, Evelyn Koay
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-093  PREVALENCE AND RISK FACTORS FOR ASPIRIN RESISTANCE IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
Yingyong Chinthammitr* (TH), Jane Jiantianikanon, Yupa Nakkinikun, Bundarka Suwanawiboon, Theera Ruchutrakool

P-TU-094  DUAL ANTIPLATELET THERAPY FOR TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) - IS IT A RIGHT CHOICE?
Janina M Stepinska* (PL), Katarzyna Czerwinska, Adam Witkowski, Maciej Dabrowski, Marek Baraszewski, Piotr Michalek, Zbigniew Chmielak, Krzysztof Kusmierski, Tomasz Hryniewiecki, Marcin Demkow

P-TU-095  PRACTICAL USE AND LIMITATIONS OF ADP AGGREGATION TESTING TO PREDICT CARDIOVASCULAR EVENTS: DESIGN AND PRELIMINARY RESULTS OF A META-ANALYSIS ON INDIVIDUAL PATIENTS DATA
Jean-Luc Reny* (CH), Pierre Fontana, Pascale Fabbro-Peray, Silvy Laporte, Josthem Wouter van Werkum, JM Ten Berg, Tobias Geisler, M Gwas, Paul A Gurbel, Marie-Christine Alessi, Thomas Cuiset, Gerald Yong, Dominick Angiolillo, Gianluca Campo, Christophe Combescure

P-TU-096  DYNAMIC RESPONSE TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROME, CLINICAL AND PROGNOSTIC IMPLICATIONS
Galia Spectre* (IL), Morris Mosseri, Nader M. Abdelrahman, Elinor Briskin, Atilla Bulut, Sasa Loncar, David Varon, Ronny Alcalai

P-TU-097  ASPIRIN RESISTANCE IN NEUROVASCULAR DISEASES
Martin Valis* (CZ), Dagmar Krajickova, Jaroslav Maly, Radovan Maly, Ilona Fatorova, Lenka Strmiskova, Pavel Semerak

P-TU-098  DISTINCTIVE ASPIRIN EFFECT ON THE ARACHIDONIC ACID PATHWAY, OXIDATIVE STRESS, NITRIC OXIDE METABOLITES AND P-SELECTIN IN DIABETES MELLITUS
Luis R Lopez* (US), Ivana Muncy, Eiji Matsuura, Joana Batuca, Kirk Guyer, Ignacio Garcia De La Torre, Paul RJ Ames

P-TU-099  THE ACTIVE METABOLITE OF PRASUGREL AUGMENTS GPIIB-IIIa ANTAGONIST INHIBITION OF PLATELET ACTIVATION AND AGGREGATION: COMPLEMENTARY ROLES FOR INHIBITION OF P2Y12 AND GPIIB-IIIa
Andrew L Frelinger* (US), Joseph A Jakubowski, Atsuhiro Sugidachi, Marc R Barnard, Alan D Michelson

P-TU-100  ONE DAILY ASPIRIN IS ENOUGH TO SUPPRESS PLATELET SECRETION WITHOUT INDUCING A COMPLETE INHIBITION OF AGGREGATION IN PATIENTS WITH CARDIOVASCULAR RISK.
Alejandro Barkovits* (CL), Monica Acevedo, Olga Panes, Carolina Valenzuela, Carlos Barria, Marcelo Carrasco, Diego Mezzano

Inherited and acquired platelet disorders

P-TU-101  TREATMENT OPTIONS FOR GLANZMANN’S THROMBASTHENIA IN PAKISTAN.
Munira Borhany* (PK), Tahir Shamsi, Zain Pahore, Arshi Naz, Tasneem Farzana, Saqib Ansari, Muhammad Nadeem

P-TU-102  RECOMBINANT FACTOR VIIa (RFVIIa) USE IN GLANZMANN’S THROMBASTHENIA (GT) AND OTHER PLATELET DISORDERS (OPDS): HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY DATA
Meera Chitlur* (US), Nadia Ewing, Eric H. Kraut, David L. Cooper
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-103  IMPAIRED PLATELET AGGREGATION TO ADP IN A NORMAL P2Y1 AND P2Y12 RECEPTORS
Eusni R M Tohit* (MY)

P-TU-104  ACQUIRED BERNARD-SOULIER SYNDROME/GLANZMANN’S THROMBASTHENIA CAUSED BY AUTOANTIBODIES AGAINST GPIB AND GPIIIA/IIIA
Naomasa Yamamoto* (JP), Toshihiro Ito, Naoki Akiu, Takaji Wakita

P-TU-105  ROLE OF FLOWCYTOMETRIC ANALYSIS OF CD 41 IN GLANZMANN’S THROMBASTHENIA
Shanthala Devi Aladahalli Mallappa* (IN), Vanamala Anand Alwar, Parimala Puttaiah, Sitalakshmi Subramanian, Karuna Rameshkumar

P-TU-106  PREVALENCE OF PLATELET AGGREGATION DEFECTS IN WOMEN WITH AND WITHOUT MENORRHAGIA
H. Marieke Knot* (NL), Andre B Mulder, Hanneke C Kluin-Nellemans, Ate van der Zee, Dick B Bogaehlman, Meijer Karina

P-TU-107  ABNORMAL PLATELET FUNCTIONS IN TWO PATIENTS WITH FILAMIN A MUTATIONS
Jean-Philippe Raymond Rosa* (FR), Marijke Bryckaert, Eliane Berron, Frederic Adam, Marilyne Lebret, Alexandre Kaushot, Martine Jandrot-Perrus, Jean-Philippe Rosa, Cyril Goizet, Alan T Nurden, Paquita Nurden

P-TU-108  A NOVEL HOMOZYGOUS MISSENSE MUTATION IN THE P2RY12 GENE RESULTS IN DEFECTIVE ADP-MEDIATED PLATELET ACTIVATION IN A PATIENT SUFFERING FROM A CHRONIC BLEEDING DISORDER.
Aine N McCormick* (UK), Y M Patel, A N McCormick, M Mitchell, J Maloney, S K Austin

P-TU-109  AQUAGLYCEROPORIN 7 IS INVOLVED IN PLATELET DENSE GRANULE SECRETION: A STUDY IN PATIENTS WITH HYPERGLYCEROLURIA HOMOZYGOUS FOR G264V
Christophe V Goubau* (BE), Jaak Jaeken, Elena Levtchenko, Chantal Thys, Michela Di Michele, Geert Martens, Erik Gerlo, Christel Van Geet, Kathleen Freson

P-TU-110  IDENTIFICATION OF 25 NOVEL MUTATIONS IN 25 PATIENTS WITH GLANZMANN’S THROMBASTHENIA
Ziqiang Yu* (CN), Qingya Cui, Jian Su, Xiaojuan Zhao, Yunwen Bu, Xia Bai, Changgeng Ruan

Laboratory tests

P-TU-111  PLATELET GENE POLYMORPHISMS RELATED TO ACUTE MYOCARDIAL INFARCTION IN YOUNG PATIENTS
Jana Ulehlova* (CZ), Ludek Slavik, Vera Krcova, Jan Galuszka, Jan Vaclavik

P-TU-112  VALIDATION OF A NOVEL ELISA-BASED VASP ASSAY FOR MONITORING ACTIVITY OF P2Y12 ANTAGONISTS IN WHOLE BLOOD
Tomoko Motomura* (JP), Naoyuki Tajima, Fumie Maruyama, Atsuhiro Sugidachi

P-TU-113  LACK OF CLINICAL PREDICTIVENESS OF SIX MAJOR PLATELET FUNCTION TESTS USED TO ASSESS ASPIRIN RESPONSE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Marie Lordkipanidze* (UK), Jean G. Diodati, Erick Schampaert, Donald A. Palisaitis, Chantal Pharand

P-TU-114  IMPACT OF NOCTURIA ON PLATELET AGGREGABILITY IN ELDERLY PATIENTS WITHOUT CARDIOVASCULAR DISEASE
Shoko Uematsu* (JP), Tomohiro Kurihara, Kenichi Mitani, Yoshio Kimura, Satoshi Murasaki, Haruhisa Noda
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-115  PLATELET FUNCTION IN PATIENTS WITH A LEFT VENTRICULAR ASSIST DEVICE
Michael Ashbrook* (US), Jeffrey Schwatz, Alain Heroux, Vicki Escalante, Walter Jeske, Jeanine Walenga, Mamdouh Bakhos

P-TU-116  IS POSTPRANDIAL PLATELET ACTIVATION RELATED TO INSULIN RATHER THAN GLUCOSE LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS?
Galia Spectre* (SE), Claes-Goran Ostenson, Nain Lin, Maud Daleskog, Ragnhild Stalesen, Paul Hjemdahl

P-TU-117  CENTRIFUGATION SPEED AFFECTS LIGHT TRANSMISSION AGGREGOMETRY RESULTS.
Michael A Nardi* (US), Michael Merolla, Jeffrey S Berger

P-TU-118  EFFECT OF LOW DOSE OMEGA-3 (N-3) ON PLATELET FUNCTION
Brad McEwen* (AU), Marie-Christine Morel-Kopp, Walter Chen, Geoffrey H Tofler, Christopher M Ward

P-TU-119  THE POTENTIAL VALUE OF IMPEDANCE AGGREGOMETRY, PLATELET FUNCTION ANALYSER AND BLEEDING TIME TO ASSESS THE BLEEDING RISK IN RENAL BIOPSY
Paul Verhezen* (NL), K Hamulyak, M Mullens, M Christiaans, Y Henskens

P-TU-120  NO EVIDENCE OF PLATELET ACTIVATION IN PATIENTS WITH ATRIAL FIBRILLATION WHO ARE TREATED WITH DABIGATRAN: A SUBSTUDY OF THE RELY TRIAL
John Eikelboom* (CA), J Oldgren, P Reilly, S Yusuf, L Wallentin, M Ezekowitz, S J Connolly

P-TU-121  THROMBOELASTOGRAPHY (TEG) : A MARKER OF PLATELET HYPERCOAGULABILITY IN TE PATIENTS WITHOUT CYTOREDUCTIVE THERAPY
Claudine Caron* (FR), Mathieu Wemeau, Anne Bauters, Emmanuelle Jeanpierre, Antoine Tournoux, Christophe Zawadzki, Nathalie Trillot, Brigitte Jude, Nathalie Cambier

Extrinsic pathway of coagulation

P-TU-122  THE IMPACT OF FLOW ON THE PRESENTATIONS OF FACTOR XA AND THROMBIN
Laura M Haynes* (US), Yves C Dubief, Kenneth G Mann

P-TU-123  CHARACTERIZATION OF TUMOR-DERIVED CIRCULATING TISSUE FACTOR IN AN ORTHOTOPIC MODEL OF HUMAN PANCREATIC CANCER
Monica Davila* (US), Evgeny Ozhegov, Liza Robles, John Francis, Vladimir Y Bogdanov, Ali Amirkhosravi

P-TU-124  TFPI ANTAGONIST APTAMER BAX499 IS A PROCOAGULANT IN VITRO AND IN VIVO
Kathleen McGinness* (US), Emily K. Waters, Ryan M. Genga, Robert C. Schwartz, Jennifer A. Nelson, Robert G. Schaub, Karen A. Olson, Jeffrey C Kurz

P-TU-125  THE PROCOAGULANT ACTIVITY OF BAX513 CORRELATES WITH THE PLASMA LEVEL OF FULL-LENGTH TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
Michael Dockal* (AT), S. Knappe, M. Paliwe, K. Panholzer-Riedrich, A. Kolm, R. Hartmann, M. Gorczyca, B. Jilma, F Scheiffinger

P-TU-126  FACTOR VII DEFICIENCY: EVIDENCE THAT IN MINOR SURGERY ONE-DAY REPLACEMENT THERAPY IS SUFFICIENT
Guglielmo Mariani* (IT), Alberto Dolce, Jorgen Ingerslev, Angelika Batorova, Marisanta Napoliito, Jean Francois Schved, Giovanni Di Minno, Gunter Auerswald, Muriel Gianpolly-Blaizot, Aronis Sofia, Sergio Siragusa, Arlet Ruiz de Saez, Annarita Tagliaferri
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-127  FUCOIDAN EFFICIENTLY IMPROVES THROMBOELASTOGRAPHIC COAGULATION PARAMETERS IN AN EX VIVO MODEL OF HEMOPHILIC GUINEA PIGS

P-TU-128  INHIBITION OF CELL-ASSOCIATED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) INCREASES FACTOR VIIIA-TF DEPENDENT FACTOR X ACTIVATION
Michael Dockal* (AT), R. Pachlinger, A. Baldin-Stoyanova, F. Knofl, R. Hartmann, A. Backovic, H. Ehrlich, F. Scheiflinger

P-TU-129  IMPROVEMENT OF HEMOSTASIS IN HEMOPHILIA BY PEPTIDES INHIBITING TISSUE FACTOR PATHWAY INHIBITOR
Michael Dockal* (AT), R. Hartmann, T. Polakowski, F. Osterkamp, W. Kammlander, E. Panholzer, A. Kolm, C. Redl, H. Ehrlich, F. Scheiflinger

P-TU-130  HIGH PLASMA LEVELS OF ENDOGENOUS TISSUE FACTOR PATHWAY INHIBITOR STRONGLY CORRELATE WITH POOR BLOOD CLOTTING WHEN FACTOR VIII IS INHIBITED

P-TU-131  IDENTIFICATION OF A FACTOR VA HEAVY CHAIN BINDING SITE IN THE FRAGMENT 2 DOMAIN OF PROTHROMBIN
Joanne E. Berridge* (CA), Nicole Brufatto, Feng Ni, Michael Nesheim

P-TU-132  CHARACTERIZATION OF AN APTAMER INHIBITOR OF TFPI: A NOVEL THERAPEUTIC STRATEGY IN HEMOPHILIA
Nigel S Key* (US), Jen-Yea Chang, Pichika Chantrathammachat, Kathleen McGinness, James C Gilbert, Robert G Schaub, Dougald M Monroe

P-TU-133  PURIFICATION, STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A NOVEL ANTICOAGULANT THREE-FINGER TOXIN FROM THE VENOM OF NAJA SIAMENSIS (INDOCHINESE BLACK SPITTING COBRA)
Mohamed AS Nazir* (SG), R Manjunatha Kini

P-TU-134  A NOVEL EXTRINSIC TENASE COMPLEX INHIBITOR FROM THE VENOM OF HEMACHATUS HAEMACHATUS (AFRICAN RINGHALS COBRA)
Girish Valletinteavide Mavelli* (SG), R Manjunatha Kini

P-TU-135  HAEMOSTASIS AND ANGIOGENESIS IN PLACENTAE FROM THROMBOPHILIC WOMEN WITH PREVIOUS ADVERSE OUTCOMES TREATED WITH LOW MOLECULAR WEIGHT HEPARIN (LMWH).
Elvira Grandone* (IT), Elena Chinni, Donatella Calaizzo, Giovanni Luca Tiscia, Patrizia Vergura, Giovanni Favuzzi, Michela Sarno, Giovanna D’andrea, Maurizio Margaglione

P-TU-136  ALTERATIONS IN COAGULATION AND FIBRINOLYSIS AFTER LEVOTHYROXINE EXPOSURE IN HEALTHY VOLUNTEERS: A CONTROLLED RANDOMIZED CROSSOVER STUDY
Bregje van Zaane* (NL), Alessandro Squizzato, Jan Debeij, Dekkers M Olaf, Joost CM Meijers, Anton P van Zanten, Harry R Buller, Victor EA Gerdes, Suzanne C Cannegieter, Dees PM Brandjes

P-TU-137  BLOCKING OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) WITH MAB 2021 PROMOTES THROMBIN GENERATION IN FVIII DEFICIENT PLASMA
Lars Christian Petersen* (DK), Ida Hilden, Soeren E. Bjerrum, Brit B. Soerensen
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-138  MODERATE PLASMA DILUTION BY ARTIFICIAL PLASMA SUBSTITUTING SOLUTIONS INTENSIFIES COAGULATION IN VITRO
Elena I Sinauridze* (RU), Alexander S Gorbatenko

P-TU-139  PRETHROMBIN-1, THE GLA-DOMAINLESS PROTHROMBIN INTERMEDIATE, IS ACTIVATED EFFICIENTLY TO THROMBIN BY PROTHROMBINASE ASSEMBLED ON THE ACTIVATED PLATELET SURFACE.
Paula B Tracy* (US), Francis Ayombil, Jay R Silveira, Jeremy P Wood

Intrinsic pathway of coagulation

P-TU-140  GENETIC DIAGNOSIS OF A PEDIGREE WITH INHERITED COAGULATION FACTOR V DEFICIENCY
Zhou Rong-Fu* (CN), Jian Ouyang, Lu Chen, Xiao-yan Shao, Jing-Yan Xu

P-TU-141  PARTIAL VERSUS COMPLETE FACTOR VIII INHIBITION IN A MOUSE MODEL OF VENOUS THROMBOSIS
Jan Emmerechts* (BE), Thomas Vanassche, Serena Loyen, Ingrid Van Linthout, Alexandre Kauskot, Clive Long, Marc Jacquemin, Marc Hoylaerts, Peter Verhamme

P-TU-142  DEVELOPMENT AND COMPARISON OF THE GAIN-OF-FUNCTION FACTOR IX VARIANTS.
Shu-Jhu Yang* (TW), Chung-Yang Kao, Chia-Ni Lin, I-Shing Yu, Mi-Hua Tao, Hua-Lin Wu, Guey-Yueh Shi, Po-Ku Chen, Shu-Rung Lin, Yung-Li Yang, Ming-Ching Shen, Shu-Wha Lin

P-TU-143  INHIBITION OF THROMBIN GENERATION USING ANTIBODIES AGAINST COAGULATION FACTOR XI
Maurits Leonard van Montfoort* (NL), Jakob Arnoud Marquart, Kamran Bakhthiari, Erik Hack, Joost Meijers

P-TU-144  TWENTY-YEAR FOLLOW-UP OF OUR PATIENTS WITH HEMOPHILIA A
Zafer Salcioglu* (TR), Arzu Akcay, Nuray Aktay Ayaz, Hulya Sayilian Sen, Gonul Aydogan, Deniz Tugcu, Ferhan Akci, Zafer Baslar

P-TU-145  A PATIENT COMBINED HEMOPHILIA A AND TYPE 1 VON WILLEBRAND’S DISEASE
Huanhuan Qin* (CN)

P-TU-146  PHARMACOKINETICS OF ACTIVATED RECOMBINANT FACTOR IX ALBUMIN FUSION PROTEINS
Hubert J Metzner* (DE), Thomas Weimer, Sabine Zollner, Wiegand Lang, Carsten Horn, Jochen Mueller-Cohrs, Gerhard Dickneite, Stefan Schulte

P-TU-147  SHEAR STRESS TRIGGERS THE UPTAKE OF FACTOR VIII-VON WILLEBRAND FACTOR COMPLEX BY PRIMARY HUMAN MACROPHAGES
Lydia Castro* (NL), Ilze Dienava, Eszter Herczenik, Koen Mertens, Alexander B. Meijer

P-TU-149  HEALTH-RELATED QUALITY OF LIFE OF CONGENITAL HEMOPHILIA PATIENTS WITH INHIBITORS (CHWI): MEASUREMENT WITH DISEASE-SPECIFIC INSTRUMENTS (HAEMO-QOL, HAEM-A-QOL)
Tami Wisniewski* (US), Allison Petrilla, Mitch DeKoven, Won Chan Lee, Natalia Holot, David L Cooper, Sylvia von Mackensen

P-TU-150  ILE290THR. A NOVEL VARIANT AT THE FXI HOMODIMER INTERFACE ASSOCIATED WITH AN ASSAY-SPECIFIC FXI:C DISCREPANCY.
Marian Hill* (UK), Charlotte Grimley, Nigel Brooks, Jonas Emsley, Gerry Dolan
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-151  PATIENT/CAREGIVER PERCEIVED BENEFITS AND BARRIERS TO ELECTIVE ORTHOPEDIC SURGERY (EOS) IN PATIENTS WITH CONGENITAL HEMOPHILIA WITH INHIBITORS
Mitch DeKoven (US), Tami Wisniewski*, Alison Petrilla, Natalia Holot, Won Chan Lee, David L Cooper

P-TU-152  COMPARISON OF GLYCOSYLATION PROFILES IN VARIOUS RECOMBINANT FVIII PRODUCTS AND THE EFFECT OF B-DOMAIN DELETION
Maria C Van Walderveen* (CA), Leslie R Berry, Anthony K C Chan

P-TU-153  EVALUATION OF THE SAFETY AND EFFICACY OF RECOMBINANT FACTOR IX (NONACOG ALFA) IN MINIMALLY TREATED AND PREVIOUSLY TREATED CHINESE PATIENTS WITH HEMOPHILIA B
Yang Renchi* (CN), Yongqiang Zhao, Xuefeng Wang, Jing Sun, Jie Jin, Depei Wu, Robert Charnigo, Amanda O’Brien, Pablo Rendo, Zheng Zhong

P-TU-154  EVALUATION OF THE SAFETY AND EFFICACY OF RECOMBINANT FACTOR VIII (MOROCTOCOG ALFA [AF-CC]) IN MINIMALLY TREATED AND PREVIOUSLY TREATED CHINESE PATIENTS WITH HEMOPHILIA A
Yang Renchi* (CN), Yongqiang Zhao, Xuefeng Wang, Jing Sun, Jie Jin, Depei Wu, Robert Charnigo, Amanda O’Brien, Cari Kollmer, Pablo Rendo, Zheng Zhong

P-TU-155  A MULTICENTER, OPEN-LABEL STUDY TO COMPARE ON-DEMAND TREATMENT WITH TWO PROPHYLAXIS REGIMENS OF RECOMBINANT COAGULATION FACTOR IX IN SUBJECTS WITH HEMOPHILIA B
Leonard A Valentino* (US), Olga Plushch, Luminita Rusen, Tatyana Andreeva, Ivo Elezovic, Robert Charnigo, James Baumann, Cari Kollmer, Lynne Smith, Pablo Rendo

Anticoagulant pathway

P-TU-157  EMPIRICAL VALIDATION OF A MATHEMATICAL MODEL OF THE PROTEIN C PATHWAY
Maria Cristina Bravo* (US), Thomas Orfeo, Kenneth G. Mann, Stephen J. Everse

P-TU-158  AGE-RELATED DIFFERENCES IN THE AMOUNT OF LATENT ANTITHROMBIN IN PLASMA
Chantal Attard* (AU), Wala’a Al-sanie, Paul Monagle, Vera Ignjatovic

P-TU-159  RIVAROXABAN RESPONSE IN CHILDREN
Chantal Attard* (AU), Paul Monagle, Vera Ignjatovic

P-TU-160  AGE-RELATED DIFFERENCES IN BINDING OF HEPARIN TO PLASMA PROTEINS
Chantal Attard* (AU), Paul Monagle, Vera Ignjatovic

P-TU-161  PROSPECTIVE COMPARISON OF A FIXED VERSUS VARIABLE DOSSING REGIMEN OF PROTHROMBIN COMPLEX CONCENTRATE TO COUNTERACT VITAMIN K ANTAGONIST THERAPY IN 255 BLEEDING EMERGENCIES
Nakisa Khorsand* (NL), Nic J.G.M Veeger, Jeroen Heidt, Renier M van Hest, Karina Meijer

P-TU-162  IN VITRO SEMULOPARIN ACTIVITY IN DIFFERENT COAGULATION TESTS
Meyer M Samama* (FR), Celine Guinet, Lena Le Fier

P-TU-163  THE PHARMACOKINETICS OF YM150, AN ORAL DIRECT FACTOR XA INHIBITOR ARE NOT AFFECTED TO A CLINICALLY RELEVANT DEGREE BY STRONG INHIBITION OR INDUCTION OF CYP3A4 AND P-GP
Marten Heeringa* (NL), Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, Takeshi Kadokura, Roelof Mol, Charlotte Eltink, Hartmut Heinzerling
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-164  CO-ADMINISTRATION OF YM150, AN ORAL DIRECT FACTOR XA INHIBITOR, WITH ACETYLSALICYLIC ACID, CLOPIDOGREL AND NAPROXEN: NO EVIDENCE OF CLINICALLY RELEVANT INTERACTIONS
Marten Heeringa* (NL), Doren Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, James Dickinson, Charlotte Ellink, Roelof Mol, Takeshi Kadokura, Ronny Renfurm, Hartmut Heinzeler

P-TU-165  A COMPREHENSIVE APPROACH TOWARDS AUTOMATED ANTI-IIA AND ANTI-XA TESTING OF UNFRACTIONATED HEPARIN
Patrick Neil Shaklee* (US), Kimberly Jeanne Reinke

P-TU-166  PROTEIN C IN CHILDREN WITH EARLY COMPLICATION AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELLS TRANSPLANTATION
Dawid Szpecht* (PL), Jolanta Kurosz, Jerzy Jaworski, Aleksandra Regdos, Krystyna Zawilska, Jacek Wachowiak

P-TU-167  PERCEPTIONS ABOUT “RAPID” WARFARIN REVERSAL TO REDUCE THE INTERNATIONAL NORMALIZED RATIO WITH FRESH FROZEN PLASMA: A DOUBLE-BLINDED SURVEY OF U.S. TRAUMA CENTERS
Jerrold H Levy* (US), Jeffrey Petrozzino, Chris Jones, Jan Hoesche

P-TU-168  ACTIVATED PROTEIN C UPREGULATES PROCOAGULANT TISSUE FACTOR ACTIVITY ON ENDOTHELIAL CELLS BY SHEDDING TFPI’S KUNITZ 1 DOMAIN
Reto A Schuepbach* (CH), Kara Velez, Matthias Riewald

P-TU-169  EFFECT OF ENDOTOXIN AND INFLAMMATORY CYTOKINES ON PROTEIN S AND C4B-BINDING EXPRESSIONS IN THE LIVER HEPG2 CELLS

P-TU-170  COAGULATION PROFILE OF EP217609, A NEW NEUTRALIZABLE ANTICOAGULANT FOR EXTRACORPOREAL CIRCULATION DURING CARDIAC SURGERY
Maurice PETITOU* (FR), Richard Swanson, Steven T Olson

P-TU-171  NO RELEVANT INTERACTIONS BETWEEN THE ORAL FACTOR XA INHIBITOR YM150 AND ANTITHROMBIN IN VITRO
Seiji Kaku* (JP), Yoshiyuki Iwatsuki, Toshiyuki Funatsu

P-TU-172  COMBINED EFFECTS OF YM150, ASPIRIN, AND CLOPIDOGREL ON COAGULATION PARAMETERS, PLATELET AGGREGATION, AND BLEEDING TIME AFTER ORAL ADMINISTRATION TO RATS
Yoshiyuki Iwatsuki* (JP), Toshiyuki Funatsu, Seiji Kaku

P-TU-173  THE DETERMINATION OF RIVAROXaban IS NOT INFLUENCED IN CHROMOGENIC SUBSTRATE ASSAYS USING PLASMA FROM PATIENTS TREATED WITH WARFARIN
Job Harenberg* (DE), Sandra Erdie, Christina Giese, Svetlana Marx, Roland Kraemer

P-TU-174  EFFECT OF DABIGATRAN ON PROTHROMBIN TIME ASSAYS USING DIFFERENT THROMBOPLASTIN TIME REAGENTS
Job Harenberg* (DE), Christina Giese, Svetlana Marx, Christel Weiss, Roland Kraemer

P-TU-175  INFLUENCE OF PROTAMINE SULFATE ON ANTITHROMBIN ACTIVITY OF SULFATED CELLULOSE FROM POPULUS TREMULA WOOD.
Elena Y Savchik* (RU), Nataliya N Drozd, Svetlana A Kuznetsova, Vladimir A Makarov, Vladimir A Levanduskii, Boris Kuznetsov

Serine protease inhibitors

P-TU-176  SERINE PROTEASE INHIBITORS

P-TU-177  THE DETECTION OF RIVAROXaban IS NOT INFLUENCED IN CHROMOGENIC SUBSTRATE ASSAYS USING PLASMA FROM PATIENTS TREATED WITH WARFARIN
Job Harenberg* (DE), Sandra Erdie, Christina Giese, Svetlana Marx, Roland Kraemer
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-176  EFFECT OF DABIGATRAN SPIKED TO HUMAN PLASMA ON VARIOUS ACTIVATED PARTIAL THROMBOPLASTIN TIME METHODS
Job Harenberg* (DE), Christina Giese, Svetlana Marx, Christel Weiss, Roland Kraemer

P-TU-177  INFLUENCE OF RIVAROXABAN ON DIFFERENT ACTIVATED PARTIAL THROMBOPLASTIN TIME ASSAYS
Job Harenberg* (DE), Christina Giese, Sandra Erdle, Svetlana Marx, Christel Weiss, Roland Kraemer

P-TU-178  EFFECT OF RIVAROXABAN ON FACTOR XA SENSITIVE CHROMOGENIC SUBSTRATE ASSAYS
Job Harenberg* (DE), Christina Giese, Svetlana Marx, Christel Weiss, Roland Kraemer

P-TU-179  ANALYSIS OF ADDITIVE EFFECTS OF RIVAROXABAN ADDED TO PLASMA OF PATIENTS TREATED WITH VITAMIN-K ANTAGONISTS
Job Harenberg* (DE), Christina Giese, Svetlana Marx, Christel Weiss, Roland Kraemer

P-TU-180  ENHANCED INHIBITION OF PLATELET-PROTHROMBINASE BY COVALENT ANTITHROMBIN-HEPARIN COMPLEX
Ivan Stevic* (CA), Howard H. Chan, Leslie R. Berry, Anthony K.C. Chan

P-TU-181  INVOLVEMENT OF ALPHA2-ANTIPLASMIN IN AGE-RELATED COGNITIVE DECLINE
Eri Kawashita* (JP), Yosuke Kanno, Haruka Asayama, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Hiroyuki Matsuno

P-TU-182  CHANGES OF PLASMA ANTITHROMBIN LEVELS IN PATIENTS WITH MULTIPLE MYELOMA
Zhou Rong-Fu* (CN), Jian Ouyang, Ping Li

Structural biology and drug design

P-TU-183  FULLY GAMMA-CARBOXYLATED TRUNCATED COAGULATION FACTOR VII (FVII) VARIANTS CAN BE SECRETED IN HIGHER YIELDS THAN WILD-TYPE FVII
Gert Bolt* (DK), Jais Rose Bjelke, Jens Jacob Hansen, Thomas Steenstrup, Claus Kristensen

P-TU-184  IDENTIFICATION OF A NOVEL DELETION IN F13A AT RNA LEVEL IN A CHINESE HEREDITARY COAGULATION FACTOR XIII DEFICIENCY FAMILY
Wangwei Cali* (CN), Qiuiling Ma

P-TU-185  INFLUENCE OF PAMAM G3 DENDRIMERS ON BLOOD PLATELETS ACTIVATION
Cezary W Watala* (PL), Katarzyna Maczynska, Kamil Karolczak, Stefan Miskiewicz

P-TU-186  LMWH CAN IMPROVE THE OUTCOME OF ART PROCEDURES
Corrado Lodigiani* (IT), Pierpaolo DiMicco, Paola Ferrazzi, Luca Libre, Michelena Benigna, Franco Polatti, Paolo Emanuele Levi Setti, Lidia Luciana Rota, Benjamin Brenner

P-TU-187  STRUCTURAL CHARACTERIZATION OF PLASMA-DERIVED (BETAFACT) AND RECOMBINANT (BENEFIX) COAGULATION FACTOR IX USING MASS SPECTROMETRY
Guillaume CHEVREUX* (FR), Valegh FAID, Nolwenn TILLY, Nicolas BHOUREAU

P-TU-188  STRUCTURAL BASIS OF FACTOR V RECOGNITION BY RUSSELL'S VIPER VENOM PROTEINASE RVV-V
Daisuke Nakayama* (JP), Youssef Ben Ammar, Soichi Takeda

P-TU-189  WHOLE BLOOD CELLS ENHANCE CLOT RESISTANCE TO LYSIS: IMPROVEMENT BY RIVAROXABAN A FACTOR XA INHIBITOR
Remi Varin* (FR), Shahsoltan Mirshahi, Pezhman Mirshahi, Christophe Klein, Jean Chidiac, Elisabeth Perzborn, Genevieve Contant, Massoud Mirshahi, Claudine Soria, Jeannette Soria
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-190  ENDOPLASMIC RETICULUM STRESS, CELL CYCLE REGULATION AND SURVIVAL PATHWAYS MAY BE INVOLVED IN THE MECHANISM OF ACTION OF AMBLYOMIN-X, A NEW TICK KUNITZ TYPE INHIBITOR
Ana Marisa Chudzinski-Tavassi* (BR), Simone Michaela Simons, Katia Luciano Pereira Morais, Carolina Maria Berra, Claudia Lameu, Sandra Alves Barreto

Exogenous hemostatic factors

P-TU-191  LONG TERM FOLLOW UP OF SECONDARY PROPHYLAXIS WITH RFVIIA IN HAEMOPHILIA PATIENTS WITH INHIBITORS
Oscar Walter Torres* (AR), Patricia Do Nascimento, Guillermo Arbesu, Sandra Borchichi, Anabel Buceta

P-TU-192  ANTITHROMBIN CONCENTRATE USE IN PAEDIATRIC PRACTICE
Christina Kozul (AU), Fiona Newall*, Paul Monagle, Vera Ignjatovic

P-TU-193  VON WILLEBRAND FACTOR ANTIGEN, PROCOAGULANT FACTOR VIII AND ACQUIRED RESISTANCE OF ACTIVATED PROTEIN C IN PATIENTS WITH MULTIPLE MYELOMA
Emilia Flochova* (SK), J. Ivankova, P. Kubisz, K. Masarova

P-TU-194  BIOSTATE - SWIFT PROGRAM

P-TU-195  UPDATE OF A LONG-TERM PHARMACOVIGILANCE PROJECT: REC. FVIII-FS FOR THE TREATMENT OF HEMOPHILIA A
Johannes Oldenburg (DE), Pia Petrini, Albert Faradji, Ingrid Pabinger, Mathias Juers*, Claudia Zacharias, Harald Lenk

P-TU-196  ANALYSIS OF FACTOR VII ACTIVATING PROTEASE (FSAP) EXPRESSION IN THE MOUSE.
Silke Leiting* (DE), Lars Muhl, Audrey A. C. Cleuren, Ralf Weiskirchen, Sandip M. Kanse

P-TU-197  LIQUID PLASMA BANK: TOWARDS A TIMELY SUPPLY IN BLEEDING EMERGENCIES
Gregor Hron* (DE), Sarah Kelmer, Thomas Thiele, Matthias Nauck, Christina Wasner, Antje Wessel, Andreas Greinacher, Kathleen Selleng

P-TU-198  CLINICAL STUDY OF A NEW FACTANE CONCENTRATION (200 IU/ML): RECOVERY AND SAFETY RESULTS
Hervé Chambost* (FR), Anne Lienhart, Pierre Chamouni, Jenny Goudemand, Natalie Stieltjes, Anne-Lise Voyer, Claudine Caron, Martine Vidal, Celine Henriet, Francoise Bridey

P-TU-199  FIVE-YEAR POST-MARKETING SURVEILLANCE OF HAEMOPHILIA B PATIENT RECEIVING A FACTOR IX CONCENTRATE: FINAL RESULTS.
Hervé Chambost* (FR), Jenny Goudemand, Marie-Elisabeth Briquel, Annie Borel-Derlon, Group Post-Marketing Study, Anne-Ocile Jaffry, Francoise Bridey, Catherine Chatelanaz, Celine Henriet

P-TU-201  FULL-LENGTH RECOMBINANT FACTOR VIII (FL-RFVIII): IS IT SAFER?
Louis M Aledort* (US), Roberta J Navickis, Mahlon M Wilkes

P-TU-202  PRECLINICAL MODELS SHOW REDUCED IMMUNOGENICITY OF PEGYLATED RECOMBINANT HUMAN FVIII RELATIVE TO UNMODIFIED FVIII
Jesper Haaning* (US), Thomas A. McDonald, Ruprecht Zierz, John E. Murphy, Inge A Ivens
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-203  SAFETY OF HIGH MOLECULAR WEIGHT POLYETHYLENE GLYCOL (PEG) IN HEMOPHILIA THERAPY
Jesper Haaning* (US), Thomas A. McDonald, John E. Murphy, Inge A. Ivens

P-TU-204  SUBGROUP ANALYSES OF ANNUALIZED NUMBER OF BLEEDS WITH THREE-TIMES-PER-WEEK PROPHYLAXIS WITH RFVIII-FS
Shadan Lalezari* (IL), Antonio Coppola, Judith Lin, Monika Maas Enriquez

Fibrinogen and other factors

P-TU-205  IDENTIFICATION OF MURINOglobulin-1 (MUG1) AS A STAT5-REGULATED INHIBITOR OF FIBRINOPEPTIDE B RELEASE
Sarah M Nordstrom* (US), Brian A Holliday, Jennifer L Tran, Brandon C Sos, Susan T Lord, Ethan J Weiss

P-TU-206  MARKEDLY SHORTENED HALF-LIFE OF THE ADMINISTERED FACTOR XIII (FXIII) CONCENTRATES DURING FIRST REPLACEMENT THERAPY IN A NEWBORN WITH SEVERE CONGENITAL FXIII DEFICIENCY
Noriko Fujii* (JP), Masayoshi Souri, Midori Shima, Chihiro Tomoyasu, Kenichi Isoda, Akitada Ichinose

P-TU-207  SSRI AND HEMOSTASIS IN HEMATOLOGICAL MALIGNANCIES PATIENTS
Dmitry E Vybornykh* (RU), Evdokiya S Urnova

P-TU-208  THROMBIN GENERATION TEST AND GENETIC ANALYSIS IN 17 PATIENTS WITH HYPOFIBRINOGENEMIA ASSOCIATED WITH THROMBOSIS.
Claire Flaujac (FR), Nadia Abakarim, Philippe De Mazancourt, Jacqueline Conard*, Genevieve Plu Bureau, Michaela Fontenay, Marie Helene Horellou

P-TU-209  BATroxobin AND THROMBIN BIND TO DISTINCT SITES ON FIBRINOGEN AND FIBRIN
Trang T Vu* (CA), Alan R Stafford, Beverley A Leslie, James C Fredenburgh, Paul Y Kim, Jeffrey I Weitz

P-TU-210  TOWARD A COMPLETE MODEL OF FIBRINOGEN IN SOLUTION
Barbara Cardinali* (US), Anna Aprile, Aldo Profumo, Patrice Vachette, Patrick England, Bertrand Raynal, Manfred Roessle, Niels Volkman, Susan T Lord, Mattia Rocco

P-TU-211  DILUTIONAL COAGULOPATHY - THE HAEMOSTATIC EFFECT OF VARIOUS SOURCES OF FIBRINOGEN
John Lauret* (UK), Christian Fenger-Eriksen, Kirsten Christiansen, Benny Sorensen, Catherine Rea

P-TU-212  CHARACTERIZING THE KINETIC ACTIVATION OF ZYMogen FXIII: THE ROLE OF FIBRINOGEN AND OF THROMBIN EXosite I
Barbara Cardinali* (US), Brian A Holliday, Susan T Lord

P-TU-213  THE INHIBITOR FORMATION DURING PRIMARY PROPHYLAXIS THERAPY IN HAEmophilia WITH LOW DOSE AND LOW INTENSITY : RESULTS OF A CENTER FROM TURKEY
Tiraje Tulin Celkan* (TR), Nihal Ozdemir, Gulen Tuysuz

P-TU-214  HEPARINS-INDUCED MODIFICATION OF THE NANOstructure OF FIBRIN CLOT
Benoit Polack* (FR), Chrstelle Yeromonahos, Raphael Marlu, Francois Caton

P-TU-215  FACTOR XIII ACTIVATION PEPTIDE - A NOVEL COMPETITIVE THROMBIN INHIBITOR?
Verena Schroeder* (CH), Hans P Kohler
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-216  DIFFERENTIAL METHYLATION OF CPGS ACROSS THE FIBRINOGEN GENE CLUSTER CORRELATED WITH FIBRINOGEN EXPRESSION
Richard J Fish* (CH), Silja Vorjohann, Corinne DiSanza, Marguerite Neerman-Arbez

Laboratory tests

P-TU-217  COMPARISON OF SENSITIVITY TO LUPUS ANTICOAGULANT (LA) ON APTT REAGENT: EFFECT OF SILICA AND ELLAGIC ACID AS ACTIVATOR
Osamu Kumano* (JP), Masahiro Ieko, Sumiyoshi Naito, Mika Yoshida, Nobuhiko Takahashi

P-TU-218  CONCENTRATION-ACTIVITY RELATIONSHIP OF UNFRACTIONATED HEPARIN OR EP217609 BEFORE CARDIAC SURGERY
Eric Neuhart* (FR), Pierre Gueret, Pascal Menestret, Jeffrey Spencer, Helen Ridgway, Chantal Krezel

P-TU-219  EFFECTS OF GABEXATE MESILATE ON RATS WITH LIPOPOLYSACCHARIDE-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION
Chin-Chen Wu* (TW), Hsin-Jung Tsai, Mei-Huei Liao, Wen-Jinn Liaw

P-TU-220  EVALUATION OF THE PERFORMANCE OF A NEW IN VITRO PROTHROMBIN TIME REAGENT
Pere Domenech* (ES), Elena Rossello, Begona Alonso, Mariona Bono, Virginia Montanini

P-TU-221  EVALUATION OF THE DG-APC REAGENT KIT ON Q HEMOSTASIS ANALYZER
Ingrid V Hrachovinova* (CZ), Magda Zemanova, Hana Novotna, Frantisek Marecek

P-TU-222  VALIDATION OF NEW AVAILABLE LIQUID CHROMOGENIC ASSAYS FOR ANTI XA ACTIVITY IN HUMAN CITRATED PLASMA
Peter Quehenberger* (AT), Johann Bartko, Sabine Belik, Ulrike Wallner, Oswald Wagner

P-TU-223  EVALUATION OF METHODS FOR POTENCY TESTING OF PEGYLATED FVIII (PEG-FVIII, BAY 94-9027)
Lilley Leong* (US), Vince Evans, Philip Ramsey, Liang Tang, John E. Murphy, Heiner Apeler, Timothy Myles, Jesper Haanning

P-TU-224  DISCREPANCIES IN INTERNATIONAL NORMALIZED RATIO RESULTS BETWEEN INSTRUMENTS; THE EFFECT OF COAGULATION FACTORS
Una Oervim Soelvik (NO), Thomas Helge Roeraas, Per Hyltoft Petersen, Grete Monsen, Anne Vegard Stavelin*, Sverre Sandberg

P-TU-225  ANTITHROMBIN MUTATIONS IN THROMBOSIS PATIENTS CAUSING DIFFERENT RESULTS IN FUNCTIONAL ANTITHROMBIN TESTING
Ronald Fischer* (DE), Matthias Philipps, Kathrin Heidinger, Anna Pavlova, Johannes Oldenburg, Bettina Kemkes-Matthes

P-TU-226  EVALUATION OF THE PERFORMANCE CHARACTERISTICS OF A NEW HUMAN THROMBIN LIQUID REAGENT FOR FIBRINOGEN DETERMINATION
Pere Domenech* (ES), Elena Rossello, Emma Camacho, Mariona Bono, Virginia Montanini

P-TU-227  HOW IS EXTERNAL QUALITY ASSESSMENT OF POINT-OF-CARE INR TESTING PERFORMED IN EUROPE?
Anne Stavelin* (NO), Dianne Kitchen, Piet Meijer, Sverre Sandberg

P-TU-228  SOLUBLE TISSUE FACTOR-BASED FVIIA ASSAY FOR BAY 86-6150, A RECOMBINANT FVIIA VARIANT IN CLINICAL DEVELOPMENT
Junliang Pan* (US), Ji-Yun Kim, Timothy Myles, Edward Blank, John E. Murphy, Jesper Haanning
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-229  “IN VITRO” RESPONSE OF DABIGATRAN AND RIVAROXABAN ON THROMBIN GENERATION (CAT) AND FIBRIN FORMATION (ROTEM)
Meyer M Samama* (FR), Celine Guinet, Lena Le Fiem, Grigoris Gerotziolas

P-TU-230  DIFFERENCES BETWEEN ONE STAGE CLOTTING AND CHROMOGENIC FACTOR VIII ASSAY RESULTS
An K Stroobants* (NL), Erik-Jan van den Dool, Bianca Bakker, Marion Heckman, Pieter-Willem Kamphuisen, Auguste Sturk

P-TU-231  EXCLUSION OF HERITABLE PROTEIN C AND PROTEIN S DEFICIENCY IN PATIENTS WITH AN ELEVATED INR
Artur Jerzy Szkotak* (CA)

P-TU-232  EVALUATION OF AN EXTERNAL QUALITY ASSESSMENT MATERIAL FOR D-DIMER POINT OF CARE TESTING KITS
Dianne Kitchen* (UK), Sheline Munroe-Pearl, Steve Kitchen, Ian Jennings, Tim Woods, Isobel Walker

P-TU-233  A QUALITY CONTROL SYSTEM FOR INR PORTABLE MONITORS
Sophie Testa* (IT), Onia Paletti, Laura Bassi, Anke Zimmermann, Anna Cogrossi, Nika Delepero, Elisabetta Spotti, Emilia Cancellieri

P-TU-234  NANOFILTRATION STEP EFFECTIVELY REMOVES TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY (TSE) MODEL AGENTS DURING HIGH PURITY FACTOR IX PRODUCTION PROCESS
Salvador Grancha* (ES), Magdalena Otegui, Francisco J Belda, Jose M Diez, Santiago Caballero, Rodrigo Gajardo, Juan I Jorquera

P-TU-235  POST-ITI HAEMOPHILIA A PATIENTS BLEED BECAUSE OF THE PRESENCE OF LOW TITRE INHIBITORS
Myriam Dardikh* (NL), Thilo Albert, Robert Polenewen, Roos Masereeuw, Johannes Oldenburg, Britta Laros-van Gorkom, Irena Novakova, Wadner van Heerde, Bert Verbruggen

P-TU-236  DETERMINATION OF HUMAN ANTITHROMBIN IN MICE PLASMA BY ELISA
Maria Isabel Bravo* (ES), Patricia Sabelia, Juan I. Jorquera

P-TU-237  EVALUATION OF A NEW CONTROL MATERIAL FOR PROTHROMBIN TIME FOR POINT-OF-CARE INSTRUMENTS
Kerstin M Gustafsson* (SE), Tomas L Lindahl

P-TU-238  ELECTIVE MAJOR ORTHOPEDIC SURGERY IN A HIGH RESPONDER INHIBITOR HAEMOPHILIA A PATIENT: LABORATORY APPROACH CONTROL WITH THROMBELASTOGRAPHY (TEG) ASSAY
Manuela Carvalho (PT), Graça Oliveira, Manuela Reis, Carla Monteiro, Luis Manuel Cunha-Ribeiro*

P-TU-239  EVALUATION OF TWO ELISA SCREENING TESTS FOR DETECTION OF ANTI-FACTOR VIII INHIBITORY ANTIBODIES
Christophe Nougier* (FR), Frederic Sobas, Christine Vinciguerra, Claude Negrier

P-TU-240  INTER-PATIENT VARIATION WITH DIFFERENT CONCENTRATES USING A QUANTITATIVE FVIII BINDING ASSAY
Kampta Sukanu* (UK), Paul Giangrande, Jane Needham, Savita Rangarajan, Peter Collins

P-TU-241  THE USE OF THROMBIN GENERATION ASSAY IN PLASMA AND WHOLE BLOOD FOR THE EVALUATION OF COAGULABILITY IN PATIENTS WITH DIFFERENT STAGES OF LIVER DISEASE
Enrique Coll (US), Enrique Coll, Eliona Rrapo*, Nikolaos Prysopoulos, Liza Robles-Carrillo, Megan Hatfield, Alane Drexler, Ali Amirkhosravi, Eduardo Reyes, Kristin Rathmann, John Francis
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-242  FIBRINOLYTIC EFFECTS OF FACTOR XIII INHIBITION ARE POTENTIATED BY TISSUE PLASMINOGEN ACTIVATOR
Jerrold H Levy* (US), Fania Szlam, Heezoo Kim, Kenichi Tanaka, Satoru Ogawa, Martin Hils, Ralf Pasterнак, Jerrold H Levy

P-TU-243  PROINFLAMMATORY CYTOKINES GENE POLYMORPHISM AND SUSCEPTIBILITY TO VENOUS THROMBOEMBOLISM IN THE POPULATION OF THE NORTH-WESTERN REGION OF RUSSIA
Anastasia Polyakova* (RU), Yulia S Drizhun, Michael N Blinov, Natalia B Saltykova, Veronika M Shmelева, Sergey I Kapustin

P-TU-244  MARKERS OF HYPERCOAGULABILITY ARE INCREASED IN SEVERE OBESITY AND RELATE BOTH TO BMI AND VISCERAL ADIPOSY AS DETERMINED BY SINGLE SLICE CT
Paradzai Boniface Chitongo* (UK), Lara Roberts, Raj Patel, Lisa Yang, Rebecca Lyall, Richard Luxton, Simon Aylwin, Roopen Arya

P-TU-245  EVALUATION OF ELISA FACTOR VIII ANTIBODY SCREENING ASSAY COMPARED TO CLOTTING BASED BETHESDA INHIBITOR ASSAY
Jane Needham* (UK), Helen Lewis, Savita Rangarajan

Experimental models

P-TU-246  PROLONGED SERUM HALF-LIFE OF A RECOMBINANT FUSION PROTEIN LINKING ACTIVATED COAGULATION FACTOR VII WITH ALBUMIN (RVIIA-FP) IN DIFFERENT PRECLINICAL SPECIES
Gerhard Dickneite* (DE), Sabine Zollner, Thomas Weimer, Stefan Schmidbauer, Elmar Raquet, Jochen Mueller-Cohrs, Ingo Pragst, Stefan Schulte

P-TU-247  MEASUREMENT OF THROMBIN GENERATION IN PLASMA FROM SEVEN LABORATORY ANIMAL SPECIES

P-TU-248  ANTHEMOSTATIC EFFECT OF A PROTEOLYTIC FRACTION FROM CARICA CANDAMARCENSIS LATEX ON WISTAR RATS PLASMA, IN VITRO
Maria das Gracas Carvalho* (BR), Rogerio Pereira Bilheiro, Carlos Edmundo Salas Bravo, Miriam Teresa Paz Lopes

P-TU-249  THE ANTITHROMBOTIC ACTIVITY OF EP224283, A NEUTRALIZABLE DUAL FACTOR XA INHIBITOR/αIIbβ3 ANTAGONIST, EXCEEDS THAT OF THE CO-ADMINISTRATED PARENT COMPOUNDS
Beatrice Hechler* (FR), Monique Freund, Ghina Alame, Cecile Leguay, Sebastien Gaertner, Jean-Pierre Cazenave, Maurice Pettitou, Christian Gachet

P-TU-250  COMPARATIVE STUDIES ON THE GENERIC VERSIONS OF ENOXAPARIN
Jawed Fareed* (US), Indermohan Thethi, Walter Jeske, Evangelos Litinas, Josephine Cunanan, Debra Hoppensteadt, Jeanine Walenga

P-TU-251  A STANDARDIZED FVIII DEPENDENT TAIL BLEEDING MODEL IN FVIII +/- MICE
Gary J Jesmok* (US), Philip Scuderi, Walter Faison, Kyle Landskroner

P-TU-252  CROSS REACTIVITY OF NATURAL HIRUDIN COMPARED TO THE RECOMBINANT HIRUDINS WITH SHEEP ANTI HIRUDIN ANTIBODY
Vijaya Paramatmuni* (US), Debra Hoppensteadt, Evangelos Litinas, Nasir Saddeghi, Jawed Fareed
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-253  EVALUATION OF PROTHROMBIN COMPLEX CONCENTRATE AND RECOMBINANT ACTIVATED FACTOR VII TO REVERSE FONDAPARINUX IN A RABBIT MODEL
Anne Godier* (FR), Bernard Le Bonniec, Marion Durand, Anne Marie Fischer, Joseph Emmerich, Thomas Lecompte, Charles Marc Samama

P-TU-254  A BAYESIAN APPROACH FOR QUALITY CONTROL IN FACTOR VIII CLOTTING ASSAY: DEFICIENT PLASMA QUALITY IMPACTS HEMOPHILIA MANAGEMENT
Frederic Sobas* (FR), Panagiotis Tsiamyrtzis, Anne Lienhart, Christophe Nougier, Claude Negrier

P-TU-255  THE INHIBITION OF LUNG METASTASIS BY INACTIVATION OF COAGULATION ACTIVITY MAY LEAD TO DISSEMINATION OF TUMOR CELLS

P-TU-256  EVALUATION OF PROTHROMBIN COMPLEX CONCENTRATE, RECOMBINANT ACTIVATED FACTOR VII AND FIBRINOGEN CONCENTRATE TO REVERSE RIVAROXABAN IN A RABBIT MODEL
Anne Godier* (FR), Anastasia Miclot, Bernard Le bonniec, Marion Durand, Joseph Emmerich, Anne Marie Fischer, Thomas Lecompte, Charles Marc Samama

P-TU-257  EVALUATION OF HEMOSTATIC DISTURBANCES CAUSED BY ADULT AND YOUNG BOTHROPS JARARACA SNAKE VENOMS AND NEUTRALIZATION BY SPECIFIC ANTIVENIN
Luana V. Senise* (BR), Marcio Y. Yano, Marcelo L. Santoro, Ida S. Sano-Martins

Plasminogen activator inhibitors

P-TU-258  IMPAIRED TNF SIGNALLING REVEALED THE ROLE OF KUPFFER CELLS IN LIVER PAI-1 AND GLUCOSE PRODUCTION
Ilse Scroyen* (FR), Delphine Bastelica, Odile Georgelin, Monique Verdier, Nico Van Rooijen, Franck Peiretti, Marie-Christine Alessi

P-TU-259  HAEMOSTATIC DISEQUILIBRIUM: THE MISSING LINK BETWEEN GADOLINIUM AND NEPHROGENIC SYSTEMIC FIBROSIS?
Ilse Scroyen* (FR), Delphine Bastelica, Jean-Francois Landrier, Odile Georgelin, Monique Verdier, Nico Van Rooijen, Franck Peiretti, Marie-Christine Alessi

P-TU-260  SPONTANEOUS PLASMA CLOT LYSIS TIME ASSAY REVEALED THE IMPORTANCE OF “COAGULATION-ASSOCIATED ENHANCEMENT OF FIBRINOLYSIS”
Tetsunei Urano* (JP), Tomasz Brzoska, Yuko Suzuki

P-TU-261  RELATIONSHIPS OF PAI-1 4G/5G POLYMORPHISM AND CONVENTIONAL RISK FACTORS FOR CORONARY ARTERY DISEASE WITH THE SEVERITY OF CORONARY STENOSIS
Chutima Rattanawan* (TH), Nantarat Komasin, Nongnuch Settasatian, Chatri Settasatian, Upa Kukongviriyapan, Pongsak Intharapetch, Suthit Hongsorn, Kasem Tantipanichteerakul, Vichai Senthong

P-TU-262  INITIATION OF INSULIN THERAPY AMELIORATES FIBRINOLYSIS IN TYPE 2 DIABETES
Bregtje Annelieke Lemkes* (NL), J.Hans De Vries, Max Nieuwdorp, Ricardo De Grooth, Joost B.L. Hoekstra, Joost C.M. Meijers, Frits Holleman

P-TU-263  SUPPRESSIVE ACTIONS OF FUCOIDAN ON LIPID DROPLET FORMATION AND PLASMINOGEN ACTIVATOR INHIBITOR-1 EXPRESSION IN ADIPOCYTES
Akira Hayashi* (JP), Yuwna Yakura, Makoto Taniguchi, Akinori Tomita, Hiroyuki Takeya
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-264 REGULATION OF LEUKOTRIENE PRODUCTION AND PLASMINOGEN ACTIVATOR INHIBITOR-1 EXPRESSION IN ADIPOSE TISSUE
Akira Hayashi* (JP), Makoto Taniguchi, Yuwma Yakura, Jyunya Miyabara, Harumi Yamamoto, Yasunori Kozutsumi, Toshiro Okazaki, Hiroyuki Takeya

New thrombolytic agents and drug design

P-TU-265 FACTORS CRITICAL FOR THE EFFICACY OF DIRECT THROMBOLYRICS
Valery Novokhatny* (US), Dean Chamberlain, John Bromirski, Jennifer Nixon, Philip Scuderi, Stephen R. Petteway, Jr

P-TU-266 COMPARISON OF PLASMIN WITH RT-PA IN LYSIS OF CEREBRAL THROMBOEMBOLI RETRIEVED FROM PATIENTS WITH ACUTE ISCHEMIC STROKE

P-TU-267 ENCAPSULATION OF STREPTOKINASE WITH INERT FILLER IN POLYETHYLENE GLYCOL (PEG) SHELLS
Roza B Aisina* (RU), Mikhail Y Levashov, Lilia I Mukhametova, Anastasia S Medvedeva, Sergei D Varfolomeyev

P-TU-268 SPECIFICITY AND IMMUNOCHEMICAL PROPERTIES OF NATTOKINASE
Hiroyuki Sumi* (JP), Sawa Naito, Chieko Yatagai, Etsuo Yoshida, Tadanori Ohsugi, Yasuhide Yanagisawa, Josuke Saito, Masugi Maruyama

P-TU-269 ELASTASE ACTIVITY AND ELASTATINAL INHIBITION OF NATTOKINASE
Hiroyuki Sumi* (JP), Sawa Naito, Josuke Saito, Masugi Maruyama

P-TU-270 A FAVORABLE OUTCOME OF DISSEMINATED INTRAVASCULAR COAGULATION IN CHILDREN USING RECOMBINANT THROMBOMODULIN
Hiroshi Yagasaki* (JP), Maiko Kato, Hiroyuki Shichino, Motoaki Chin, Hideo Mugishima

P-TU-271 OPTIMIZATION TECHNOLOGY FOR OBTAINING THROMBIN-LIKE ENZYME FROM AGKISTRODON BLOMHOFFII USSURIENSIS VENOM FOR INDUSTRIAL SCALING OPTION
Bolor Buyanbadrakh* (MN), Sumiya Byambasuren, Punsaldulam Dashnyam

P-TU-272 DEVELOPMENT OF THE NEW DRUG DELIVERY SYSTEM FOR THROMBOLYSIS WITH ULTRASOUND IN ACUTE CORONARY SYNDROME
Hiroyuki Kawata* (JP), Tsunenari Soeda, Ji-Hee Sung, Yoshiko Uesugi, Yasuhiko Tabata, Kiyotaka Umaki, Keiji Kato, Yoshihiko Saito

P-TU-273 MULTIFUNCTIONAL METALLOPROTEINASE FROM VIPERA LEBETINA VENOM
Ene Siigur* (EE), Katrin Trummal, Mari Sarvet, Kyyli Tonismagi, Heiki Vija, Juhan Subbi, Juri Siigur

P-TU-274 OPTIMIZATION OF MODIFIED RECOMBINANT ALBUMINS THAT SPEED CLOT LYSIS BY COMPETING FOR CROSSLINKING OF ANTIPLASMIN
William P Sheffield* (CA), Louise J Eltringham-Smith

P-TU-275 POTENTIATION OF PLASMIN ACTIVITY BY ENZAMIN, AN EXTRACT OF METABOLITE FROM BACILLUS SUBTLILIS AK AND LACTOBACILLUS IN VITRO AND IN VIVO
Yukinori Tamura* (JP), Kiyotaka Okada, Naoyuki Kawao, Masato Yano, Shigeru Ueshima, Nobuo Nagai, Osamu Matsuo
POSTER PRESENTATIONS

Tuesday, July 26, 2011

Laboratory tests

P-TU-276  DURATION OF POST-OPERATIVE FIBRINOLYSIS AFTER MAJOR HIP OR KNEE SURGERY: A BIOLOGICAL FOLLOW-UP STUDY
Nadia Rosencher* (FR), Lorenn Bellamy, Antonia Blanie, Yarad Rhayem, Claire Flaujac, Michaela Fontenay

P-TU-277  MONITORING HEMOSTASIS WITH OVERALL HEMOSTATIC POTENTIAL (OHP) ASSAY DURING LENALIDOMIDE AND DEXAMETHASONE (LEN/DEX) THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (R-MM)
Jennifer L Curnow* (AU), Caroline Reddel, Kate Burbury, Peter Gambill, Amanda Choo, Judith Trotman, Kevin Lynch, Hang Quach, H Miles Prince, David Westerman, Jennifer Curnow

P-TU-278  STUDY UTILISING A NEW BIOMARKER (GEL POINT) TO DETERMINE AT WHAT STAGE FIBRINOLYSIS MODIFIES CLOT DEVELOPMENT AND STRUCTURE
Matthew James Lawrence* (UK), Sophia Stanford, Karl M Hawkins, Simon Davidson, P Rhodri Williams, Phillip Adrian Evans

P-TU-279  ANALYSIS OF THROMBOLYSIS PROCESS IN PLASMA WITH TWO D-DIMER ORIGINAL QUANTITY KITS
Yasuo Magari* (JP), Tomoharu Okazaki

P-TU-280  CROTALUS DURISSUS ACCIDENT: CHANGES IN NATURAL ANTIocoAGULATION AND FIBRINolyTIC SYSTEMS
Luciana Moreira Lima* (BR), Maria das Gracas Carvalho, Luci Maria Santanna Dusse, Carlos FS Amaral

P-TU-281  DIAGNOSIS OF NONOVERT DISSEMINATED INTRAVASCULAR COAGULATION USING CRITERIA FROM THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HEMOSTASIS WITH REJECTING NEGATIVE SCORES
Jonghwa Lee* (KR), Jawoo Song

P-TU-282  CLOT LYSIS TIME IN PLATELET-RICH PLASMA: METHOD ASSESSMENT, RESPONSE TO TRANEXAMIC ACID AND COMPARISON WITH THE ASSAY IN PLATELET-POOR PLASMA
Panes Olga* (CL), Oslando Padilla, Claudia G Saez, Alejandro Berkovits, Jaime Pereira, Diego Mezzano

P-TU-283  AN ATTENUATED FIBRINOLYTIC PROFILE IS ASSOCIATED WITH RISK OF A FIRST MYOCARDIAL INFARCTION AS MEASURED USING A GLOBAL HEMOSTATIC ASSAY
Shu He* (SE), Karin Leander, Margareta Blomback, Hakan Wallen

P-TU-284  PROLONGED CLOT LYSIS TIME (CLT) IN PRP AND PPP IN HYPERCHOLESTEROLEMIA (HYPERCH): PROTECTIVE EFFECT OF HDL-CHOLESTEROL AND PARTIAL CORRECTION BY ATORVASTATIN
Diego Mezzano* (CL), Monica Acevedo, Valeria Matus, Alejandro Berkovits, Jaime Pereira, Olga Panes

Deep vein thrombosis and pulmonary embolism

P-TU-285  VENOUS THROMBOEMBOLISM IN NEUROSURGERY PATIENTS
Kerry Hitos* (AU), John P Fletcher

P-TU-286  ACCURACY OF WELLS SCORING IN PREDICTION OF DEEP VEIN THROMBOSIS
Małgorzata Dybowska (PL), Witold Z Tomkowski*, Renata Gralec, Janusz Burakowski, Adam Jozwik, Pawel Kuca
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-287  RISK FACTORS, ANTITHROMBOTIC TREATMENT AND OUTCOME IN RETINAL VEIN OCCLUSION: AN AGE-RELATED PROSPECTIVE COHORT STUDY
Maria Teresa Sartori* (IT), Sofia Barbar, Annalisa Dona', Stefano Piermarocchi, Elisabetta Pilo,ta, Graziella Saggiorato, Andrea Ballin, Paolo Prandoni

P-TU-288  PREVENTION OF THROMBOEMBOLIC EVENTS IN TRAUMATOLOGIC SURGERY: A META-ANALYSIS OF RANDOMIZED TRIALS
Celine Chapelle* (FR), Nadia Rosencher, Paul Zufferey, Patrick Mismetti, Michel Cucherat, Silvy Laporte

P-TU-289  BODY HEIGHT AS A RISK FACTOR FOR RECURRENT VENOUS THROMBOSIS
Linda E Flinterman* (NL), Astrid Hylckama Vlieg, Frits R Rosendaal, Suzanne C Cannegieter

P-TU-290  EFFICACY AND SAFETY OF THERAPEUTIC DOSAGES OF LOW-MOLECULAR WEIGHT HEPARIN IN HIGH-RISK PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY
Jan Beyer-Westendorf* (DE), Lars Donath, Joerg Luetzner, Sebastian Werth, Norbert Weiss

P-TU-291  A PROSPECTIVE STUDY ON VENOUS THROMBOEMBOLISM FOLLOWING SPINAL SURGERY: USE OF THROMBOPROPHYLAXIS AND ASSOCIATED BLEEDING COMPLICATIONS
Kerry Hitos* (AU), James Rogers, Gavin Soo, Andrew Cree, Mark Dexter, Gordon Dandie, Charles New, Michael Fearnside, John Cummine, Brian Owler, John P Fletcher

P-TU-292  ALGORITHM FOR THE MANAGEMENT OF PORTAL VEIN THROMBOSIS: A PROSPECTIVE STUDY IN PATIENTS WITH LIVER CIRRHOSIS
Maria Teresa Sartori* (IT), Marco Senzolo, Valeria Rossetto, Patrizia Burra, Umberto Cillo, Patrizia Boccagni, Paolo Gasparini, Emmanuel Tschochatzis, Paolo Simioni, Andrew K. Burroughs

P-TU-293  STATIN USE AND FIRST VENOUS THROMBOSIS RISK: A SUBGROUP ANALYSIS WITHIN THE MEGA STUDY INTO CLINICAL UTILITY AND MECHANISM
Willem M Lijfering* (NL), Astrid van Hylckama Vlieg, Frits Rosendaal, Frits Cannegieter

P-TU-294  RISK OF VENOUS THROMBOSIS ASSOCIATED WITH COAGULATION FACTOR VIII AND ITS INTERRELATIONSHIP WITH OTHER PROCAGULANT AND ENVIRONMENTAL RISK FACTORS
Willem M Lijfering* (NL), Frits Rosendaal, Pieter Reitsma, Suzanne Cannegieter

P-TU-295  THE ASSOCIATION OF CONCOMITANT USE OF ESTROGEN HORMONES AND STATINS AND THE RISK OF VENOUS THROMBOSIS
Astrid van Hylckama Vlieg* (NL), Nicholas L. Smith, Willem M. Lijfering, Frits R. Rosendaal, Bruce M. Psaty

P-TU-296  IMPLEMENTATION OF A VENOUS THROMBOEMBOLISM (VTE) RISK ASSESSMENT TOOL TO IMPROVE INPATIENT THROMBOPROPHYLAXIS
Gunjan Varma* (UK), Sarah Mills, Charles Gutteridge, Peter MacCallum

P-TU-297  THE INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN EAST LONDON
James Uprichard* (UK), K Booma, S Mills, C Gutteridge, P K MacCallum

P-TU-298  ANATOMICAL LOCATION OF THROMBI AND A COMPARISON OF THROMBUS LENGTH AS A MARKER OF EXTENSIVENESS IN PATIENTS WITH PULMONARY EMBOLI VERSUS DEEP-VEIN THROMBOSIS
Kirsten van Langevelde* (NL), S. C. Cannegieter, P. W.J. Vincfen, C. J. van Rooden, F. R. Rosendaal, A. Sramek

P-TU-299  EFFICACY AND SAFETY OF VTE PROPHYLAXIS WITH FONDAPARINUX OR LOW-MOLECULAR WEIGHT HEPARIN IN A LARGE COHORT OF CONSECUTIVE PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY
Jan Beyer-Westendorf* (DE), Lars Donath, Sebastian Werth, Joerg Luetzner, Norbert Weiss
### POSTER PRESENTATIONS

**Tuesday, July 26, 2011**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TU-301</td>
<td>FONDAPARINUX FOR ISOLATED SUPERFICIAL-VEIN THROMBOSIS OF THE LEGS: A COST-EFFECTIVENESS ANALYSIS</td>
<td>Marc Blondon* (CH), Marc Righini, Henri Bounaumeaux, David L Veenstra</td>
</tr>
<tr>
<td>P-TU-302</td>
<td>SHOULD PATIENTS WITH SUSPECTED NON-MASSIVE PULMONARY EMBOLISM RECEIVE ANTICOAGULATION PRIOR TO THE DEFINITE DIAGNOSIS? A DECISION ANALYSIS</td>
<td>Marc Blondon* (CH), Gregoire Le Gal, Drahomir Aujesky, Marc Righini, Arnaud Perrier</td>
</tr>
<tr>
<td>P-TU-303</td>
<td>VENOUS THROMBOEMBOLISM (VTE) IS A RARE COMPLICATION WITHOUT APPARENT RISK FACTORS IN JAPANESE MYELOMA PATIENTS TREATED WITH THALIDOMIDE</td>
<td>Atsushi Kato* (JP), Keiichiro Hattori, Michiro Mikoshiba, Hina Takano, Minoru Nakane</td>
</tr>
<tr>
<td>P-TU-304</td>
<td>MOLECULAR ANALYSIS OF THE PHENOTYPES AND GENOTYPES IN TWO CHINESE FAMILIES WITH INHERITED ANTITHROMBIN DEFICIENCY</td>
<td>Yan Xia* (CN)</td>
</tr>
<tr>
<td>P-TU-305</td>
<td>EVALUATION OF THE RISK FACTORS OF VENOUS THROMBOEMBOLISM IN JAPANESE SURGICAL AND NON-SURGICAL PATIENTS USING ELECTRONIC PATIENT DATABASE</td>
<td>Masaato Sakon* (JP), Yoshihiko Maehara, Takao Kobayashi, Norimasa Seo, Hiroshi Kobayashi, Toru Shimazui, Yasushi Ozeki</td>
</tr>
<tr>
<td>P-TU-307</td>
<td>RISK OF VENOUS THROMBOSIS FOR COMMON INFECTIOUS AND INFLAMMATORY DISEASES: A CASE-CONTROL STUDY</td>
<td>Daniel Dias Ribeiro* (BR), Willem Lijfering, Astrid Van Hylckama Vlieg, Frits Rosendaal, Suzanne Cannegieter</td>
</tr>
<tr>
<td>P-TU-308</td>
<td>GIESSEN THROMBOPHILIA STUDY: LIPOPROTEIN (A) IN VENOUS THROMBOEMBOLISM</td>
<td>Bettina Kemkes-Matthes* (DE), Anette Kirsch-Altena, Angela Korb-Bangang, Kathrin Heidinger, Ronald Fischer</td>
</tr>
<tr>
<td>P-TU-309</td>
<td>GIESSEN THROMBOPHILIA STUDY: FACTOR VIII:C IN VENOUS THROMBOEMBOLISM</td>
<td>Bettina Kemkes-Matthes* (DE), Anette Kirsch-Altena, Kathrin Heidinger, Ronald Fischer</td>
</tr>
<tr>
<td>P-TU-311</td>
<td>CORRELATION BETWEEN CLINICAL SUSPICION AND BIOLOGICAL DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): EXPERIENCE FROM A SINGLE CENTER</td>
<td>Amparo Santamaria* (ES), Albert Esquiroi, Amparo Santamaria, Montserrat Borrell, Dolors Llobet, Cristina Vallve, Veronica Orantes, Jordi Fontcuberta</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-313  REPEATED NT-PROBNP TESTING AND RISK FOR ADVERSE CLINICAL OUTCOME AFTER ACUTE PULMONARY EMBOLISM
Wendy Zondag* (NL), Mariette Agterof, Roger Schutgens, Olaf Dekkers, Douwe Biesma, Menno Huisman

P-TU-314  RIGHT VENTRICULAR DYSFUNCTION IN PATIENTS WITH PULMONARY EMBOLISM TREATED AT HOME OR IN THE HOSPITAL
Wendy Zondag* (NL), Birgitta I. Hiddinga, Geert Labots, Lies M. A. Vingerhoets, Lucia J.M. Kroft, Menno V. Huisman

P-TU-315  VENOUS THROMBOEMBOLISM IN PATIENTS WITH DEMENTIA
Adriana Visona* (IT), Manuel Jesus Nunez, Joan Carles Villalba, Ernesto Cebrian, Luciano Lopez-Jimenez, Marta Nunez, Tali-Anne Szwebel, Jose Manuel Luque, Maria Jesus Jaras, Manuel Monreal, and the RIETE INVESTIGATORS

P-TU-316  SEASONAL VARIATION OF VENOUS THROMBOSIS: A CONSECUTIVE CASE SERIES WITHIN THE MEGA AND TROMSO STUDY
Daniel Dias Ribeiro* (BR), Sigríð K. Braekkan, Willem M. Lijfering, Ellen E. Brodin, Frits R. Rosendaal, John-Bjarne Hansen

P-TU-317  THE IMPLEMENTATION OF THE PADUA PREDICTIVE SCORE HAS THE POTENTIAL TO INCREASE THE RATE OF VTE PROPHYLAXIS IN HIGH-RISK MEDICAL PATIENTS
Valeria Rossetto* (IT), Sofia Barbar, Alessandra Ferrari, Daniela Tormene, Antonio Pagnan, Paolo Prandoni

P-TU-319  FOUR DIFFERENT CLINICAL DECISION RULES IN THE DIAGNOSTIC WORK-UP OF PE IN PATIENTS WITH A MALIGNANCY

P-TU-320  A CLINICAL AUDIT INTO THE USE OF A VENOUS THROMBOEMBOLISM RISK ASSESSMENT TOOL IN A LARGE TERTIARY REFERRAL HOSPITAL IN NORTHERN IRELAND
Daniel Gerard O’Callaghan* (UK), Claire Corrigan, Gary Benson

P-TU-321  EFFECT OF LOW ALBUMIN ON AVAILABLE MONITORING METHODS FOR THERAPEUTIC UNFRACTIONATED HEPARIN THERAPY
Oxana Tcherniantchouk* (US), Ali Reza Rejali, Sylvia Martin Stone

P-TU-322  ARTERIAL AND VENOUS THROMBOSIS IN DIALYSIS PATIENTS

P-TU-323  RISK FACTORS FOR POST-DISCHARGE BLEEDING IN US MEDICALLY ILL PATIENTS AT RISK OF VENOUS THROMBOEMBOLISM (VTE)
Charles Mahan* (US), Winslow Klasakla, Maxine Fisher, An-Chen Fu, Larry E Fields, Roger Mills, Judith J Stephenson, Tom Wasser, Joseph Singer, Alex C Spyropoulos

P-TU-324  SEVERITY OF ILLNESS STRONGLY PREDICTS DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED MEDICAL PATIENTS WITHOUT CANCER
Richard H White* (US), Beate Danielsen, Daniel J Tancredi, Calvin H Hirsch, Jeffrey Schein, Larry E Fields, CV Damaraju, Monika Raut, Scott Kaatz

P-TU-325  AUTOPSY RATES AND THE INCIDENCE OF PULMONARY EMBOLISM: AN UNDERCOUNT
John A Heit (US), Kent R Bailey, Tanya M Petterson*, Aneel A Ashrani, Daniel J Crusan, Cynthia L Leibson
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-326  THE PREVALENCE OF VARIOUS CLINICAL MANIFESTATIONS OF VENOUS THROMBOEMBOLISM IN THE GROUP OF 441 PATIENTS
Jana Hirmerova* (CZ), Jitka Seidlerova

P-TU-327  DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA WITH WHOLE BLOOD PLATELET AGGREGATION TEST AND ELISA ANTI PF4 HEPARIN TEST
Mariette D Lepine-Martin* (CA), Annie Lacroix, Patrice Beauregard, Jean Dufresne, Line Delisle, Rami Korb, Hans Knecht, Richard Leblanc, Carole St-Onge

P-TU-328  EFFECT OF RACE/ETHNICITY ON THE RISK OF ACUTE VENOUS THROMBOEMBOLISM (VTE) DURING MEDICAL HOSPITALIZATION AND AFTER HOSPITAL DISCHARGE
Richard H White* (US), Beate Danielsen, Daniel J Tancredi, Calvin H Hirsch, Jeffrey Schein, Larry Fields, CV Dajamaru, Monika Raut, Scott Kaatz

P-TU-329  COMPARATIVE EFFECTIVENESS OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) PROPHYLAXIS IN MORBIDLY OBESE AND LESS OBESE PATIENTS UNDERGOING TOTAL KNEE ARTHROPLASTY (TKA)
Richard H White* (US), Banafsheh Sadeghi, Amy Strater, Laurie Hensley, Julie Cereso, Greg Maynard, Patrick S Romano

P-TU-330  FREQUENCY OF ARTERIOVENOUS THROMBOSIS IN END STAGE RENAL DISEASE PATIENTS
Munira Borhany* (PK), Tahir Shamshi, Arshi Naz, Zafar Mirza Naqi, Syed Anwar Naqi, Rizvi Adribul Hassan

P-TU-331  TRANSFUSIONS, BLEEDINGS, AND PREVENTION OF VENOUS THROMBOSIS WITH ENOXAPARIN OR FONDAPARINUX IN REAL-LIFE PRACTICE
Philippe Girard* (FR), Joelle Demaria, Raffaele Caliandro, Daniele Girard, Alice De Sanctis, Jean-Baptiste Stern

P-TU-332  MDCT-DETECTED EMBOLIC BURDEN AND CLINICAL OUTCOME IN PATIENTS WITH ACUTE PULMONARY EMBOLISM
Cecilia Becattini* (IT), Maria Cristina Vedovati, Marthe Schreuder, Luca Masotti, Piotr Pruszczysz, Franco Casazza, Aldo Salvi, Stefano Grifoni, Anna Carugati, Stavros Konstantinides, Pieter Kamphuisen, Michele Duranti, Giancarlo Agnelli

P-TU-333  THYROID DISEASE, ANTITHYROID OR THYREOMIMETIC AGENTS, AND THE RISK OF PULMONARY EMBOLISM
Breggie van Zaane* (NL), Alessandro Squizzato, Sara Biere-Rafi, Patrick C Souverein, Dees PM Brandjes, Harry R Buller, Victor EA Gerdes, Antonius de Boer

P-TU-334  TWO NOVEL MUTATIONS IN TWO UNRELATED SUBJECTS WITH HEREDITARY PROTEIN S DEFICIENCY
Zhifang Xing* (CN)

P-TU-335  A RARE SPLICING MUTATION IN PROS1 GENE OF KOREAN PATIENT WITH TYPE I HEREDITARY PROTEIN S DEFICIENCY
Jonghyeon Choi (KR), Duck Jin Hong*, Seung Jun Choi, Hee-Jin Kim, Myung Hee Chang, Sue Jung Kim, Jaewoo Song, Jong Rak Choi, Jong-Ha Yoo

Genetic determinants and epidemiology

P-TU-336  INTRA-INDIVIDUAL VARIABILITY IN STEADY PATIENTS ON LONG-TERM ACENOOCUMAROL THERAPY
Virginia Perez-Andreu* (ES), Vanessa Roldan, Javier Corral, JR Gonzalez-Porras, F Ferrando, F Lopez Fernandez, Cristina Pascual, Nuria Garcia-Barbera, Jordi Fontcuberta, Vicente Vicente Garcia, Rocío Gonzalez-Concejero
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-337  GENETIC DETERMINANTS OF PLATELET COUNTS AND IMMATURE PLATELET FRACTION (IPF). RESULTS FROM THE GAIT PROGRAM
Nuria Pujol-Moix* (ES), Anna Brichs, Miquel Vazquez-Santiago, Angel Martinez-Perez, Josep F Nomdedeu, Ramon Ayats, Jordi Fontcuberta, Joan Carles Souto, Jose Manuel Soria

P-TU-338  GENETIC DETERMINANTS OF BLOOD CELL COUNTS AND RETICULOCEYTE COUNTS. RESULTS FROM THE GAIT PROGRAM
Nuria Pujol-Moix* (ES), Anna Brichs, Joan Carles Souto, Leonor Rib, Ramon Ayats, Jordi Fontcuberta, Josep F Nomdedeu, Jose Manuel Soria

P-TU-339  CEREBRAL VENOUS THROMBOSIS: RISK FACTORS
Antonella Tufano* (IT), Mirko Di Capua, Matteo Nicola Dario Di Minno, Anna Guida, Anna Maria Cerbone, Giovanni Di Minno

P-TU-340  PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF “ATYPICAL” MUTATIONS OF THE PROTHROMBIN GENE IN 23 PATIENTS
Claire Flaujac (FR), Sophie Lobies, Olivier Kosmider, Etienne Audureau, Jacqueline Conard*, Marie-Helene Horellou, Michaela Fontenay

P-TU-341  INHERITED THROMBOPHILIA AND THROMBOSIS IN GEORGIAN POPULATION
Nugzar SH. Pargalava* (GE), Nino A. Pirtskhelani, Nugzar Sh. Pargalava, Mamuka G. Bokuchava, Nino Kochiashvili

P-TU-342  FAMILY HISTORY OF MYOCARDIAL INFARCTION AS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM AMONG WHITES AND BLACKS
Fatima Donia Mill* (US), W. Craig Hooper, Cathy Lally, Harland Austin

P-TU-343  INFLAMMATION AND RISK OF COGNITIVE DECLINE IN BLACK AND WHITE AMERICANS IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) STUDY
Sarah Gillett* (US), Leslie A McLure, Virginia G Wadley, Stephen P Glasser, Virginia J Howard, Brett M Kissela, Frederick W Unverzagt, Nancy S Jenny, Mary Cushman

P-TU-344  CYP2C9 POLYMORPHISM IN NORMAL SAUDI INDIVIDUALS AND PATIENTS WITH VENOUS THROMBOSIS AND THOSE REQUIRING LOW DOSE WARFARIN - A PROSPECTIVE STUDY
Jalal Saour* (SA), Atia Sheereen, Basil Saour, Layla Mammo

P-TU-345  INHERITED THROMBOPHILIA IN NORMAL SAUDIS AND THOSE WITH VENOUS THROMBOSIS - THE SAUDI THROMBOPHILIA AND FAMILIAL THROMBOPHILIA REGISTRY
Jalal Saour* (SA), Atia Sheereen, Tanya Saour, Mohammed Shoukri, Layla Mammo

P-TU-346  PROTHROMBIN MUTATION GENE (G-A 20210) IN THROMBOPHILIC PATIENTS AND GENERAL POPULATION
Jan Stasko* (SK), Peter Kubisz, Juraj Chudej, Daniela Kotulicova, Radoslava Camajova, Lenka Bartosova, Ivana Plamenova, Juraj Sokol

P-TU-347  ANTITHROMBIN DEFICIENCY: A CLINICAL AND GENETIC STUDY OF NINE TAIWANESE PATIENTS
Yeu-Chin Chen* (TW), Shin-Nan Cheng, Hu Shu-Hsia, Yiang Amy

P-TU-348  ASSOCIATION OF P-SELECTIN GENE POLYMORPHISMS WITH ARTERIAL ISCHEMIC STROKE IN CHILDREN
Desiree Coen Herak* (HR), Marina Pavic, Margareta Radic Antolic, Jasna Lenicek Krleza, Renata Zrinski Topic, Slavica Dodig, Renata Zadro
POSTER PRESENTATIONS

Tuesday, July 26, 2011

Antiphospholipid syndrome

P-TU-349  THE 4G/5G POLYMORPHISM OF THE PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) GENE AND THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME

P-TU-350  THE SIGNIFICANCE OF PHOSPHATIDYLSERINE (PHS) AS PREDICTOR OF ANTIPHOSPHOLIPID SYNDROME (APS)
Tarek Owaidah* (SA), Haeethm Khogeer

P-TU-351  ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Katia M Taouli* (DZ), Rawda Sari, El Hadj Kendouci, Omar Bougdhene Stambouli, Jean Francois Schved

P-TU-352  PHOSPHATIDYLSERINE-DEPENDENT ANTIPROTHROMBIN ANTIBODIES (APS/PT) IS A USEFUL PREDICTIVE MARKER OF THROMBOSIS IN PATIENTS WITH AUTOIMMUNE DISEASES
Kotaro Otomo* (JP), Olga Amengual, Tatsuya Atsumi, Yuichiro Fujieda, Masaru Kato, Tetsuya Horita, Shinsuke Yasuda, Walter Binder, Takao Koike

P-TU-353  EXPERIENCE WITH THE SAPPORO CRITERIA FOR THE ANTIPHOSPHOLIPID SYNDROME (APS) IN A PUBLIC CITY HOSPITAL
Michael A Nardi* (US), Fauzia Beig, Margaret Karpatkin

P-TU-354  EVALUATION OF DIFFERENT ASSAYS AND METHODS FOR INTERPRETATION OF RESULTS FOR LUPUS ANTICOAGULANT (LA) TESTING, ACCORDING TO 2009 SSC/ISTH GUIDELINES
Elizabeth M Duncan* (AU), Oi-Lin Lee, Olivia Yacoub, Simon McRae

P-TU-355  DISCRIMINATION OF A LUPUS ANTICOAGULANT CAUSED BY ANTIPHOSPHOLIPID ANTIBODIES OR RIVAROXABAN USING TAIPAN VENOM TIME
Gwendolyn Margaretha van Os* (NL), Bas de Laat, Pieter Willem Kamphuisen, Joost C. Meijers, Philip G. de Groot

P-TU-356  EVOLUTIONARY CONSERVATION OF β2-GLYCOPROTEIN 1 IN VERTEBRATES
Cetin Agar* (NL), Philip G. de Groot, Arnoud J. Marquart, Joost C.M. Meijers

P-TU-357  EVALUATION OF LUPUS ANTICOAGULANTS DETECTION BY PHOTO-OPTICAL AND MECHANICAL COAGULOMETERS
Napaporn Archararit* (TH), Kacharin Aryurachai, Bubpha Rachakom, Pantep Angchaisuksiri, Suporn Chuncharunee

P-TU-358  PREVALENCE AND LABORATORY IDENTIFICATION OF LUPUS ANTICOAGULANTS IN THAI PATIENTS
Kacharin Aryurachai* (TH), Napaporn Archararit, Bubpha Rachakom, Pantep Angchaisuksiri, Suporn Chuncharunee

P-TU-359  RESIDUAL VENOUS THROMBOSIS AS A MARKER OF ATHEROSCLEROSIS DEVELOPMENT IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
Witold Z Tomkowski* (PL), Bogdan Hajduk, Grzegorz Malek, Pawel Kuca, Małgorzata Dybowska, Małgorzata Sobieszczanska - Malek, Martyna Meissner, Witold Tomkowski

P-TU-360  OUTCOME OF KIDNEY TRANSPLANTATION IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A CASE SERIES
Karen A Breen* (UK), K Sritharan, J Olsburgh, BJ Hunt
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-361  ANTITHROMBOTIC EFFECTS OF HYDROXYCHLOROQUINE IN PATIENTS WITH ANTI PHOSPHOLIPID ANTIBODIES AND SYSTEMIC LUPUS ERYTHEMATOSUS
Karen A Breen* (UK), K Parmar, BJ Hunt

Disseminated intravascular coagulation

P-TU-362  DYSREGULATION OF INFLAMMATORY AND HEMOSTATIC MARKERS IN DISSEMINATED INTRAVASCULAR COAGULATION
Debra A Hoppensteadt* (US), Josephine Cunanan, Cafer Adiguzel, Jawed Fareed, Inder Kaul

P-TU-363  THE CLINICAL FEATURES AND GOOD OUTCOMES OF 35 DISSEMINATED INTRAVASCULAR COAGULATION (DIC) CASES TREATED WITH RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN (RTM)
Noriaki Kawano* (JP), Shuro Yoshida, Nobuyuki Ono, Daisuke Himeji, Naoko Ikeda, Ikuo Kikuchi, Kiyoshi Yamashita, Akira Ueda

P-TU-364  SPATIAL CLOT GROWTH CAN PREDICT PROTHROMBOTIC CHANGES OF COAGULATION STATE IN SEPSIS
Natalya P Soshitova* (RU), Sergey S Karamzin, Anna N Balandina, Olga A Fadeeva, Anna V Kretchetova, Gennady M Galstian, Mikhail A Panteleev, Fazoil I Ataullakhanov

P-TU-365  THE ROLE OF DIC IN “EARLY” SEPSIS DEVELOPMENT IN SEVERE BURNED M.V.
PRESNYAKOVA NIZHNY NOVGOROD RESEARCH INSTITUTE OF TRAUMATOLOGY AND ORTHOPEDICS NIZHNY NOVGOROD, RUSSIA
Kazuo Kawasugi* (JP), Tadashi Yamamoto, Ryousuke Shirasaki, Haruko Tashiro, Nobu Akiyama, Naoki Shirafuji

P-TU-366  INCREASED LEVELS OF HISTONE IN HUMAN PLASMA IN SEPTIC PATIENTS WITH DIC
M. Vladimirovna Presnyakova* (RU)

P-TU-367  ON THE CLASSIFICATION OF ACUTE DIC SYNDROME
Nadezda A. Vorobyeva* (RU)

P-TU-368  DEGRADATION OF CROSS-LINKED FIBRIN BY LEUKOCYTE ELASTASE AS ALTERNATIVE PATHWAY FOR PLASMIN-MEDIATED FIBRINOLYSIS IN SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION
Seiji Madoiwa* (JP), Hideyuki Tanaka, Yutaka Nagahama, Yui Kashiwakura, Asuka Sakata, Atsushi Yasumoto, Tsukasa Ohmori, Jun Mimuro, Yoichi Sakata

P-TU-369  POST MARKETING SURVEILLANCE OF THE SAFETY AND EFFECTIVENESS OF THROMBOMODULIN ALFA IN JAPANESE PATIENTS WITH DIC
Tatsuhiko Kuroda* (JP), Yoichi Sakata, Hoyu Takahashi, Hajime Tsuji, Jun Mimuro, Yutaka Eguchi, Isao Kitajima, Tadashi Matsushita

P-TU-370  ISTH DIC SCORE: INTEREST OF PLATELET ACTIVATION MARKERS IN ICU PATIENTS
Barry J Woodhams* (FR), Philippe Cauchie, Sandra Ollieuz, Barry Woodhams, Mariette Adam, Karim Zouaoui Boudjellida, Nadine Deschepper, Charles Cauchie, Patrick Biston

P-TU-371  RECOMBINANT THROMBOMODULIN IMPROVES PROGRESSION OF COAGULOPATHY AND ORGAN INJURY BY INHIBITING HIGH MOBILITY GROUP BOX 1 PROTEIN IN SEVERE ACUTE PANCREATITIS
Toshihisa Tamura* (JP), Kohji Okamoto, Masaru Nagato, Noritaka Minagawa, Alichirou Higure, Koji Yamaguchi
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-372  THERAPEUTIC EFFECT OF RECOMBINANT THROMBOMODULIN ON THE HEMOSTATIC AND INFLAMMATORY RESPONSE IN PATIENTS WITH SEPTIC DIC
Noritaka Yada* (JP), Kenji Nishio, Keisuke Takano, Hideki Asai, Tomoo Watanabe, Tadahiko Seki, Tooru Ueyama, Hidetada Hukushima, Yasuyuki Urizono, Tomoaki Hata, Kazuo Okuchi

P-TU-373  ENHANCED HOST DEFENSE TO E. COLI BY INHIBITION OF COAGULATION IS ASSOCIATED WITH INCREASED TNF PRODUCTION, DECREASED MKP-1 EXPRESSION AND INCREASED P38 PHOSPHORYLATION
Cornelis van 't Veer* (NL), Keizer Veer, Kelly Maijoor, Nigel Mackman, Danielle Kruiswijk, Petra van den Pangaart, Tom van der Poll

P-TU-374  EFFICACY OF THE COMBINED THERAPY WITH RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN AND ANTITHROMBIN IN SEPTIC DIC PATIENTS
Taisuke Kitamura* (JP), Hiroyasu Ishikura, Akira Murai, Junichi Tanaka, Takeshi Nishida, Daiki Ohita, Takanori Kamitani, Takehiro Umemura, Tomoko Sugimura, Kunihiro Matsuo

P-TU-375  PROTECTIVE EFFECTS OF RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN ON ISCHEMIA-REPERFUSION INJURY OF RAT LIVER WERE MEDIATED BY HIGH MOBILITY GROUP BOX 1 PROTEIN
Kohji Okamoto* (JP), Toshihisa Tamura, Masaru Nagato, Aiichirou Higure, Koji Yamaguchi

P-TU-376  EFFICACY OF RECOMBINANT THROMBOMODULIN IN SEPTIC DISSEMINATED INTRAVASCULAR COAGULATION REFRACTORY TO ANTITHROMBIN CONCENTRATE ANALYZED BY MOLECULAR MARKERS
Yutaka Eguchi* (JP)

Pregnancy, hormones, women’s issues

P-TU-377  CLINICAL CHARACTERISTICS OF WOMEN WHO EXPERIENCE VENOUS THROMBOEMBOLISM DURING COMBINED ORAL CONTRACEPTIVE USE
Elizabeth Femma van Vlijmen* (NL), Nic Veeger, Marieke Knol, Vladimir Tichelaar, Anja Makelburg, Hanneke Klui-Nellemans, Karina Meijer

P-TU-378  THE TEAM PROJECT: SPANISH REGISTRY OF THROMBOEMBOLIC DISEASE (TD) IN WOMEN RELATED WITH SPECIAL CLINICAL SETTINGS
Amparo Santamaria* (ES), Dolors Tassies, Oscar Martinez, Javier Rodriguez-Martorell, Im Ramirez, M Lecumberri, M Casellas, M Gutierrez-Pimentel, Pilar Llamas, Ana Redondo-Izal

P-TU-379  STRATEGIES FOR THROMBOEMBOLISM PREVENTION IN PREGNANCY: INTEGRATION BETWEEN HOSPITAL AND PRIMARY HEALTH CARE UNITS
Sophie Testa* (IT), Oriana Paololetti, Enrica Ronca, Alberto Rigolli, Emilia Cancellieri, Anke Zimmermann, Deborah Mammoliti, Aldo Riccardi

P-TU-380  INCREASED LEVELS OF SEX HORMONE BINDING GLOBULIN IN ASSOCIATION WITH VENOUS THROMBOSIS
Bernardine H Stegeman* (NL), Hans L Vos, Frans M Helmerhorst, Astrid Van Hylckama Vlieg, Pieter H Reitsma, Frits R Rosendaal

P-TU-381  ANTI XA LEVELS IN PREGNANT WOMEN OF DIFFERENT WEIGHTS RECEIVING ENOXAPARIN THROMBOPROPHYLAXIS DURING PREGNANCY
Karen A Breen* (UK), K Bramham, K Parmar, S Robinson, C Nelson-Pierce, BJ Hunt

P-TU-382  DOES LONG-TERM PROPHYLAXIS INFLUENCE THE BONE MINERAL DENSITY OF PREGNANT WOMEN?
Zdenka Hajsmanova* (CZ), Jitka Slechtova
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-383  ELEVATED LIPOPROТЕINE (A) LEVELS AND THE HPA1-B ALLELE OF THE PLATELET INTEGRIN ALPHAIIB-BETA3 ARE RISK DETERMINANTS OF SEVERE INTRAUTERINE GROWTH RESTRICTION (IUGR)
Andrea Gerhardt* (DE), Heimo Beneke, Ruediger E. Scharf, Rainer B. Zottz

P-TU-384  FREQUENCY OF F V LEIDEN MUTATION IN 600 FEMALES WITH VENOUS THROMBOEMBOLISM IN ASSOCIATION WITH ORAL CONTRACEPTIVE USE
Petr Dulicek* (CZ), Jaroslav Maly, Martin Beranek

P-TU-385  THROMBOSIS AND PREGNANCY IN HEREDITARY THROMBOPHILIAS
Ivo Elezovic* (RS), Darko Antic, Predrag Miljic, Valentina Djordjevic, Ljudmila Stojanovic, Olivera Markovic, Mirjana Kovac

P-TU-386  THROMBOPHILIA, INFLAMMATION IN PREGNANT PATIENTS WITH METABOLIC SYNDROME
Tatiana B Radulovich (RU), Ekaterina B Perederyaeva, Alexander D Makatsariya*

P-TU-387  PREGNANCY-RELATED ISCHEMIC STROKE: A COHORT STUDY
Elvira Grandone* (IT), Giovanni Luca Tiscia, Donatella Colaizzo, Fiomena Cappucci, Vincenzo Inchingolo, Carlo Vigna, Lucia Fischetti, Patrizia Vergura, Maurizio Margaglione

P-TU-388  FIBRIN MONOMER (FM) LEVELS IN PREGNANT PATIENTS PRESENTING WITH SYMPTOMS OF DEEP VEIN THROMBOSIS (DVT)
Marilyn A Johnston* (CA), Mala Rupwate, JS Ginsberg, WS Chan

P-TU-389  TISSUE FACTOR DEPENDENT AND INDEPENDENT THROMBIN GENERATION ACROSS PREGNANCY
Kelley Carmelite Wulfkuhle* (US), Saulius Butenas, Ira Bernstein, Kathleen Brummel-Ziedins

P-TU-390  A PILOT AUDIT OF THROMBOPROPHYLAXIS COMPLIANCE WITH LOW MOLECULAR WEIGHT HEPARIN IN PREGNANCY
Gillian N Pike* (UK), Miranda Hobson, Elizabeth Hay, Michael Nash, Charles Hay, Louise Byrd

P-TU-391  A PILOT AUDIT OF THROMBOPROPHYLAXIS COMPLIANCE WITH GRADUATED COMPRESSION STOCKINGS IN PREGNANCY
Gillian N Pike* (UK), Miranda Hobson, Elizabeth Hay, Michael Nash, Charles Hay, Louise Byrd

P-TU-392  INFLUENCE OF HYPERPROLACTINEMIA TREATMENT ON HEMOSTATIC SYSTEM ACTIVITY
Gorana Mitic* (RS), Milica Medic-Stojanoska, Dragan T. Spasic, Nikola Curuc, Igor M. Mitic

Cancer and thrombosis

P-TU-393  PROCOAGULANT ACTIVITY OF INTRAVASCULAR TISSUE FACTOR IS DEPENDENT ON CARRIER BURDEN
Garth William Tormoen* (US), Andras Gruber, Owen JT McCarty

P-TU-394  LONG-TERM CLINICAL OUTCOME OF INCIDENTALLY DIAGNOSED PULMONARY EMBOLISM IN PATIENTS WITH MALIGNANCY
Paul L den Exter* (NL), Jose Hooijer, Olaf M Dekkers, Menno V Huisman

P-TU-395  DETECTION OF CIRCULATING HEPARIN IN CANCER PATIENTS AFTER PORT FLUSH OF INDWELLING VENOUS ACCESS DEVICES: IMPLICATIONS FOR BEVACIZUMAB ASSOCIATED PLATELET ACTIVATION
Ali Amirkhosravi* (US), Todd Meyer, Meghan Hatfield, Hina Desai, Mildred Amaya, Alane Drexler, Glenn Bigsby IV, Eduardo Reyes, John Barranco, Kristin Rathman, John Francis
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-396  D-DIMER LEVEL IN PEDIATRIC PATIENTS WITH SOLID AND HEMATOLOGIC MALIGNANCIES, SHIRAZ, SOUTHERN IRAN
Mehran Karimi* (IR), Nasrin Saki, Forugh Saki, Mohammad Reza Saki

P-TU-397  ALTERATIONS OF HEMOSTATIC PARAMETERS IN THE EARLY DEVELOPMENT OF ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION RELATED COMPLICATIONS
Yue Han* (CN), Depei Wu, Li Zhu, Luping Hu, Lili Zhou, Yongya Ren, Wei Zhang, Xiaojin Wu, Xiaohui Hu, Xiang Zhang, Aining Sun, Zhaoyue Wang, Changgeng Ruan

P-TU-398  HYDROXYUREA REDUCES THROMBIN GENERATION (TG)
Claudine Caron* (FR), Mathieu Wemeau, Nathalie Cambier, Emmanuelle Jeanpierre, Antoine Tounoys, Christophe Zawadzki, Nathalie Trillot, Brigitte Jude, Anne Bauters

P-TU-399  THROMBOTIC COMPLICATIONS IN ADULT PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A REPORT OF 40 PATIENTS
Mahdia Saidi* (DZ), Fatema Zohra Soltani, Mounira Bitam, Rabah Chafai, Fatima Belhadri, Nadjoua Saidane

P-TU-400  EXTERNAL VALIDATION OF THE MODIFIED OTTAWA RULE FOR RISK STRATIFICATION OF RECURRENT VENOUS THROMBOEMBOLISM IN CANCER PATIENTS
Aurelien Delluc* (FR), Xavier Savary, Mikael Le Henaff, Emmanuelle Le Moigne, Karine Lacut, Dominique Mottier, Gregoire Le Gal

P-TU-401  MICROPARTICLE TISSUE FACTOR ACTIVITY IS INCREASED IN CANCER PATIENTS PRIOR TO THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM
Ankie Kleinjan* (NL), Frederiek F. van Doormaal, Rene J. Berckmans, Nigel Mackman, David A. Manly, Pieter W. Kamphuisen, Dick J. Richel, Harry R. Buller, Augustine Sturk, Rienk Nieuwland

P-TU-402  PRO-THROMBOTIC INDICES AND INvasive-ANGIogenic PROPERTIES OF BLOOD FROM PANCREATIC CANCER (PC) PATIENTS IMPROVE AFTER CANCER RESECTION: A PROSPECTIVE CONTROLLED STUDY
Hussein H Jassim Echrish* (UK), Leigh Madden, John Greenman, Kevin Wedgwood, Dowmitra Dasgupta, Anthony Maraveyas

P-TU-403  OUTCOME AND CHARACTERISTICS OF CANCER PATIENTS WITH INCIDENTAL PE MANAGED UNDER A SPECIALISED CARE PATHWAY PROTOCOL
Georgios Bozas* (UK), June Palmer, Ged Avery, Anthony Maraveyas

P-TU-404  SOME ASPECTS OF HEMOSTASIS IN MELANOMA
Nadezda A. Vorobyeva* (RU), Maria N. Smirnova

P-TU-405  PROPHYLAXIS AND TREATMENT STRATEGIES OF VENOUS THROMBOEMBOLISM IN HEMATOLOGICAL MALIGNANCIES AMONG HEMATOLOGISTS AND ONCOLOGISTS IN THE NETHERLANDS: A NATIONAL SURVEY
Marielle MQBM Beckers* (NL), Bart J Biemond, Hans-Martin Otten, Pieter-Willem Kamphuisen

P-TU-406  EFFECT OF PREVENTIVE ANTITHROMBOTIC MEASURES ON THROMBOTIC RISK IN ADULT PATIENTS TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA
Mandy Nicole Lauw* (NL), Bronno Van der Holt, Saskia Middeldorp, Bart J Biemond
POSTER PRESENTATIONS

Tuesday, July 26, 2011

Pediatric thrombosis

P-TU-407  ASSESSMENT OF FUNCTIONAL FIBRINOLYSIS IN NEONATES USING MODIFIED THROMBOELASTOMETRY
Gili Kenet* (IL), Rakefet Sidlik, Tzipora Strauss, Boris Shenkman, Ilya Tamarin, Aharon Lubetsky, Jacob Kuint, Uri Martinowitz

P-TU-408  ABNORMALITY OF GLOBAL FIBRINOLYTIC ACTIVITY AND EXCESS OF PAI-1 LEVEL IN CHILDREN WITH THROMBOEMBOLISM
Rungrote Natesirinilkul* (TH), Werasak Sasanakul, Ampaiwan Chuansumrit, Praguaywan Kadekasam, Ananit Visudibhan, Pakawan Wongwerawat-Anakoon, Nongnuch Sirachainan

P-TU-409  THE CYP4F2 V433M POLYMORPHISM DOES NOT CORRELATE WITH VITAMIN K ANTAGONIST DOSING IN A PEDIATRIC POPULATION
Lesley G Mitchell* (CA), Kevin Dietrich, Ulrike Nowak-Gottl, Daria Schaffranek, Noha Sharaf Eldin, Yutaka Yasui, Christof Geisen

P-TU-410  ORAL ANTICOAGULANT THERAPY IN CHILDREN: THE DUTCH EXPERIENCE
Cornelia Helena van Ommen* (NL), Jamie Kornet, Odette D.M. Pauwwe-Insinger, Anke H.H. van Geest-Daalderoop, Marjolein Peters

P-TU-411  PHENPROCOUMON AND ACENOCOUMAROL TREATMENT IN PEDIATRIC PATIENTS
Cornelia Helena van Ommen* (NL), Nienke Spoor, Felix J.M. van der Meer, Barbara A. Hutten, Frans Smiers

P-TU-412  CRITICALLY ILL CHILDREN WITH H1N1 INFLUENZA AND STAPHYLOCOCCUS AUREUS INFECTION ARE AT A GREATER RISK FOR DEVELOPING DISSEMINATED INTRAVASCULAR COAGULATION (DIC)
Trung Chanh Nguyen* (US), Ursula G Kyle, Nancy Jaimon, M. Hossein Tcharmtchi, Fong W Lam, Jun Teruya, Jorge A Coss-Bu, Laura Loftis

P-TU-413  HYPERCOAGULATION PANEL IN PEDIATRIC SETTING. - IS IT WARRANTED?
Jun Teruya* (US), Ozlem Bilen, Maha Mohamed, Eiman Hussein, Lisa Bomgaars

P-TU-414  QUALITY OF LIFE ASSESSMENT OF CHILDREN REQUIRING LONG-TERM ORAL ANTICOAGULANT THERAPY
Sophie Jones* (AU), Paul Monagle, Elizabeth Manias, Aisha Bruce, Fiona Newall

P-TU-415  COUMARIN-INDUCED SKIN NECROSIS ASSOCIATED WITH A RARE THROMBOPHILIC COMBINATION DEFECT IN A 14-YEAR-OLD GIRL
Holger Seidel* (DE), Hans-Jurgen Laws, Sebastian Weinspach, Luise Weiss, Arndt Borkhardt, Mariana Santos, Till Hoffmann, Barbara Bomke, Rudiger E Scharf

P-TU-416  CEREBRAL SINOVENOUS THROMBOSIS (CSV) IN CHILDREN BEYOND NEONATAL PERIOD
Helen Pergantou* (GR), Maria Avgeri, Vasillis Hatziantoniou, Panagiota Xafaki, Helen Platokouki

P-TU-417  INCIDENCE OF INFECTIONOUS, THROMBOTIC AND SUBSEQUENT POST-THROMBOTIC COMPLICATIONS AFTER FEMORAL VEIN CATHETERIZATION IN A PEDIATRIC INTENSIVE CARE UNIT
Cornelia Helena van Ommen* (NL), Jeanine J. Sol, Aukje Betlem, Majorie de Neef, Anne Smets, Hennie Kroester

P-TU-418  THROMBIN GENERATION TEST TO ASSESS THE HAEMOSTATIC POTENTIAL OF CHILDREN DURING TREATMENT FOR ACUTE LYMPHOBlastic LEUKEMIA (ALL)
Anne Claire Demulder* (BE), Laurence Rozen, Denis Noubouossie, France Debaugnies, Sophie Huybrechts, Phu Quoc Le, Alina Ferster
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-419  HEPARIN INDUCED SKIN NECROSIS IN A CHILD IN THE ABSENCE OF MEASURABLE HIT ANTIBODIES
Yaser Diab* (CA), Suzan Williams, Leonardo Brandao, Veerle Labarque, Frederico Xavier, Darlene Castle, Paul Thorner, Elena Pope, Walter Kahr

P-TU-420  ENDOTHELIAL CELL INJURY: A POSSIBLE PATHOGENESIS OF THROMBOSIS IN IRON DEFICIENCY ANEMIA
Pornchanok Iamsirirak* (TH), Ampaiwan Chuansumrit, Werasak Sasanakul, Praguywan Kadegasem, Pakawan Wongwerawattanakorn, Nongnuch Sirachainan

Arterial vascular diseases

P-TU-421  ACTIVATION MARKERS OF THROMBOGENESIS AND ENDOTHELIAL DYSFUNCTION IN END STAGE RENAL DISEASE
Vinod Bansal* (US), Korosh Shareain, Debra Hoppensteadt, Evangelos Litinas, Jawed Fareed

P-TU-422  D-DIMER IS AN INDEPENDENT PREDICTOR OF MORTALITY AT LONG-TERM FOLLOW-UP IN PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME
Trygve Brugger-Andersen* (NO), Volker Poenitz, Patrycja Naesgaard, Harry Staines, Heidi Grundt, Dennis WT Nilsen

P-TU-424  PROPORTION OF PLATELETS, FIBRIN, AND RED BLOOD CELLS DIFFERS IN CARDIOEMBOLIC AND ATEROATHEROTHROMBOTIC THROMBI
Yuichiro Sato* (JP), Hatsue Ueda, Kinta Hatakeyama, Atsushi Yamashita, Yujiro Asada

P-TU-425  THE RELATIONSHIP BETWEEN VENOUS THROMBOSIS AND SUBSEQUENT ARTERIAL CARDIOVASCULAR DISEASE: CAUSAL OR MEDIATED BY COMMON ETILOGIC FACTORS?
Rachel E.J. Roach* (NL), Willem M. Liftering, Linda E. Flinterman, Frits R. Rosendaal, Suzanne C. Cunnegieter

P-TU-426  STATINS FOR ACUTE ISCHEMIC STROKE: A COCHRANE META-ANALYSIS
Alessandro Squizzato* (IT), Erica Romualdi, Francesco Dentali, Walter Ageno

P-TU-427  WARFARIN USE AND RISK OF CORONARY ARTERY CALCIFICATION

P-TU-428  HAEMOSTATIC VARIABLES AND RISK OF PERIPHERAL ARTERIAL DISEASE AND ITS COMPLICATIONS: SYSTEMATIC REVIEW
Olivia Wu* (UK), Gordon Lowe

P-TU-429  PLASMA LEVELS OF FVII-ACTIVATING PROTEASE (FSAP) IN ISCHEMIC STROKE
Ellen Hanson* (SE), Sandip M Kanse, Amit Joshi, Katarina Jood, Christian Blomstrand, Christina Jern

P-TU-430  BIOCHEMICAL AND HEMOSTATIC BIOMARKERS FOR PREDICTING CORONARY ARTERY DISEASE
Maria das Gracas Carvalho* (BR), Luciana Moreira Lima, Daniela Rezende Garcia Junqueira, Matheus Oliveira Sousa

P-TU-431  USE OF HUMAN PLACENTA-DERIVED MESENCHYMAL STEM CELLS TO TREAT CRITICAL LIMB ISCHEMIA
Zhong Chao Han* (CN), Zhi Bo Han, Jian Hua Li, Jun Hong Jia, Guang Sheng Zhuo
POSTER PRESENTATIONS
Tuesday, July 26, 2011

Clinical trials and registries

P-TU-432  SOLUBLE TISSUE FACTOR IN PRIMARY HIV INFECTION
Beverley J Hunt* (UK), Elizabeth Hamlyn, Kiran Parmar, Stephen Hickling, John Frater, Rodney Phillips, Myra McClure, Sarah Fidler

P-TU-433  LOW ACHIEVEMENT OF TARGET INTERNATIONAL NORMALIZED RATIO IN PATIENTS TAKING WARFARIN EVEN IN A SPECIALIST CLINIC: A STUDY IN OMANI PATIENTS AND REVIEW OF LITERATURE
Chao Hung Ho* (OM), David Gravell

P-TU-434  HIT ANTIBODY SEROPOSITIVITY DOES NOT PREDICT THROMBOEMBOLIC EVENTS AFTER CARDIAC SURGERY
Ian Welsby* (US), Thomas Ortel, David Kong, Elizabeth Krakow, Nicole Whitlach, John Heit, Eliot C Williams, Shahar Bar Yosel, Susan Martinelli

P-TU-435  IMMEDIATELY STARTED LEG COMPRESSION IN ACUTE DEEP VENOUS THROMBOSIS: A DOUBLE-EDGED INTERVENTION
Werner Blaettler* (CH), Horst E Gerlach, Felix Amsler, Irene K Blaettler, Iris Baumgartner

P-TU-436  A CONTROLLED COHORT STUDY ON THE USE AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN DURING PREGNANCY
Paeivi Johanna Galambosi* (FI), Veli-Matti Ulander, Risto Juhani Kaaja

P-TU-438  VITAMIN K ANTAGONIST DOSING METHODS AND INDIVIDUAL PATIENT QUALITY OF INR CONTROL IN THE INTERNATIONAL ACTIVE W ANTICOAGULATION STUDY
Robby Nieuwlaat* (CA), Jennifer Ng, Stuart J Connolly

P-TU-439  FOUR WEEKS VERSUS TWELVE WEEKS DOSING INTERVAL FOR STABLE PATIENTS ON WARFARIN: A RANDOMIZED TRIAL
Sam Schulman* (CA), Sameer Parpia, Clare Stewart, Lisa Rudd-Scott, Jim Julian, Mark Levine

Health service and outcomes

P-TU-441  HOW DO CLINICIANS MONITOR TREATMENT WITH VITAMIN K ANTAGONISTS: AN INTERNATIONAL SURVEY
Ann-Helen Kristoffersen* (NO), Geir Thue, Eva Ajzner, Neree Claes, Mujdat Aytekin, Andrea Rita Horvath, Kaja Kallion, Steve Kitchen, Marge Kutt, Piet Meijer, Mathias Muller, Elisabeth Nilsson, Carmen Perich, Inger Plum, Carmen Ricos, Dunja Rogic, Joseph Watine, Sverre Sandberg

P-TU-442  PREVALENCE OF THROMBOPHILIA IN PATIENTS WITH RETINAL VASCULAR OCCLUSIONS
Maria T DeSancho* (US), John Chapin, Karen Sue Carlson, Karen Powell-Boone

P-TU-443  MONITORING INTRA-OPERATIVE ANTICOAGULATION WITH ACTIVATED CLOTTING TIME IN A PATIENT WITH ANTIPHOSPHOLIPID ANTIBODIES AND A PROLONGED ACTIVATED PARTIAL THROMBOPLASTIN TIME
Maria T DeSancho* (US), John Chapin, Mikhail Roshal, Barbara Hempstead, William Debois
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TU-444</td>
<td>THE STOP (STOP SMOKING THERAPY FOR ONTARIO PATIENTS) STUDY: EFFECTIVENESS OF MAILED NICOTINE REPLACEMENT TO MOTIVATED SMOKERS</td>
<td>Peter L Selby* (CA), Laurie Zawertailo, Susan Bondy, Rosa Dragonetti</td>
</tr>
<tr>
<td>P-TU-445</td>
<td>NEW LATEX-BASED ASSAY FOR THE DETECTION OF ANTI PF4-HEPARIN ANTIBODIES ON AUTOMATED COAGULOMETERS USEFUL IN THE DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)</td>
<td>Lourdes Davalos* (ES), Encarna Ingles, Miquel Sales</td>
</tr>
<tr>
<td>P-TU-446</td>
<td>SYSTEMATIC EVALUATION OF THE PERFORMANCE OF A PORTABLE MONITOR OF PROTHROMBIN TIME IN PATIENTS WITH SUPRATHERAPEUTIC INR LEVELS</td>
<td>Erich de Paula* (BR), Marina Pereira Colella, Maiara Marx Luz Fiuza, Tania Fatima Gomes Siegl Machado, Sueli Custodio, Fernanda Andrade Orsi, Joyce Maria Annichino-Bizzacchi</td>
</tr>
<tr>
<td>P-TU-447</td>
<td>RISK MANAGEMENT PLAN (RMP) FOR NEW ANTICOAGULANTS IN FRANCE: FIRST RESULTS WITH DABIGATRAN ETEXILATE (PRADAXA)</td>
<td>Agnes Lillo Le Louet* (FR), Christine Le Beller, Herve Le Louet</td>
</tr>
<tr>
<td>P-TU-448</td>
<td>ORAKAY IS AS EFFECTIVE AS KONAKION (PHYTOMENADIONE) IN THE CORRECTION OF SUPRATHERAPEUTIC INRS IN PATIENTS RECEIVING WARFARIN ANTICOAGULATION</td>
<td>Rhona M Maclean* (UK), James W Taylor, Stuart Rollings, Linda Carver, Joost van Veen</td>
</tr>
<tr>
<td>P-TU-449</td>
<td>AN EVALUATION OF THE QUALITY OF ORAL ANTICOAGULATION MANAGEMENT IN AN OUTPATIENT PHARMACIST-ASSISTED CLINIC</td>
<td>Ming Chai Kong* (SG), Yi Feng Lai, Mei Huey Fiona Tee, Heng Joo Ng, Lai Heng Lee</td>
</tr>
</tbody>
</table>

**von Willebrand disease**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TU-450</td>
<td>STRUCTURE-FUNCTIONAL RELATIONSHIP OF 4 NOVEL MISSENSE MUTATIONS IN VWF GENE PREDICTED BY MOLECULAR MODELLING</td>
<td>Arijit Biswas* (DE), Hamideh Yadegari, Driesen Julia, Pavlova Anna, Oldenburg Johannes</td>
</tr>
<tr>
<td>P-TU-451</td>
<td>FIRST RESULTS OF A LONG-TERM PHARMACOVIGILANCE WITH PLASMA DERIVED VON-WILLEBRAND-FACTOR/FACtor VIII CONCENTRATE</td>
<td>Manuela Krause (DE), Michael Ververine, Rainer B Zolz, Claudia Niekrens, Ute Scholz, Andrea Gerhardt, Bettina Kemkes-Matthes, Beate Kramer-Steiner, Mathias Juers*, Claudia Zacharias, Guenter Auerswald</td>
</tr>
<tr>
<td>P-TU-452</td>
<td>CONCURRENCE OF TYPE II VON WILLEBRAND DISEASE AND SEVERE HEMOPHILIA B IN A TAIWANESE: A CASE REPORT AND REVIEW OF LITERATURE</td>
<td>Chia-Yau Chang* (TW), Chen-Hua Tsai, Jia-ruey Tsai, Geng-Chang Yeh, Ing-Jy Tseng</td>
</tr>
<tr>
<td>P-TU-453</td>
<td>MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) SCREENING OF THE VWF GENE: IDENTIFICATION OF 3 NOVEL DELETIONS AND A CAUTIONARY OBSERVATION</td>
<td>Bimal D M Theophilus* (UK), Lesley M Baugh, Andrea M Guilliatt, Jonathan T Wilde, Jayashree Motwani, Michael D Williams</td>
</tr>
<tr>
<td>P-TU-454</td>
<td>LABORATORY, MULTIMERIC AND MOLECULAR CHARACTERISATION OF VON WILLEBRAND DISEASE IN THE SOUTH MORAVIAN POPULATION (CZECH REPUBLIC): THE BRNO-VWD STUDY</td>
<td>Alain Peter Gadisseur* (BE), Petr SMEJKAL, Inge VANGENECHTEN, O ZAPLETAL, Fatima BOUDDOUNT, J ZAVRELLOVA, J BLATNY, M PENKA, JJ MICHELS</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-455  UTILITY OF VON WILLEBRAND FACTOR COLLAGEN BINDING ASSAYS (VWF:CB) WITH TYPE VI COLLAGEN IN THE DIAGNOSIS OF VWD
Veronica H Flood (US), Sandra L Haberichter, Kenneth D Friedman, Steven R Lentz, Raymond G Hoffmann, Joan Cox Gill, Robert R Montgomery*

P-TU-456  INTRACRANIAL HEMORRHAGE IN VON WILLEBRAND DISEASE: A REPORT ON 6 PEDIATRIC CASES
Veerle Labarque* (CA), Ann Marie Stain, Victor Blanchette, Walter H. Kahr, Manuel D. Carcao

P-TU-457  TYPE 2B VON WILLEBRAND DISEASE: ONE CENTER EXPERIENCE (DEPARTMENT OF HEMATOLOGY, JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE, KRAKOW, POLAND)
Joanna Zdziarska (PL), Teresa Iwaniec, Beata Mazurek, Jolanta Ras, Jacek Musiat*, Aleksander Bartlomiej Skotnicki

P-TU-458  CASE REPORT: VON WILLEBRAND FACTOR INHIBITOR IN A FIVE YEAR OLD GIRL WITH TYPE III VWD AND RESPONSE TO ITI
Natasha M Wiles* (UK), Julia Spires, Gary Moore, James Maloney, Jayanthi Alamelu

P-TU-459  THE CONDENSED MCMDM1-VWD BLEEDING QUESTIONNAIRE: UTILITY AS A DIAGNOSTIC TOOL IN THE HEMATOLOGY CLINIC
Shannon Jackson (CA), Man-Chiu Poon, Julie Grabell, David Lillicrap, Paula D James*

P-TU-460  THROMBOELASTOGRAPHY REFLECTS VARIATIONS OF HAEMOSTATIC PATTERN IN TYPE 2B VON WILLEBRAND DISEASE PATIENTS WITH R1306W MUTATION
Mazen Toukh* (CA), Anne Angelillo-Scherrer, Maha Othman

P-TU-461  HETEROGENEITY OF THE CLINICAL, LABORATORY AND MOLECULAR MARKERS OF VWD TYPE 3: RESULTS FROM THE RETROSPECTIVE/PROSPECTIVE STUDIES ON 122/52 ITALIAN PATIENTS
Augusto B Federici* (IT), Paolo Bucciarelli, Giancarlo Castaman, Emily Oliovecchio, Alfonso Iorio, Pier M Mannucci

P-TU-462  19 NOVEL MUTATIONS IN VWF GENE CAUSING VON WILLEBRAND DISEASE IN 17 CHINESE PEDIGREES
Huanhuan Qin* (CN)

ADAMTS13

P-TU-463  A NEW ADAMTS13 MISSENSE MUTATION (A4085T) IN THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) DIAGNOSED IN PREGNANCY
Julio C Calderazzo Pereyra* (AR), Ana C Kempleir, Yanina P Powazniak, Ileana R Lopez, Analia Sanchez-Luceros, Maria A Lazzari

P-TU-464  ALTERATIONS OF VON WILLEBRAND FACTOR ANTIGEN AND ADAMTS13 ACTIVITY IN PATIENTS WITH CANCER
Xia Bai* (CN), Yue Han, Luping Hu, Xiaohui Hu, Changgeng Ruan

P-TU-465  NEUTROPHIL OXIDANTS INACTIVATE ADAMTS13
Xiaoyun Fu* (US), Yi Wang, Junmei Chen, Minhua Ling, Thomas Jordan, Jose A Lopez, Dominic W Chung, Xiaoyun Fu

P-TU-466  ADAMTS13 ANTIGEN LEVELS VARY IN PERIPHERAL VERSUS INFARCT-RELATED CORONARY BLOOD IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Hendrik B Feys* (BE), Aaron Peace, Fabio Mangiacapra, Micaela Conte, Luigi Di Serafino, Yiannis Ntarladimas, Olivier Muller, Argyrios Ntalianis, Etienne Puymirat, Karen Dierickx, Leen Delrue, Jozef Bartunek, Karen Vanhoorelbeke, Emanuele Barbato
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-467  VON WILLEBRAND FACTOR AND ADAMTS13: A CANDIDATE COUPLE FOR PREECLAMPSIA PATHOPHYSIOLOGY
Alain Stepanian* (FR), Marie Cohen-Moatti, Thibaut Sanglier, Paulette Legendre, Nejma Ameziane, Vassilis Tsatsaris, Laurent Mandelbrot, Dominique De Prost, Agnes Veyradier

P-TU-468  VON WILLEBRAND FACTOR O-LINKED GLYCANS INFLUENCE ITS INTERACTION WITH ADAMTS13
Agata Nowak* (UK), Thomas McKinnon, Hughes Jenny, Mike Laffan

P-TU-469  E. COLI DERIVED VON WILLEBRAND FACTOR-A2 DOMAIN FRAGMENTS QUANTIFY PLASMA ADAMTS13 ACTIVITY IN FRET AND FLOW CYTOMETRY BASED ASSAYS
Sriram Neelamegham* (US), Shobhit Gogia, Kannayakanahalli M Dayananda

P-TU-470  PROBING THE DETERMINANTS OF VWF SUBSTRATE SPECIFICITY FOR ADAMTS13 BY M13 FILAMENTOUS PHAGE DISPLAY
Colin Kretz* (US), Karl Desch, David Ginsburg

P-TU-471  SUBSTRATE SUITABILITY EVALUATION OF HUMAN RECOMBINANT ADAMTS13 WITH VON WILLEBRAND FACTOR FROM DIFFERENT MAMMALIAN SPECIES
Barbara Plaimauer* (AT), Claudia Kitzler, Gabriele Mohr, Peter L. Turecek, Hanspeter Rottensteiner, Friedrich Scheiffinger

P-TU-472  DEVELOPMENT OF A MANUFACTURING PROCESS FOR RADAMTS13
Friedrich Scheiffinger* (AT), Christa Mayer, Christian Fiedler, Leopold Grillberger, Meinhard Hasslacher, Martin Kaliwoda, Wilfried Woehrer, Manfred Reiter, Artur Mitterer, Wolfgang Mundt

P-TU-473  ADAMTS13 SINGLE-NUCLEOTIDE POLYMORPHISMS IN GEOGRAPHICALLY-DIVERSE POPULATIONS
Benjamin Kim* (US), Kevin R. Viel, Victor J. Marder, Tom E. Howard

P-TU-474  TRANSITIONS OF PLASMA VWF PROPEPTIDE, VWF AND ADAMTS13 IN PATIENTS WITH SEPTIC DIC
Hidetada Fukushima* (JP), Kenji Nishio, Kazuo Okuchi, Ayami Isonishi, Masanori Matsumoto, Yoshiiro Fujimura, Keisuke Takano, Hideki Asai, Tomoo Watanabe, Shingo Ito, Tadahiko Seki, Yasuyuki Urizono, Michiaki Hata, Masaaki Doi, Yasuaki Shida, Hiteto Matsui, Mitsuhiko Sugimoto

Experimental models

P-TU-475  THE ASSAY OF VON WILLEBRAND FACTOR (VWF) PROPEPTIDE TO ANTIGEN RATIO (VWFPP/VWF) IDENTIFIES A REDUCED VWF SURVIVAL PHENOTYPE IN MICE
Paula M. Jacobii* (US), Ashley L Gehrand, Scot A Fahn, Robert R Montgomery, Jill M Johnsen, Sandra L Haberichter

P-TU-477  IMAGING ANALYSIS OF THE INTERACTION BETWEEN UNUSUALLY LARGE VON-WILLEBRAND FACTOR MULTIMERS AND PLATELETS ON VASCULAR ENDOTHELIAL CELLS IN LIVING ANIMALS
Tomasz Brzoska* (JP), Mirosław Rybaltowski, Yuko Suzuki, Hideo Mogami, Iwona Chlebinska, Aki Tanaka, Fumiaki Banno, Toshiyuki Miyata, Tetsuemei Urano
POSTER PRESENTATIONS

Tuesday, July 26, 2011

Hemophilia

P-TU-478  MALIGNANCIES IN ITALIAN HEMOPHILIA PATIENTS
Annarita Tagliaferri (IT), Caterina Di Perna, Cristina Santoro, Piercarla Schinco, Rita Santoro, Gina Rossetti*, Antonio Coppola, Massimo Morfini, Giancarlo Castaman, Francesco Antonio Scaraggi, Samantha Pasca, Silvia Macchi, Lelio Valdè, Ezio Zanon, Marialuisa Serino, Marisanta Napolitano, Isabella Cantori, Anna Chiara Giuffrida, Grazia Delios, Paolo Radossi, Massimo Franchini

P-TU-479  ACUTE PROMYELOYTIC LEUKEMIA (APL) IN A 3.5-YEARS-OLD CHILD WITH SEVERE HEMOPHILIA A: DIAGNOSTIC ISSUES AND COAGULOPATHY TREATMENT CHALLENGE
Manuela Carvalho (PT), Manuela Reis, Carla Monteiro, Victor Costa, Maria Joao Milheiro, Alzira Carvalhais, Luis Manuel Cunha-Ribeiro*

P-TU-480  IMPLEMENTATION OF A TELEMETRIC SMARTPHONE APPLICATION FOR IMPROVED SURVEILLANCE OF HEMOPHILIA HOME TREATMENT
Andreas Roesch* (DE), David Schmoldt, Wolfgang Mondorf, Hartmut Pollmann

P-TU-481  SCREENING HEMOPHILIA IN THE WEST OF ALGERIA AND DIFFERENTIAL DIAGNOSIS BETWEEN HEMOPHILIA A AND WILLEBRAND’S DISEASE
Driss Benlaldj* (DZ), Khedidja Moulasserdoun, Chakib Rahal, Fatima Seghier

P-TU-482  AWARENESS OF CARRIER STATUS AS A RESULT OF GENETIC COUNSELING IMPROVES HEMOPHILIA PATIENT CARE
F.van Herrewegen* (NL), M.A. Legdeur, C. Valk, Ommen C.H. van, I.B. Mathijssen, M. Peters

P-TU-483  MLPA ASSAY IN HAEMOPHILIA; A SECOND-LINE TEST IN GENE MUTATION DETECTION
Giuseppe Tagariello* (IT), Roberta Salvato, Donata Belvini, Federica Pierobon, Roberta Callegari, Nilla Maschio, Paolo Radossi, Renzo Risato, Roberto Sartori, Cristina Tassinari

P-TU-484  BODY WEIGHT AND FAT MASS INDEX AS STRONG PREDICTORS OF IN VIVO FACTOR VIII RECOVERY IN ADULTS WITH HEMOPHILIA A
Severine Henrard* (BE), Cedric Hermans, Niko Speybroeck

P-TU-485  ESTABLISHMENT OF THE CDC HEMOPHILIA A MUTATION PROJECT (CHAMP) TO PROVIDE STANDARDIZED F8 MUTATION DATABASES
Connie H Miller* (US), Amanda Payne, Fiona Kelly, J. Michael Soucie, W. Craig Hooper

P-TU-486  HYPOCOAGULABILITY DOES NOT PROTECT AGAINST ATHEROSCLEROSIS IN HEMOPHILIA A PATIENTS WITH OBESITY
Sara Biere-Rafi* (NL), Atte Tuinenburg, Bas Haak, Marjolin Peters, Eric De Groot, Peter Verhamme, Kathelijne Peerlinck, Frank Visseren, Marieke Kruij, Britta Laros-van Gorkom, Harry Builer, Victor Gerdes, Roger Schuutgens, Pieter Kamphuisen

P-TU-487  THE AGE AT DIAGNOSIS OF HEMOPHILIA. SITUATION IN BOSNIA AND HERZEGOVINA
Jelica Samardzic Predojevic* (BA), Edo Hasanbegovic, Biljana Banjac

P-TU-488  INTERLEUKIN-28B (IL28B) POLYMORPHISM AS PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE AFTER ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN PATIENTS WITH HEMOPHILIA
Maria Elisa Mancuso* (IT), Alessio Aghemo, Elena Santagostino, Maria Grazia Rumi, Raffaele Bruno, Massimo Colombo, Pier Mannuccio Mannucci

P-TU-489  TRANSIENT ELASTOGRAPHY (FIBROSCAN) AS A TOOL TO ASSESS LIVER FIBROSIS IN PATIENTS WITH HEMOPHILIA AND CHRONIC HEPATITIS C
Maria Elisa Mancuso* (IT), Alessio Aghemo, Gianmaria Prati, Maria Grazia Rumi, Elena Santagostino, Massimo Colombo
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-490  PRENATAL DIAGNOSIS FOR HAEMOPHILIA AT CASTELFRANCO VENETO: A 15 YEAR EXPERIENCE IN MOLECULAR DIAGNOSIS
Giuseppe Tagariello* (IT), Donata Belvini, Roberta Salvato, Federica Pierobon, Barbara Callegari, Nilla Maschio, Paola Radossi, Renzo Risato, Roberto Sartori, Cristina Tassinari

P-TU-491  CORONARY ARTERY CALCIFICATION IN HEMOPHILIA A: NO EVIDENCE FOR A PROTECTIVE EFFECT OF FACTOR VIII DEFICIENCY ON ATHEROSCLEROSIS

P-TU-492  30-YEARS' EXPERIENCE OF PRENATAL DIAGNOSIS OF HAEMOPHILIA IN SWEDEN
Annika Martensson (SE), Ulf Tedgard, Rolf Ljung*

P-TU-493  HIGH FREQUENCY OF ASYMPTOMATIC THROMBOSIS ASSOCIATED WITH CENTRAL VENOUS LINES IN CHILDREN WITH HAEMOPHILIA
Olof Rask (SE), Ola Bjorgell, Cecilia Wattsgard, Rolf Ljung*

P-TU-494  A BASIC MRI SCALE FOR HEMOPHILIC ARTHROPATHY FROM THE INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG)
B Lundin (SE), M Manco-Johnson, SF Miller, R Moineddin, D Ignas, Rolf Ljung*, AL Dunn, GE Rivard, P Babyn, SN Keshava, S Gibikote, V Blanchette, A Doria

P-TU-495  IMPAIRED MICROVASCULAR ENDOTHELIAL FUNCTION IN ADULT MALES WITH HEMOPHILIA
Shannon Claire Jackson* (CA), Morna Brown, Carol Spitzer, Leah Odiaman, Marinda Fung, Todd J. Anderson, Man-Chiu Poon

P-TU-496  ABNORMAL DYNAMIC PLATELET AGGREGATION IN HAEMOPHILIA A FOLLOWING TISSUE FACTOR INITIATED ENDOGENOUSLY GENERATED THROMBIN STIMULATION
Maria Sander Jensen* (DK), Ole Halfdan Larsen, Kirsten Christiansen, Christian Fenger-Eriksen, Jorgen Ingerslev, Benny Sorensen

P-TU-497  EFFECTIVENESS OF HAEMOPHILIA MEDICATION THERAPY ADHERENCE CLINIC (HMTAC) IN IMPROVING TREATMENT ADHERENCE USING A MODIFIED VERITAS-PRN SCORE
Shu Ping Wong* (MY), Jameela Sathar, Adibah Md Shariff, Yeok Siew Lim

P-TU-498  DOES HAEMOPHILIA A PROTECT AGAINST LIVER FIBROSIS IN AN EXPERIMENTAL MODEL?
Stephane L Eeckhoudt* (BE), Isabelle Leclercq, Cedric Hermans, Dominique Latinne, Yves Horsmans

P-TU-499  INHIBITORS IN HEMOPHILIA B: THE ITALIAN EXPERIENCE
Giuseppe Tagariello* (IT), Giancarlo Castaman, Maria Messina, Massimo Morfini, Angiola Rocino, Antonio Scaraggi, Pier Mannuccio Mannucci

P-TU-500  CONSTRUCTION OF NONSENSE-MUTATED EUKARYOTIC EXPRESSION VECTORS OF FACTOR IX GENE AND ITS EXPRESSION
linhua Yang* (CN), Xin Nie, Yuan Zhang
POSTER PRESENTATIONS

Tuesday, July 26, 2011

Hemophilia therapy

P-TU-501 PHARMACOKINETIC AND DYNAMIC PROPERTIES OF RECOMBINANT VS. PLASMA DERIVED FIX IN PATIENTS WITH HAEMOPHILIA B: A PROSPECTIVE CROSS-OVER STUDY
Jayanthi Alamelu* (UK), Benny Sorensen, Savita Rangarajan

P-TU-502 THE POST-AUTHORIZATION SAFETY SURVEILLANCE (PASS) PROGRAM CONFIRMED ACTUAL CLINICAL SAFETY AND EFFICACY OF RECOMBINANT PLASMA/ALBUMIN-FREE METHOD FACTOR VIII IN JAPAN
Katsuyuki Fukutake* (JP), Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Midori Shima, Akira Shirahata, The Advate PASS Study Group

P-TU-503 RFVIIA-ANALOGUE AND RFVIIA ENHANCE CLOT STABILITY MORE THAN FVIII IN HAEMOPHILIA A
Catherine J Rea* (UK), Mirella Ezban, Jonathan H Foley, Benny Sorensen

P-TU-504 INCREASED HAEMOSTATIC EFFECT OF HIGH DOSE RFVIIA COMPARED TO PD-APCC IN A TREATMENT-REFRACTORY PATIENT WITH HAEMOPHILIA A AND INHIBITORS
Catherine J Rea* (UK), David Bevan, Benny Sorensen

P-TU-505 MEDICO-ECONOMIC AND QUALITY OF LIFE STUDY OF REPLACEMENT THERAPY FOR HAEMOPHILIA B IN FRANCE: THE EQOFIX STUDY
Benoit Polack* (FR), Thierry Calvez, Segolene Claeyssens, Herve Chambost, Annie Derlon, Jenny Goudemand, Chantal Rothschild, Marie-Christine Woronoff-Lemsi

P-TU-506 SECONDARY PROPHYLAXIS IS MANDATORY IN ADULT/ELDER HEMOPHILIACS HIV-WITH NEOPLASMAS UNDERGOING TO CHEMOTHERAPY AND/OR RADIOTHERAPY
Margaret Musso* (IT), Anna Musso, Luca Maugeri, Luciano Messina

P-TU-507 LIVER DISEASE DAMAGE PROGRESSION AND HEPATOCARCINOMA OCCURRENCE IN HCV+/HBV+/HIV- HEMOPHILIACS DESPITE LASTING HCV/HBV VIRUS REPLICATION ABSENCES AFTER ANTIVIRAL THERAPIES
Margaret Musso* (IT), Anna Musso, Luca Maugeri, Roberto Musso

P-TU-508 TRANEXAMIC ACID WITHOUT PROPHYLACTIC FACTOR REPLACEMENT FOR PREVENTION OF BLEEDING IN PATIENTS WITH HEREDITARY BLEEDING DISORDERS UNDERGOING ELECTIVE ENDOSCOPY: A PILOT STUDY
Amanda Davis* (AU), Alison Street, Huyen Tran, Megan Walsh, Penny McCarthy, Chun Fong, Gregor Brown, Stuart Roberts

P-TU-509 CONSEQUENCES OF SWITCHING FROM PROPHYLACTIC TREATMENT TO ON-DEMAND TREATMENT IN LATE TEENS AND EARLY ADULTS WITH SEVERE HEMOPHILIA A
Marilyn J Manco-Johnson* (US), Joann Sanders, Nadia Ewing

P-TU-510 CLINICAL EXPERIENCE OF PREVIOUSLY UNTREATED PATIENTS WITH ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD FROM POST-AUTHORIZATION SAFETY SURVEILLANCE IN JAPAN
Masashi Taki* (JP), Hideji Hanabusa, Katsuyuki Fukutake, Tadashi Matsushita, Midori Shima, Akira Shirahata, Study Group the Advate PASS

P-TU-511 PROSPECTIVE ADVATE IMMUNE TOLERANCE REGISTRY (PAIR) IN JAPANESE HEMOPHILIA A PATIENTS WITH INHIBITORS: AN INTERIM REPORT
Tadashi Matsushita* (JP), Hideji Hanabusa, Katsuyuki Fukutake, Masashi Taki, Midori Shima, Akira Shirahata, Study Group the Advate PASS
**Inhibitors: pathogenesis, prevention and treatment**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TU-512</td>
<td><strong>IMPACT OF POLYMORPHISMS IN GENES INVOLVED IN AUTOIMMUNE DISEASE ON</strong></td>
<td><strong>INHIBITOR DEVELOPMENT IN CHINESE PATIENTS WITH HAEMOPHILIA A</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Yeling Lu</strong> (CN), Xuefeng Wang, Qiulan Ding, Jing Dai, Hongli Wang, Xiaodong Xi</td>
<td></td>
</tr>
<tr>
<td>P-TU-513</td>
<td><strong>DID RITUXIMAB (ANTI-CD20) INFLUENCE THE OUTCOME OF LATE IMMUNE</strong></td>
<td><strong>TOLERANCE INDUCTION (ITI) IN AN ADULT WITH SEVERE HAEMOPHILIA A (HA) AND HIGH-RESPONDER INHIBITOR?</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Albert Faradji</strong> (FR), Lelia Grunebaum, Dominique Desprez, Veronica Goldbarg, Geraldine Lavigne-Lissa, Anne Dory, Anne Cecile Gerout, Natacha Chiintseva-Natorov, Alice Eschen, Olivier Feugeas, Patrick Karcher</td>
<td></td>
</tr>
<tr>
<td>P-TU-514</td>
<td><strong>COMPARISON OF THE EFFICACY OF TWO RECOMBINANT FACTOR VIIA AGENTS</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Gennady M Galstyan</strong> (RU), Vladimir Yu Zorenko, Tatyana Yu Polyanska, Magomed Sampiev, Tatyana Severova, Nadezhda Konyashina, Irina Gribkova, Elena Orel, Vladimir Gorodetsky</td>
<td></td>
</tr>
<tr>
<td>P-TU-515</td>
<td><strong>SUCCESSFUL IMMUNOTOLERANCE INDUCTION IN 2 BOYS WITH HAEMOPHILIA B AND INHIBITOR</strong></td>
<td><strong>Anna Klukowska</strong> (PL), Pawel Laguna, Beata Waleszkiewicz-Majewska</td>
</tr>
<tr>
<td>P-TU-516</td>
<td><strong>COAGIL-VII APPLICATION IN ORTHOPEDIC SURGERY IN INHIBITOR HEMOPHILIA A PATIENTS</strong></td>
<td><strong>Vladimir Zorenko</strong> (RU), Tatyana Polianska, G. Galstian, M. Sampiev, T. Severova, N. Koniashina, E. Orel, I. Gribkova, M. Aleksanian</td>
</tr>
<tr>
<td>P-TU-517</td>
<td><strong>EVALUATION OF DIFFERENT REGIMENS OF RECOMBINANT ACTIVATED FACTOR VIIA ON BLEEDING AND PAIN RESOLUTION IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS</strong></td>
<td><strong>Peter Salaj</strong> (CZ), Miroslav Penka, Petra Ovesna</td>
</tr>
<tr>
<td>P-TU-518</td>
<td><strong>SAFETY OF EXPOSURE TO RECOMBINANT ACTIVATED FVII (RFVIIA) DOSES IN PATIENTS WITH CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI) TO FACTORS VIII OR IX</strong></td>
<td><strong>Amy D Shapiro</strong> (US), Ellis J. Neufeld, Victor S. Blanchette, Herve Chambost, David L. Cooper</td>
</tr>
<tr>
<td>P-TU-519</td>
<td><strong>RECOMBINANT FVIIA (RFVIIA) USE FOR SURGERY IN CONGENITAL HEMOPHILIA WITH INHIBITORS (CHWI) PATIENTS: DATA FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY</strong></td>
<td><strong>Ellis Neufeld</strong> (US), Kapil Saxena, David L. Cooper</td>
</tr>
<tr>
<td>P-TU-520</td>
<td><strong>BYPASS THERAPY EXPERIENCE IN ROUTINE CLINICAL MANAGEMENT: A POST-AUTHORIZATION SAFETY STUDY (PASS) WITH ANTI INHIBITOR COAGULATION COMPLEX (AICC)</strong></td>
<td><strong>Allison Quaglino</strong> (US), Manfred Pirck, Wing-Yen Wong, Gerald Spotts, Robert P Numerof</td>
</tr>
<tr>
<td>P-TU-521</td>
<td><strong>POTENTIAL IMPACT OF THE AVAILABILITY OF A LARGER NOVOSEVEN® (RFVIIA) VIAL SIZE IN THE TREATMENT OF ACUTE BLEED EPISODES IN PATIENTS WITH HAEMOPHILIA</strong></td>
<td><strong>Paulo Andre Palhares de Miranda</strong> (CH), Kathryn Starzyk</td>
</tr>
</tbody>
</table>
Inherited coagulation disorders (except for von Willebrand disease)

P-TU-522  A CASE OF FACTOR FIVE DEFICIENCY ASSOCIATED WITH GONADAL AGENESIS
Valizadeh Nasim* (IR), Nasser Jahanbakhsh

P-TU-523  RECOMBINANT FACTOR VIIa (RFVIIa) TREATMENT OF BLEEDING IN CONGENITAL FACTOR VII DEFICIENCY (C7D): ANALYSIS FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY
Kapil Saxena* (US), Ellis J. Neufeld, Eric H. Kraut, David L. Cooper

P-TU-524  MOLECULAR ANALYSIS OF TWO NOVEL MUTATIONS IN A CHINESE PEDIGREE WITH HEREDITARY FVII DEFICIENCY
Zhifang Xing* (CN), Xuefeng Wang

P-TU-525  NOVEL MUTATIONS AND THEIR STRUCTURAL ANALYSIS IN 20 UNRELATED FAMILIES WITH INHERITED FACTOR VII DEFICIENCY SEEN IN TAIWAN
Hsiang Chun Liu* (TW), Ming Ching Shen, Ching Yeh Lin, Bo Do Lin, Wei Tsay, Shyuann Yuh Lin, Su Feng Kuo, Jen Shiou Lin, Mei Hua Hong

P-TU-526  IS A PROLONGED PTT, CAUSED BY A DEFICIENCY OF FACTOR XII, HMWK- OR PREKALLIKREIN, ASSOCIATED WITH A HEMORRHAGIC DIATHESIS?
Sonja R Alesci* (DE), Kofler D Stefan, Genet Asmelash, Wolfgang Miesbach

P-TU-527  ASSESSING BLEEDING IN RARE BLEEDING DISORDERS (RBDS) WITH BLEEDING SCORE: RESULTS FROM THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN-RBD)
Roberta Palla* (IT), Marzia Menegatti, Simona Maria Siboni, Claudia Mistretta, Alain Gadiesseur, Muriel Giansily-Blaizot, Susan Halimeh, Lidija Kitanoiski, Danijela Mikovic, Nihal Ozdemir, Helen Pergiantou, Flora Peyvandi

P-TU-528  STRUCTURE-FUNCTIONAL RELATIONSHIP OF 5 NOVEL MISSENSE MUTATIONS IN F13A GENE PREDICTED BY MOLECULAR MODELLING
Arijit Biswas* (DE), Vytautas Ivaskevicius, Anne Thomas, Johannes Oldenburg

Acquired coagulation disorders

P-TU-532  TREATMENT OF ACUTE BLEEDS IN ACQUIRED HEMOPHILIA WITH RECOMBINANT FACTOR VIIa (RFVIIa): AN UPDATED ANALYSIS FROM THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY
Alice Ma* (US), Craig M. Kessler, Robert Z. Gut, David L. Cooper
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-533  HYPOFIBRINOGENEMIA AND CRYOPRECIPITATE USE IN ON-PUMP CARDIAC SURGERY
Jerome Teitel* (CA), Gail Rockman, C David Mazer, Katerina Pavenski

P-TU-534  THE EFFECT OF HYDROXYETHYL STARCH PLASMA EXPANDER ON WHOLE BLOOD PLATELET FUNCTION
Christian Fenger-Eriksen* (DK), Else Toennesen, David Bevan, Joergen Ingerslev, Benny Soerensen

P-TU-535  OVERCOMING BARRIERS TO RAPID DIAGNOSIS OF BLEEDING DISORDERS AND ACQUIRED HEMOPHILIA (AH) BY HEALTH CARE PRACTITIONERS (HCP): THE COAGS UNCOMPLICATED IPHONE APPLICATION
Craig M Kessler (US), Ellinor I. Peerschke, Gretchen Eberhart, Robert Z. Gut, David L. Cooper*

P-TU-536  PERINATAL INTRAVENTRICULAR HEMORRHAGE (IVH) RELATED TO MATERNAL WARFARIN
Patcharee Komvilaisak* (TH), Pakaphan Kiatchoosakun, Junya Jirapradittha, Amnat Kittkhuandee, Suda Vannapasasht

P-TU-537  CLINICAL ANALYSIS OF 42 PATIENTS WITH ACQUIRED DEFICIENCY OF VITAMIN K-DEPENDENT COAGULATION FACTORS
Hai Fei Chen* (CN), Tian Qin Wu, Ling Juan Jin, Jie Qing Tang, Hong Shi Shen, Zheng Yang Li, Jing Jing Zhu, Long Mei Qin, Zi Qiang Yu, Zhaoyue Wang

P-TU-538  LR AND HEXTEND RESUSCITATION ON COAGULATION FOLLOWING TISSUE INJURY AND SEVERE HEMORRHAGE IN PIGS
Wenjun Z Martini* (US), Douglas Cortez, Shavaughn Colvin, Jill Sondeen, Michael Dubick, Lorne Blackbourne

P-TU-539  REPEATED ADMINISTRATION OF LOW DOSE MONOCLONAL ANTICD20 ANTIBODY RITUXIMAB (RTX) IN REFRACTORY ACQUIRED HEMOPHILIA A (AHA): A CASE REPORT
Regina - Pileckyte* (LT), Neringa Gailiute, Ligita Malciute, Audrone Drungiene, Laimonas Griskevicius

P-TU-540  DISSEMINATED INTRAVASCULAR COAGULATION IN NEWLY DIAGNOSED ACUTE LEUKEMIA: PREVALENCE AND IMPACT
Theera Ruchutarakot* (TH), Saranya Pongudom, Yupapornkunkun, Bundarika Suwanwiboon, Yingyong Chinthammitr, Surapol Issaragrisil

P-TU-541  SAFETY AND EFFICACY OF PROTHROMBIN COMPLEX CONCENTRATES IN THE EMERGENCY REVERSAL OF WARFARIN COAGULOPATHY
Ammar Hussain Majeed* (SE), Anna Eelde, Margareta Holmstrom, Sam Schulman

P-TU-542  PATHOGENESIS OF SYSTEMIC HEMOSTATIC DISTURBANCES IN BOTHROPS JARARACA ENVENOMATION IN RATS
Karine Miki Yamashita* (BR), Marcelo Larami Santoro

P-TU-543  THE USE OF RECOMBINANT FACTOR VIIa IN WARFARIN PATIENTS WITH TRAUMATIC BRAIN INJURY
Emma DeLoughery* (US), Thomas DeLoughery

Experimental models

P-TU-544  DOES FIBRINOGEN REPLACEMENT INCREASE THE RISK OF VASCULAR OCCLUSION AFTER CARDIAC SURGERY?
Kenichi Tanaka* (US), Satoru Ogawa, Fania Szlam, Jerrold H Levy, Tomoko Ohnishi, Kazuya Hosokawa
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-545  PROTHROMBIN COMPLEX CONCENTRATE (PCC) INCREASES SURVIVAL BY REDUCING BLOOD LOSS, ASSOCIATED WITH ENHANCED THROMBIN GENERATION IN A PIG MODEL OF BLUNT LIVER INJURY
Henri M H Spronk* (NL), Oliver Grottke, T Braunschweig, Rene van Oerle, Hugo ten Cate, R Rossaint, Henri M.H. Spronk

P-TU-546  EXPERIMENTAL ACUTE TRAUMATIC COAGULOPATHY IS DUE TO SYSTEMIC ACTIVATION OF PROTEIN C DURING HYPOPERFUSION
Daniel Frith* (UK), Maria Lima Baptista, Mitchell Cohen, Rupert Pearse, Chris Thiemer mann, Karim Brohi

P-TU-547  STREPTOCOCCUS MUTANS, A PATHOGEN OF DENTAL CARIES, AGGRAVATES CEREBRAL HEMORRHAGE BY ITS CELL-SURFACE COLLAGEN-BINDING PROTEIN
Kazuya Hokamura* (JP), Koichiro Wada, Kazuhiko Nakano, Min Thura, Takashi Ooshima, Kazuo Umemura

Atherosclerosis

P-TU-548  INTERLEUKIN-33 INDUCES UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 IN HUMAN ENDOTHELIAL CELLS IN VITRO
Svitlana Demyanets* (AT), Stefan Stojkovic, Christoph Kaun, Gerald Maurer, Kurt Huber, Johann Wojta

P-TU-549  DIMINISHED NEUTROPHIL INTRAPLaque RECRUITMENT IN RESPONSE TO GENETICALLY IMPOSED HYPOPROTHROMBINEMIA RESULTS IN ATHEROSCLEROTIC PLAQUE STABILITY IN HYPERLIPIDEMIC MICE
Julian I. Borissoff* (NL), Sarah T.B.G. Loubele, Sylvia Heeneman, Peter Leenders, Rene van Oerle, Karly Hamulyak, Erik A. Bissens, Jay L. Degen, Tilman M. Hackeng, Mat J.A.P. Daemen, Henri M.H. Spronk, Hugo ten Cate

P-TU-550  MONOMERIC C-REACTIVE PROTEIN IMPAIRS ENDOTHELIAL PROGENITOR CELL FUNCTION AND DIFFERENTIATION VIA UP-REGULATION OF INTERFERONE ALPHA RESPONSIVE GENES
Ingo Ahrens* (DE), Helena Domeij, Steffen Eisenhardt, Madlin Albrecht, Denijal Topic, Ephraem Leitner, Jeremy Jowett, Martha Lappas, Izhak Haviv, Christoph Bode, Karthheinz Peter

P-TU-551  THE EFFECT OF ELASTIN AND FIBULIN-5 GENE EXPRESSIONS IN CAROTID ARTERY DISEASE DEVELOPMENT
Mehmet Kurtoglu* (TR), Emre Sivrikoz, Umit Zeybek, Arzu Ergen, Ozlem Timirci, Murat Aksoy

P-TU-552  EFFECT OF ATORVASTATIN ON INFLAMMATORY MARKERS, NITRIC OXIDE METABOLITES AND CAROTID INTIMA MEDIA THICKNESS IN SYSTEMIC LUPUS ERYTHEMATOSUS. A PLACEBO CONTROLLED STUDY
Paul Richard Julian Ames* (UK), Kathrina Benita Sokoll, Helen MavIver, Joana Batuca, Luis Lopez, Paul Emery

P-TU-553  EFFECT OF BETAINE ON TISSUE FACTOR EXPRESSION IN ACTIVATED HUMAN ENDOTHELIAL CELLS: A NEW PATHWAY OF VASCULAR PROTECTION
Emanuela Napo loleone (IT), Antonella Cutrone, Daniela Cugino, Iolanda Santimone, Licia Iacoviello, Enzo Grossi, Giovanni de Gaetano, Maria Benedetta Donati, Roberto Lorenzet*

P-TU-554  DOWNREGULATION OF TISSUE FACTOR EXPRESSION IN HUMAN MONONUCLEAR CELLS AND MACROPHAGES BY CONJUGATED LINOLEIC ACID ISOMERS
Antonella Cutrone (IT), Emanuela Napo loleone, Giulia Colavecchia, Daniela Cugino, Licia Iacoviello, Giovanni de Gaetano, Orina Belton, Maria Benedetta Donati, Roberto Lorenzet*
POSTER PRESENTATIONS

Tuesday, July 26, 2011

**P-TU-555** MOLECULAR AND CELLULAR COMPONENTS OF HUMAN CAROTID ARTERY Atherosclerotic Plaques Relevant for Thrombus Formation
Patrizia Marchese* (US), Patrizia Marchese, Chiara Foglieni, Andras Gruber, Zaverio M. Ruggeri

**P-TU-556** HISTOPATHOLOGICAL DIFFERENCES BETWEEN PTX3 AND CRP IN CORONARY Atherosclerotic PLAQUE
Yunosuke Matsuura* (JP), Kinta Hatakeyama, Takuroh Imamura, Yoshisato Shibata, Tatsuhiro Kodama, Kazuo Kitamura, Yujiro Asada

**P-TU-557** SELECTIVE DISRUPTION OF THE CD40L/MAC-1 INTERACTION BY A SMALL Peptide INHIBITOR IMITATING THE EQLLKSXKTL MOTIF ATTENUATES INFLAMMATION AND Atherogenesis in Mice
Andreas Zirlik* (DE), Dennis Wolf, Ansgar Wiedemann, Jan David Hohmann, Nicole Bassler, Peter Libby, Karlheinz Peter, Christoph Bode

**Endothelial cells**

**P-TU-558** STANDARDIZATION OF MICROPARTICLE MEASUREMENT BY FLOW CYTOMETRY
Shosaku Nomura* (JP), Norihito Inami, Shinya Fujita, Ryotaro Ozasa, Shuji Higashi, Yutaka Nagai

**P-TU-559** CLOPIDOGREL INDUCED INHIBITION OF PLATELET REACTIVITY PREDICT ENDOTHELIAL INJURY DURING PERCUTANEOUS CORONARY ANGIOPLASTY

**P-TU-560** NICOTINAMIDE AND 1-METHYLNICOTINAMIDE PRESENT LOWVASODILATING ACTIVITY. FUNCTIONAL AND IN VITRO STUDIES
Cezary W Watala* (PL), Tomasz Przygodzki, Piotr Kazmierczak

**P-TU-561** EXPOSURE TO CARBON NANOPARTICLES INDUCES UPREGULATION OF FACTOR VIII PRODUCTION BY HUMAN PULMONARY MICROVASCULAR ENDOTHELIAL CELLS
Tina Shahani* (BE), Jan Emmerechts, Sophie Deckx, Marc Hoylaerts, Marc Jacquemin

**P-TU-562** THE INTERACTION OF CD146/MCAM WITH GALECTIN-1 IS INVOLVED IN THE CONTROL OF ENDOTHELIAL CELL APOPTOSIS
Francoise Dignat-George* (FR), Nathalie Jouve, Nicolas Despoix, Marion Espeli, Karim Fallague, Nathalie Bardin, Marcel Blot-Chabaud, Laurent Gauthier, Frederic Vely, Claude Schiff, Aurélie Leroyer

**P-TU-563** IMPAIRED MICROVASCULAR FUNCTION DURING ATORVASTATIN THERAPY IN PATIENTS WITH TYPE 1 DIABETES
Sara Tehrani* (SE), Fariborz Moharrez, Aleksandra Antovic, Per-Eric Lins, Ulf Adamson, Peter Henriksson, Hakan Wallen, Gun Jorneskog

**P-TU-564** IDENTIFICATION OF SOLUBLE-FORM EXTRACELLULAR TIE-2 WITH FULL FUNCTIONAL DOMAINS: INVOLVEMENT OF TIMP-INSENSITIVE ADAM9 IN ITS PRODUCTION IN ENDOTHELIAL CELLS
Mitsuho Onimaru* (JP), Yoshikazu Yonemitsu, Hanako Suzuki, Katsuo Sueishi

**P-TU-565** KRINGLE1-5 OF PLASMINOGEN MEDIATES ANTIANGIOGENESIS BY ACTIVATION OF PKA AND DOWNREGULATES THROMBOMODULIN EXPRESSION
Chia-Fong Cho* (TW), Hua-Lin Wu, Guey-Yueh Shi
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-566  PAI-1 AND PAI-2 INHIBIT PROTEASOME ACTIVITY FAVORING PROAPOPTOTIC SIGNALING IN ENDOTHELIAL CELLS
Joanna M Boncela* (PL), Izabela Papiewska-Pajak, Patrycja Przygodzka, Elzbieta Wyroba, Czeslaw S Cierniewski

P-TU-567  INVOLVEMENT OF NALP3 INFLAMMASOME AND NFKAPPAB IN THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN ADVANCED CHRONIC KIDNEY DISEASE: PROTECTIVE ROLE OF ANTIOXIDANT MOLECULES
Carolina Caballo* (ES), Marta Palomo, Aleix Cases, Patricia Molina, Manel Vera, Xavier Bosch, Gines Escolar, Maribel Diaz-Ricart

P-TU-568  CIRCULATING ENDOTHELIAL CELLS AND ENDOTHELIAL PROGENITOR CELLS IN ACUTE MYOCARDIAL INFARCTION: CORRELATION WITH PLASMA VASCULAR MARKERS
Maribel Diaz-Ricart* (ES), Ander Regueiro, Marta Palomo, Isaac Subirana, Joan Vila, Juan Sanchis, Susana Novella, Ana Oliveras, Gines Escolar, Jaume Roquer, Magda Heras

Inflammatory cells and cytokines

P-TU-569  THE INHIBITORY EFFECTS OF DISINTEGRIN, RHODOSTOMIN, ON THE ACTIVATION OF TOLL-LIKE RECEPTOR 2
Chun-Chieh Hsu* (TW), Tur-Fu Huang

P-TU-570  STRESS-INDUCED ADIPOSE INFLAMMATION PROMOTES A PROCOAGULANT STATE AND IMPAIRS INSULIN SENSITIVITY BY ADIPOCYTE-DERIVED MONOCYTE CHEMOATTRACTANT PROTEIN-1
Yasuhiro Uchida* (JP), Kyosuke Takeshita, Koji Yamamoto, Ryosuke Kikuchi, Takayuki Nakayama, Tadashi Matushita, Hideo Nakamura, Tetsuhito Kojima, Toyoaki Murohara

P-TU-571  RECOMBINANT CD93 SUPPRESSES INFLAMMATORY RESPONSES IN EXPERIMENTAL INFLAMMATORY MODELS
Yuan-Chung Kao* (TW), Shi Guey-Yueh, Hsu Hsin-I, Wu Hua-Lin

P-TU-572  POTENT INHIBITION OF SUPEROXIDE ANION PRODUCTION IN ACTIVATED HUMAN NEUTROPHILS BY A SMALL CHEMICAL COMPOUND, HTL-9807
Hwang Tsong-Long* (TW), Yann-lieh Leu

P-TU-573  EVALUATION OF THE EFFECTS OF THE COMBINED TP AND 5-HT2 RECEPTOR ANTAGONIST NAFTIDROFURYL IN THE RAT POST-ISCHEMIC KIDNEY
Virginie Voisin* (BE), Vanessa Colombo, Laetitia Giordano, Isabelle Habsch, Lucie Burette, Francois Mullier, Jean-Michel Dogne, Nathalie Caron

P-TU-574  SOLUBLE TWEAK PLASMA LEVELS AS A NOVEL BIOMARKER OF ENDOTHELIAL FUNCTION IN PREVALENT ORTHOTOPIC HEART TRANSPLANT RECIPIENTS
Jolanta Malyszko* (PL), Piotr Przybylowski, Jacek Małyszko, Mysliwiec Michal

P-TU-575  TRAIL IS A MARKER OF KIDNEY FUNCTION AND INFLAMMATION IN HEART AND KIDNEY TRANSPLANT RECIPIENTS
Jolanta Malyszko* (PL), Piotr Przybylowski, Jacek Stanislaw Malyszko, Ewa Koc-Zorawska, Jerzy Sadowski, Michal Mysliwiec

P-TU-576  CXCR4 ANTAGONISM IS EQUALLY EFFECTIVE AS SIROLIMUS IN REDUCING NEOINTIMA FORMATION AFTER ARTERIAL INJURY WITHOUT IMPAIRING RE-ENDOTHELIALIZATION
Karim Hamesch* (DE), Pallavi Subramanian, Xiaofeng Li, Anna Thiemann, Kathrin Heyl, Klaus Dembowsky, Eric Chevalier, Christian Weber, Andreas Schober
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-577  EFFECT OF RIVAROXABAN ON THROMBIN-INDUCED PRO-INFLAMMATORY GENE EXPRESSION IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS
Peter Ellinghaus* (DE), Volker Laux, Elisabeth Perzborn

Redox status

P-TU-579  INTRACELLULAR REDOX HOMEOASTASIS IS DEPENDENT ON VITAMIN K AND THE VKORC1 HOMOLOGUE VKORC1L1
Matthias Watzka* (DE), Matthias Watzka, Philipp Westhofen, Milka Marinova, Moritz Hass, Gregor Kirfel, Jens Mueller, Nancy Blaurock, Carville G Bevans, Johannes Odenburg

Progenitor cells and stem cells

P-TU-581  INHIBITION OF TISSUE FACTOR ON CD34+ALPHA(A)-SMA+ CELLS IS ASSOCIATED WITH REDUCED ANGIOPOIETIN-DEPENDENT CXCR4 EXPRESSION AND REPAIR AFTER ENDOVASCULAR INJURY
Daxin Chen* (UK), Li El Tham, John H McVey, Anthony Dorling

P-TU-582  TISSUE FACTOR- AND ANGIOPOIETIN-DEPENDENT CROSS-TALK BETWEEN CD34+ALPHA(A)-SMA+ AND CD34+CD31+ CELLS SUPPORTS EARLY RECRUITMENT OF ENDOTHELIAL CELLS AFTER ENDOVASCULAR INJURY
Daxin Chen* (UK), Li El Tham, John H McVey, Anthony Dorling

P-TU-583  TISSUE FACTOR PATHWAY INHIBITOR-DEPENDENT CHANGES IN ANGIOPOIETIN EXPRESSION BY CD34+ ALPHA-SMOOTH MUSCLE ACTIN (A-SMA)+PROGENITORS ASSOCIATED WITH ENDOVASCULAR REPAIR
Daxin Chen* (UK), Li El Tham, John H McVey, Anthony Dorling

P-TU-584  LACK OF TISSUE FACTOR- AND ANGIOPOIETIN-DEPENDENT CXCL12 EXPRESSION BY CD34+ALPHA-SMOOTH MUSCLE ACTIN (A-SMA)+CELLS ASSOCIATES WITH REPAIR AFTER ENDOVASCULAR INJURY
Daxin Chen* (UK), Li El Tham, John H McVey, Anthony Dorling

P-TU-585  INVOLVEMENT OF THE ANTIMICROBIAL PEPTIDE LL-37 (CAMP) IN THE DIFFERENTIATION OF CORD BLOOD DERIVED CD34+ CELLS INTO ENDOTHELIAL PROGENITOR CELLS
Ingo Ahrens* (DE), Helena Domeij, Denijal Topcic, Izhak Haviv, Alex Agrotis, Ephraem Leitner, Jeremy Jowett, Martha Lappas, Christoph Bode, Karlheinz Peter

P-TU-586  ADMA INDUCES ENDOTHELIAL PROGENITOR CELLS APOPTOSIS BY P38/JNK MAPK SIGNALING PATHWAYS
Shilong Xiong* (CN), Wang Qian, Zheng Lei, Bao Jie, Cai Zhen

P-TU-587  THE METABOLIC SYNDROME INDUCES APOPTOSIS IN BONE MARROW CELLS AND DECREASES THEIR PROLIFERATIVE CAPACITIES
Sophie Susen* (FR), Matthieu Barthelemy, Madjid Tagzrit, Alexandre Ung, Joke Breynne, Delphine Corseaux, Philippe Marchetti, Brigitte Jude, Eric Van Belle, Frederic Mouquet

P-TU-588  HUMAN BONE MARROW RESIDENT STEM/PROGENITOR CELLS AND STATIN THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE
Olena Dotsenko* (UK), Qingbo Xu, Marjan Jahangiri
POSTER PRESENTATIONS

Tuesday, July 26, 2011

Imaging technologies

P-TU-589 THE ASSESSMENT METHOD OF TISSUE FACTOR PATHWAY INITIATION ACTIVITY---PLASMA RECALCIFICATION TIME DIFFERENCE RATIO
Xiaofan He* (CN), Jing Hu, Hongjian Wang, Bangtao Li, Xudong Tang, Zhhibin Wen, Shilin He

P-TU-590 SEQUENTIAL MAGNETIC RESONANCE SIGNAL CHANGE OF VENOUS THROMBUS RELATES TO ORGANIZING PROCESSES AND THROMBOLYTIC RESPONSES IN RABBITS

P-TU-591 ULTRASOUND IN THE EVALUATION OF HAEMOPHILIC ARTHROPATHY OF ANKLES AND KNEES: A NEW TOOL IN HAEMOPHILIA CARE
Alessandro Gringeri* (IT), Myrve Ma-Purja, Lucia Mangiafico, Silvia Riva, Beata Maria Grochowska, Francesco Fusco, Debora Mago

P-TU-592 PERFORMANCE CHARACTERISTICS OF THE THE ENHANCED HEPARIN INSENSITIVE ALERE INRATIO(R)/INRATIO(R2) PT/INR MONITORING SYSTEM
Grace DeSantis* (US), Mae Zhang, Karl Kalvelage, Anne Lacorte, Elena Garcia, Ken Kupfer, Rick SanGeorge

P-TU-593 IMAGING SPATIAL DYNAMICS OF FIBRIN CLOT FORMATION: POSSIBILITIES FOR DETECTION OF PROTHROMBOTIC AND BLEEDING TENDENCIES
Mikhail A Panteleev* (RU), Anna N Balandina, Vladimir M Emelianenko, Olga A Fadeeva, Gennadii M Galstian, Sergey S Karamzin, Elena N Lipets, Natalia P Soshitova, Ivan D Tarandovskii, Fazoil I Ataullakhanov

P-TU-594 ARFI ULTRASOUND FOR IN VIVO MONITORING OF SOFT-TISSUE BLEEDING AND HEMOSTASIS IN A DOG MODEL OF HEMOPHILIA
Mallory Renee Scola* (US), Timothy C Nichols, Melissa C Caughey, Elizabeth P Merricks, Robin A Raymer, Paul Marginitis, Katherine A High, Caterina M Gallippi

P-TU-595 PREDICTION OF THE EVOLUTION OF ABDOMINAL AORTIC ANEURYSM ON A ANIMAL MODEL BY PET-CT
Ziad Touat* (BE), Pierre Drion, Jean-Francois Monville, Geoff Warnock, Betty Nutsgens, Alain Collie, Alain Cyclotron Research Center, ULG, Belgium Plenevaux, Olivier Defraigne, Naizi Sakalihasan

P-TU-596 OPTICAL COHERENCE TOMOGRAPHY AS A NOVEL TOOL FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION FROM PULMONARY ARTERIAL HYPERTENSION
Nobuhiro Yaota* (JP), Shunsuke Tatebe, Yoshihiro Fukumoto, Hisanori Horiuchi, Hiroaki Shimokawa

P-TU-597 2-D DIGE AS A NOVEL ANALYTICAL TOOL TO ANALYZE THE STRUCTURE OF RECOMBINANT FVIII AND ITS PEGYLATED VARIANTS
Hanspeter Rottensteiner* (AT), Christina Monetti, Herbert Gritsch, Alfred Weber, Friedrich Scheifflinger, Peter L. Turecek

P-TU-598 COST IMPLICATIONS OF POTENTIAL DIFFERENCES IN FVIII PRODUCT HALF-LIVES IN A SWEDISH SOCIETY SETTING
Flemming Lund Axelsen* (CH), Alec Miners

P-TU-600 DIAGNOSTIC OPTICAL COMPOSITE COMPLEX FOR IN VIVO IMAGING OF PLATELETS
Irina Vasilenko* (RU), Vladislav Metelin, Irina Kastrikina, Olga Lopyreva, Marina Nalgieva, Roman Lifenko, Benjamin Agadzhanian, Irina Ivanyuta
POSTER PRESENTATIONS

Tuesday, July 26, 2011

P-TU-601  PREDICTION OF PERIPROCEDUAL ISCHEMIC COMPLICATION IN CAROTID ARTERY STENTING WITH FILTER EMBOLIC PROTECTION DEVICE BY USING MAGNETIC RESONANCE (MR) PLAQUE IMAGING
Kimihiko Kichikawa* (JP), Katsutoshi Takayama, Hiroyuki Nakagawa, Kaoru Miyouchi, Toshiaki Taoka, Masahiko Sakamoto, Takeshi Wada, Shinichiro Kurokawa
Scientific Program
Wednesday, July 27, 2011
Wednesday, July 27, 2011

**Presidential Symposium 11:15-12:45**

**Historical Perspective and Future Direction**  
*Main Hall*

*Chairpersons: Yasuo Ikeda (JP) and Frits R. Rosendaal (NL)*

**Historical perspective and future direction in platelet research**  
*Barry S. Coller (US)*  
11:15 – 11:45

**Historical perspective and future direction of coagulation research**  
*Hidehiko Saito (JP), Tadashi Matsushita, Tetsuhito Kojima*  
11:45 – 12:15

**Historical perspective and future direction of fibrinolysis research:**  
The re-discovery of plasmin  
*Victor J. Marder (US)*  
12:15 – 12:45

**State-of-the-Art Lecture 9:45-10:45**

**Atherothrombosis**  
*Main Hall*

*Chairpersons: Anna Falanga (IT) and Shinya Goto (JP)*

**Atherothrombosis and the role of antiplatelet therapy**  
*Philippe G. Steg (FR)*  
09:45 – 10:15

**Improving reperfusion therapy for acute ischemic stroke**  
*Jeffrey L. Saver (US)*  
10:15 – 10:45

**Platelet Activation**  
*Annex Hall 1*

*Chairpersons: Kenneth J. Clemetson (CH) and Mitsuhiko Sugimoto (JP)*

**Novel platelet activation receptor CLEC-2: From discovery to prospects**  
*Katsue Suzuki-Inoue (JP), Osamu Inoue, Yukio Ozaki*  
09:45 – 10:15

**Platelet adhesion and activation mechanisms in arterial thrombosis and ischemic stroke**  
*Bernhard Nieswandt (DE), Pleines Irina, Bender Markus*  
10:15 – 10:45
Wednesday, July 27, 2011

Genetics in Thrombosis  Annex Hall 2
Chairpersons: Willem H. Ouwehand (UK) and Toshiyuki Miyata (JP)

Discovery of novel platelet aggregation and platelet function loci through genome-wide studies  
Andrew D. Johnson (US)  
SA-WE-005  09:45 – 10:15

Lessons from genome-wide association studies in venous thrombosis  
Pierre-Emmanuel Morange (FR), Tregouet David-Alexandre  
SA-WE-006  10:15 – 10:45

Hemorrhagic and Thrombotic Disorders in Women  Room A
Chairpersons: Nigel Key (US) and Takao Kobayashi (JP)

Women with inherited bleeding disorders  
Flora Peyvandi (IT), Isabella Garagiola, Marzia Menegatti  
SA-WE-007  09:45 – 10:15

Antithrombotic treatment for recurrent pregnancy loss?  
Ian A. Greer (UK)  
SA-WE-008  10:15 – 10:45

Symposia  8:00-9:30

Thrombotic Disorders  Main Hall

Venous Thromboembolism Prophylaxis  
Chairpersons: Meyer-Michel Samama (FR) and Masato Sakon (JP)

Thromboprophylaxis in surgical patients: How reliable are clinical trials?  
Ajay Kakkar (UK)  
SY-WE-001  08:00 – 08:30

Direct factor Xa and thrombin inhibitors: Clinical trial update  
Alexander G. G. Turpie (CA)  
SY-WE-002  08:30 – 09:00

Preventing VTE in non-surgical patients  
Alexander Stephen Gallus (AU)  
SY-WE-003  09:00 – 09:30
Wednesday, July 27, 2011

Platelet (Basic and Clinical)  Annex Hall 1

Platelets Beyond Hemostasis
Chairpersons: Guy A. Zimmerman (US) and Paul Harrison (UK)

Platelets: Multi-talents in vascular biology  SY-WE-004
Steffen Massberg (DE) 08:00 – 08:30

Platelet signaling and the regulation of lymphatic vascular development  SY-WE-005
Mark L. Kahn (US) 08:30 – 09:00

The functions of platelets and platelet microparticles in inflammatory arthritis  SY-WE-006
Eric Boilard (CA), Nathalie Cloutier, Richard Farndale, Brisson Alain
09:00 – 09:30

Coagulation Factors and Inhibitors  Annex Hall 2

Coagulation Initiation and Amplification
Chairpersons: Bjarne Østerud (NO) and Pantep Angchaisuksiri (TH)

Alternatively spliced tissue factor: A physiological or pathological phenomenon?  SY-WE-007
Henri H. Versteeg (NL) 08:00 – 08:30

Factor IX-Triple, an improvement upon natural factor IX for treating hemophilia B?  SY-WE-008
Shu-Wha Lin (TW), Chung-Yang Kao, Chia-Ni Lin 08:30 – 09:00

Prothrombinase activation  SY-WE-009
Sriram Krishnaswamy (US) 09:00 – 09:30
### ORAL COMMUNICATIONS

#### Wednesday, July 27, 2011

**Innovation and Technology**  
Chairpersons: Jian Chun Chen and Masaru Ishii (JP)  
Room C-1

<table>
<thead>
<tr>
<th>Oral</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-WE-001</td>
<td>08:00-08:15</td>
<td><strong>NOVEL SINGLE-CHAIN ANTIBODY-TARGETED MICROBUBBLES FOR DETECTION OF ARTERIAL THROMBOSIS VIA CONTRAST ENHANCED ULTRASOUND</strong></td>
<td>Xiaowei Wang* (AU), Christoph E Hagemeyer, Fu Jia, Ephraem Leitner, Ingo Ahrens, Karlheinz Peter</td>
</tr>
<tr>
<td>O-WE-002</td>
<td>08:15-08:30</td>
<td><strong>DEVELOPMENT OF A QUANTITATIVE DIFFERENTIAL INTERFERENCE CONTRAST-BASED REFRACTOMETRY METHOD FOR THE CHARACTERIZATION OF RARE BLOOD CELL SUBPOPULATIONS</strong></td>
<td>Owen J McCarty* (US), Steven Jacques, Kevin Phillips</td>
</tr>
<tr>
<td>O-WE-003</td>
<td>08:30-08:45</td>
<td><strong>TISSUE FACTOR-TRIGGERED PROCOAGULANT ACTIVITY OF MESENCHYMAL STEM CELLS</strong></td>
<td>Kohei Tatsumi* (JP), Kazuo Ohashi, Yoshinori Matsubara, Ayako Kohori, Hiroshi Kakidachi, Akihiro Horii, Teruo Okano</td>
</tr>
<tr>
<td>O-WE-004</td>
<td>08:45-09:00</td>
<td><strong>A QUANTUM DOT APPROACH TO PLATELET SIGNALING</strong></td>
<td>Joseph E Aslan* (US), Thomas Jacob, Owen JT McCarty, Tania Q Vu</td>
</tr>
<tr>
<td>O-WE-005</td>
<td>09:00-09:15</td>
<td><strong>NONINVASIVE PRENATAL DIAGNOSIS OF HEMOPHILIA BY MICROFLUIDICS DIGITAL PCR ANALYSIS OF MATERNAL PLASMA DNA</strong></td>
<td>Rezan A Kadir* (UK), Nancy B. Y. Tsui, Allen Chan, Claudia Chi, Gillian Mellars, Edward G Tuddenham, Tak Y Leung, Tze K Lau, Rossa W K, Chiu, Dennis Y M Lo</td>
</tr>
<tr>
<td>O-WE-006</td>
<td>09:15-09:30</td>
<td><strong>PLATELET BEHAVIOR ON VON WILLEBRAND FACTOR UNDER ARTERIAL FLUID SHEAR DIFFERS BETWEEN HEALTHY INDIVIDUALS AND PATIENTS WITH CARDIOVASCULAR DISEASE ON DUAL ANTIPLATELET THERAPY</strong></td>
<td>Gerardene R Meade* (IE), Sinead O’Brien* (IE), Martin Somers, Gail Plumkett, Colm McAlamney, Antonio J Ricco, Dermot Kenny</td>
</tr>
</tbody>
</table>

**Fibrinogen and Other Factors II**  
Chairpersons: Yoshihiro Kokubo (JP) and  
Room C-2

<table>
<thead>
<tr>
<th>Oral</th>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-WE-007</td>
<td>08:00-08:15</td>
<td><strong>QUANTITATIVE MONITORING OF CLOT FORMATION AND FXIII ACTIVITY IN REAL TIME USING MURINE IN VIVO MODEL OF THROMBOSIS</strong></td>
<td>Majid Ali* (UK), Richard Pease, Victoria Ridger, Gareth Howells, Peter Grant, Robert Ariens, Helen Philippou</td>
</tr>
</tbody>
</table>
WRITTEN COMMUNICATIONS

Wednesday, July 27, 2011

O-WE-008  08:15 - 08:30
THE RECENTLY DISCOVERED INTRON K NT29576 C>G FACTOR XIII B SUBUNIT GENE POLYMORPHISM DECREASES THE RISK OF MYOCARDIAL INFARCTION AND FACTOR XIII LEVEL IN YOUNG ADULTS
Laszlo Muszbek* (HU), Zoltan A Mezei, Zsuzsanna Bereczky, Laszlo Balogh, Eva Katona, Istvan Edes

O-WE-009  08:30 - 08:45
INHIBITION OF STAPHYLOTHROMBIN BY DABIGATRAN REDUCES STAPHYLOCOCCUS AUREUS ADHESION TO CATHETER AND OTHER FOREIGN SURFACES IN VITRO AND ABDSCES VOLUME IN VIVO
Thomas Vanassche* (BE), Willy E Peetemans, Jan Verhaegen, Joanne van Ryn, Marc F Hoylaerts, Peter Verhamme

O-WE-010  08:45 - 09:00
A NEW, SAFE AND EFFECTIVE RECOMBINANT PROPHYLACTIC TREATMENT FOR PATIENTS WITH CONGENITAL FXIII-A SUBUNIT DEFICIENCY
Manuel Carcao* (CA), Aida Inbal, Johannes Oldenburg, Anders Rosholm, Ramin Tehranchi, Diane Nugent

O-WE-011  09:00 - 09:15
ARTIFICIAL PLASMA SUBSTITUTING SOLUTIONS (PSSS) DON’T WORSEN THROMBIN-FIBRINOGEN AND FACTOR XIII-FIBRIN POLYMER INTERACTIONS
Elena I Sinauridze* (RU), Irina V Gribkova

O-WE-012  09:15 - 09:30
GENDER DIFFERENCES IN FIBRIN NETWORK IN TYPE 2 DIABETES: A STUDY OF CLOT STRUCTURE CHARACTERISTICS AND ASSOCIATIONS WITH VASCULAR AND CARDIOMETABOLIC PARAMETERS
Katharina Hess* (DE), Saad H Alzahrani, Jackie F Price, Mark WJ Strachan, Paul D Baxter, Richard Cubbon, Fladja Phoenix, Toby Gamlen, Nikolaus Marx, Peter J Grant, Ramzi Ajjan

Coagulation Factors: Experimental Models II Room D

Chairpersons: Hans Deckmyn (BE) and Hidemi Ishii (JP)

O-WE-013  08:00 - 08:15
EP217609, A NOVEL NEUTRALIZABLE ANTICOAGULANT IN CARDIOPULMONARY BYPASS
Eric Neuhart* (FR), Yves Fromes, Pierre Gueret, Chantal Krezel, Maurice Petitou

O-WE-014  08:15 - 08:30
ANTI-APOPTOTIC EFFECT OF ACTIVATED PROTEIN C DURING GLUTAMATE-TOXICITY: MOLECULAR MECHANISM
Lyubov Gorbacheva* (RU), Irina Savinkova, Vsevolod Pinelis, Schin’ichi Ishiwata, Georg Reiser, Svetlana Strukova

O-WE-015  08:30 - 08:45
PROTECTIVE ROLE OF PROTEIN S IN LIVER FIBROSIS
Rumi Moroka* (JP), Paloma Gil Bernabe, Corina D’Alessandro-Gabazza, Daniel Boveda Ruiz, Masaaki Toda, Yasushi Miyake, Atsushi Yasukawa, Masahiro Naito, Takehiro Takagi, Motoh Iwasa, Osamu Taguchi, John Morser, Yoshiyuki Takei, Esteban C Gabazza
ORAL COMMUNICATIONS

Wednesday, July 27, 2011

O-WE-016  08:45 - 09:00
THROMBIN-THROMBOMODULIN INTERACTIONS ARE AN IMPORTANT DETERMINANT OF METASTATIC POTENTIAL
Netanel Horowitz* (US), Elizabeth A Blevins, Whitney M Miller, Ashley R Perry, Kathryn E Talmage, Eric S Mullins, Brett Monia, Jay L Degen, Joseph S Palumbo

O-WE-017  09:00 - 09:15
ROLE OF PDI IN THROMBUS FORMATION AND FIBRIN GENERATION IN A COLLAGEN INDUCED PATHWAY
Dolores Bellido Martin* (US), Lola Bellido-Martin, Bruce Furie, Barbara Furie

O-WE-018  09:15 - 09:30
DIAGNOSIS, MECHANISM AND THERAPY OF HEREDITARY ANGIODEMA TYPE III
Jenny Bjorkqvist* (SE), Felicitas Mueller, Sabine Wilhelm, Sven Cichon, Markus Nothen, Thomas Renne

Atherosclerosis and Atherothrombosis Room E

Chairpersons: Shinichiro Kurosawa (US) and Henri M.H. (NL)

O-WE-019  08:00 - 08:15
FACTOR SEVEN ACTIVATING PROTEASE (FSAP) INHIBITS THE ACTIVITY OF PLATELET DERIVED GROWTH FACTOR-BB (PDGF-BB) IN VITRO AND IN VIVO
Sandip M Kanse* (DE), Jan-Marcus Daniel, Karin Hersemeyer, David M Kaetzel, Daniel Sedding

O-WE-020  08:15 - 08:30
THE ROLE OF THE EXTRACELLULAR RNA/RNASE SYSTEM IN CARDIOVASCULAR DISEASE AND INFLAMMATION
Klaus T Preissner* (DE), Silvia Fischer, Christiane Thoelen, Tobias Grantzow, Nicole Kral, Julia Gansler, Thomas Weimer, Markus Sperandio, Elisabeth Deindl, Daniel Sedding

O-WE-021  08:30 - 08:45
BM-573 INHIBITS THE EARLY Atherosclerotic Lesions In APO E DEFICIENT MICE BY BLOCKING TP RECEPTORS AND THROMBOXANE SYNTHASE
Celine Cherdon* (BE), Stephanie Rolin, Julien Hanson, Annie Ooms, Laurent de Leval, Pierre Drion, Carine Michiels, Bernard Pirotte, Francois Muller, Natzi Sakalihassan, Jean-Olivier Defraigne, Jean-Michel Dogne

O-WE-022  08:45 - 09:00
ADMINISTRATION OF ORAL DABIGATRAN ETIXILATE SUBSTANTIALLY COUNTERACTS INFLAMMATION AND ENHANCES PLAQUE STABILITY IN A HYPERCOAGULABLE MODEL OF AGGRESSIVE ATHEROSCLEROSIS
Julian I. Borissoff* (NL), Sarah T.B.G. Loubele, Sylvia Heeneman, Peter Leenders, Rene van Oerle, Oliver Soehnlein, Karly Hamulyak, Erik A. Biessen, Hartmut Weiler, Joanne van Ryn, Tilman M. Hackeng, Mat J.A.P. Daemen, Henri M.H. Spronk, Hugo ten Cate
ORAL COMMUNICATIONS

Wednesday, July 27, 2011

O-WE-023  INNATE IMMUNE RESPONSE THROUGH TLR4 IS ASSOCIATED WITH PLATELET ACTIVATION AND INFLAMMATION IN PATIENTS WITH ACUTE CORONARY SYNDROME
Kagari M Murasaki* (JP), Hisako Omori, Yoshio Uetsuka, Nobuhisa Hagiwara

09:00 - 09:15

O-WE-024  INTEGRIN MAC-1 FACILITATES THE Anti-INFLAMMATORY ACTIVITY OF ACTIVATED PROTEIN C
Li Zhang* (US), Chunzhang Cao, Yamei Gao, Yang Li, Toni M Antalis, Francis J Castellino

09:15 - 09:30

Hemophilia: Inhibitor Treatment

Chairpersons: Elena Santagostino (IT) and Claude Negrier (FR)

O-WE-025  UPDATE ON THE IMMUNE TOLERANCE AND ECONOMICS RETROSPECTIVE REGISTRY (ITER) OF PATIENTS WITH HAEMOPHILIA A (HA) AND FACTOR VIII INHIBITORS
Alessandro Gringeri* (IT), Angiola Rocino, Jan Astermark, Maria Joao Diniz, Karin Fijnvandraat, Robert Klamroth, Geraldine Lavigne-Lissalde, Thierry Lambert, Maria Fernanda Lopez-Fernandez, Massimo Morfini, Carmen Altisent, EHTSB Members

08:00 - 08:15

O-WE-026  COST OF IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A PATIENTS: RESULTS FROM THE ITER STUDY
Alessandro Gringeri* (IT), Luciana Scalone, Lorenzo Giovanni Mantovani, Angiola Rocino, Carmen Altisent, Jan Astermark, Maria Joao Diniz, Karin Fijnvandraat, Robert Klamroth, Thierry Lambert, Geraldine Lavigne-Lissalde, Maria Fernanda Lopez Fernandez, Massimo Morfini, EHTSB Members

08:15 - 08:30

O-WE-027  EFFECTIVENESS AND SAFETY OF SECONDARY PROPHYLAXIS WITH RFVIIA IN HAEMOPHILIA PATIENTS WITH INHIBITORS: RESULTS FROM THE PRO-PACT OBSERVATIONAL STUDY
Victor S Blanchette* (CA), Elena Santagostino, Massimo Morfini, Guenter K Auerswald, Thierry Lambert, Victor Jimenez-Yuste, Guy Young

08:30 - 08:45

O-WE-028  SURGERY IN HAEMOPHILIA PATIENTS WITH INHIBITORS TO FVIII/FIX: THE NORWEGIAN SINGLE CENTRE STUDY
Pal Andre Holme* (NO), Hoa Thi Tyet Tran, Albert Paus, Geir E Tjonnfjord

08:45 - 09:00

O-WE-029  CLINICAL AND LABORATORY RESULTS FROM ADEPTTM 1, A PHASE 2 TRAIL INVESTIGATING THE USE OF RECOMBINANT ACTIVATED FVII ANALOGUE IN CONGENITAL HAEMOPHILIA PATIENTS WITH INHIBITORS
Erich de Paula* (BR), Kaan Kavakli, Johnny Mahlangu, Yasmin Ayob, Steven R. Lentz, Massimo Morfini, Laszlo Nemes, Silva Zupancic Salek, Midori Shima, Jerzy Windyga, Slike Ehrenforth, Henning Friis Andersen, Ampaiwan Chuansumrit, on behalf of 1804 (adeptTM 1) Investigators

09:00 - 09:15
ORAL COMMUNICATIONS

Wednesday, July 27, 2011

O-WE-030  09:15 - 09:30

CLINICAL PHARMACOLOGICAL STUDY OF A PLASMA-DERIVED FACTOR VIIA AND FACTOR X MIXTURE (MC710) IN HAEMOPHILIA PATIENTS WITH INHIBITORS - PHASE I TRIAL -
Tadashi Matsushita* (JP), Akira Shirahata, Katsuyuki Fukutake, Jun-ichi Mimaya, Junki Takamatsu, Midori Shima, Hideo Hanabusa, Hideyuki Takedani, Yoshihumi Takashima, Akio Tawa, Satoshi Higasa, Noboru Takata, Michio Sakai, Kiyoshi Kawakami, Yasuo Ohashi, Hidehiko Saito

Antiphospholipid Syndrome: Clinical Room A

Chairpersons: Tatsuya Atsumi (JP) and Philip de Groot (NL)

O-WE-031  08:00 - 08:15

OBSERVATIONAL STUDY OF THE VARIOUS ANTIPHOSPHOLIPID ANTIBODIES-RELATED DEEP VENOUS THROMBOTIC RISK IN WOMEN WITH AN OBSTETRICAL ANTIPHOSPHOLIPID SYNDROME
Jean-Christophe Raymond Gris* (FR), Erik Mercier, Eva Cochery-Nouvellon, Jean-Pierre Balducchi, Pierre Mares, Isabelle Quere, Michel Dauzat

O-WE-032  08:15 - 08:30

IMPACT OF PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES ON SYMPTOMATIC THROMBOEMBOLISM IN CHILDREN: A SYSTEMATIC REVIEW & META-ANALYSIS [OBSERVATIONAL STUDIES]
Ulrike Nowak-Gottl* (DE), Gili Kenet, Mariana Bonduel, Anthony Chan, Neil A Goldenberg, Susanne Holzhauer, Alfonso Iorio, Janna Journeykake, Ralf Junker, Christoph Male, Patricia Masicotte, Paul Monagle, Heleen C Van Ommen, Leslie Raffini, Paolo Simioni, Guy Young

O-WE-033  08:30 - 08:45

THROMBOGENIC EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES ARE AMELIORATED IN TISSUE FACTOR DEFICIENT MICE
Zurina Romay-Penabad (US), Ana Laura Carrera-Marín, Nigel Mackman, Silvia S Pierangelii*

O-WE-034  08:45 - 09:00

PREDOMINANT PREVALENCE OF STROKE IN JAPANESE PATIENTS WITH THE ANTIPHOSPHOLIPID SYNDROME
Yuichiro Fujieda* (JP), Tatsuya Atsumi, Kotaro Otomo, Masaru Kato, Kenji Oku, Olga Amegual, Shinsuke Yasuda, Tetsuya Horita, Takao Koike

O-WE-035  09:00 - 09:15

DEVELOPMENT OF AUTO-ANTIBODIES AGAINST β2-GLYCOPROTEIN I IN MICE
Gwendolyn Margaretha van Os* (NL), Joost M Meijers, Cetin Agar, Mercedes Valls Seron, Arnoud Marquart, Per Akesson, Rolf T Urbanus, Ron H Derksen, Heiko Herwald, Matthias Morgelin, Philip G. de Groot

O-WE-036  09:15 - 09:30

β2-GLYCOPROTEIN I: A NOVEL COMPONENT OF INNATE IMMUNITY
Cetin Agar* (NL), Philip G de Groot, Matthias Morgelin, Stephanie D.D.C. Monk, Gwendolyn M.A. van Os, Johannes H.M. Levels, Bas de Laat, Rolf T Urbanus, Heiko Herwald, Tom van der Poll, Joost C.M. Meijers
ORAL COMMUNICATIONS

Wednesday, July 27, 2011

**Microparticles**

Chairpersons: Shosaku Nomura (JP) and Benjamin Brenner

**O-WE-037**  08:00 - 08:15

MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PANCREATIC- AND BRAIN CANCER PATIENTS: IMPACT ON THROMBOSIS RISK AND SURVIVAL

Johannes Thaler* (AT), Cihan Ay, Rogier M. Bertina, Silvia Koder, Alexandra Kaider, Marosi Christine, Gabriela Kornek, Christoph Zielinski, Ingrid Pabinger

**O-WE-038**  08:15 - 08:30

CHARACTERIZATION OF THE PROCOAGULANT ACTIVITY OF TWO DIFFERENT MICROPARTICLE SPECIES

Ludwig Traby* (AT), Marietta Kollars, Khalid Shoumariyeh, Ansgär Weltermann, Paul Alexander Kyrle, Sabine Eichinger, Daniel Lechner

**O-WE-039**  08:30 - 08:45

PHOSPHATIDYLSERINE EXTERNALIZATION AND ITS VESICULATION IN GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY

Duangdao Nantakomol* (TH), Attakorn Palasuwan, Suphan Soogarun, Supantitra Chanprasert, Pornlada Nuchnoi

**O-WE-040**  08:45 - 09:00

LABEL-FREE DISTINCTION BETWEEN PLATELET AND ERYTHROCYTE MICROPARTICLES BY RAMAN MICROSCOPY

Edwin van der Pol* (NL), C M Hau, C Otto, A Sturk, T G van Leeuwen, R Nieuwland

**O-WE-041**  09:00 - 09:15

REDUCTION OF PRO-COAGULANT PHOSPHOLIPID AND PLATELET ACTIVATION DURING TISSUE ISCHEMIA AND REPERFUSION IN UPPER LIMB TRAUMA

Ross Ian Baker* (AU), M Wenk, Elizabeth Gardiner, James Thom, Tomas Corcoran

**O-WE-042**  09:15 - 09:30

IMPROVEMENT OF MICROPARTICLE DETECTION USING A NEW HIGH-SENSITIVITY ROUTINE FLOW CYTOMETER: EXPLORING THE HIDDEN PART OF THE ICEBERG

Stephane Robert* (FR), Romaric Lacroix, Philippe Poncelet, Jennifer Wischhusen, Karim Harhouri, Tarik Bouriche, Jose Sampol, Francoise Dignat-George

**Plasminogen Activation System: Tissue Remodeling**

Chairpersons: HIROYUKI MATSUNO (JP) and Johan Wojta

**O-WE-043**  08:00 - 08:15

LAP DEGRADATES: A NOVEL BLOOD BIOMARKER OF PLASMA KALLIKREIN-DEPENDENT TGF-β ACTIVATION REFLECTING EARLY STAGE OF THE LIVER FIBROGENESIS

Soichi Kojima* (JP)
ORAL COMMUNICATIONS

Wednesday, July 27, 2011

O-WE-044  08:15 - 08:30

UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR) REGULATES ANGIOGENESIS VIA DIRECT INTERACTION WITH LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR-) LIKE PROTEIN IN ENDOTHELIAL CELLS
Rene Novotny (AT), Matthias Unseld, Marina Poettler, Waclawa Kalinowska, Margarethe Geiger, Christoph Zielinski, Gerald Prager*

O-WE-045  08:30 - 08:45

THE EXPRESSION OF ANNEXIN II IN APL CELLS AND ITS ROLE IN THE FIBRINOLYTIC ACTIVITY IN PATIENTS WITH APL
Zhaoyue Wang* (CN), Yanhui Liu, Miao Jiang, Lan Dai, Wei Zhang

O-WE-046  08:45 - 09:00

IDENTIFICATION OF NOVEL PLASMINOGEN RECEPTOR ON HEPATOCYTES
Taeichiro Seki* (JP), Mayuko Arima, Nobuaki Okumura, Hiromi Shigematsu, Kasumi Ishii, Takashi Hosono, Jun Ogihara, Toyohiko Ariga

O-WE-047  09:00 - 09:15

TAFI DEFICIENCY ACCELERATES LIVER DAMAGE IN MURINE MODELS OF CHRONIC AND ACUTE LIVER FAILURE
Greg Hugenholtz* (NL), Jelle Adelmeijer, Robert J Porte, Joost CM Meijers, Ton Lisman

O-WE-048  09:15 - 09:30

ENDOGENOUS ALPHA-2-ANTIPLASMIN IS PROTECTIVE DURING SEVERE GRAM-NEGATIVE SEPSIS (MELIOIDOSIS)
Liesbeth M Kager* (NL), Gavin CKW Koh, W Joost Wiersinga, Joris J Roelofs, Joost C Meijers, Cornelis Van ‘t Veer, Tom Van der Poll
POSTER PRESENTATIONS

Wednesday, July 27, 2011

Signal transduction of platelet activation

P-WE-001  FORMATION OF A PROCOAGULANT PROTEIN COAT ON THE SURFACE OF THE PHOSPHATIDYLSERINE-EXPOSING PLATELETS BY TRANSGLUTAMINASES
Vladimir N Kolyadko* (RU), Yana N Kotova, Fazoil I Ataullakhanov, Mikhail A Panteleev

P-WE-002  A ROLE FOR SHIP1 IN PLATELET INTERNAL CONTRACTION
Marie-Pierre Gratacap* (FR), Sonia Severin, Alessandra Consonni, Gaetan Chicanne, Sophie Allart, Monique Plantavid, Bernard Payrastre

P-WE-003  IDENTIFICATION OF SIGNAL TRANSDUCTION PATHWAYS INVOLVED IN THE FORMATION OF PLATELET SUBPOPULATIONS DURING ACTIVATION
Nikolay N Topalov* (RU), Yana N Kotova, Sergey A Vasiliev, Mikhail A Panteleev

P-WE-004  EXOGENOUS PDI MEDIATES INTEGRIN-DEPENDENT ADHESION BOTH AS A CHAPERONE-LIKE ACTIVITY AND AS AN OXIDOREDUCTASE
Vera Sheptovitzky (IL), Nunit Rosenberg, Ronit Mor-Cohen, Judith Lahav*

P-WE-005  PROTEIN KINASE Cδ MEDIATES THE ACTIVATION OF PROTEIN KINASE D2 IN PLATELETS
Dheeraj Bhavanasi* (US), Soochong Kim, Larry E Goldfinger, Satya P Kunapuli

P-WE-006  INTRODUCTION OF THE CRGT PEPTIDE INTO PLATELET CYTOPLASM LEADS TO THE DISSOCIATION OF C-SRC FROM THE INTEGRIN β3 TAIL WITHOUT AFFECTING ITS BASAL KINASE ACTIVITY
Jiansong Huang* (CN), Xiaodong Xi, Nelly Kieffer, Yulan Zhou, Lanlan Tao, Yongkui Kong, Xiaofeng Shi

P-WE-007  A LACK OF REGULATOR OF G-PROTEIN SIGNALING 2 (RGS2) IN MICE DOES NOT AFFECT THROMBUS FORMATION AT SITES OF VASCULAR INJURY
Fumiaki Banno* (JP), Takahiro Nojiri, Sachiko Matsumoto, Kei Kamide, Naoki Mochizuki, Toshiyuki Miyata

P-WE-008  PYK2 IS PREREQUISITE FOR GPVI-INDUCED PLATELET ROS PRODUCTION, BUT NOT AGGREGATION
Tony Gerard Walsh* (IE), Naadiya Carrim, Pat Metharom, Michael C Berndt

P-WE-009  THE ROLE OF THE MOLECULAR TARGET OF RAPAMYCIN COMPLEX (MTORC)2 IN AKT REGULATION IN HUMAN PLATELETS
Ingeborg Hers* (UK), Roger W Hunter, Samantha F Moore

P-WE-010  INTERNALIZATION OF TISSUE FACTOR BY PLATELETS PROMOTES REVERSIBLE CYTOSKELETAL ASSEMBLY THROUGH ACTIVATION OF RHOA AND PI3-KINASE. EFFECTS OF INHIBITORY STRATEGIES
Irene Lopez-Vilchez* (ES), Maribel Diaz-Ricart, Ana M Galan, Merce Roque, Patricia Molina, James G White, Gines Escolar

P-WE-011  GLUTATHIONE REGULATES STORE-OPERATED CALCIUM ENTRY BY REMODELING ACTIN CYTOSKELETON IN HUMAN PLATELETS
Ekaterina V Shamova* (BY), Marina A Gispenko, Mihail V Goltayev, Irina V Gorudko, Sergey N Cherevkevich
POSTER PRESENTATIONS

Wednesday, July 27, 2011

Biology of platelets

P-WE-012  ROLE OF INNATE IMMUNE RECEPTORS, TLR2 AND IL1R1, IN MODULATING THE EFFECTS OF OBESITY ON MEGAKARYOCYTES AND PLATELETS
Lea M Beaulieu* (US), Rebecca Iafrati, Selim Tannirverdi, Bahadir Ercan, Olga Vitseva, Kahraman Tannirverdi, Jane E Freedman

P-WE-013  IDENTIFICATION OF A BIDIRECTIONAL LEUKOCYTE CONVEYANCE MECHANISM AT SITES OF VASCULAR INJURY
Yuping Yuan* (AU), Ghasemzadeh Mehran, Alwis Imala, Schoenwaelder M Simone, Nesbitt S Warwick, Westein Erik, Kaplan Zane, Jackson P Shaun

P-WE-014  ROLE OF PLASMA FIBRONECTIN IN THROMBOSIS AND HEMOSTASIS: EVIDENCE FOR THE FIBRIN-DEPENDENT AND -INDEPENDENT PATHWAYS
Yiming Wang* (CA), Adili Reheman, Jalil Kalantari, Wuxun Jin, Peter Gross, Margaret Rand, John Freedman, Heyu Ni

P-WE-015  PLATELET ACTIVATION IS NEGATIVELY REGULATED BY THE MOLECULAR INTERACTION OF PLATELET SURFACE CD226 WITH CD112 EXPRESSED ON ENDOTHELIAL CELLS
Yukinori Kozuma* (JP), Haruhiko Ninomiya, Kazuko Shibuya, Akira Shibuya, Hiroshi Kojima

P-WE-016  LOW CONCENTRATION DETERGENT SCLEROSANTS INDUCE PLATELET ACTIVATION BUT INHIBIT AGGREGATION IN VITRO
Kurosh Parsi* (AU), Anne Pilotelle, David E Connor, Joyce Low, David D.F. Ma, Joanne E Joseph

P-WE-017  RELEASE REACTION OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) THROUGH PAR1 ACTIVATION AND ITS TWO DISTINCT POOLS IN HUMAN PLATELETS
Shogo Tamura* (JP), Hidenori Suzuki, Yuji Hiroiwatari, Ayumi Nagasawa, Masanao Hatase, Tetuya Tsunematsu, Kazuhiko Matsuno, Selichi Kobayashi, Takanoi Moriyama

P-WE-018  INDIRECT PLATELET RECRUITMENT BY STAPHYLOCOCCUS AUREUS THROUGH STAPHYLOCOAGULASE-MEDIATED FIBRIN
Thomas Vanassche* (BE), Katrien Cludts, Serena Loyen, Marc F Hoylaerts, Peter Verhamme

P-WE-019  EXTRACELLULAR PROTEIN DISULFIDE ISOMERASE REGULATES THROMBIN-INDUCED THROMBIN BURST ON THE PLATELET SURFACE VIA MODULATION OF COAGULATION FACTOR BINDING
Kerstin Jurk* (DE), Judith Lahav, Beate E. Kehrel

P-WE-020  ACTIVATED PLATELETS MODULATE TISSUE REGENERATION BY PROMOTING ANGIOGENESIS AND RETINOL METABOLISM, AND SUPPRESSING INFLAMMATION
Rima Dardik* (IL), Livia Theodor

P-WE-021  HUMAN ALPHA-DEFENSINS ACTIVATE PLATELETS
Anne Bertling* (DE), Meike Horn, Martin F. Brodde, Anja Mueller, Joachim Roth, Christina Stuerzel, Christine Heilmann, Georg Peters, Kerstin Jurk, Beate E. Kehrel

Integrins and other glycoproteins

P-WE-022  IMPAIRED ANGIOGENESIS CONTRIBUTES TO PATHOGENESIS OF FETAL AND NEONATAL IMMUNE THROMBOCYTOPENIA
Sean Lang* (CA), Hong Yang, Shelley Boyd, Pingguo Chen, Xu Zhao, Conglei Li, Siavash Piran, Guangheng Zhu, John Freedman, Heyu Ni
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-023  IMPACT OF PLASMA LIGANDS ON CELL ADHESION AND ON OUTSIDE-IN SIGNALING IN HEK293 CELLS TRANSFECTED WITH THE POLYMORPHIC PLATELET INTEGRIN ALPHAIIB BETA3
Marianna Gyenes* (DE), Abdel El-Khattouti, Volker R. Stoldt, Ruediger E. Scharf

P-WE-024  PLATELET INTEGRIN αIIBβ3: POLYMORPHIC VARIANTS DISPLAY DIFFERENT RECEPTOR ACTIVATION STATES
Abdelouahid El-Khattouti* (DE), Volker R. Stoldt, Benjamin Chahem, Ruediger E. Scharf

P-WE-025  LOW-CONCENTRATED COATING OF RGD-LIGANDS MODULATES ADHESION OF HPA-1B/1B PLATELETS UNDER HIGH SHEAR RATES
Volker R. Stoldt* (DE), Saskia Schlesinger, Ruediger E. Scharf

P-WE-026  UNFOLDING OF FIBRONECTIN BY PLATELET β3 INTEGRINS UNDER STATIC AND FLOW CONDITIONS
Khon Chan Huynh* (DE), Ruediger E. Scharf, Volker R. Stoldt

P-WE-027  KINETICS, THERMODYNAMICS AND THE MECHANISM OF SINGLE-MOLECULE INTERACTIONS OF THE PLATELET INTEGRIN αIIBβ3 WITH CYCLIC RGD AND THE FIBRIN(OGEN) γC-DODECAPEPTIDE
Rustem I Litvinov* (US), Valeri Barsgegov, Olga Kononova, Paul C Billings, Craig Streu, Joel S Bennett, John W Weisel

P-WE-028  ROLE OF THE FIBRIN(OGEN) α CHAIN RGD MOTIFS AND THE γA/γ' CHAIN POLYMORPHISM IN αIIBβ3-FIBRIN INTERACTIONS
Rustem I Litvinov* (US), David H Farrell, John W Weisel, Joel S Bennett

P-WE-029  THE EFFECT OF STIR-SPEED ON GPVI-DEPENDENT PLATELET AGGREGATION
Philip DM Leadbeater* (UK), Richard W Farndale, Jane A Mitchell, Timothy D Warner

P-WE-030  ANALYSIS OF PLATELET RECEPTOR EXPRESSION IN ITP
Huy Tran* (AU), Jian Lin Qiao, Mu Fi-tjen, Robert K Andrews, Elizabeth E Gardiner

P-WE-031  SEPARATION OF THE TWO EXTRACELLULAR TAILS IS REQUIRED TO PROPAGATE ACTIVATION SIGNALS INITIATED IN THE CYTOPLASMIC TAILS OF αIIBβ3 INTEGRIN
Tetsuji Kamata* (JP), Makoto Handa, Yohko Kawai, Yasuo Ikeda

P-WE-032  PROTEOME ANALYSIS AND BIOLOGICAL CHARACTERIZATION OF NOVEL RHOD EFFECTORS
Akira Katsuura* (JP), Marina Takasu, Miki Kobayashi, Norio Kaneda, Tadashi Matsushima, Tetsuhiro Kojima, Tamaki Naoe, Kozo Kaibuchi

Platelets as drug targets

P-WE-033  HEPARIN-INDUCED THROMBOCYTOPENIA AND THROMBOSIS - A NEW EMERGING THERAPEUTIC STRATEGY
Jaa Y New* (AU), Jose Sail Perdomo, Xing-Mai Jiang, Beng H Chong

P-WE-034  ASPIRIN DOES NOT AUGMENT INHIBITION OF HUMAN PLATELET RESPONSES TO THROMBIN IN THE PRESENCE OF P2Y12 ANTAGONISM
Frederick Ofosu* (CA), Mehar Raja, Matthew Chong, Joseph Jakubowski, Atsuniro Sugidachi

P-WE-035  P2Y12 ANTAGONISM PROVIDES MORE EFFECTIVE INHIBITION OF PLATELET RESPONSES TO THROMBIN THAN PAR-1 OR PAR-4 ANTAGONISM
Frederick Ofosu* (CA), Kenneth Nkonge, Matthew Chong, Joseph Jakubowski, Atsuniro Sugidachi
POSTER PRESENTATIONS

Wednesday, July 27, 2011

**P-WE-036**  A SELECTIVE PHOSPHODIESTERASE 3 INHIBITOR, K-134, SUPPRESSES VWF-GPIB/V/IX-MEDIATED PLATELET THROMBUS FORMATION VIA ELEVATION OF INTRACELLULAR CAMP BUT NOT CGMP LEVEL
Hideo Yoshida* (JP), Yosuke Okamura, Naohide Watanabe, Souhei Tanabe, Yasuo Ikeda, Makoto Handa

**P-WE-037**  DOSE-DEPENDENT EFFECTS OF PRASUGREL ON ADP- AND COLLAGEN-INDUCED PLATELET AGGREGATION ON A BACKGROUND OF ASPIRIN IN MINIATURE PIGS
Kousaku Ohno* (JP), Atsuyuki Tomizawa, Joseph A Jakubowski, Atsuhiro Sugidachi

**P-WE-038**  COMPARISON OF PRASUGREL AND TICAGRELOR ON ANTIPLATELET, ANTI THROMBOTIC AND ANTIHAEMOSTATIC ACTIONS IN RATS
Atsuyuki Tomizawa* (JP), Kousaku Ohno, Joseph A Jakubowski, Atsuhiro Sugidachi

**P-WE-039**  IN VITRO EFFECTS OF PRASUGREL’S ACTIVE METABOLITE ON A NOVEL ELISA-BASED WHOLE BLOOD VASP ASSAY
Shinji Yamaguchi* (JP), Kousaku Ohno, Joseph A Jakubowski, Atsuhiro Tomizawa, Atsuhiro Sugidachi

**P-WE-040**  MITOCHONDRIAL DYSFUNCTION AND THROMBOSIS: PLATELET STIMULATION BY THE CITRIC ACID CYCLE INTERMEDIATE SUCCINATE AS A POTENTIAL CAUSE OF CLOPIDOGREL AND ASPIRIN RESISTANCE
Florian Langer* (DE), Brigitte Spalth, Arne Hansen, Carsten Bokemeyer

**P-WE-041**  FLAVONOLS IMPROVE BLOOD FLOW IN A MODEL OF ACUTE ARTERIAL THROMBOSIS
Sapha Mosawy* (AU), Owen L Woodman, Matthew D Linden

**P-WE-042**  QUERCETIN AND 3', 4'-DIHYDROXYFLAVONOL INHIBIT PLATELET FUNCTION IN VITRO
Sapha Mosawy* (AU), Owen L Woodman, Matthew D Linden

**P-WE-043**  ENDOCANNABINOIDS AND CANNABIS SATIVA USE INHIBIT HUMAN PLATELET FUNCTION
Valentina De Angelis* (NL), Coen Maas, Flip G. de Groot, Rolf T. Urbanus, Mark Roest

**P-WE-044**  LOW CONCENTRATIONS OF DABIGATRAN PREVENT THROMBIN-MEDIATED PLATELET AGGREGATION AND PARTIALLY INHIBIT PAR-1 AND PAR-4 ACTIVATION
Frederick Ofosu* (CA), Yingqi Song, Hina Bhakta

**Novel methodologies**

**P-WE-045**  THE RELATIONSHIP OF LIGHT TRANSMISSION AGGREGOMETRY AND FLOW CYTOMETRY TO PLATELET COUNT IN PLATELET FUNCTION TESTING
Gillian Clare Lowe* (UK), Ban B Dawood, William A Lester, Jonathan T Wilde, Steve P Watson

**P-WE-046**  A NOVEL, COLORIMETRIC PLATELET ACTIVATION ASSAY FOR DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA (HIT)
M. Margaret Prechel* (US), Vicki Escalante, Amanda F. Drenth, Jeanine M. Walenga

**P-WE-047**  NEW SENSITIVE MARKERS OF PLATELET'S REACTIVITY IN CLOPIDOGREL TREATED PATIENTS: RESULTS OF FLOW CYTOMETRY AND GENETIC ANALYSIS
Olga V Sirotkina* (RU), Anastasiya B Laskovets, Nataliya A Bogankova, Larisa B Gaykovaya, Tatiana V Vavilova

**P-WE-048**  LOW ANGLE LIGHT SCATTERING ANALYZER: A NOVEL METHOD FOR QUANTITATIVE CHARACTERIZATION OF HUMAN PLATELET RECEPTOR FUNCTIONS
Jorg Geiger* (DE), Igor Mindukshev, Igor Krichenko, Stepan Gambaryan, Anna Kobsar, Anna Rukoyatkina, Ulrich Walter
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-049  IMMOBILISED METAL AFFINITY CHROMATOGRAPHY (PROTEIN IMAC) AS A METHOD TO ENRICH FOR LOW ABUNDANCE PROTEINS IN RESTING AND GPVI-STIMULATED PLATELETS
Ronald Geoffrey Stanley* (UK), Bernice Wright, William Kaiser, Jonathan Gibbins

P-WE-050  ANALYSIS OF PROTEIN NETWORKS IN RESTING AND COLLAGEN RECEPTOR (GPVI)-STIMULATED PLATELET SUB-PROTEOMES
Ronald Geoffrey Stanley* (UK), Bernice Wright, William Kaiser, Jonathan Gibbins

P-WE-051  QUANTIFICATION OF PLATELET mRNA FROM HIGHLY PURIFIED PLATELETS REVEALS SIGNIFICANT EXPRESSION OF COMPONENTS OF THE INNATE IMMUNE SYSTEM IN PLATELETS
Ingo Ahrens* (DE), Madlin Albrecht, Christoph Bode, Karlheinz Peter

P-WE-052  THE SIGNIFICANCE OF LEUKOCYTE-PLATELET AGGREGATES FORMATION BY PLATELET ACTIVATION
Ayumi Nagasawa* (JP), Shogo Tamura, Kouji Hayasaka, Takanori Moriyama, Kazuhiro Matsuno

P-WE-053  PROPORTION AND MORPHOMETRIC PARAMETERS OF LARGE PLATELETS AND SMALL PLATELETS IN HEALTHY PEOPLE
Elizaveta Vlasova* (RU), Irina Vasilenko

P-WE-054  MEASUREMENT OF VASP-PHOSPHORYLATION USING A NEW ASSAY BASED ON BEAD TECHNOLOGY
Jacqueline Glenn* (UK), Jackie Glenn, Kiren Dhillon, Natalia Dovlatova, Sue Fox, Stan Heptinstall

P-WE-055  FIRST COMPARISON STUDY FOR THE INFLUENCES OF TICAGRELOR AND CLOPIDOGREL ADMINISTRATION ON PLATELET-FIBRIN CLOT STRENGTH MEASURED BY THROMBELASTOGRAPHY
Young-Hoon Jeong* (US)

ITP

P-WE-056  AUTOANTIBODY TO PLATELET GPIB/IX IS A PREDICTIVE FACTOR FOR POOR RESPONSE TO INTRAVENOUS IMMUNOGLOBULIN IN ADULTS WITH SEVERE IMMUNE THROMBOCYTOPENIA
Jun Peng* (CN), Shi-hui Ma, Xi-min Liu, Rui-rong Xu, Cheng-shan Guo, Heyu Ni, Ming Hou

P-WE-057  NEUTRALIZING TH17 CYTOKINES SUPPRESSES IMMUNE DISORDERS IN IMMUNE THROMBOCYTOPENIA
Yu Hu* (CN), Daoxin Ma, Shuang Yu, Ji Ma, Yanan Min, Ming Hou

P-WE-058  ELEVATED TC17 AND ITS CORRELATION WITH TH17 IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
Daoxin Ma* (CN), Yu Hu, Ming Hou

P-WE-059  EFFECT OF SPLENECTOMY ON THE INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) AND SEPSIS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
Ted Wun* (US), Soames Boyle, Ann Brunson, Richard White

P-WE-060  THE USE OF PLATELET ASSOCIATED IGG (PAIGG) BY FLOW CYTOMETRY IN THE DIAGNOSIS OF IMMUNE THROMBOCYTOPENIA
Theera Ruchutrakool* (TH), Siriporn Leelatanapipat, Yupa Nakkinkun, Bundarika Suwanwiboon, Yingyong Chinthammitr, Wanchai Wanachiwanawin
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-061 THE CLINICAL SIGNIFICANCE OF DETECTION OF IMMUNE INDEX IN THE PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA
Jianfang Chen* (CN), Linhua Yang, Junqing Liu, Lixian Chang, Jianjun Feng

P-WE-062 EFFECTS OF CD70 AND CD11A IN IMMUNE THROMBOCYTOPENIA PATIENTS
Li Ma* (CN), Zeping Zhou, Hongmei Wang, Aiping Qi, Hu Zhou, Huiyuan Li, Hairong Jia, Renchi Yang

P-WE-063 INCREASED DNA METHYLTRANSFERASE CONTRIBUTE TO CD70 PROMOTER HYPMETHYLATION AND OVER EXPRESSION OF CD70 IN ITP
Li Ma* (CN), Renchi Yang, Zeping Zhou, Hu Zhou, Hongmei Wang, Huiyuan Li

P-WE-064 OUTCOMES IN IMMUNE THROMBOCYTOPENIA (ITP): A RETROSPECTIVE AUDIT ON A SINGLE TERTIARY REFERRAL CENTRE
Philip Young-III Choi* (AU), Beng Hock Chong

P-WE-065 EFFECTIVE CHILDREN TREATMENT SUFFER FROM ITP WITH INTRAVENOUS IMMUNOGLOBULIN
Pavel Svirin* (RU), E.V Ageenkova, V.Y Petrov, E.K. Donyush, G.I Soskov, E.A. Yatsenko, V.V. Vdovin

HIT

P-WE-066 HEPARIN INDUCED THROMBOCYTOPENIA IN INTENSIVE CARE UNIT PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION
Borae G Park* (KR), Seongsoo Jang, Hyoeun Shim, Chan-Jeoung Park, Hyun-Sook Chi, Sang-Bum Hong

P-WE-067 FREQUENCY OF ANTI-HEPARIN-PF4 COMPLEX ANTIBODIES (HIT ANTIBODIES) IN PATIENTS UNDERGOING ON CHRONIC INTERMITTENT HEMODIALYSIS
Chiara Adele Elena Novelli* (IT), Benedetto Morelli, Nicoletta Erba, Vanessa Proserpio, Vincenzo Toschi, Corrado Turri, Carlo Maria Guastoni

P-WE-068 PF4-HEPARIN ANTIBODIES IN PATIENTS UNDERGOING EXTRACORPOREAL CIRCULATION CARDIAC SURGERY (ECCS)
Nicoletta Erba* (IT), Vanessa Proserpio, Amando Gamba, Chiara Novelli, Benedetto Morelli, Vincenzo Toschi

P-WE-069 PLATELET MICROPARTICLE GENERATION ASSAY: A VALUABLE ALTERNATIVE TO 14C-SRA FOR HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS
Francois Mullier* (BE), Nicolas Bailly, Yvan Cornet, Severine Robert, Jean-Claude Osselaer, Christian Chatelain, Ismail Elalamy, Jean-Michel Dogne, Bernard Chatelain

P-WE-070 IDENTIFYING PATIENT- AND TREATMENT-RELATED FACTORS RELATED TO AMPUTATION RISK IN CASES OF HEPARIN-INDUCED THROMBOCYTOPENIA TREATED WITH ARGATROBAN
Sylvia Katharina Haas* (DE), Bruce E Lewis

P-WE-071 NOT ALL EIA-TESTS TO DETECT HEPARIN/PLATELET FACTOR 4 (H/PF4)-ANTIBODIES ARE EQUAL - MORE CONFUSION AFTER COMPARISON OF FOUR COMMERCIALY AVAILABLE ASSAYS
Frauke Bergmann* (DE), Christiane Bruns, Andreas Czwalinna, Annette Klemens, Siegfried Krell, Burghard Arndt, Helga Dalluegge-Tamm, Arndt Groening
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-072  THROMBIN GENERATION TO DIAGNOSE DANAPAROID CROSS REACTIVITY IN HIT PATIENTS
Brigitte Tardy-Poncet* (FR), Michele Piot, Patrick Mismetti, Lydia Campos, Olivier Garraud, Herve Decousus, Bernard Tardy

P-WE-073  HEPARIN-INDUCED THROMBOCYTOPENIA AS A RESULT OF CROSS-REACTIVE ANTIBODIES IN THE SETTING OF BACTERIAL INFECTIONS
Prapti A Patel* (US), Melody Smith, Jonathan Dowell, Eugene Frenkel, Ravi Sarode, Yu Min Shen

P-WE-074  EXPERTS’ OPINION OR SEROTONIN RELEASE ASSAY AS GOLD STANDARD FOR THE DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA (HIT)?
Bernard Tardy* (FR), Emilie Presles, Madjid Akrour, Emmanuel De Maistre, Thomas Lecompte, Brigitte Tardy-Poncet

P-WE-075  AGREEMENT BETWEEN LOCAL EXPERT OPINION, AN INDEPENDENT EXPERT COMMITTEE AND SRA RESULTS ABOUT HIT DIAGNOSIS: FIRST RESULTS OF AN INTERNATIONAL MULTICENTRIC PROSPECTIVE STUDY
Thomas Lecompte (FR), Bernard Tardy*, Madjid Akrour, Emilie Presles, Claire Pouplard, Martine Alhenc-Gelas, Philippe Nguyen, Ismail Elalamy, Andreas Greinacher, Emmanuel De Maistre, Marie-Helene Horellou, Brigitte Tardy-Poncet

P-WE-076  LEPIRUDIN USE AND LABORATORY MONITORING IN PATIENTS ON CHRONIC HAEMODIALYSIS WITH A HISTORY OF TYPE II HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
Chée W Tan* (AU), Christopher Ward, Margaret Aboud, Timothy Planta

Antiplatelet therapy

P-WE-077  NON COMPLIANCE AND ASPIRIN RESISTANCE IN ACUTE STROKE: A PILOT STUDY
Mauro Silingardi* (IT), Maria Cristina Leone, Annalisa Pilia, Attilia Pizzini, Dimitry Arioli, Sofia Chiaramone-Ranieri, Nerina Bonacini, Maria Grazia Bonini, Luigi Vecchia, Ido Iori

P-WE-078  POINT-OF-CARE ASSESSMENT AFTER CLOPIDOGREL TREATMENT PREDICTS CLINICAL OUTCOMES OF PATIENTS WITH CARDIOVASCULAR DISEASE: A META-ANALYSIS OF 6 STUDIES
Yusuke Yamaguchi* (JP), Takayuki Abe, Yuji Sato, Takanori Moriki, Mitsuru Murata

P-WE-079  CYCLOOXYGENASE-1(COX-1)-DEPENDENT AND COX-1-INDEPENDENT PLATELET REACTIVITY IN ASPIRIN-TREATED PATIENTS WITH ACUTE CEREBRAL STROKE OR TIA
Maria Teresa Santos* (ES), Aida Lago, Antonio Moscardo, Belen Cortina, Ana LaTorre, Vera Parkhutik, Jose Tembl, Juana Valles

P-WE-080  USE OF PLATELET P-SELECTIN TO MONITOR P2Y12 BLOCKADE IN CARDIAC PATIENTS
Yanushi Dullewe Wijeyeratne* (UK), Andrew Johnson, Jane May, Sue Fox, Robert Henderson, Stan Heptinstall

P-WE-081  IS ASPIRIN AN ANTIFIBRINOLYTIC DRUG? ANTICOAGULANT EFFECT IS ASSOCIATED WITH PROLONGED CLOT LYSIS TIME IN PLATELET-RICH PLASMA OF OLDER
Alejandro Berkovits* (CL), Diego Mezzano, Monica Acevedo, Carolina Valenzuela, Carlos Barria, Marcelo Carrasco, Olga Panes

P-WE-082  CLOPIDOGREL DEGRADATION BY ESTERASES IS A MAJOR CONTRIBUTOR TO THE ATTENUATED RESPONSE TO CLOPIDOGREL OBSERVED IN SUBJECTS WHO ARE LOW RESPONDERS
Ludovic Drouet* (FR), Natacha Berge, Claire Bal dit Sollier
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-083  NATURAL HISTORY OF HIGH ON TREATMENT PLATELET REACTIVITY BY ADP IN PATIENTS WITH ACS UNDERGOING PCI
Rossella Marcucci* (IT), Rita Paniccia, Anna Maria Gori, Alessia Fabbri, Emilia Antonucci, Giulia Casola, Niccolo’ Maggini, Marco Miranda, Betti Giusti, Gian Franco Gensini, Rosanna Abbate

P-WE-084  HIGH-ON CLOPIDOGREL PLATELET REACTIVITY IS A DETERMINANT OF 1-YEAR MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS: DATA FROM AMI-FLORENCE 2 STUDY
Rossella Marcucci* (IT), Anna Maria Gori, Rita Paniccia, Betti Giusti, Antonella Cordisco, Daniela Balzi, Alessandro Barchielli, Nazario Carrabba, Serafina Valente, Cristina Giglioli, Rosanna Abbate, Gian Franco Gensini

P-WE-085  HIGH-ON TREATMENT PLATELET REACTIVITY BY DIFFERENT STIMULI IS A DETERMINANT OF 1 YEAR MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS: DATA FROM AMI-FLORENCE 2 STUDY
Rossella Marcucci* (IT), Anna Maria Gori, Rita Paniccia, Betti Giusti, Antonella Cordisco, Daniela Balzi, Alessandro Barchielli, Serafina Valente, Cristina Giglioli, Rosanna Abbate, Gian Franco Gensini

P-WE-086  MONITORING OF PLATELET FUNCTION IN PATIENTS WITH CEREBRAL ARTERY ANEURYSMS UNDERGOING ENDOVASCULAR TREATMENT WITH STENTS: A REVIEW OF 56 CASES
Rossella Marcucci* (IT), Rita Paniccia, Arturo Consoli, Niccolo’ Maggini, Marco Miranda, Emilia Antonucci, Giulia Casola, Rosanna Abbate, Gian Franco Gensini, Salvatore Mangiafico

P-WE-087  THROMBIN GENERATION AND PROCOAGULANT MICROPARTICLES IN PATIENTS WITH CONORARY SYNDROME UNDER DOUBLE ANTIPLATELET THERAPY
Concepcion Brocal* (ES), Emma Lopez, Ana Mauricio, Pascual Marco, Santiago Heras, Juan Miguel Ruiz, Vicente Arrarte

P-WE-088  TIME-RELATED CHANGES OF THE SENSITIVITY TO ANTI-PLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER PERCUTANEOUS CORONARY INTERVENTION
Krytyna Maria Zawilska* (PL), Maria Jamrozek-Jedlinska, Malgorzata Duszynska, Ireneusz Jedlinski, Marek Slomczynski

P-WE-089  PGE2 INHIBITS THROMBOGENESIS VIA THE EP4 RECEPTOR IN A PROTEIN KINASE C MEDIATED PATHWAY
Sonia Philipose* (AT), Rufina Schuligoi, Akos Heinemann

Inherited and acquired platelet disorders

P-WE-090  GLANZMANN’S THROMbasthenia does not protect from severe coronary disease
Susana Sara Meschengieser* (AR), Analia Sanchez Luceros, Emilse Bermejo, Maria Fabiana Alberto, Maria Angela Lazzari

P-WE-091  DESCRIPTION OF SEVEN NOVEL MUTATIONS IN αIIB AND β3 GENES IN 21 CHINESE PEDIGREES WITH GLANZMANN THROMbastHENIA
Huanhuan Qin* (CN)

P-WE-092  PROSPECTIVE VALIDATION OF THE CONDENSED MCMDM1-VWD BLEEDING QUESTIONNAIRE FOR PLATELET FUNCTION DISORDERS
Paula D James* (CA), Mackenzie Bowman, Julie Grabell, Louise Dwyre, Dilys Rapson
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-093  GLYCOPROTEIN IB-IX-V AND EFFECT OF RECOMBINANT FACTOR VIIa - A WHOLE BLOOD STUDY FROM BERNARD-SOULIER PATIENTS AND THEIR RELATIVES
Ole Halfdan Larsen* (DK), Pål T Onundarson, Brynja R Gudmundsdottir, Hekla Sigmundsdottir, Kirsten Christiansen, Brynjar Vidarsson, Jørgen Ingerslev, Benny Sorensen

P-WE-094  THROMBOCYTOSIS IN CANCER IS ASSOCIATED WITH PLATELET ACTIVATION AND A PRO-ANGIOGENIC STATE
Alok A Khorana* (US), Gregory Connolly, Brian H. Smith, Nigel Mackman, Richard P. Phipps, Mark Taubman, Charles W. Francis

P-WE-095  PLATELET ACTIVATION IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
Hans-Heinrich Wolf* (DE), Monique Cernota, Angelika Fruehauf, Ursula Wolf-Jacobs

P-WE-096  CARDIOVASCULAR RISK IN PATIENTS WITH FIRST EPISODE OF SCHIZOPHRENIA
Jiri Masopust* (CZ), Radovan Maly, Dita Kalnicka, Jan Bazant, Citrad Andrys, Ladislav Hosak

P-WE-097  ACQUIRED PLATELET DYSFUNCTION WITH EOSINOPHILIA PRESENTING AS SUBGALEAL HEMATOMA
Piti Techavichit* (TH), Darintr Sosothikul, Panya Seksarn

Laboratory tests

P-WE-098  EVALUATION OF WHOLE BLOOD LUMIAGGREGOMETRY AS A TOOL FOR DIAGNOSIS OF PLATELET DYSFUNCTION IN PAEDIATRIC PATIENTS
A N McCormick (UK), J Alamelu

P-WE-099  SOLUBLE CD40 LIGAND AND CD40 LIGAND/PLATELET RATIO ARE PREDICTORS OF VENTRICULAR FUNCTION AND ADVERSE CLINICAL OUTCOME AMONG ACUTE CORONARY SYNDROME PATIENTS
Putrika P.R. Gharini* (ID), Anggoro B Hartopo, Budi Y Satianto

P-WE-100  DIAGNOSIS OF GLANZMANN’S THROMBASTHENIA USING THE WHOLE BLOOD IMPEDENCE MULTIPLATE ANALYZER
Tarek Owaidah* (SA), Abdulfajeed Albyanyan, Abdulrahman Almusa

P-WE-101  PNEUMATIC TUBE TRANSPORT OF PLATELET CONCENTRATES DOES NOT AFFECT IN VITRO PLATELET FUNCTION
Yvonne Henskens* (NL), Marcus Lance, Rene Van Oerle, Maurice Theunissen, Marco Marcus

P-WE-102  PLASMA AND WHOLE BLOOD SEROTONIN LEVELS IN PATIENTS WITH ABDOMINAL AORTIC ANEURYSM AND PERIPHERAL ARTERIAL DISEASE MEASURED BY AN IMPROVED HPLC METHOD
Hiroyuki Sugawara* (JP), Akira Sato, Hitoshi Goto, Munetaka Hashimoto, Daijiro Akamatsu, Takuya Shimizu, Tsutomu Zukeran, Fukashi Serizawa, Ken Tsuchida, Susumu Satomi, Yuji Hirowatari

P-WE-103  COMPARISON OF VENOUS AND ARTERIAL BLOOD SAMPLING FOR THE ASSESSMENT OF PLATELET AGGREGATION WITH WHOLE BLOOD IMPEDANCE AGGREGOMETRY
Sam Kafian* (SE), Fariborz Mobarez, Majid Kalani, Hakan Wallen, Bassem A. Samad

P-WE-104  PLATELET FUNCTION IN TRAUMA PATIENTS
Cristina Solomoni* (AT), Herbert Schochli

P-WE-105  A NOVEL PLATELET STABILIZING FORMULA MAINTAINS FUNCTIONAL WHOLE BLOOD AGGREGATION RESPONSES OVER PROLONGED SPECIMEN STORAGE
Keith Moskowitz* (US), Pia Guinto, Daniel J. Marchiarullo, Craig A. Gelfand
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-106  COMPARING PLATELET AGGREGOMETRY BY CHRONLOG 560VS AGREGOMETER WITH SYSMEX CS2000I COAGULOMETER
Shenbagapriya P* (IN), Inbakumar David, Kavitha ML, Srivastava Alok, Nair Sukesh Chandran

P-WE-107  PLATELET REACTIVITY IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE USING ASPIRIN: CORRELATION BETWEEN DIFFERENT TESTS AND ASSOCIATION WITH SUBJECT CHARACTERISTICS
Jaapjan D. Snoep (NL), Jaap Jan Zwaginga, Jeroen CJ Eikenboom, Mark Roest, Carlo Patrono, Bianca Rocca, Davide Pocaterra, Frits R Rosendaal, Johanna G van der Bom*

P-WE-108  THE PROFILE OF PLATELET MICROPARTICLES (PMP) IN ACUTE CORONARY SYNDROME (ACS) PATIENTS AT SARDJITO HOSPITAL YOGYAKARTA INDONESIA
Ira Puspitawati* (ID), Anggoro Budi Hartopo, Elizabeth-Henny Heningtyas

New antiplatelet agents

P-WE-109  EFFECTS OF P2Y1 RECEPTOR ANTAGONISM ON THE REACTIVITY OF PLATELETS FROM PATIENTS WITH STABLE CORONARY ARTERY DISEASE USING ASPIRIN AND CLOPIDOGREL
Arnaud Bonnefoy* (CA), Benoit Labarthe, Judith Babin, Pierre Theroux, Marijke Bryckaert

P-WE-110  PURIFICATION AND CHARACTERIZATION OF PLATELET AGGREGATION INHIBITOR FROM AGGKISTRODON BLOMHOFFI BREVICAUDUS
Punsaldulam Dashnyam Chimgeen* (MN), Sumiya Byambasuren Otgontaij, Bolor Buyanbadrakh, Khongorzul Odgerel

P-WE-111  DISCOVERY OF AN ORALLY AVAILABLE PAR-1 ANTAGONIST
Sunkyung Lee* (KR), Chul-Min Park, Jong-Whan Song, Dong-Chul Lim, Woo-Young Cho

Extrinsic pathway of coagulation

P-WE-112  FACTOR VIIA-ANTITHROMBIN COMPLEXES PLASMA LEVELS IN HEALTHY SUBJECTS
Luca Spiezia (IT), Maria Bon, Elena Campello, Sabrina Gavasso, Barry Woodhams*, Paolo Simioni

P-WE-113  FACTOR VIIA-ANTITHROMBIN COMPLEXES PLASMA LEVELS IN PREECLAMPTIC WOMEN
Luca Spiezia (IT), Fabio Dalla Valle, Cristina Bulato, Sabrina Gavasso, Silvia Visentin, Erich Cosmi, Barry Woodhams*, Paolo Simioni

P-WE-116  THE EXPRESSION OF TISSUE FACTOR RELEASED FROM ACUTE MYELOBLASTIC LEUKEMIA CELLS
Yi Fang** (CN), Jiayi Cai, Jihua Zhong, Hua Zhong, Hairong Wang, Fangyuan Chen

P-WE-117  LYSO-SULFATIDE BINDS FACTOR XA OUTSIDE OF THE GLA DOMAIN AND POTENTLY INHIBITS THROMBIN GENERATION
Subramanian Jegneswaran (US), Yajnavalka Banerjee, Jose Fernandez*, Hiroshi Deguchi, John Griffin

P-WE-118  FACTOR VIIA-ANTITHROMBIN COMPLEXES IN CHILDREN WITH ISCHEMIC STROKE
Luca Spiezia (IT), Elena Campello, Chiara Gentiliomo, Sabrina Gavasso, Barry Woodhams*, Anna Maria Laverda, Paolo Simioni

P-WE-119  BALANCE BETWEEN FACTOR VII COMPETITION FOR TISSUE FACTOR AND FACTOR VII ACTIVATION DETERMINES INITIATION AND PROPAGATION OF BLOOD COAGULATION
Alexey M Shibeko* (US), Samuel A Woodle, Timothy K Lee, Mikhail V Ovanesov
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-120  THE TIMED UP AND GO TEST CORRELATED STRONGLY WITH OTHER JOINT SCORES IN A HEALTH OUTCOME STUDY COMPARING A COHORT OF AFFECTED MALES WITH MILD HEMOPHILIA A WITH THEIR SIBLINGS
Mary-Frances Scully* (CA), Andrea Hanin, Aicha Traore, Ya-Gang Xie, Brendan Barrett

P-WE-121  CONFIRMATION OF THE QUALITY OF PLASMA DERIVED FVIIA/FX MIXTURE AGENT (MC710) BY THE VALIDATED ASSAYS

P-WE-122  CONGENITAL COAGULATION FACTOR VII DEFICIENCY: A CLINICAL AND GENETIC STUDY OF FIVE TAIWANESE PATIENTS
Nan Shin Cheng* (TW), Yeu Chin Chen

P-WE-123  BLEEDING SCORE RESULTS IN A HEALTH OUTCOME STUDY COMPARING AFFECTED MALES WITH MILD HEMOPHILIA A AND THEIR MUTATION NEGATIVE RELATIVES
Mary-Frances Scully* (CA), Aicha Traore, Brendan Barrett, Ya-Gang Xie

P-WE-124  CHARACTERISATION OF VWF INTERACTION, COFACTOR ACTIVITY AND RATES OF ACTIVATION AND INACTIVATION OF A SELECTIVELY 40K O-GLYCOPEPEGYLATED RECOMBINANT FACTOR VIII (N8-GP)
Kristoffer Winther Balling* (DK), Egon Persson, Ida Hilden, Marianne Kjalke, Eva HN Olsen, Henning R Stennicke

P-WE-125  EFFECT OF NON-SYNONYMOUS POLYMORPHISMS ON COAGULATION FACTOR VII
Shu-wen W. Chen (FR), Muriel Giansilly-Blaizot, Jean-Luc Pellequer*

P-WE-126  INHIBITION OF TFPi EFFICIENTLY IMPROVES HEMOSTASIS IN HEMOPHILC MICE
Werner Hoellriegl* (AT), Michael Dockal, Alexandra Schiviz, John Philip Lawo, Dagmar Verdino, Peter Leidenmuhlner, Hans-Peter Schwarz, Hartmut Ehrlich, Rudolf Hartmann, Eva-Maria Muchitsch, Friedrich Scheiflinger

P-WE-127  COST-EFFECTIVENESS OF PROTHROMBIN COMPLEX (OCTAPLEX™) USAGE IN AN EMERGENCY ROOM
Manuel Quintana* (ES), Santiago Perez-Cachafeiro, Sara Fabra-Cadenas, Alberto Borobia

P-WE-128  DOWNREGULATION OF THE PROCOAGULANT POTENTIAL OF HUMAN BREAST CARCINOMA CELLS BY INHIBITION OF THE RENIN-ANGIOTENSIN SYSTEM
Emanuela Napoleone (IT), Antonella Cutrone, Daniela Cugino, Concetta Amore, Angelomaria Di Santo, Licia Iacoviello, Giovanni de Gaetano, Maria Benedetta Donati, Roberto Lorenzet*

Intrinsic pathway of coagulation

P-WE-129  A PRELIMINARY MOLECULAR STUDY MAY EXPLAIN THE LOW FREQUENCY OF SEVER HEMOPHILIC A WITH INHIBITORS IN TUNISIA
Hejer Elmahmoudi* (TN), Houssein Khodjet-el-Khil, Kaouther Zahra, Dorothe Pellechia, Christine Vinciguerra, Belkis Meddeb, Amel Elgaaied Ben Ammar, Emna Gouider

P-WE-130  BLOCKING THE INTRINSIC PATHWAY OF COAGULATION WITH RNA APTAMERS
Becky Woodruff* (US), Juliana Layzer, Bruce Sullenger
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-131  RECOMBINANT FVIII FC FUSION PROTEIN IS FULLY ACTIVE IN TREATING ACUTE INJURY AND DEMONSTRATES PROLONGED PROPHYLACTIC EFFICACY IN HEMOPHILIA A MICE
Tongyao Liu* (US), Xin Zhang, Douglas Drager, Todd Hoehn, Jennifer Dumont, Glenn Pierce, Haiyan Jiang

P-WE-132  THE FIRST REPORT OF THE SAUDI NATIONAL SCREENING PROGRAM FOR FACTOR VIII AND IX HEMOPHILA INHIBITORS
Tarek Owaidah* (SA), Abdulkareem Al Momeen

P-WE-133  SIGNIFICANCE OF MISSENSE MUTATIONS WITHIN THE FACTOR 8 GENE FOR INHIBITOR FORMATION
Rainer Schwaab* (DE), Anna Pavlova, Thilo Albert, Johannes Oldenburg

P-WE-134  FACTOR XII DEPLETION PROTECTS AGAINST THE DEVELOPMENT OF PULMONARY FIBROSIS
Malgorzata Wygrecka* (DE), Ewa Jablonska, Thomas Renne, Andreas Guenther, Philipp Markart, Klaus T Preissner

P-WE-135  INTERIM RESULTS OF THE USEFULNESS OF PRIMARY PROPHYLAXIS IN HEMOPHILIA PATIENTS AT OUR HEMOPHILIA CENTER
Chiai Nagae* (JP), Tomoko Ashikaga, Atsuki Yamashita, Shinji Muto, Kaoru Kikkawa, Kimie Yoshikawa, Satoshi Yamazaki, Masashi Taki

P-WE-136  THE HEMOPHILIA INHIBITOR GENETICS STUDY (HIGS): IMMUNE TOLERANCE INDUCTION (ITI) THERAPY AND OUTCOME
Jan Astermark* (SE), Erika Menius, Sharyne Donfield, Erik Berntorp

P-WE-137  LONG-TERM INTERMITTENT USE OF RITUXIMAB TO CONTROL INHIBITORS IN CONGENITAL SEVERE HEMOPHILIA A
M Dawn Goodyear* (CA), John K Wu, Man-Chiu Poon

P-WE-138  MICROPARTICLES GENERATE THROMBIN IN A FACTOR XII-DEPENDENT MANNER
Paola Van der Meijden* (NL), Muriel Van Schilfgaarde, Rene Van Oerle, Felicitas Muller, Thomas Renne, Hugo Ten Cate, Henri Spronk

P-WE-139  DEMOGRAPHIC ANALYSES AND JOINTS STATUS OF PATIENTS WITH HEMOPHILIA A, B AND VON WILLEBRAND DISEASE
Sefika Selvi* (TR), Feride Duru, Emel Ozyurek, Canan Albayrak, Davut Albayrak, Berna Tander, Tunc Fisgin

P-WE-140  EFFECTS OF A FVIII INHIBITOR TB-402 ON COAGULATION: REVERSIBILITY WITH PRO-COAGULANTS
Clive J Long* (BE), Peter Verhamme, Jan Emmerechts, Marc Hoynaerts, Marc Jacquemin, Peter Giesen

P-WE-141  FACTOR VIII-HYDROLYZING MONOCLONAL ANTIBODIES IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA
Ankit Mahendra* (FR), Frederic Davi, Sebastien Andre, Cyril Plainchais, Ivan Peyron, Jordan Dimitrov, Alain Friboulet, Srinivas Kaveri, Sebastien Lacroix-Desmazes

P-WE-143  ELEVATED SERUM AMYLOID A IS ASSOCIATED WITH BLOOD COAGULABILITY AND WITH VENOUS THROMBOEMBOLISM
Hiroshi Deguchi* (US), Darlene J Elias, Silvia Navarro, Espana Francisco, John H Griffin

P-WE-144  COAGULATION VELOCITY AND ACCELERATION CORRELATE WITH CLINICAL PHENOTYPE OF PATIENTS WITH ACQUIRED FACTOR V INHIBITORS
Tomoko Matsumoto* (JP), Keiji Nogami, Kenichi Ogiwara, Nobuyuki Tsuji, Midori Shima
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-145  ELEVATED PLASMA LEVELS OF FACTOR VIII ENHANCE THROMBUS FORMATION THOUGH EXCESS THROMBIN GENERATION IN RABBIT JUGULAR VEIN
Chihiro Sugita* (JP), Atsushi Yamashita, Shuntaro Matsuda, Sayaka Goto Moriguchi, Tomoko Matsumoto, Osamu Inoue, Takashi Iwakiri, Yunosuke Matsuura, Midori Shima, Yujiro Asada

Contact phase activation

P-WE-146  ACTIVATED FACTOR XII TYPE A INDEPENDENTLY PREDICTS LONG TERM MORTALITY WITHIN SEVEN YEARS FOLLOW UP IN PATIENTS ADMITTED WITH SUSPECTED ACUTE CORONARY SYNDROME
Volker Poenitz* (NO), Trygve Bruegger-Andersen, Heidi Grundt, Patrycja Naesgaard, Harry Staines, Dennis Winston Trygve Nilsen

P-WE-147  THE PREVALENCE OF THE PLASMINOGEN ACTIVATOR INHIBITOR-1 GENE 4G/5G POLYMORPHISM IN PATIENTS WITH CHRONIC VENOUS LEG ULCERATION
Adam Wisniewski* (PL), Ksenia Bykowska, Piotr Szopinski

P-WE-148  CATHETER THROMBOSIS WITH FONDAPARINUX IS PREVENTED BY THROMBIN INHIBITION IN VITRO AND IN RABBITS
Jonathan W Yau* (CA), Alan R Stafford, Peng Liao, James C Frederburgh, Robin Roberts, Jeffrey I Weitz

P-WE-149  SMALL HAIRPIN-STRUCTURED NUCLEIC ACIDS PROMOTE COAGULATION
Julia Gansler* (DE), Miriam Jaax, Andreas Greinacher, Klaus T. Preisssner, Silvia Fischer

Anticoagulant pathway

P-WE-150  URINY PROTHROMBIN FRAGMENTS (F1+2) AS A DIAGNOSTIC TOOL FOR VENOUS THROMBO-EMBOLISM AND MYOCARDIAL INFARCTION: A PILOT STUDY
Josien van Es* (NL), Sara Rafe, Mohamed Ahdi, Pieter W. Kamphuisen, Joost C.M. Meijers, Victor E.A. Gerdes

P-WE-151  DECREASED FREE PROTEIN S LEVELS AND VENOUS THROMBOSIS IN THE ACUTE SETTING, A CASE-CONTROL STUDY
Rene Mulder* (NL), Vladimir Y.I.G. Tichelaar, Willem M. Lijfering, Andre M Mulder, Karina Meijer

P-WE-152  ANTITHROMBOTIC AGENTS PURIFIED FROM AGKISTRODON BLOMHOFFII BREVICAUDUS
Muniya Byambasuren Otgontaij* (MN), Bolor Buyanbadrakh, Khongorzul Odgerel, Punsaldulam Dashnyam Chimgeen
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-157 GENOME-WIDE ASSOCIATION STUDY (GWAS) FOR DISCOVERY OF GENES MODULATING ANTITHROMBIN ACTIVITY. ROLE OF LARGE, AN N-ACETYLGlcOSAMINYLTRANSFERASE.
Maria Eugenia de la Morena-Barrio* (ES), Alfonso Bull, Ana Isabel Anton, Antonia Minano, Juan Carlos Souto, Irene Martinez-Martinez, Ricardo Gutierrez-Gallego, Jose Navarro-Fernandez, Sonia Aguilas, Vicente Vicente, Jordi Fontcuberta, Jose Manuel Soria, Javier Corral

P-WE-158 CHARACTERISTICS OF FIBRIN FORMATION AND CLOT STABILITY IN INDIVIDUALS PREDISPOSED TO THROMBOSIS
Jonathan H Foley* (US), Lauren Ferris, Kathleen Brummel-Ziedins

P-WE-159 DIRECT COMPARISON OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF APIXABAN AND RIVAROXABAN
Charles Frost* (US), Yan Song, Yu Chen Barrett, Jessie Wang, Tong Li, Frank LaCreta

P-WE-160 THE CHOICE OF THERAPY IN THE ACENOCOUMAROL OVERDOSE IS INR INDEPENDENT AND ILLNESS SEVERITY DEPENDENT
Manuel Quintana* (ES), Alberto Borobia, Sara Fabra, Ana Martinez Virto, Marcelino Sanchez Casado

P-WE-161 PMX-60056 KINETICS IN REVERSAL OF HEPARIN AND LMWH ANTAGOGULATION
Ronald Eric McAllister* (US), Richard Scott, Bozena Korczak

P-WE-162 PMX-60056 RAPIDLY REVERSES LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) TINZAPARIN ANTICOAGULATION IN MAN
Ronald Eric McAllister* (US), Richard Scott, Bozena Korczak

P-WE-163 REVERSAL OF SURGICAL DOSES OF HEPARIN BY PMX-60056 IS PREDICTABLE AND SAFE
Ronald Eric McAllister* (US), Richard Scott, Bozena Korczak

P-WE-164 PATIENTS WITH MUTATIONS IN VKORC1: A CHALLENGING PROBLEM IN CLINICAL PRACTICE
Johannes Oldenburg* (DE), Christof Geisen, Carville Bevans, Erhard Seifried, Matthias Watzka

P-WE-165 GENERATION OF KNOCK-IN MICE CARRYING A K196E POINT MUTATION IN PROTEIN S
Fumiaki Banno* (JP), Toshiyuki Kita, Hiroji Yanamoto, Koichi Kokame, Koji Iihara, Toshiyuki Miyata

P-WE-166 PROTEIN S AND C4BBP MUTATIONAL SCREENING IN ATYPICAL HAEMOLYIC URAEMIC SYNDROME PATIENTS
Jorine S Koenderman* (NL), Dineke Westra, Elena B Volokhina, Pieter H Reitsma, Lambert P Van den Heuvel

P-WE-167 HIGH ACTIVATED PROTEIN C LEVELS ATTENUATE ALLERGIC LUNG INFLAMMATION IN A MURINE ASTHMA MODEL USING INTRANASAL INOCULATION OF HOUSE DUST MITE EXTRACT
Johannes Daan De Boer* (NL), C Van t Veer, M Schouten, J Yang, JJWT Roelofs, JS Van der Zee, BH Isermann, T Van der Poll

P-WE-168 THE INFLUENCE OF UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN ON VASCULAR ENDOTHELIUM AND PLATELETS IN PATIENTS WITH CHRONIC RENAL FAILURE UNDERGOING HEMODIALYSIS
Elizaveta Vlasova* (RU), Irina Vasilenko, Vera Samoylenko, Vladimir Suslov
POSTER PRESENTATIONS

Wednesday, July 27, 2011

Serine protease inhibitors

P-WE-169  CHANGES OF LEVELS OF FIBRINOGEN, D-DIMER AND ANTITHROMBIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY
Zhou Rong-Fu* (CN), Jian Ouyang, Ping Li, Jing-yan Xu, Bing Chen, Yong-gong Yang, Qi-guo Zhang, Xiao-yan Shao

P-WE-170  COMPARISON OF THE ANTICOAGULANT EFFECTS IN PLASMA SAMPLES SPIKED WITH DABIGATRAN AND RIVAROXABAN
Job Harenberg* (DE), Christina Giese, Svetlana Marx, Roland Kraemer

P-WE-171  THE ACTION MECHANISM OF DIRECT THROMBIN INHIBITORS DURING COAGULATION
Robert Johan Wagenvoord* (NL), Rob Wagenvoord, Coen Hemker

P-WE-172  PREVALENCE OF HEREDITARY ANTITHROMBIN DEFICIENCY HIGHER THAN ESTIMATED?
Ronald Fischer* (DE), Dominik Eisenburger, Kathrin Heidinger, Bettina Kemkes-Matthes

P-WE-173  SIX NOVEL PROTEIN C MUTATIONS CAUSING HEREDITARY PROTEIN C DEFICIENCY
Ronald Fischer* (DE), Bettina Kemkes-Matthes, Anna Pavlova, Johannes Oldenburg, Hanna Meillage

P-WE-174  EFFECTS OF MDCO-2010 ON ACTIVATED CLOTTING TIME IN BLOOD OBTAINED FROM PATIENTS UNDERGOING CARDIOPULMONARY BYPASS
Heezoo Kim* (KR), Fania Szlam, Kenichi Tanaka, Satoru Ogawa, Andreas van de Locht, Jerrold H Levy

P-WE-175  INHIBITION OF COAGULATION FACTORS BY COVALENT ANTITHROMBIN-HEPARIN IN THE PRESENCE OF ENDOTHELUM
Helen M. Atkinson* (CA), Leslie R. Berry, Anthony K. C. Chan

P-WE-176  COMPARISON OF THE EFFECTS OF EDOXABAN, AN ORAL FACTOR XA INHIBITOR, AND OTHER ANTICOAGULANTS ON THROMBIN GENERATION
Jeanne Mendell* (US), Yan Li, Meyer Michel Samama, Abdel-Baset Halim, Sae-Heum Song, Francois Depasse, Satoshi Kunitada

P-WE-177  INHIBITION OF THROMBIN GENERATION BY EDOXABAN
Jeanne Mendell* (US), Meyer Michel Samama, Yan Li, Abdel-Baset Halim, Sae-Heum Song, Francois Depasse, Quinet Celine, Satoshi Kunitada

P-WE-178  PROTEIN C INHIBITOR INHIBITS TUMOR CELL GROWTH, BUT PROMOTES TUMOR CELL METASTASIS BY ITS PROCOAGULANT PROPERTIES IN VIVO

P-WE-179  BLEEDING IS A RARE MANIFESTATION IN PATIENT WITH LUPUS ANTICOAGULATION IN CHILDREN
Patcharee Komvilaisak* (TH), Arunee Jetsrisuparb, Surapon Wiangnon

P-WE-180  REVERSAL OF DABIGATRAN USING RECOMBINANT ACTIVATED FACTOR VII AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES IN THROMBOELASTOGRAPHY ASSAY
Howard H.W. Chan* (CA), Helen M Atkinson, Mykhaylo Goncharenko, Leslie R. Berry, Anthony K.C. Chan
POSTER PRESENTATIONS

Wednesday, July 27, 2011

Exogenous hemostatic factors

P-WE-181  ESPP, AN EXTRACELLULAR SERINE PROTEASE FROM ENTEROHEMORRHAGIC E. COLI, INDUCES COAGULOPATHY IN HUMAN PLASMA AND FIBRINOLYSIS IN WHOLE BLOOD
Shekeb Khan* (CA), Kuo H. M. Kevin, Elena Brnjac, Margaret L. Rand, Emil F. Pai, Alden E. Chesney

P-WE-182  FACTORS AFFECTING WARFARIN THERAPY IN CHILDREN FOLLOWING THE FONTAN PROCEDURE
Elizabeth Crone* (AU), Nabby Saliba, Elizabeth Hume, Swapna George, Sophie Jones, Fiona Newall

P-WE-183  COMPARISON OF IN VIVO RECOVERY OF RECOMBINANT FACTOR IX AND PLASMA DERIVED FACTOR IX IN PREVIOUSLY TREATED JAPANESE HEMOPHILIA B PATIENTS
Atsuki Yamashita* (JP), Chiai Nagaie, Tomoko Ashikaga, Shinji Muto, Satoshi Yamaizaki, Shigenobu Takayama, Masashi Taki

P-WE-184  PHENOTYPES OF ALLO- AND AUTO-IMMUNE ANTIBODY RESPONSES TO FVIII CHARACTERIZED BY SURFACE PLASMON RESONANCE
Kenneth B Lewis* (US), Phuong-Cac T Nguyen, Colette Norby-Slycord, Tom E Howard, Nigel S Key, Kathleen P Pratt

P-WE-185  DIFFERENTIAL PROTEIN COMPOSITION AND CATALYTIC ACTIVITY OF SERINE PROTEASES AFFECTING HEMOSTASIS FROM THREE SOUTH AMERICAN REAR-FANGED SNAKE VENOMS
Marcelo Larami Santoro* (BR), Stephen P Mackessy, Maria E Peichoto

P-WE-186  DENTAL EXTRACTIONS IN ANTICOAGULATED PATIENTS- COMPARISON OF LOCAL HAEMOSTATIC MODALITIES WITH AND WITHOUT SUTURING
Branislav Bajkin (RS), Nebojsa Rajic*

P-WE-187  SUPPRESSION OF LONGSTANDING, REFRACTORY INHIBITORY ANTIBODIES TO FVIII OR FIX IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A (HA) OR B (HB) USING RITUXIMAB
Adam Giermasz* (US), Darcy Phelan, Susan Karp, Patrick F. Fogarty

P-WE-188  CLINICAL EXPERIENCE IN A WAR SETTING OF A UNIVERSAL FREEZE DRIED PLASMA
Sylvain Ausset* (FR), Jean-Louis Daban, Anne-Virginie Deshayes, Anne Godier, Anne Sailliol

P-WE-189  ESTIMATED VIAL REDUCTION WITH THE AVAILABILITY OF NEW FACTOR VIII DOSAGE STRENGTHS
Joshua Davin Epstein* (US), David Suggitt

P-WE-190  INTERACTION OF VARIOUS RECOMBINANT FVIII CONCENTRATES WITH VON WILLEBRAND FACTOR
Danielle Pillitteri* (DE), Thomas Scholz, Manuela Krause, Ann-Kathrin Pilgrimm, Carl Kirchmaier

P-WE-191  ESTIMATED PATIENT BENEFITS OF REDUCING FACTOR VIII RECONSTITUTION VOLUMES
Joshua Davin Epstein* (US), Jacquelyn Lam

P-WE-192  OCTANATE SHOWS LOW INHIBITOR INCIDENCE IN TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HAEMOPHILIA A
Anna Klukowska* (PL), Vladimir Komrasko, Martina Jansen, Peter Laguna
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-193  CLONING AND CHARACTERIZATION OF FACTOR V AND FACTOR X ACTIVATORS FROM VIPERA URSINII RENARDI VENOM
Inn-Ho Tsai* (TW), Xin-Hong Yu, Hong-Sen Chen

P-WE-194  IMMUNE TOLERANCE THERAPY (ITI) IN CHILDREN WITH FVIII INHIBITORS: PROGRESS REPORT
Vladimir Vdovin* (RU), Pavel Svirin, Ekaterina Shiller, Tatiana Andreeva, Nina Klimova, Natalia Osmulskaya, Andrey Momot, Andrey Mamaev, Irina Blazhievich, Ekaterina Smirnova, Ludmila Okladnikova

Fibrinogen and other factors

P-WE-195  MOLECULAR MODELING STUDY ON THE STRUCTURAL AND DYNAMIC PROPERTIES OF COAGULATION FACTOR XIII IN ITS ACTIVE AND INACTIVE CONFORMATIONS
Istvan Komaromi* (HU), Laszlo Muszbek

P-WE-196  CONGENITAL AFIBRINOGENEMIA DUE TO MATERNAL ISODISOMY OF CHROMOSOME 4 CONTAINING A NOVEL TRP293STOP MUTATION IN FIBRINOGEN Bβ-CHAIN GENE
Qi OuYang* (CN), Qianlun Ding, Xueling Wang, Hongli Wang, Xiaodong Xi

P-WE-197  RESEARCH OF PHENOTYPE AND GENOTYPE IN THREE CHINESE PEDIGREES WITH INHERITED DYSFIBRINOGENEMIA
Qi OuYang* (CN), Qianlun Ding, Xueling Wang, Hongli Wang, Xiaodong Xi

P-WE-198  COMPARISON OF THE FIBTEM AND FUNCTIONAL FIBRINOGEN ASSAYS USING THE ROTEM AND TEG DEVICES
Cristina Solomon* (AT), Niels Rahe-Meyer, Herbert Schoechl

P-WE-199  FACTOR XIII IMPROVES PLATELET ADHESION TO FIBRINOGEN BY PROTEIN DISULFIDE ISOMERASE-MEDIATED ACTIVITY
Judith Lahav* (IL), Ariela Tivo, Zsuzsa Bagoly, Aida Inbal

P-WE-200  HAEMOSTATIC THERAPY IN CORONARY ARTERY BYPASS GRAFT PATIENTS WITH DECREASED PLATELET FUNCTION: COMPARISON OF FIBRINOGEN CONCENTRATE WITH ALLOGENEIC BLOOD PRODUCTS
Cristina Solomon* (AT), Herbert Schoechl, Alexander Hanke, Andreas Calatzis, Christian Hagl, Kerichen Tanaka, Niels Rahe-Meyer

P-WE-201  PROCINGIIANT PHOSPHOLIPIDS CLOTTING TIME IN NORMAL PREGNANCY AND PREECLAMPSIA
Luca Spiezia (IT), Elena Campello, Maria Bon, Sabrina Gavasso, Silvia Visentin, Erich Cosmi, Barry Woodhams*, Paolo Simioni

P-WE-202  SPECIFIC PROTEOLYTIC CLEAVAGE OF REELIN BY COAGULATION FACTOR X
Wei-Lien Tseng* (TW), Yen-Shu Huang, Chia-Chun Huang, Chun-Fang Yeh, Tzu-Hsuan Chen, Ju-Chien Cheng, Ching-Ping Tseng

P-WE-203  A CHILD WITH CONGENITAL FACTOR X DEFICIENCY
Kun Soo Lee* (KR), Ye Jee Shim

P-WE-204  TWO NOVEL MUTATIONS OF THE FIBRINOGEN GENE IN TWO UNRELATED AFIBRINOGENEMIC PATIENTS
Elvira Grandone* (IT), Lucia Fischetti, Filomena Cappucci, Rossana Santacroce, Fiorenza Soli, Giovanni Favuzzi, Cristina Legnani, Giovanni Luca Tiscia, Maria Antonietta Rizzo, Guatiero Palareti, Maurizio Margaglione
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-205  LEVELS OF FIBRINOGEN AND THROMBOELASTOMETRY FIBRIN POLYMERISATION FOLLOWING TREATMENT WITH DESMOPRESSIN (DDAVP)
Benny Sorensen* (UK), Gary Moore, Gerald Hochleitner, Christian Fenger-Eriksen

Laboratory tests

P-WE-206  EVALUATION OF ASSAY METHODOLOGY ON EFFECTIVE MANAGEMENT OF REPLACEMENT THERAPY IN HAEMOPHILIA B
Jane Needham* (UK), Jayanthi Alamelu, Helen Lewis, Savita Rangarajan

P-WE-207  CHARACTERIZATION OF PROS1 MUTATION-NEGATIVE HEREDITARY PROTEIN S DEFICIENCY
Rene Mulder* (NL), Min Ki ten Kate, Hugo ten Cate, Henri M.H. Spronk, Hanneke C. Kluijf-Nelemans, Andre B. Mulder

P-WE-208  ACQUIRED INHIBITOR TO FACTOR XII IN PATIENT WITH SERONEGATIVE RHEUMATOID ARTHRITIS
Darko Antic* (RS), Ivo Elezovic, Predrag Milijic, Mirjana Mitrović, Maja Zlatanovic

P-WE-210  HERITABLE THROMBOPHILIA TESTING AT A PUBLIC TEACHING HOSPITAL
Gabriela Mainetti* (AR), Maria Eugenia Pagliaro, Corina Naymark, Laura Fischer, Ines Engelberguer, Roxana Zarate, Ricardo Hermes, Beatriz Grand

P-WE-211  COMPARISON BETWEEN ELISA BASED TEST FOR DETECTION OF FACTOR VIII ANTIBODIES SCREEN AND STANDARD BETHESDA
Tarek Owaidah* (SA), Rasheed Nasr, Abdulkareem Al Moomn

P-WE-213  PLASMA CONCENTRATIONS OF TOTAL PROTEIN S ANTIGEN ARE NOT RELATED WITH BODY FAT MASS BUT WITH TRIGLYCERIDE LEVELS IN OBESE JAPANESE WOMEN
Maiko Ueda* (JP), Eri Nakazono, Tomohide Tsuda, Xiu Ri Jin, Shuji Nakano, Hiroko Tsuda

P-WE-215  EFFECT OF RAMADAN FASTING ON INTERNATIONAL NORMALIZED RATIO AMONG PATIENTS TREATED BY ORAL ANTICOAGULANT
Faouzi Addad* (TN), Majdi Amami, Rym Chrigui, Nadia Hammami, Samira Chine, Aref Ben Halima, Ikram Kamoun, Sadok Yahlaoui, Salem Kachboura

P-WE-217  EVALUATION OF ROTEM AND TEG FOR ASSESSING ANTICOAGULATION WITH WARFARIN
Despoina Adamidou* (UK), Pratima Chowdary, Saman Aghighi, Paul Priest, Lida Moghaddam, Anne Riddell

P-WE-218  RIVAROXABAN INTERFERES WITH FACTOR VIII MEASUREMENTS
Vladimir Tichelaar* (NL), Hanneke C. Kluijf-Nelemans, J. Hendrik Nijland, Karina Meijer, Andre B. Mulder
## POSTER PRESENTATIONS

**Wednesday, July 27, 2011**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-WE-219</td>
<td>DEVELOPMENTAL CHANGES OF COMMON COAGULATION PARAMETERS MEASURED ON SYMEX CA-1500 ANALYZER</td>
<td>Inge M Appel* (NL), Tineke Henniphof, Carla van Kessel-Bakvis, Rolinda Stigter, Auke Beishuizen</td>
</tr>
<tr>
<td>P-WE-220</td>
<td>IN VITRO AND IN VIVO THROMBIN GENERATION IN DEVELOPMENTAL HAEMOSTASIS: ETP VERSUS F1+2 AND TAT</td>
<td>Inge M Appel* (NL), Tineke Henniphof, Carla van Kessel-Bakvis, Rolinda Stigter, Auke Beishuizen</td>
</tr>
<tr>
<td>P-WE-221</td>
<td>FORMATION OF THE SECOND PEAK IN PLATELET-RICH PLASMA THROMBIN GENERATION CURVE IS LINKED WITH PHOSPHATIDYLSERINE EXPRESSION DURING PLATELET ACTIVATION</td>
<td>Ivan Dmitrievitsh Tarandovskiy* (RU), Mikhail Panteleev, Elena Sinauridze, Nikolai Topalov, Elena Artemenko, Nadejda Podoplelova, Fazoil Aitaulakhanoov</td>
</tr>
<tr>
<td>P-WE-223</td>
<td>THROMBOELASTOGRAPHY AND THROMBOELASTOMETRY IN PAEDIATRICS: COMPARISON OF HAEMOSCOPE TEG AND TEM ROTEM</td>
<td>Inge M Appel* (NL), Tineke Henniphof, Carla van Kessel-Bakvis, Rolinda Stigter, Auke Beishuizen</td>
</tr>
<tr>
<td>P-WE-224</td>
<td>PRP THROMBIN GENERATION (TG) IN PATIENTS ON ORAL ANTICOAGULATION WITH WARFARIN: INFLUENCE OF TISSUE FACTOR (TF) CONCENTRATION AND CORN TRYPsin INHIBITOR (CTI)</td>
<td>Despoina Adamidou* (UK), Anne Riddell, Saman Aghighi, Shaila Bates, Pratima Chowdary</td>
</tr>
<tr>
<td>P-WE-225</td>
<td>INCREASED HEPARANASE PROCOAGULANT ACTIVITY IN ORTHOPEDIC SURGERY PATIENTS RECEIVING PROPHYLACTIC DOSE OF ENOXAPARIN</td>
<td>Eli Peled (IL), Alexie Robitzki, Elena Axelman, Doron Normam, Benjamin Brenner, Yona Nadir*</td>
</tr>
<tr>
<td>P-WE-226</td>
<td>CLINICOHAEMATOLOGICAL PROFILE OF PATIENTS WITH FACTOR VIII: C INHIBITORS</td>
<td>Sitalakshmi Subramanian* (IN), Karuna Ramesh kumar, Cecil Reuben Ross, Vanamala Anand Alwar, Shanthala Devi AM, Parimala Puttaiah</td>
</tr>
<tr>
<td>P-WE-227</td>
<td>ROLE OF ANTITHROMBIN, PROTEIN C AND PROTEIN S DEFICIENCY ON INCIDENCE OF SYMPTOMATIC THROMBOSIS IN CHILDREN AND THEIR RELATIVES: A MULTICENTER EUROPEAN COHORT STUDY</td>
<td>Susanne Holzhauer (DE), Kristin Jochmans, Gili Kenet, Ralf Knoefler, Rosemarie Schobess, Ulrike Nowak-Gottil*</td>
</tr>
<tr>
<td>P-WE-228</td>
<td>THROMBIN GENERATION TEST IN NEONATES</td>
<td>Martin Prochazka* (CZ), Jana Prochazkova, Veronika Lattova, Ludek Slavik, Jana Ulehlova, Radovan Pilkai</td>
</tr>
<tr>
<td>P-WE-229</td>
<td>IMMUNE TOLERANCE INDUCTION TO ERADICATE INHIBITORS IN VENEZUELAN HEMOPHILIA A PATIENTS: A PRELIMINARY REPORT</td>
<td>Apsara V Boadas de Sanchez* (VE), Luisa N Hernandez, Mercedes E Mijares, Marion M Echenagucia, Norma B de Bosch, Arlette V Ruiz-Saez</td>
</tr>
<tr>
<td>P-WE-230</td>
<td>THE REFERENCE RANGES OF D-DIMER LEVELS ARE DIFFERENT IN PREGNANT WOMEN USING VARIOUS D-DIMER ASSAYS</td>
<td>Petr Kessler* (CZ), Roman Petrik, Hynek Poul, Maria Kusnierova, Gabriel Horkay</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-231 SUCCESSFUL CONSERVATIVE TREATMENT OF RECURRENT INTRACRANIAL HEMORRHAGE IN INFANT WITH CONGENITAL FVII DEFICIENCY
Dragan Micic* (RS), Milena Jovic, Olivera Serbic, Kuzmanovic Milos

P-WE-232 EFFECT OF NOISE GENERATED BY MICROPLATE READER ON THE PERFORMANCE OF THE THROMBIN GENERATION TEST
Samuel Woodle* (US), Dominique T Monteil, Mikhail V Ovanesov

P-WE-233 OPTIMIZATION OF A THROMBIN GENERATION TEST FOR THE ANALYSIS OF FACTOR XIA CONTAMINATION IN IMMUNOGLOBULINS
Samuel Woodle* (US), Alexey M Shibeko, Mikhail V Ovanesov

P-WE-234 INTERPRETATION AND SIGNIFICANCE OF ANTI-FVIII ANTIBODIES DETECTED BY ELISA AND WESTERN BLOTTING
Satoshi Yamazaki* (JP), Shigenobu Takayama, Tomoko Ashikaga, Atsuki Yamashita, Shinji Muto, Chai Nagae, Masashi Taki

P-WE-235 THE ACTIVATED PARTIAL THROMBOPLASTIN TIME IN PREKALLIKREIN DEFICIENCY VARIES WIDELY WITH REAGENT TYPE, ACTIVATION TIME AND CLOT DETECTION PRINCIPLE: A CASE REPORT
Geoffrey Kershaw* (AU), Diane Zebljan

P-WE-236 EVALUATION OF NOVEL TOTAL PROTEIN S ASSAY SYSTEM FOR SCREENING OF PROTEIN S TYPE II DEFICIENCY
Tomohide Tsuda* (JP), Xiuri Jin, Hiroko Tsuda, Eriko Morishita, Takao Kobayashi, Naotaka Hamasaki

P-WE-237 DEVELOPMENT OF A NEW QUANTITATIVE TOTAL PROTEIN S ASSAY SYSTEM FOR SCREENING OF PROTEIN S TYPE II DEFICIENCY
Xiuri Jin* (JP), Tomohide Tsuda, Hiroko Tsuda, Masahiro Ieko, Tomoko Adachi, Naotaka Hamasaki

Experimental models

P-WE-238 THE ROLE OF THROMBOMODULIN IN SEPSIS CAUSED BY BURKHOLDERIA PSEUDOMALLEI
Liesbeth M Kager* (NL), W Joost Wiersinga, Gavin CKW Koh, Joris J Roelofs, Joost C Meijers, Edward M Conway, Hartmut Weiler, Cornelia Van ’t Veer, Tom Van der Poll

P-WE-239 EVALUATION OF SEPSIS OUTCOMES IN MICRONEAL MODELS OF HEMOPHILIA A AND B
Erich de Paula* (BR), Suley Mara Chaddad Vancine, Susan Kelly Picoli-Quaino, Devanira Souza Paixao Costa, Silmara Aparecida Lima Montalva, Margareth Castro Ozelo, Joyce Maria Annichino-Bizzacchi

P-WE-240 ACTIVATION OF PROTEASE ACTIVATED RECEPTOR-2 IMPAIRS HOST DEFENSE DURING MURINE STREPTOCOCCUS PNEUMONIAE PNEUMONIA BY A MECHANISM INDEPENDENT OF TISSUE FACTOR/FACTOR VIIA
Floor E. van den Boogaard* (NL), Marcel Schouten, Xanthe Brands, Marcus J. Schultz, Corneliis van ’t Veer, Tom van der Poll

P-WE-241 MAINTENANCE AND BREAK OF IMMUNE TOLERANCE IN A NEW MOUSE MODEL THAT IS IMMUNOLOGICALLY TOLERANT TO NATIVE HUMAN FACTOR VIIA
Christine Lenk* (AT), Sabine Unterthurner, Gerhard Antoine, Markus Weiller, Rafi Uddin Ahmad, Maurus de la Rosa, Hans-Peter Schwarz, Birgit Maria Reipert
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-242  MAST CELLS PLAY AN UNFAVORABLE ROLE DURING MURINE STREPTOCOCCUS PNEUMONIAE PNEUMONIA
Floor E. van den Boogaard* (NL), Xanthe Brands, Joris J.T.H. Roelofs, Cornelis van ’t Veer, Tom van der Poll

P-WE-243  ANTI-HAEMOPHILIC FACTOR (FACTOR VIII) AND THROMBIN GENERATION IN CAMEL PLASMA - A COMPARATIVE STUDY WITH HUMANS
Abdel Galil M Abdel Gadir* (SA), Al Momen M Abdul Karim, Abdulqader A Alhaider, Brooks Catalfamo Brooks, James L Catalfamo, Ahmed A Al Haidari

P-WE-244  THROMBIN GENERATION TEST (TGT), A POWERFUL EX VIVO SCREENING TOOL TO PREDICT IN VIVO ANTITHROMBOTIC EFFICACY: APPLICATION TO COUMARINS TARGETING THROMBIN
Severine Robert* (BE), Raphael Frederick, Philippe Devel, Francois Mullier, Bernard Chatelain, Bernard Masereel, Lionel Pochet, Jean-Michel Dogne

P-WE-245  PROTECTIVE EFFECT OF THROMBOMODULIN IN A MURINE MODEL OF ALLERGEN-INDUCED ASTHMA

P-WE-246  ANTICOAGULANT AND FIBRINOLYTIC EFFECTS OF GLYPROLINES IN CONDITIONS OF IMMOBILIZATION STRESS
Marina E Grigorjeva* (RU), Ludmila A Lyapina

P-WE-247  MODELLING AND SIMULATION OF REDISTRIBUTION OF DABIGATRAN AFTER ELIMINATION BY HEMODIALYSIS IN PATIENTS WITH END STAGE RENAL DISEASE
Karl-Heinz Liesenfeld (DE), T. Lehr, V. Moschetti, S. Formella*, A. Clemens, A. Staab, S. Haertter

P-WE-248  ACTIVATED PROTEIN C MODULATES EPCR AND PAR1 EXPRESSION IN NEURONS AT EXITOTOXICITY
Irina Savinkova* (RU), Lubov Gorbacheva, Vsevolod Pinelis, Svetlana Strukova, Georg Reiser

P-WE-248*  ACTIVATED PROTEIN C MODULATES MAST CELL FUNCTIONS AND SURVIVAL AT INFLAMMATION
Svetlana Strukova* (RU), Aleksey Piskunov, Anna Rusanova, Lubov Gorbacheva, Fumi Ono, Schin’ichi Ishiwata

TAFI

P-WE-249  DETERMINATION OF COAGULATION AND FIBRINOLYSIS MARKERS UPON ANTI-TAFI TREATMENT IN A MOUSE THROMBOEMBOLISM MODEL
Ellen Vercauteren* (BE), Jan Emmerechts, Miet Peeters, Marc F Hoylaerts, Paul J Declerck, Ann Gils

P-WE-250  CLONING AND CHARACTERIZATION OF AN ANTIBODY-BASED INHIBITOR OF TAFI
Tine L Wyseure* (BE), E. Vercauteren, A. Gils, P.J. Declerck

P-WE-251  REGULATION OF THE SURVIVAL AND APOPTOSIS SIGNALS WITH TAFI IN THE PRIMARY CULTURED RAT HEPATOCYTES
Kasumi Ishii* (JP), Nobuaki Okumura, Mayuko Arima, Ai Hashizume, Keiichi Akiyama, Takashi Hosono, Taichiro Seki, Toyohiko Ariga

P-WE-252  ANTIFIBRINOLYTIC ACTIVITY OF THROMBIN AND TAFIA GENERATED OUTSIDE THE CLOT. DO ANTICOAGULANTS ENHANCE CLOT LYSIS?
Mario Colucci* (IT), Francesca Incampo, Cosimo Carrieri, Laura La Grasta, Nicola Semeraro
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-253 PROFIBRINOLYTIC ACTIVITY OF DIFFERENT ANTICOAGULANTS IN BLOOD. RELATION WITH CLOTTING INHIBITION AND INFLUENCE OF PLATELETS
Mario Colucci* (IT), Cosimo Carrieri, Francesca Incampo, Rita Galasso, Nicola Semeraro

P-WE-254 REPRESSION OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) EXPRESSION BY NOBILETIN IN HUMAN HEPATOMA HEPG2 CELLS
Kimihiko Takada* (JP), Toru Seike, Tomoyuki Sasaki, Yutaka Masuda, Hidemi Ishii

P-WE-256 TAFI ACTIVATION, FIBRINOLYSIS AND THROMBIN GENERATION IN HEMOPHILIA A CASES BEFORE AND AFTER TREATMENT WITH FVIII OR RECOMBINANT FVIIIA
Norma de Bosch* (VE), Belsy Guererro, Maria Lucia D’Errico, Apsara Boadas, Arlette Ruiz-Saez, Zoila Carvajal, Ana Maria Salazar, Norma de Bosch

PA system in CNS

P-WE-257 TISSUE-TYPE PLASMINOGEN ACTIVATOR TRANSIENTLY ENHANCED THE PERMEABILITY OF BLOOD BRAIN BARRIER IN ISCHEMIA
Yasuhiro Suzuki* (JP), Nobuo Nagai, Kazuo Umemura

PA system in immunity and inflammation

P-WE-258 THE ROLE OF CHYMASE, A NOVEL FIBRINOLYSIS ENZYME, IN ADIPOSE TISSUE
Misako Kikuzawa* (JP), Tomohiro Ando, Yuri Shimamura, Shouta Nonaka, Kanako Okuyama, Shinichi Kenzaki*, Hitomi Sekine, Takashi Hosono, Taiichiro Seki, Toyohiko Ariga

P-WE-259 IMPAIRED ACCUMULATION OF MACROPHAGES AND ABSENCE OF THEIR PHENOTYPE HETEROGENEITY DURING LIVER REPAIR IN UROKINASE-DEFICIENT MICE
Naoyuki Kawao* (JP), Nobuo Nagai, Yukinori Tamura, Katsumi Okamoto, Kiyotaka Okada, Masato Yano, Yasuhiro Suzuki, Kazuo Umemura, Shigeru Ueshima, Osamu Matsu

Experimental models

P-WE-260 MECHANISM OF THE ANTITHROMBOTIC EFFECT OF AN APPLE VARIETY INVOLVES ENHANCEMENT OF ENDOGENOUS FIBRINOLYTIC ACTIVITY
Junichiro Yamamoto* (JP), Mai Morishita, Aki Naemura, Kanae Hyodo, Yuko Tsuba, Yoshio Okada, Kiyotaka Okada, Osamu Matsu

P-WE-261 CALORIC RESTRICTION OF OBESE MICE IMPROVES ADIPOSITY, INFLAMMATION AND METABOLIC PROFILE
Matthias Van Hul* (BE), Bianca Hemmeryckx, Henri Roger Lijnen

P-WE-263 A SIMPLE FIRST-LINE SCREENING METHOD FOR THE EVALUATION OF THROMBOLYTICS BY INTRAVITAL MICROSCOPY
Benoit Ho-Tin-Noe* (FR), Yacine Boulaftali, Lamia Lamrani, Marie-Catherine Paoli, Marie-Christine Bouton, Martine Jandrot-Perrus

P-WE-264 REAL TIME IMAGING OF PLASMINOGEN BINDING TO PLATELET-RICH MICROTHROMBUS IN VIVO
Tetsumaei Urano* (JP), Aki Tanaka, Yuko Suzuki, Tomasz Brzoska, Hideo Mogami
POSTER PRESENTATIONS

Wednesday, July 27, 2011

Deep vein thrombosis and pulmonary embolism

P-WE-265  THE AGE-ADJUSTED D-DIMER SAFELY EXCLUDES A HIGH NUMBER OF PULMONARY EMBOLISMS IN COMBINATION WITH FOUR DIFFERENT CLINICAL DECISION RULES

P-WE-266  CLINICAL AND ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM AMONG U.S. AMBULATORY CANCER PATIENTS UNDERGOING CHEMOTHERAPY
Jay Lin* (US), Alok Khorana, Mehul Dalal, Gregory Connolly

P-WE-267  LONG TERM OUTCOME IN PATIENTS WITH SUPERFICIAL VEIN THROMBOSIS OF THE LEGS TREATED WITH THERAPEUTIC DOESES OF LOW MOLECULAR WEIGHT HEPARIN
Monika Stalc* (SI), Tjasa Vizintin Cuderman, Matija Kozak, Nina Vene

P-WE-268  IMPROVED PERFORMANCE OF HEMOSIL D-DIMER HS500 ASSAY TO RULE OUT VENOUS THROMBOEMBOLISM IN ELDERLY OUT-PATIENTS WITH LOW AND INTERMEDIATE PTP USING AGE-ADJUSTED CUT-OFF VALUES
Pierre A Toulon* (FR), Christina Legnani, Dimitrios Scarvelis, Jorgin R Wu, Gualtiero Palaretti

P-WE-269  PERIOPERATIVE HEPARIN BRIDGING IN PATIENTS RECEIVING ORAL ANTICOAGULATION: META-ANALYSIS OF BLEEDING AND THROMBOEMBOLIC RATES
Deborah Siegal* (CA), Jovana Yudin, Wendy Lim, Scott Kaatz, James D. Douketis, Alex C. Spyropoulos

P-WE-270  PREVALENCE OF SYMPTOMATIC VENOUS THROMBOEMBOLISM IN MEDICAL IN-PATIENTS AT SIRIRAJ HOSPITAL
Yingyong Chinthammitr* (TH), Busakorn Sae-aeng, Harutaya Kasayanan, Bundarka Suwanwiboon, Theera Ruchutrakool

P-WE-271  SAFE EXCLUSION OF PULMONARY EMBOLISM USING THE WELLS RULE AND A POINT-OF-CARE OR LABORATORY BASED D-DIMER TEST IN PRIMARY CARE: A DIAGNOSTIC VALIDATION STUDY
Geert-Jan Geersing* (NL), Petra Erkens, Wim Lucassen, Harry Buller, Arno Hoes, Ruud Oudega, Martin Prins, Henri Stoffers, Hugo ten Cate, Henk van Weert, Karel Moons

P-WE-272  ATTITUDES TOWARDS AND PRACTICE OF VENOUS THROMBOEMBOLISM PREVENTION IN GENERAL INTERNAL MEDICINE WARDS: A PAN-EUROPEAN SURVEY
Moshe Vardi* (IL), Lorenzo Dagna, Michal Haran, Roger W Duckit

P-WE-273  THROMBOELASTOGRAPHY MONITORS HYPERCOAGULABILITY FOLLOWING CPAP TREATMENT IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA
Mazen Toukh* (CA), Effie J Pereira, Bani J Falcon, Christina Llak, Marina Lerner, Wilma M Hopman, Steve Iscoe, Michael F Fitzpatrick, Maha Othman

P-WE-274  PREVALENCE AND INDICATORS OF DEEP VEIN THROMBOSIS IN FEMALE MEDICAL PATIENTS WITH IMMOBILIZATION ON ADMISSION IN HOSPITAL
Koichi Sato* (DE), Kazuhiko Hanazawa, Takeshi Okamoto, Roland Hetzer, Jun-ichi Hayashi

P-WE-275  STICKERS IN MEDICAL RECORDS AS A TOOL TO REMEMBER THE IMPORTANCE OF VENOUS THROMBOEMBOLISM PROPHYLAXIS
Beatriz Eugenia Grand* (AR), Bernabe Demaria, Julio Hammoe, Ramiro Gutierrez, Oscar Mando
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-276 GENETIC ASSOCIATIONS OF PULMONARY EMBOLISM AMONG THOSE WITH A DEEP VEIN THROMBOSIS
Nicholas L Smith* (US), Marine Germain, Weihong Tang, Martina Teichert, Guillaume Pare, Mary Cushman, William Cohen, Pierre Morange, Aaron Folsom, Lynda Rose, Daniel I Chasman, Edwin T. Bovill, David-Alexandre Tregouet, Saonti Basu, Bruno Stricker, Paul Ridker

P-WE-277 IS THROMBIN GENERATION AT THE TIME OF AN ACUTE THROMBOEMBOLIC EPISODE A PREDICTOR OF RECURRENCE RISK? THE LINKOPING STUDY ON THROMBOSIS (LIST) - A 7-YEAR FOLLOW-UP
Roza Chaireti* (SE), Cecilia Jennersjo, Tomas Lindahl

P-WE-278 HOW ARE THROMBIN GENERATION AND THROMBOSIS RECURRENCE RATES AFFECTED BY AGE AND GENDER? THE LINKOPING STUDY ON THROMBOSIS (LIST) - A 7 YEAR FOLLOW-UP
Roza Chaireti* (SE), Cecilia Jennersjo, Tomas Lindahl

P-WE-279 INCIDENCE OF VENOUS THROMBOEMBOLISM IN PSYCHIATRIC UNITS
Karine Lacut* (FR), Aurelien Delfuc, Stephanie Montavon, Ollivier Canceil, Marc Carpentier, Luc Bressollette, Sylvie Etienne, Michel Walter, Jean-Pierre Olie, Dominique Mottier

P-WE-280 MEASUREMENT OF FVIII LEVELS OVER TIME IN CONSECUTIVE PATIENTS AFTER DEEP VEIN THROMBOSIS
Arina J ten Cate-Hoek* (NL), K Hamulyak, P Verheezen, H ten Cate

P-WE-281 IS THE PREDICTIVE QUALITY OF D-DIMER FOR THE RECURRENCE OF THROMBOSIS TIME DEPENDENT?
Arina J ten Cate-Hoek* (NL), P Erkens, K Hamulyak, P Verhezen, H ten Cate

P-WE-282 INCIDENCE AND PATTERNS OF VENOUS THROMBOEMBOLIC EVENTS AMONG HOSPITALIZED MEDICAL PATIENTS IN A TERTIARY SINGAPORE INSTITUTION
Hein Than* (SG), Heng Joo Ng, Ying Hua Leong, Lai Heng Lee

P-WE-283 MANAGEMENT AND ASSESSMENT OF PREOPERATIVE PULMONARY EMBOLISM IN THE JAPANESE ACADEMIC MEDICAL CENTER
Chikao Yasuda* (JP), Mitsugu Taniguchi, Masao Akagi, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Eizaburoh Ishimaru, Ryuji Kajikawa, Yasutaka Shikawa, Yoshifumi Takeyama, Kiyotaka Okuno, Hitoshi Shiozaki

P-WE-284 THE INCIDENCE OF DEEP VEIN THROMBOSIS AFTER RESECTION OF MUSCULOSKELETAL TUMOR

P-WE-285 PROGNOSTIC CLINICAL PREDICTION RULES FOR IDENTIFYING LOW-RISK PULMONARY EMBOLISM: A SYSTEMATIC REVIEW AND META-ANALYSIS
Alessandro Squizzato* (IT), Marco Donadini, Luca Galli, Francesco Dentali, Walter Ageno

P-WE-286 DISTRIBUTION OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN THE ELDERLY
Marissa Josephina Engbers* (NL), Jeanet Blom, Mary Cushman, Frits Rosendaal, Astrid van Hylckama Vlieg

P-WE-287 CLINICAL RELEVANCE OF COMPRESSION ULTRASONOGRAPHY IN CASE OF SYMPTOMATIC ISOLATED SUPERFICIAL VEIN THROMBOSIS OF LOWER LIMBS
Jean-Philippe Galanaud* (FR), Isabelle Quere, Alain Leizerovicz, Jean-Philippe Galanaud, Emilie Presles, Francois Becker, Marie-Therese Barrellier, Gilles Desprairies, Herve Guenneguez, Patrick Mismetti, Anne Vinel, Herve Decousus
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-288  RECURRENT VENOUS THROMBOSIS AND POST-THROMBOTIC SYNDROME AFTER CATHETER-DIRECTED THROMBOLYSIS IN ILEOFEMORAL DEEP VENOUS THROMBOSIS (DVT)
Waleed Ghanima* (NO), Ingrid Wiig Kleven, Tone Enden, Antonio Rosales, Hilde Skuterud Wik, Paal Andre Holme, Per Morten Sandset

P-WE-289  EARLY PROGNOSIS OF SYMPTOMATIC ISOLATED SUPERFICIAL-VEIN THROMBOSIS IN THE REAL LIFE: A POOLED ANALYSIS OF OBSERVATIONAL STUDIES
Jean-Philippe Galanaud* (FR), Isabelle Quere, Celine Genty, Emilie Presles, Jean-Luc Bosson, Herve Decousus, Alain Leizervicz

P-WE-290  D-DIMER AND PULMONARY EMBOLISM SEVERITY INDEX IN RELATION TO RIGHT VENTRICULAR FUNCTION
Marten Soderberg* (SE), Rikka Rydman, Marten Soderberg, Flemming Larsen, Mahbubul Alam, Kenneth Caidahl

P-WE-291  FRAILTY AND VENOUS STASIS AS RISK FACTORS OF VENOUS THROMBOSIS IN THE ELDERLY
Mariassa Josehpina Engbers* (NL), Jeanet Blom, Mary Cushman, Frits Rosendaal, Astrid van Hylckama Vlieg

P-WE-292  PERFORMANCE OF FOUR CLINICAL DECISION RULES IN THE DIAGNOSTIC MANAGEMENT OF ACUTE PULMONARY EMBOLISM; THE PROMETHEUS DIAGNOSTIC ACCURACY STUDY
Inge C.M. Mos* (NL), Renee A. Douma, Petra M.G. Erkens, Tessa A.C. Nizet, Marc F. Durian, Marcel M.M. Hovens, Anja A. van Houten, Herman M.A. Hofstee, Frederikus A. Klok, Hugo ten Cate, Erik F. Ullmann, Harry R. Buller, Pieter W. Kamphuisen, Menno V. Huisman

P-WE-293  CONGESTION AND INFLAMMATION ASSOCIATED CALF COMPARTMENT SYNDROME IN ACUTE PROXIMAL DEEP VENOUS THROMBOSIS ASSESSED WITH MAGNETIC RESONANCE TOMOGRAPHY
Hong H Keo* (CH), Torsten Willenberg, Werner Blaettler

P-WE-294  EVALUATING THE USE OF NEGATIVE D-DIMER AND LOW WELLS SCORE IN EXCLUDING ABOVE KNEE DEEP VENOUS THROMBOSIS IN AN OUTPATIENT POPULATION AT A MAJOR LONDON TEACHING HOSPITAL
Shirish G Prabhudesai* (UK), Anshul Rastogi, Sean Platton, David McClinhton, Deirdre Norris, Louise Bowles, Peter K MacCallum, Emma Friedman

P-WE-295  HEALTH RELATED QUALITY OF LIFE (HRQOL) AFTER CATHETER-DIRECTED THROMBOLYSIS IN DEEP VENOUS THROMBOSIS (DVT) - A CONTROL STUDY
Waleed Ghanima* (NO), Hilde Skuterud Wik, Kleven Wiig Ingrid, Tone Enden, Per Morten Sandset

P-WE-296  METABOLIC SYNDROME IS ASSOCIATED WITH UNPROVOKED VENOUS THROMBOEMBOLISM: A PATIENT-LEVEL META-ANALYSIS
Walter Ageno* (IT), Matteo ND Di Minno, Cihan Ay, Moon J Jang, Ingrid Pabinger, Doyeun Oh, Giovanni Di Minno, Alessandro Squizzato, Francesco Dentali

P-WE-297  DIFFERENTIAL INHIBITION OF FIBRINOGENESE BY UNFRACTIONATED HEPARINS AND DEPOLYMERIZED HEPARINS
Angel L Gray* (US), Josephine Cunanan, Debra Hoppensteadt, Jawed Fareed

P-WE-298  RESEARCH OF THE RELATIONSHIP BETWEEN PHENOTYPE AND GENOTYPE IN THREE CHINESE PEDIGREES WITH INHERITED ANTITHROMBIN DEFICIENCY
Qi OuYang* (CN), Qulan Ding, Xuefeng Wang, Hongli Wang, Xiaodong Xi
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-299  HIGH PREVALENCE OF LATE SYMPTOMS AFTER PULMONARY EMBOLISM IN PATIENTS WITH NORMAL ECHOCARDIOGRAPHY AND PULMONARY FUNCTION TESTS

P-WE-300  RISK FACTORS OF VENOUS THROMBOEMBOLISM AT THE PATIENTS NEEDY IN PLANNED HIP OR KNEE REPLACEMENT
Svetlana A. Bozhkova* (RU), Raashid M Tikhilov, Evgenia L Nesenyuk, Anatoliy V Yarmilko, Alexandre V Stoyanov, Anatoliy V Sementkovskiy

P-WE-301  PRODUCT ASSOCIATED VARIATION IN GENERIC ENOXAPARIN. POTENTIAL CLINICAL IMPLICATIONS.
Jawed Fareed* (US), Debra Hoppensteadt, Walter Jeske, Angel Gray, Jeanine Walenga, Evi Kalodiki, Indemohran Thethi, Rakesh Wahi

P-WE-302  LIPID PARAMETERS MIGHT INFLUENCE VTE EXTENSION
Thomas Gary* (AT), Klara Belaj, Franz Hafner, Harald Froehlich, Ernst Pilger, Marianne Brodmann

P-WE-303  MARKERS OF THROMBOGENESIS IN PATIENTS WITH ACUTE PSYCHOSIS
Jiri Masopust* (CZ), Radovan Maly, Ctirad Andrys, Martin Valis, Jan Bazant, Ladislav Hosak

P-WE-304  COMPARISON OF 5 D-DIMER REAGENTS AND APPLICATION OF AN AGE ADJUSTED CUT-OFF FOR THE DIAGNOSIS OF VTE IN EMERGENCY DEPARTMENT
Francois Mullier* (BE), Dominique Vanpee, Jacques Jamart, Eric Dubuc, Yvan Cornet, Christian Chatelain, Jean-Michel Dogne, Bernard Chatelain

P-WE-305  PLASMA D-DIMETER TESTING FOLLOWED BY ULTRASONOGRAPHY FOR PREDICTING VENOUS THROMBOEMBOLISM IN PATIENTS WITH GYNECOLOGIC DISEASE
Haruta Shoji* (JP), Ryuji Kawaguchi, Yasuhiro Tanase, Akira Nagai, Shozo Yoshida, Naoto Furukawa, Yoshihiko Yamada, Hidekazu Oi, Yoshiro Hirai, Hiroshi Kobayashi

P-WE-306  EFFECTS OF INTERMITTANT PNEUMATIC COMPRESSION DEVICES
Mehmet Kurtoglu* (TR), Alper Ozturk, Emre Sivirkoz, Hakan Yanar, Murat Aksoy

P-WE-307  EXAMINATION OF THE DEEP VEIN THROMBOSIS BY LAPAROSCOPIC SURGERY
Kazuteru Komuro* (JP), Noriko Yokoyama, Hiromitsu Doumen, Yoshitsugu Nakaniishi, Nozomu Iwashiro, Masanori Ohara, Masanori Ishizaka, Kaoru Komuro, Kazuya Yonezawa

P-WE-308  EXAMINATION OF THE DEEP VEIN THROMBOSIS BY SURGERY
Noriko Yokoyama* (JP), Kazuteru Komuro, Kaoru Komuro, Hiromitsu Doumen, Yoshitsugu Nakaniishi, Nozomu Iwashiro, Masanori Ohara, Masanori Ishizaka, Kazuya Yonezawa

P-WE-309  ACTIVATION OF HAEMOSTASIS IN PATIENTS WITH NEWLY DIAGNOSED OF PSYCHOSIS BEFORE AND DURING ANTIIPSCHYTIC TREATMENT: MATCHED CASE-CONTROL ANTRE STUDY
Radovan Maly* (CZ), Jiri Masopust, Ctirad Andrys, Dita Kalnicka, Jan Bazant, Ladislav Hosak

P-WE-310  THE IMPACT OF A VENOUS THROMBOEMBOLISM RISK ASSESSMENT TOOL ON USAGE OF LOW MOLECULAR WEIGHT HEPARIN AND INCIDENCE OF PULMONARY EMBOLISM IN A LARGE ORTHOPAEDIC HOSPITAL
Claire Corrigan* (UK), Daniel O’Callaghan, Cathy Jack, Gary Benson

P-WE-311  PLATELET INTEGRIN BETA-3 DELETION OR PHARMACOLOGIC BLOCKADE AUGMENTS FIBRIN IN LARGE-VEIN THROMBOSIS
Brian C. Cooley* (US)
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-313  BIOCHEMICAL DETERMINANTS OF ANTI-XA AND APTT DISCORDANCE FOR UFH MONITORING
Clifford Takimoto* (US), Kenneth Shermock, Peggy Kraus, Dana Moore, Peter Greene, David Thiemann, Brent Petty, Redonda Miller, Michael Streiff, Thomas Kickler

P-WE-314  HYPOBARIC HYPOXIA INDUCES HYPERCOAGULABLE STATE: ROLE OF INFLAMMATION AND ENDOTHELIAL DYSFUNCTION
Gausal Azam Khan* (IN), Garg Iit, Indranil Biswas, Bandana Singh, Pawan Agarwal

P-WE-315  RISK OF RECURRENT VENOUS THROMBOSIS ASSOCIATED WITH ELEVATED D-DIMER LEVELS
Astrid van Hylckama Vlieg* (NL), Caroline A. Baglin, Roger Luddington, Frits R. Rosendaal, Trevor P. Baglin

P-WE-316  POTENTIAL INTERACTIONS BETWEEN BLOOD TYPE AND THROMBOGENIC LIFESTYLE FACTORS. A DANISH FOLLOW-UP STUDY
El-Galaly Tarec* (DK), Kim Overvad, Soeren Risom Kristensen, Rudi Steffensen, Marianne Tang Severinsen

P-WE-317  FATAL PULMONARY EMBOLISM (PE), AS AN OUTCOME FROM HOSPITAL ACQUIRED THROMBOSIS (HAT): A SINGLE CENTRE EXPERIENCE
Yin M Thi* (UK), Monica Beauchamp, Timothy JC Nokes

P-WE-318  MYELOPROLIFERATIVE DISORDERS IN PATIENTS WITH ACUTE PORTAL, MESENTERIC OR SPLENIC VEIN THROMBOSES
Andrea Buchmuller-Cordier* (FR), Karine Rivron-Guillot, Silvy Laporte, Beatrice Trombert-Paviot, Herve Decousus

Genetic determinants and epidemiology

P-WE-319  FACTOR XIII VAL34LEU POLYMORPHISM AND SUSCEPTIBILITY TO VENOUS THROMBOEMBOLISM IN NORTH-WESTERN RUSSIA
Sergey Igorevich Kapustin* (RU), Yulia Semenovna Drizhun, Lyudmila Ivanovna Filanovskaya, Viktor Dmitrievich Kargin, Lyudmila Petrovna Papayan, Michail Nikolaevich Blinov

P-WE-320  FREQUENCY OF FACTOR V LEIDEN AND PROTHROMBIN MUTATION IN TESTED SAMPLES FOR THROMBOPHILIA, AND CONCORDANCE OF FUNCTIONAL AND MOLECULAR TESTS FOR FACTOR V LEIDEN MUTATION
Abdulaziz alshaikh (SA), Tarek Owaidah*

P-WE-321  THE JAK2 V617F MUTATION REPRESENTS A GENDER-RELATED SUSCEPTIBILITY ALLELE FOR SPLANCHNIC VENOUS THROMBOSIS
Elvira Grandone* (IT), Donatella Colaluzio, Giovanni Luca Tiscia, Patrizia Vergura, Gennaro Vecchione, Filomena Cappucci, Valeria Bafunno, Maurizio Margaglione

P-WE-322  FACTOR V LEIDEN AND SLOVAK POPULATION
Peter Kubisz* (SK), Jan Stasko, Ivana Plamenova, Lenka Bartosova, Juraj Chudej, Pavol Holly, Peter Chudy

P-WE-323  GENOME WIDE ASSOCIATION STUDY IDENTIFIES NOVEL SUSCEPTIBILITY GENES FOR PEDIATRIC STROKE AT THE INTERFACE BETWEEN VASCULAR BIOLOGY AND COAGULATION
Monika Stoll* (DE), Ulrike Nowak-Goettl, Milan Hiersche, Christoph Preuss, Frank Ruehle, Anika Sietmann, Thomas Niederstadt, Karin Kurnik
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-324  THE INFLUENCE OF ABO BLOOD GROUP GENOTYPES AND THE INTERACTION OF NON-O BLOOD GROUP WITH THE FACTOR V LEIDEN AND PROTHROMBIN 20210A MUTATIONS ON VTE RISK
Olivia Wu* (UK), Peter Clark

P-WE-325  PRIORITIZED-GWAS BASED ON LINKAGE INFORMATION IDENTIFIES NOVEL PUTATIVE LOCI INFLUENCING FACTOR XII PLASMA LEVELS
France Gagnon* (CA), Apostolos Dimitromanolakis, Guillemette Antoni, Angel Martinez, Nicholas Greliche, Alfonso Bull, Jose Manuel Soria, Pierre Emmanuel Morange, Philip Wells, David Alexandre Tregouet, Lei Sun

P-WE-326  GENETIC RISK FACTORS FOR RECURRENT VENOUS THROMBOSIS
Linda E Flinterman* (NL), Astrid Hylckama Vlieg, Lance A Bare, Suzanne C Cannegieter, Andre R Arellano, Pieter H Reitsma, James J Devlin, Frits R Rosendaal

P-WE-327  NEW CANDIDATE LOCI MODULATING VWF AND FVIII PLASMA LEVELS: RESULTS FROM A META-ANALYSIS OF THREE GWAS IN SELECTED SAMPLES
Tiphaine Oudot-Mellakh (FR), Guillemette Antoni, Apostolos Dimitromanolakis, Marine Germain, William Cohen, Philip Wells, Mark Lathrop, David-Alexandre Tregouet, France Gagnon, Pierre-Emmanuel Morange*

P-WE-328  THE IMPACT OF FAMILY HISTORY OF VENOUS THROMBOEMBOLISM, FACTOR V LEIDEN AND PROTHROMBIN 20210G>A MUTATIONS, AND ACQUIRED RISK FACTORS ON THE RISK OF VENOUS THROMBOEMBOLISM
Fatima Donia Mili* (US), W. Craig Hooper, Cathy Lally, Harland Austin

Antiphospholipid syndrome

P-WE-330  MARKERS OF ENDOTHELIAL ANGIOGENIC DYSFUNCTION IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
Karen A Breen* (UK), K Parmar, BJ Hunt

P-WE-331  ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH PAROXYSMAL NOCTURMAL HEMOGLOBINURIA RECEIVING ECUULIZUMAB
Dominique Helley* (FR), Luc Darnige, Regis Peffault de Latour, Laurence Zemori, Gerard Socie, Anne-Marie Fischer

P-WE-332  SUPERFICIAL VENOUS THROMBOSIS PREDICTS THROMBOEMBOLIC EVENTS IN LUPUS AND ANTIPHOSPHOLIPID PATIENTS. A PROSPECTIVE COHORT STUDY.
Stephane Zuily* (FR), Veronique Regnault, Francis Guillemin, Pierre Kaminsky, Thomas Lecompte, Denis Wahl

P-WE-333  RETINAL VEIN OCCLUSION IN ASSOCIATION WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES: A SINGLE CENTRE CASE SERIES
John Laurie* (UK), Karen Breen, Beverley J Hunt

P-WE-334  EVALUATION OF THE CRITERIA FOR LUPUS ANTIICOAGULANT DETECTION. MA NARDI AND M KARPATKIN. DEPARTMENTS OF PEDIATRICS AND PATHOLOGY. BELLEVUE-NYU MEDICAL CENTER. NY, NY, USA.
Michael A Nardi* (US), Margaret Karpatin
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-335  PRIMARY ANTIPHOSPHOLIPID SYNDROME AND RENAL VASCULAR DISEASE
Jitka Slechtova* (CZ), Zdenka Hajsmanova, Pavla Sigutova

P-WE-336  MONITORING DISEASE ACTIVITY AND RESPONSE TO THERAPY IN CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME
Michiel Coppens* (NL), Erik Jan Van den Dool, Joost C.M. Meijers, An K Stroobants, Bert Jan Van den Born

P-WE-337  PROLONGED CLINICAL OBSERVATION OF A GROUP OF PATIENTS WITH ASYMPTOMATIC ANTIPHOSPHOLIPID ANTIBODIES
Krystyna Maria Zawilska* (PL), Agata Maria Lehmann-Kopydlowska

P-WE-338  ELEVATED CYTOKINE AND CHEMOKINE LEVELS IN ANTIPHOSPHOLIPID ANTIBODY (APL)-POSITIVE PATIENTS
Vijaya Murthy (US), Shraddha Jatwani, Laura Aline Martinez-Martinez, Renan Aguilar-Valenzuela, Ellis Doan, Elizabeth Papalardo, Joann Vega, Emilio B Gonzalez, Douk Erkan, Silvia S Pierangelii

P-WE-339  STUDIES OF MICROPARTICLES IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS)
Anna Vikerfors (SE), Fariborz Mobarrez*, Katarina Bremme, Margareta Holmstrom, Anna Agren, Anna EeIde, Maria Bruzelius, Aleksandra Antovic, Hakan Wallen, Elisabet Svenungsson

P-WE-340  A SINGLE CENTRE EVALUATION OF MORTALITY PREDICTORS IN THROMBOTIC PRIMARY ANTIPHOSPHOLIPID SYNDROME
Paul Richard Julian Ames* (UK), Luigi Iannaccone, Antonio Ciampa, Catello Tommasino, Vincenzo Brancaccio

P-WE-341  LUPUS ANTOCOAGULANT IN WOMEN WITH OBSTETRIC COMPLICATIONS: PERSISTENCE OF RESULTS BETWEEN SAMPLES
Andrea Laura Avigliano* (AR), Maria Cecilia Goni, Juan Carlos Galli, Beatriz Eugenia Grand

P-WE-342  AUTOANTIBODIES TO THE COMPLEX OF PS/PT IN 67 FINNISH PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
Marja Kaarina Puurunen* (FI), Kustaa Lehtonen, Petra Makkonen, Kajia Javela

Pregnancy, hormones, women’s issues

P-WE-343  THE INCIDENCE OF HEMORRHAGIC AND THROMBOEMBOLIC COMPLICATIONS OF THERAPEUTIC AND PROPHYLACTIC LOW MOLECULAR WEIGHT HEPARIN REGIMEN DURING PREGNANCY
Gorana Mitic* (RS), Mirjana Kovac, Pavica Radovic, Aleksandra Novakov-Mikic

P-WE-344  THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR ANTIGEN AND MICROPARTICLES’ PROCOAGULANT ACTIVITY DURING PREGNANCY IN HEALTHY WOMEN AND WOMEN WITH AUTOIMMUNE DISEASES
Magdalena Celinska-Lowenhoff* (PL), Teresa Iwaniec, Anna Wojtowicz, Magdalena Pulka, Jacek Musial

P-WE-345  THROMBOPHILIA AND PLACENTAL ABRUPTION
Olga Panfilova* (RU), Natalia Makatsaria, Marina Kiria

P-WE-346  HEMOSTATIC AND LIPID PROFILE OF PATIENTS WITH HYPERTHYROIDISM BEFORE AND AFTER TREATMENT
Ana Paula Fernandes* (BR), Michelle Aparecida Borges, Pedro Wesley Rosario, Luci Maria Sant’ Ana Dusse, Kathryna Fontana Rodrigues, Maria das Gracas Carvalho
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-347 THROMBOPHILIA AND COMPLICATIONS OF MULTIPLE AND SINGLE PREGNANCY AFTER IVF
Natalia Makatsaria* (RU), Olga Panfilova, Marina Kiria

P-WE-348 MORPHOFUNCTIONAL FEATURES OF THROMBOCYTES IN THE FIRST TRIMESTER OF THE PREGNANCY COMPLICATED WITH DIABETES TYPE 1
Irina A Burenkova (RU), Irina M Ordianov*, Mikhail B Tamarkin, Irina A Vasilenko

P-WE-349 PATHOGENESIS AND PROPHYLAXIS OF PROSTHETIC VALVE THROMBOSIS DURING PREGNANCY
Alexander D. Makatsaria* (RU), Svetlana V. Akinshina, Viktoria O. Bitzadze, Vyacheslav B. Nemyrovs'kiy, Nestor T. Meskhi

P-WE-350 ROLE OF HAEMOSTATIC DISORDERS DETECTION IN WOMEN WITH HISTORY OF ISCHEMIC STROKE FOR PREGNANCY MANAGEMENT
Svetlana V. Akinshina* (RU), Alexander D. Makatsaria, Viktoria O. Bitzadze, Seda M. Baimuradova, Vyacheslav B. Nemyrovs'kiy

P-WE-351 PREVENTION OF RECURRENT THROMBOTHIC AND THROMBOEMBOLIC COMPLICATIONS DURING PREGNANCY
Svetlana V. Akinshina* (RU), Alexander D. Makatsaria

P-WE-352 PATHOGENETIC PROPHYLAXIS OF RECURRENT ANTENATAL FETAL DEATH AND BIRTH DEFECTS IN PARENTS WITH GENETICALLY DETERMINED HYPERHOMOCYSTEINEMIA
Viktoria O. Bitsadze* (RU), Irina N. Talalaeva, Alexander D. Makatsaria

P-WE-353 PATHOGENETIC PROPHYLACTIC STRATEGY IN WOMEN WITH THROMBOPHILIA AND HISTORY OF PREECLAMPSIA IN FUTURE PREGNANCY
Viktoria O. Bitsadze* (RU), Alexander D. Makatsaria, Seda M. Baimuradova, Svetlana V. Akinshina

P-WE-354 F XIII AND PLATELETS IN PREGNANCY
Annelie Siegemund* (DE), Elena Mirson, Thomas Siegemund, Ute Scholz

P-WE-355 LATE OBSTETRIC MORBIDITY IN WOMEN WITH AND WITHOUT INHERITED OR ACQUIRED THROMBOPHILIA: MANAGEMENT AND OUTCOMES
Anja B Drebes* (UK), Asma Khalil, Patrick O’Brien, Hannah Cohen

P-WE-356 THE UTILITY OF THE WELLS CLINICAL PREDICTION MODEL AND VENTILATION-PERFUSION SCANNING FOR PULMONARY EMBOLISM IN PREGNANCY
Briony A Cutts* (AU), Huyen Tran, Eileen Merriman, Dee Nandurkar, Geoffrey Soo

P-WE-357 VASCULAR ENDOTHELIAL GROWTH FACTOR GENE POLYMORPHISMS IN SPONTANEOUSLY ABORTED EMBRYOS
Young Joo Jeon (KR), Ji Hyang Kim, Soo Yeon Kim, KuyBeom Kwack, Tae Ki Yoon, Dong Hee Choi, Nam Keun Kim*

P-WE-358 HORMONAL THERAPY (HT) ASSOCIATED THROMBOEMBOLISM. RETROSPECTIVE ANALYSIS OF 81 CASES AND LONG TERM FOLLOW UP, EXPERIENCE FROM A SINGLE CENTER
Emmanuel Papadakis* (GR), Anastasia Spyrou, Eleni Gatsa, Konstantina Tsimirika, Konstantinos Loukidis, Elissaveli Georgiou, Smaragda Efaimidou, Parthena Kapali, Anna Kioumi, Ioannis Korantzis, Georgia Papaiouannou

P-WE-359 THROMBIN GENERATION PROFILES AND ASSOCIATION WITH OBESITY AND INFLAMMATION IN WOMEN WITH VTE
Kristina Sonnevi* (SE), Svetlana Tchaikovski, Margareta Holmstrom, Katarina Bremme, Jan Rosing, Gerd Larfars
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-360  HAPLOTYPE-BASED ASSOCIATION OF ACE, AT1R, AND AGT POLYMORPHISMS IN RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM GENES IN IDIOPATHIC RECURRENT SPONTANEOUS ABORTIONS
Yi Seul Choi (KR), Hwang Kwon, Young Joo Jeon, Tae Ki Yoon, Dong Hee Choi, Doyeun Oh, Nam Keun Kim*

Atrial fibrillation and thrombosis

P-WE-361  UNDERUSE OF ORAL ANTICOAGULANTS IN ISCHEMIC STROKE PATIENTS WITH ATRIAL FIBRILLATION
Birsen Ince* (TR), Gulcin Benbir, Feray Bolukbasi

P-WE-362  INFLUENCE OF CARDIAC FUNCTION ON THE HEMOSTATIC STATUS OF PATIENTS WITH CARDOEMBOLIC STROKE UNDERGOING ANTICOAGULANT THERAPY
Takehiko Nagao* (JP), Hideki Takubo, Yasuo Katayama, Shin-ichiro Uchiyama

P-WE-363  RACE/ETHNICITY BUT NOT SOCIOECONOMIC STATUS IS A STRONG AND INDEPENDENT RISK FACTOR FOR INCIDENT ATRIAL FIBRILLATION IN WOMEN
David Conen* (CH), Julie E Buring, Brendan M Everett, Michelle A Albert, Christine M Albert

P-WE-364  CHRONIC KIDNEY DISEASE IN PATIENTS WITH ATRIAL FIBRILLATION; A DIFFICULTY FOR THE TREATMENT WITH THE NEW ORAL ANTITHROMBOTIC AGENTS?
Judith Kooiman* (NL), Wilke van de Peppel, Felix JM van der Meer, M V Huisman

P-WE-365  BRIDGING LOW MOLECULAR WEIGHT HEPARIN DURING WARFARIN INITIATION IN PATIENTS WITH ATRIAL FIBRILLATION
Scott Kaatz* (US), Abdallah Kobeissy, Geoffrey D Barnes, Xiaokui Gu, Leaden Hickman, Steven Almany, Jay Kozlowski, Dennis Besley, Marcella Novakosky, Thomas Leyden, James B Froelich

P-WE-366  EFFECT OF AMIODARONE ON THE TIME IN THERAPEUTIC INR RANGE FOR PATIENTS INITIATED ON WARFARIN, RESULTS OF THE MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT INITIATIVE (MAQI2)
Scott Kaatz* (US), Abdallah Kobeissy, Geoffrey D Barnes, Xiaokui Gu, Leaden Hickman, Steven Almany, Jay Kozlowski, Dennis Besley, Marcella Novakosky, Thomas Leyden, James B Froelich

P-WE-367  CAN THE CHADS2 SCORE PREDICT POSTOPERATIVE STROKE RISK IN PATIENTS WITH CHRONIC ATRIAL FIBRILLATION WHO ARE HAVING ELECTIVE NON-CARDIAC SURGERY?
Scott Kaatz* (US), James D Douketis, Richard H White, Hong Zhou

P-WE-368  BRIDGE TRIAL: BRIDGING ANTICOAGULATION IN PATIENTS WHO REQUIRE TEMPORARY INTERRUPTION OF WARFARIN FOR ELECTIVE SURGERY/PROCEDURE: DESIGN, RATIONALE AND CLINICAL IMPLICATIONS
Alex Spyropoulos (CA), James Douketis*, Scott Kaatz, Tom Ortel

Cancer and thrombosis

P-WE-369  DISCUSSION OF THE CORRELATION BETWEEN JAK2V617F MUTATION AND THROMBOEMBOLISM IN MYELOPROLIFERATIVE NEOPLASM PATIENTS
Liang Xia* (CN), Jing-sheng Wu, Kai-yang Ding, Qing-shub Zeng, Xiao-yan Cai, Wei-bo Zhu, Lin-lin Wu, Xin Liu, Hui-zhi Yang
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-370  A THROMBOELASTOGRAPHY STUDY TO EVALUATE THE EFFECT OF THROMBOCYTOPENIA ON CLOT FORMATION IN THE PRESENCE OF UNFRACTIONATED HEPARIN
Lih Yeen Tan* (CA), Mohammed S. Almakadi, Anthony K.C. Chan, Howard H.W. Chan

P-WE-371  THE INCIDENCE AND PROGNOSTIC IMPLICATIONS OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH COLORECTAL CANCER
Keun-Wook Lee* (KR), Seyoun Choi, Soo-Mee Bang, Jeong-Ok Lee, Yu Jung Kim, Jee Hyun Kim, Duck-Woo Kim, Sung-Bum Kang, Jong Seok Lee

P-WE-372  ANTICOAGULANT THERAPY IN PATIENTS WITH THROMBOCYTOPENIA: A SYSTEMATIC REVIEW OF CASE SERIES IN MEDICAL LITERATURE
Mohammed Almakadi* (CA), Anthony K.C. Chan, Howard H.W. Chan

P-WE-373  INCIDENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY
Cecilia Becattini* (IT), Maria Cristina Vedovati, Fabio Rondelli, Michela Boncompagni, Giuseppe Camporese, Enrico Mariani, Giovanni Natalini, Giancarlo Agnelli

P-WE-374  THE CPS DISC CENTRIFUGE: A NEW ORIGINAL METHOD TO DETECT MICROPARTICLES (MPS)
Julie Hardjij* (BE), Jorge Mejia, Damien Gheldof, Emilie Varin, Carine Michiels, Francois Mullier, Stephane Lucas, Bernard Chatelain, Jean-Michel Dogne

P-WE-375  THROMBOTIC COMPLICATIONS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Monica S Martinez* (AR), Alejandra Costa, Fernanda Cuello, Virginia Schuttemberg, Liliana Alba, Marcela Aznar, Ramiro Fernandez, Sandra Formisano, Sandra Arguello, Sergio Gomez, Luis Pistaccio, Alcira Fynn

P-WE-376  CHARACTERISTICS OF CANCER ASSOCIATED AND NON-CANCER ASSOCIATED VENOUS THROMBOEMBOLISM (VTE) AMONG ADULTS OBTAINING CARE AT US THROMBOSIS AND HEMOSTASIS CENTERS
Claire S Philipp* (US), Imran Khan, Ambarina Faiz, Michele G Beckman, Kristy M Kenney, Paula Bockenstedt, John A Heit, Roshni Kulkarni, Marilyn Manco-Johnson, Stephan Moll, Thomas L Ortel

P-WE-377  THE APPLICATION OF CLINICAL VARIABLES AND MODELS TO PREDICT PULMONARY EMBOLISM (PE) IN CANCER PATIENTS. A COMPREHENSIVE CANCER CENTER EXPERIENCE.
Hikmat N. Abdel-Razeq* (JO), Assem H Mansour, Youssef M Ismael, Rim N Turfa, Mahmoud A Abu Nasser, Hussain A Abu Ali

P-WE-378  A NATION-WIDE ANALYSIS OF VENOUS THROMBOEMBOLISM IN 497,180 CANCER PATIENTS WITH THE DEVELOPMENT AND VALIDATION OF A RISK-STRATIFICATION SCORING SYSTEM
Yuan-Bin Yu* (TW), Jyh-Pyng Gau, Chun-Yu Liu, Muh-Hwa Yang, Shu-Chiung Chiang, Hui-Chi Hsu, Ying-Chung Hong, Liang-Tsai Hsiao, Jin-Hwang Liu, Tzeon-Jye Chiou, Po-Min Chen, Tzong-Shyuan Lee, Li-Fang Chou, Cheng-Hwai Tzeng, Tzeng-Ji Chen

P-WE-379  A MODIFIED KHORANA RISK SCORE MODEL FOR VENOUS THROMBOEMBOLISM IN AMBULATORY CANCER PATIENTS RECEIVING CHEMOTHERAPY: THE PROTECHT SCORE
Melina Verso* (IT), Giancarlo Agnelli, Roberto LaBianca, Giampietro Gasparini, Sandro Barni, Erminio Bonizzoni, Matteo Brighenti, Mario Mandala*, Fausto Petrelli, Carlo Bianchini, Tania Perrone
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-380  NOVEL THROMBOGENIC BIOMARKERS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (R-MM) TREATED WITH LENALIDOMIDE (LEN) AND DEXAMETHASONE (DEX) THERAPY
Kate L Burbury* (AU), Peter Gambell, Amanda Choo, Caroline Reddel, Kevin Lynch, H Miles Prince, Hang Quach, Simon Harrison, David Ritchie, Jennifer Curnow, David Westerman

P-WE-381  ANTICOAGULANT PROPERTIES OF CURCUMIN
Severine Robert* (BE), Philippe Devel, Francois Mullier, Bernard Chatelain, Lionel Pochet, Fabian Priem, Jean-Michel Dogne

P-WE-382  MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY, VENOUS THROMBOSIS AND POOR SURVIVAL IN PANCREATIC CANCER PATIENTS
Patricia Garcia Rodriguez* (NL), Margot E Tesselaar, Fred P Romijn, Irma K van der Linden, Rogier M Bertina, Susanne Osanto

P-WE-383  THROMBOSIS IN NEWBORNS WITH HOMOZYGOUS ANTITHROMBIN DEFICIENCY
Katarina Zervan* (AT), Katharina Thom, Christine Mannhalter, Christoph Male

P-WE-384  A PREDICTION MODEL FOR THROMBOSIS RISK IN CHILDHOOD CANCER PATIENTS
Lesley G Mitchell* (CA), Jacqueline Halton, Maria Spavor, Evelyn Sharek, Sara Isaels, Kevin Dietrich, Cheri Roberts, Sharon Abish, Qu Liu, Yutaka Yasui

P-WE-385  RISK FACTORS FOR THE DEVELOPMENT OF IN-HOSPITAL VENOUS THROMBOEMBOLISM IN CHILDREN: A CASE-CONTROL STUDY EMPLOYING DIAGNOSTIC VALIDATION
Brian R Branchford* (US), Peter Mourani, Lalit Bajaj, Marilyn Manco-Johnson, Michael Wang, Neil Goldenberg

P-WE-386  THROMBOSIS IN THAI INFANTS AND CHILDREN: 5 YEARS PROSPECTIVE COHORT STUDY
Darintr Sosothikul* (TH), Piti Techavichit, Yodkwan Aphikulchatkit, Viroj Pongpanlert, Parinya Seksarn

P-WE-387  COMPARISON OF BONE MINERAL DENSITY IN POST-FONTAN CHILDREN: ASPIRIN VS. WARFARIN
Chengde Pham* (AU), Paul Monagle, Fergus Cameron, Sue Kantor, Fiona Newall

P-WE-388  NON-HAEMATOLOGICAL EFFECTS OF UNFRACTIONATED HEPARIN IN NEONATES
Fiona Newall* (AU), Eliza Mertyn, Paul Monagle

P-WE-389  INBORN PROTEIN C DEFICIENCY CASE IN NEWBORN
Nadezda A. Vorobyeva* (RU), Alyona I. Vorobyeva, Elena V. Tsyganova, Andrei I. Lobanov, Tatjana A. Kosix, Petr A. Lavrinov

P-WE-390  INTRACARDIAC THROMBOSIS IN NEONATES. CASE REPORTS.
Pavel Svirin* (RU), A.Y. Perepyolkin, I.I. Ryumina, I.V. Orlovskaya, N.V. Yevleeva, V.V. Vdovin

P-WE-391  EFFECTIVE TREATMENT OF BOY WITH EXTRAHEPATIC PORTAL HYPERTENSION AND RECURRENT THROMBOSIS OF PORTAL-SYSTEMIC SHUNT WITH PROTEIN C. CASE REPORT.
Pavel Svirin* (RU), L.E. Larina, G.A. Sukhanova, Y.V. Averianova, V.V. Vdovin

P-WE-392  BODY MASS INDEX AND THROMBOEMBOLISM IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES
Ruta Tuckuviene* (DK), Trishana Nayiager, Anthony Chan, Uma Athale
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-393 CONTINUOUS INTRAVENOUS ENOXAPARIN THERAPY IN TREATMENT OF SEVERE ARTERIAL AND VENOUS THROMBOTIC COMPLICATIONS IN PEDIATRIC AND ADULT PATIENTS
Hans-Joerg Hertfelder* (DE), Beatrix Wiebe, Christian Rabe, Frauke Verrel, Eckfried Hoebert, Martin Schneider, Michael Ehlen, Tilmann Sauerbruch, Peter Bartmann, Johannes Oldenburg, Andreas Mueller

P-WE-394 CENTRAL VENOUS LINE RELATED NON-OCCLUSIVE THROMBOSIS IN CHILDREN—DO WE HAVE TO TREAT?
Suzan Williams* (CA), Viola van Eimeren, Leo Brandao, Walter Kahr

P-WE-395 THE FIRST NATIONAL SURVEY OF PEDIATRIC THROMBOEMBOLISM IN JAPAN
Akira Ishiguro* (JP), Masashi Taki, Atsushi Manabe, Chitose Ogawa, Midori Shima

P-WE-396 VALIDATION OF THE SCORING SYSTEM FOR THE KIDCLOT PAC QL; A NOVEL APPROACH
Aiko MD Bruce* (CA), M Patricia Massicotte, Mary Bauman

Microparticles

P-WE-397 MICROPARTICLES CARRY ACTIVE TISSUE FACTOR AND FIBRINOLYTIC FACTORS IN ACUTE PROMYELOCYTIC LEUKEMIA AND ARE MOSTLY DERIVED FROM MYELOID CELLS
Hau C Kwaan* (US), Eduardo M Rego, Brandon McMahon, Ivy Weiss, James Marvin

P-WE-398 NEUTROPHILS AS WELL AS MONOCYTES PHAGOCYTOSE PLATELET REMNANTS AND DAMAGED ENDOTHELIAL CELLS IN PATIENTS WITH ACUTE CORONARY SYNDROME
Mathie Leers* (NL), Jeffrey Keuren, Mark Huts, Hans Kragten, Asiong Jie

P-WE-399 INCREASED LEVELS OF MONOCYTE AND ENDOTHELIAL DERIVED MICROPARTICLES EXPRESSING TISSUE FACTOR AND ALTERED FIBRIN NETWORK IN PATIENTS WITH GRAVES’ DISEASE
Fariborz Mobatrez* (SE), Mirna Abraham-Nordling, Inger Friberg, Aleksandra Antovic, Gun Jorneskog, Hakan Wallen

P-WE-400 TISSUE-FACTOR BEARING, GLIAL AND ENDOTHELIAL DERIVED MICROPARTICLES IN PATIENTS WITH GLIOBLASTOMA MULTIFORME: A POSSIBLE CONTRIBUTION TO A PROTHROMBOTIC STATE
Maria Teresa Sartori* (IT), Alessandro Della Puppa, Andrea Ballin, Claudia Maria Radu, Graziella Saggiorato, Elena Campello, Luca Spiezia, Domenico d’Avella, Giuseppe Cella, Paolo Simioni

P-WE-401 PROCOAGULANT ACTIVITY OF MICROPARTICLES IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
Karen A Breen* (UK), K Parmar, BJ Hunt

P-WE-402 MODULATION OF CIRCULATING MICROPARTICLE LEVEL ANALYSIS IN ELDERLY PATIENTS WITH ACUTE HIP FRACTURE TREATED WITH HEPARINS
Jawed Fareed* (US), Humza Azam, Evangelos Litinas, William Hopkinson, Debra Hoppensteadt, Michael Lassen, Rakesh Wahi

P-WE-403 STAPHYLOCOCCUS AUREUS ACCELERATES THROMBIN GENERATION THROUGH INCREASED TISSUE FACTOR AND MICROPARTICLES IN WHOLE BLOOD
Zechariah Gideon Franks* (US), Robert C Campbell, Guy A Zimmerman, Andrew S Weyrich, Matthew T Rondina
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-404  REQUIREMENT OF SEVERAL TECHNIQUES TO STUDY TISSUE-FACTOR BEARING MICROPARTICLES IN THROMBOSIS ASSOCIATED WITH BREAST CANCER
Francois Mullier* (BE), Emilie Varin, Damien Gheldof, Julie Hardil, Severine Robert, Nicolas Bailly, Philippe Devel, Chantal Doyen, Christian Chatelain, Carine Michiels, Bernard Chatelain, Jean-Michel Dogne

P-WE-405  PROCOAGULANT MICROPARTICLES AND THROMBIN GENERATION IN TRAUMA
Barbara AL Owen* (US), Myung S Park, Robert S Litwiller, Claude Deschamps, Michael G Sarr

P-WE-406  CELLULAR ORIGIN AND PROCOAGULANT ACTIVITY OF TISSUE FACTOR-EXPOSING MICROPARTICLES IN CANCER PATIENTS
Ankie Kleinjan* (NL), Rene J. Berckmans, Anita N. Boing, Auguste Sturk, Harry R. Buller, Pieter W. Kamphuisen, Rienk Nieuwland

Arterial vascular diseases

P-WE-408  THE SPLEEN AS PROTECTOR AGAINST THE DEVELOPMENT OF CARDIOVASCULAR EVENTS AFTER TREATMENT OF HODGKIN LYMPHOMA
Hilde A.M. Kooistra* (NL), J. C. Kluin-Nelemans, M. A.E. van der Kaaij

P-WE-409  SERUM URIC ACID, BUT NOT RS7442295 POLYMORPHISM OF SCL2A9 GENE, PREDICTS TOTAL AND CARDIOVASCULAR MORTALITY IN SEVERE CORONARY ARTERY DISEASE
Nicola Martinelli* (IT), Letizia Consoli, Laura Annarumma, Giovanni Malerba, Francesca Pizzolo, Simonetta Friso, Thomas Illig, Pier Franco Pignatti, Roberto Corrocher, Domenico Girelli, Oliviero Olivieri

P-WE-410  PLATELET P-SELECTIN IS ASSOCIATED WITH TISSUE FACTOR EXPRESSION IN PLATELET-MONOCYTE AGGREGATES IN PATIENTS WITH PULMONARY HYPERTENSION
Christina Christersson* (SE), Gerhard Wikstrom, Agneta Siegbahn

P-WE-411  DELAYED INITIATION BUT PROLONGED THROMBIN GENERATION IN ACUTE ISCHEMIC STROKE
Ross Ian Baker* (AU), Grace Gilmore, Rosa Szollosi, Matthew Cooper, James Thom, Graeme Hankey

P-WE-412  INVESTIGATION ON THE RELATIONSHIP OF PROLACTIN LEVELS AND ARTERIAL THROMBOTIC DISEASE
Ning Tang* (CN), Huijun Li, Jing Peng, Biyu Zhang

P-WE-413  THALASSEMIA TRAIT AND ARTERIAL THROMBOEMBOLIC EVENTS: A SYSTEMATIC REVIEW AND A META-ANALYSIS OF THE LITERATURE
Francesco Dentali* (IT), Erica Romualdi, Walter Ageno, Maria D Cappellini, Pier Mannuccio Mannucci

P-WE-414  ROSUVASTATIN DECREASES SERUM LEVELS OF OXIDIZED LOW-DENSITY LIPOPROTEIN/BETA2 GLYCOPROTEIN I COMPLEX THROUGH THE NITRIC OXIDE PATHWAY IN DIABETES MELLITUS
Luis R Lopez* (US), Eiji Matsuura, Joana Batuca, Ignacio Garcia De La Torre, Paul RJ Ames

P-WE-415  CEREBRAL THROMBOEMBOLIC EVENTS IN PATIENTS WITH BETA-TALASSEMIA: A SYSTEMATIC-REVIEW
Mehran Karimi* (IR), Sezaneh Haghpanah
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-416  ASSOCIATION BETWEEN KINASE INSERT DOMAIN-CONTAINING RECEPTOR (KDR) GENE POLYMORPHISM AND HAPLOTYPES AND ISCHEMIC STROKE
Nam Keun Kim* (KR), Seung-Hun Oh, Kyung Tae Min, Young Joo Jeon, Hyun Sook Kim, Eun Kyung Park, Doyeon Oh, Ok Joon Kim, Hyun Seok Kim

P-WE-417  GENETIC POLYMORPHISMS OF ENDOTHELIN-RELATED GENES ASSOCIATED WITH RISK OF CHRONIC KIDNEY DISEASE IN JAPANESE HYPERTENSIVES
Mariko Banno* (JP), Kei Kamide, Takeshi Horio, Toshiyuki Miyata, Yuhei Kawano

Clinical trials and registries

P-WE-418  A PHASE II STUDY OF ECULIZUMAB IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) RECEIVING CHRONIC PLASMA EXCHANGE/INFUSION: INTERIM ANALYSIS
Christoph Licht* (CA), Petra Muus, Christophe Legendre, Kenneth Douglas, Maryvonne Hourmant, Yahsou Delmas, Maria Herthelius, Antonella Trivelli, Timothy Goodship, Camille Bedrosian, Chantal Loirat

P-WE-419  ECULIZUMAB IS EFFECTIVE IN PATIENTS RESISTANT TO PLASMA EXCHANGE/INFUSION WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
Camille Bedrosian* (US), Sunil Babu, Richard Furman, Neil Sheerin, David Cohen, Osama Gaber, Frank Etmer, Yahsou Delmas, Chantal Loirat, Larry Greenbaum, Lothar Zimmerhackl, Christophe Legendre

P-WE-420  CHARACTERISING VTE RISK, PROPHYLAXIS USE AND EXTENDED PROPHYLAXIS NEED IN HOSPITALISED VERSUS OUTPATIENT MEDICAL PATIENTS (STATUS REGISTRY)
Sylvia Katharina Haas* (DE), Knut Kroger, Vera Regitz-Zagrosek, Sebastian M Schellong, Rainer B Zotz, Carsten Kienitz

P-WE-421  EVALUATION OF A SIMPLIFIED CLINICAL DECISION RULE (I-DVT) IN PATIENTS WITH A SUSPECTED ACUTE DEEP VEIN THROMBOSIS
Melanie Tan* (NL), Gerben C. Mol, Antonio Iglesias del Sol, Olaf M Dekkers, Frederikus A Klok, Marcel A van de Ree, Menno V Huisman

P-WE-422  VENOUS THROMBOEMBOLISM RISK IN THE ACUTE OUTPATIENT CARE SETTING: RESULTS OF THE SURVEY FROM THE PROFIL STUDY IN POLAND
Wojciech J. Sydor* (PL), Jacek Musial, Grzegorz Oszkinis, Piotr Pruszczczyk, Jerzy Windyga

P-WE-423  ELECTRONIC ALERT DOES NOT INCREASE THE THROMBOPROPHYLAXIS USE IN THE ACUTE OUTPATIENT CARE SETTING: RESULTS OF THE PROFIL STUDY
Wojciech Juliusz Sydor* (PL), Jacek Musial, Grzegorz Oszkinis, Piotr Pruszczczyk, Jerzy Windyga

P-WE-424  META-EMBOL: A WEB-BASED APPLICATION PROVIDING DYNAMIC INTERACTIVE SYSTEMATIC REVIEWS AND META-ANALYSES OF CLINICAL TRIALS IN THE THROMBOSIS FIELD
Silvy Laporte* (FR), Celine Chapelle, Laurent Bertoletti, Michel Cucherat, Paul Zufferey, Carine Labruyere, Patrick Mismetti, Collaborators Meta-Embol

P-WE-425  GUIDELINES FOR VENOUS THROMBOEMBOLISM (VTE) PREVENTION IN HOSPITALISED MEDICAL PATIENTS: A VALIDATION STUDY PILOT
Nicola Helen Chapman* (AU), Marissa N Lassere, Mary Clarke, Beng Hock Chong
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-426  VITAMIN K ANTAGONISTS (VKA) AND DRUG INTERACTIONS: A MULTICENTER PHARMACOVIGILANCE SYSTEM (FARMAMICO)
Sophie Testa* (IT), Roberto Del Bono, Daria Bettoni, Giuliana Martini, Volpi Roberta, Oriana Paciotti, Anke Zimmermann, Catia Barosi, Anna Falanga, Simona Pedrini, Maria Bertoli, Lidia Rota, Emilia Lalli, D. Paganotti

P-WE-427  IMPACT OF PHARMACOKINETIC (CYP2C9) AND PHARMACODYNAMIC (VKORC1, GGCX, CALU, EPHX1, F7, PROC) GENE VARIANTS ON PHENPROCOUMON THERAPY
Christof Geisen* (DE), Beate Luxembourg, Matthias Watzka, Katja Sittinger, K. Schneider, Stefan W Toennes, Milka Marinova, Nicolas von Ahsen, Edelgard Lindhoff-Last, Erhard Seifried, Johannes Oldenburg

Post-thrombotic syndrome

P-WE-428  INFLAMMATION AND PERIPHERAL VENOUS DISEASE: THE SAN DIEGO POPULATION STUDY
Mary Cushman* (US), Peter W Callas, Julie O Denenberg, Michael H Criqui

P-WE-429  EYTHROCYTE DERIVED MICROPARTICLES AND PROCOAGULANT PHOSPHOLIPIDS INDUCE ACCELERATION OF THROMBIN GENERATION IN PATIENTS WITH STEADY STATE SICKLE CELL ANEMIA
Grigoris Gerotziafas (FR), Mourad Chaari, Patrick Van Dreden, Barry Woodhams*, Francois Lionel, Robert Girot, Vasso Galea, Ismail Elalamy

P-WE-430  EARLY USE OF COMPRESSION STOCKINGS FOLLOWING DEEP VEIN THROMBOSIS IS ASSOCIATED WITH REDUCED EARLY INCIDENCE OF POST-THROMBOTIC SYNDROME AND IMPROVED QUALITY OF LIFE
Lara N Roberts* (UK), Raj K Patel, Lynda Bonner, Roopen Arya

P-WE-431  INDIVIDUALLY TAILORED ELASTIC COMPRESSION THERAPY AND POST THROMBOTIC SYNDROME, A RANDOMIZED MULTICENTRE TRIAL (IDEAL DVT STUDY)
Arina J ten Cate-Hoek* (NL), M Joore, K Hamulyak, J Veraert, M H Phins, H ten Cate

Innovative therapies for thrombotic disorders

P-WE-432  CROSS REACTIVITY OF RABBIT ANTI-RECOibri (HUMAN RECOMBINANT THROMBIN) WITH MOLECULAR VARIANTS OF HUMAN THROMBIN AND BOVINE THROMBIN PREPARATIONS
Nasir Sadeghi* (US), He Zhu, Debra Hoppensteadt, Indermohan Thethi, Rakesh Wahi, Jawed Fareed

P-WE-433  LASER-INDUCED SELECTIVE THROMBOLYSIS WITHOUT VESSEL DAMAGE IN THE RAT THROMBOSIS MODELS

P-WE-434  THE INFLUENCE OF CARVEDILOL VERSUS METOPROLOL ON SYMPATHETIC ACTIVITY AND HEMOSTASIS IN PATIENTS WITH HEART FAILURE
Olav R De Peuter* (NL), Wouter E Kok, Hein J Verberne, Bas van den Bogaard, Jasper Truijen, Marianna C Schaap, Rienk Nieuwland, Joost C Meijers, J A Verheul, C A De Groot, Ad Bakx, G A Somsen, Lizzy M Brewster, Harry R Buller, Pieter W Kamphuisen
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-435  REVERSAL OF RIVAROXABAN AND DABIGATRAN BY PROTHROMBIN COMPLEX CONCENTRATE: A RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER STUDY IN HEALTHY SUBJECTS
Elise S Eerenberg* (NL), Pieter W Kamphuisen, Meertien K Sijpkens, Joost CM Meijers, Harry R Buller, Marcel Levi

P-WE-436  HIGH-DENSITY LIPOPROTEIN ACCELERATES DEGRADATION OF A BLOOD CLOT AS MEASURED BY THROMBOELASTOGRAPHY
Simone Talens* (NL), Frank W.G. Leebeek, Dick C. Rijken

P-WE-437  THE EFFECT OF RIVAROXABAN: A NEW FXA INHIBITOR ON ROUTINE HAEMOSTASIS ASSAYS
Lucy Hawkins (FR), Lucia Rugeri, Christophe Nougier, Christine Vinciguerra*, Claude Negrier, Yesim Dargaud

P-WE-438  THE EFFECT OF TOTAL HIP AND KNEE REPLACEMENT SURGERY AND DABIGATRAN ON THROMBIN GENERATION
Laura Green* (UK), Andrew S Lawrie, Rahul Patel, Robert CM Stephens, Ian J Mackie, Andy Chitolie, Fares S Haddad, Samuel J Machin

P-WE-439  INHALATIONAL USE OF ANTITHROMBOTIC AGENTS: EVIDENCE FOR USE
Kate Monagle* (AU), Eliza Merten, Michele Hepponstall, Paul Monagle, Fiona Newall

P-WE-440  ORAL, DIRECT FACTOR XA INHIBITOR FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT
Maria Hulikova* (SK), Ivan Stasko, Stefan Hulik, Janka Hulikova

P-WE-441  EGF1-EGFP PROTEIN-CONJUGATED PEG-PLGA NANOPARTICLES ALLOW GENE DELIVERY INTO CEREBRAL INFARCTION REGIONS VIA INTRAVENOUS ADMINISTRATION
Wei Shi* (CN), Yu Hu, Heng Mei, Jun Deng, Huafang Wang, Tao Guo, Chen Chen, Bo Zhang, Zhiqing Pang, Xinguo Jiang, Mao Lei

P-WE-442  ONSET OF PURPURA FULMINANS AND RAPID RESOLUTION OF SYMPTOMS BY ADMINISTERING PROTEIN C CONCENTRATE IN A HOMOZYGOUS PROTEIN C DEFICIENT PATIENT WITH ORAL ANTICOAGULATION
Hans-Joerg Hertfelder* (DE), Derya Sivritas, Elke Odenthal, Rainer Woitas, Marcus Gorschlueter, Johannes Oldenburg

P-WE-443  REVERSAL OF ANTICOAGULANT PROPERTIES OF ANTXA AND ANTI IIA ANTICOAGULANT BY NON SPECIFIC HAEMOSTATIC DRUGS: AN EX VIVO STUDY IN HEALTHY VOLUNTEERS
Gilles Pernod* (FR), Raphael Marlu, Adeline Paris, Enkelejda Hodaj, Pierre Albaladejo, Benoit Polack, Jean Luc Crackowski

P-WE-444  ECOLIZUMAB (ECU) THERAPY FOR ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) IN PEDIATRIC PATIENTS: EFFICACY AND SAFETY OUTCOMES FROM A RETROSPECTIVE STUDY

P-WE-445  CALIBRATED CLOTTING AND CHROMOGENIC METHODS FOR MEASURING DABIGATRAN IN PLASMA
Marie PEYRAFITTE* (FR), Joachim STANGIER, Jean AMIRAL
POSTER PRESENTATIONS

Wednesday, July 27, 2011

von Willebrand factor

P-WE-446  INFLUENCE OF ABH ANTIGEN ON CLEARANCE OF VON WILLEBRAND FACTOR IN VIVO
Dafna Groeneveld* (NL), Ronella Wiegers, Pieter Reitsma, Jeroen Eikenboom

P-WE-447  LIVER AND SPLEEN MACROPHAGE DEPLETION INCREASES THE PLASMA HALF-LIFE OF VON WILLEBRAND FACTOR
Dafna Groeneveld* (NL), Bart van Vlijmen, Ka Lei Cheung, Ronella Wiegers, Pieter Reitsma, Jeroen Eikenboom

P-WE-448  INFLUENCE OF ABH ANTIGEN ON CLEARANCE OF VON WILLEBRAND FACTOR IN MICE
Dafna Groeneveld* (NL), Bart van Vlijmen, Ka Lei Cheung, Pieter Reitsma, Jeroen Eikenboom

P-WE-449  REASSIGNMENT OF THE MODULAR ARCHITECTURE OF VON WILLEBRAND FACTOR: NOVEL STRUCTURAL INSIGHTS INTO THE NON-A REPEAT REGION REVEALING THE MAJOR FVIII BINDING REGION
Nuha Shiltagh* (UK), D. Flemming Hansen, Keith Gomez, Stephen J Perkins, Edward GD Tuddenham

P-WE-450  COMPREHENSIVE GENETIC STUDY OF TYPE 2 VON WILLEBRAND DISEASE IN IRANIAN PATIENTS
Maryam Rassoulzadegan* (IR), Mohammad Jazebi, Shirin Ravanbod, Said Enayat, Ghasem Rastegar Lari, Fereydoun Ala

P-WE-451  ESTABLISHMENT OF VON WILLEBRAND FACTOR STRINGS IN A NON-ENDOTHELIAL SYSTEM
Jiong-Wei Wang* (NL), Karine M Valantijn, Jack A Valantijn, Bieuwke Dragt, Jan Voorberg, Pieter H Reitsma, Jeroen Eikenboom

P-WE-452  DYNAMIC CHANGES IN VON WILLEBRAND FACTOR MULTIMERS REFLECT THE SEVERITY OF OBSTRUCTIVE SLEEP APNEA
Noriko Koyama* (JP), Masanori Matsumoto, Shinji Tamaki, Masanori Yoshikawa, Yoshihiro Fujimura, Hiroshi Kimura

P-WE-453  CONVERSION OF VON WILLEBRAND FACTOR INTO ITS GLYCOPROTEIN IB-BINDING CONFORMATION INDUCES BINDING AND UPTAKE BY MACROPHAGES

P-WE-454  PRE-CLINICAL TESTING OF HUMAN RECOMBINANT VON WILLEBRAND FACTOR: ADAMTS13 CLEAVAGE CAPACITY IN ANIMALS AS CRITERION FOR SPECIES SUITABILITY
Eva Maria Muchitsch* (AT), Barbara Dietrich, Hanspeter Rottensteiner, Wilfried Auer, Herbert Grötsch, Hartmut Ehrlich, Peter Turecek, Friedrich Scheiffinger, Hans Peter Schwarz

P-WE-455  FUNCTIONAL IN VIVO ANALYSIS OF VON WILLEBRAND FACTOR O-GLYCOSYLATIONS
Cecile V Denis* (FR), Idinath Badirov, Julie Rayes, Paulette Legendre, Peter J Lenting, Olivier D Christophe, Cecile V Denis

P-WE-456  GALECTINS INFLUENCE VON WILLEBRAND FACTOR STRING ASSEMBLY AT THE ENDOTHELIAL SURFACE
Peter Lenting* (FR), Beatrijs D Oortwijn, Soline Odouard, Philip G de Groot, Cecile V Denis
POSTER PRESENTATIONS

Wednesday, July 27, 2011

von Willebrand disease

P-WE-457 THE DIAGNOSIS AND MANAGEMENT OF VON WILLEBRAND DISEASE (VWD) ASSOCIATED ANGIODYSPLASIA
Michael Makris* (UK), Augusto Federici, Thynn T Yee, Tom Abshire, Eric Berntorp, Pier M Mannucci

P-WE-458 IDENTIFICATION AND FUNCTIONAL STUDIES OF A NOVEL VON WILLEBRAND FACTOR MUTATION IN A FAMILY WITH TYPE 2A VON WILLEBRAND DISEASE
Jing Dong* (CN), Xiaojuan Zhao, Qingyu Wu, Changgeng Ruan, Ningzheng Dong

P-WE-459 USE OF RECOMBINANT FACTOR VIIA PLUS CONTINUOUS INFUSION OF RECOMBINANT FACTOR VIII IN THE HEMOSTASIS OF TYPE 3 VON WILLEBRAND DISEASE WITH ANAPHYLACTIC ANTI-VWF INHIBITOR
Nobuaki Suzuki* (JP), Naomi Sanda, Tadashi Matsushita, Tetsuhito Kojima, Koji Yamamoto, Akira Katsumi, Kanji Hirashima, Youko Kajitura, Mayumi Takatsu, Tomoki Naoe

P-WE-460 RESPONSE TO DESMOPRESSIN IN VON WILLEBRAND DISEASE MONITORED BY PFA-100
Teresa Agata Iwaniec* (PL), Joanna Zdziarska, Zbigniew Walter, Aleksander Skotnicki, Jacek Musial

P-WE-461 IDENTIFICATION OF THE ELUSIVE MUTATION CAUSING THE HISTORICAL VON WILLEBRAND DISEASE TYPE IIC MIAMI
Reinhard Schneppenheim* (DE), Marlies Ledford-Kraemer, Jean-Maurice Lavergne, Rolf Marschalek, Robert Montgomery, Tobias Obser, Florian Oyen, J. Evan Sadler, Sonja Schneppenheim, Ulrich Budde

P-WE-462 LONG-TERM SECONDARY PROPHYLAXIS FACTOR REPLACEMENT THERAPY WITH WILATE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH VON WILLEBRAND DISEASE
Susan Halimeh* (DE), Anne Kruempel, Hannelore Rott, Ulrich Budde, Britta Faeser, Ulrike Nowak-Goettl

P-WE-463 THALIDOMIDE PLUS VWF/FVIII PROPHYLAXIS AS A SUCCESSFUL TREATMENT FOR REPEATED INTESTINAL BLEEDING IN A PATIENT WITH VON WILLEBRAND DISEASE.
Alexander Wild* (SK), Erika Cellarova, Vladislav Volek, Viera Stulajterova, Elena Balintova, Anna Vallova

P-WE-464 STANDARDIZED BLEEDING SCORING SYSTEM AND PLATELET FUNCTION ANALYZER IN DIAGNOSIS OF PATIENTS WITH VON WILLEBRAND DISEASE: A SURVEY FROM A SINGLE CENTRE (THE BRNO-VWD STUDY)
Petr Smejkal* (CZ), Ondrej Zapletal, Alain Gadisseur, Inge Vangenechten, Jirina Zavrelova, Jan Blatny, Jan Jacques Michiels, Miroslav Penka

P-WE-465 GENOTYPE-PHENOTYPE CORRELATION IN VON WILLEBRAND DISEASE
Hamideh Yadegari* (DE), Julia Driesen, Anna Pavlova, Helena Dermer, Inga Schuerer, Hans-Joerg Hertfelder, Johannes Oldenburg

P-WE-466 EFFICACY AND SAFETY EVALUATION IN CHILDREN WITH VWD FOLLOWING PRODUCT SWITCH TO A NEW GENERATION HIGH PURITY, DOUBLE VIRUS INACTIVATED VWF/FVIII CONCENTRATE
Kate Khair* (UK), Mary Mathias, Ri Liesner
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-467  GYNECOLOGICAL & OBSTETRICAL EVENTS FROM A FRENCH POST-MARKETING SURVEY OF A VON WILLEBRAND FACTOR CONCENTRATE WITH A LOW FACTOR VIII CONTENT
Annie Borel-Derlon* (FR), Jenny Goudemand, Catherine Boyer-Neumann, Segolene Claeyssens, Marie-Anne Bertrand, Group Post-Marketing Study, Celine Henriet, Catherine Chatelanaz, Francoise Bridey

P-WE-468  PREGNANCY IN PLATELET-TYPE VWD: A CASE SERIES
David O'Connor* (UK), Willi Lester, Sara Willoughby, Jonathan T Wilde

P-WE-469  MANAGEMENT OF JOINT REPLACEMENT SURGERY WITH A VON WILLEBRAND FACTOR PRODUCT WITH A LOW FVIII CONTENT IN VON WILLEBRAND DISEASE PATIENTS
Annie Borel-Derlon* (FR), Augusto B Federici, Jenny Goudemand, Valerie Roussel-Robert, Group Post-Marketing Study, Catherine Chatelanaz, Celine Henriet, Francoise Bridey

P-WE-470  CHARACTERISATION OF VON WILLEBRAND FACTOR A1 DOMAIN MUTANTS 1416N AND I1416T: APPLICATION OF FLOW-BASED PLATELET ADHESION ASSAYS
Thomas McKinnon* (UK), Agata Nowak, Anna Goyder, Anne Riddell, Mike Laffan, Carolyn Millar

TTP and related disorders

P-WE-473  TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIC SYNDROME IN SERBIA: CLINICAL EXPERIENCE WITH 28 PATIENTS
Dragica A Vucelic* (RS), Danijela Mikovic, Nebojsa Savic, Zoran Rajic, Slobodan Obradovic, Dragana Jevtic

P-WE-474  SURVIVAL, RELAPSE AND OUTCOME IN PATIENTS WITH IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA: A SINGLE CENTER EXPERIENCE
Marc Heizmann* (CH), Johanna A. Kremer Hovinga, Ramona O. Merki, Mario J. Bargetzi

P-WE-475  ANTI-ADAMTS13 INHIBITOR BOOSTING WITH PLASMA EXCHANGE IN ACQUIRED TTP: CHARACTERIZATION OF INHIBITORS AND EFFICIENT TREATMENT WITH RITUXIMAB
Ayami Isonishi* (JP), Barbara Plaimauer, Friedrich Scheiflinger, Kenji Nishio, Mitsuhiro Uchiba, Yuji Yonemura, Masanori Matsumoto, Yoshihiro Fujimura

Laboratory tests

P-WE-476  SIZE OF VWF MULTIMERS, MODULATED BY THERAPEUTIC REGIMENS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, DETERMINE AN ADVERSE REACTION TO BLEEDING OR THROMBOTIC MICROANGIOPATHY
Masanori Matsumoto* (JP), Kayo Yamada, Keiko Nakayama, Ayami Isonishi, Seiji Kato, Yoshihiro Fujimura

P-WE-477  ESTIMATED PATIENT NUMBER OF CONGENITAL ATYPICAL HUS WITHIN A TMA PATIENT REGISTRY ACROSS JAPAN: A REGISTRY OF NARA MEDICAL UNIVERSITY
Masaki Hayakawa* (JP), Masanori Matsumoto, Yoko Yoshida, Ayami Isonishi, Seiji Kato, Yoshihiro Fujimura

P-WE-478  MEASURING ADAMTS-13 ACTIVITY: A COMPARISON OF FRET AND ELISA METHODS USING THREE COMMERCIALLY AVAILABLE KITS
Ronda Crist* (US), Nana K Sono-Koree, George M Rodgers, Kristi J Smock

P-WE-479  PERFORMANCE OF A NEW AUTOMATED VON WILLEBRAND FACTOR ACTIVITY ASSAY BASED ON GPIbα BINDING
Juergen Patzke* (DE), Heidrun Muth, Matthias Wilkens, Reinhard Schneppenheim
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-480  THE EVALUATION OF A NEW VWF:CB KIT FOR QUANTITATIVE DETERMINATION OF VWF ACTIVITY FOR THE DIAGNOSIS OF VWD.
Kampta Sukhu* (UK), Rhiannon Marr, James Beavis, David Keeling

P-WE-481  CDNA CLONING AND EXPRESSION OF BOTROCEIN-LIKE PROTEIN
Taei Matsui* (JP), Taei Matsui, Yukio Suzuki, Fumio Matsushita, Jiharu Hamako, Izumi Furuta, Youhei Nashimoto, Masanori Matsumoto, Yoshihiko Sakurai, Yoshihiro Fujimura

P-WE-482  ADAPTATION OF THE VON WILLEBRAND FACTOR RISTOCETIN COFACTOR ASSAY (VWF:RCO) ON AN AUTOMATED COAGULATION ANALYZER USING AN IMMUNOLOGICAL TEST PRINCIPLE
Vanessa Chan* (CA), William Brien, Cindy Ing

P-WE-483  HIGH THROUGHPUT DETECTION OF VON WILLEBRAND’S DISEASE USING A NEW COAGULATION ANALYSER
Andrew S Lawrie* (UK), Maria Teresa Canciani, Jessica Iseppi, Ian J Mackie, Samuel J Machin, Flora Peyvandi

P-WE-484  VWF PROPEPTIDE - A USEFUL MARKER IN PATIENTS WITH VON WILLEBRAND DISEASE?
Annelie Siegemund* (DE), Natalie Adam, Ute Scholz

P-WE-485  AUTOMATED VON WILLEBRAND FACTOR RISTOCETIN COFACTOR ASSAY ON THE SYSMEX CS2000I COAGULOMETER.
Shenbagapriya P* (IN), Inbakumar David, kavitha ML, Srivastava Alok, Nair Sukesh Chandran

Hemophilia

P-WE-486  EFFECTIVENESS OF HAEMOPHILIA MEDICATION THERAPY ADHERENCE CLINIC (HMTAC) IN IMPROVING HOME-TREATMENT KNOWLEDGE IN A TERTIARY HOSPITAL
Shu Ping Wong* (MY), Adibah Md Shariff, Jameela Sathar, Yeok Siew Lim

P-WE-487  HIGH DOSAGE PROPHYLACTIC TREATMENT OF SEVERE PATIENTS WITH HAEMOPHILIA B
Olga Plyushe* (RU), Maria Kumskova, Irina Velichko

P-WE-488  QUALITY OF LIFE IN ADULT PATIENTS WITH HAEMOPHILIA. A SINGLE CENTRE EXPERIENCE FROM SWEDEN
Karin Lindvall* (SE), Erik Berntorp, Sylvia von Mackensen

P-WE-489  A FOUNDER EFFECT OF THE FACTOR 8 GENE TYR1680PHE MUTATION IN 52 PATIENTS WITH MODERATE SEVERE HAEMOPHILIA A
Anna Pavlova* (DE), Laura Heinen, Philipp Westhofen, Benaz Pezeshkpoor, Simone Hasenmueller, Johannes Oldenburg

P-WE-490  MORTALITY AND CAUSES OF DEATH AMONG HAEMOPHILIA PATIENTS IN THE WESTERN DANISH POPULATION
Peter Noerkjaer Laursen* (DK), Catherine Rea, Benny Sorensen, Jorgen Ingerslev

P-WE-491  HERO, AN INTERNATIONAL INITIATIVE EXPLORING UNMET PSYCHOSOCIAL NEEDS IN HAEMOPHILIA: CHARACTERISTICS OF A QUANTITATIVE SURVEY TARGETING 1200 SUBJECTS IN 12 COUNTRIES
Alfonso Iorio* (CA), Felipe Querol, Angela Forsyth, Frederica Cassis
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-492  HERO - AN INTERNATIONAL INITIATIVE EXPLORING UNMET PSYCHOSOCIAL NEEDS IN HAEMOPHILIA: RESULTS FROM A QUALITATIVE SURVEY TARGETING 150 SUBJECTS IN 7 COUNTRIES
Alfonso Iorio* (CA), Frederica Cassis, Felipe Querol, Angela Forsyth

P-WE-493  PSYCHOSOCIAL ASPECTS OF LIVING WITH HAEMOPHILIA: THE HERO PROJECT AND A NARRATIVE REVIEW OF THE PUBLISHED LITERATURE
Alfonso Iorio* (CA), Angela Forsyth, Frederica Cassis, Felipe Querol

P-WE-494  SPORADIC SEVERE HEMOPHILIA B IN NEW-BORN CHILD: STILL NOW A MISLEADING AND BELATED DIAGNOSIS.
Margaret Musso* (IT), Anna Musso, Luca Maugeri, Luciano Messina, Roberto Musso

P-WE-495  OUTCOMES OF MENTORED FELLOWSHIP TRAINING IN HEMOSTASIS/THROMBOSIS: FINDINGS FROM A NESTED CASE-CONTROL SURVEY STUDY OF THE NHF-BAXTER CLINICAL FELLOWSHIP, 2002-2010
Neil Goldenberg* (US), Rebecca Kruse-Jarres, Neil Frick, Steven W Pipe, Leissinger A Cindy, Craig M Kessler

P-WE-496  EVALUATION OF A POPULATION PHARMACOKINETIC MODEL OF A RECOMBINANT FVIII (ADVATE) IN PATIENTS WITH HEMOPHILIA A USING EXTERNAL DATA
MyungShin Oh* (US), Sven Bjorkman, Phillip Schroth, Sandor Fritsch, Peter W Collins, Kathleen Casey, Gerald D Spotts, Bruce M Ewenstein

P-WE-497  PROFILE OF HEMOPHILIA IN MANADO
Stefanus Gunawan* (ID), Juliawaty Salim, Max Mantik, Carel Eckmann, Anjo Veerman, Eveline Mauser-Bunschoten

P-WE-498  ILIOPSOAS HEMATOMA IN PATIENTS WITH HEMOPHILIA: RESULTS FROM ONE BRAZILIAN CENTER.
Paula R Villaca* (BR), Elbio A D’Amico, Jorge DA Carneiro, Erica Okasaki, Audrey K.Z. Valim, Eliane P.N. Sandeval, Dalton A.F. Chamone

P-WE-499  VALIDATION OF THREE-DIMENSIONAL GAIT ANALYSIS FOR THE ASSESSMENT OF HEMOPHILIC LOWER LIMBS ARTHROPATHY
Sebastien Lobet* (BE), Cedric Hermans, Christine Detrembleur

P-WE-500  TWO DE NOVO FACTOR VIII MUTATIONS IN THE FAMILY OF AN ISOLATED HAEMOPHILIA A PATIENT
Zoey Kapsimali* (GR), Anna Pavlova, Helen Pergantou, Elftychia Adamtziki, Johannes Oldenburg, Helen Platokouki

P-WE-501  TREATMENT OF HAEMOPHILIA IN AUSTRIA: DATA FROM THE AUSTRIAN HAEMOPHILIA REGISTRY
Sylvia Kepa* (AT), Sylvia Elisabeth Reitter, Werner Streif, Stefan Oberbichler, Christoph Male, Wolfgang Muntean, Ingrid Pabinger-Fasching

P-WE-502  HOW DOES TRANSITION FROM ADOLESCENCE TO ADULTHOOD IMPACT ON THE HEALTH-RELATED QUALITY OF LIFE OF HAEMOPHILIA PATIENTS. RESULTS OF THE HYOOL-EUROPE STUDY
Sylvia von Mackensen* (DE), Robert Klamroth, Alessandro Gringeri

P-WE-503  MILD AND MODERATE HAEMOPHILIA A IN POLAND
Beata Baran* (PL), Anna Pavlova, Ewa Stefanska-Windyga, Johannes Oldenburg, Jerzy Windyga

P-WE-504  TREATMENT METHODS OF HAEMOPHILIA IN RUSSIAN FEDERATION
Olga Plyusch* (RU), L. M. Kudryavceva
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-505  COMPREHENSIVE CARE FOR HEMOPHILIA IN SHIZUOKA CHILDREN’S HOSPITAL
Yasuo Horikoshi* (JP), Taemi Ogura, Eriko Kakazu, Yasuko Abe, Nobuhiro Watanabe,
Kazuko Kudo, Takashima Yoshihumi, Jun-ichi Mimaya

P-WE-506  DISTRIBUTION OF N9-GP, A GLYCOPEPEGYLATED RECOMBINANT FIX DERIVATIVE
- DETERMINED BY QUANTITATIVE WHOLE BODY RADIOGRAPHY (QWBA) AND
IMMUNOHISTOCHEMICAL (IHC) STAINING.
Estelle Watson* (DK), Jette Nowack, Lene Hansen, Mikael Tranholm, Phil Fernyhough,
Hanne Kjaer Offenberg

P-WE-507  A RECURRENT F8 MUTATION (R2016W) IN A COHORT OF ITALIAN HAEMOPHILIA A
PATIENTS: EVIDENCE FOR A FOUNDER EFFECT
Flora Peyvandi* (IT), Mimosa Mortarino, Isabella Garagliola, Maria Elisa Mancuso,
Elena Santagostino

Hemophilia therapy

P-WE-508  THE GREAT IMPORTANCE OF LOCAL BLEEDING CONTROL MEASURES IN PATIENTS
WITH HEMOPHILIA AND INHIBITORS
Nebojsa Rajic* (RS), Stevan Popovic, Aleksandar Savic, Ivanka Savic, Ivana Urosevic,
Ivana Milosevic, Goran Marusic, Milan Popov, Aleksandar Knezevic, Branimir Bajkin

P-WE-509  NEW APPROACH FOR PROPHYLACTIC TREATMENT OF SEVERE ADULT PATIENTS
WITH HAEMOPHILIA A
Olga Plyusch* (RU), Maria Kumskova, Konstantine Kopylov, Irina Velitchko

P-WE-510  VARIABLE ACTIVATION KINETICS OF DIFFERENT RECOMBINANT FULL LENGTH AND
B DOMAIN DELETED FACTOR VIII CONCENTRATES
Anna Pavlova* (DE), Saskia Pahl, Jens Mueller, Holger Brondke, Johannes Oldenburg

P-WE-511  FACTOR XII AS A HAEMOSTATIC AGENT IN SEVERE HAEMOPHILIA
Catherine J Rea* (UK), Benny Sorensen

P-WE-512  DOSING DECISIONS IN SEVERE HEMOPHILIA A: CAN WE AIM LOWER? FVIII USE IN A
COHORT OF CANADIAN PATIENTS IN 2009.
Cecily Bos* (CA), Anthony Chan, Kathryn Webert, Irwin Walker, Theresa Almonte, Kay Decker,
Rebecca Goldsmith, Karen Strike, Linda Waterhouse

P-WE-513  AN ANALYSIS OF FACTORS AFFECTING THE INCIDENCE OF INHIBITOR FORMATION IN
PATIENTS WITH CONGENITAL HAEMOPHILIA IN JAPAN
Akira Shirahata (JP), Katsuyuki Fukutake, Satoshi Higasa, Junichir Mimaya, Toshiaki Oka,
Midori Shimaa*, Junko Takamatsu, Masashi Taki, Maiko Taneichi, Akira Yoshioka

P-WE-514  ON-DEMAND TREATMENT OF BLEEDS IN HEMOPHILIA PATIENTS WITH INHIBITORS:
STRATEGIES FOR SECURING AND MAINTAINING PREDICTABLE EFFICACY WITH
RECOMBINANT ACTIVATED FACTOR VII
Benny Sorensen* (UK), Yesim Dargaud, Gill Kenet, Jeanne Lusher, Andrew D Mumford,
Steven Pipe, Andreas Tiede

P-WE-515  BIOEQUIVALENCE OF B-DOMAIN DELETED AND PLASMA DERIVED FVIII
CONCENTRATES
Massimo Morfini (IT), Alfonso Iorio*, Maria Gabriella Mazzucchetti, Sandro Cinotti, Ezio Zanon,
E Paladino, Emanuela Marchesini, Cristina Santoro
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-516  PERIOPERATIVE HEMOSTATIC MANAGEMENT FOR COARCTATION OF AORTA IN AN EARLY INFANT WITH SEVERE HAEMOPHILIA A
Shoko Furukawa* (JP), Hiroyuki Yoshizawa, Kenichi Ogiwara, Keiji Nogami, Katsumi Nishiya, Ichiro Tanaka, Yoshiro Yoshikawa, Midori Shima

P-WE-517  PROCOAGULANT EFFECT OF TRANEXAMIC ACID WITH MINIMAL UROKINASE ON EX Vivo HUMAN HEMOPHILIA MODEL UNDER BLOOD FLOW.
Kenichi Ogiwara* (JP), Keiji Nogami, Kazuya Hosokawa, Tomoko Matsumoto, Midori Shima

P-WE-518  BAXTER’S RECOMBINANT FACTOR VIIA: COMPARATIVE PRECLINICAL IMMUNOGENICITY ASSESSMENT USING NOVEL MOUSE MODELS
Frank Horling* (AT), Christine Lenk, Raffi Uddin Ahmad, Markus Weiller, Maria Schuster, Hans-Peter Schwarz, Birgit M Reipert

Inhibitors: pathogenesis, prevention and treatment

P-WE-519  INTRACRANIAL BLEEDING IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS
Maria Jose Paloma* (ES), Victor Jimenez-Yuste, Maria Fernanda Lopez-Fernandez, Carmen Altisent, Ana Rosa Cid, Ramiro Nunez, Inmaculada Soto, Eva Mingot, Manuel Prieto, Carmen Sedano

P-WE-520  REAL WORLD OUTCOMES ASSOCIATED WITH THE TREATMENT OF ACUTE BLEDGES WITH RFVIIA IN HAEMOPHILIA PATIENTS WITH INHIBITORS: RESULTS FROM THE INTERNATIONAL ONE REGISTRY
Elena Santagostino* (IT), Herve Chambost, Kaan Kavakli, Mike Laffan, for the Steering Committee of the ONE Registry

P-WE-521  SCREENING OF FVIII INHIBITORS IN HEMOPHILIA A PATIENTS USING THE MODIFIED BETHESDA ASSAY IN THE WEST OF ALGERIA
Driss Benlaldj* (DZ), Khedidja Moulasserdoun, Chakib Rahal, Fatima Seghier

P-WE-522  INSIGHT IN TREATMENT OF INHIBITORS IN MILD AND MODERATE HEMOPHILIA A
Alice S. van Velzen* (NL), Alice S. van Velzen, Corien L. Eckhardt, Daniel P. Hart, Marjolein Peters, Johanna G. van der Born, Thynn T. Yee, Karin Fijnvandraat

P-WE-523  A SYSTEMATIC REVIEW AND META-ANALYSIS COMPARING THE EFFICACY OF BYPASSING AGENTS IN HEMOPHILIA PATIENTS WITH INHIBITORS
Zheng-Yi Zhou* (US), Joel W Hay

P-WE-524  RISK FACTORS FOR INHIBITOR DEVELOPMENT IN PATIENTS WITH HEMOPHILIA A: THE ROLE OF FACTOR VIII (FVIII) PRODUCT TYPE.
Maria Elisa Mancuso* (IT), Pier Mannuccio Mannucci, Angiola Rocino, Isabella Garagiola, Annarita Tagliaferri, Caterina Di Perna, Elena Santagostino

P-WE-525  TREATMENT OF PEOPLE WITH HEMOPHILIA AND INHIBITORS IN MACEDONIA
Rumjana Apostolovska* (MK), Violeta Dejanova, Violeta Neceva, Ivanka Nikoloska

P-WE-526  SURGICAL INTERVENTIONS WITH FEIBA (SURF): AN INTERNATIONAL Registry-BASED ANALYSIS OF SURGERY IN HAEMOPHILIA PATIENTS WITH INHIBITORY ANTIBODIES
Claude Negrier* (FR), Murielle Pousse, Robert Numerof, Darby Stephens, Wing Yen Wong, Fariba Baghela, Thynn Yee
## POSTER PRESENTATIONS

**Wednesday, July 27, 2011**

<table>
<thead>
<tr>
<th>P-WE-527</th>
<th>INHIBITORS IN SEVERE HAEMOPHILIA A INCREASE ABOVE THE AGE OF 60 YEARS BUT ARE REDUCED BY HIV: A 20 YEAR FOLLOW UP STUDY FROM UK HAEMOPHILIA CENTRE DOCTORS’ ORGANISATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Peter W Collins* (UK), Benjamin Palmer, Elizabeth Chalmers, Ri Liesner, Rhona Maclean, Savita Rajaragan, Michael Williams, Charles RM Hay</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-528</th>
<th>FACTOR VIII SUPPLEMENTATION IMPROVES HEMOPHILIA A THROMBIN GENERATION IN THE PRESENCE OF FVIII INHIBITORS AND RECOMBINANT FACTOR VIIA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Shannon L Meeks* (US), Bagirath Gangadharan, Christopher B. Doering</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-529</th>
<th>THE FREQUENCY OF INHIBITORS IN HAEMOPHILIA A PATIENTS INCREASES IN SWEDEN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frida Holmberg (SE), Pia Petrini, Rolf Ljung*</td>
</tr>
</tbody>
</table>

### Inherited coagulation disorders (except for von Willebrand disease)

<table>
<thead>
<tr>
<th>P-WE-530</th>
<th>BLEEDING RISKS ASSOCIATED WITH INHERITED PLATELET DISORDERS: RESULTS FROM A PROSPECTIVE COHORT STUDY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Menaka Pai* (CA), Grace Wang, Yang Liu, Emmy Arnold, Richard J. Cook, Kathryn E. Webert, Nancy M. Heddle, Catherine P.M. Hayward</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-531</th>
<th>A PROSPECTIVE COHORT STUDY OF BLEEDING SYMPTOMS AMONG PERSONS REFERRED TO HEMATOLOGISTS WHO ARE DIAGNOSED WITH OR EXCLUDED OF HAVING BLEEDING DISORDERS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Menaka Pai* (CA), Grace Wang, Yang Liu, Emmy Arnold, Richard J. Cook, Kathryn E. Webert, Nancy M. Heddle, Catherine P.M. Hayward</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-532</th>
<th>THE MOLECULAR MECHANISM OF THE INHERITED FACTOR XII DEFICIENCY IN TWO UNRELATED FAMILIES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Zhifang Xing* (CN)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-533</th>
<th>A RETROSPECTIVE ANALYSIS OF 157 SURGICAL PROCEDURES PERFORMED WITHOUT REPLACEMENT THERAPY IN 83 FACTOR VII-DEFICIENT PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Muriel Giansily-Blaizot* (FR), Thibaut Mura, Fatma Benlakhal, Jean-Francois Schved, F S Group</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-534</th>
<th>PHE283LEU IN F11 IS ASSOCIATED WITH VARIABILITY OF FACTOR XI CLOTTING ACTIVITY IN DEFICIENT PATIENTS.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Despoina Adamidou* (UK), Keith Gomez</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-535</th>
<th>FACTOR V DEFICIENCY DUE TO A FV P190S HOMOZYGOUS MUTATION, BUT NO BLEEDING TENDENCY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Keiko Shinozawa* (JP), Kazuhsa Maeda, Kagehiro Amano, Masahiro Abe, Hiroshi Inaba, Katsuyuki Fukutake</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-536</th>
<th>TWO NOVEL MUTATIONS IN THE PROTHROMBIN GENE IDENTIFIED IN A PATIENT WITH COMPOUND HETEROZYGOUS TYPE 1/2 PROTHROMBIN DEFICIENCY, PRESENTING WITH A UMBILICAL CORD BLEEDING</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Natasja Dors* (NL), Daan van de Kerkhof, P Reitsma, Jacqueline van Sluijs, Feiko Halbertsma, Philip Kuiper</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P-WE-537</th>
<th>TWO CASES OF FACTOR V DEFICIENCIES CAUSED BY NOVEL MUTATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sue Jung Kim* (KR), Kim Yoonjung, Song Jaewoo</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Wednesday, July 27, 2011

Acquired coagulation disorders

P-WE-538 BITES BY YOUNG BOTHROPS JARARACA SNAKES PROVOKE MORE SEVERE HEMOSTATIC DISTURBANCES THAN THOSE INFLECTED BY ADULT SNAKES
Marcelo Larami Santoro* (BR), Ida S Sano-Martins, Ceila MS Malaque, Hui W Fan

P-WE-539 VARIABLE EFFICACY OF FONDAPARINUX AND RIVAROXABAN IN THE TREATMENT OF INTRAVASCULAR COAGULOPATHY ASSOCIATED WITH LARGE CONGENITAL VENOUS MALFORMATION
Jean-Baptiste Valentin* (FR), Benedicte Delahousse, Denis Herbreteau, Ludovic Drouet, Yves Gruel

P-WE-540 EFFICACY AND SAFETY OF PROTHROMBIN COMPLEX CONCENTRATE AND VITAMIN K IN A COHORT OF 76 PATIENTS WITH ANTICOAGULATION-RELATED ACUTE INTRACRANIAL HEMORRHAGE
Berardino Pollio* (IT), Grazia Delios, Giorgia Matta, Gabriella Toroni, Marco Tucciarone, Gabriele Aitoro, Piercarla Schinco, Mauro Girotto

P-WE-541 POTENTIAL BLEEDING LESIONS IN MULTIPLE TRAUMA. A PILOT STUDY
Manuel Quintana* (ES), Milagros Marti, Sara Fabra, Isabel Casado, Inmaculada Pinilla, Ana Martinez Virto

P-WE-542 EPIDEMIOLOGY OF ALLOGENEIC BLOOD TRANSFUSION IN THE EMERGENCY ROOM: A PILOT STUDY
Manuel Quintana* (ES), Alberto Borobia, Sara Fabra, Begona Reche, N Medrano, H Tong, Ana Martinez

P-WE-543 ARE WE DOING WELL THE ALLOGENEIC BLOOD TRANSFUSION IN EMERGENCY ROOM?
Manuel Quintana* (ES), Sara Fabra, Alberto Borobia, Begona Reche, Itziar Pozuelo, Camino Guallar, Pablo Millan, Ana Martinez Virto

P-WE-544 A MAJOR HAEMORRHAGE PROTOCOL IMPROVES BLOOD PRODUCT ADMINISTRATION AND WASTAGE COMPARED TO TRADITIONAL MASSIVE TRANSFUSION PROTOCOLS
Sirat Khan* (UK), Karim Brohi, Ross Davenport, Imran Raza, Joanna Manson, Anita West, Henry De’Ath, CatherineSpoors, ShubhaAllard, Daniel Hart

P-WE-545 LYOPHILISATION PRESERVE GLOBAL HEMOSTATIC CAPACITIES OF FRENCH FREEZED DRIED PLASMA
Sophie Susen* (FR), Christophe Martinaud, Corinne Civadier, Anne Godier, Sylvain Ausset, Anne Virginie Deshayes, Anne Saillol

P-WE-546 OXIDATIVE MODIFICATION OF FIBRINOGEN DURING TRAUMATIC SHOCK: A PILOT STUDY
Nathan J White* (US), Dominic Chung, Xiaoyun Fu, Jason Newton, Kevin Ward, Jose A Lopez

P-WE-547 DILUTIONAL COAGULOPATHY FOLLOWING BLOOD TRANSFUSION IN TRAUMA
Imran Raza* (UK), Ross Davenport, Karim Brohi, Claire Rourke, Sean Platton, Sirat Khan, Henry De’Ath, CatherineSpoors, JoannaManson

P-WE-548 SERIAL CHANGES IN CLOT STABILITY FOLLOWING CARDIAC SURGERY USING TRANEXAMIC ACID
Mariann Tang* (UK), Kirsten Christiansen, Joergen Ingerslev, Jacob Greisen, Vibeke Hjortdal, Benny Soerenensen
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-549  ENHANCED THROMBIN GENERATION IN CIRRHOTICS WITH COAGULOPATHY AND VARICEAL BLEEDING
Paul Harrison* (UK), Vipul Jairath, Amber Raja, Simon Stanworth, Jane Collier, Mike Murphy, Ellie Barnes

Hemorrhagic disorders in children

P-WE-550  COMPARISON BETWEEN THROMBOELASTOGRAPHY AND CONVENTIONAL CLOTTING TESTS AFTER CARDIO-PULMONARY BYPASS SURGERY (CPB) IN A PAEDIATRIC INTENSIVE CARE UNIT
Simon J Davidson* (UK), Judith Pekelharing, Duncan Macrae, Anke Furck

P-WE-551  MILD VERSUS SEVERE HAEMOPHILIA A: THE DILEMMA OF AN UNDERESTIMATED DISEASE
Christoph Bidlingmaier* (DE), Susanne Knorr, Martin Olivieri, Karin Kurnik

P-WE-552  IDENTIFICATION OF CHILDREN WITH SIGNIFICANT EPISTAXIS: COMPARISON OF THE KATSANIS ET AL EPISTAXIS SCORING SYSTEM AND THE PEDIATRIC BLEEDING QUESTIONNAIRE EPISTAXIS SCORE
Catherine I Segbefia* (GH), Tina T Bis, Dewi S Clark, Paula D James, Victor S Blanchette, Margaret L Rand

P-WE-553  PROSPECTIVE VALIDATION OF TWO BLEEDING SCORES IN ONE HUNDRED CHILDREN INCLUDING THEIR FAMILIES
Christoph Bidlingmaier* (DE), Martin Olivieri, Ulrich Budde, Karin Kurnik

P-WE-554  BODY CONTACT IN CHILDHOOD PHYSICAL ACTIVITY: RECOMMENDATIONS FOR CHILDREN PRONE TO BLEEDING INJURIES
Leonardo Rodrigues Brandao* (CA), Patricia E Longmuir, LiAnn Yap, Carolyn Bravo, Ban Lee, Brian W McCrindle, Leonardo R Brandao

P-WE-555  RATIONALE FOR TAILORED PROPHYLAXIS WITH RECOMBINANT FVIIA IN SEVERE CONGENITAL FACTOR VII DEFICIENCY
Amir Kuperman* (IL), Tami Livnat, Andrei Braester, Nickol Amar, Gili Kenet

P-WE-556  PERIPHERALLY INSERTED CENTRAL CATHETERS (PICC) IN CHILDREN WITH INHERITED BLEEDING DISORDERS: EXPERIENCE OF A SINGLE ITALIAN COMPREHENSIVE HEMOPHILIA CENTER
Berardino Pollio* (IT), Maria Messina, Roberto Albiani, Cristina Mesiti, Mauro Pagliarino

P-WE-557  THE LUPUS ANTICOAGULANT HYPOPROTHROMBINEMIA SYNDROME (LAHPS): A RARE BLEEDING DISORDER SEEN MOSTLY IN CHILDREN.
Jonathan M Ducore* (US), Brian Gablehous, Douglas Taylor

P-WE-558  THE ROLE OF THE HEMATOLOGIST IN THE ASSESSMENT OF HEMOSTASIS IN CHILDREN WITH SUSPECTED MALTREATMENT
Lesleigh Selina Abbott* (CA), Eileen McBride, Steven Bellemare, Amy Ornstein, Colleen O’Connell, Victoria Price

P-WE-559  UTILITY OF THE PAEDIATRIC BLEEDING QUESTIONNAIRE AS A SCREENING TOOL IN CHILDREN REFERRED FOR EVALUATION OF A POSSIBLE BLEEDING DISORDER.
Jeremy David Robertson* (AU), Rebecca Mary Smith

P-WE-560  THE BLOOD COAGULATION SYSTEM IN VERY LOW BIRTH WEIGHT INFANTS WITH HEMORRHAGIC MANIFESTATIONS IN THE EARLY NEONATAL PERIOD
Leyla Alieva* (RU), Albert Antonov, Alexander Mishchenko
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-561  LOW RATE OF INHIBITORS IN PEDIATRIC COHORT OF INHERITED FACTOR DEFICIENCIES FROM 1990S TO 2010S
Phu-Quoc LE* (BE), Caroline La, Thomas Reygaerts, Anne Demulder, Lambert Leenders, Catherine Heijmans, Sophie Huybrechts, Alina Ferster

P-WE-562  ALGERIAN REGISTRY OF HEMOPHILIA : THE UPDATE STATUS
YASMINA BERKOUK-REDJIMI* (DZ), HAKIM BRAHIMI, KARIMA WAFIA CHENNOUKH, MERIEM BENMEGHERBI, MERIEM FADILA BELHANI

P-WE-563  COMBINED BLEEDING DISORDERS: EXPERIENCE AT A SINGLE HAEMOPHILIA TREATMENT CENTRE
Jayashree Motwani* (UK), Bimal DM Theophilus, Andrea M Guillatt, Michael D Williams

P-WE-564  CHALLENGES IN TREATING CHILDREN WITH SEVERE BLEEDING DISORDERS AND SEVERE AUTISM: A SINGLE CENTRE EXPERIENCE
Jayashree Motwani* (UK), Dianne Marshall, Priscilla Niatunga, Shaun Emitt, Leah Denver, Michael Williams

P-WE-565  PERIOPERATIVE POSSIBILITIES OF ROTATION THROMBELASTOMETRY METHOD TO PREDICT THE NEEDESSITY OF BLOOD PRODUCT TRANSFUSION DURING LIVER TRANSPLANTATION
Assya Georgieva Stancheva* (BG), Lubomir Dimitrov Spassov

P-WE-566  KAOLIN, USED TO TRIGGER COAGULATION IN THROMBIN GENERATION TEST, INCREASES SENSITIVITY OF THE METHOD IN HEMOPHILIA PATIENTS
Irina V Gribkova* (RU), Gennady Galstyan, Elena Sinauriadze

P-WE-567  A NOVEL QUICK POINT OF CARE TEST OF COAGULATION FACTOR XIII ACTIVITY BASED ON CLOT RETRACTION IN HUMANS
Makoto Kaneko* (JP), Nobuko Kanno, Akiko Suzuki, Ryoko Tanaka, Masayoshi Souri, Yutaka Yatomi, Akitada Ichinose

P-WE-568  REPLICATION STUDY OF PRIOR GWAS CANDIDATE GENES/LOCI FOR CORONARY ARTERY DISEASES IN THE GENETIC ISOLATED NEWFOUNDLAND AND LABRADOR POPULATION
Ya-Gang Xie* (CA), Jianxun Cui, Edward Randell, James Renouf, Shuo Li, Angela Pope, Guang Sun, Wayne Gulliver, Bruce Sussex, Fei-Yu Han

P-WE-569  ANALYSIS OF FLAER BINDING WITH WBC BY FLOW CYTOMETRY
Mingqing Zhu* (CN), Wenhong Shen, Li Chen, Lan Dai, Changpeng Ruan

P-WE-570  ELEVATED INTERLEUKIN-27 ENHANCES TH1 CELL POLARIZATION AND THE PRODUCTION OF PROINFLAMMATORY CYTOKINES IN IMMUNE THROMBOCYTOPENIC PURPURA
Huiyuans Li* (CN), Donglei Zhang, Jianping Li, Renchi Yang

P-WE-571  ROTATION THROMBOELASTOMETRY FOR A RAPID ASSESSMENT OF PLASMA FIBRINOGEN DURING CARDIOPULMONARY BYPASS SURGERY
Satoru Ogawa* (US), Fania Szlam, Jerrold H Levy, Kenichi A Tanaka

P-WE-572  THROMBOELASTGRAPHIC CHANGES IN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS
Amir Kuperman* (IL), Andrei Braester, Kamal Hassan
**POSTER PRESENTATIONS**

**Wednesday, July 27, 2011**

**P-WE-573** ASSESSMENT OF THROMBIN GENERATION IN THE PRESENCE OF PLATELET PRE- AND POST CARDIAC SURGERY AND ITS RELATION WITH BLEEDING POST-OPERATIVELY
Raed Al Dieri* (NL), Yvonne Bosch, Hugo Ten Cate, Bas Mochtar, H Coen Hemker

**P-WE-574** PREDICTION OF BLEEDING TENDENCIES IN HEMOPHILIA A PATIENTS ON PROPHYLACTIC TREATMENT USING A NOVEL REACTION-DIFFUSION ASSAY OF HEMOSTASIS
Anna N Balandina* (RU), Mariya A Kumskova, Konstantin G Kopylov, Sergey S Karamzin, Olga A Fadeeva, Mikhail A Panteleev, Yuri V Zorenko, Olga P Plyushch, Fazoi I Alaulikhanov

**Atherothrombosis**

**P-WE-576** INDUCTION OF CYTOKINE EXPRESSION IN NKT CELLS BY S1P: IMPLICATIONS FOR INSULIN RESISTANCE AND Atherothrombosis
Shiori Ito* (JP), Keiko Koike, Soichiro Iwaki, Kazuya Iwabuchi, Ryunosuke Ohkawa, Yutaka Yatomi, Satoshi Fuji

**P-WE-577** BMP-2 INHIBITS TF EXPRESSION IN ACTIVATED HUMAN MONONUCLEAR CELLS VIA DOWNREGULATION OF ERK1/2 AND P38, BUT NOT JNK SIGNALING PATHWAYS
Mikhail Sovershaev (NO), Timofey Sovershaev, Elena Egorina, John-Bjarne Hansen*

**P-WE-578** INCREASED EXPRESSION OF TF IN BMP-7-TREATED HUMAN MONONUCLEAR CELLS DEPENDS ON ACTIVATION OF P38 AND ERK1/2 SIGNALING PATHWAYS
Elena Egorina* (NO), Timofey Sovershaev, Birgit Svensson, Mikhail Sovershaev, John-Bjarne Hansen

**P-WE-579** BMP-7-INDUCED TF EXPRESSION IN HUMAN MONONUCLEAR CELLS IS ASSOCIATED WITH INCREASED NF-KB, BUT NOT AP-1 TRANSCRIPTIONAL ACTIVITY
Mikhail Sovershaev (NO), Elena Egorina, Timofey Sovershaev, John-Bjarne Hansen*

**P-WE-580** RELATIONSHIP BETWEEN OXIDATIVE STRESS, ENDOTHELIAL INJURY AND COAGULATION ACTIVATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Oleksii M. Korzh* (UA), Sergiy Krasnokutskyi, Elizaveta Lavrova

**P-WE-581** HUMAN C-REACTIVE PROTEIN ENHANCES THROMBUS FORMATION AFTER NEOINTIMAL BALLOON INJURY IN TRANSGENIC RABBITS

**P-WE-582** EVEN MILD HYPERGLYCEMIA DISTURBS VASCULAR HOMEOSTASIS IN HUMANS
Bregtje Annelieke Lemkes* (NL), Sarah E. Siegelaar, Max Nieuwdorp, Wim Kulik, Joost B.L. Hoekstra, Joost C.M. Meijers, Frits Holieman

**P-WE-583** VASCULAR ENDOTHELIAL ENDOTHELIAL GROWTH FACTOR AS THROMBOSIS RISK MARKER IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA PATIENTS
Sry Suryani Widjaja* (ID), Stephen L KOH, Karmel Tambunan, Evelyn Koay

**P-WE-584** CD39 GENE-ELUTING STENT PREVENTS SUBACUTE IN-STEM THROMBOSIS IN INJURED ARTERY
Hiroyuki Kawata* (JP), Yasuhiro Takemoto, Soeda Tsunenari, Ji-Hee Sung, Masanori Matsumoto, Yoshihiro Fujimura, Yasuhiko Tabata, Yoshihiko Saito
POSTER PRESENTATIONS

Wednesday, July 27, 2011

Endothelial cells

P-WE-585  THROMBOMODULIN PROMOTES CELL MIGRATION THROUGH INTEGRATED PLASMINOGEN ACTIVATION SYSTEM ON CELL SURFACE
Po-Ku Chen* (TW), Bi-Ing Chang, Guey-Yueh Shi, Hua-Lin Wu

P-WE-586  THE ENDOTHELIAL P2Y1 RECEPTOR PLAYS A ROLE IN TNFα-INDUCED RECRUITMENT OF LEUKOCYTES TO HUMAN CORONARY ARTERY ENDOTHELIAL CELLS UNDER FLOW CONDITIONS
Murielle Zerr* (FR), Beatrice Hechler, Jean-Pierre Cazenave, Pierre Mangin, Christian Gachet

P-WE-587  AUTOCRINE EFFECTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR-D (VEGF-D) ON ENDOTHELIAL CELLS AFTER TRANSDUCTION WITH ADENOVIRUS VECTOR (AD-VEGF-DANAC)
Izabela J Papiewska-Pajak* (PL), Wiktor Koziolekiewicz, Anna Kozaczuk, Joanna Boncela, Emilia Stec-Martyna, Czeslaw Cierniewski

P-WE-588  RENAL AND URINARY LEVELS OF EPCR CORRELATE WITH ACUTE RENAL ALLOGRAFT REJECTION
Lionel Lattenist* (NL), Jesper Kers, Ineke J ten Berge, Sandrine Florquin, Joris J Roelofs

P-WE-589  E-SELECTIN, L-SELECTIN AND COAGULATION ACTIVATION IN MYELOID LEUKEMIA PATIENTS WITH LEUKOCYTOSIS
Lugyanti - Sukrisman* (ID), Karmel Lidow Tambunan

P-WE-590  ENDOTHELIAL MICROPARTICLES AS MARKERS FOR ENDOTHELIAL DYSFUNCTION: DO PLASMA LIPIDS INTERFERE?
Sabrina van Ierssel* (BE), Vicky Y Hjmans, Emeline M Van Craenenbroeck, Viggo F Van Tendeloo, Viviane M Conraads, Philippe G Jorens

P-WE-591  PORCINE ENDOTHELIAL CELLS TRANSGENIC FOR HUMAN ENDOTHELIAL PROTEIN C RECEPTOR AND/OR THROMBOMODULIN GENERATE DIFFERENT LEVELS OF HUMAN ACTIVATED PROTEIN C
Cristiana Bulato* (IT), Claudia Maria Radu, Sabrina Gavasso, Luca Spiezia, Cesare Galli, Emanuele Cozzi, Paolo Simioni

P-WE-592  ENDOTHELIAL PROTEIN C RECEPTOR PLAYS AN IMPORTANT ROLE IN PROTEIN C ACTIVATION BY ENDOTHELIAL CELLS IN XENOGRAFTS
Claudia Maria Radu* (IT), Cristiana Bulato, Sabrina Gavasso, Luca Spiezia, Cesare Galli, Emanuele Cozzi, Paolo Simioni

P-WE-593  PROTECTIVE EFFECT OF DEFIBRATIDE ON ACTIVATED ENDOTHELUM: MECHANISM FOR PREVENTION OF ACUTE GVHD
Simona Somaini* (IT), Maria Distaso, Jawed Fareed, Debra Hoppensteadt, Massimo Iacobelli, Cinara Echart

P-WE-594  RAB27A IS NOT A NEGATIVE REGULATOR OF WPB EXOCYTOSIS IN POST-CONFLUENT CULTURED ENDOTHELIAL CELLS
Ruben Bierings* (UK), Robert Rowlands, Nicola Hellen, Bijal Patel, Laura Knipe, Lindsay Hewlett, Tom Carter, Matthew Hannah
POSTER PRESENTATIONS

Wednesday, July 27, 2011

Smooth muscle cells

P-WE-595  SILENCING OF THE F11R GENE REVEALS A ROLE FOR F11R/JAM-A IN THE MIGRATION OF INFLAMED VASCULAR SMOOTH MUSCLE CELLS IN ATHEROSCLEROSIS
Bani Mekisha Azari* (US), Jonathan D. Marmur, Moro O. Salifu, Yigal H. Ehrlich, Elizabeth Kornecki, Anna Babinska

P-WE-596  ADMISSION LEVEL OF PREGNANCY-ASSOCIATED PLASMA PROTEIN A PREDICTS LONG TERM MORTALITY WITHIN SEVEN YEARS FOLLOW UP IN PATIENTS ADMITTED WITH SUSPECTED ACUTE CORONARY SYNDROME
Volker Poenitz* (NO), Trygve Bruegger-Andersen, Heidi Grundt, Oistein Mjelva, Harry Staines, Dennis Winston Trygve Nilsen

P-WE-597  BUTEIN INHIBITS PDGF-INDUCED RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY
Yen-Nien Chen* (TW), Tur-Fu Huang, Ching-Hu Chung

Hemodynamics and shear stress

P-WE-598  CORONARY MICROVASCULAR DYSFUNCTION DUE TO ESSENTIAL THROMBOCYTHEMIA AND POLICYTHEMIA VERA: THE MISSING PIECE OF THE PUZZLE OF THEIR INCREASED CARDIOVASCULAR RISK?
Giuseppe Cella* (IT), Francesco Tona, Giulia Famoso, Andrea Ballin, Elena Osto, Sabino Iliceto, Grazia Faggionato

P-WE-599  VOLUME REPLACEMENT RESUSCITATES IN HEATSTROKE RATS BY RESTORING HOMEOSTATIC FUNCTION AND REDUCING VITAL ORGANS DAMAGE
Kuen-Bor Chen* (TW), Mei-Fen Shih, Wu-Tien Huang, Hsin-Mao Tsai, Tsai-Hsiu Yang, Chia-Chyuan Liu

P-WE-600  RHEOLOGICAL AND MICROSTRUCTURAL STUDIES OF INCIPIENT CLOTS FORMED UNDER “IN-VIVO” CONDITIONS
Karl Hawkins* (UK), Matthew Lawrence, Rhodri Williams, Ahmed Sowedan, Nafiseh Badiei, Adrian Evans

Genomics and proteomics

P-WE-601  PROTEINCHIP ARRAY PROFILING OF MOLECULAR VARIANTS OF HIRUDINS USING SURFACE ENHANCED LASER DESORPTION IONIZATION (SELDI) TECHNIQUE.
Vijaya Paramatamuni* (US), Rahul Brijlane, Evangelos Litis, Nasir Saddeghi, Walter Jeske, Debra Hoppensfeadit, Jawed Fareed

P-WE-602  TOWARDS PLATELET-SPECIFIC RNA INTERFERENCE
Tim Thijs* (BE), Katleen Broors, Isabelle I Salles, Stefaan Soenen, Aline Vandenbulcke, Jose A Lopez, Karen Vanhoorelbeke, Hans Deckmyr

P-WE-603  DOES ABO BLOOD GROUP INCREASE THE RATE OF RECURRENT EVENTS AFTER INITIAL TREATMENT FOR A FIRST UNPROVOKED VENOUS THROMBOEMBOLISM (VTE) EVENT? REVERSE COHORT SUBGROUP ANALYSIS
Esteban Gandara* (CA), Michael J. Kovacs, Susan Kahn, Phil Wells, David A. Anderson, Susan Solymoss, Gregoire Le Gal, Isabelle Chagnon, Mark A. Crowther, Nicole Langlois, Arnaud Perrier, Richard A. White, Marc Carrier, Nancy Carson, Julian Little, Tim Ramsay, Marc A Rodger
POSTER PRESENTATIONS

Wednesday, July 27, 2011

P-WE-604  MULTIPLEXED NEXT-GENERATION DNA SEQUENCING OF THE HEMOSTATIC EXOME IN DEEP VEIN THROMBOSIS

P-WE-605  A CUSTOM TILING EXPRESSION MICROARRAY AS A NOVEL APPROACH TO STUDY A CORONARY ARTERY DISEASE GENETIC RISK LOCUS
Fiona R Green* (UK), Lesley D Beeton, Prillilata Chivers, Theodosios Kyriakou, Anuj Goel, John Peden
Scientific Program
Thursday, July 28, 2011
**Thursday, July 28, 2011**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:45-10:30</td>
<td>Plenary Lecture</td>
<td>Main Hall</td>
</tr>
<tr>
<td><strong>Kenneth M. Brinkhous Memorial Lecture</strong></td>
<td>Molecular mechanism of inside-out integrin regulation</td>
<td>PL-TH-001</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Michael Berndt (IE) and Yoshiaki Tomiyama (JP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mark H. Ginsberg (US), Feng Ye, Chungho Kim</td>
<td>09:45 – 10:30</td>
</tr>
<tr>
<td>13:30-14:15</td>
<td>Plenary Lecture</td>
<td>Main Hall</td>
</tr>
<tr>
<td><strong>Wright-Schulte Memorial Lecture</strong></td>
<td>Serpin structure, function and dysfunction</td>
<td>PL-TH-002</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Pieter H. Reitsma (NL) and Takehiko Koide (JP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>James A. Huntington (UK)</td>
<td>13:30 – 14:15</td>
</tr>
<tr>
<td>11:00-12:00</td>
<td>State-of-the-Art Lecture</td>
<td>Main Hall</td>
</tr>
<tr>
<td><strong>Hemophilia</strong></td>
<td>Immune tolerance induction in hemophilia: Evidence and the way forward</td>
<td>SA-TH-001</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: David Lillicrap (CA) and Katsuyuki Fukutake (JP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Donna Marie DiMichele (US)</td>
<td>11:00 – 11:30</td>
</tr>
<tr>
<td></td>
<td>Management of acquired haemophilia a</td>
<td>SA-TH-002</td>
</tr>
<tr>
<td></td>
<td>Peter W. Collins (UK)</td>
<td>11:30 – 12:00</td>
</tr>
<tr>
<td></td>
<td><strong>Platelet and Vascular Wall</strong></td>
<td>Annex Hall 1</td>
</tr>
<tr>
<td></td>
<td><strong>Discovery of the cardiovascular system: From galen to william harvey</strong></td>
<td>SA-TH-003</td>
</tr>
<tr>
<td></td>
<td>Chairpersons: Gerhard Johnson (US) and Ryozo Nagai (JP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>William C. Aird (US)</td>
<td>11:00 – 11:30</td>
</tr>
<tr>
<td></td>
<td><strong>How platelets safeguard vascular integrity</strong></td>
<td>SA-TH-004</td>
</tr>
<tr>
<td></td>
<td>Denisa D. Wagner (US)</td>
<td>11:30 – 12:00</td>
</tr>
</tbody>
</table>
Thursday, July 28, 2011

Coagulation Activation

Chairpersons: Ton Lisman (NL) and Takashi Morita (JP)

Toxins in thrombosis and hemostasis: Potential beyond imagination

Manjunatha R. Kini (SG)

SA-TH-005
11:00 – 11:30

Nanoscale studies of protein-membrane interactions in blood clotting

James H. Morrissey (US), E. Tajkhorshid, C.M. Rienstra

SA-TH-006
11:30 – 12:00

Congenital and Acquired Thrombotic Disorders

Chairpersons: Bernhard Lämmle (CH) and Seonyang Park (KR)

Molecular pathophysiology of the antiphospholipid syndrome: The role of oxidative posttranslational modification of beta 2 glycoprotein I

Steven Krilis (AU), Freda Passam, Bill Giannakopoulos, Peyman Mirarabshahi

SA-TH-007
11:00 – 11:30

Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan

Yoshihiro Fujimura (JP), Masanori Matsumoto, Ayami Isonishi, Hideo Yagi, Koichi Kokame, Kenji Soejima, Mitsuru Murata, Toshiyuki Miyata

SA-TH-008
11:30 – 12:00

Symposia

8:00-9:30

Thrombotic Disorders

Pathogenesis, Diagnosis and Treatment of Septic DIC

Chairpersons: Hidesaku Asakura (JP), Doyeun Oh (KR)

Pathogenesis, diagnosis and treatment of septic DIC

William K. Hoots (US)

SY-TH-001
08:00 – 08:30

New approach to diagnosing DIC

Cheng-Hock Toh (UK)

SY-TH-002
08:30 – 09:00

New strategy for treatment of septic DIC

Satoshi Gando (JP)

SY-TH-003
09:00 – 09:30
Thursday, July 28, 2011

**Platelet (Basic and Clinical) Annex Hall 1**

**Mechanisms of Platelet Adhesive Function**
*Chairpersons: Edward F. Plow (US) and Makoto Handa (JP)*

- **Integrin cytoskeletal interactions**
  *David A. Calderwood (US)*
  08:00 – 08:30

- **STIM1 and Orai in calcium-dependent platelet activation and thrombosis**
  *Wolfgang Bergmeier (US)*
  08:30 – 09:00

- **Genetic analysis of integrin signaling in mice**
  *Markus Moser (DE)*
  09:00 – 09:30

**Coagulation Factors and Inhibitors Annex Hall 2**

**Structural Biology in Thrombosis**
*Chairpersons: Soichi Takeda (JP) and Philip Hogg (AU)*

- **Structural basis for ADAMTS13 function**
  *Masashi Akiyama (JP), Daisuke Nakayama, Soichi Takeda, Toshiyuki Miyata*
  08:00 – 08:30

- **Crystal structure and function of VKOR and its redox partner**
  *Weikai Li (US), Li Weikai, Sol Schulman, Tom Rapoport, Jon Beckwith, Dana Boyd, Melinda Wang, Rachel Dutton*
  08:30 – 09:00

- **Structural origins of clot and thrombus mechanical properties**
  *John W. Weisel (US)*
  09:00 – 09:30

**Symposia 14:30-16:00**

**VWF/VWD and ADAMTS13 Main Hall**

**Function and Dysfunction of von Willebrand Factor**
*Chairpersons: Ian R. Peake (UK) and Augusto B. Federici (IT)*

- **von Willebrand factor and α-thrombin at the cross-road of hemostasis and thrombosis**
  *Zaverio M. Ruggeri (US)*
  14:30 – 15:00
### Thursday, July 28, 2011

#### Genetic basis of type 1 von Willebrand disease

*Ian R. Peake (UK)*

**SY-TH-011**

15:00 – 15:30

#### Functional analysis of von willebrand factor (VWF) using VWF knockout mice

*Cecile V. Denis (FR)*

**SY-TH-012**

15:30 – 16:00

---

### Hemorrhagic Disorders

**Annex Hall 1**

#### Molecular Mechanisms of Coagulation Disorders

*Chairpersons: Hugo Ten Cate (NL) and Tetsuhito Kojima (JP)*

- **Genetic mechanisms of the royal disease**
  
  *Evgeny I. Rogaev (US)*
  
  **SY-TH-013**
  
  14:30 – 15:00

- **Molecular mechanisms of factor VII deficiency and variants**
  
  *Mirko Pinotti (IT), Francesco Bernardi*
  
  **SY-TH-014**
  
  15:00 – 15:30

- **Diverse molecular mechanisms of congenital and acquired factor XIII/13 deficiency and its newly proposed biological functions**
  
  *Akitada Ichinose (JP)*
  
  **SY-TH-015**
  
  15:30 – 16:00

---

### Vascular Biology

**Annex Hall 2**

#### Angiogenesis and Vasculogenesis

*Chairpersons: Toshio Suda (JP) and William C. Aird (US)*

- **The ins and outs of VEGF signaling**
  
  *Luisa Iruela-Arispe (US)*
  
  **SY-TH-016**
  
  14:30 – 15:00

- **Control of angiogenesis and vascular homeostasis through the angiopoietin/tie system**
  
  *Hellmut G. Augustin (DE)*
  
  **SY-TH-017**
  
  15:00 – 15:30

- **Regulation of TGF-beta signaling and vascular diseases**
  
  *Kohei Miyazono (JP)*
  
  **SY-TH-018**
  
  15:30 – 16:00
Symposia 16:15-17:45

**Coagulation Factors and Inhibitors** Main Hall

**Protein C System**
*Chairpersons: Tilman Hackeng (NL) and Yongqiang Zhao (CN)*

**Reevaluation of the role of HDL in the anticoagulant protein C system**
*SY-TH-019*
*16:15 – 16:45*
*Björn Dahlbäck (SE)*

**Protein S deficient mice**
*SY-TH-020*
*16:45 – 17:15*
*Anne Angelillo-Scherrer (CH), Francois Saller, Sara Calzavarini*

**Therapeutic efficacy of activated protein C in murine endotoxemia**
*SY-TH-021*
*17:15 – 17:45*
*Hartmut Weiler (US), Edward Kerschen, Irene Hernandez, John H. Griffin, Jose A. Fernandez*

**Fibrinolysis and Proteolysis** Annex Hall 1

**Plasminogen Activation and Its Modulation**
*Chairpersons: Nuala Booth (UK) and Tetsumei Urano (JP)*

**Plasminogen receptors and their regulation on macrophages**
*SY-TH-022*
*16:15 – 16:45*
*Edward F. Plow (US), Riku Das*

**Unique secretory mechanism of t-PA and the expression of fibrinolytic activity on vascular endothelial cells**
*SY-TH-023*
*16:45 – 17:15*
*Yuko Suzuki (JP), Tetsumei Urano*

**Targeting TAFI/TAFIa through different pathways: In vitro and in vivo evaluation**
*SY-TH-024*
*17:15 – 17:45*
*Paul J. Declerck (BE), Ann Gils*

**Late Breaking Clinical Research** Annex Hall 2

**Late Breaking Clinical Research**
*Chairpersons: Yasuo Ikeda (JP) and Sam Schulman (CA)*

**Sixty-eight genetic loci uncover new gene functions in hematopoiesis and platelet formation**
*SY-TH-025*
*16:15 – 16:45*
*Willem Hendrik Ouwehand (UK), Christian Gieger, Nicole Soranzo*
High residual platelet reactivity assessed with specific and global tests in the ADRIE study: Comparative predictive values for the recurrence of ischemic events

Jean-Luc Reny (CH), Philippe Berdague, Christophe Combescure, Severine Nolli, Isabelle Barazer, Pascale Fabbro-Peray, Jean-Francois Schved, Henri Bounaumeaux, Francois Mach, Philippe de Moerloose, Pierre Fontana

16:45 – 17:15

First results of the phase II TITAN trial: Anti-von willebrand factor nanobody as adjunctive treatment for patients with acquired thrombotic thrombocytopenic purpura

Flora Peyvandi (IT), Dimitri A. Breems, Paul Kncebl, Caroline De Man, Ka Lung Wu, Christophe Lyssens, Josefin-Beate Holz

17:15 – 17:45
<table>
<thead>
<tr>
<th>ORAL COMMUNICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thursday, July 28, 2011</strong></td>
</tr>
<tr>
<td><strong>Inherited Platelet Disorders</strong></td>
</tr>
<tr>
<td><strong>Room C-1</strong></td>
</tr>
<tr>
<td><strong>Chairpersons:</strong> Catherine Hayward (CA) and</td>
</tr>
<tr>
<td><strong>O-TH-001</strong> 08:00 - 08:15</td>
</tr>
<tr>
<td><strong>MEGAKARYOCYTE AND PLATELET ABNORMALITIES RESULTING FROM CONGENITAL DEFECTS IN FILAMIN A</strong> <strong>DELINEATE A NOVEL PHENOTYPE OF CONGENITAL THROMBOCYTOPENIA</strong></td>
</tr>
<tr>
<td>Paquita Nurden* (FR), Najet Debili, Manjke Bryckaert, Ibtissam Youlyyouz-Marfak, Isabelle Coupry, Caroline Rooryck, Jean-Marie Daniel Lamaziere, Anne-Cécile Pons, Chloe James, Alan Nurden, Cyril Goizet</td>
</tr>
<tr>
<td><strong>O-TH-002</strong> 08:15 - 08:30</td>
</tr>
<tr>
<td><strong>THE FRENCH MYH9 SYNDROME COHORT: PHENOTYPE, GENOTYPE AND EPIDEMIOLOGICAL ASPECTS. ON BEHALF OF THE NATIONAL FRENCH REFERENCE CENTER ON INHERITED PLATELET DISORDERS (CRRP).</strong></td>
</tr>
<tr>
<td>Nicole Schlegel* (FR), Beatrice Saposnik, Sylvie Binard, Odile Fenneteau, Alan Nurden, Paquita Nurden, Nicole Schlegel</td>
</tr>
<tr>
<td><strong>O-TH-003</strong> 08:30 - 08:45</td>
</tr>
<tr>
<td><strong>TWO NEW MUTATIONS IN THE LYST/CHS1 GENE IN PATIENTS WITH CHEDIAK-HIGASHI SYNDROME. FIRST CASE OF A MISSENSE MUTATION IN A CASE OF SEVERE CHILDHOOD CHEDIAK-HIGASHI</strong></td>
</tr>
<tr>
<td>Ana I Anton* (ES), I Sanchez-Guiu, J Navarro-Fernandez, JL Fuster, JM Couselo, C Martinez, V Vicente, J Rivera, ML Lozano</td>
</tr>
<tr>
<td><strong>O-TH-004</strong> 08:45 - 09:00</td>
</tr>
<tr>
<td><strong>A NEW Mutation IN THE FERMT3 Gene CAUSES THE ABSENCE OF KINDLIN-3 IN PLATELETS AND LEUKOCYTES: CONSEQUENCES ON INTEGRIN DEPENDENT AND INDEPENDENT ADHESION.</strong></td>
</tr>
<tr>
<td>Matthias Canault* (FR), Philippe Robert, Charlotte Grosidier, Catherine Farmarier, Nurden T Alan, Vincent Barlogis, Pierre Bongrand, Anne Pierres, Herve Chambost, Marie-Christine Alessi</td>
</tr>
<tr>
<td><strong>O-TH-005</strong> 09:00 - 09:15</td>
</tr>
<tr>
<td><strong>COMMON SIGNALING PATHWAYS INVOLVING PI3K BETA IN THE REGULATION OF PLATELET INHIBITION VIA GS IN SUBJECTS WITH NORMAL OR ALTERED GS FUNCTION</strong></td>
</tr>
<tr>
<td>Frauke Swieringa* (NL), Marion A.H. Feijje, Yvonne M.C. Henskens, Connie T Schrander-Stumpel, Estela Rubio-Gozalbo, Paola E Van der Meijden, Irene M.L.W. Keularts, Johan W.M. Heemskerk</td>
</tr>
<tr>
<td><strong>O-TH-006</strong> 09:15 - 09:30</td>
</tr>
<tr>
<td><strong>ROLE OF TMEM16F IN AGONIST-INDUCED BUT NOT APOPTOSIS-INDUCED PHOSPHATIDYLSERINE EXPOSURE IN SCOTT PLATELETS</strong></td>
</tr>
<tr>
<td>Roger van Kruchten* (NL), Roger van Kruchten, Jef L. N. Wolfs, Marion A. H. Feijje, Nadine J. A. Mattheij, Peter Collins, Johan W. M. Heemskerk, Edouard M. Bevers</td>
</tr>
</tbody>
</table>
## ORAL COMMUNICATIONS

**Thursday, July 28, 2011**

### Serine Protease Inhibitors II

**Chairpersons:** Margarethe Geiger (AT) and Masayoshi Souri (JP)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-TH-007</td>
<td>PROTEIN Z-DEPENDENT PROTEASE INHIBITOR AND PROTEIN Z INCREASE IN NORMAL PREGNANCIES BUT NOT IN PATIENTS WITH UNEXPLAINED RECURRENT MISCARRIAGE</td>
<td>Mayumi Sugiura-Ogasawara* (JP), Masayoshi Souri, Shigeru Saito, Betina Kemkes-Matthes, Joost C.M. Meijers, Akitada Ichinose</td>
</tr>
<tr>
<td>O-TH-008</td>
<td>DISCREPANCY IN RESULTS OF ANTITHROMBIN ACTIVITY USING FIVE DIFFERENT COMMERCIALLY AVAILABLE METHODS - CLINICAL IMPLICATIONS IN DETECTING AT DEFICIENCY</td>
<td>Marja Kaarina Puurunen* (FI), Sari Engelbarth, Kaja Javele</td>
</tr>
<tr>
<td>O-TH-009</td>
<td>HOW CONTROL OF THROMBIN BY SERPINS IN VERTEBRATES AROSE</td>
<td>Hermann Ragg* (DE), Yunjie Wang</td>
</tr>
<tr>
<td>O-TH-010</td>
<td>STABLE OVEREXPRESSION OF TFPI IN BREAST CANCER CELLS CHANGES THE EXPRESSION OF MRNAS AND MICRORNAS INVOLVED IN IMMUNE RESPONSE AND CANCER DEVELOPMENT</td>
<td>Benedicte Stavik* (NO), Grethe Skretting, Marit Sletten, Christi Olstad, Per Morten Sandset, Nina Iversen</td>
</tr>
<tr>
<td>O-TH-011</td>
<td>RETENTION OF THROMBIN INHIBITORY ACTIVITY BY RECOMBINANT SERPINS EXPRESSED AS INTEGRAL MEMBRANE PROTEINS TETHERED TO THE SURFACE OF MAMMALIAN CELLS</td>
<td>William P Sheffield* (CA), Richard F Gierczak, Jason S Sutherland, Varsha Bhakta, Lisa J Tolll, Patricia Ci Liaw</td>
</tr>
</tbody>
</table>

### Coagulation Factors I

**Chairpersons:** and Jun Mizuguchi (JP)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-TH-013</td>
<td>HYPERGLYCOSYLATED FACTOR IX VARIANTS WITH IMPROVED PHARMACOKINETIC PROPERTIES IN ANIMALS</td>
<td>Alan Brooks* (US), Chandra Patel, Xiaqiao Jiang, Eric Blasko, Liang Tang, Derek S. Sim, Rick Feldman, Xia-Yan Zhao, Uwe Gritzan, Ulrich Haupts, Heiner Apeler, Jesper Haaning, John E. Murphy</td>
</tr>
<tr>
<td>O-TH-014</td>
<td>BAY86-6150, A NOVEL RECOMBINANT FACTOR VIIA VARIANT, HAS A HIGHER THERAPEUTIC INDEX THAN WILDTYPE RFVIIA IN MURINE HEMOPHILIA A THROMBOSIS AND BLEEDING MODELS</td>
<td>Derek S. Sim* (US), Cornell Mallari, Perry Liu, Cristina Loomis, Maria Koellinberger, John E. Murphy, Jesper Haaning</td>
</tr>
</tbody>
</table>
### ORAL COMMUNICATIONS

**Thursday, July 28, 2011**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-TH-015</td>
<td>PEGYLATION OF FVIII RESULTS IN REDUCED UPTAKE BY HUMAN DENDRITIC CELLS AND A SIGNIFICANT REDUCTION IN HUMAN FVIII-SPECIFIC T-CELL RESPONSE IN VITRO</td>
<td>John E. Murphy* (US), Xie Jinger, Pedro Paz, Marc Jacquemin, Renaud Lavendhomme, Jesper Haaning, Fred Aswad</td>
</tr>
<tr>
<td>O-TH-017</td>
<td>EFFECT OF THE EXTRACELLULAR RNA IN THE ANTICOAGULANT FUNCTION OF ANTITHROMBIN</td>
<td>Jose Navarro-Fernandez* (ES), Irene Martinez-Martinez, Horacio Perez-Sanchez, Antonia Minano, Nataliya Bohdan, Maria Eugenia de la Morena-Barrio, Sonia Aguila, Vicente Vicente, Javier Corral</td>
</tr>
<tr>
<td>O-TH-018</td>
<td>RESVERATROL, A PHYTOESTROGEN FOUND IN RED WINE, DOWN-REGULATES PROTEIN S EXPRESSION IN HEPG2 CELLS</td>
<td>Hiroko Tsuda* (JP), Yoshie Hiroto, Kana Tedokoro, Tomohide Tsuda, Eri Nakazono, Keizo Ohnaka, Ryoichi Takayanagi, Naotaka Hamasaki</td>
</tr>
</tbody>
</table>

**Platelets as Drug Targets**

Room E

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-TH-019</td>
<td>STORE-OPERATED CALCIUM ENTRY AS A POTENTIAL TARGET TO SUPPRESS ARTERIAL THROMBUS FORMATION</td>
<td>Roger van Kruchten* (NL), Attila Braun, Marion A. H. Feige, David E. Schmidt, Peter Kraft, Guido Stoll, Marijke J. E. Kuipers, Edouard M. Bevers, Bernhard Nieswandt, Johan W. M. Heemskerk</td>
</tr>
<tr>
<td>O-TH-020</td>
<td>A SMALL MOLECULE INHIBITOR OF PROTEIN DISULFIDE ISOMERASE INHIBITS THROMBUS FORMATION IN A MOUSE LASER-INDUCED THROMBOSIS MODEL</td>
<td>Reema Jaasuja* (US), Freda Passam, Daniel Kennedy, Sarah Kim, James R Dilks, Bruce Furie, Barbara C Furie, R Flaumenhaft</td>
</tr>
<tr>
<td>O-TH-021</td>
<td>DIANNEXIN, A HOMODIMER OF ANNEXIN A5 (A5), BINDS PHOSPHATIDYLSERINE (PS) WITH HIGH AFFINITY AND IS A POTENT INHIBITOR OF ARTERIAL THROMBOSIS IN MICE</td>
<td>Margaret L Rand* (CA), Alan Stafford, Ran Ni, Hong Wang, Anthony C Allison, Jeffrey I Weitz, Peter L Gross</td>
</tr>
<tr>
<td>O-TH-022</td>
<td>ADENOSINE DERIVED FROM ADP CAN CONTRIBUTE TO INHIBITION OF PLATELET AGGREGATION IN THE PRESENCE OF A P2Y12 ANTAGONIST</td>
<td>Jacqueline Glenn* (UK), David Espinosa Iyu, Ann White, Susan Fox, Stan Heptinstall</td>
</tr>
</tbody>
</table>
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-023  09:00 - 09:15
INTERACTION BETWEEN IMPAIRED THROMBIN GENERATION AND IMPAIRED THROMBIN-INDUCED PLATELET ACTIVATION IN MOUSE MODELS OF HEMOSTASIS AND THROMBOSIS.
Tovo David* (US), Cherry L Concengo, Daniel Ha, Ivo Cornelissen, Shaun R Coughlin

O-TH-024  09:15 - 09:30
DEVELOPMENT OF ANTITHROMBOTIC ALLOSTERIC MODULATORS OF PAR1
Louisa Dowal* (US), Derek Sim, James Dilks, Lynn VerPlank, Price Blair, Sarah Beaudry, Bradley Denker, Georgios Koukos, Athan Kuliopulos, Daniel Smith, Albert Mairuhu, Joseph Negri, Chris Dockendorff, Lawrence MacPherson, Michelle Palmer, Stuart Scheiber, Robert Flaumenhaft

Hemophilia: Pathophysiology

Chairpersons: Aida Inbal (IL) and Kathleen P (US)

O-TH-025  08:00 - 08:15
UP-REGULATION OF PLATELET ACTIVATION IN HEMOPHILIA A
Esther Ruth van Bladel* (NL), Mark Roest, Philip G. de Groot, Roger E.G. Schutgens

O-TH-026  08:15 - 08:30
HEME REDUCES PRO-COAGULANT ACTIVITY OF FACTOR VIII
Jordan D Dimitrov* (FR), Yohann Repesse, Ivan Peyron, Elika Farrokhi Moshai, Laurent Kiger, Michael C Marden, Srinivas V Kaveri, Sebastien Lacroix-Desmazes

O-TH-027  08:30 - 08:45
USE OF A CALIBRATED AUTOMATED THROMBIN GENERATION ASSAY TO QUANTIFY ACCURATELY FACTOR VIII LEVELS IN SEVERE AND MODERATE HAEMOPHILIA A
Marisa Ninivaggi* (NL), Yesim Dargaud, Coenraad H. Hemker, Theo Lindhout

O-TH-028  08:45 - 09:00
HEPATIC CLEARANCE OF B-DOMAINLESS FACTOR VIII DOES NOT REQUIRE ITS PRIOR ACTIVATION TO FACTOR VIIIA
Dudley Strickland* (US), Mary Migliorini, Ernest T Parker, Pete Lollar

O-TH-029  09:00 - 09:15
UPTAKE OF BLOOD COAGULATION FACTOR VIII BY DENDRITIC CELLS IS MEDIATED VIA ITS C1 DOMAIN
Eszter Herczenik* (NL), Simon D. van Haren, Aleksandra Wroblewska, Alexander B. Meijer, Luisa Martinez-Pomares, Anja ten Brinke, Jan Voorberg

O-TH-030  09:15 - 09:30
LARGE SCALE SEQUENCING OF THE F8 GENE USING A HIGH DENSITY OLIGONUCLEOTIDE ARRAY
Pamala Kanagasabapathy* (UK), Keith Gomez, John H McVEY
Thursday, July 28, 2011

**Thrombotic Disorders: Clinical Trials II**

**Room A**

**O-TH-031** 08:00 - 08:15

APIXABAN VERSUS ENOXAPARIN AFTER KNEE OR HIP SURGERY: EFFICACY AND SAFETY IN KEY CLINICAL SUBGROUPS
Graham F. Pineo* (CA), Alex Gallus, Gary Raskob, Luz Margarita Ramirez, Robert Wright, Dalei Chen, Michael Rud Lassen

**O-TH-032** 08:15 - 08:30

RANDOMIZED, OPEN-LABEL, DOSE-RANGING STUDY OF DABIGATRAN, A NOVEL, ORAL, DIRECT THROMBIN INHIBITOR, IN ELECTIVE PCI, (THE D-FINE STUDY)
Frank W G Leebeek* (NL), Moniek P. de Maat, Russell Jones, Linda van Campen, Jeffrey Friedman, Paul Reilly, Pascal Vranckx

**O-TH-033** 08:30 - 08:45

DABIGATRAN OR WARFARIN FOR EXTENDED MAINTENANCE THERAPY OF VENOUS THROMBOEMBOLISM
Sam Schulman* (CA), Henry Eriksson, Samuel Zachary Goldhaber, Ajay K. Lord Kakkar, Clive Kearon, Anne Mathilde Kvamme, Patrick Mismetti, Sebastian Schellong, Janet Schnee

**O-TH-034** 08:45 - 09:00

A MULTICENTRE, RANDOMISED, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE BEMIPARIN SODIUM VS UNFRACTIONATED HEPARIN AS BRIDGING THERAPY FOR AMBULATORY SURGERY: “BERTA” STUDY.
AMPARO SANTAMARIA* (ES), A. UGARRIZA, C. MUNOZ, I. DE DIEGO, F. LOPEZ, JAVIER MARTINEZ-GONZALEZ, JORDI FONTCUBERTA

**O-TH-035** 09:00 - 09:15

TIME TO REACH THERAPEUTIC ANTICOAGULATION FOR POST-OPERATIVE ORTHOPEDIC PROPHYLAXIS, RESULTS OF THE MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT INITIATIVE (MAQIQ)
Scott Kaatz* (US), Vlad Golgotiu, Geoffrey D Barnes, Xiaokui Gu, Jay Kozlowski, Steven L Almany, Dennis Besley, Paul Ponstein

**O-TH-036** 09:15 - 09:30

PERSISTENT REDUCTION OF ADAMTS13 ACTIVITY IN ACUTE ISCHEMIC STROKE WHICH IS INDEPENDENT OF VWF LEVELS AND ADAMTS13 INHIBITOR
Ross Ian Baker* (AU), James Thom, Quintin Hughes, Barbara Plaimauer, Fritz Schellinger, Hanspeter Rottensteiner, Graeme Hankey

**VTE: Laboratory Tests II**

**Room B-1**

**O-TH-037** 08:00 - 08:15

DOES THE PULMONARY EMBOLISM SEVERITY INDEX ACCURATELY IDENTIFY LOW RISK PATIENTS ELIGIBLE FOR OUTPATIENT TREATMENT?
Petra MG Erkens* (NL), Esteban Gandara, Phil Wells, Alex Yi-Hao Shen, Gauruv Bose, Gregoire Le Gal, Marc Rodger, Martin H Prins, Marc Carrier
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-038  08:15 - 08:30
THE ROLE OF MULTIPLE BIOMARKERS IN THE DIAGNOSIS OF PULMONARY EMBOLISM
Kerstin Hogg* (CA), Edward Hinchliffe, Shonagh Haslam, Fiona Lecky

O-TH-039  08:30 - 08:45
THROMBIN GENERATION IN PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS WITH AND WITHOUT CIRRHOSIS.
Valeria Rossetto* (IT), Marco Senzolo, Maria Teresa Sartori, Krisia Rodriguez, Mariangela Fadin, Patrizia Zerbinati, Sabrina Gavasso, Patrizia Burra, Paolo Simioni

O-TH-040  08:45 - 09:00
TARGETED GENE SEQUENCING OF THE PROTEIN C AND EPCR GENES IN A LARGE POPULATION OF PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM
Dhruva J. Dwivedi* (CA), Cynthia Wu, Laura Pepler, Zakhar Lysov, John Waye, Jim Julian, Clive Keareon, Patricia Liaw

O-TH-041  09:00 - 09:15
FV LEIDEN PSEUDO-HOMOZYGOTES HAVE A MORE PRONOUNCED HYPERCOAGULABLE STATE THAN HOMOZYGOTES DUE TO LOW PLASMA TFPI LEVELS
Connie Duckers (NL), Paolo Simioni, Daniela Tormene, Sara Carraro, Jan Rosing, Elisabetta Castoldi*

O-TH-042  09:15 - 09:30
RECURRENT VENOUS THROMBOEMBOLISM IS ASSOCIATED WITH FACTOR V LEIDEN MUTATION
Signy Vala Sveinsdottir* (SE), Ymir Saemundsson, Nazim Isma, Anders Gottsater, Peter J. Svensson

Von Willebrand Factor  Room B-2

Chairpersons: Jan Voorberg (NL) and Jim Crawley (UK)

O-TH-043  08:00 - 08:15
SIGLEC-5 MODULATES PLASMA LEVELS OF THE FACTOR VIII-VON WILLEBRAND FACTOR COMPLEX
Peter Lenting* (FR), Julie Pegon, Cecile V Denis, Soline Odouard, Caterina Casari, Olivier D Christophe

O-TH-044  08:15 - 08:30
PLATELET CAPTURE UNDER VERY HIGH SHEAR BY CONTOURED VWF NETS
David N KU* (US), Peter Wellings

O-TH-045  08:30 - 08:45
GENOME-WIDE ASSOCIATION STUDIES IDENTIFY NEW DETERMINANTS OF LOW VON WILLEBRAND FACTOR PLASMA LEVELS
Janine E. van Loon* (NL), Janine van Loon, Weihong Tang, Ming-Huai Chen, David Strachan, Stelia Trompet, Caroline Hayward, Nicholas L. Smith, Moniek P.M. de Maat
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-046  08:45 - 09:00
PLATELET-DERIVED VON WILLEBRAND FACTOR GLYCOSYLATION MEDIATES RESISTANCE TO ADAMTS13 PROTEOLYSIS
Rachel Therese McGrath* (IE), Maartje van den Biggelaar, Barry Byrne, Emily McRae, Orla Rawley, Richard O’Kennedy, Jan Voorberg, James S O’Donnell

O-TH-047  09:00 - 09:15
MACROPHAGE LRP1 IS INVOLVED IN THE CLEARANCE OF VON WILLEBRAND FACTOR
Peter Lenting* (FR), Ghasem Ratergarlari, Julie Pegon, Soline Odouard, Anna-Maria Navarette, Caterina Casari, Nathalie Saint-Lu, Olivier D Christophe, Cecile V Denis

O-TH-048  09:15 - 09:30
O-LINKED GLYCANS MEDIATE THE INTERACTION OF VON WILLEBRAND FACTOR WITH PLATELET RECEPTOR GLYCOPROTEIN IB UNDER SHEAR CONDITIONS
Agata Nowak* (UK), Mike Laflan, Thomas Mckinnon

Platelet Signaling II

Room C-1

Chairpersons: Mark Kahn  and Wolfgang Bergmeier (US)

O-TH-049  14:30 - 14:45
STIM1 DEFICIENCY RESULTS IN IMPAIRED PLATELET PROCOAGULANT ACTIVITY AND PROTECTION FROM ARTERIAL THROMBOSIS
Firdos Ahmad* (US), Lucia Stefanini, Timothy Daniel Ouellette, Tesholl Greene, Stefan Feske, Wolfgang Bergmeier

O-TH-050  14:45 - 15:00
THE ROLE OF THE FOCAL ADHESION KINASE PYK2 IN PLATELET ACTIVATION
Ilaria Canobbio* (IT), Lina Cipolla, Alessandra Consonni, Gianni Guidetti, Stefania Moni, Barbara Oliviero, Marco Falasca, Mitsuiiko Oikigaki, Cesare Balduni, Paolo Gresele, Mauro Torti

O-TH-051  15:00 - 15:15
THE TYROSINE KINASE PYK2 MEDIATES THE CROSS-TALK BETWEEN PLATELET INTEGRINS α2β1 AND αIIβ3.
Gianni F Guidetti* (IT), Alessandra Consonni, Lina Cipolla, Ilaria Canobbio, Elisa Ciraoelo, Emilio Hirsch, Marco Falasca, Mitsuhiko Oikigaki, Cesare Balduni, Mauro Torti

O-TH-052  15:15 - 15:30
TYROSINE PHOSPHORYLATED C-CBL REGULATES PLATELET FUNCTIONAL RESPONSES MEDIATED BY OUTSIDE-IN SIGNALING
Claudia Lorena Buitrago* (US), Wallace Langdon, Archana Sanjay, Satya Kunapuli

O-TH-053  15:30 - 15:45
JAM-A PROTECTS FROM THROMBOSIS BY ATTENUATING C-SRC ACTIVATION BY RECRUITING CSK TO THE INTEGRIN αIIβ3 AND SUPPRESSES OUTSIDE-IN SIGNALING IN PLATELETS
Meghna U Naik* (US), Ulhas P Naik
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-054  15:45 - 16:00
PAIRWISE AGONIST SCANNING OF HUMAN PLATELETS REVEALS THE HIGH-DIMENSIONAL CALCIUM RESPONSE TO COMBINATORIAL MEDIATORS OF THROMBOSIS
Scott L Diamond* (US), Manash Chatterjee, Jeremy Purvis, Matt Flamm

Contact Phase Activation  Room C-2

O-TH-055  14:30 - 14:45
FUNCTIONS OF PLASMA KALLIKREIN FOR THROMBOSIS AND VASCULAR LEAKAGE IN VIVO
Coen Maas* (SE), Chris Oschatz, Thomas Renne

O-TH-056  14:45 - 15:00
FACTOR XII INTERACTION WITH PHOSPHATIDYLSERINE MEDIATES THE PROCOAGULANT ACTIVITY OF APOPTOTIC CELLS AND THEIR CLEARANCE
Aizhen Yang* (CN), Xuemei Zhu, Xuefeng Wang, Qiulan Ding, Raymond B. Birge, Yi Wu, Robert W. Colman

O-TH-057  15:00 - 15:15
DISTINCT FUNCTIONS OF EXTRINSIC AND INTRINSIC COAGULATION PATHWAYS IN THROMBUS FORMATION ON RUPTURED PLAQUES IN VIVO AND IN VITRO
Judith M.E.M. Cosemans* (NL), Marijke J.E. Kuijpers, Paola E.J. van der Meijden, Nadine J.A. Mattheij, Johan W.M. Heemskerk

O-TH-058  15:15 - 15:30
MAST CELL-HEPARIN INCREASES VASCULAR PERMEABILITY IN VIVO BY CONTACT SYSTEM-DRIVEN BRADYKININ FORMATION
Chris Tina Oschatz* (SE), Coen Maas, Jenny Bjorkqvist, Werner Mueller-Esten, Walter A. Wuillemin, Thomas Renne

O-TH-059  15:30 - 15:45
COAGULATION FACTOR XIIA INFLUENCES HUMAN FIBRIN CLOT STRUCTURE INDEPENDENT OF ADDITIONAL THROMBIN GENERATION
Joke Konings* (NL), Jose WP Govers-Riemsdag, Helen Philippou, Nicola J Mutch, Julian I Borissoff, Sumitra Mohan, Guido Tans, Hugo Ten Cate, Robert AS Ariens

O-TH-060  15:45 - 16:00
MECHANISM AND THERAPY OF FAT EMBOLISM
Felicitas E Mueller* (SE), Paolo Parini, Robert Flaimenhaft, Thomas Renne

Protein C  Room D

O-TH-061  14:30 - 14:45
ZYMOGEN PROTEIN C AS A PROTECTIVE MODULATOR OF TUMOR PROGRESSION IN MURINE MODELS
Valder R Arruda* (US), Geerte Van Sluis, Paris Margaritis, Jenna Mauer, Armida Faella, Shangzhen Zhou, Katherine A High, C. Arnold Spek
### ORAL COMMUNICATIONS

**Thursday, July 28, 2011**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-TH-063</td>
<td>DISCRETE REGIONS OF THE FACTOR V B DOMAIN PROTECTS THE PROCOFACTOR FROM INACTIVATION BY ACTIVATED PROTEIN C</td>
<td>Haein Kim* (US), Laura Castellano, Mettine H.A. Bos, Rodney M. Camire</td>
</tr>
<tr>
<td>O-TH-065</td>
<td>INHIBITION OF THROMBIN FORMATION BY ACTIVE SITE MUTATED ACTIVATED PROTEIN C *</td>
<td>Gerry A F Nicolaes* (NL), Karin C.A.A. Wildhagen, Kenneth Segers, B. Dahlback, Jan Rosing, Paul E. Bock</td>
</tr>
<tr>
<td>O-TH-066</td>
<td>SPECIFICITY OF ACTIVATED PROTEIN C (APC)-MEDIATED PROTEASE RECEPTOR 3 (PAR3) PROTEOLYSIS PROVIDES A MOLECULAR EXPLANATION FOR DIVERGENT PATTERNS FOR APC VS THROMBIN SIGNALING</td>
<td>Laurent O Mosnier* (US)</td>
</tr>
</tbody>
</table>

#### Laboratory Tests in Platelet Function

*Chairpersons: Robert Andrews (AU) and Jonathan Miller*

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-TH-067</td>
<td>SPONTANEOUS PLATELET AGGREGATION IN PATIENTS WITH ACUTE CORONARY SYNDROME CORRELATES WITH RECURRENT THROMBOTIC EVENTS AND THE LEVEL OF VWF</td>
<td>Natalia Dovlatova* (UK), Natalia Dovlatova, Julia Lange, Mark Thomas, Jane May, Stan Heptinstall</td>
</tr>
<tr>
<td>O-TH-068</td>
<td>MEASUREMENT OF PLATELET ADENOSINE TRIPHOSPHATE RELEASE UNEXPECTEDLY NORMALIZES AGGREGATION FINDINGS IN SOME SUBJECTS, INCLUDING PERSONS WITH QUEBEC PLATELET DISORDER</td>
<td>Catherine P M Hayward* (CA), Karen Ann Moffat, Jean Francois Castilloux, Jodi Seecharan, Cormier Anik, Georges Etienne Rivard</td>
</tr>
<tr>
<td>O-TH-069</td>
<td>INSIGHTS ON THE MECHANISM OF PLATELET INHIBITION BY OMEGA-3 POLYUNSATURATED FATTY ACIDS. RESULTS OF THE LEAP TRIAL.</td>
<td>Joseph S Rossi* (US), Mauricio G Cohen, Alison Motsinger, Allison Dupont, Regina Bowling, Jennifer Garbarino, Don Gabriel</td>
</tr>
</tbody>
</table>
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-070  15:15 - 15:30
P-SELECTIN IS ASSOCIATED WITH SUBSEQUENTATHEROTHROMBOTIC EVENTS IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROMES TREATED WITH CLOPIDOGREL
Mark Thomas* (UK), Yanushi Wijeyeratne, Jane May, Sue Fox, Stan Heptinstall

O-TH-071  15:30 - 15:45
PATIENTS WITH RHEUMATOID ARTHRITIS HAVE A DECREASED RESPONSE TO COLLAGEN INDUCED PLATELET AGGREGATION AND INCREASED PLASMA LEVELS OF SOLUBLE GPVI.

O-TH-072  15:45 - 16:00
THROMBIN BINDING TO PLATELETS OF YOUNG PATIENTS WITH A HISTORY OF ACUTE MYOCARDIAL INFARCTION
Grazia Loredana Mendolicchio* (IT), Monica Bacci, Dennis Zavalloni, Lidia Rota, Zaverio Marcello Ruggeri

Hemophilia: Clinical Study  Sakura

Chairpersons: □ □ and Alessandro Gringeri (IT)

O-TH-073  14:30 - 14:45
SWEDISH VERSUS DUTCH PROPHYLACTIC STRATEGY FOR HEMOPHILIA: DIFFERENCE IN OUTCOME IS SMALL BUT COST-DIFFERENCE IS LARGE
Kathelijn Fischer* (NL), Katarina Steen-Carlsson, Pia Petrini, Margareta Holmstrom, Rolf Ljung, Erik Berntorp

O-TH-074  14:45 - 15:00
FIRST ANALYSIS OF 10-YEAR TREND IN NATIONAL FACTOR CONCENTRATES USAGE IN HEMOPHILIA: DATA FROM THE CANADIAN HEMOPHILIA ASSESSMENT AND RESOURCE MANAGEMENT SYSTEM.
Aicha N Traore* (CA), Anthony K. C. Chan, Kathryn E. Webert, Nancy Heddle, Bruce Ritchie, Jean St-Louis, Irwin Walker

O-TH-075  15:00 - 15:15
QUALITY OF LIFE OF CHILDREN WITH HEMOPHILIA A UNDERGOING PROPHYLAXIS OR EPISODIC TREATMENT: RESULTS FROM THE ESPRIT STUDY
Sylvia von Mackensen* (DE), Silvia Riva, Francesco Fusco, Lorenzo Mantovani, Alessandro Gringeri

O-TH-076  15:15 - 15:30
PRACTICE PATTERNS OF CANADIAN CHILDREN AND ADULTS WITH HEMOPHILIA A (HA) WHO ARE ON PROPHYLACTIC HOME INFUSION OF FACTOR VIII (FVIII)
Jerome Teitel* (CA), Victor Blanchehtte, Dorine Belliveau

O-TH-077  15:30 - 15:45
DIFFERENCES IN THE CARE OF CHILDREN WITH HAEMOPHILIA IN EUROPE
Rolf Ljung* (SE), Alessandro Gringeri, Laszlo Nemes, Margit Serban, Karin Berger, Wolfgang Schramm
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-078  15:45 - 16:00
LIFE-LONG PROPHYLAXIS IN A LARGE COHORT OF ADULT PATIENTS WITH SEVERE HAEMOPHILIA SHOWS A BENEFICIAL EFFECT ON ORTHOPAEDIC OUTCOMES AND QUALITY OF LIFE.
Mohammed Khawaji* (SE), Jan Astermark, Erik Berntorp

Thrombotic Disorders: Clinical II  Room A

O-TH-079  14:30 - 14:45
MORTALITY DUE TO PULMONARY EMBOLISM, MYOCARDIAL INFARCTION, AND STROKE AMONG PATIENTS STARTING DIALYSIS
Gurbey Ocak* (NL), Karlijn J. van Stralen, Marion Verduijn, Fredo W. Dekker, Kitty J. Jager

O-TH-080  14:45 - 15:00
ENHANCED ENDOGENOUS THROMBIN POTENTIAL IS ASSOCIATED WITH THE SEVERITY OF CORONARY ATHEROSCLEROSIS

O-TH-081  15:00 - 15:15
BLEEDING RISK IN VERY OLD PATIENTS ON VKA TREATMENT: RESULTS OF A PROSPECTIVE COLLABORATIVE STUDY
Daniela Poli* (IT), Emilia Antonucci, Elisa Grifoni, Leonardo Di Gennaro, Anna Falanga, Pietro Faico, Marco Valerio Grasso, Francesco Marongiu, Simona Pedrini, Pasquale Pignatelli, Scortechni Rita Anna, Sophie Testa, Walter Ageno, Gualtiero Palareti

O-TH-082  15:15 - 15:30
INFLUENCE OF NON-GENETIC AND GENETIC FACTORS ON THE MAINTENANCE DOSE IN ELDERLY INPATIENTS ON FLUINDIONE, A NON-COUMARIN VITAMIN K ANTAGONIST
Virginie SIGURET (FR), Caroline MOREAU, Charlotte DEVÉLIE, Eric PAUTAS, Marion ANDRO, Karine LACUT, Franck LÉBOURGEOIS, Isabelle PEYRON, Jean-Louis GOLMARD, Joseph EMMERICH*, Marie-Anne LORIOT, Isabelle GOUIN-THIBAULT

O-TH-083  15:30 - 15:45
SAFETY AND TOLERABILITY OF THE ORAL FACTOR XA INHIBITOR, YM150 VERSUS WARFARIN IN 1297 PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: A DOSE CONFIRMATION STUDY (OPAL-2)
Gregory YH Lip* (UK), Jonathan L Halperin, Palle Petersen, George M Rodgers, Ronny W Renfurm

O-TH-084  15:45 - 16:00
ATTRAL FIBRILLATION RESULTS IN THE GENERATION OF UNIQUE BIOMARKERS AS STUDIED BY PROTEINCHIP AND BIOCHIP ARRAY TECHNIQUES
Debra A Hoppensteadt* (US), Bruce Lewis, Indermohan Thethi, Josephine Cunanan, Evangelos Litisnas, Rakesh Wahi, Jawed Fareed
ORAL COMMUNICATIONS

Thursday, July 28, 2011

VTE: Risk Factors II

Chairpersons: Fred Anderson (US) and Sergio Coccheri

O-TH-085  14:30 - 14:45
NT-PRO-BNP LEVELS IN PATIENTS WITH ACUTE PULMONARY EMBOLISM ARE CORRELATED TO RIGHT AND NOT LEFT VENTRICULAR VOLUME AND FUNCTION
Sharif M Pasha* (NL), Noortje Van Der Bijl, Frederik A Klok, Albert De Roos, Lucia JM Kroft, Menno V Huisman

O-TH-086  14:45 - 15:00
COMPARATIVE EFFECTIVENESS OF THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS ACROSS THE US ACUTE HOSPITAL SETTING
Wei Huang* (US), Frederick A Anderson, Alexander T Cohen

O-TH-087  15:00 - 15:15
VENOUS THROMBOEMBOLISM (VTE): DISEASE BURDEN AND OUTCOMES - VTE EPIDEMIOLOGY GROUP (VEG) STUDY
Carlos Martinez* (DE), Stephan Rietbrock, Luke Bamber, Alexander T Cohen

O-TH-088  15:15 - 15:30
RISK FACTORS FOR VENOUS THROMBOEMBOLISM (VTE) IN SURGICAL PATIENTS IN THE VTE EPIDEMIOLOGY GROUP (VEG) STUDY
Carlos Martinez* (DE), Stephan Rietbrock, Luke Bamber, Alexander T Cohen

O-TH-089  15:30 - 15:45
RISK FACTORS FOR VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL PATIENTS IN THE VTE EPIDEMIOLOGY GROUP (VEG) STUDY
Alexander T Cohen* (UK), Stephan Rietbrock, Carlos Martinez

O-TH-090  15:45 - 16:00
SAFE EXCLUSION OF DEEP VEIN THROMBOSIS IN PRIMARY AND SECONDARY CARE USING THE WELLS-RULE; A LARGE INDIVIDUAL PATIENT DATA META-ANALYSIS
Geert-Jan Geersing* (NL), Peter Zuithoff, Clive Kearon, David Anderson, Johan Elf, Shannon Bates, Arno Hoes, Kristel Janssen, Roderik Kraaijenhagen, Ruud Oudega, Roger Schutgens, Scott Stevens, Phil Wells, Karel Moons

Pregnancy and Thrombosis II

Chairpersons: Grégoire LE GAL (FR) and Per-Morten Sandset (NO)

O-TH-091  14:30 - 14:45
LOW MOLECULAR WEIGHT HEPARIN FOR THE SECONDARY PREVENTION OF PLACENTAL-MEDIATED PREGNANCY COMPLICATIONS: A SYSTEMATIC REVIEW AND META ANALYSIS.
Marc Alan Rodger* (CA), Jean-Christophe Gris, Evelyne Rey, Marc Carrier, Grégoire Le Gal
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-092  14:45 - 15:00
PREGNANCY RELATED VENOUS THROMBOSIS IS ASSOCIATED WITH REduced SENSITIVITY TO ACTIVATED PROTEIN C IN THE ABSENCE OF THE FACTOR V LEIDEN POLYMORPHISM
Astrid Bergrem* (NO), Astrid Bergrem, Anders E.A Dahm, Anne Flem Jacobsen, Marie-Christine Mowinckel, Leiv Sandvik, Per Morten Sandset

O-TH-093  15:00 - 15:15
WOMEN WITH FACTOR V LEIDEN MUTATION AND UNEXPLAINED RECURRENT MISCARRIAGE HAVE A SHORTER TIME TO PREGNANCY THAN NON-CARRIERS; AN EVOLUTIONARY ADVANTAGE?
Thijs E van Mens* (NL), Stef P Kaandorp, Mariette Goddijn, Barbara A Huten, Saskia Middeldorp

O-TH-094  15:15 - 15:30
GENETIC VARIABILITY OF LXRBETA GENE MIGHT CONTRIBUTE TO PREECLAMPSIA
Jean-Christophe Raymond Gris* (FR), Kevin Mouzat, Erick Mercier, Anne Polge, Alexandre Evrard, Jean-Marc A. Lobaccaro, Jean-Paul Brouillet, Serge Lumbroso

O-TH-095  15:30 - 15:45
ENOXAPARIN FOR THE SECONDARY PREVENTION OF PLACENTAL VASCULAR COMPLICATIONS IN WOMEN WITH PREVIOUS SEVERE PRE-ECLAMPSIA: THE PILOT RANDOMISED CONTROLLED NOH-PE STUDY.
Jean-Christophe Raymond Gris* (FR), Celine Chauleur, Pierre Mares, Eva Nouvellon, Eric Mercier, Sylvie Bouvier, Isabelle Queure, Jean-Yves Lefrant, Bassam Haddad, Michel Dauzat

O-TH-096  15:45 - 16:00
ATTENUATION OF THROMBIN SIGNALING, BUT NOT PLATELET AGGREGATION, RESCUES FETAL LOSS IN A MURINE MODEL OF FACTOR V LEIDEN-ASSOCIATED PLACENTAL FAILURE.
Rashmi Sood* (US), Magarya S Waitara, Jianzhang An, Michelle Bordas, Brian G Petrich

Platelet Granules

Room C-1

O-TH-097  16:15 - 16:30
LOSS OF PIKFYVE IN MURINE PLATELETS LEADS TO ABERRANT PLATELET GRANULE BIOGENESIS AND A PLEOMORPHIC PHENOTYPE WITH MULTIORGAN FAILURE
Sang Hee Min* (US), Aae Suzuki, Liang Zhao, Lurong Lian, Sidney W Whiteheart, Michael S Marks, John Choi, Charles S Abrams

O-TH-098  16:30 - 16:45
THE PF4-VARIANT CHEMOKINE CXCL4L1 AND PF4 ARE STORED IN MEGAKARYOCYTE ALPHA GRANULES VIA THE SAME PATHWAY
Jean-Philippe Raymond Rosa* (FR), AMINE BAZAA, ESSID HELA, ODILE ISSERTIAL, LEBRET MARILYNE, ANNE DUBART-KUPPERSCHMITT, JEAN-PHILIPPE ROSA

O-TH-099  16:45 - 17:00
IMPAIRMENT OF THROMBUS FORMATION IN MUNC13-4 DEFICIENT MICE
Joshua S Savage* (UK), Olga Konopatskaya, Alastair W Poole
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-100  17:00 - 17:15
MEMBRANE REMODELING DURING PLATELET SPREADING REQUIRES MUNC13-4-DEPENDENT EXOCYTOSIS OF α-GRANULES EXPRESSING VAMP7
Robert Flaumenhaft* (US), Christian G. Peters

O-TH-101  17:15 - 17:30
INHIBITION OF NEUTROPHIL TRANSMIGRATION BY TREM-LIKE TRANSCRIPT (TLT)-1
Anthony Valance Washington* (PR), Jessica Morales, Linette Rivera, Rysienid Hernandez, Karina Villa, James Gattis, Giovanni Ortiz, Michael Gomez, Monica Fernandez, Marlene Martinez, Robert Hunter

O-TH-102  17:30 - 17:45
MRP4 MEDIATED TRANSPORT IS PART OF THE PHYSIOLOGICAL MECHANISM OF ELIMINATION CYCLIC NUCLEOTIDES FROM HUMAN PLATELETS
Alessandra Borgognone* (IT), Fabio Maria Pulcinelli

Thrombin Generation Test  Room C-2

Chairpersons: \[ \text{and Joost Meijers (NL)} \]

O-TH-103  16:15 - 16:30
REGULATION OF THROMBIN GENERATION AND CLOT GROWTH BY MUTANT FACTOR VIII MOLECULES
Jean-Claude Bordet* (FR), Mickael Panteleev, Jean-Luc Plantier, Yesim Dargaud, Fazly Ataullakhano, Claude Negrier

O-TH-104  16:30 - 16:45
ERYTHROCYTE-DEPENDENT THROMBIN GENERATION IN WHOLE-BLOOD
Marisa Ninivaggi* (NL), Rafael Apitz-Castro, Theo Lindhout, Coenraad H. Hemker

O-TH-105  16:45 - 17:00
RELATION OF BLEEDING TENDENCY IN RARE BLEEDING DISORDERS WITH DEFICIENCIES IN FACTOR II, V, VII, X, XIII, AND FIBRINOGEN AND SIMULTANEOUS THROMBIN AND PLASMIN GENERATION.
Mark van Geffen* (NL), Fiora Peyvandi, Marzia Menegatti, Arnoud Loof, Paul Lap, Mehran Karimi, Britta Laros-van Gorkom, Paul Brons, Waaander van Heerde

O-TH-106  17:00 - 17:15
THE IMPACT OF VITAMIN K-DEPENDENT PROCOAGULANT PROTEINS ON THROMBIN GENERATION IN A CELL-BASED MODEL OF WARFARIN ANTICOAGULATION
Yesim Dargaud* (FR), Maureen Hoffman, Leana LeFrapper, Dougald M Monroe

O-TH-107  17:15 - 17:30
EFFECT OF LOW DOSE OMEGA-3 ON FIBRIN, THROMBIN AND COAGULATION
Brad McEwen* (AU), Marie-Christine Morel-Kopp, Walter Chen, Geoffrey H Tofler, Christopher M Ward
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-108  17:30 - 17:45
REGULATION OF CLOT GROWTH BY FACTOR XI THROUGH THE GENERATION OF THROMBIN INSIDE THE CLOT
Mikhail V Ovanesov* (US), Li W William, Fazoil I Ataullakhanov, David Gailani, Alexey M Shibeko

Coagulation Factors II  Room D

Chairpersons: Arnold Spek (NL) and Saulius Butenas (US)

O-TH-109  16:15 - 16:30
ACTIVATED FACTOR X IS A NOVEL REGULATOR OF MONOCYTE TOLL-LIKE RECEPTOR SIGNALING
Eimear Marie Gleeson* (IE), Fionnuala Ni Ainle, Bridget-Ann Kenny, James S. O'Donnell, Roger J.S. Preston

O-TH-110  16:30 - 16:45
THE ROLE OF FACTOR V ACTIVATION IN THRESHOLDING BEHAVIOUR IN PROTHROMBIN ACTIVATION BY PROTHROMBINASE
P. Michael Cook* (CA), Harry Zhou, Michael E. Nesheim

O-TH-111  16:45 - 17:00
RECOMBINANT FIX FC FUSION PROTEIN IS EFFECTIVE FOR ON-DEMAND TREATMENT WITH SIGNIFICANTLY PROLONGED EFFICACY FOR PROPHYLAXIS IN HEMOPHILIA B MICE
Tongyao Liu* (US), Xin Zhang, Susannah Patarroyo-White, Douglas Drager, Glenn Pierce, Haiyan Jiang

O-TH-112  17:00 - 17:15
FACTOR IX-R338L (FIX PADUA) IS AN EFFECTIVE ALTERNATIVE FOR THE TREATMENT OF CANINE SEVERE HEMOPHILIA B.
Jonathan Douglas Finn* (US), Timothy Nichols, Paolo Simioni, Nikos Svoronos, Scott N Ashley, Shangzhen Zhou, Katherine A High, Valder R Arruda

O-TH-113  17:15 - 17:30
GENETIC DETERMINANTS OF PLASMA FACTOR VIII ANTIGEN LEVELS: A TARGET GENE SNP ANALYSIS OF THE ARIC COHORT
Marco Campo (US), Ashley Buchanan, Full Yu, Maja Barbaic, Woody Chambless, Christie Ballantyne, Aaron Folsom, Eric Boerwinkle, Jing-fei Dong*

O-TH-114  17:30 - 17:45
HISTIDINE-RICH GLYCOPROTEIN BINDS FIBRINOGEN WITH HIGH AFFINITY AND MODULATES THROMBIN BINDING TO THE \( \gamma \)-CHAIN
Trang T Vu* (CA), Alan R Stafford, Beverly A Leslie, James C Fredenburgh, Paul Y Kim, Jeffrey I Weitz

Angiogenesis and Lymphangiogenesis  Room E

Chairpersons: Ulhas Naik (US) and Yoshihiko Saito (JP)

O-TH-115  16:15 - 16:30
JUNCTIONAL ADHESION MOLECULE-A DIFFERENTIALLY REGULATES FGF2- AND VEGF-INDUCED ANGIOGENESIS.
Meghna U Naik* (US), Ulhas P Naik
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-116  16:30 - 16:45
THE ROLE OF BREAST CANCER CELLS MICROPARTICLES IN THROMBOPENICITY AND ANGIogenesis FOLLOWING CHEMOTHERAPY
Anat Aharon* (IL), Benjamin Brenner

O-TH-117  16:45 - 17:00
DISTINCT PLATELET SECRETION AND SURFACE EXPRESSION OF PROANGIOGENIC AND ANTIANGIOGENIC FACTORS UPON DIFFERENT PLATELET STIMULI
Nailin Li* (SE), Madhumita Chatterjee, Zhangsen Huang, Wei Zhang, Lei Jiang, Kjell Hultenby, Linjing Zhu, Hu Hu, Gunnar P. Nilsson, Nailin Li

O-TH-118  17:00 - 17:15
PLATELETS REGULATE THE FORMATION OF THE LYMPHATIC VASCULATURE BY MODULATING THE MIGRATORY POTENTIAL OF LYMPHATIC ENDOTHELIAL CELLS
Leyre Navarro-Nunez* (UK), Leyre Navarro-Nunez, Brenda A Finney, Gerard B Nash, Steve P Watson

Hemophilia: Innovative Therapy II  
Sakura

Chairpersons: CS Manno and Benny Sorensen

O-TH-121  16:15 - 16:30
ENHANCED PLATELET BINDING OF A FACTOR VIIA ANALOG WITH ENHANCED TISSUE FACTOR-INDEPENDENT ACTIVITY
Maureane Hoffman* (US), Maureane Hoffman, Egon Persson, Mirella Ezban, Dougald M Monroe

O-TH-122  16:30 - 16:45
PHASE 3 DOSE SETTING FOR N9-GP, A RECOMBINANT FIX DERIVATIVE, IN HAEMOPHILIA B PATIENTS USING EXTRAPOLATIONS OF PHASE 1 DATA WITH POPULATION PHARMACOKINETIC MODELLING
Peter W Collins* (UK), Peter W Collins, Estelle Watson, Karin Knobe, Andreas Groth, Judi Moss

O-TH-123  16:45 - 17:00
EVALUATING THE EFFICACY OF A STEM CELL-BASED GENE THERAPY STRATEGY IN A CANINE MODEL OF HEMOPHILIA A.
Margareth C Ozelo* (BR), Christine Brown, Carol Hegadorn, Andrea Labelle, Morag McMurray, Lori Harpell, Sandra Powell, James F Hulvat, Janine Handforth, Andrew Winterborn, Christine Hough, David Lillicrap
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-124  17:00 - 17:15
DOSE-DEPENDENT ACTIVATION OF CAPSID-SPECIFIC T CELLS AFTER AAV SEROTYPE 8 VECTOR ADMINISTRATION IN A CLINICAL STUDY FOR HEMOPHILIA B

O-TH-125  17:15 - 17:30
INHIBITOR ERADICATION AND VECTOR READMINISTRATION IN A NON-HUMAN PRIMATE MODEL OF AAV-MEDIATED LIVER GENE TRANSFER FOR HEMOPHILIA B
Federico Mingozzi* (US), Federico Mingozzi, Yifeng Chen, Shangzheng Zhou, Samuel L Murphy, Mark Metzger, Robert E Donahue, Fraser J Wright, Cynthia J Dunbar, Katherine A High

O-TH-126  17:30 - 17:45
PROPAGATION AND GENETIC MODIFICATION OF AUTOLOGOUS HEPATOCYTES TOWARD GENE AND CELL THERAPY FOR HEMOPHILIA B
Kohei Tatsumi* (JP), Kazuo Ohashi, Chise Tateno, Hiroyuki Nakai, Anja Ehrhardt, Rie Utoh, Katsutoshi Yoshizato, Teruo Okano

VTE: Risk Factors III  Room A

O-TH-127  16:15 - 16:30
CLINICAL HISTORY OF PATIENTS WITH CEREBRAL VEIN THROMBOSIS: RESULTS OF A LARGE MULTICENTER INTERNATIONAL COHORT STUDY
Francesco Dentali* (IT), Daniela Poli, Umberto Scoditti, Matteo ND Di Minno, Valerio De Stefano, Sergio Siragusa, Milan Kostal, Gualtiero Palareti, Maria Teresa Sartori, Elvira Grandone, Maria Cristina Vedovati, Dan Witt, Mauro Silingardi, Anna Falanga, Sophie Testa, Giovanni Barilliari, Stefano Barco, Marina Bianchi, Emanuele Rezoagli, Walter Ageno

O-TH-128  16:30 - 16:45
PROTHROMBINEX-VF (PTX-VF) USAGE FOR REVERSAL OF COAGULOPATHY: PROSPECTIVE EVALUATION OF THROMBOGENIC RISK
Eileen Grace Merriman* (NZ), Louise Bobbitt, Jacqueline Raynes, Ross Henderson, Hilary Blacklock, Sanjeev Chunilal

O-TH-129  16:45 - 17:00
EMERGING CONCEPTS: IDENTIFYING, MONITORING AND REDUCING PREVENTABLE MAJOR BLEEDS IN THE HOSPITAL SETTING
Deborah Caraballo* (US), Charles E Mahan

O-TH-130  17:00 - 17:15
ISOLATED DISTAL DEEP-VEIN THROMBOSIS IS NOT A POOR PROVIDER OF VENOUS THROMBOEMBOLIC RECURRENT
Jean-Philippe Galanaud* (FR), Celine Genty, Marie-Antoinette Sevestre, Isabelle Quere, Jean-Luc Bosson
ORAL COMMUNICATIONS

Thursday, July 28, 2011

O-TH-131  17:15 - 17:30
CHRONIC KIDNEY DISEASE AND RISK OF VENOUS THROMBOSIS: AN INDICATION FOR THROMBOPHYLAXIS?
Gurbey Ocak* (NL), Willeim M. Lijfering, Marion Verduijn, Friedo W. Dekker, Carla Y. Vossen, Frits R. Rosendaal

O-TH-132  17:30 - 17:45
THE RISK OF VENOUS THROMBOSIS RELATED TO CHRONIC KIDNEY DISEASE IS MEDIATED BY HIGH LEVELS OF FACTOR VIII
Gurbey Ocak* (NL), Carla Y. Vossen, Marion Verduijn, Friedo W. Dekker, Willeim M. Lijfering, Frits R. Rosendaal

Thromboprophylaxis in Children  Room B-1
Chairpersons: Marilyn Manco-Johnson (US) and

O-TH-133  16:15 - 16:30
SUBCUTANEOUS PROTEIN C CONCENTRATE IN THE PROPHYLAXIS OF THROMBOSIS IN SEVERE PROTEIN C DEFICIENCY
Adrian MB Minford (UK), Mary Mathias, Mary Morgan, Michele David, Natividad Gomez Gomez, Wolfgang Behnisch, Martin Olivieri, Ulrike Nowak-Gottl, Hans-Joerg Hertfelder*, Paul Brons

O-TH-134  16:30 - 16:45
CHARACTERIZATION OF POST-THROMBOTIC SYNDROME IN CHILDREN WITH CONGENITAL HEART DISEASE: A COMPARISON OF INSTRUMENTS
Leonardo Rodrigues Brandao* (CA), Cedric Manlhiot, Suzan Williams, Brian C. McCreindle

O-TH-135  16:45 - 17:00
SAFETY AND EFFICACY OF LOW MOLECULAR WEIGHT HEPARINS IN CHILDREN: A SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS OF SINGLE ARM STUDIES
Ulrike Nowak-Gottl* (DE), Christoph Bidlingmaier, Gili Kenet, Karin Kurnik, Daniela Manner, Prasad Mathew, Ralf Junker, Lesley Mitchell, Anne Katarina Krumpel, Ulrike Nowak-Gottl

O-TH-136  17:00 - 17:15
PROPHYLACTIC ANTICOAGULATION DECREASES CATHETER-RELATED THROMBOSIS AND OCCLUSION IN CHILDREN WITH HOME PARENTERAL NUTRITION
Cornelia Helena van Ommen* (NL), Irene L. Vegting, Merit M. Tabbers, Marc A. Benninga, Jim C. Wilde, Mireille J. Serlie

O-TH-137  17:15 - 17:30
RANDOMIZED CONTROLLED TRIAL COMPARING HIGH-DOSE VERSUS LOW-DOSE HEPARINIZATION PROTOCOLS FOR PROPHYLAXIS OF THROMBOTIC COMPLICATIONS DURING CC IN CHILDREN (HEARTCAT STUDY)
Andreas Hanslik (AT), Erwin Kitzmueller, Katharina Thom, Haumer Markus, Wolfgang Milekusch, Ulrike Salzer-Muhar, Ina Michel-Bhenke, Christoph Male*

O-TH-138  17:30 - 17:45
THROMBOTIC COMPLICATIONS AND THROMBOPHYLAXIS IN SINGLE VENTRICLE HEART PALLIATION IN CHILDREN
Leonardo Rodrigues Brandao* (CA), Cedric Manlhiot, Judith Kwok, Stefan Kegel, Ines B. Menjak, Cailtin L. Carew, Anthony K. Chan, Christopher A. Caldarone, Glen S. Van Arsdell, Brian W. McCreindle
ORAL COMMUNICATIONS

Thursday, July 28, 2011

Thrombotic Disorders: Genetic Determinations and Epidemiology

Chairpersons: Vicente Vicente (ES) and Mary Cushman (US)

O-TH-139  16:15 - 16:30
SOCIAL RISK FACTORS FOR VENOUS THROMBOEMBOLISM (VTE) IN THE VTE EPIDEMIOLOGY GROUP (VEG) STUDY
Alexander T Cohen* (UK), Stephan Rietbrock, Carlos Martinez

O-TH-140  16:30 - 16:45
IDENTIFICATION OF BTN2A1 AS A SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION IN JAPANESE INDIVIDUALS BY A GENOME-WIDE ASSOCIATION STUDY
Yoshiji Yamada* (JP)

O-TH-141  16:45 - 17:00
EXOME SEQUENCING IDENTIFIES NBEAL2 AS THE CAUSATIVE GENE FOR GRAY PLATELET SYNDROME
Cornelis A Albers* (UK), Ana Cvejic, Remi Favier, Evelien E Bouwmans, Marie-Christine Alessi, Paul Bertone, Gregory Jordan, Graham Kiddle, Myrto Kostadima, Randy J Read, Botond Sipos, Peter Smethurst, Jonathan Stephens, Katrin Voss, Alan Nurden, Augusto Rendon, Paquita Nurden, Willem H Ouwehand

O-TH-142  17:00 - 17:15
NOVEL GENETIC DETERMINANTS OF PLASMA VON WILLEBRAND FACTOR AND FIBRINOGEN ANTIGEN LEVELS IN A POPULATION OF HEALTHY SIBLINGS
Karl Desch* (US), Jun Li, Ayse Bilge Ozel, David Siemieniak, David Ginsburg

O-TH-143  17:15 - 17:30
HAPLOTYPES IN THE CYP1A2 AND CYP3A4 GENES AND THE RISK OF ORAL CONTRACEPTIVE-ASSOCIATED VENOUS THROMBOSIS
Bernardine H Stegeman* (NL), Hans L Vos, Frans M Helmerhorst, A Van Hylckama Vlieg, Pieter H Reitsma, Frits R Rosendaal

O-TH-144  17:30 - 17:45
GENETIC RISK SCORE FROM GWA STUDIES IS STRONGLY ASSOCIATED WITH ANGIOGRAPHICALLY-DEFINED CORONARY ARTERY DISEASE, BUT NOT WITH MORTALITY IN THE SETTING OF SECONDARY PREVENTION
Nicola Martinelli* (IT), Oliviero Olivieri, Patrizia Guarini, Simonetta Friso, Francesca Pizzolo, Letizia Consoli, Roberta Micaglio, Fabiana Busti, Domenico Girelli
POSTER PRESENTATIONS
Thursday, July 28, 2011

Signal transduction of platelet activation

P-TH-001  REGULATION OF PLATELET FUNCTIONAL AND MECHANICAL PROPERTIES BY NITRIC OXIDE DONORS
Volha D Bichan* (BY), Ekaterina V Shamova, Elizaveta S Drozd, Irina V Gorudko, Sergey A Chizhik, Konstantin B Shumaev, Sergey N Cherehkevich, Anatoliy F Vanin

P-TH-002  GAS6 RECEPTORS, TYRO3, AXL AND MER, DIFFERENTIALLY PARTICIPATE IN GLYCOPROTEIN VI-MEDIATED PLATELET ACTIVATION
Junsong Zhou* (CN), Lu Wang, Qingxian Lu, Katsue Suzuki-Inoue, Yi Wu, Yukio Ozaki

P-TH-003  AGONIST-INDUCED PLATELET ACTIVATION IS REGULATED BY ASK1 THROUGH MKK6/P38 KINASE PATHWAY
Ulhas P Naik* (US), Ramya Turaga, Hidinori Ichijo, Meghna U Naik

P-TH-004  AN RNAI SCREENING TO IDENTIFY THE MOLECULES INVOLVED IN INTEGRIN αIIBβ3 ACTIVATION
Yasuyuki Matsuda* (JP), Shigenori Honda, Toshiyuki Miyata

P-TH-005  GLUTATHIONE-DEPENDENT PLATELET INTERACTIONS WITH NEUTROPHILS AND TUMOR CELLS
Irina Gorudko* (BY), Ekaterina Shamova, Anna Mukhortova, Luda Shishlo, Sergey Gusev, Oleg Panasenko, Sergey Cherenkevich

P-TH-006  CHARACTERIZATION OF MYOSIN LIGHT CHAIN ACTIVATION DURING CLOT RETRACTION
Christilla Bachelot-Loza* (FR), Marion Egot, Tristan Mirault, Francoise Grelac, Genevieve Baujat, Dominique Lasne, Christilla Bachelot-Loza

P-TH-007  DUAL REGULATION OF IN VIVO THROMBOSIS BY POLO-LIKE KINASE 3: SUPPORT AGONIST-INDUCED GRANULAR SECRETION, BUT SUPPRESS OUTSIDE-IN SIGNALING
Ulhas P Naik* (US), Meghna U Naik, Brendan Bachman, John C Kostyak, Wei Dai

P-TH-008  STAT3 REGULATES COLLAGEN-INDUCED PLATELET AGGREGATION INDEPENDENT OF ITS TRANSCRIPTION FACTOR ACTIVITY
Zhou Zhou* (US), Francisca C. Gushiken, Angela L. Bergeron, Wensheng Sun, Niloufar Aghakasiri, Vinod K. Vijayan, Rolando Rumbaut, Jose A. Lopez, Jing-fei Dong

P-TH-009  A NOVEL SYK-INDEPENDENT PI-3 KINASE DEPENDENT TYROSINE KINASE PATHWAY LEADING TO FIBRINOGEN ACTIVATION IN PLATELETS
Todd M. Getz* (US), Lorena Buitrago, YingYing Mao, Satya Kunapuli

P-TH-010  SYK-DEPENDENT AND -INDEPENDENT GENERATION OF REACTIVE OXYGEN SPECIES DOWNSTREAM OF GPVI ENGAGEMENT
Jane F Arthur* (AU), Elizabeth E Gardiner, Jing Jing, Amanda K Davis, Michael C Berndt, Robert K Andrews

P-TH-011  ROLE OF MITOCHONDRIA IN THE PROCESS OF PLATELET ACTIVATION AND THROMBUS FORMATION UNDER BLOOD FLOW CONDITIONS
Noriko Tamura* (JP), Yohei Nanazawa, Shinya Goto
POSTER PRESENTATIONS
Thursday, July 28, 2011

Biology of platelets

P-TH-012  STAPHYLOCOCCAL EXTRACELLULAR ADHERENCE PROTEIN (EAP) INDUCES PLATELET ADHESION, AGGLUTINATION, AGGREGATION AND PROCOAGULANT ACTIVITY
Anne Bertling* (DE), Silke Niemann, Muzaffar Hussain, Martin F. Brodde, Silke Pohl, Tina Schifferdecker, Joachim Roth, Kerstin Jurk, Anja Mueller, Georg Peters, Christine Heilmann, Beate E. Kehrel

P-TH-013  MOLECULAR MECHANISMS INVOLVED IN THE ANTITHROMBOTIC ACTIVITY OF AEGYPTIN, A NOVEL MOSQUITO-DERIVED COLLAGEN-BINDING PROTEIN
Daniella M Mizurini* (BR), Eric Calvo, Ivo M Francischetti, Robson Q Monteiro

P-TH-015  IN VIVO ROLES OF DISABLED-2 (DAB2) IN HAEMOSTASIS AND PLATELET FUNCTION: STUDIES USING A MEGAKARYOCYTE LINEAGE-RESTRICTED DAB2 KNOCKOUT
Chien-Ling Huang* (TW), Chung-Ching Lin, Yao-Wen Chang, Jonathan A. Cooper, Ju-Chien Cheng, Ching-Ping Tseng

P-TH-016  IN VIVO ACTIVATED PLATELETS EXPRESS CD40L IN HUMANS RESULTING IN ENDOTHELIAL ACTIVATION
Paolo Gresele* (IT), Silvia Giannini, Emanuela Falcinelli, Loredana Bury, Giuseppe Guglielmini, Roberta Rossi, Stefania Momì

P-TH-017  PLATELET-DERIVED MATRIX METALLOPROTEINASE-2 (MMP-2) REGULATES PLATELET AND LEUKOCYTE MIGRATION THROUGH LUNG TISSUE IN A MURINE MODEL OF ALLERGIC INFLAMMATION
Stefania Momì* (IT), Simon C Pitchford, Clive P Page, Paolo Gresele

P-TH-018  THE 78 KDA GLUCOSE RESPONSE PROTEIN (GRP78) IS RECRUITED TO THE SURFACE OF ENDOTHELIUM BY INTERACTING WITH THROMBOMODULIN AND IT DEMONSTRATES ANTITHROMBOTIC ACTIVITY
Anup Ramashankar Sharma* (AU), Xiang-Ming Zhang, Carly Selan, Anushka Samudra, Lisa Murray-Segal, Evelyn Salvaris, Belinda Michell, Bruce Kemp, Conway E.D., Yuping Yuan, Anthony dApice, Peter Cowan, Harshal Nandurkar

P-TH-019  OREXIN BUT NOT OBESTATIN OR NEUROPEPTIDE Y INHIBITS ADP INDUCED PLATELET AGGREGATION: IMPACT ON OBESITY RELATED CARDIOVASCULAR DISEASE
Hisham S Elbatarny* (CA), Donald H Maurice

P-TH-020  EXPRESSION AND LOCALIZATION OF THE MEMBRANE-BINDING AND -DEFORMING PROTEIN, PACSIN 2, IN PLATELETS AND MEGAKARYOCYTES
Herve Falet* (US), Terese Joensson, Antonija Jurak Begonja, John H Hartwig, Herve Falet

P-TH-021  INTERACTION BETWEEN PLATELETS AND ADAMTS-13
Kimberly MacEachern* (CA), Carlene Lott, Alexander Hamilton, Kayleen Elicich, Maha Othman

Platelet receptors

P-TH-022  A CRITICAL ROLE FOR THE ADP RECEPTOR, P2Y12, IN STREPTOCOCCUS ORALIS INDUCED PLATELET ACTIVATION
Dorothea O Tilley* (IE), Sarah A Maume, Dermot Cox, Albert Smolenski, CW Ian Douglas, Steven W Kerrigan
### POSTER PRESENTATIONS

**Thursday, July 28, 2011**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-023</td>
<td>GLYCOPROTEIN IBα IS A MECHANORECEPTOR WHICH CLUSTERS UPON COLD STORAGE AND HYDRODYNAMIC FORCE</td>
<td>Eelco Gitz* (NL), Hans Deckmyn, Cornelis A Koekman, Dave J van den Heuvel, Hans C Gerritsen, Jan-Willem Akkerman</td>
</tr>
<tr>
<td>P-TH-024</td>
<td>NOVEL MOLECULAR ASSOCIATION OF ADP PURINERGIC RECEPTOR, P2Y12 WITH TETRASPAVIN SUPERFAMILY MEMBER, CD151 IN HUMAN PLATELETS</td>
<td>Fatemeh Moheimani* (AU), Leonie K Ashman, Mark D Wright, Denise E Jackson</td>
</tr>
<tr>
<td>P-TH-025</td>
<td>THE CX3C CHEMOKINE FRACKALKINE MEDIATES PLATELET ADHESION VIA THE VON WILLEBRAND RECEPTOR GLYCOPROTEIN IB</td>
<td>Sascha Meyer dos Santos* (DE), Ute Klinkhardt, Klaus Scholich, Karen Nelson, Nadejda Monsefi, Hans Deckmyn, Karina Kuczka, Anita Zorn, Sebastian Harder</td>
</tr>
<tr>
<td>P-TH-026</td>
<td>INCREASED PLATELET COUNTS CORRELATE WITH DECREASED FUNCTION OF PLATELET P2Y12 RECEPTORS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM</td>
<td>Hung Chang* (TW), Lee-Yung Shih, Po Dunn, Alan D. Michelson, Andrew L. Frelinger, Po-Nan Wang, Ming-Chung Kuo, Tung-Liang Lin, Jin-Hou Wu, Tzung-Chih Tang</td>
</tr>
<tr>
<td>P-TH-027</td>
<td>MODIFICATIONS IN PLATELET BEHAVIOUR IN RESPONSE TO MMP-DIGESTED COLLAGENS</td>
<td>Joanna-Marie Howes* (UK), Nicholas Pugh, Richard W Farndale</td>
</tr>
<tr>
<td>P-TH-028</td>
<td>THE NEW SELECTIVE P2Y12 ANTAGONIST RADIOLIGAND [3H]PSB-0413 IS A HIGHLY ACCURATE TOOL TO QUANTIFY</td>
<td>Christian Gachet* (FR), Philippe Ohlmann, Anna Lecchi, A El Tayeb, Christa Muller, Marco Cattaneo, Christian Gachet</td>
</tr>
<tr>
<td>P-TH-029</td>
<td>PLATELET GLYCOPROTEIN VI DIMERISATION IS AN ACTIVE PROCESS INDUCING RECEPTOR COMPETENCE</td>
<td>Martine Jandrot-Perrus* (FR), STEPHANE LOYAU, BENOITTE DUMONT, VERONIQUE OLLIVIER, YACINE BOUAFULLALI, LAURENT FELDMAN, NADINE AJZENBERG, MARTINE JANDROT-PERRUS</td>
</tr>
<tr>
<td>P-TH-030</td>
<td>P2Y12 ANTAGONISTS AND AN EP3 ANTAGONIST PROMOTE THE INHIBITORY EFFECTS OF MODULATORS OF PLATELET AGGREGATION THAT ACT VIA CAMP</td>
<td>Jacqueline Glenn* (UK), David Espinosa Iyu, Ann White, Susan Fox, Natalia Dovlatova, Stan Heptinstall</td>
</tr>
<tr>
<td>P-TH-031</td>
<td>ANALYSIS OF PLATELET FUNCTION AND GPVI REGULATION IN MICE LACKING THE METALLOPROTEINASES ADAM10 AND ADAM17</td>
<td>Markus Bender* (DE), Sebastian Hofmann, David Stegner, Martina Morowski, Peter Kraft, Guido Stoll, Athena Chalaris, Atilia Braun, Juergen Schellier, Stefan Rose-John, Bernhard Nieswandt</td>
</tr>
</tbody>
</table>

**Platelets as drug targets**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-032</td>
<td>THE EFFECT OF TIME ON PLATELET AGGREGATION ASSESSED BY LIGHT TRANSMISSION</td>
<td>Philip DM Leadbeater* (UK), Jane A Mitchell, Timothy D Warner</td>
</tr>
<tr>
<td>P-TH-033</td>
<td>THE EFFECT OF STIR-SPEED AND TIME ON TP-RECEPTOR INDUCED PLATELET AGGREGATION IN THE PRESENCE OF ASPIRIN AND P2Y12 RECEPTOR BLOCKADE</td>
<td>Philip DM Leadbeater* (UK), Jane A Mitchell, Timothy D Warner</td>
</tr>
<tr>
<td>P-TH-034</td>
<td>PLATELET INHIBITION BY CLOPIDOGREL PROTECTS AGAINST ACUTE KIDNEY INJURY</td>
<td>Joris J Roelofs* (NL), Gwendoline J. Teske, Nike Claessens</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-035  ASPIRIN AUGMENTS THE ANTI-PLATELET EFFECTS OF PARTIAL BUT NOT COMPLETE P2Y12 RECEPTOR BLOCKADE BY TICAGRELOR
Nicholas S Kirkby* (UK), Philip DM Leadbeater, Melissa V Chan, Sven Nylander, Jane A Mitchell, Timothy D Warner

P-TH-036  SYNERGISTIC INHIBITION OF PLATELET AGGREGATION BY NITRIC OXIDE AND PROSTACYCLIN IS POTENTIATED BY P2Y12 BLOCKADE
Nicholas S Kirkby* (UK), Rachit Singhal, Jane Á Mitchell, Timothy D Warner

P-TH-037  EFFECT OF PAR1 AND PAR4 AGONISTS ON PLATELET ACTIVITY
Liudmila I Buryachkovskaya* (RU), Svetlana M Strukova, Irina A Uchitel, Alexander B Sumarokov

P-TH-038  FIBRINOGEN BINDING TO ACTIVATED PLATELETS IN THE PRESENCE OF PLASMA CONCENTRATION OF THE NATURAL LIGAND MAY BE SUFFICIENT TO ALLOW THERAPEUTIC TARGETING
Julie A. Oliver* (US), Evan S. Krystofiak, Linda G. Westrick

P-TH-039  INHIBITORY EFFECTS OF POLYPEPTIDES DERIVED FROM SNAKE VENOM C-TYPE LECTIN, AGGREGIN, ON TUMOR CELL-INDUCED PLATELET AGGREGATION
Chien-Hsin Chang* (TW), Ching-Hu Chung, Tur-Fu Huang

P-TH-040  DESTRUCTION OF ACTIVATED PLATELETS WITH FIBRINOGEN-CONJUGATED CORE-SHELL NANOPARTICLES
Julie A. Oliver* (US), Evan S. Krystofiak

P-TH-041  THAN 40 EXHIBITS ANTIPLATELET ACTIVITY IN VIVO AND EX VIVO
Zui-ying Wu* (TW), Jin-Cherng Lien, Sheng-Chu Kuo, Tur-Fu Huang

P-TH-042  BETA-NITROSTYRENES INHIBIT PLATELET AGGREGATION CAUSED BY HUMAN BREAST CANCER MDA-MB-231 CELLS
Chin-Chung Wu* (TW), Chien-Kai Wei

P-TH-043  A NOVEL QUANTITATIVE AND SENSITIVE HIGH THROUGHPUT-READY TECHNIQUE FOR DETECTION OF CYCLIC NUCLEOTIDE MODULATING DRUG EFFECTS
Jorg Geiger* (DE), Katharina Hubertus, Walter Ulrich, Reinhard Schinzel

Genetics and proteomics of platelets

P-TH-044  THE TRANSCRIPTION FACTOR MEIS1 MARKS A MEGAKARYOCYTE-SPECIFIC ALTERNATIVE PROMOTER OF THE DNLM3 LOCUS AT THE POSITION OF A GWAS SEQUENCE VARIANT FOR PLATELET VOLUME
Sylvia Nuernberg (UK), Peter A. Smethurst*, Rafik Rizkallah, Nicole Soranzo, Augusto Rendon, Willem Ouwehand

P-TH-045  THE USE OF HIGH RESOLUTION MELTING (HRM) ANALYSIS FOR THE SCREENING OF GENETIC DEFECTS IN GLANZMANN THROMBASTHENIA
Xavier Pilolo* (FR), Mathieu Fiore, Roland Heilig, Paquita Nurden, Alan Nurden

P-TH-046  THE PROTEOME OF PLATELET-DERIVED MICROPARTICLES VARIES DEPENDING ON THE STIMULUS: IMPLICATION OF SIGNALING PROTEINS
Angel Garcia* (ES), Ela Shai, Andres F Parguina, Isaac Rosa, David Varon

P-TH-047  THROMBIN ACTIVATION ALTERS mRNA SIGNATURE AND PROTEIN SYNTHESIS IN HUMAN PLATELETS
Abdimajid Osman* (SE), Knut Falker, Tomas L Lindahl
### POSTER PRESENTATIONS

**Thursday, July 28, 2011**

**P-TH-048** PROTEOMIC IDENTIFICATION OF PLATELET SIGNALING PATHWAYS PLAYING A MAJOR ROLE IN ACUTE CORONARY SYNDROME  
Angel Garcia* (ES), Andres F Parguina, Lilian Grigorian-Shamajian, Rosa M Agra, Diego Lopez, Isaac Rosa, Jana Alonso, Jose Ramon Gonzalez-Juanatey

**P-TH-049** ELUCIDATING THE CLEC-2 SIGNALING CASCADE USING A GLOBAL PROTEOMICS APPROACH  
Angel Garcia* (ES), Andres F Parguina, Isaac Rosa, Johannes A Eble

**P-TH-050** NOVEL LOCI INVOLVED ON PLATELET FUNCTION AND PLATELET COUNT IDENTIFIED BY A GWAS PERFORMED IN CHILDREN  
Jose Antonio Guerrero* (ES), Jose Rivera, Teresa Quiroga, Angel Martinez-Perez, Ana Isabel Anton, Constantino Martinez, Olga Panes, Vicente Vicente, Diego Mezzano, Jose Manuel Soria, Corral Javier

**P-TH-051** P-SELECTIN VARIANT THR715PRO IMPAIRS TERMINAL GLYCOSYLATION OF P-SELECTIN  
Harihara Manikandan Ponniahpillai Subramanian* (AT), Christine Mannhalter

**P-TH-052** OLIGOPHRENIN-1 IS PRESENT IN PLATELETS AND REGULATES FILOPODIA FORMATION UPON GPVI STIMULATION  
Thijs C van Holten* (NL), Onno B Blijerveld, Rolf T Urbanus, Richard W Farndale, Philip G de Groot, Albert JR Heck, Arjen Scholten, Mark Roest

**P-TH-053** GENE EXPRESSION WITHIN A THROMBUS: FURTHER REGULATION OF THE HAEMOSTATIC RESPONSE  
Joy R Wright* (UK), Cordelia Langford, Nicholas A Watkins, Willem H Ouwehand, Alison H Goodall

**P-TH-054** PROTEINS INVOLVED IN “STICKY PLATELET SYNDROME” PLATELET ACTIVATION  

**P-TH-055** PROTEOMICS PROFILES OF PLATELETS ACCORDING TO HIGH ON TREATMENT PLATELET REACTIVITY AND CARDIOVASCULAR EVENTS (APICE PROJECT)  
Betti Giusti* (IT), Claudia Boccardi, Anna Maria Gori, Rossella Marcucci, Silvia Rocchiccioli, Ilaria Romagnuolo, Niccolo’ Maggini, David Antoniucci, Oberdan Parodi, Lorenzo Citti, Rosanna Abbate

**P-TH-056** THE SMALL RNA PROFILE OF HUMAN PLATELETS  
Patrick Provost* (CA), Helene Fle, Patricia Landry, Ashley Benham, Preethi Gunaratne

**ITP**

**P-TH-057** PREDICTORS FOR RESOLUTION WITHIN 6 MONTHS IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA  
Shoshana Revel-Vilk* (IL), Shlomzion Frank, Tal Ben-Ami, Mira Harit, Elisha Waldman, Iris Fried, Aker Meret, Polina Stepenski, Michael Weintraub

**P-TH-058** FACTORS ASSOCIATED WITH FAVORABLE RESPONSE TO CORTICOSTEROIDS IN THAI PATIENTS DIAGNOSED WITH IMMUNE THROMBOCYTOPENIA  
Bundarika Suwanawaro* (TH), Kritichat Kamjornpreecha, Sirawit Bantornwa, Yingyong Chinthammith, Theera Ruchtrakool, Wanchai Wanachiwanawin

**P-TH-059** RITUXIMAB PLUS RECOMBINANT HUMAN THROMBOPOIETIN YIELDS RAPID AND SUSTAINED RESPONSE IN ADULT PATIENTS WITH GLUCOCORTICOID RESISTANT PRIMARY IMMUNE THROMBOCYTOPENIA  
Xiaoyuan Dong* (CN), Ming Hou, Jie Li, Jun Peng, Hao Li, Luqun Wang
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-060  A MULTI-CENTRE RETROSPECTIVE ANALYSIS OF RITUXIMAB USE IN IMMUNE THROMBOCYTOPENIA PURPURA (ITP) IN THE REPUBLIC OF IRELAND
Denis J Okeeffe* (IE), Aine Burke, Suzanne Mc Pherson, Mirfan Khan, Yassir Mahdi, Mary Gleeson, Joy Lewis, Jill Mackarel, Janusz Krawczyk, Sahar Khan, Karen Murphy, Brian Hennessy, Catherine Flynn, Philip Murphy, Patrick Thornton, Peter O’Gorman, Conaigh Gilligan, Michael O Dwyer, Margaret Murray, Helen Enright, Gerry Crotty

P-TH-061  REVERSIBLE, RECURRENT, DOSE-DEPENDENT LEUKOERYTHROBLASTOSIS ASSOCIATED WITH USE OF A THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN CHRONIC IMMUNE THROMBOCYTOPENIA (ITP).
Adam Giermasz* (US), Joan Etzell, Patrick F. Pogarty

P-TH-062  EVALUATION OF PLATELET FUNCTION IN IMMUNE THROMBOCYTOPENIA DURING ELTROMBOPEG TREATMENT
Johanna Haselboeck* (AT), Simon Panzer, Ingrid Pabinger

P-TH-063  LOW-DOSE INTERFERON-ALPHA THERAPY FOR CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA (ITP) IN CHILDREN

P-TH-064  THE PLATELET COUNT OF PATIENTS WITH THROMBOCYTOPENIA MAY BE UNDERESTIMATED WHEN MEASURED IN EDTA SAMPLES IN ROUTINE LABORATORIES
Marco Cattaneo* (IT), Gian Marco Podda, Mariateresa Pugliano, Eli Alessandra Femia, Anna Maria Mezzasoma, Paolo Gresele, Giovanni Carpani

P-TH-065  THROMBOPOIETIN RECEPTOR AGONISTS (TPOA) DO NOT CAUSE ACTIVATION OF THE COAGULATION-FIBRINOLYTIC SYSTEM IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP)
Waleed Ghanima* (NO), Sarah Barsam, Per Morten Sandset, Allison Miller, James B Bussel

Antiplatelet therapy

P-TH-066  ANTITHROMBOTIC EFFECTS OF ASPIRIN BASED ON PLA1/A2 GLYCOPROTEIN IIIA POLYMORPHISM IN PATIENTS WITH CORONARY ARTERY DISEASE
Jerzy Dropinski* (PL), Jerzy Dropinski, Marek Sanak, Bogdan Jakiela, Wojciech Wegryn, Andrzej Szczeklik, Jacek Musial

P-TH-067  RESISTANCE TO CLOPIDOGREL BASED ON PLATELET GLYCOPROTEIN IIIA POLYMORPHISM IN CORONARY ARTERY DISEASE PATIENTS
Jerzy Dropinski* (PL), Marek Sanak, Bogdan Jakiela, Wojciech Wegryn, Andrzej Szczeklik, Jacek Musial

P-TH-068  ADDITIONAL ANTIPLATELET EFFECT OF CLOPIDOGREL IN PATIENTS TREATED WITH ASPIRIN
Jerzy Dropinski* (PL), Bogdan Jakiela, Marek Sanak, Wojciech Wegryn, Andrzej Szczeklik, Jacek Musial

P-TH-069  ASPIRIN TREATED SUBJECTS SHOW ATTENUATED ELECTRON MICROSCOPIC EVIDENCE OF PLATELET ACTIVATION AND A PARALLEL ATTENUATION IN THROMBIN STIMULATED PLATELET ACTIVATION ANTIGENS
Mary Rose Cahill* (IE), Marion Macey, Adrian C Newland

P-TH-070  THE FIRST DEMONSTRATION OF RACE AND GENDER INFLUENCE ON PLATELET REACTIVITY WITHIN CYP2C19 GENOTYPES
Paul Alfred Gurbel* (US), Kevin P Bliden, Young-Hoon Jeong, Tantry S Tantry
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-071  HIGH POST-TREATMENT PLATELET REACTIVITY AND IMPAIRED CLINICAL PROGNOSIS BUT ADEQUATE RESPONSE TO THIENOPYRIDINE IN ELDERLY PATIENTS WITH UNSTABLE CORONARY DISEASE
Marie-Christine Alessi* (FR), Thomas Cuisset, Jacques Quilici, Charlotte Grosdidier, Laurent Fourcade, Benedicte Gaborit, Mathieu Pankert, William Cohen, Laurent Molines, Marc Lambert, Pierre-Emmanuel Morange, Jean Louis Bonnet

P-TH-072  INFLUENCE OF GENETIC POLYMORPHISMS ON PLATELET INHIBITION BY ADJUNCTIVE CILOSTAZOL TO CLOPIDOGREL AND CLOPIDOGREL: RESULTS OF THE ACCEL-TRIPLE STUDY
Young-Hoon Jeong* (US), In-Suk Kim, Yongwhi Park, Seong-Eun Yun, Tae Jung Kwon

P-TH-073  CELLULARITY OF POLYURETHANE SURFACE IN THE POLISH EXTRACORPOREAL VENTRICULAR ASSIST DEVICE IN LONG TERM USAGE
Roman Kustosz* (PL), Magdalena Koscielniak Ziemniak, Karolina Gorka, Artur Kapis, Romuald Wojnicz, Ewa Reichman-Warmusz

P-TH-074  FIRST COMPARISON OF THROMBELASTOGRAPHY VERSUS LIGHT TRANSMITTANCE AGGREGOMETRY TO DEFINE HIGH PLATELET REACTIVITY
Young-Hoon Jeong* (US), Kevin P. Bliden, Mark J. Antonino, Udaya S. Tantry, Paul A. Gurbel

P-TH-075  IMPACT OF THE CYTOCHROME P450 2C19*3 POLYMORPHISM ON PLATELET REACTIVITY AND ADVERSE CLINICAL EVENTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Young-Hoon Jeong* (US), Jin-Sin Koh, Tae Jung Kwon, Yongwhi Park, In-Suk Kim

P-TH-076  EVALUATION OF BIOEQUIVALENCE OF BISULFATE AND AND BESYLATE CLOPIDOGREL ON THE INHIBITION OF ADP INDUCE PLATELET AGGREGATION IN PATIENTS WITH CORONARY ARTERY DISEASE
John Zarifis* (GR), Cristos Zafiris, George Tsinopoulos, Evagelos Kaltzas, Spyrou Gerou, Ismail Elalamy, Grigoris T. Gerotziafas

Platelets in transfusion medicine

P-TH-077  EFFECTS OF IN-VITRO ADULT PLATELET TRANSFUSIONS ON NEONATAL HEMOSTASIS
Francisca Ferrer-Marín* (US), Chaitanya Chavda, Michael Lampa, Alan D Michelson, Frelinger III Andrew L., Martha Sola-Visner

P-TH-078  OPTIMIZATION OF PLATELET-RICH PLASMA PREPARATION METHOD FOR IMPROVEMENT OF ITS QUALITY
Saleh Nasri* (IR)

P-TH-079  REAL-TIME QUANTIFICATION OF HPA-1A ANTIBODY IN SERUM OF MOTHERS WITH NEONATAL ALLOIMMUNE THROMBOCYTOPENIA DURING MANAGED PREGNANCIES BY SURFACE PLASMON RESONANCE TECHNIQUE
Tamam Bakchoul* (DE), G Bertrand, S Kubiak, Ulrich Sachs, Gregor Bein, Sentot Santoso, Cécile Kaplan

Inherited and acquired platelet disorders

P-TH-080  MOLECULAR GENETIC ANALYSIS AND PLATELET FUNCTION TESTING IN 27 GLANZMANN’S THROMBASTENIA PATIENTS
Ann-Kathrin Pilgrim* (DE), Daniele Piliitteri, Thomas Scholz, Manuela Krause, Carl M Kirchmaier
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-081  CLASSIFICATION OF MILD PLATELET-BASED BLEEDING DISORDERS USING LUMI-AGGREGOMETRY
Ban B Dawood* (UK), Jonathan T Wilde, Martina E Daly, Paul Gissen, Mike Makris, Andrew D Mumford, Steve P Watson

P-TH-082  THROMBOCYTOPENIA AND THE QUESTION OF PLATELET FUNCTION
Ingvild Birschmann* (DE), Judith Schmoekel, Anja Zamow, Arnold Ganser

P-TH-083  MAY-HEGGLIN ANOMALY DURING PREGNANCY
Brwa Ali Hussein* (UK), Keith Gomez, Rezan Kadir

P-TH-084  INHERITED THROMBOCYTOPENIA WITH RUNX1 VARIANTS: NEW FRENCH CASES WITH POINT MUTATIONS OR LARGE DELETIONS AND EVIDENCE FOR A DEFECT IN DENSE GRANULES
Thomas P Lecompte* (FR), Veronique Latger-Cannard, Alexandre Bouquet, Christophe Philippe, Claude Preudhomme, Philippe Jonveaux, Thomas Lecompte, Remi Favier

P-TH-085  HERMANSKY-PUDLAK SYNDROME DURING PREGNANCY
Brwa Ali Hussein* (UK), Keith Gomez, Rezan Kadir

P-TH-086  TWO NOVEL MISSENSE MUTATIONS IN THE ITGB3 GENE CHARACTERIZING A COMPOUND HETEROZYGOUS GLANZMANN THROMBASTHENIA (GT) PATIENT
Loredana Bury* (IT), Eva Zetterberg, Teresa Corazzi, Paquita Nurden, Alan T Nurden, Paolo Gresele

P-TH-087  INTERMITTENT X-LINKED THROMBOCYTOPENIA DUE TO THE P.THR45MET WASP GENE MUTATION
Margareth C Ozelo* (BR), Lucia H Siqueira, Marina P Colella, Mariana Gil, Joyce M Annichino-Bizzacchi, Enich V De Paula, Margareth C Ozelo

Laboratory tests

P-TH-089  VALIDATION AND ASSESSMENT OF MEPACRINE TESTING IN DELTA STORAGE POOL DISEASE: A 3-CENTRE STUDY
Francois Mullier* (BE), Veronique Latger-Cannard, Marie Toussaint-Hacquard, Marie-France Hurtaud, Nicolas Bailly, Jean-Michel Dogne, Bernard Chatelain, Thomas Lecompte

P-TH-090  DIRECT COMPARISON OF DIFFERENT PROCEDURES TO PREPARE PLATELET-RICH PLASMA FOR LIGHT TRANSMISSION AGGREGOMETRY
Marco Cattaneo* (IT), Eli Alessandra Femia, Mariateresa Pugliano, Gian Marco Podda, Klodiana Dosti

P-TH-091  FLOW CYTOMETRY IDENTIFIES PLATELET DYSFUNCTION IN PATIENTS WITH THROMBOCYTOPENIA AND THROMBOCYTOSIS
David E Connor* (AU), Joanne E Joseph

P-TH-092  HERITABILITY OF PLATELET-LEUKOCYTE CONJUGATES AND CELL ACTIVATION MARKERS IN FAMILIES WITH AND WITHOUT JUVENILE MYOCARDIAL INFARCTION
Chiara Cerletti* (IT), Francesco Gianfagna, Chiara Tamburrelli, Bransislav Vonhout, Marilena Crescente, Benedetta Izzi, Agnieszka Pampuch, Amalia De Curtis, Augusto Di Castelmuvo, Antonella Cutrone, Emanuela Napoleone, Bamidele Tayo, Roberto Lorenzet, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello, Investigators Moli-family Study

P-TH-093  IDENTIFICATION OF COMMON DRUGS INTERFERING WITH THE PFA CLOSURE TIME
Andreas R. Rechner* (DE), Anja Borchert, Anette Immel, Annette Merte-Schulz, Norbert Zander
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-094  VARIABILITY OF ADP-INDUCED HUMAN PLATELET AGGREGATION IS REDUCED IN THE PRESENCE OF ASPIRIN
Chao-Zong Liu* (TW), Jia-Ming Weng, Ling-Ya Chang

P-TH-095  PLATELET FUNCTION IN TRAUMA MEASURED BY MULTIPLE ELECTRODE AGGREGOMETRY
Catherine Mary Spoors* (UK), Ross Davenport, Henry De’Ath, Sirat Khan, Joanna Manson, Imran Raza, Claire Rourke, Per Johansson, Karim Brohi

P-TH-096  POSSIBLE ROLE OF PLATELET ACTIVATION IN THE CARDIOVASCULAR COMPLICATIONS ASSOCIATED WITH HIV INFECTION: DIFFERENTIAL EFFECTS OF ABACAVIR (ABC) VERSUS TENOFOVIR (TDF)
Paolo Gresele* (IT), Daniela Francisci, Emanuela Falcinelli, Barbara Belfiori, Eleonora Petito, Tiziana Fierro, AnnaMaria Mezzasoma, Franco Baldelli

P-TH-097  WHITE BLOOD CELL COUNT, SEX AND AGE ARE MAJOR DETERMINANTS OF PLATELET INDICES HETEROGENEITY IN AN ADULT GENERAL POPULATION: RESULTS FROM THE MOLI-SANI PROJECT
Chiara Cerletti* (IT), Iolanda Santimone, Augusto Di Castelnuovo, Amalia De Curtis, Maria Spinelli, Daniela Cugino, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello, Investigators Moli-sani Project

P-TH-098  PAK™LX: A NEW LUMINE®-BASED ASSAY TO DETECT AND IDENTIFY ANTIBODIES TO HUMAN PLATELET ANTIGENS (HPA) IN PATIENT SERUM
Rathore Vipul* (US), Patrick Coghlan, Adrian Fleet, Grant Mraz, Matthew Meyers

P-TH-099  COMPARING FIVE PLATELET FUNCTION TESTS (PRP AGGREGOMETRY, MULTIPLATE, P-SELECTIN, VERIFYNOW AND BIOCYTEX VASP) DESIGNED TO ASSESS RESPONSES TO ASPIRIN AND P2Y₁₂ ANTAGONISTS
Susan Fox* (UK), Jane May, Jacqueline Glenn, Andrew Johnson, Ann White, Natalia Dovlatova, David Iyu, Yanushi Wijeyeratne, Stan Heptinstall

P-TH-100  SEVERE PREECLAMPSIA: PLATELET PARAMETERS ROLE FOR ITS PREDICTION
Luci Maria SantAna Dusse* (BR), Luci Maria Dusse, Leticia Goncalves Freitas, Patricia Nessralla Alpoin, Denise Silva Kattah, Maria Graca Carvalho, Karina Braga Gomes

Extrinsic pathway of coagulation

P-TH-101  INCREASED EXPRESSION OF TFPI BY SODIUM BUTYRATE INVOLVES THE PI3K AND NF-κB PATHWAYS
Grethe Skretting* (NO), Christiane Filion Myklebust, Nina Iversen, Anders Dahm, Per Morten Sandset

P-TH-102  THE COAGULANT ACTIVITY OF TISSUE FACTOR DOES NOT REQUIRE ASSOCIATION WITH LIPID RAFTS
Guus Sturk* (NL), Anita Boing, Chi Hau, Jan van Marle, Rienk Nieuwland

P-TH-103  POSTTRANSLATIONAL MODIFICATIONS AND ACTIVITY OF NATURAL HUMAN TISSUE FACTOR
Jolanta T Krudysz-Amblo* (US), Mark E Jennings II, Dwight E Matthews, Kenneth G Mann, Saulius Butenas

P-TH-104  ENHANCED THROMBIN GENERATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): DEPENDENCE ON PLASMA FACTOR COMPOSITION
Milosz Jankowski (PL), Anetta Undas*, Przemyslaw Kaczmarek, Kathleen E Brummel-Ziedins
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-105  LEPTIN UPREGULATES TISSUE FACTOR EXPRESSION IN THE HUMAN BREAST CANCER CELL LINE MCF7: A POSSIBLE ROLE OF TNF-α
Emanuela Napoleone (IT), Antonella Cutrone, Maria Carmela Latella, Daniela Cugino, Licia Iacoviello, Giovanni di Gaetano, Maria Benedetta Donati, Roberto Lorenzet*

P-TH-106  SUBSTANCE P (SP)-NEUROKININ-1 RECEPTOR (NK-1R) INTERACTION PROMOTES UPREGULATION OF MONOCYTETISSUE FACTOR (TF)
Mohammad Munir Hossain Khan* (US), Steven D Douglas, Tami Benton

P-TH-107  SYNERGISTIC AMPLIFICATION OF THROMBIN GENERATION IN PLASMA THROUGH MINIMALLY ACTIVATED EXTRINSIC AND INTRINSIC COAGULATION PATHWAYS
Yuichi Kamikubo* (US), Andrew J Gale, Wolfram Ruf, Zaverio M Ruggeri

P-TH-108  MOUSE TISSUE FACTOR PROCOAGULANT ACTIVITY IS DEPENDENT ON THE PRESENCE OF THE CYS190-CYS213 ALLOSTERIC DISULFIDE
Lisa G van den Hengel* (NL), Pieter H Reitsma, Henri H Versteeg

P-TH-109  ALTERNATIVELY SPliced AND FULL-LENGTH TISSUE FACTOR REVEAL A NON-IDENTICAL RELATIONSHIP TO CLINICOPATHOLOGICAL PARAMETERS IN A LARGE COHORT OF HUMAN BREAST CANCER
Yascha W Van den Berg* (NL), J Sven D Mieog, Esther M De Kruifj, Jiongwei Wang, Anita Sajet, Peter JK Kuppen, Cornelis JH Van de Velde, Pieter H Reitsma, Susanne Osanto, Vladimir Y Bogdanov, Henri H Versteeg

P-TH-110  SELECTION OF ANTIBODY CLONES INFLUENCE MEASUREMENT OF TISSUE FACTOR EXPRESSION IN BLOOD CELLS
Bjarne Osterud* (NO), Manjunath Goolyam Basavaraj, Jan Ole Olsen, Bjarne Osterud, John-Bjarne Hansen

P-TH-111  EFFECTS OF HISTAMINE ON TISSUE FACTOR EXPRESSION IN MONOCYTES OF BLOOD
Bjarne Osterud* (NO), Bjarne Osterud, Jan Ole Olsen, Eliana Lakis

P-TH-112  MALIGNANCY ASSOCIATED ACQUIRED FACTOR VII DEFICIENCY
Rhona M Maclean* (UK), Peter Cooper, Steve Kitchen, Michael Makris

P-TH-113  TRANSCRIPTION FACTOR NFAT BUT NOT NF-κB IS ESSENTIAL FOR THROMBIN-INDUCED TISSUE FACTOR EXPRESSION
Yuwna Yakura* (JP), Makoto Taniguchi, Kaori Morimoto, Akira Hayashi, Hiroyuki Takeya

P-TH-114  A REVIEW OF SEVERE FACTOR X DEFICIENCY IN PATIENTS IN THE REPUBLIC OF IRELAND
Mary Kavanagh* (IE), Ann O’Sullivan, Imelda Kelly, Irene Regan, Mary Byrne, Vince Jenkins, Dympna Cawley, James O’Donnell, Beatrice Nolan

P-TH-115  FACTOR VIIA/ANTITHROMBIN COMPLEXES IN CIRRHTICS WITH AND WITHOUT PORTAL VEIN THROMBOSIS: A POSSIBLY MARKER OF INCREASED THROMBOTIC RISK?
Valeria Rossetto (IT), Luca Spiezia, Sabrina Gavasso, Mariangela Fadin, Elena Campello, Maria Teresa Sartori, Marco Senzolo, Krissia Rodriguez, Barry Woodhams*, Paolo Simioni

P-TH-116  KOREAN HEMOPHILIA’S PREVALENCE AND REALITIES
Ji-Yoon Kim* (KR), Kun Soo Lee, Yong-Mook Choi, Tai Ju Hwang, Ki Young Yoo
POSTER PRESENTATIONS

Thursday, July 28, 2011

Intrinsic pathway of coagulation

P-TH-117  ANTIGEN LEVELS OF INTRINSIC COAGULATION PROTEINS AND THE RISK OF MYOCARDIAL INFARCTION AND ISCHAEMIC STROKE IN YOUNG WOMEN: RESULTS FROM THE RATIO CASE-CONTROL STUDY
Bob Siegerink* (NL), A Algra, Frits R Rosendaal

P-TH-118  ACQUIRED HEMOPHILIA A ASSOCIATED WITH AUTOIMMUNE BULLOUS DISEASE; CHARACTERIZATION OF AUTOANTIBODIES OF TWO CASES AND REVIEW OF THE LITERATURE
Koji Miyazaki* (JP), Shinichi Makita, Takumi Aoki, Mikio Danbara, Masaaki Higashihara

P-TH-119  MILD CLINICAL PHENOTYPE IN A SEVERE HEMOPHILIA A WITH ARG1781HIS SUBSTITUTION ASSOCIATED WITH INCREASED FACTOR XA GENERATION
Koji Yada* (JP), Keiji Nogami, Kenichi Ogiwara, Masaru Shibata, Midori Shima

P-TH-120  A SINGLE CENTER CLINICAL SURVEY ON THE TREATMENT OF 24 CASES OF ACQUIRED HEMOPHILIA A: A 2011 UPDATE
Ogata Kyoichi* (JP), Takashi Suzuki, Manabu Otaki, Ikuo Seita, Takashi Muramatsu, Mihoko Yotsumoto, Takeshi Hagiwara, Kagehiro Amano, Katsuyuki Fukutake

P-TH-121  AGE OF FIRST FACTOR VIII INFUSION DO NOT INFLUENCE THE DEVELOPMENT OF INHIBITORS IN A BRAZILIAN COHORT OF CHILDREN WITH SEVERE HEMOPHILIA A
Jorge D Aivazoglou Carneiro* (BR), Paula Ribeiro Villaca, Eliane P Nobre Sandoval, Dalton A Fischer Chamone, Elbio Antonio D’amico

P-TH-122  ANTICOAGULANT ACTIVITY AND BEHAVIOR OF FXIIA INHIBITORS
Severine Robert* (BE), Henri M Spronk, Rene van Oerle, Philippe Devel, Francois Mullier, Bernard Chatelain, Lionel Pochet, Hugo ten Cate, Jean-Michel Dogne

P-TH-123  AGE-DEPENDANT INCREASE OF COAGULATION FACTOR LEVELS IN PATIENTS AND CARRIERS WITH HAEMOPHILIA A, VON WILLEBRAND DISEASE AND CORRELATION TO THE GENE DEFECT AND CO-MORBIDITY
Wolfgang Miesbach* (DE), Christine Delbrueck, Sybille Mueller, Vida Makki, Genet Asmelash, Stefanie Krekeker, Sonja Alesci

P-TH-124  INTEREST OF FACTOR VIII ACTIVITY/VON WILLEBRAND ANTIGEN RATIO IN THE EARLY DIAGNOSIS OF ACQUIRED HEMOPHILIA A RELAPSE
Armelle LEFRANCOIS* (FR), Julie Graveleau, Armelle Lefrancois, Marc Fouassier, Marianne Sigaud, Mohamed Haridou, Marc Trossaert

P-TH-125  ACUTE LEUKEMIA COMPLICATING HEREDITARY COAGULATION FACTOR XII DEFICIENCY CAUSED BY COMPLEX MUTATIONS
XU YE* (CN), YING FENG, XUHONG ZHOU, YIYAN LAI

P-TH-126  THE EVALUATION OF PROTEIN Z LEVELS OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA DURING INDUCTION THERAPY
Hale Oren* (TR), Aydan Cankal, Ozlem Tufekci, Salih Gozmen, Tuba Hilay Karapinar, Sebnem Yilmaz, Faize Yuksel, Canan Vergin, Gulersu Irken

P-TH-127  UNUSUAL PATTERN OF HEREDITARY BLEEDING DISORDERS AS REPORTED IN THE NEWFOUNDLAND AND LABRADOR, CANADA, REGISTRY OF RARE BLEEDING DISORDERS
Mary-Frances Scully* (CA), Charlotte Sheppard, Jill MacDonald
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-128  ACQUIRED FACTOR VIII INHIBITOR: A PRELIMINARY REPORT OF THREE CASES TREATED WITH AZATHIOPRINE
Audrey Kruse Zeinad Valim* (BR), Erica Okazaki, Paula Ribeiro Villaca, Patricia Lima Junqueira, Dalton Fischer Chamone, Elbio Antonio D’Amico

P-TH-129  PROPHYLAXIS IN HEMOPHILIA A: A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 4 CLINICAL STUDY OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM)
Wing-Yen Wong* (US), Vasily Mamonov, Andrzej Hellman, Doris Quon, Julian C Desmond, Phillip Schroth, Leonard A Valentino

P-TH-130  A PAIRED LC-MS/MS UNTARGETED METABOLOMICS INVESTIGATION OF PLASMA FROM PATIENTS ON WARFARIN IDENTIFIES NOVEL PROCOAGULANT PLASMA LIPIDS
Hiroyoshi Deguchi* (US), Darlene J Elias, Sunia Trauger, Huimin Zhang, Ewa Kalsiak, Gary Siuzdak, John H Griffin

P-TH-131  THE IMMUNOLOGICAL BASIS OF VARYING F8 INHIBITOR TITERS IN HEMOPHILIA A PATIENTS
Han-Mou Tsai* (US), M. Elaine Eyster, Wenhua Zhou

P-TH-132  INHIBITOR PROBLEM AND TREATMENT OF BLEEDING EPISODES IN A HEMOPHILIA B PATIENT
Osman Alphan Kupesiz* (TR), Vedat Uygun, Funda Tayfun, Mediha Akcan, Akif Yesilipek

Contact phase activation

P-TH-133  REAL TIME VISUALIZATION OF FVIII DISTRIBUTION IN MICE
Rupa Shree Appa* (DK), Ditte Maria Karpf, Lene Hansen, Mikael Kofod Hansen, Henrik Agersoe, Henning Stennicke

P-TH-134  THE INFLUENCE OF PNEUMATIC TUBE SYSTEM VERSUS MANUAL TRANSPORT ON ACTIVATION OF COAGULATION MEASURED WITH THROMBOELASTOMETRY AND THROMBIN GENERATION
Gerhardus J.A.J.M. Kuiper* (NL), Marcus D. Lance, Mathijis Sloep, Henri M.H. Spronk, Rene Van Oerle, Yvonne M.C. Henkens, Marco A.E. Marcus, Hugo Ten Cate

P-TH-136  CORN TRYPSIN INHIBITOR COATING ATTENUATES THE PROTHROMBOTIC PROPERTIES OF CORONARY CATHETERS IN VITRO AND IN RABBITS
Jonathan W Yau* (CA), Alan R Stafford, Peng Liao, James C Fredenburgh, Robin Roberts, John L Brash, Jeffrey I Weitz

P-TH-137  DISTINCTIVE CONTACT SYSTEM ACTIVATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IF PREVIOUS CARDIOVASCULAR DISEASE OR NOT

P-TH-138  FACTOR V LEIDEN MICE ARE VULNERABLE FOR ISCHEMIC STROKE
Toshiyuki Kita* (JP), Fumiaki Banno, Yukako Nakajo, Hiroki Yanamoto, Koji Ihara, Toshiyuki Miyata

P-TH-139  SUPPRESSION OF ACUTE PLASMA LEAKAGE IN GUINEA PIGS BY SUBCUTANEOUS ADMINISTRATION OF A NOVEL LOW-MOLECULAR-WEIGHT PLASMA KALLIKREIN INHIBITOR, AS1845069
Takehiro Shigenaga* (JP), Yumiko Moritani, Satoshi Nishijima, Yoshimasa Imamura, Kazuhiro Tetsuka
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-140  NON-FAMILIAL RECURRENT ANGIOEDEMA CASES EXPLAINED BY A COAGULATION FACTOR XII MUTATION
Georg Dewald* (DE), Emel Aygoeren-Pursun, Eva Rusicke, Immaculada Martinez Saguer, Wolfhart Kreuz

Anticoagulant pathway

P-TH-141  THE VITAMIN K-DEPENDENT ANTI-COAGULANT FACTOR, PROTEIN S, REGULATES MERTK-MEDIATED PHAGOCYTOSIS OF APOPTOTIC SUBSTRATE BY SERTOLI CELLS FROM SEMINIFEROUS EPITHELIUM
Omar Benzakour* (FR), Marina Yefimova, Nadia Messaddeq, Thomas Harnois, Anais Noblanc, Michel Philippe, Nicolas Bourmeyster, Omar Benzakour

P-TH-142  ROLE OF THE KUNITZ 1 AND KUNITZ 3 DOMAINS OF TFPI IN THE MECHANISM OF FXA INHIBITION
Sameera Peraramelli* (NL), Dennis Suylen, Jan Rosing, Tilman M Hackeng

P-TH-143  POOR ANTICOAGULANT RESPONSE TO TFPI IN PATIENTS WITH ACQUIRED OR INHERITED PROTEIN S DEFICIENCY
Brigitte Tardy-Poncet* (FR), Michele Piot, Dominique Brunet, Celine Chapelle, Pierre Morange, Patrick Mismetti, Herve Decousus, Bernard Tardy

P-TH-144  C6ORF105-ENCODED PROTEIN REGULATES TFPI- AND ANDROGEN-DEPENDENT ENDOTHelial ANTIcoagulant FUNCTION
Cristina Lupu* (US), Hua Zhu, Narcis Ioan Popescu, Jonathan David Wren, Florea Lupu

P-TH-145  CONTRIBUTION OF THE ACTIVATED PROTEIN C SYSTEM TO THE DYNAMICS OF THROMBIN FORMATION BY HUMAN VASCULAR CELLS AND DERIVED MICROPARTICLES
Veronique Regnault* (FR), Rose Said, Thomas Lecompte, Jean-Pierre Max, Huguette Louis, Patrick Lacolley, Denis G Wahl, Veronique Regnault

P-TH-146  IS IT POSSIBLE TO OBTAIN A TYPICAL HEPARIN FROM BOVINE INTESTINE?
Roberto Jose Castro Fonseca* (BR), Ana MF Tovar, Nina VM Capille, Bruno C Vairo, Gustavo RC Santos, Paulo AS Mourao

P-TH-147  ABSENCE OF PLATELET TISSUE FACTOR PATHWAY INHIBITOR (TFPI) REDUCES BLEEDING IN FVIII DEFICIENT MICE
Susan A Maroney* (US), Brian C Cooley, Catherine E Bonesho, Josephine P Ferrel, Lars C Petersen, Alan E Mast

P-TH-148  IS IT POSSIBLE USING A GLOBAL HEMOSTASIS ASSAY TO MONITOR THERAPY WITH DIRECT THROMBIN INHIBITORS?
Margareta Blomback* (SE), Hakan Wallen, Niklas Bark, Shu He

P-TH-149  THE ANTI-COAGULANT FACTOR PROTEIN S AND ITS STRUCTURAL HOMOLOG GAS6, REGULATE NEURAL STEM CELL PROLIFERATION.
Omar Benzakour* (FR), Valerie Coronas, Aurore Gely-Pernot, Arnaud Monvoisin, Pablo Garcia De Frutos, Michel Philippe, Omar Benzakour

P-TH-150  MOLECULAR BASIS OF ANTITHROMBIN DEFICIENCY. IDENTIFICATION OF 27 NEW MUTATIONS AND ASSOCIATIONS WITH OTHER GENETIC RISK FACTORS
Consuelo Martinez-Redondo* (ES), Ana I Anton, Jordi Fontcuberta, Francisco Espana, Natividad Gomez, Maria F Lopez, Pilar Llamas, Carmen De Cos, Ignacio Alberca, Cristina Pascual, Joaquin Martinez, Rosa Maia, Vanessa Roldan, Irene Martinez-Martinez, Antonia Minano, Jose Padilla, Vicente Vicente, Javier Corral
**POSTER PRESENTATIONS**

Thursday, July 28, 2011

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-151</td>
<td>ANTICOAGULANTS SYSTEM STATE IN MULTIPLE MYELOMA</td>
<td>Olga Smirnova* (RU), E. A. Hait, L. P. Papayan</td>
</tr>
<tr>
<td>P-TH-152</td>
<td>PROTEIN C LEVELS ARE REGULATED BY EDEM2 INDEPENDENT OF SOLUBLE EPCR LEVELS</td>
<td>Carolina Pintao* (NL), Frits R Rosendaal, Pieter H Reitsma</td>
</tr>
<tr>
<td>P-TH-153</td>
<td>PROTEIN C MUTATION (A267T) RESULTS IN ER RETENTION AND UNFOLDED PROTEIN RESPONSE ACTIVATION</td>
<td>Lena Tjeldhorn* (NO), Nina Iversen, Kirsten Sandvig, Jonas Bergan, Per Morten Sandset, Grethe Skretting</td>
</tr>
<tr>
<td>P-TH-154</td>
<td>EFFECTS OF FLUVASTATIN ON THE EXPRESSION OF TISSUE FACTOR PATHWAY INHIBITOR IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS</td>
<td>Eriko Morishita* (JP), Hiroki Torishima, Keiko Maruyama, Akiko Sekiya, Hidesaku Asakura, Shigeki Ohtake</td>
</tr>
</tbody>
</table>

### Serine protease inhibitors

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-156</td>
<td>TYPE IIHBS ANTITHROMBIN DEFICIENCY: CLINICAL SYMPTOMS AND LABORATORY DIAGNOSIS</td>
<td>Laszlo Muszbek* (HU), Zsuzsanna Bereczky, Zsolt Olah, Bettina Kovacs, Boda Zoltan</td>
</tr>
<tr>
<td>P-TH-157</td>
<td>GENETIC VARIABILITY AND PROMOTER MUTATIONS IN THE SERPINC1 GENE: IMPLICATION FOR INTERINDIVIDUAL VARIATIONS OF ANTITHROMBIN DEFICIENCY</td>
<td>Maria Eugenio de la Morena-Barrio* (ES), Ana Isabel Anton, Irene Martinez-Martinez, Jose Padilla, Antonia Minano, Jose Navarro-Fernandez, Lorena Velazquez, Sonia Aguila, Nataliya Bohdan, Vicente Vicente, Javier Corral</td>
</tr>
<tr>
<td>P-TH-158</td>
<td>ANTITHROMBIN KRAKOW: A NOVEL Mutation LEADING TO TYPE I DEFICIENCY ASSOCIATED WITH PROTHROMBOTIC FIBRIN CLOT PHENOTYPE IN A POLISH FAMILY</td>
<td>Magdalena Celinska-Lowenhoff* (PL), Teresa Iwaniec, Martine Alhenc-Gelas, Jacek Musial, Anetta Undas</td>
</tr>
<tr>
<td>P-TH-159</td>
<td>ELUCIDATING NOVEL UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITORS</td>
<td>Emma L. Smith* (UK), Emma Louise Smith, Spencer John, Maryam Abdinejad, Jayakanth Kankanala, Colin W.G. Fishwick, Emma Philippou</td>
</tr>
<tr>
<td>P-TH-160</td>
<td>PROTEIN C INHIBITOR - INTERACTION WITH ENTEROPEPTIDASE AND POSSIBLE FUNCTION IN THE PANCREAS</td>
<td>Thomas A. Prohaska* (AT), Felix Wahlmueller, Margarethe Geiger</td>
</tr>
<tr>
<td>P-TH-161</td>
<td>PROTEIN C INHIBITOR: A BROOMSTICK IN APOPTOTIC CELL CLEARANCE?</td>
<td>Daniela Rieger* (AT), Margarethe Geiger, Margareta Furtmueller, Katrin Einfinger, Sokolikova Barbora</td>
</tr>
<tr>
<td>P-TH-162</td>
<td>PROTEIN C INHIBITOR ON MICROPARTICLES AND ITS POSSIBLE FUNCTIONAL ROLES IN COMPLEMENT ACTIVATION</td>
<td>Katrin Einfinger* (AT), Margarethe Geiger, Margarete Furtmueller, Daniela Rieger, Felix Wahlmueller</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-163 DETECTION OF MUTATIONS IN THE ATIII GENE IN PATIENTS WITH VTE AND ATIII DEFICIENCY
Maria Tsaooudisidou (GR), Zisis Moschidis, Iwanna Anastasopoulou, Anastasia Karafoulidou, Olga Katsarou, Paraskevi Kotsi*

P-TH-164 PROTEIN C INHIBITOR (PCI) AND JFC1 INTERACTION IN PROSTATE CELLS
Barbora Sokolikova* (AT), Julia M. Malleier, Bernd R. Binder, Margarethe Geiger

P-TH-165 STABILITY OF THE BIOTIN MOIETY IN EP217609, A NEW PARENTERAL ANTICOAGULANT NEUTRALIZABLE BY AVIDIN
Maurice Petitou* (FR), Jean Amiral, Chantal Krezel, Eric Neuhart, Maurice Petitou

P-TH-166 INTRACELLULAR INTERACTION PARTNERS OF PROTEIN C INHIBITOR (PCI)
Margareta Furtmueller* (AT), Johannes Alfred Schmid, Bettina Sarg, Herbert Lindner, Margarethe Geiger

Structural biology and drug design

P-TH-167 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP) CLUSTER II INTERACTS WITH THE FACTOR (F)VIII LIGHT CHAIN VIA AN EXTENDED SURFACE COMPRISING MULTIPLE LYSINE RESIDUES
Maartje van den Biggelaar* (NL), Carmen van den Zwaan, Koen Mertens, Alexander B Meijer

P-TH-168 STABILIZATION OF RECOMBINANT HUMAN FIX BY GLYCOPEGLYATION
Anders Dybdal Nielsen* (DK), Lisbeth Palm, Finn Stausholm Nielsen

P-TH-169 PHARMACODYNAMIC DIFFERENCES OF AN ANTI-FXA ENRICHED ULTRA LOW MOLECULAR WEIGHT HEPARIN, AVE5026 IN COMPARISON TO ENOXAPARIN AND UNFRACTIONATED HEPARIN
Debra A Hoppensteadt* (US), Angel Gray, Evangelos Litinas, Walter Jeske, Jawed Fareed

P-TH-170 ISOLATION AND FUNCTIONAL CHARACTERIZATION OF A SINGLE CHAIN FORM OF RECOMBINANT FACTOR VIII
Lars Thim* (DK), Louise K Gram, Hermann Pelzer, Helle Knudsen, Kristoffer W Balling, Marianne Kjalke

P-TH-171 ZINC AND COPPER IONS IN A RECOMBINANT COAGULATION FACTOR VIII
Ole Hvilsted Olsen* (DK), L.A. Svensson, L. Thim, E.M. Nicolaisen

P-TH-172 AN OPEN LABEL, NON RANDOMIZED, PROSPECTIVE PHASE IV CLINICAL TRIAL EVALUATING THE IMMUNOGENICITY OF BRANDED ENOXAPARIN VERSUS BIOSIMILARS IN HEALTHY VOLUNTEERS
Marise Gomes* (US), Eduardo Ramacciotti, Debra Hoppensteadt, Jeanine Walenga, Bruce Lewis, Walter Jeske, Indermohan Thethi, Jawed Fareed

P-TH-173 MOLECULAR MIMICRY IN THE ADULTERATION OF HEPARIN. SCIENTIFIC BASIS FOR THE DEVELOPMENT OF OVERSULFATED CHONDROITIN SULFATE AND RELATED COMPONENTS.
Jawed Fareed* (US), Rakesh Wahi, Indermohan Thethi, Debra Hoppensteadt, Jeanine Walenga, Walter Jeske, Vinod Bansal, Harry Messmore

P-TH-174 THE TWO DIFFERENT ACTIVATED FORMS OF FXIII, FXIII*I AND FXIII*Iα, HAVE SIMILAR STRUCTURES, CATALYTIC ACTIVITY AND SUBSTRATE SPECIFICITY
Lene Hoerlyck* (DK), Mette Dahl Andersen, Johan Henrik Faber, Gunhild Klarskov Kristiansen, Benedicte Kiehr, Eva H. Norling Olsen
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-175  SHOULD GENERIC VERSIONS OF LOW MOLECULAR WEIGHT HEPARINS BE CONSIDERED AS GENERIC OR BIOSIMILAR DRUGS. A REGULATORY DILEMMA.
Jawed Fareed* (US), Walter Jeske, Jeanine M. Walenga, Debra Hoppensteadt, Rakesh Wahi, Russell Hull

P-TH-176  SERINE PROTEASE GENERATION BY OVESSULAFTED CHONDROITIN SULFATE AND CONTAMINANTS IN HEPARIN: CLINICAL IMPLICATIONS
Debra A Hoppensteadt* (US), Jacqueline Champlain, Josephine Cunanan, Hussein Khan, Walter Jeske, Jawed Fareed

Exogenous hemostatic factors

P-TH-177  DIFFERENTIAL EFFECTS OF GAS6 AND PROTEIN S IN HUMAN EOSINOPHILS
Koa Hosoki* (JP), Masaaki Toda, Atsushi Yasukawa, Yasushi Miyake, Daniel Boveda, Paloma Gil-Bernabe, Takehiro Takagi, Rumi Morooka, Mizuho Nagao, Corina D’Alessandro-Gabazza, John Morser, Takao Fujisawa, Osamu Taguchi, Esteban Gabazza

P-TH-178  ECONOMIC ANALYSIS OF AN EARLY PROPHYLAXIS REGIMEN TO REDUCE FVIII INHIBITOR DEVELOPMENT IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HAEMOPHILIA A
Guenter Auerswald* (DE), Karin Kurnik, Joshua D Epstein, Roberto Crea, Armin J Reininger

P-TH-179  IMMunosupressive ACTIVITY OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC): A NEW STEP TOWARD THE ERADICATION OF INHIBITORS AGAINST FACTOR VIII?

P-TH-180  ITI WITH A VWF/ FVIII CONCENTRATE IN HAEMOPHILIA A PATIENTS WITH INHIBITORS AND A POOR PROGNOSIS FOR ITI SUCCESS: PROGRESS REPORT ON OCTANATE IN THE OBSITI STUDY

P-TH-181  THE USE OF A VWF CONTAINING PLASMA DERIVED FVIII PRODUCT (VWF/ PD-FVIII) IN HEMOPHILIA A PATIENTS WITH INHIBITORS IN PRIMARY OR RESCUE IMMUNE TOLERANCE INDUCTION (ITI)
Victor Jimenez-Yuste* (ES), Saturnino Haya, Rosario Perez, Lydia Abad-Franch, Ana Rosa Cid, Inmaculada Soto, Carmen Altisent, Ihosvany Fernandez-Bello, Jordi Fontcuberta, Rosario Gonzalez-Bouillosa, Montserrat Maicas, Ramiro Nunez, Fernando Ortega, Maria Jose Paloma, Maria Angeles Palomo, Manuel Prieto, Margarita Redondo, Francisco Javier Rodriguez-Martorell, Jose Luis Sastre

P-TH-182  THE FIRST NATIONAL ANNUAL TENDER FOR FACTOR CONCENTRATES IN MACEDONIA
Violeta Dejanova-Ilijevska* (MK), Rumjana Apostolovska

P-TH-183  ALLERGIC REACTION AFTER REPLACEMENT THERAPY IN HAEMOPHILIA B PAEDIATRIC PATIENT WITH INHIBITOR TO FACTOR IX
Paola Giordano* (IT), Rosanna Scaraggi, Giuseppe Lassandro, Renato Marino, Domenico De Mattia, Francesco Antonio Scaraggi
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-184 SIGNIFICANT IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE WITH PROPHYLAXIS IN SEVERE HEMOPHILIA A: RESULTS FROM THE RAHF-PFM RANDOMIZED, CONTROLLED PROPHYLAXIS STUDY
Amy D Shapiro* (US), Elena Santagostino, Joshua D Epstein, Phillip Schroth, Wing-Yen Wong

P-TH-185 TOWARDS A LIQUID PLASMA BANK. OPTIMAL STORAGE CONDITIONS AND METHYLEN-BLUE PATHOGEN INACTIVATION OF THAWED PLASMA
Thomas Thiele* (DE), Sarah Khilner, Gregor Hron, Christina Wasner, Matthias Nauck, Andreas Greinacher, Kathleen Selleng

P-TH-186 SUBCUTANEOUS DELIVERY OF RFIXFC FOR THE TREATMENT OF HEMOPHILIA B
Susan M Dallabrida* (US), Todd D. Hoehn, Li Shuanglian, Douglas Drager, Tongyao Liu, Susannah Paratroyo-White, Nancy Moore, Glenn F. Pierce, Haiyan Jiang

P-TH-187 AN OPTIMIZED LOW VOLUME FACTOR IX PRODUCT CONCEPT SUPPLYING 400 IU/ML
Oliver Hegener* (CH), Lutz Hoffer, Marietta Putz, Gerhard Gruber

P-TH-188 PROCOAGULANT MICROPARTICLES IN THERAPEUTIC PLASMAS
Thomas P Lecompte* (FR), Marie Hacquard, Carole Pellegrini, Lysiane Chevreux, Sylvie Gross, Thierry Schneider

P-TH-189 FACTOR XI CONCENTRATE AS REPLACEMENT THERAPY FOR INHERITED FXI DEFICIENCY: DATA FROM A FRENCH COHORT OF 44 PATIENTS
Frederic Bauduer (FR), Emmanuelle De Raucourt, Jenny Goudemand, Catherine Boyer-Neumann, Marc Trossaert, Philippe Beurrier, Group Post-Marketing Study, Francoise Briday*, Catherine Chatelainaz, Celine Henriet*

P-TH-190 LOSAC, THE FIRST HEMOLIN THAT EXHIBITS PROCOAGULANT ACTIVITY THROUGH SELECTIVE FACTOR X PROTEOLYTIC ACTIVATION
Ana Marisa Chudzinski-Tavassi* (BR), Daniel Furlin, Oscar Henrique Pereira Ramos, Andrea Balan, K Konno, Miryam Paola Alvarez Flores

Fibrinogen and other factors

P-TH-191 IMPACT OF HEMODILUTION WITH CRYSTALLOIDS AND COLLOIDS ON PRIMARY HEMOSTASIS AND COAGULATION PARAMETERS: REVERSION OF THE COAGULOPATHY WITH PLASMA CONCENTRATES
Carolina Caballo* (ES), CAROLINA CABALLO, ANA M. GALAN, MARIBEL DIAZ-RICART, IRENE LOPEZ-VILCHEZ, ARTURO PEREIRA, MIGUEL LOZANO, JOAN CID, JOAN BELTRAN, MISERICORDIA BASORA, GINES ESCOLAR

P-TH-192 A COMPARISON OF RECOMBINANT AND PLASMA-DERIVED HUMAN FIBRINOGEN ON EX-VIVO CLOT FORMATION IN WHOLE BLOOD SAMPLES FROM CARDIAC SURGERY PATIENTS
Fariba Baghaei* (SE), Vladimir Radulovic, Inger Fagerberg Blixter, Susann Samuelsson, Anders Jeppsson

P-TH-193 FAMILIAL FIBRINOGEN DONGHAE: A NOVEL DYSFIBRINOGENEMIA WITH GAMMA ALANINE-367 TO ASPARTATE SUBSTITUTION
Eunkyung Park* (KR), Eunyoung Jeon, Hee-Jin Kim, Inho Kim, Seonyang Park

P-TH-194 FIBRIN ARCHITECTURE IS ALTERED IN ABDOMINAL AORTIC ANEURYSMS AND CORRELATES WITH ANEURYSM SIZE
Cedric Duval* (UK), Julian D A Scott, Priya Prasad, Daniel Whalley, Andy Kordowicz, Ramzi A Aijan, Helen Philippou, Robert A S Ariens
P-TH-195  ON DEMAND THERAPY AFTER ITT FAILURE IN A PATIENT WITH VON WILLEBRAND DISEASE TYPE 3 AND ALLOANTIBODIES
Manuela Krause* (DE), Thomas Scholz, Christoph Koenigs, Daniele Piliitteri, Ann-Kathrin Pilgrimm, Carl Maximilian Kirchmaier, Wolfhard Kreuz

P-TH-196  FIBRIN NANOMECHANICS: STRUCTURAL UNDERPINNINGS AND UNFOLDING MECHANISM UNDERLYING FORCED ELONGATION OF FIBRIN(OGEN) MONOMERS AND POLYMERS
John W Weisel* (US), Artem Zhmurov, Andre E.X. Brown, Rustem I. Litvinov, Ruxandra I. Dima, Valeri Barsegov, John W. Weisel

P-TH-197  CLEAVAGE OF FIBRINOGEN FPA BY THROMBIN INDUCES STRUCTURAL CHANGES WITHIN BBETA121-138 REGION OF MOLECULE
Eduard Vitalievich Lugovskoy* (UA), Lesya Petrovna Urvant, Evgeniy Mitrofanovich Makogonenko, Nataliya Eduardovna Lugovskaya, Nikolay Aleksandrovich Pydiura, Tatyana Anatolevna Koshel, Irina Nikolaevna Kolesnikova, Serhey Vasilievich Komisenenko

P-TH-198  VISFATIN INDUCES TISSUE FACTOR EXPRESSION IN MONOCYTES BY NF-KAPPA-B-DEPENDENT PATHWAY
Li Jun-ling* (CN), Shi-long Xiong, Ping Zhou, Wen-hui Zhu, Feng Gao

P-TH-199  POLYMERIZATION OF THE αC-DOMAINS IN FIBRIN RESULTS IN THE EXPOSURE OF THEIR CRYPTIC TPA- AND PLASMINOGEN-BINDING SITES
Leonid Medved* (US), Galina Tsurupa, Ariza Mahid

P-TH-200  CAN HAEMOCOMPLETTAN (A FIBRINOGEN CONCENTRATE) AND/OR FIBROGAMMIN (A FXIII CONCENTRATE) BE USED AS ANTIDOTES TO THE BLEEDING COMPLICATIONS OF ANTITHROMBOTIC THERAPY ?
Shu He* (SE), Hakan Wallen, Bark Niklas, Johnsson Hans, Blomback Margareta

P-TH-201  PROCAGULANT PHOSPHOLIPIDS IN PATIENTS WITH LIVER CIRRHOSIS WITH AND WITHOUT PORTAL VEIN THROMBOSIS.
Valeria Rossetto (IT), Luca Spiezia, Elena Campello, Sabrina Gavasso, Maria Bon, Marco Serzolo, Krissa Rodriguez, Maria Teresa Sartori, Barry Woodhams*, Paolo Simioni

P-TH-202  TISSUE TRANSGLUTAMINASE INHIBITOR IN A PATIENT WITH ACQUIRED FXIII DEFICIENCY
Aaron Lubetsky* (IL), Rima Dardik, Gil Kenet, Ilia Tamarin, Uri Martinowitz

Laboratory tests

P-TH-203  PRELIMINARY PERFORMANCE DATA OF A NEW FREE PROTEIN S ANTIGEN ASSAY*
Mechthild Merz* (DE), Andreas Eidam, Edelgard Lindhoff-Last

P-TH-204  AN INNOVATIVE TOOL TO INVESTIGATE THE IMMUNE RESPONSE DIRECTED AGAINST FVII IN PATIENTS WITH BLOOD COAGULATION DISORDERS TREATED BY RFVIIA
Caroline Pfeiffer* (FR), Geraldine Lavigne-Lissalde, Pauline Logghe, Huseyin Tokgoz, Jean-Luc Pellequer, Jean-Francois Schved, Muriel Giansily-Blalot, . the french group of FVII deficiency

P-TH-205  MARKERS OF BLOOD CELL ACTIVATION AND COMPLEMENT ACTIVATION IN FACTOR IX CONCENTRATES
Martin F Brodde* (DE), Beate Kehrel
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-206 MEASUREMENT OF RIVAROXaban PLASMA CONCENTRATIONS USING CALIBRATORS AND CONTROLS &0150; RESULTS OF THE PROTHROMBIN TIME AND THE ANTI-FACTOR XA CHROMOGENIC ASSAY FIELD TRIALS
MEYER MICHEL SAMAMA* (FR), Genevieve Contant, Elisabeth Perzborn, Celine Guinet, Yves Gourmelin, Lena Le Fliern, Jean Luc Martinoli, Francois Depasse, Gabriele Rohde, Theodore E. Spiro

P-TH-207 EFFECT OF N-ACETYLCYSTEINE ON COAGULATION AND CLOT FORMATION.
Carolina Caballo* (ES), Carolina Caballo, Annabel Blasi, Miguel Lozano, Ana M. Galan, Pilar Taura, Gines Escolar

P-TH-208 FEATURES OF A NEW CHROMOGENIC KIT FOR DETERMINATION OF FIX ACTIVITY IN PLASMA AND FIX CONCENTRATES.
Pia Bryngelshed* (SE), Per Rosen, Steffen Rosen

P-TH-209 ACCIDENTAL DIAGNOSIS OF REDUCED FVIII LEVELS IN FEMALES: WHAT DOES IT MEAN?
Rima Dardik* (IL), Ariella Zivelin, Gili Kenet, Shadan Lalezari, Uriel Martinowitz

P-TH-210 A PATIENT DISCREPANT IN ASSAYS OF FREE PROTEIN S ANTIGEN
Kieron P Hickey* (UK), Kieron Hickey, Peter Cooper, Steve Kitchen, Rhona Maclean

P-TH-211 ACQUIRED FACTOR V INHIBITOR DEVELOPING IN A PATIENT WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Minoo Ahmadnejad* (IR), Nader Roushan, Hassan Abolghasemi

P-TH-212 THROMBIN GENERATION AND ANTITHROMBOTIC ACTIVITY OF FONDAPARINUX AFTER TOTAL HIP REPLACEMENT
Lauri Virtanen* (FI), Birgitta Salmela, Jari Leinonen, Lotta Joutsi-Korhonen, Riitta Lassila

P-TH-213 EVALUATION OF THROMBIN GENERATION IN SICKLE CELL PATIENTS AND CORRELATION TO CLINICAL DISEASE
Nirmish R Shah* (US), Marilyn Telen, Thomas Ortel

P-TH-214 STUDY ON THE METHOD FOR ASSAYING FVIII INHIBITOR TITER USING FVIII CONCENTRATE FOR THE NEUTRALIZATION THERAPY.
Tatsuya Araki* (JP), Kohi Hashimoto, Sayaka Oonishi-Kanakuri, Noriyuki Ishihara, Kuzuhiko Tomokiyo, Takayoshi Hamamoto, Tonomihiro Nakagaki, Hideji Hanabusa

P-TH-215 A FILTER SPOT TEST FOR OVERSULFATED CONTAMINANTS IN HEPARIN
Helga Szelke* (DE), Ulrich Warttinger, Annamaria Naggi, Giangiacomo Torri, Job Harenberg, Roland Kraemer

P-TH-216 ANTICARDIOLIPID ANTIBODIES IN THE REAL WORLD: WHAT IS THE IMPACT OF A CONFIRMATORY TEST AT 12 WEEKS?
Jean Devignes (FR), Denis Wahl, Stephane Zuly, Thomas Lecompte*

P-TH-217 THE EFFECTS OF VARYING HEMOGLOBIN/HEMATOCRIT AND PLATELET COUNT ON NOVEL THROMBOElastographic METHODS WHICH ARE SENSITIVE FOR HYPERCOAGULABILITY
Richard Har Ko* (US), Jenily Malvar, Guy Young

P-TH-218 EVALUATION OF THE COAGULATION ANALYZER CEVERON ALPHA WITH THE NEW OPTIMIZED FLUOROGENIC MODULE FOR STANDARDIZED TGA MEASUREMENT
Lieselotte Wagner* (AT), Viktoria Kaufmann, Jutta Mager, Wolfgang Manak

P-TH-219 LABORATORY EVALUATION AND MUTATIONAL ANALYSIS OF A COHORT OF PATIENTS WITH ANTITHROMBIN DEFECTS
Mary Byrne* (IE), Carol Ryan, Lisa Preston, Ruth Gilmore, James O’Donnell, Peter V Jenkins
Thursday, July 28, 2011

P-TH-220  EVALUATION OF DIRECT THROMBIN INHIBITORS ASSAY FOR MEASURING DABIGATRAN PLASMA CONCENTRATIONS USING CALIBRATOR AND CONTROLS
Omid Safa* (US), Ralph Bottenus, Mark Triscott

P-TH-221  THROMBIN GENERATION - EXPERIENCE IN A ONE YEAR OBSERVATION PERIOD UNDER ROUTINE CONDITIONS
Annelie Siegemund* (DE), Thomas Siegemund, Natalie Adam, Ute Scholz

P-TH-222  THE RATIO BETWEEN THE ACTIVITIES OF COAGULATION FACTOR XII AND C1 ESTERASE INHIBITOR IN PATIENTS WITH ANGIOEDEMA - UPDATE
Georg Moessmer* (DE)

P-TH-223  SIBLINGS WITH HEMOPHILIA A AND INHIBITORS SHOW SIMILAR REACTIVITY WITH FVIII EPITOPES
Christoph Koenigs* (DE), Joerg Kahle, Aleksander Orlowski, Diana Stichel, Nicole Krause, Karin Becker-Peters, Christine Heller, Sharyne Donfield, Erik Berntorp, Wolthart Kreuz, Jan Astermann

P-TH-224  LIQUID ANTI-XA ASSAY: RAPID MONITORING OF XA INHIBITORS
Valeri Krougliak* (US), Chun Kung, Mark Triscott

P-TH-225  A NEW LATERAL-FLOW DEVICE IN URINE TO ASSESS COAGULATION ACTIVITY IN PATIENTS WITH OR WITHOUT VENOUS THROMBOEMBOLIC COMPLICATIONS AFTER TOTAL HIP OR KNEE ARTHROPLASTY
Lars Carl Borris* (DK), Morten Breindahl, Michael Rud Lassen, Akos Ferenc Pap, Frank Mielstwitz

P-TH-226  USE OF PROTEIN C CONCENTRATE IN ADULT PATIENTS WITH CANCER AND DISSEMINATED INTRAVASCULAR COAGULATION
Alessandra Malato* (IT), Giorgia Saccullo, Clementina Caracciolo, Lucio Lo Coco, Sergio Siragusa

P-TH-227  LABORATORY FOLLOW-UP AND CLINICAL MANAGEMENT OF A PATIENT CASE WITH SEVERE BLEEDING COMPLICATION ON DABIGATRAN FOR ATRIAL FIBRILLATION
Riitta Lassila* (FI), E Munsterhjelm, L Joutsi-Korhonen, Elina Armstrong

P-TH-228  CIRCADIAN CHANGES IN THROMBOTIC POTENTIAL IN OBSTRUCTIVE SLEEP APNEA (OSA): A RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER STUDY
Brad McEwen* (AU), Marie-Christine Morel-Kopp, Craig Phillips, David Sullivan, Christopher M Ward, Ron Grunstein, Geoffrey H Tofler

P-TH-229  COMPARING THROMBIN GENERATION ASSAY WITH ACTIVATED PARTIAL THROMBOPLASTIN TIME FOR MONITORING THERAPY IN A PATIENT WITH ACQUIRED HEMOPHILIA
Franco Carmassi* (IT), Ferdinando De Negri, Alessandra De Serio

P-TH-230  CORRELATION BETWEEN HEPARIN DOSE AND CLINICAL MONITORING TEST RESULTS INCLUDING APTT IN PATIENTS TREATED WITH UNFRACTIONATED HEPARIN
Sumiyoshi Naito* (JP), Masahiro Ieko, Mika Yoshida, Nobuhiko Takahashi, Osamu Kuman, Masumi Murakami, Chizuru Morikawa, Shinji Fujita, Yutaka Toyoda, Shigeru Arima

P-TH-231  LEVEL OF KNOWLEDGE AMONG TUNISIAN PATIENTS UNDERGOING LONG-TERM ACENOCOUMAROL TREATMENT
Faouzi Addad* (TN), Iella zohr Rezine, Khalil Mahmoudi, Rym Chrigui, nadi Hammami, Samir Chine, Majdi Amami, Sami Gargouri, Afef Ben Halima, Ikram Kamoun, Salem Kachboura

P-TH-232  D-DIMER LEVELS AND PREECLAMPSIA: A SYSTEMATIC REVIEW
Luci Maria SantAna Duise* (BR), Melina Barros Pinheiro, Fernanda Fonseca Coelho, Maria Graca Carvalho, Ana Paula Fernandes, Daniela Rezende Junqueira, Karina Braga Gomes
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-233  COAGULATION ABNORMALITIES IN PATIENTS WITH COLON CANCER OPERATED FOR ACUTE INTRA-ABDOMINAL SEPSIS.
Dmitriy Gurzhiy* (RU), Khizri Ahmedovich Gamzatov

P-TH-234  REVIEW OF OUT OF HOUR COAGULATION SCREEN REQUESTS IN TWO UNIVERSITY TEACHING HOSPITALS
Siamak Arami* (UK), Charlotte Foley, John Hanley

Experimental models

P-TH-235  DIRECT FLUORESCENCE ASSAY FOR THE QUANTIFICATION OF HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARINS IN CLINICAL SAMPLES
Helga Szelke (DE), Christina Giese, Roland Kraemer, Job Harenberg*

P-TH-236  SEVERE HEMOPHILIA A IN A MALE DOG WITH A C TO T TRANSITION IN EXON 12 OF FACTOR VIII GENE LEADING TO A PREMATURE STOP CODON
Timothy Charles Nichols* (US), Jay N Lozier, Mark T Kloos, Elizabeth P Merricks, Robin A Raymer, Nathaly Lemoine, Dwight Bellinger

P-TH-237  COMPARISON OF UNFRACTIONATED HEPARIN, ENOXAPARIN, LOW-DOSE AND HIGH-DOSE RIVAROXaban IN PREVENTING THROMBUS FORMATION ON MECHANICAL HEART VALVES: RESULTS OF AN IN VITRO STUDY
Anja Kaeberich* (DE), Iris Reindl, Uwe Raaz, Lars Maegdefessel, Alexander Vogt, Torsten Linde, Ulrich Steinseifer, Elisabeth Perzborn, Nancy Cook Bruns, Baerbel Hauroeder, Michael Buerke, Karl Werdan, Axel Schlitt

P-TH-238  LONG-TERM ESTROGEN TREATMENT OF THROMBOSIS PRONE MICE INDUCES A SUSTAINED INCREASE IN THE ENDOGENOUS THROMBIN POTENTIAL WITHOUT AFFECTING THE THROMBOTIC PHENOTYPE
Audrey CA Cleuren* (NL), Rene van Oerle, Hugo ten Cate, Pieter H Reitsma, Henri M Spronk, Bart JM van Vlijmen

P-TH-239  THROMBOMODULIN MODULATES MATURATION AND ANTIGEN PRESENTATION OF MURINE DENDRITIC CELLS IN VITRO
Masaaki Toda* (JP), Takehiro Takagi, Osamu Taguchi, Daniel Boveda Ruiz, Paloma Gil Bernabe, Corina N D’Alessandro-Gabazza, Yasushi Miyake, Atsushi Yasukawa, John Morser, Esteban C Gabazza

P-TH-240  ALLERGEN-INDUCED BRONCHIAL ASTHMA IN THE FACTOR V LEIDEN MOUSE
Atsushi Yasukawa* (JP), Takehiro Takagi, Osamu Taguchi, Masaaki Toda, Daniel Boveda Ruiz, Paloma Gil Bernabe, Corina N D’Alessandro-Gabazza, Yasushi Miyake, John Morser, Esteban C Gabazza

P-TH-241  THE ROLE OF THROMBIN IN ALLERGIC BRONCHIAL ASTHMA IS MEDIATED BY DENDRITIC CELLS
Yasushi Miyake* (JP), Masaaki Toda, Atsushi Yasukawa, Yuki Matsushima, Corina N Gabazza, Takehiro Takagi, Masahiro Naito, Daniel Boveda Ruiz, Paloma Gil Bernabe, John Morser, Osamu Taguchi, Esteban C Gabazza

P-TH-242  THE PRINCIPAL RESULTS OF THE INTERNATIONAL IMMUNE TOLERANCE STUDY: EFFICACY AND PREDICTORS OF OUTCOME.
Charles RM Hay* (UK), Donna M Di Michele, and ITI Study Group

P-TH-243  THE PRINCIPAL RESULTS OF THE INTERNATIONAL IMMUNE TOLERANCE STUDY: MORBIDITY.
Charles RM Hay* (UK), Donna M Di Michele, and The ITI study Group
### POSTER PRESENTATIONS

**Thursday, July 28, 2011**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-244</td>
<td>CARBON MONOXIDE-RELEASING MOLECULE-DERIVED CO REGULATES TISSUE FACTOR IN HUMAN ENDOTHELIAL CELLS AND PERIPHERAL BLOOD MONONUCLEAR CELLS</td>
<td>Keiko Maruyama* (JP), Eriko Morishita, Takeo Yuno, Akiko Sekiya, Hidesaku Asakura, Shigeki Ohtake</td>
</tr>
<tr>
<td>P-TH-245</td>
<td>THE PROTEIN C SYSTEM DOES NOT PLAY A ROLE IN HOST DEFENSE DURING EXPERIMENTAL TUBERCULOSIS</td>
<td>Liesbeth M Kager* (NL), Catharina W Wieland, Alex F De Vos, Joris J Roelofs, Joost CM Meijers, Berend Isermann, Charles T Esmon, Cornelis Van ‘t Veer, Tom Van der Poll</td>
</tr>
<tr>
<td>P-TH-246</td>
<td>CHARACTERISATION OF BASELINE AND CYTOKINE-STIMULATED ENDOTHELIAL CELL COAGULANT PHENOTYPE AND CORRELATION WITH TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION.</td>
<td>Asad Luqmani* (UK), Mike A Lafian, Ayeshia R Khan, Abdullah Alsuiman</td>
</tr>
</tbody>
</table>

#### Plasminogen and plasminogen activators

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-247</td>
<td>HIGH AFFINITY BINDING OF PLASMINOGEN TO FIBRIN IS NOT ESSENTIAL FOR EFFICIENT ACTIVATION BY TISSUE PLASMINOGEN ACTIVATOR</td>
<td>Paul Y. Kim* (CA), Long D. Tieu, Alan R. Stafford, James C. Frederburgh, Jeffrey I. Weitz</td>
</tr>
<tr>
<td>P-TH-248</td>
<td>IDENTIFICATION OF MOLECULAR TARGET OF SMTP, A CANDIDATE THERAPEUTIC COMPOUND FOR STROKE</td>
<td>Eriko Suzuki* (JP), Naoki Matsumoto, Keiji Hasumi</td>
</tr>
<tr>
<td>P-TH-249</td>
<td>CROSS-EFFECTS OF HYPOTENSIVE AND ANTIFIBRINOLYTIC DRUGS ON THE KEY ENZYMES ACTIVITY OF FIBRINOLYTIC SYSTEM (FS) AND RENIN-ANGIOTENSIN SYSTEM (RAS) IN VITRO</td>
<td>Dmitry A Gulin* (RU), Lilia I Mukhametova, Roza B Aisina, Olga A Kost, Irina I Nikolskaya, Karina B Gershkovich</td>
</tr>
<tr>
<td>P-TH-250</td>
<td>OCCULT ACTIVATION OF FIBRINOLYSIS IN TRAUMA</td>
<td>Imran Raza* (UK), Ross Davenport, Claire Rourke, Sean Platton, Joanna Manson, Catherine Spoors, Henry De’Ath, Sirat Khan, Shuba Allard, Daniel Hart, K John Pasi, Beverley J Hunt, Simon Stanworth, Peter MacCallum, Karim Brohi</td>
</tr>
<tr>
<td>P-TH-251</td>
<td>PLASMINOGEN/PLASMIN MODULATES BONE METABOLISM BY REGULATING THE OSTEOBLAST AND OSTEOCLAST FUNCTION.</td>
<td>Yosuke Kanno* (JP), Eri Kawashita, Kiyotaka Okada, Shigeru Ueshima, Osamu Matsuo, Hiroyuki Matsumo</td>
</tr>
<tr>
<td>P-TH-252</td>
<td>DIABETES-INDUCED POST-TRANSLATIONAL MODIFICATIONS IN PLASMINOGEN ALTER PROTEIN ACTIVITY AND INTERACTION WITH FIBRIN</td>
<td>Ramzi A Ajjan* (UK), Toby Gamlen, Kristina F Standeven, Salihah Mughal, Katharina Hess, Paul Thornalley, Fladia Phoenix, Helen Philippou, Peter J Grant</td>
</tr>
<tr>
<td>P-TH-253</td>
<td>INSIGHTS INTO THE DIFFERENT CONFORMATIONAL FORMS OF PLASMIN(ogen)</td>
<td>Bernadine G C Lu* (AU), Ruby H P Law, Paul B Coughlin, Anita J Horvath</td>
</tr>
<tr>
<td>P-TH-254</td>
<td>PLASMIN-ANTIPLASMIN COMPLEX IS AN USEFUL MARKER FOR DIAGNOSIS OF AL AMYLOIDOSIS</td>
<td>Mitsuhiko Uchiba* (JP), Hiroyuki Hata, Yuji Yonemura, Mitsuharu Ueda, Hiroaki Mitsuya, Yukio Ando</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-255  
ZN⁺ DELAYS GLU- AND LYS-PLASMINOGEN ACTIVATION BY TISSUE PLASMINOGEN ACTIVATOR AND INHIBITS PLASMIN ACTIVITY TOWARD MACROMOLECULAR SUBSTRATES
Sultan Chaudhry* (CA), Paul kim, Alan Stafford, Beverly Leslie, James Frederburgh, Jeffrey Weitz

P-TH-256  
EFFECT OF FIBRINOGEN ON CELL-STIMULATED ACTIVATION OF PLASMINOGEN
Valeryi K Lishko* (US), Ivan S Yermolenko, Tatiana P Ugarova

P-TH-257  
A NEW SYNTHETIC PEPTIDE (SP) ENHANCES PLASMINOGEN ACTIVATION BY T-PA
Kiyotaka Okada* (JP), Shigeru Ueshima, Hiroyuki Matsuno, Naoyuki Kawao, Yukinori Tamura, Masato Yano, Nobuo Nagai, Osamu Matsuo

P-TH-258  
MODELLING PLASMINOGEN ACTIVATION IN FIBRIN USING VARIANTS OF TISSUE PLASMINOGEN ACTIVATOR
Colin Longstaff* (UK), Craig Thelwell, Marta Silva

TAFI

P-TH-259  
EVALUATION OF TAFI ACTIVATION IN PLASMAS WITH ABNORMAL THROMBIN GENERATION. ROLE OF PROGRESSIVE DOSIS OF THROMBIN IN THE ASSAY.
Maria Lucia D’Errico (VE), Norma de Bosch*, Apsara Boadas, Carlos Ibbarra, Ana Maria Salazar, Arilette Ruiz-Saez, Belsy Guerrerro

P-TH-260  
HYPOFIBRINOLYSIS AND THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM: A PROSPECTIVE COHORT STUDY
Ludwig Traby* (AT), Georg Heinze, Marietta Kollars, Lisbeth Eicher, Sabine Eichinger, Paul Alexander Kyrle

P-TH-261  
EFFECT OF ORAL ANTICOAGULANT TREATMENT ON TAFI/TAFIA LEVELS AND CLOT RESISTANCE TO FIBRINOLYSIS
Mario Colucci* (IT), Francesca Incampo, Cosimo Carrieri, Rita Galasso, Frarancesca Di Serio, Nicola Semeraro

P-TH-262  
ASSOCIATIONS BETWEEN TAFI LEVELS, THE TAFI GENE POLYMORPHISMS AND THE CLOT LYSIS IN DEEP VEINS IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN RUSSIAN POPULATION

P-TH-263  
PROTECTIVE ROLE OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN ALLERGIC BRONCHIAL ASTHMA

P-TH-264  
THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR SYSTEM IN CANCER PATIENTS WITH OR WITHOUT VENOUS THROMBOEMBOLISM
Claudia Maria Radu (IT), Luca Spiezia, Elena Campello, Cristiana Bulato, Sabrina Gavasso, Fabio Dalla Valle, Sara Carraro, Valeria Ferri, Barry Woodhams*, Paolo Simonelli

P-TH-265  
ACTIVATION OF THE COMPLEMENT SYSTEM IN DIABETIC THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR/APOLIPOPROTEIN-E DOUBLE KNOCKOUT MICE.
Paloma Gil Bernabe* (JP), Corina N. D’Alessandro-Gabazza, Masaaki Toda, Takehiro Takagi, Daniel Boveda Ruiz, Yasushi Miyake, John Morser, Esteban C. Gabazza
## POSTER PRESENTATIONS

**Thursday, July 28, 2011**

### P-TH-266 HYPOFIBRINOLYSIS IN PATIENTS WITH PORTAL VEIN THROMBOSIS AND LIVER CIRRHOSIS.
Valeria Rossetto (IT), Luca Spiezia, Sabrina Gavasso, Patrizia Zerbinati, Elena Campello, Marco Serzolo, Krisssia Rodriguez, Maria teresa Sartori, Maria Bon, Barry Woodhams*, Paolo Simioni

### MMPs

#### P-TH-267 MODULATION OF GELATINASES DURING WEIGHT LOSS IN OBESE MICE
Matthias Van Hul* (BE), Bianca Hernmeryckx, Henri Roger Lijnen

#### P-TH-268 HIGH LEVEL OF MATRIX METALLOPROTEINASE-2 IS RELATED TO THROMBOTIC EVENTS IN PATIENTS WITH STABLE CORONARY DISEASE.
Andrey Komarov* (RU), Anatoly Dobrovolsky, Elena Titaeva, Olga Shakmatova, Tatiana Ilyushchenko, Gulara Dzhaililova, Aleksander Deev, Elisaveta Panchenko

### Deep vein thrombosis and pulmonary embolism

#### P-TH-269 INTAKE OF FATTY FISH IS ASSOCIATED WITH LOWER RISK OF VTE. A DANISH FOLLOW-UP STUDY
Marianne Tang Severinsen* (DK), Kim Overvad, Erik Berg Schmidt, Soeren Risom Kristensen

#### P-TH-270 A NOVEL MISSENSE MUTATION OF FACTOR V (FACTOR V NARA : W1920R) MANIFESTED THROMBOSIS AND DEMONSTRATED A POSITIVE RESULT OF ACTIVATED PROTEIN C RESISTANCE ASSAY
Keiko Shinozawa* (JP), Keiji Nogami, Kenji Ogwara, Tomoko Matsumoto, Kagehiro Amano, Midori Shima, Katsuyuki Fukutake

#### P-TH-271 RESULTS OF THROMBOPHILIA SCREENING IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN NORTH WEST RUSSIA.
Veronika Shmeleva* (RU), Sergei Kapustin, Michail Blinov, Vera Kobilyanskaya, Ludmila Papayan

#### P-TH-272 THE INCIDENCE OF RECURRENT VENOUS THROMBOEMBOLISM IN A DEFINED POPULATION
Inge C.M. Mos* (NL), Melanie Tan, Madelief Klinkenberg, Felix J.M. van der Meer, Menno V. Huisman

#### P-TH-273 ONYX-3, A DOUBLE-BLIND COMPARISON OF ONCE- OR TWICE-DAILY DOSING WITH YM150 (30 OR 60 MG DAILY) FOR PREVENTING VENOUS THROMBOEMBOLISM AFTER ELECTIVE HIP ARTHROPLASTY
Bengt I Eriksson* (SE), Giancarlo Agnelli, Alexander S Gallus, Michael R Lassen, Martin H Prins, Ronny W Renfurum, Alexander GG Turpie

#### P-TH-274 PROTEIN S MUTATIONS IN THAI PATIENTS WITH DEEP VEIN THROMBOSIS
Worawan - Chumpia* (TH), Pantep Angchaisuksiri, Chatlada Thabthimngam, Yada Moonpjit, Panutas Kritpetchrarut

#### P-TH-275 DABIGATRAN ETExilate IS EFFECTIVE IN OVERWEIGHT AND OBESE PATIENTS - EFFECT OF BODY MASS INDEX (BMI) ON THE EFFICACY OF DABIGATRAN ETExilate: A POOLED ANALYSIS
Bengt I Eriksson* (SE), Andreas A Kurth, Ola E Dahl, Martin Feuring, Andreas Clemens, Herbert Noack, Stefan Hantel, Richard J Friedman, Michael Huo
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-276 ORAL DABIGATRAN ETIXilate VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP ARTHROPLASTY: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS
Bengt I Eriksson* (SE), Andreas A Kurth, Ola E Dahl, Andreas Clemens, Janet Schnee, Stefan Hantel, Martin Feuring, Richard J Friedman, Michael Huo

P-TH-277 RIVAROXABAN: SAFETY, USEFULNESS AND PRACTICAL DETAILS OF DRUG MONITORING.
François Mullier* (BE), Jonathan Douxfils, Severine Robert, Philippe Devel, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogne

P-TH-278 DABIGATRAN: SAFETY, USEFULNESS AND PRACTICAL DETAILS OF DRUG MONITORING.
François Mullier* (BE), Jonathan Douxfils, Severine Robert, Philippe Devel, Christian Chatelain, Bernard Chatelain, Jean-Michel Dogne

P-TH-279 RISK ASSESSMENT FOR RECURRENT VENOUS THROMBOEMBOLISM (VTE) AFTER 6 TO 14 MONTHS OF ANTICOAGULANT TREATMENT
Gary E Raskob* (US), Lensing W.A. Anthonie, Martin H. Prins, Sebastian Schellong, Harry R. Buller

P-TH-280 ANTICOAGULATION AND BLEEDING: THE EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, ACETYLSALICYLIC ACID, OR OTHER PLATELET AGGREGATION INHIBITORS
Bruce L Davidson* (US), Anthonie W.A. Lensing, Benjamin Brenner, Martin H. Prins, Martin Gebel, Martin Homering, Harry R. Buller

P-TH-281 THE RELATIVE EFFICACY OF RIVAROXABAN VERSUS VITAMIN K ANTAGONISTS (VKA) IN RELATION TO TIME IN THERAPEUTIC RANGE (TTR) IN PATIENTS WITH DEEP VEIN THROMBOSIS (DVT)
Martin H Prins* (NL), Anthonie W.A. Lensing, Phil Wells, Alice Benson, Karina Meijer, Harry R. Buller

P-TH-282 THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM AND MAJOR BLEEDING IN FRAGILE PATIENTS WITH DEEP VEIN THROMBOSIS
Peter Verhamme* (BE), Anthonie W.A. Lensing, Barry Jacobson, Akos F. Pap, Martin H. Prins, Harry R. Buller

P-TH-283 ANTICOAGULATION AND BLEEDING: THE EFFECT OF BLOOD PRESSURE
Herve Decousus* (FR), Anthonie W.A. Lensing, Franco Piovella, Martin H. Prins, Akos F. Pap, Harry R. Buller

P-TH-284 PATIENT-REPORTED TREATMENT SATISFACTION WITH ORAL RIVAROXABAN VERSUS STANDARD THERAPY IN THE TREATMENT OF SYMPTOMATIC DEEP VEIN THROMBOSIS (DVT)
Luke Bamber* (DE), Stefan J. Cano, Donna L. Lamping, Maria Y. Wang, Martin H. Prins, Rupert Bauersachs, Alexander S. Gallus, Anthonie W.A. Lensing

P-TH-285 INITIATION OF RIVAROXABAN FOLLOWING LOW MOLECULAR WEIGHT HEPARIN FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS
Roger M Mills* (US), Chandrasekhar Rao V. Damaraju, Lisa K Jennings, Peter Wildgoose

P-TH-286 THE EFFECT OF PRERANDOMIZATION USE OF THERAPEUTIC ANTICOAGULANTS ON THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH DEEP VEIN THROMBOSIS TREATED WITH RIVAROXABAN
Martin H Prins* (NL), Henri Bounaumeaux, Anthonie Lensing, Akos F. Pap, Harry R. Buller
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-287  EVALUATION OF AN AGE ADJUSTED D-DIMER TEST CUT-OFF POINT IN PATIENTS WITH CLINICALLY SUSPECTED ACUTE DEEP-VEIN THROMBOSIS
Melanie Tan* (NL), Gerben C Mol, Antonio Iglesias del Sol, Marcel A van de Ree, Merino V Huisman

P-TH-288  THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM DURING VITAMIN K ANTAGONIST TREATMENT IN RELATION TO TIME IN THERAPEUTIC RANGE IN PATIENTS WITH DEEP VEIN THROMBOSIS
Martin H Prins* (NL), Anthonie W.A. Lensing, Gary E. Raskob, Alexander S. Gallus, Alice Benson, Harry R. Buller

P-TH-289  ASYMPTOMATIC PULMONARY EMBOLISM AND ITS PROGNOSTIC IMPACT - FINDING FROM RIETE
Inna Tzoran* (IL), G Saharov, V Valdes, J Villalta, A Bura-Riviere, B Brenner, M Monreal

P-TH-290  IS HYPOTHERMIA BENEFICIAL DURING RESUSCITATION OF MASSIVE PULMONAL EMBOLI? A PORCINE MODEL OF PULMONAL EMBOLI
Soren Risom Kristensen* (DK), Benedict Kjaergaard, Bodil Steen Rasmussen, Susanne de Neergaard

P-TH-291  PROGNOSTIC VALUE OF D-DIMER IN PATIENTS WITH VENOUS THROMBOEMBOLISM
Natalya Mikhaylovna Vorobyeva* (RU), Anatoliy B. Dobrovolsky, Elena V. Titaeva, Alexandr I. Kirienko, Elizaveta P. Panchenko

P-TH-292  PROTEIN S ACTIVITY ASSAYS. TIME FOR LABORATORIES TO FOLLOW NATIONAL GUIDELINES?
Ian Jennings* (UK), Steve Kitchen, Dianne P Kitchen, Timothy AL Woods, Isobel D Walker

P-TH-293  VARIABILITY IN ANTICOAGULANT DOSING RECOMMENDATIONS: RESULTS FROM PRIMARY AND SECONDARY CARE IN A UK NEQAS FOR BLOOD COAGULATION EXERCISE.
Ian Jennings* (UK), Steve Kitchen, Dianne P Kitchen, Timothy AL Woods, Isobel D Walker

P-TH-294  ALTERED FIBRIN CLOT PROPERTIES ARE ASSOCIATED WITH RESIDUAL VENOUS THROMBOSIS
Anetta Undas* (PL), Mariola Ciesla-Dul, Tomasz Drazkiewicz, Jerzy Sadowski

P-TH-295  TRANSPORT OF HEPARIN ACROSS RAT ILEAL MUCOSA IS ENHANCED BY PEYER’S PATCHES
Linda Marie Hiebert* (CA), Bita Moazed, Linda M Hiebert

P-TH-296  IS THE PREDICTIVE QUALITY OF TG IN CONSECUTIVE PATIENTS AFTER DVT INCREASED BY REPETITIVE MEASUREMENTS?
Arina J ten Cate-Hoek* (NL), P Erkens, R van Oerle, H.M.H Spronk, H ten Cate

P-TH-297  ESTRUCTURAL AND FUNCTIONAL FIBRONECTIN CHANGES MEDIATED BY HOMOCYSTEINE-THIOLACTONE
Valeria Genoud* (AR), Ana Rovetta, Lucia Kordich, Irene Quintana

P-TH-298  ACUTE AND CHRONIC CARDIAC FINDINGS FOLLOWING PULMONARY EMBOLISM IN CHILDREN: FINDINGS FROM A PROSPECTIVE INCEPTION COHORT STUDY
Michael Wang* (US), Hayley Suzanne Hancock, Katja Gist, Shelley Miyamoto, Marilyn Manco-Johnson, Neil Goldenberg

P-TH-299  RISK OF RECURRENCE IN PATIENTS WITH PULMONARY EMBOLISM: PREDICTIVE ROLE OF D-DIMER AND OF RESIDUAL PERFUSION DEFECTS ON LUNG SCINTIGRAPHY.
Daniela Poli* (IT), Caterina Cenci, Elisa Grifoni, Emilia Antonucci, Chiara Arcangeli, Domenico Prisco, Rosanna Abbate, Massimo Miniati
POSTER PRESENTATIONS
Thursday, July 28, 2011

P-TH-300  PREDICTIVE FACTORS FOR ASYMPTOMATIC PULMONARY EMBOLISM
Anja Boc* (SI), Alenka Mavri

P-TH-301  DISTRIBUTION OF THROMBOPHILIC FACTORS IN CHRONIC PORTAL VEIN THROMBOSIS
Neila Ben Romdhane* (TN), Sonia Mahjoub, Houda Kaabi, Hela Baccouche, Nabil Bel Feki, Zeineb Manai, Hmida Slama

P-TH-302  IN MEDICAL INPATIENTS INCIDENCE AND PROGNOSIS OF ASYMPTOMATIC DISTAL DEEP VEIN THROMBOSIS. THE IMPACT STUDY
Gabriele Ciuti* (IT), Gabriele Ciuti, Elisa Grifoni, Andrea Pavellini, Daniele SOD di Angiologia Righi, Lorenzo Zanasi, Rosanna Abbate, Domenico Prisco, Alberto Moggi Pignone

P-TH-303  BIOMARKERS IN MORTALITY PREDICTION AFTER VENOUS THROMBOEMBOLISM
Kerstin Hogg* (CA), Edward Hinchliffe, Shonagh Haslam, Esteban Gandara, Fiona Lecky

P-TH-304  VENOUS THROMBOEMBOLISM FOLLOWING MAJOR SURGERY AND RISK OF RECURRENT: A POPULATION-BASED COHORT STUDY
Vicky Tagalakis* (CA), Dimple Kondal, Susan Rebecca Kahn

P-TH-305  PROGNOSTIC VALUE OF MULTIDETECTOR COMPUTED TOMOGRAPHIC PULMONARY ANGIOGRAPHY AND CLINICAL SCORES IN PATIENTS WITH PULMONARY EMBOLISM
Suely Meireles Rezende* (BR), Thiago Horta Soares, Bruna Vilaca de Carvalho, Wanderval Moreira, Cristiane Pena Cabral, Luciano Fagundes de Paula, Marcos de Bastos, Suely Meireles Rezende

P-TH-306  THROMBOPHILIC MARKERS IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)
Angelika Batorova* (SK), Iveta Simkova, Denisa Jankovicova, Tatiana Prigancova, Anna Morongova

P-TH-307  “IN VITRO” EFFECT OF ENOXAPARIN ON THROMBIN GENERATION IN PLASMA OF CIRRHOTIC PATIENTS AT DIFFERENT STAGES OF LIVER DISEASE
Valeria Rossetto* (IT), Krisia Rodriguez, Marco Senzolo, Maria Teresa Sartori, Sabrina Gavasso, Mariangela Fadin, Patrizia Zerbinati, Patrizia Burra, Paolo Simioni

P-TH-308  THE IMPACT OF VENOUS THROMBOEMBOLISM IN CRITICALLY ILL PATIENTS: A META-ANALYSIS OF MAJOR CLINICAL OUTCOMES
Alessandro Malato* (IT), Francesco Dentali, Francesco Fabbiano, Giorgia Saccullo, Sergio Siragusa

P-TH-309  REPEATED DOSE ORAL UNFRACTIONATED HEPARIN PREVENTS THROMBOSIS IN A PIG MODEL
Linda Marie Hiebert* (CA), Linda Hiebert, Tilly Ping, Sandra Wice

P-TH-310  HIGH LEVELS OF THYROIDHINE INCREASE LEVELS OF COAGULATION FACTORS AND THE RISK OF VENOUS EMBOLISM: RESULTS OF A POPULATION-BASED CASE-CONTROL STUDY (MEGA-STUDY)
Jan Debeij* (NL), Bregje van Zaane, Olaf M Dekkers, Johannes WA Smit, Anton PS van Zanten, Dees PM Brandjes, Harry R Buller, Victor EA Gerdes, Frits R Rosendaal, Suzanne C Cannegieter

P-TH-311  LEVELS OF PROLACTIN IN RELATION TO LEVELS OF COAGULATION FACTORS AND THE RISK OF VENOUS EMBOLISM: RESULTS OF A POPULATION-BASED CASE-CONTROL STUDY (MEGA-STUDY)
Danka JF Stuijver (NL), Jan Debeij*, Olaf M Dekkers, Victor EA Gerdes, Frits R Rosendaal, Suzanne C Cannegieter
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-312  THE MALMO POLYMORPHISM OF COAGULATION FACTOR IX (FIX) AND THE RISK OF VENOUS THROMBOSIS
Cristiana Bulato* (IT), Elena Campello, Luca Spiezia, Maria Bon, Valeria Rossetto, Patrizia Zerbinati, Mariangela Fadin, Paolo Simioni

P-TH-313  A COMPARISON OF LOW MOLECULAR WEIGHT, ULTRA LOW MOLECULAR WEIGHT, AND UNFRACTIONATED Heparins IN A PURIFIED ANTITHROMBIN SYSTEM
Angel L Gray* (US), Debra Hoppensteadt, Walter Jeske, Jeanine M Walenga, Jawed Fareed

P-TH-314  PHARMACODYNAMIC DIFFERENCES IN TWO GENERIC BRANDS OF ENOXAPARIN
Debra A Hoppensteadt* (US), Walter Jeske, Jeanine M Walenga, Rakesh Wahi, Indermohan Thethi, Jawed Fareed

P-TH-315  AGE IS A MAJOR RISK FACTOR OF VENOUS THROMBOEMBOLISM (VTE)
Francis Couturaud* (FR), Nicolas Bizien, Elise Noel Savina, Cecile Tromeur, A Delluc, Dominique Mottier, Christophe Leroyer

P-TH-316  MANDATORY ELECTRONIC RISK ASSESSMENT MODEL IMPROVES COMPLIANCE WITH GUIDELINES FOR VTE PROPHYLAXIS
Hanady R Samaha* (LB), Nabil A Diab, Mirna C Waked, Nader Wansa, Imad P Hajj

P-TH-317  FACTOR IX ACTIVITY/ANTIGEN RATIO AND THE RISK OF UNPROVOKED VENOUS THROMBOSIS.
Elena Campello* (IT), Luca Spiezia, Maria Bon, Valeria Rossetto, Sabrina Gavasso, Daniela Tormene, Paolo Simioni

P-TH-318  ERYTHROCYTE AND PLATELET ADHESIVE PROPERTIES ARE NOT INCREASED IN PATIENTS WITH VTE AFTER AN ACUTE PERIOD OF ANTICOAGULATION
Kiara Cristina Senger Zapponi* (BR), Luis Fernando Bittar, Carla Franco Penteado, Nicola Corran, Erich Vinicios De Paula, Joyce Maria Annichino-Bizzacchi

P-TH-319  DESCRIPTION OF A COHORT OF PATIENTS WITH THROMBOSIS ASSOCIATED WITH HIV INFECTION IN A COLOMBIAN HOSPITAL
Juan Carlos Arrieta* (CO), Eugenia Lopez, Diana Patricia Giraldo, Luisa Escobar, Maria Fernanda Saldarriaga, James Samir Diaz, Luis Felipe Gomez

P-TH-320  DESCRIPTION OF A COHORT OF PATIENTS TREATED WITH PHLEGMASIA CERULEA DOLENS TREATED IN A COLOMBIAN HOSPITAL
Diana Patricia Giraldo* (CO), Juan Carlos Arrieta Bechara, Jhon Catano, Paola Arteaga, Juan David Ramirez, Eugenia Lopez

Genetic determinants and epidemiology

P-TH-321  DECREASED COMPLEMENT FACTOR H IS ASSOCIATED WITH ENHANCED COMPLEMENT ACTIVATION AND CARDIOVASCULAR RISK IN SOUTH ASIAN RELATIVES OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
Victoria R Richardson* (UK), Somani Riyaz, Kristina F Standeven, Angela M Carter

P-TH-322  THROMBOPHILIA IN IRANIAN WOMEN WITH PREGNANCY COMPLICATIONS
Minoo Ahmadinejad* (IR), Elham Farhadi, Nooshin Ahmadzadeh, Somaeih Baluch, Kamran Atarodi, Ladan Seyed Mortaz, Zahra Ahmadinejad, Shahin Negari, Mahtab Maghsudlu, Hasan Abolghasemi

P-TH-323  METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) AND THYMIDYLATE SYNTHASE (TS) POLYMORPHISMS IN OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURE (OVCF) AMONG POSTMENOPAUSAL KOREAN WOMEN
Nam Keun Kim* (KR), Soo Yeon Kim, Young Sun Chung, Seung Ho Hong, Young Joo Jeon, Dong Eun Shin, Dong Ah Shin
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-324  JAK-2 MUTATION IN ESSENTIAL THROMBOCYTOSIS CORRELATES WITH HIGHER HEMOGLOBIN VALUES.

P-TH-325  IMPACT OF OTHER RISK FACTORS ON THE ASSOCIATION OF OBESITY WITH VENOUS THROMBOSIS: THE LONGITUDINAL INVESTIGATION OF THROMBOEMBOLISM ETIOLOGY (LITE) STUDY
Mary Cushman* (US), Ellen S O'Meara, Susan R Heckbert, Neil A Zakai, Aaron R Folsom

P-TH-326  THE CHROMOSOME 9P21 IS ASSOCIATED WITH ISCHEMIC STROKE IN CHINESE POPULATION
Shuo Li (CA), Yuming Xu*, Hong Zheng, Jianxin Cui, Haizhen Wang, Guang Sun, Wayna Gulliver, Fei-Yu Han, Ya-Gang Xie*

P-TH-327  THREE NOVEL 3'END PROTHROMBIN GENE POLYMORPHISMS AND THEIR ASSOCIATION WITH THROMBOPHILIA
Valentina Djordjevic* (RS), Iva Pruner, Mirjana Kovac, Predrag Miljic, Nebojsa Antonijevic, Snezana Kojic, Dragica Radijovic

P-TH-328  FACTOR XI POLYMORPHISMS (RS2289252 AND RS2036914) MODULATE FACTOR XI ACTIVITY LEVELS AND APTT RATIO IN THROMBOTIC BUT NOT IN ASYMPTOMATIC WOMEN
Barbara Lunghi* (IT), Michela Cini, Cristina Legnani, Silvia Lorenzi, Gaullierlo Palareti, Giovanna Marchetti, Francesco Bernardi

P-TH-329  COMORBIDITES DO NOT EXPLAIN THE INCREASED VTE RISK ASSOCIATED WITH RACE AND NON-O BLOOD TYPES
Chunhui Fang (US), Hillel W Cohen, Henny H Billett*

P-TH-330  ESTABLISHED RISK FACTORS FOR VENOUS THROMBOEMBOLISM AND THEIR RECURRENT RISK IN A LARGE PANEL OF SMALL THROMBOPHILIA FAMILIES (GIFT STUDY)
Mariene C.H. de Visser* (NL), Rick van Minkelen, Jeroen C.J. Eekboomboom, Willem M. Lilfering, Rogier M. Bertina

P-TH-331  FIBRINOGEN-BETA -249C/T POLYMORPHISM IS A NOVEL GENETIC PREDICTOR FOR RECURRENCE OF DEEP VEIN THROMBOSIS IN RUSSIAN POPULATION
Natalya Mikhailyovna Vorobyeva* (RU), Zubkha B. Khazanova, Natalya A. Doroshchuk, Anton Yu. Postnov, Alexander I. Kirienko, Elizaveta P. Panchenko

P-TH-332  CARDIOVASCULAR AND THROMBOPHILIC RISK FACTORS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION
JERZY DROPSINSKI* (PL)

P-TH-333  THE RISK FOR RECURRENT VENOUS THROMBOEMBOLISM IN CARRIERS OF FACTOR V LEIDEN AND PROTHROMBIN MUTATION
Daniela Tormene* (IT), Sara Carraro, Valeria Ferri, Paolo Simioni

P-TH-334  SUDDEN SENSORINEURAL HEARING LOSS: A POSSIBLE ROLE OF THROMBOPHILIA AND CARDIOVASCULAR RISK FACTORS
Corrado Lodigiani* (IT), Rosaria Lorusso, Paola Ferrazzi, Luca Libret*, Lidia Luciana Rota, Arturo Mario Poletti
Antiphospholipid syndrome

P-TH-335  CIRCULATING IMMUNOCOMPLEXES CONTAINING $\beta_2$-GLYCOPROTEIN I ($\beta_2$-GPI) IN PATIENTS WITH APS: DETECTION BY MEANS OF HEPARIN (HEP) AFFINITY CHROMATOGRAPHY.
Alessandra Banzato* (IT), Roberta Frasson, Vincenzo De Filippis, Gentian Denas, Seena Jose Padayattil, Amelia Ruffatti, Vittorio Pengo

P-TH-336  SOLUBLE P-SELECTIN IN PATIENTS WITH THE LUPUS ANTICOAGULANT AND WITHOUT THROMBOSIS
Silvia Koder* (AT), Johanna Haselboeck, Simon Panzer, Ingrid Pabinger

P-TH-337  ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IS ASSOCIATED WITH LOW LEVELS OF COMPLEMENT COMPONENTS C3 AND C4
Lamya Garabet* (NO), Inge-Margrethe Gilboe, Marie-Christine Mowinckel, Tor Eirik Mollnes, Per Morten Sandset, Leif Wille, Eva Marie Jacobsen

P-TH-338  PROTHROMBOTIC ACTIVITY OF PURIFIED ANTI-$\beta_2$GPI AUTOANTIBODIES IN PATIENTS IS INDEPENDENT OF THEIR PLASMA LEVEL
Valerie Proulle* (US), Richard Furie, Barbara Furie, Bruce Furie

P-TH-339  INTERNATIONAL MULTICENTRE EVALUATION OF A NEW ASSAY TO DETECT LUPUS ANTICOAGULANTS CAUSED BY ANTI-$\beta$-GLYCOPROTEIN AUTOANTIBODIES

P-TH-340  LUPUS ANTICOAGULANT GUIDELINES: HOW FAR HAVE THESE BEEN ADOPTED BY LABORATORIES?
Ian Jennings* (UK), Steve Kitchen, Dianne P Kitchen, Timothy AL Woods, Isobel D Walker

P-TH-341  ANTITHROMBIN III LEVEL IN STROKE AT BETHESDA HOSPITAL, YOGYAKARTA, INDONESIA
Usi Sukorini* (ID), Ira Puspitawati, Yohanes Sugiri, Laksmi Asanti

P-TH-342  AUTOANTIBODIES TO PROTEIN DISULFIDE ISOMERASE (PDI) AS POTENTIAL MEDIATORS OF THE PROTHROMBOTIC PHENOTYPE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Narcis Ioan Popescu* (US), Stan Kamp, Joan T. Merrill, Florea Lupu

P-TH-343  MYOCARDITIS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME- A CASE REPORT.
Antonella Tufano* (IT), Anna Guida, Matteo Nicola Dario Di Minno, Angela Maria De Gregorio, Anna Cerbone, Ernesto Cimino, Giovanni Di Minno

P-TH-344  DIAGNOSTIC VALUE OF ANTIPHOSPHATIDYLTHERINE ANTIBODIES IN PATIENTS WITH COLLAGENOPATHIES AND/OR CLINICALLY SUSPECTED OF ANTIPHOSPHOLIPID SYNDROME
Susana Maria Ouvina* (AR), Alberto Maneyro, Silvina Lopez Morgan, Santiago Delgado Villalba, Celeste Jagoe, Luis Quiroga, Daniela Antonio, Silvana Cugliari, Layla Noya, Augusto Mirolli, Luis Palmer

P-TH-345  NEW MEASUREMENT METHOD FOR DETECTING LUPUS ANTICOAGULANT WITHOUT INTERFERENCE CAUSED BY WARFARIN THERAPY
Chizuru Morikawa* (JP), Masahiro Ieko, Naito Sumiyoshi, Mika Yoshida, Nobuhiko Takahashi
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-346  IS PLASMA SEPARATED FROM BLOOD BY DOUBLE CENTRIFUGATION USEFUL FOR DETERMINATION OF LUPUS ANTICOAGULANT?
Mika Yoshida* (JP), Masahiro Ieko, Sumiyoshi Naito, Chizuru Morikawa, Osamu Kurnano, Masumi Murakami, Nobuhiko Takahashi, Tatsuya Atsumi

P-TH-347  D-DIMER AND UMBILICAL ARTERY SYSTOLIC-DIASTOLIC RATIO AS ANTEPARTUM MONITORING PARAMETERS IN WOMEN WITH PREGNANCY LOSS FOR THE TIMING OF PROPHYLACTIC ANTICOAGULANTS
Tubagus Djamhuna Atmakusuma* (ID), Raden Muhamad, Andi Hudono, Fitriyadi Kusumah

Pregnancy, hormones, women’s issues

P-TH-348  THE ROLES OF THROMBOXANE A2 IN HIGH SALT INDUCED-DEFECT DURING PREGNANCY
Chen-Hsueh Pai* (TW), Ching-Tzu Yen, Shu-Rung Lin, Shu-Wha Lin

P-TH-349  THE ASSOCIATION OF ANTIPHOSPHOLIPID ANTIBODIES WITH INTRAUTERINE FETAL DEATH: A CASE-CONTROL STUDY
Linda Bjork Helgadottir* (NO), Finn Egil Skjeldestad, Anne Flem Jacobsen, Per Morten Sandset, Eva-Marie Jacobsen

P-TH-350  THE ASSOCIATION OF INHERITED THROMBOPHILIA AND INTRAUTERINE FETAL DEATH: A CASE-CONTROL STUDY
Linda Bjork Helgadottir* (NO), Finn Egil Skjeldestad, Anne Flem Jacobsen, Per Morten Sandset, Eva-Marie Jacobsen

P-TH-351  PREVALENCE OF THROMBOPHILIC DEFECTS IN WOMEN WITH ADVERSE PREGNANCY OUTCOMES
Minoo Ahmadinejad* (IR), Ali Rajabi, Kamran Atradi, Somaie Baluch, Maryam Mohammadi, Seyed Mohammad Reza Tabatabaei, Seyedeh Ladan Seyed Mortaz, Sedigheh Amini Kafi Aabad, Hassan Aboolehsani

P-TH-352  D-DIMER IN NORMAL PREGNANCY - COMPARISON OF THREE COMMERCIALLY AVAILABLE ASSAYS AND DETERMINATION OF REFERENCE VALUES
Frauke Bergmann* (DE), Nadine Pingel, Melanie Mescheder, Florian Guenther, Kathrin Hansmann, Andreas Czwalinna, Christina Platzer, Matthias Koch

P-TH-353  ASSESSMENT OF ADMA PLASMA LEVELS IN SEVERE PRE- ECLAMPSIA
Lucia Maria Sant'Ana Dusse* (BR), Patricia Nessralla Alpoim, Lara Carvalho Godei, Leticia Goncalves Freitas, Melina Barros Pinheiro, Fabiana Kalina Marques, Maria Braga Carvalho, Ana Paula Fernandes, Karina Braga Gomes

P-TH-354  ASSESSMENT OF GLU298ASP POLYMORPHISM IN ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE IN SEVERE PRE- ECLAMPSIA
Lucia Maria Sant'Ana Dusse* (BR), Patricia Nessralla Alpoim, Lara Carvalho Godei, Melina Barros Pinheiro, Leticia Goncalves Freitas, Fabiana Kalina Marques, Ana Paula Fernandes, Maria Carica Carvalho, Karina Braga Gomes

P-TH-355  APPLICATION OF LOW MOLECULAR-WEIGHT HEPARIN
Elena Vorobiova* (GE), Nurgaz Pargalava, Bokuchava Mamuka, Japaridze Nino

P-TH-356  IMPACT OF ENOXAPARIN SODIUM ON PUERPERANT'S BLOOD SERUM ENDOTOXIN CONCENTRATION AFTER ABDOMINAL DELIVERY
Aleksey V Pyregov* (RU), Efim M Shifman, Oksana I Shestakava, Igor I Baranov
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-357  SUCCESSFUL MANAGEMENT OF THREE PREGNANCIES IN A PATIENT WITH HOMOZYGOUS PROTEIN C DEFICIENCY AND RECURRENT VENOUS THROMBOEMBOLIC EVENTS
Sabine Struve* (DE)

P-TH-358  ASSOCIATION BETWEEN MIGRAINE AND BIOLOGICAL THROMBOPHILIA: PRELIMINARY RESULTS OF THE PROMIS STUDY
Lorraine Maitrot-Mantelet (FR), Marie-Helene Horelliou, Helene Massiou, Anne Gompel, Jacqueline Conard, Genevieve Plu-Bureau*

P-TH-359  PREVENTION OF RECURRENT PREECLAMPSIA IN WOMEN WITH THROMBOPHILIA
Alexander D. Makatsaria* (RU), Viktoria O. Bitsadze, Seda M. Baimuradova, Svetlana V. Akinshina

P-TH-360  RECURRENT FETAL LOSS SYNDROME IN PATIENTS WITH THROMBOPHILIA: PREVENTION IS POSSIBLE
Alexander D. Makatsaria* (RU), Viktoria O. Bitsadze, Seda M. Baimuradova, Svetlana V. Akinshina, Djamilya H. Khizroeva

P-TH-361  PREVENTION OF RECURRENT ANTENATAL FETAL DEATH AND BIRTH DEFECTS IN PARENTS WITH DEFECTS OF FOLATE METABOLISM AND HYPERHOMOCYSTEINEMIA
Alexander D. Makatsaria* (RU), Viktoria O. Bitsadze, Inna N. Talalaeva, Svetlana V. Akinshina

P-TH-362  THROMBOSIS RISK SCORE IN PREGNANCY: PRELIMINARY RESULTS FROM A MODEL
Venina Viana Barros* (BR), Andre Longo De Oliveira, Fernanda Spadotto Baptista, Maria Rita Lemos Bortolotto, Ana Maria Kondo Igai, Regina Schultz, Rossana Vieira Francisco, Roberto Bittar, Marcelo Zugaib

P-TH-363  THE ROLE OF ANTICOAGULANT PROPHYLAXIS IN REDUCING THE RISK OF IMPLANT FAILURE IN IVF PROCEDURES
Daniela Tormene* (IT), Sara Carraro, Francesca Vigano, Valeria Ferri, Guido Ambrosini, Paolo Simioni

P-TH-364  HIGH LEVELS OF LIPOPROTEIN-A (LPA) AND PREGNANCY OUTCOMES
Venina Viana Barros* (BR), Andre Longo Oliveira, Fernanda Spadotto Baptista, Maria Rita Lemos Bortolotto, Ana Maria Kondo Igai, Regina Schultz, Rossana Vieira Francisco, Roberto Eduardo Bittar, Marcelo Zubaib

P-TH-365  EFFECTIVENESS OF PROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN DURING PREGNANCY AND POSTPARTUM IN CARRIERS OF ANTIITHROMBIN, PROTEIN C AND PROTEIN S DEFICIENCY
Daniela Tormene* (IT), Sara Carraro, Valeria Ferri, Sabrina Gavasso, Paolo Simioni

Atrial fibrillation and thrombosis

P-TH-366  TWO YEARS THROMBOSIS SERVICE MAINZ (TDM): THE PATIENT POPULATION OF THE TDM
Helmut Schinzel* (DE), Betina Zeiter, Philipp Wild, Heike Schuhmacher, Irene Kraemer, Thomas Muenzel

P-TH-367  RESEARCH INTO AGE DEPENDING INDICATIONS OF VITAMIN K-ANTAGONISTS THERAPY (VKA)
Helmut Schinzel* (DE), Betina Zeiter, Britta Wimmer, Johannes Lotz, Juergen Prochaska, Thomas Muenzel
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-368  PLASMA VON WILLEBRAND FACTOR LEVELS ARE AN INDEPENDENT RISK FACTOR FOR ADVERSE EVENTS, MORTALITY AND MAJOR BLEEDING IN ANTICOAGULATED ATRIAL FIBRILLATION PATIENTS
Vanessa Roldan* (ES), Francisco Marin, Begona Muina, Jose Miguel Torregrosa, Pilar Gallego, Rocío Gonzalez-Conejero, Lip YH Gregory, Vicente Vicente

P-TH-369  USE OF STATINS AND RECURRENCE OF ATRIAL FIBRILLATION AFTER CATHETER ABLATION OR ELECTRICAL CARDIOVERSION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Francesco Dentali* (IT), Monica Gianni, Alessandro Squizzato, Walter Ageno, Luana Castiglioni, Lorenzo Maroni, Elaine Hylek, Anna Maria Grandi, Achille Venco, Luigina Guasti

P-TH-370  LOW BLEEDING RISK OF VERY OLD ATRIAL FIBRILLATION WOMEN ON VKA TREATMENT: RESULTS FROM A PROSPECTIVE COLLABORATIVE STUDY. ON BEHALF OF THE AD HOC STUDY GROUP OF FCSA
Daniela Poli* (IT), Emilia Antonucci, Elisa Grifoni, Umberto Carini, Antonio Ciampa, Paolo Da Col, Loreto Galbo, Antonio Insana, Giovanni Nante, Domenico Restifo, Sophie Testa, Walter Ageno, Gualtiero Palareti

P-TH-371  BLEEDING AND STROKE RISK IN A 'REAL WORLD' PROSPECTIVE PRIMARY PREVENTION COHORT OF ATRIAL FIBRILLATION PATIENTS.
Daniela Poli* (IT), Sophie Testa, Emilia Antonucci, Elisa Grifoni, Chiara Paoletti, Gregory YH Lip

P-TH-372  IMPACT OF GLOMERULAR FILTRATION ESTIMATE ON BLEEDING RISK IN VERY OLD PATIENTS TREATED WITH VKA: RESULTS OF A PROSPECTIVE COLLABORATIVE STUDY.
Daniela Poli* (IT), Emilia Antonucci, Maria Zanazzi, Elisa Grifoni, Roberto Cappelli, Eugenio Lucherini, Francesco Orlandini, Fabio Pini, Antonietta Piana, Antonietta Piana, Lucia Ruocco, Eros Tiraferri, Sophie Testa, Walter Ageno, Gualtiero Palareti

P-TH-373  EFFICACY OF THE ORAL FXA INHIBITOR, YM150 ON BIOMARKERS FOR THROMBOGENESIS IN 1297 PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION:
PHASE IIB DOSE CONFIRMATION STUDY (OPAL-2)
George M Rodgers* (US), Ronny W Renfurm, Jonathan L Halperin, Palle Petersen, Gregory YH Lip

Cancer and thrombosis

P-TH-375  INCREASED THROMBIN GENERATION AND PROCOAGULANT ACTIVITY OF CIRCULATING MICROPARTICLES FROM PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
Marina Marchetti* (IT), Annamaria Leuzzi, Marina Panova-Noeva, Carmen Julia Tartari, Laura Russo, Alessandro Rambaldi, Guido Finazzi, Tiziano Barbi, Barry Woodhams, Anna Falanga

P-TH-376  ON THE ACQUISITION OF A PROCOAGULANT PATTERN BY HUMAN GLOIABLESTOMA CELLS
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-377  XA INHIBITOR IS EFFECTIVE IN THE PREVENTION OF POSTOPERATIVE VENOUS THROMBOEMBOLISM - A STUDY OF THE EFFECTIVENESS OF SELECTIVE XA INHIBITOR FONDAPARINUX -
Norihito Yoshioka* (JP), Nao Suzuki, Hiroka Hata, Kimie Murayama, Tatsuru Ohara, Yoshiko Nishigaya, Akiko Tozawa, Kazushige Kiguchi, Bunpei Ishizuka

P-TH-378  DEVELOPING THE THROMBOPROPHYLAXIS RESEARCH AGENDA IN ADVANCED CANCER: A QUALITATIVE STUDY
Simon Ian Robert Noble* (UK), Annmarie Nelson, Ilora Finlay

P-TH-379  ASSESSMENT OF PLATELET FUNCTION AND SELECTED PARAMETERS OF COAGULATION IN PATIENTS WITH MULTIPLE MYELOMA BEFORE AND AFTER THALIDOMIDE THERAPY.
Krzysztof Chojnowski* (PL), Marta Robak, Jacek Trelinski

P-TH-380  SOLUBLE FIBRIN DETERMINATION IN ADVANCED CANCER PATIENTS.
Shahsultan Mirshahi* (FR), Shahsultan Mirshahi, Massoud Mirshahi, Jean Chidiac, Remi Varin, Dalei Azzazene, Eric Pujade-Lauraine, Claudine Soria, Jeannette Soria

P-TH-381  THE RISK OF CANCER FOLLOWING IDIOPATHIC VENOUS THROMBOEMBOLISM: A POPULATION-BASED COHORT STUDY
Vicky Tagalakis* (CA), Dimple Kondal, Susan Rebecca Kahn

P-TH-382  VENOUS THROMBOEMBOLISM IN CANCER PATIENTS FOLLOWING MAJOR SURGERY
Vicky Tagalakis* (CA), Tierry Haim Toledano, Dimple Kondal, Susan Rebecca Kahn

P-TH-383  INCREASED THROMBIN POTENTIAL AND VON WILLEBRAND FACTOR INDICATE THROMBOTIC RISK AFTER LAPAROSCOPIC RADICAL PROSTATECTOMY
Jolán Harštalo* (HU), Tibor Flasko, Zsuzsanna Molnar, Zoltán Batta, Matyas Bényo

P-TH-384  EVALUATION OF THE HAEMOSTATIC STATUS IN PATIENTS WITH PROSTATE CANCER USING THROMBOELASTOGRAPHY AND TISSUE FACTOR-MICROPARTICLES
Mazen Toukh* (CA), Angela Black, Robert D Siemens, Maha Othman

P-TH-385  JAK2V617F MUTATION AND THROMBOSIS IN THE MYELOPROLIFERATIVE NEOPLASMS
Fatih Demirkan* (TR), Serdar Kaiklan, Selda Kahraman, Sunay Tunali, Abdullah Katgi, Ozden Piskin, Mehmet Ali Ozcan, Hayri Guler Ozsan, Bulent Undar

P-TH-386  DIFFERENTIAL LOCALIZATION OF FULL LENGTH TISSUE FACTOR AND ALTERNATIVELY SPliced TISSUE FACTOR IN BREAST CANCER CELLS
Begum Kocaturk* (NL), Yascha W van den Berg, Pieter H Reitsma, Vladimir Y Bogdanov, Henri H Versteeg

P-TH-387  PROTEASE-ACTIVATED RECEPTOR-2 (PAR-2) INDUCES VEGF PRODUCTION THROUGH ERK1/2 PATHWAYS IN HUMAN GlioBLASTOMA CELL LINES
Andrea Mariano Oliveira* (BR), Angelica Dutra Oliveira, Robson Queiroz Monteiro

Pediatric thrombosis

P-TH-388  LONG-TERM OUTCOME OF CHILDHOOD PULMONARY EMBOLISM
Suzan Williams* (CA), Viola van Eimeren, Leonardo Brandao, Walter Kahr

P-TH-389  A RECENT NATIONAL SURVEY OF NEONATAL THROMBOSIS IN JAPAN. COMPARISON WITH MAILING QUESTIONNAIRES IN 2004
Chiharu Kawaguchi* (JP), Yukihiro Takahashi
**POSTER PRESENTATIONS**

**Thursday, July 28, 2011**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-390</td>
<td>THROMBUS PERSISTENCE AND THROMBOTIC-RELATED COMPlications AFTER PEDIATRIC CARDIAC SURGERY</td>
<td>Leonardo Rodrigues Brandao* (CA), Cedric Manthiot, Janet A. McMullen, Anthony K. Chan, Suzan Williams, Ben Sivarajan, Steven M. Schwartz, Brian W. McCrindle</td>
</tr>
<tr>
<td>P-TH-391</td>
<td>INHERITED HETEROZYGOUS PROTEIN S DEFICIENCY: A REPORT OF 6 CASES.</td>
<td>Piti Techavichit* (TH), Darintr Sosothikul, Panya Seksarn</td>
</tr>
<tr>
<td>P-TH-392</td>
<td>INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA</td>
<td>Turkan Patiroglu* (TR), Yasemin Altuner Torun, Mehmet Akif Ozdemir, Yusuf Ozkul, Ali Yikilmaz, Musa Karaküçcu</td>
</tr>
<tr>
<td>P-TH-393</td>
<td>THROMBOTIC EVENTS IN CHILDREN WITH MALIGNANCIES IN RELATION TO TREATMENT COMPONENTS OF CHEMOTHERAPY</td>
<td>Alexandra A Russo* (DE), Charis von Auer, Nesrin Karabul, Matthias Dittrich, Peter Gutjahr, Inge Scharrer, Joerg Faber</td>
</tr>
<tr>
<td>P-TH-394</td>
<td>PEDIATRIC ANTICOAGULATION: SIMILAR BLEEDING BUT FEWER THROMBOEMBOLIC COMPLICATIONS THAN ADULTS</td>
<td>Cameron C Trenor* (US), Kathy M. Harney, Juliann McSweeney, Alan D. Michelson, Ellis J. Neufeld, Cameron C. Trenor</td>
</tr>
<tr>
<td>P-TH-395</td>
<td>PEDIATRIC HEPARIN-INDUCED THROMBOCYTOPENIA: THE 4T SCORING SYSTEM PREDICTS PATIENTS AT LOW RISK</td>
<td>Cameron C Trenor* (US), Esther A. Obeng, Kathy M. Harney, Ellis J. Neufeld, Cameron C. Trenor</td>
</tr>
<tr>
<td>P-TH-397</td>
<td>INTRACARDIAC THROMBOSIS IN TWO CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION</td>
<td>Osman Alphan Kupesiz* (TR), Vedat Uygun, Mediha Akcan, Gulsun Karasu, Volkan Hazer, Mehmet Akif Yesilipek</td>
</tr>
<tr>
<td>P-TH-398</td>
<td>GENETIC AND ACQUIRED RISK FACTORS IN BRAZILIAN CHILDREN AND ADOLESCENTS DIAGNOSED WITH PORTAL VEIN THROMBOSIS (PVT) WITH NO HEPATIC DISEASES</td>
<td>Ana Paula Fernandes* (BR), Priscila Menezes Ferri, Daniel Dias Ribeiro, Eleonora Druve Tavares Fagundes, Karina Braga Gomes, Luci Sant’Ana Dusse, Maria das Gracas Carvalho, Alexandre Rodrigues Ferreira</td>
</tr>
<tr>
<td>P-TH-399</td>
<td>ANTICOAGULATION IN PEDIATRIC PATIENTS WITH THE HEARTMATE II VENTRICULAR ASSIST DEVICE (VAD)</td>
<td>Lisa Bomgaars* (US), Mona Shah, Donald Yee, Jun Teruya, Joe Rossano, David Morales, Donald Mahoney</td>
</tr>
<tr>
<td>P-TH-400</td>
<td>THE ITALIAN REGISTRY OF CHILDHOOD THROMBOSIS (RITI - REGISTRO ITALIANO TROMBOSI INFANTILE) ON BEHALF OF THE GROUP FOR THE ITALIAN REGISTRY OF CHILDHOOD THROMBOSIS (GIRT)</td>
<td>Chiara Gentilomo* (IT), Paola Saracco, Manuela Agostini, Rossana Bagna, Bianca Bassi, Paola Giordano, Anna Maria Laverda, Angelo Claudio Molinari, Luca Antonio Ramenghi, Paolo Simioni</td>
</tr>
<tr>
<td>Microparticles</td>
<td>CORRELATION BETWEEN CD144 POSITIVE MICROPARTICLES AND CD142 POSITIVE MICROPARTICLES IN PATIENTS WHO HAVE UNDERGONE PCI.</td>
<td>Yutaka Nagai* (JP), Norihito Inami, Shinya Fujita, Ryotaro Ozasa, Shuji Higashi, Shosaku Nomura</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-402  PROCOAGULANT PHOSPHOLIPIDS (PPL) LEVELS IN PREGNANT PATIENTS PRESENTING WITH SYMPTOMS OF DEEP VEIN THROMBOSIS (DVT)
Marilyn A Johnston* (CA), Nancy McEwen, JS Ginsberg, WS Chan

P-TH-403  PROCOAGULANT MICROVESICLES ARE ELEVATED IN ACUTE TRAUMATIC INJURY.
Nicola S Curry* (UK), Amber Raja, Karim Brohi, Tina Gaarder, Per I. Johansson, Simon J. Stanworth, Paul Harrison

P-TH-404  PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION HAVE INCREASED CONCENTRATIONS OF MICROPARTICLES FROM DIFFERENT CELLS
Christina Christersson* (SE), Gerhard Wikstrom, Agneta Siegbahn

P-TH-405  A MULTICOLOR FLOW CYTOMETRIC ASSAY FOR MEASUREMENT OF MICROPARTICLES OF DIFFERENT CELLULAR ORIGINS AND THEIR DIFFERENTIATION FROM CELL MEMBRANE FRAGMENTS
Fariborz Mobarrez* (SE), Jovan Antovic, Gun Jorneskog, Nils Egberg, Hakan Wallen

P-TH-406  SEPARATION INDEX: A USEFUL TOOL TO FOLLOW-UP AND COMPARE INSTRUMENT PERFORMANCE FOR MICROPARTICLE ANALYSIS BY FLOW CYTOMETRY
Francois Mullier* (BE), Philippe Poncelet, Nicolas Bailly, Stephane Robert, Romaric Lacroix, Francine Garnache-Ottou, Sabeha Blichle, Jean-Michel Dogne, Francoise Dignat-George, Bernard Chatelain

P-TH-407  THE INFLUENCE OF ELECTIVE PERCUTANEOUS INTERVENTION ON THE PLASMA MICROPARTICLES CONCENTRATION IN PATIENTS WITH CORONARY ARTERY DISEASE
Krystyna Maria Zawiliska* (PL), Justyna Maria Wachowiak

P-TH-408  PLASMA MICROPARTICLE TISSUE FACTOR IS ELEVATED IN ANTIPHOSPHOLIPID SYNDROME
Nigel S Key* (US), Rose Willemze, Robert Bradford, Robert AS Roubey

P-TH-409  OPTIMIZATION OF MICROPARTICLE ANALYSIS PROTOCOLS FOR FLOW CYTOMETERS: FORWARD OR SIDE SCATTER ?
Philippe Poncelet* (FR), Stephane Robert, Anne-Marie Faussat, Cecile Gameiro, Nicolas Bailly, Francois Mullier, Bernard Chatelain

P-TH-410  QUANTIFICATION OF MICROPARTICLES BY FLOW CYTOMETRY IN WHOLE BLOOD: APPLICATION TO THE DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS AND HEPARIN-INDUCED THROMBOCYTOPENIA
Francois Mullier* (BE), Nicolas Bailly, Christian Chatelain, Jean-Michel Dogne, Bernard Chatelain

Arterial vascular diseases

P-TH-411  CHARACTERIZATION OF NAFTIDROFURYL AS A THROMBOXANE RECEPTOR ANTAGONIST.
Severine Robert* (BE), Stephanie Rolin, Jonathan Douxfils, Julie Hardij, Emilie Varin, Bernard Chatelain, Julien Hanson, Kristel Vandenbosch, Nathalie Caron, Francois Mullier, Jean-Michel Dogne

P-TH-412  FXIII LEVELS AND GENOTYPE IN MYOCARDIAL INFARCTION: POTENTIAL NOVEL PROGNOSTIC BIOMARKERS?
Donato Gemmati* (IT), Giulia Zeri, Rosella Mari, Elisa Orioli, Monica Bovara, Vicente Sarquella, Stefano Moratelli, Mirko Pinotti, Francesco Bernardi, Rosaria M Stomeo, Roberto Ferrari, Lucia Ansani, Luisa M Serino
POSTER PRESENTATIONS
Thursday, July 28, 2011

P-TH-413 INTERACTION BETWEEN LRP D2080N POLYMORPHISM AND COAGULATION FACTOR VIII LEVELS MODULATES THE RISK OF MYOCARDIAL INFARCTION IN THE CHINESE HANS
Honggang Ren* (CN), Tao Guo, Huafang Wang, Chunyan Sun, Xiaoping Zhang, Heng Mei, Liang Tang, Xiaohong Liu, Yu Hu

P-TH-414 ACUTE CORONARY SYNDROME PATIENTS WITH DIFFERENT CLINICAL FEATURES ARE CHARACTERIZED BY DIFFERENT WHOLE PERIPHERAL BLOOD GENE EXPRESSION PROFILES
Betti Giusti* (IT), Luciana Rossi, Ilaria Lapini, Alberto Magi, Anna Maria Palombella, Rossella Marcucci, Antonella Cordisco, David Antoniucci, Gian Franco Gensini, Rosanna Abbate

P-TH-415 LIPID PENTAD INDEX (LPi), LIPID TETRAD INDEX (LTI) AND ATHEROGENIC INDEX OF PLASMA (AIP) IN CENTRAL AND PERIPHERAL ARTERIAL DISEASES
Luciana Moreira Lima* (BR), Maria Elisabeth Renno Santos, Maria das Gracas Carvalho, Adriano de Paula Sabino, Ana Paula Lucas Mota, Marilene Oliveira Sousa

P-TH-416 DEFICIENCY OF COAGULATION INHIBITORS IN YOUNG ADULTS WITH ISCHEMIC STROKE
Neila Ben Romdhane* (TN), hela Baccouche, Malak Lahmar, Sonia Mahjoub, Zeineb Manai

P-TH-417 CONVENTIONAL AND NOVEL RISK FACTORS IN YOUNGER AND OLDER PATIENTS WITH MYOCARDIAL INFARCTION
Nebojsa M Antonijevic* (RS), Antonijevic M Nebojsa, Bojan D Stojanovic, Aco Radanovic, Branko Jakovljevic, Slobodan Obradovic, Ivana Zivkovic, Mirjana Kovac, Valentina Djordjevic, Nebojsa Radovanovic, Jovan Perunicic

P-TH-418 SOLUBLE RECEPTOR FOR ADVANCED GLYCAATION END-PRODUCTS (SRAGE): A NEW BIOMARKER OF ARTERIAL THROMBOSIS DURING SYSTEMIC LUPUS ERYTHEMATOSUS
Helene Maillard-Lefebvre* (FR), Nathalie Costedoat-Chalumeau, Nicolas Grossin, Julia Salleron, Sylvain Dubucquoi, Lucile Musset, Jean-Charles Piette, Eric Hachulla, Pierre-Yves Hatron, Eric Boulanger, Zahir Amoura, Marc Lambert

P-TH-419 AN INCREASED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) ACTIVITY IS ASSOCIATED WITH MYOCARDIAL INFARCTION IN YOUNG WOMEN; RESULTS FROM THE RATIO STUDY
Kristien Winckers* (NL), Bob Siegerink, Connie Duckers, Lisbeth M Maurissen, Guido Tans, Elisabetta Castoldi, Henri M.H. Spronk, Ten Cate Hugo, Ale Algra, Tilman Hackeng, Frits Rosendaal

P-TH-420 HYPERCOAGULATION, VASCULAR ENDOTHELIUM SUFFERING AND DAMAGE, PULMONARY ARTERIAL HYPERTENSION IN SICKLE CELL DISEASE
Margaret Musso* (IT), Ignacio Bianchi, Roberto Musso, Luca Maugeri

P-TH-421 CORRELATION BETWEEN PLASMA HOMOCYSTEINE LEVELS AND DEGREE OF LOWER LIMB ISCHEMIA IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE
Ternitil Gamzatov* (RU), Anna Alexandrovna Gurzhiy, Veronika Mikhailovna Shmeleva, Ludmila Petrovna Papayan, Alexander Emelianovich Barsukov, Alexey Vladimirovich Svetlikov

Health service and outcomes

P-TH-422 FONDAPARINUX: APPLICATION AND SAFETY ASPECTS - A PROSPECTIVE GERMAN SINGLE-CENTER EXPERIENCE
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-423  THROMBOPHILIA TESTING IS OVER-UTILISED - AN AUDIT OF 500 CONSECUTIVE SCREENS
Joyce Low* (AU), Susan Jarvis, Joanne Joseph

P-TH-424  RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN HOSPITALIZED MEDICAL PATIENTS
Ponlapat Rojnuckarin* (TH), Noppacharn Uaprasert, Patinut Buranasupkajorn, Sarawut Siwamogsatham, Pranee Sutcharitchan

P-TH-425  AN INNOVATIVE CLINIC APPROACH FOR WARFARINIZED ADULTS WITH CONGENITAL HEART DISEASE TO INCREASE PARTICIPATION IN THEIR HEALTH CARE
Aiko MD Bruce* (CA), Mary Bauman, M Patricia Massicotte

P-TH-426  AN INNOVATIVE CLINIC APPROACH FOR CHILDREN REQUIRING LONG TERM WARFARIN THERAPY TO INCREASE PARTICIPATION IN THEIR HEALTH CARE
Aiko MD Bruce* (CA), Mary Bauman, M Patricia Massicotte

P-TH-427  EMERGING CONCEPT: PREVENTABLE VENOUS THROMBOEMBOLISM IS AN ADVERSE EVENT
Charles Mahan* (US), Mark T Holdsworth, Shawn M Welch, Matt E Borrego, Alex C Spyropoulos

P-TH-428  COST-EFFECTIVENESS OF PHARMACOLOGICAL PROPHYLAXIS IN PREVENTING VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS IN GYNAECOLOGICAL ONCOLOGY SURGERY
Kerry Hitos* (AU), Charles Stratton, John P Fletcher

P-TH-429  COST-EFFECTIVENESS OF PHARMACOLOGICAL PROPHYLAXIS IN PREVENTING VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
Kerry Hitos* (AU), Charles Stratton, John P Fletcher

P-TH-430  HEMORRHAGIC COMPLICATIONS OF ANTICOAGULANT TREATMENT
Aleksandar R Maslac* (RS), Mirjana K Kovic

Experimental models

P-TH-431  THE SAFETY/EFFICACY OF DABIGATRAN AND INFLUENCE OF VITAMIN K ON AV-SHUNT MODEL IN RAT.
Tsuyoshi Ohmura* (JP), Kozaburo Ikegami, Joanne van Ryn, Katsuhiro Hori, Jeffrey Encinas, Ikuro Maruyama

P-TH-432  EFFECTS OF ANTI-HUMAN VWF A3 DOMAIN MONOCLONAL ANTIBODY SZ-123 ON PLASMA VWF BINDING TO COLLAGEN AND PLATELET AGGREGATION OF RHESUS MONKEY AND BEAGLE DOG IN VITRO
Yiming Zhao* (CN), Shundong Ji, Yang He, Miao Jiang, Fei Shen, Yunxiao Zhao, Changpeng Ruan

P-TH-433  NDRG4-DEFICIENT MICE EXHIBIT SPATIAL LEARNING DEFICITS AND VULNERABILITIES TO CEREBRAL ISCHEMIA WITH THE DECREASED LEVEL OF BDNF IN THE CORTEX
Hitomi Yamamoto* (JP), Koichi Kokame, Tomohiko Okuda, Yukako Nakajo, Hiroji Yamamoto, Toshiyuki Miyata

P-TH-434  COMBINATION OF EDOXABAN, AN ORALLY ACTIVE FACTOR XA INHIBITOR WITH ASPIRIN AND CLOPIDOGREL IN A RAT MODEL OF ARTERIAL THROMBOSIS
Yoshiyuki Morishima* (JP), Yuko Honda, Chikako Kamisato, Akemi Kita, Naoko Edo, Toshihiko Kumada, Toshiro Shibano
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-435  EDOXABAN, AN ORAL DIRECT FACTOR XA INHIBITOR, AMELIORATES COAGULATION, MICROTHROMBI FORMATION, AND ACUTE LIVER INJURY IN LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA RATS
Yoshiyuki Monshima* (JP), Yuko Honda, Tomoko Shibutani, Kengo Noguchi, Yusuke Ito, Toshiro Shibano

P-TH-436  IN VITRO COMPARISON OF EP217609, UNFRACTIONATED HEPARIN, ENOXAPARIN AND FONDAPARINUX IN THE PREVENTION OF CARDIAC CATHETER THROMBOSIS
ERIC NEUHART* (FR), Anja Kaebenich, Uwe Raaz, Alexander Vogt, Lars Maededefess, Claire Bal dit Sollier, Natacha Berge, Ludovic Drouet, Baerbel Hauroeder, Chantal Krezel, Michael Buerke, Karl Werdan, Axel Schlitt

P-TH-437  GENERIC ARGATROBAN PREPARATIONS DIFFER IN THEIR ANTICOAGULANT AND ANTIPROTEASE RESPONSES IN PATIENTS WITH LIVER DISEASE. DOSING IMPLICATIONS.
Jawed Fareed* (US), Debra Hoppensteadt, Sofia Masood, Jurgita Zeimys, David VanThiel, Magdalena George, Vinod Bansal

P-TH-438  SIMULTANEOUS OCCURRENCE OF NATURAL IMMUNITY, ATHEROGENIC IN VIVO LDL OXIDATION AND THROMBOXANE-MEDIATED PLATELET ACTIVATION IN ATHEROSCLEROSIS-PRONE (LDLR-/- AND APOE-/-) MICE
Eiji Matsuura* (JP), Lianhua Shen, Yukana Matsunami, Nanhu Quan, Kazuo Kobayashi, Yehuda Schoenfeld, Keiji Oguma, Luis R Lopez

P-TH-439  ANTI-ATHEROGENIC PLAQUE REDUCTION, INHIBITION OF OXLDL/B2GPI AUTOANTIGEN AND THROMBOXANE-MEDIATED PLATELET ACTIVATION BY PERSIMMON (DIOXYROS KAKI) PEEL IN LDLR-/- DEFICIENT MICE
Eiji Matsuura* (JP), Nanhu Quan, Kazuo Kobayashi, Yukana Matsunami, Masahiro Ide, Marina Makarova, Lianhua Shen, Soichi Ohno, Yang Zheng, Haruo Kobayashi, Luis R Lopez

P-TH-440  IN VIVO FLUORESCENCE IMAGING OF THROMBOGENESIS IN MICROSURGICAL VESSEL REPAIRS
Brian C. Cooley* (US), Glenn Shi, Roger A. Daley

P-TH-441  HIGH FAT DIET BUT NOT OBESITY AS DETERMINANT OF THROMBIN GENERATION IN PLASMA
Caroline Sanchez* (FR), Pierre Morange, Matthias Canault, Ilse Scroyen, Stephane Tanguy, Michel Grino, Marie-christine Alessi

P-TH-442  COAGULATION AND COMPLEMENT ACTIVATION AFTER INTRAPULMONARY CHALLENGE WITH HOUSE DUST MITE EXTRACT AND/OR LIPOPOLYSACCHARIDE IN ASTHMA PATIENTS
Johannes Daan De Boer* (NL), M Berger, PJ Sterk, D Wouters, S Zeerleder, JS Van der Zee, T Van der Poll

P-TH-443  A NITRIC OXIDE (NO)-DONATING STATIN DISPLAYS ENHANCED ANTI-INFLAMMATORY AND ANTI-ATHEROGENIC ACTIVITIES IN A MODEL OF ATHEROSCLEROSIS-RELATED INFLAMMATION IN MICE
Stefania Momi* (IT), Emanuela Falcinelli, Paolo F Alberti, Angela Monopoli, Daniela Mlglletta, Ennio Ongini, Paolo Gresele

von Willebrand factor

P-TH-444  IN VIVO CLEAVAGE OF RECOMBINANT VWF IN PRECLINICAL AND CLINICAL SETTINGS
Peter L. Turecek* (AT), Katalin Varadi, Hanspeter Rottensteiner, Julita Schreiner, Friedrich Scheiffinger
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-445  ADAMTS13 IN VON WILLEBRAND FACTOR (VWF) CONCENTRATES: IS AN INTACT VWF TRIPLET STRUCTURE IMPORTANT FOR VWF FUNCTION?  
Christoph Kannicht* (DE), Barbara A. Solecka, Mario Kroening, Birte Fuchs

P-TH-446  ESSENTIAL ROLE OF THE P3 RESIDUE (LEU1603) OF VON WILLEBRAND FACTOR IN SCISSILE BOND CLEAVAGE BY ADAMTS13  
Yaozu Xiang* (UK), Rens de Groot, James TB Crawley, David A Lane

P-TH-447  VWF CONTRIBUTES TO LONGER CIRCULATING HALF-LIFE (T1/2) OF PEGYLATED FVIII IN VIVO  
John E. Murphy* (US), Lilley Leong, Derek S. Sim, Elena Ho, Peter Kretschmer, Jian-Ming Gu, Fred Aswad, Rick Feldman, Jesper Haaning, Liang Tang

P-TH-448  INDUCTION OF ENDOTHELIAL VON WILLEBRAND’S FACTOR EXPRESSION BY PRECURSOR B LYMPHOBLASTS  
Derek C. H. Chan* (CA), Helen M. Atkinson, Leslie R. Berry, Urna H. Athale, Anthony K. C. Chan

P-TH-449  AMELIORATION OF MURINE VWD BY PLATELET-SPECIFIC EXPRESSION OF VWF  
Sachiko Kanaji* (US), Scot A Fahs, Qizhen Shi, Sandra L Haberichter, Robert R Montgomery

P-TH-450  SINGLE NUCLEOTIDE GENE POLYMORPHISMS DIFFERENTIALLY ASSOCIATE WITH PLASMA LEVELS OF VON WILLEBRAND FACTOR IN EUROPEAN AND AFRICAN AMERICANS: AN ARIC STUDY  
Marco Campo (US), Ashley Buchanan, Fuli Yu, Maja Barbalic, Woody Chambless, Aaron Ilosom, Eric Boerwinkle, Jing-fei Dong*

P-TH-451  GENETIC VARIATIONS IN THE VON WILLEBRAND FACTOR GENE AMONG DIFFERENT ETHNICITIES: FINDINGS FROM THE 1000 GENOME PROJECT  
Fuli Yu (US), Jin Yu, Marco Campos, Richard Gibbs, Jing-fei Dong*

P-TH-452  EVALUATION OF VON WILLEBRAND FACTOR (VWF) CONCENTRATES BY PLATELET ADHESION TO TYPE III COLLAGEN USING A HIGH SHEAR IN VITRO FLOW ASSAY  
Anne Riddell* (UK), Thomas McKinnon, Saravanan Vinayagam, Keith Gomez

P-TH-453  ASSOCIATION OF VWF -1793 C/G POLYMORPHISM WITH DIABETES, VASCULAR COMPLICATION AND CONVENTIONAL RISK FACTORS FOR CORONARY ARTERY DISEASE IN THAIS  
Nantarat Komanasin* (TH), Saran Saensiriphan, Boonsong Benjangkaprasert, Paisal Mongkolwongroj, Montien Puntumetakul

von Willebrand disease

P-TH-454  LATEST INTERIM RESULTS FROM A GERMAN PROSPECTIVE POST-MARKETING SURVEILLANCE OF TREATMENT OF VON WILLEBRAND’S DISEASE WITH A NEW GENERATION VWF/FVIII CONCENTRATE  
Mario von Depka* (DE), S. Alesci, J. Feddern, J. Kadar, W. Miesbach, M. Rieke, I. Scharrer

P-TH-455  EXPERIENCE WITH A HIGH-PURITY VON WILLEBRAND FACTOR CONCENTRATE IN LONG-TERM PROPHYLAXIS: FINAL ANALYSIS OF A FRENCH COHORT STUDY  
Jenny Goudemand* (FR), Annie Borel-Derlon, Chantal Rothschild, Jeanne-Yvonne Borg, Group Post-Marketing Study, Anne-Cecile Jaffry, Francoise Bridey, Celine Henriet, Catherine Chatelanaz
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-457  BIOLOGICAL AND CLINICAL RESPONSES TO DESMOPRESSIN IN CHILDREN: PROSPECTIVE STUDY OF A LARGE COHORT WITH TYPE 1 VWD AND TYPE 2 VWD IN ONE SINGLE ARGENTINIAN CENTER
Mariana Bonduel* (AR), Gabriela Scruccati, Mirta Hepner, Juan Pablo Fronroth, Graciela Pieroni, Aurora Feliu-Torres, Eliana Annetta, Mercedes Castanon

P-TH-458  EXPRESSION STUDIES OF EIGHT MISSENSE MUTATIONS SPREAD THROUGHOUT THE VON WILLEBRAND FACTOR (VWF) IN TYPE 3 VON WILLEBRAND DISEASE (VWD) PATIENTS.
Luciano Baronciani* (IT), Maria Solimando, Silvia La Marca, Giovanna Cozzi, Francesca Stufano, Maria Teresa Cancian, Augusto B Federici, Flora Peyvandi

P-TH-459  SEX-CHANGE SURGERY IN A TYPE 3 VWD PATIENT
Bulent Zulfikar* (TR), Ozcan Gurhan, Fikret Bezgal, Ergul Berber

P-TH-460  ANALYSIS OF VON WILLEBRAND PROPEPTIDE RATIO IN THE SOUTH MORAVIAN POPULATION (CZECH REPUBLIC): THE BRNO-VWD STUDY.
Alain Peter Gadisseur* (BE), P Smejkal, I Vangenechten, O Zapletal, F Bouddount, J Zavrelova, J Blatny, M Penka, JJ Michiels

P-TH-461  CLINICAL EVALUATION OF A NEW VON WILLEBRAND FACTOR ACTIVITY ASSAY*.
Ulrich Budde* (DE), Reinhard Schnepenheim, Adriana Mendez, Juergen Patzke, Heidrun Muth

P-TH-462  TWO UNRELATED VON WILLEBRAND DISEASE (VWD) TYPE 2A (IIE) FAMILIES CAUSED BY SKIPPING OF EXON 26 ON THE VON WILLEBRAND FACTOR (VWF) MRNA.
Luciano Baronciani* (IT), Inmaculada Garcia-Oya, Maria Solimando, Silvia La Marca, Giovanna Cozzi, Francesca Stufano, Maria Teresa Canciani, Flora Peyvandi

P-TH-463  EVALUATION OF PLATELET FUNCTION AND BLEEDING HISTORY IN VON WILLEBRAND DISEASE DIAGNOSTICS
Timea Szanto* (FI), Lotta Joutsi-Korhonen, Riitta Lassila

P-TH-464  MISSING MUTATION IN TYPE 1 VON WILLEBRAND DISEASE IN THE MCMDM-1VWD STUDY
Nasher Hussain Alyami* (UK), Daniel J Hampshire, Jenny Goudemand, Giancarlo Castaman, Augusto B Federici, Ian R Peake, Anne C Goodeve, on behalf of the EU-VWD and ZPMCB-VWD study groups

P-TH-465  CHARACTERISATION OF VON WILLEBRAND DISEASE MUTATIONAL SPECTRUM IN A TURKISH PATIENT COHORT
Daniel J Hampshire* (UK), Adel M Abuzeinah, Nawal S Al-Shammari, Michaela Eckert, Rachael E Coyle, Ahlam M Al-Buhairan, Sarah L Messenger, Turki Gursel, Jorgen Ingerslev, Ian R Peake, Anne C Goodeve

P-TH-466  FREQUENCY OF VON WILLEBRAND DISEASE AND OTHER BLEEDING DISORDERS AMONG WOMEN WITH IDIOPATHIC MENORRHAGIA IN CENTRAL PART OF IRAN
Manjeh Lak* (IR), Ra Sharifian, Gh Toogeh, M Valadan, S Roostaei, K Karimi, M Managhchi, H Mansouroirghabeh

P-TH-467  GENETIC ANALYSIS IN PATIENTS WITH A PHENOTYPE-BASED PUTATIVE DIAGNOSIS OF VON WILLEBRAND DISEASE TYPE I
Michael Steiner* (DE), Manuela Hesse, Goran Matic, Beate Krammer-Steiner

P-TH-468  THE USE OF DESMOPRESSIN (DDAVP) IN FOR TREATMENT AND PROPHYLAXIS OF BLEEDING DISORDERS IN PREGNANCY .A SYSTEMATIC REVIEW
Rezan A Kadir* (UK), Deri Trigg, Iosifina Stergiotou, Rezan Abdul-kadir
POSTER PRESENTATIONS

Thursday, July 28, 2011

TTP and related disorders

P-TH-469  THE DEVELOPMENT OF ACUTE IDIOPATHIC TTP IS NOT ASSOCIATED WITH CHANGES IN T CELL OR T-REGULATORY CELL NUMBERS.
Vickie McDonald* (UK), Arnold Pizzey, Samuel J Machin, Marie A Scully

P-TH-471  THE STRUCTURAL COMPONENTS OF ADAMTS13 REQUIRED FOR SYSTEMIC ANTI-ARTERIAL THROMBOSIS IN VIVO
Juan (Jenny) Xiao* (US), Sheng-Yu Jin, X. Long Zheng

P-TH-472  THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) AND PREGNANCY IN THE UK: IDENTIFICATION OF SUBTYPE, MANAGEMENT AND OUTCOME OF SUBSEQUENT PREGNANCIES.
Mari R Thomas* (UK), Raymond S Camilleri, Samuel J Machin, Amanda Clark, Desmond Creagh, Gillian Evans, Marie A Scully

P-TH-473  PLATELET REACTIVE CONFORMATION AND MULTIMERIC PATTERN OF VON WILLEBRAND FACTOR IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING ACUTE DISEASE AND REMISSION
Luca A Lotta* (IT), Rossana Lombardi, Mariagabriella Mariani, Stefano Lancellotti, Raimondo De Cristofaro, Martine J Hollestelle, Pier Mannuccio Mannucci, Flora Peyvandi

P-TH-474  ADAMTS13 ACTIVITY AND ANTIBODIES IN THE ANTIPHOSPHOLIPID SYNDROME
Manuel Cesar Campos* (PT), Duarte Rego, Sara Morais, Monica Pereira, Margarida Lima

P-TH-475  THROMBOTIC POTENTIAL IN HIV AND HIV ASSOCIATED TTP
Muriel Meiring* (ZA), Mike Webb, Dominique Goedhals, Marius Coetzee, Vernon Louw

P-TH-476  ACTIVATION OF COAGULATION AND FIBRINOLYSIS IN THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIC SYNDROME
Matthias Mottini (CH), Irmela Sulzer, Manuela Albisetti, Bernhard Laemmle, Johanna A Kremer Hovinga*

Laboratory tests

P-TH-477  CORRELATION BETWEEN VON WILLEBRAND FACTOR (VWF) COLLAGEN BINDING AND HEMOSIL VWF ACTIVITY ASSAYS
Manuela Carvalho (PT), Susana Fernandes, Manuela Reis, Bas van Haren, Waander van Heerde, Luis Manuel Cunha-Ribeiro*

P-TH-478  COLLAGEN BINDING ASSAY IN THE LABORATORY DIAGNOSIS OF VON WILLEBRAND DISEASE
Ksenia Bykowska (PL), Maria Podolak-Dawidziak, Ewa Stefanska-Windyga, Edyta Odnoczko, Jerzy Windyga*

P-TH-479  COMPARATIVE EVALUATION OF A NEW VON WILLEBRAND FACTOR ACTIVITY ASSAY*
Andreas R. Huber* (CH), Ulrich Budde, Johann Patzke, Heidrun Muth

P-TH-480  ESTABLISHMENT OF AN AUTOMATED VWF:RCO ASSAY FOR MEASURING PLASMA SAMPLES WITH LOW ACTIVITY
Katalin Varadi* (AT), Hanspeter Rottensteiner, Eveline Gruber, Juergen Siekmann, Tobias Suiter, Friedrich Scheiflinger, Peter L. Turecek
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-481  REFERENCE INTERVAL FOR FACTOR VIII TO VON WILLEBRAND FACTOR ANTIGEN IS LOWER FOR INFANTS UNDER 6 MONTHS OF AGE COMPARED TO OLDER CHILDREN AND ADULTS
Rowena Punzalan* (US), Joan Cox Gill, Robert R Montgomery, Sandra L Haberichter, Kenneth D Friedman

P-TH-482  LOW DOSE RISTOCETIN INDUCED PLATELET AGGREGATION. WHICH DOSE IS LOW ENOUGH?
Juan Pablo Frontroth* (AR), Mirta Hepner, Graciela Pieronri, Eliana Annetti, Mercedes Castanon, Gabriela Ssciuccati, Aurora Feliu-Torres, Mariana Bonduel

P-TH-483  EVALUATION OF AN AUTOMATED METHOD FOR THE MEASUREMENT OF RISTOCETIN COFACTOR ACTIVITY OF VON WILLEBRAND FACTOR (VWF:RCO)
Hannah Fortune (IE), Marie Rafferty, Niamh O’Connell, James O’Donnell, Mary Byrne*

P-TH-484  A MODIFIED AUTOMATED VWF:RCO ASSAY WITH ENHANCED DETECTION RANGE AND REDUCED VARIABILITY IN COMPARISON TO STANDARD AUTOMATED METHODS
Gerhard Gruber* (AT), Monika Stadler, Bruce Schwartz, Sandra Janisch, Cornelia Zapfl, Christian Hadrer, Andreas Hillarp

P-TH-485  UTILITY OF PLATELET FUNCTION ANALYZER AS A SCREENING TOOL FOR THE DIAGNOSIS OF VON WILLEBRAND DISEASE IN ADOLESCENTS WITH MENORRHAGIA
Swati Naik* (US), Jun Teruya, Jennifer Dietrich, Purvi Jariwala, Lakshmi Venkateswaran

Hemophilia

P-TH-486  LONG TERM OUTCOME OF TOTAL ELBOW ENDOPROSTHESIS IN HEMOPHILIA ARTHROPATHY MAY BE SUPERIOR TO RADIAL HEAD PROSTHESIS: SOME CASE REPORTS
Peter Staritz* (DE), Rainer Zimmermann, Peter Lages, Angela Huth-Kuehne

P-TH-487  AN INVERSE SHIFTING-POLYMERASE CHAIN REACTION FOR GENOTYPING HEMOPHILIA-CAUSATIVE REARRANGEMENTS INVOLVING INT22H AND INT1H HOTSPOTS IN THE F8 GENE
Leila Kokabee* (IR), Mostafa kokabee, Sirous Zeinali, Morteza karimipoor

P-TH-488  THROMBIN GENERATION IN MILD AND MODERATE HAEMOPHILIA A
Simon Mcrae* (AU), Susan Rodgers, Reanuga Gopal, Lay Tay, Andrew Atkins

P-TH-489  IMPROVED PROGNOSIS OF ACQUIRED HEMOPHILIA A (AHA): RESULTS OF THE DUESSELDORF MONOCENTER STUDY.
Rudiger E. Scharl* (DE), Roya Gheisari, Barbara Bomke, Till Hoffmann

P-TH-490  AGE DISTRIBUTION OF THE HEMOPHILIC POPULATION IN EUROPE - AN EMERGING OLDER COHORT
Gerard Dolan* (UK), Cedric Hermans, Jerzy Windyga

P-TH-491  HEMARTHROSIS INCREASES THE ARTICULAR FIBRINOLYTIC SYSTEM IN A MURINE HEMOPHILIA MODEL
Roger EG Schutgens* (NL), Laurens Nieuwenhuizen, Goris Roosendaal, Douwe Biesma, Floris Lafeber

P-TH-492  DIFFERENCE IN TISSUE FACTOR PATHWAY INHIBITOR (TFPI) LEVELS BETWEEN HEMOPHILIA A AND B PATIENTS
Brigitte Tardy-Poncet* (FR), Michele Piot, Celine Chapelle, Claire Berger, Lydia Campos, Patrick Mismetti, Herve Decousus, Bernard Tardy
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-493  DELETION OF F8 GENE INVOLVING THE SEGMENTAL REPEAT INT22H AND ONE OF THE TWO EXTRAGENIC COPIES IN A CARRIER WOMAN.
Pilar Casana* (ES), Ana Rosa Cid, Silvestre Jose Oltra, Francisco Martinez, Carmen Orellana, Monica Pilar Rosello, Sandra Monfort, Saturnino Haya, Jose Antonio Aznar

P-TH-494  VARIOUS COMPLICATIONS IN HAEMOPHILIACS MANAGED BY HOSPITAL UNIVERSITY OF BATNA, ALGERIA
Nadjoua SAIDANE* (DZ), Mahdia SAIDI, Chaouki DERDOUS, Samir ROUABHIA, Fatima SOLTANI, Yamina OUARHLENT

P-TH-495  MECHANISM OF COMBINED INT1H-RELATED INVERSION, DELETION AND DUPLICATION INVOLVING F8 EXPLAINS RECURRENT ABNORMAL DIAGNOSTIC PATTERN IN SEVERE HEMOPHILIA A
Suely M. Rezende* (BR), Simone F. Pio, Sheila Soares, G. Correa, Christiane Muehle

P-TH-496  BONE MINERAL DENSITY AND BONE TURNOVER IN PATIENTS WITH HAEMOPHILIA
Angelika Batorova* (SK), Denisa Jankovicova, Emoke Stenova, Boris Steno, Tatiana Prigancova, Anna Morongova

P-TH-497  CENTRAL VENOUS ACCESS DEVICE-ASSOCIATED MORBIDITY IN PAEDIATRIC PATIENTS WITH SEVERE HAEMOPHILIA
Jeremy David Robertson* (AU), Katie Leanne Reeves

P-TH-498  SEQUENTIAL INFUSION OF RFVIIA AND PLASMA-DERIVED ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE IN HAEMOPHILIA A PAEDIATRIC PATIENT WITH INHIBITORS
Paola Giordano* (IT), Lassandro Giuseppe, Scaraggi Rosanna, Capriati Teresa, De Mattia Domenico, Scaraggi Francesco Antonio

P-TH-499  BENEFITS OF A SPECIFIC AQUA-TRAINING FOR ADULT HAEMOPHILIA PATIENTS - RESULTS OF THE LONGITUDINAL WATERCISE STUDY (WAT-QOL)
Sylvia von Mackensen* (DE), Barbara Elfrig, Dorothea Zaeck, Astrid Wieloch, Janis Kalnins, Wolfgang Zeller

P-TH-500  HAEMOPHILIA A FAMILIES WITH THE SAME MUTATION ARE OFTEN RELATED - A SURVEY OF THE SWEDISH POPULATION
Christer Hallden (SE), Rolf Ljung*

P-TH-501  SCREENING OF F8 GENE IN THE MAJORITY OF SLOVENIAN HEMOPHILIA A PATIENT POPULATION
Marusa Debeljak* (SI), Lidija Kitanovski, Majda Benedik Dolnicar

P-TH-502  Efficacy and Safety of Antithrombotic Prophylactic Therapy with Low-Molecular-Weight Heparin (LMWH) after Orthopaedic Surgery in Haemophilia Patients
Francesca Biondo* (IT), Erminia Baldacci, Filippo La Cava, Annalena Leporace, Luana Poggini, Cristina Santoro, Francesco Falez, Adriana Antonaci, Maria Gabriella Mazzucchini

P-TH-503  Effectiveness of Tools for Monitoring of Haemophilic Arthropathy
Yesim Oymak* (TR), Aysen Turedi Yildirim, Muge Gurcinar, Yontem Yaman, Cavit Ozgur, Ozez Gulcihan, Altinay Firat, Canan Razidey Vera

P-TH-504  Thrombin Generation in Platelet-Rich Plasma Compared to Platelet-Poor Plasma - Better Clinical Correlation in Inhibitor Patients?
Bettina Geissler* (DE), Hans-Georg Topf, Grischa Lischetzki, Manfred Rauh
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-505  LIFE QUALITY ASSESSMENT IN HAEMOPHILIA PATIENTS AND EFFECT OF ARTHROPATHY
Yesim Oymak* (TR), Aysen Turedi Yildirim, Erhan Eser, Arife Kaygusuz, Yontem Yaman, Cerrit Ozgur, Gulcihan Ozek, Burcak Tatli Guney, Kaan Kavakili, Muget Gurcinar, Altinay Firat, Mural Hizarcioglu, Canan Raziiye Vergin

P-TH-506  THE NOVEL EXONIC SPLICE SITE AS A CAUSE OF MILD TYPE HEMOPHILIA A
Ingrid V Hrachovinova* (CZ), Dana Provaznikova, Frantisek Marecek, Alena Janouskova, Alena Radosvka, Petr Smejkal, Peter Salaj

P-TH-507  SPONTANEOUS ILIOPSOAS HEMATOMA IN PATIENTS WITH VON WILLEBRAND DISEASE AND HEMOPHILIA A
Bijan Keikhaei* (IR)

Hemophilia therapy

P-TH-508  STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF A RECOMBINANT HUMAN FACTOR IX DRUG CANDIDATE
Hanspeter Rottensteiner* (AT), Peter L Turecek, Susanne Vejda, Katalin Varadi, Ernst Boehm, Manfred Reiter, Martin Kaliwoda, Wolfgang Mundt, Hartmut J Ehrlich, Friedrich Scheiffinger

P-TH-509  BLEEDING PROPHYLAXIS WITH AN ANTI-INHIBITOR COAGULANT COMPLEX (AICC) IN PATIENTS WITH HEMOPHILIA A AND INHIBITORS CAN IMPROVE QUALITY OF LIFE: RESULTS OF THE PRO-FEIBA STUDY
Alessandro Gringeri* (IT), Cindy Leissinger, Paolo Cortesi, Lorenzo Giovanni Matovani

P-TH-510  DIRECT COSTS OF CHILDREN WITH HAEMOPHILIA A UNDERGOING PROPHYLAXIS OR EPISODIC TREATMENT: RESULTS FROM THE ESPRIT STUDY.
Alessandro Gringeri* (IT), Francesco Fusco, Silvia Riva, Sylvia von Mackensen, Lorenzo Giovanni Mantovani

P-TH-511  THE EFFECTS OF REPEATED RADIOACTIVE SYNOVECTOMY ON THE TREATMENT OF HEMOPHILIC ARTHROPATHY
Bulent Zulfikar* (TR), Onder Kilicoglu, Cuneyt Turkmen, Fikret Bezgal, Nesilhan Diler, Omer Taser

P-TH-512  EUHASS: THE FIRST TWO YEARS OF ADVERSE EVENT MONITORING IN PERSONS WITH INHERITED BLEEDING DISORDERS IN EUROPE
Michael Makris* (UK), Kathelin Fischer, Gabriele Calizzani, Charles Hay, Christopher Ludlam, Thierry Lambert, Riitta Lassila, Pier Mannucci

P-TH-513  MANAGEMENT OF CORONARY ARTERY DISEASE IN PATIENTS WITH HAEMOPHILIA
Barbara Bomke* (DE), Ruediger E Schaf

P-TH-514  PROPHYLAXIS TREATMENT IN YOUNG SEVERE HEMOPHILIA A PATIENTS: EFFICACY, FVIII CONSUMPTION, TROUGH FVIII LEVELS AND THERAPY COMPLIANCE
Francesca Biondo* (IT), Cristina Santoro, Erminia Baldacci, Annapaola Leporace, Maria Gabriella Mazzuccconi

P-TH-515  ORTHOPAEDIC STATUS OF SEVERE HAEMOPHILIA A.B PATIENTS IN ONE HAEMATOLOGY DEPARTMENT IN ALGIERS
Meriem Bensadok* (DZ), Salim Fourmas, Karima Wafia Chennoukh, Milad Aribi, Meriem Fadila Belhani
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-516 THE DRAMATICALLY COMPLICATED SIXTH DECADE IN LIFE OF THE PATIENT WITH SEVERE HEMOPHILIA A (FRACTURES, INHIBITOR, LOWER EXTREMITY AMPUTATION, SUCCESSFUL ITI, THROMBOSIS)
Petr Smejkal* (CZ), Alena Bulikova, Miloslava Matyskova, Gabriela Chlupova, Jarmila Kissova, Marie Slechtova, Miroslav Panka

P-TH-517 DYNAMICS OF PLASMA FACTOR VIII DURING THE CONTINUOUS INFUSION OF FACTOR VIII CONCENTRATES IN TWENTY PATIENTS WITH HEMOPHILIA A
Katsumi Nishiya* (JP), Keiji Nogami, Ichiro Tanaka, Masaru Shibata, Kenichi Ogiwara, Tomoko Matsumoto, Midori Shima

P-TH-518 SPORTS ACTIVITIES WITH PROPHYLACTIC THERAPY CAN ENHANCE QOL OF HEMOPHILIC CHILDREN
Hisaya Nakadate* (JP), Akira Ishiguro, Hirokazu Sakai

Inhibitors: pathogenesis, prevention and treatment

P-TH-519 IN VITRO CORRECTION OF THROMBIN GENERATION AND IMPROVEMENT OF CLOT STRUCTURE BY RECOMBINANT PORCINE FACTOR VIII IN PLASMA CONTAINING ANTI-FACTOR VIII INHIBITORY ANTIBODIES
Claude Negrier* (FR), Johannes Oldenburg, Uri Martinowitz, Bernd Poetzsch, Jean-Claude Bordet, Raed Al Dieri, Yesim Dargaud, Coen Hemker, Martin Lee

P-TH-520 USE OF ARTIFICIAL NEURAL NETWORKS FOR LARGE SCALE PREDICTION OF FACTOR VIII DERIVED CD4 T CELL EPITOPES.
Daniel P Hart* (UK), Stuart Skelton, David S Moss, Clare E Sansom, Keith Gomez, Adrian J Shepherd

P-TH-521 DIFFERENTIAL EXPRESSION OF CYTOKINE GENES BETWEEN INHIBITOR AND NON-INHIBITOR HA GROUPS
Sung ho Hwang* (KR), Jeong A Lim, Hugh C Kim, Hyun Woo Lee, Ki Young Yoo, Hye Sun Kim

P-TH-522 SEVERE HEMORRHAGE FROM ACQUIRED FACTOR V INHIBITOR WITH 2ND EXPOSURE TO TOPICAL BOVINE THROMBIN, RAPID RESPONSE TO STEROIDS AND PLASMAPHERESIS.
Futoshi Iioka* (JP), daiki simomura, Yoshitomo Maesako, Fumihiko Nakamura, Takamasa Hayashi, Ohno Youichirou

P-TH-523 ASSESSMENT OF QUALITY OF LIFE IN HEMOPHILIA PATIENTS WITH INHIBITORS. DEVELOPMENT OF AN INHIBITOR-SPECIFIC QUESTIONNAIRE
Sylvia von Mackensen* (DE), Silvia Riva, Kate Khair, Thynn Thynn Yee, Angiola Rocino, Carmen Escuriola, Johannes Oldenburg, Alessandro Gringeri

P-TH-524 HEMOJUVELIN IS RELATED TO IRON METABOLISM AND KIDNEY FUNCTION IN RENAL AND HEART ALLOGRAFT RECIPIENTS
Jolanta Malyszko* (PL), Jacek Malyszko, Piotr Przybylowski, Ewa Koc-Zorawska, Michal Mysliwiec, Sylwia Kozłowska, Jerzy Sadowski

P-TH-525 INHIBITORS IN MILD AND MODERATE HEMOPHILIA A: A HETEROGENEOUS PROBLEM
Christine L Kempton* (US), Geoff Allen, Cynthia Gauger, Jeffery Hord, Rebecca Kruse-Jarres, Rajiv Pruthi, Christopher Walsh, Guy Young, J. Michael Soucie

P-TH-526 IMMUNE RESPONSE GENE POLYMORPHISMS AND INHIBITOR DEVELOPMENT IN SEVERE HEMOPHILIA A PATIENTS IN INDIA.
Patricia Pinto* (IN), Kanjaksha Ghosh, Bipin Kulkarni, Shrimati Shetty
## POSTER PRESENTATIONS

### Thursday, July 28, 2011

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-527</td>
<td>INHIBITOR DEVELOPMENT IN A MILD HAEMOPHILIA A MIMICKING ACQUIRED HAEMOPHILIA</td>
<td>Simon Mcrae* (AU), Vaughan Williams, Ram Suppiah, C Pham</td>
</tr>
<tr>
<td>P-TH-528</td>
<td>DEEP VENOUS THROMBOSIS IN A PATIENT WITH ACQUIRED HEMOPHILIA A: A CASE REPORT AND LITERATURE REVIEW</td>
<td>Zhou Rong-Fu* (CN), Jian Ouyang, Hong Tao</td>
</tr>
<tr>
<td>P-TH-529</td>
<td>&quot;LOW-DOSE&quot; IMMUNE TOLERANCE INDUCTION REGIMENS AND RITUXIMAB IN PEDIATRIC PATIENTS WITH CONGENITAL HEMOPHILIA A &amp; B</td>
<td>Geoffrey A Allen* (US)</td>
</tr>
<tr>
<td>P-TH-530</td>
<td>SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN A SEVERE 66-YEAR OLD HEMOPHILIA A PATIENT WITH A HIGH-TITRE INHIBITOR</td>
<td>Riitta Laasila* (FI), Heidi Asmundela, Elina Armstrong</td>
</tr>
</tbody>
</table>

### Inherited coagulation disorders (except for von Willebrand disease)

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-531</td>
<td>INHERITED FXI DEFICIENCY IN POLAND</td>
<td>Jerzy Windyga* (PL), Eryta Odnowczko, Beata Baran, Anna Pavlova, Anna Buczma, Johannes Oldenburg, Jerzy Windyga</td>
</tr>
<tr>
<td>P-TH-532</td>
<td>THROMBIN GENERATION AND BLEEDING SCORE IN A LARGE GROUP OF PATIENTS WITH FVII DEFICIENCY</td>
<td>Marzia Menegatti* (IT), Simona Maria Siboni, Marigrazia Clerici, Lidia Padovan, Veena Chantarangkul, Flora Peyvandi</td>
</tr>
<tr>
<td>P-TH-533</td>
<td>INTRA-ABDOMINAL HEMATOMA AND AFBINOGENEMIA DIFFICULTIES TO DETECT THE ORIGIN OF BLEEDING</td>
<td>ZOHRA KACI* (DZ), HADJIRA AHMIDATOU, KARIMA WAFIA CHENNOUKH, MIERIM FADILA BELHANI</td>
</tr>
<tr>
<td>P-TH-534</td>
<td>IF THE PATIENT TOLD THE TRUTH: ASPIRIN-LIKE DEFECT</td>
<td>Zsuzsanna Wolf* (DE), Marc Schindewolf, Edelgard Lindhoff-Last</td>
</tr>
<tr>
<td>P-TH-535</td>
<td>THROMBOSIS IN PATIENTS WITH FACTOR VII DEFICIENCY AFTER TREATMENT WITH CONCENTRATE</td>
<td>Michael Makris* (UK), Michael Makris, Ewa Stefanska-Windyga, Silvia Horneff, Flora Peyvandi, Toshko Lissitchkov, Annarita Tagliaferri, Johannes Oldenburg, Jerzy Wyndiga</td>
</tr>
<tr>
<td>P-TH-536</td>
<td>RECURRENCE OF THE P.GLY262ASP MUTATION AND A NOVEL P.THR176.GLNL186 DELETION IN TWELVE PATIENTS WITH CONGENITAL FACTOR X DEFICIENCY</td>
<td>Ahmet F Oner* (TR), Serdar Epcacan, Andrea Cairo, Marzia Menegatti, Sinan Akbayram, Flora Peyvandi, Ahmet F Oner</td>
</tr>
<tr>
<td>P-TH-537</td>
<td>RARE BLEEDING DISORDERS: TWELVE YEARS OF DIAGNOSIS IN THE HAEMOSTASIS LABORATORY OF THE UNIVERSITY HOSPITAL OF BENI MEHHOUS (ALGIERS, ALGERIA)</td>
<td>Karima W Chennoukh* (DZ), Meriem Bensadok, Yasmina Berkouk, Nadia Zidani, Zohra Kaci, Mohamed Ramaoun, Meriem Belhani</td>
</tr>
<tr>
<td>P-TH-538</td>
<td>FVII DEFICIENCY PLASMA LEVEL &amp; BLEEDING HISTORY</td>
<td>Karima W Chennoukh* (DZ), Meriem Bensadok, Yasmina Berkouk, Nadia Zidani, Zohra Kaci, Meriem Belhani</td>
</tr>
<tr>
<td>P-TH-539</td>
<td>ISSUES IN THE AGING INDIVIDUAL WITH HEMOPHILIA AND OTHER INHERITED BLEEDING DISORDERS: UNDERSTANDING THE PATIENT'S PERSPECTIVE</td>
<td>Shannon Claire Jackson* (CA), Claude Bartholomew, Neale Smith</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Thursday, July 28, 2011

Acquired coagulation disorders

P-TH-540  ACQUIRED SEVERE FACTOR VII DEFICIENCY IN TWO PATIENTS WITH SEPSIS ROLE OF POLYMORPHISMS OF THE F7 GENE
Elisabeth Mazoyer* (FR), Anthony Leon, Jean Devignes, Muriel Giansily-Blaizot, Marie Toussaint, Thomas Lecompte

P-TH-541  OWREN-BASED INR ANALYSIS IS SUPERIOR TO QUICK-BASED METHODS IN PATIENTS WITH CHRONIC LIVER DISEASE
Maria Magnusson (SE), Margareta Sten-Linder*, Annika Bergquist, Bjorn Fischer, Antal Nemeth

P-TH-542  ACQUIRED HEMOPHILIA A IN A PATIENT WITH AUTOIMMUNE HEPATITIS, AUTOIMMUNE THYREOIDITIS AND SERONEGATIVE RHEUMATOID ARTHRITIS
Christian Pfrepper* (DE), Mathias Bruegel, Susette Unger, Dietger Niederwieser, Leahte Braunert

P-TH-543  FIBRINOGEN REPLACEMENT IN TRAUMATIC BLEEDING
Nicola S Curry* (UK), Claire Rourke, Sirat Khan, James Beavis, Sarah Kingsland, Karim Brohi, Simon J. Stanworth

P-TH-544  HIGHLY PURIFIED VWF/FVIII COMPLEX CONCENTRATE AS FIRST LINE THERAPY IN THREE PATIENTS AFFECTED BY ACQUIRED HAEMOPHILIA A AND CARDIOVASCULAR DISEASE
Sofia Barbar* (IT), Marta Milan, Barbara Brandolin, Luca Spiezia, Grazziella Saggiorato, Ezio Zanon

P-TH-545  PROSPECTIVE CLINICAL AND BIOLOGICAL EVALUATION OF ANTIHEMORRHAGIC TREATMENT WITH FEIBA (FACTOR EIGHT INHIBITOR BYPASSING ACTIVITY) IN ACQUIRED HEMOPHILIA A, FEIBHAC STUDY
Jeanne-Yvonne Borg* (FR), Claude Negrier, Isabelle Durieu, Herve Levesque, Sophie Voisin, Anne Lienhart, Sandra Regina, Anne Borel-Derlon, Study Group French FEIBHAC

P-TH-546  ACQUIRED INHIBITORS AGAINST COAGULATION FACTOR IX IN AN OTHERWISE HEALTHY 3-YEAR-OLD GIRL WITH MILD BLEEDING SYMPTOMS - A CASE REPORT
Michael Damgaard* (SE), Fariba Baghaei

P-TH-547  CHANGES IN GLOBAL HAEMOSTASIS IN PEDIATRIC LIVER TRANSPLANTATION : A SINGLE CENTER EXPERIENCE
Johannes Schelling* (DE), David Schmidt, Michael Melter, Selim Corbacioglu

P-TH-548  HAEMORRHAGIC DISTURBANCES OF UNUSUAL CAUSES. DIAGNOSTIC CHALLENGES.
Gyorgy Pfliegler* (HU), Erzsebet Kovacs, Krisztian Urban, Zsuzsa Bereczki

P-TH-549  IN VITRO EFFECTS OF RESUSCITATION FLUIDS ON COAGULATION AND MARKERS OF INFLAMMATION IN HUMAN BLOOD
Michael A Dubick* (US), Michael S Scherer, Martin G Schwacha

P-TH-550  SUCCESFUL CLINICAL REMISSION OF ACQUIRED GLANZMANN’S THROMBASTHENIA WITH HIGH-DOSE PREDNISOLONE AND MULTIPLE PLASMAPHERESIS
Zsuzsanna Wolf* (DE), Marc Schindewolf, Jan Schwonberg, Nguyen Duc Xuan, Edelgard Lindhoff-Last

P-TH-551  UNEXPLAINED POST-OPERATIONAL BLEEDING IN A PATIENT WITH ANTI-FACTOR XIII B SUBUNIT ANTIBODY
Kohei Murata* (JP), Masataka Ikeda, Masayoshi Souri, Akitaeda Ichinose
### POSTER PRESENTATIONS

**Thursday, July 28, 2011**

#### Hemorrhagic disorders in women

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-TH-552</td>
<td><strong>SEVERE POST-PARTUM HAEMORRHAGE TREATED WITH RECOMBINANT ACTIVATED FACTOR VII IN EIGHTY WOMEN - DATA FROM THE UNISEVEN REGISTRY</strong></td>
<td>Jan Blatny* (CZ), Dagmar Seidlova, Miroslav Penka, Petra Ovesna, Petr Brabec, Pavel Sevcik, Pavel Venturba, Vladimir Cerny</td>
</tr>
<tr>
<td>P-TH-553</td>
<td><strong>MULTIDISCIPLINARY CLINICS LEAD TO AN IMPROVED CLINICAL OUTCOME AND MARKED COST SAVINGS IN WOMEN WITH VON WILLEBRAND’S DISEASE (VWD)</strong></td>
<td>Bella Madan* (UK), Stacey Ferris, Debra Holloway</td>
</tr>
<tr>
<td>P-TH-554</td>
<td><strong>THIRD TRIMESTER AMNIOCENTESIS IN WOMEN WITH INHERITED BLEEDING DISORDERS (IBD) TO GUIDE MANAGEMENT OF LABOUR AND DELIVERY</strong></td>
<td>Bella Madan* (UK), Jacqueline Cutler, Lucy Chappell, Pippa Kyle</td>
</tr>
<tr>
<td>P-TH-555</td>
<td><strong>RISK FACTORS FOR POSTPARTUM HAEMORRHAGE IN A COHORT OF 6011 ITALIAN WOMEN</strong></td>
<td>Eugenia Biguzzi* (IT), Franca Franchi, Federico Ambrogi, Buthaina Ibrahim, Paolo Bucciarelli, Barbara Acaia, Tatiana Radaelli, Elia Biganzoli, Pier Mannuccio Mannucci</td>
</tr>
<tr>
<td>P-TH-556</td>
<td><strong>THE PREVALENT OF BLEEDING DISORDERS IN UNEXPLAINED AND EXPLAINED MENORRHAGIA</strong></td>
<td>H. Marieke Knot* (NL), Andre B Mulder, Dick H. Bogchelman, Hanneke C. Kluin-Nelemans, Ale G.J. van der Zee, Karina Meijer</td>
</tr>
<tr>
<td>P-TH-557</td>
<td><strong>LOW VON WILLEBRAND FACTOR (VWF) LEVEL IS THE MORE FREQUENT FINDING IN A PROSPECTIVE COHORT OF CHILDBEARING WOMEN WITH BLEEDING HISTORY</strong></td>
<td>Anaia Sanchez-Luceros* (AR), Adriana I Woods, Susana S Meschengieser, Silvia H Grosso, Alicia Blanco, Maria F Alberto, Emilse Bermejo, Maria A Lazzari</td>
</tr>
<tr>
<td>P-TH-558</td>
<td><strong>PREVALENCE AND CHARACTERISTICS OF COAGULATION ABNORMALITIES IN WOMEN WITH MULTIFETAL PREGNANCY AND INTRAUTERINE DEATH OF ONE TWIN</strong></td>
<td>Predrag S Miljic* (RS), Aleksandar Jovanovic, Aleksandar Ljubic</td>
</tr>
<tr>
<td>P-TH-559</td>
<td><strong>MENORRHAGIA IN HEMORRHAGIC DISORDERS: A NEW, SIMPLE QUANTITATIVE METHOD FOR ITS EVALUATION</strong></td>
<td>Guglielmo Mariani* (IT), Mariasanta Napolitano, Elvira Grandone, Assunta Orecchioni, Sergio Siragus, Gaspare Carta, Giovanni Di Minno, Colaiuzzo Donatella, Mariagrazia Perilli, Alberto Dolce</td>
</tr>
<tr>
<td>P-TH-560</td>
<td><strong>POINT-OF-CARE PROTHROMBIN TIME TESTING AS AN EARLY PREDICTOR OF SEVERE POST PARTUM HEMORRHAGE</strong></td>
<td>Sophie Susen* (FR), Anne Bauters, Clotaire Pilla, Catherine Barre, Antoine Tournoy, Alain Duhamel, Sandrine Depret-Mosser, Brigitte Jude, Anne-Sophie Ducloy</td>
</tr>
<tr>
<td>P-TH-561</td>
<td><strong>VARIOUS PRIMARY HAEMOSTATIC DISORDERS AND PRIMARY COAGULOPATHIC MASSIVE OBSTETRICAL HAEMORRHAGE</strong></td>
<td>Alexander D. Makatsaria* (RU), Viktoria O. Bizadze, Valentina V. Smyrigina, Svetlana V. Akinshina, Djamila H. Khiziroeva</td>
</tr>
<tr>
<td>P-TH-562</td>
<td><strong>INHERITED FACTOR VII DEFICIENCY IN POLISH WOMEN</strong></td>
<td>Beata Baran* (PL), Ewa Stefanska-Windyga, Beata Baran, Anna Pavlova, Johannes Oldenburg, Ksenia Bykowska, Jerzy Windyga</td>
</tr>
<tr>
<td>P-TH-563</td>
<td><strong>INCREASED BLEEDING IN CARRIERS OF HAEMOPHILIA AND SUBJECTS WITH VON WILLEBRAND’S DISEASE RESULT IN MENORRHAGIA AND REDUCED QUALITY OF LIFE</strong></td>
<td>Cornelia Wermes* (DE), Roswith Eisert, Arnold Ganser</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-564  ELECTRONIC BLEEDING QUESTIONNAIRE, ELECTRONIC PBAC AND THROMBOELASTOGRAPHY: NOVEL APPROACHES IN THE DIAGNOSIS OF MILD BLEEDING DISORDERS IN WOMEN
Kimberly MacEachern* (CA), Alexander Hamilton, Stephen Scovil, Hisham S Elbatarny, Maha Othman

Laboratory tests

P-TH-565  COMPARISON OF PERIOPERATIVE THROMBOELASTOGRAPHY (TEG) WITH CONVENTIONAL COAGULATION TESTS (PLATELET COUNT, APTT, INR AND FIBRINOGEN) IN SURGICAL PATIENTS
Anna Agren* (SE), Agneta Taune Wikman, Anders Ostlund, Gustaf Edgren

P-TH-566  ENHANCED UNDERSTANDING OF PATHOPHYSIOLOGY AND PHENOTYPE IN CONGENITAL AFIGRINOGENEMIA USING MULTIPLE GLOBAL ASSAYS OF COAGULATION.
Cristina Santoro (IT), Mindy L Simpson, Neil A Goldenberg, Linda Jacobson, Lisa Villalobos-Menuey, Marilyn J Manco-Johnson*

P-TH-567  THROMBOELASTOGRAPHY AS A GLOBAL ASSAY TO MONITOR BYPASSING AGENTS IN HEMOPHILIA PATIENTS WITH INHIBITORS
Cristina Santoro (IT), Linda Jacobson, Michael Wang, Marilyn J Manco-Johnson*

P-TH-568  EVALUATION OF APTT CLOT WAVEFORM ANALYSIS BY IL ACL TOP IN PATIENTS WITH HAEMOPHILIA AND COMPARISON TO CLOT WAVE FORM ANALYSIS WITH MDA 180
Anne Riddell* (UK), Saman Aghighi, Tejas Gandhi, Elicid Vijayakumar, Sarah Brooks, Pratima Chowdry

P-TH-569  A COMMERCIAL ELISA METHOD FOR IDENTIFYING TYPE 2N VON WILLEBRAND DISEASE PATIENTS AND CARRIERS
Alessandra Casonato* (IT), Elena Pontara, Francesca Sartorello, Maria Grazia Cattini, Viviana Daidone, Alessandra Casonato

P-TH-570  AN APPROACH TO AN EXTERNAL QUALITY ASSURANCE PROGRAM (EQA) FOR THE PLATELET FUNCTION ANALYZER PFA-100: APPLICATION TO A SYSTEMATIC SCREENING OF PLATELET DISORDERS
Gines Escolar* (ES), Gines Escolar, Marcos Pino, Patricia Molina, Ana Maria Galan, Albert Barraso, Eduardo Arellano-Rodrigo, Juan Carlos Reverter, Gabriela Gutierrez, Maribel Diaz-Ricart

P-TH-571  IS ENDOGENOUS THROMBIN POTENTIAL A USEFUL TOOL TO ADAPT THE PROPHYLACTIC TREATMENT SCHEME IN PEDIATRIC HEMOPHILIAC PATIENTS: A PRELIMINARY STUDY
Caroline La* (BE), Phu Quoc Le, Laurence Rozen, Alina Ferster, Thomas Reyengaerts, Lambert Leenders, Anne Demulder

P-TH-572  SCREENING OF BLEEDING DISORDERS USING A THROMBOELASTOMETRIC THROMBIN GENERATION ASSAY
Thomas Siegemund* (US), Natalie Adam, Ute Scholz, Annelie Siegemund

P-TH-573  DISCREPANCY IN THE MEASURED RESPONSE TO PLASMA-DERIVED FVII CONCENTRATE DEPENDING ON THROMBOPLASTIN SOURCE
Anne Riddell* (UK), William Pickering, Sarah Brooks, Keith Gomez
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-574 PREVALENCE OF HEMOSTATIC ALTERATIONS IN A LARGE CASE SERIES OF PATIENTS WITH RECURRENT SPONTANEOUS SUBCONJUNCTIVAL HEMORRHAGE (THE RED EYE)
Paolo Gresele* (IT), Tiziana Fierro, Bartolini Anna, Mezzasoma AnnaMaria, Guglielmini Giuseppe, Cagini Carlo, Gresele Paolo

Inflammatory cells and cytokines

P-TH-575 NOVEL BIOMARKERS OF PROCOAGULANT ACTIVITY PRESENT IN THE PLASMA OF CIRRHOTICS WITH NOT PRESENT IN CIRRHOTICS WITHOUT ASCITES
David Hoffman Van Thiel* (US), Christopher Mark Moore, Bashar M Attar, Magdalena M George, Niculae Ion Nedelcu, Evengelos Litas, Giuliano Ramadori, Jawed Fareed, Raza Hamdani, Thethi Indermohan

P-TH-576 PLASMA CLOTS INDUCE MONOCYTE INFLAMMATORY CYTOKINE PRODUCTION: NEW LINKS BETWEEN THROMBOSIS AND INFLAMMATION
Robert Adrian Campbell* (US), Robert A Campbell, Tammy L Smith, Zechariah G Franks, Guy A Zimmerman, Andrew S Weyrich

P-TH-577 5-HYDROXY-2-(4-HYDROXY-3-METHOXYPHENYL)-3,7-DIMETHOXY-4H-CHROMEN-4-ONE (MSF-2) SUPPRESSES FMLP-MEDIATED RESPIRATORY BURST IN HUMAN NEUTROPHILS
Chang-Hui Liao* (TW), Jih-Jung Chen, Jieru-Egeria Lin, Chia-Hsin Liu, Ching-Ping Tseng, Tao-Yuan Day

P-TH-578 RECENT THYMIC EMIGRANTS ESTIMATION AS AN APPROACH TO PREMATURE IMMUNOSENESCENCE SYNDROMES STUDY
Mark V Golovizin* (RU), Natalia S Lakhonina, Almira D Donetskova, Margarita F Nikonova, Alexander A Yarilin, Yulia R Buldakova, Anna S Tektova, Vitaly T Timofeev

P-TH-579 PERIPHERALISATION OF T-LYMPHOCYTES SELECTION PROCESSES AS A POSSIBLE CAUSE OF VASCULAR TRANSFORMATIONS IN SYSTEMIC AUTOIMMUNE INFLAMMATORY DISEASES
Mark V Golovizin* (RU), Yulia R Buldakova, Natalia S Lakhonina, Vitaly T Timofeev

P-TH-580 LUTEIN, A NATURALLY OCCURRING CAROTENOID, MODULATES ACTIVITY OF MURINE MACROPHAGES
Wen-Bin Wu* (TW), Huey-Ming Lo, Pi-Hui Wu

P-TH-581 ANTI-INFLAMMATORY ACTIVITY OF RECOMBINANT THROMBOMODULIN PROTEINS
Hua-Lin Wu* (TW), Yu-Ming Cheng, Bi-Ing Chang, Cheng-Hsiang Kuo, Guey-Yueh Shi

P-TH-582 FACTOR XI STIMULATES NEUTROPHIL OXIDATIVE BURST AND INHIBITS CHEMOTAXIS
Asako Itakura* (US), Norah G Verbout, David Gailani, Andras Gruber, Owen J McCarty

P-TH-583 MONOCYTE SUBSETS DIFFERENTLY EXPRESS CD59 AND CORRELATE WITH CARDIOVASCULAR RISK FACTORS IN STABLE CAD PATIENTS
Konstantin A. Krychtiuk* (AT), Stefan P. Kastl, Stefan Pfaffenberger, Katharina M. Katsaros, Sebastian L. Hofbauer, Anna Wonnerth, Walter S. Speidl, Gerald Maurer, Kurt Huber, Johann Wojta

P-TH-584 BIOMARKERS OF INFECTION SEVERITY IN EMERGENCY DEPARTMENT PATIENTS
Eric Shappell* (US), Mark Cichon, Jeanine Walenga, Debra Hoppensteadt, Jawed Fareed
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-585  THROMBOMODULIN PHENOTYPE OF A DISTINCT MONOCYTE SUBTYPE IS AN INDEPENDENT PROGNOSTIC MARKER FOR DISSEMINATED INTRAVASCULAR COAGULATION
Ji Eun Kim* (KR), Hwang Sang Mee, Han Kyou-Sup, Kim Hyun Kyung

Extracellular matrix

P-TH-586  THROMBIN-CLEAVED FRAGMENTS OF OSTEOPONTIN ARE ELEVATED IN THE CEREBRAL SPINAL FLUID OF PRIMARY GLIOBLASTOMA AND AFFECT GLIOMA CELL BEHAVIOR
John Morser* (US), Yasuto Yamaguchi, Shadi Sharif, Xiaoyan Du, Timothy Myles, Larry Recht, Laung L. K. Lawrence

Vascular development

P-TH-587  PROGNOSTIC VALUE OF CIRCULATING ANNEXIN A5 IN PATIENTS WITH HEART FAILURE
Leon J Schurgers* (NL), Thor Ueland, Leonard Hofstra, Lars Gullesstad, Pal Aukrust, Jagat Narula, Chris P Reutelingsperger

P-TH-588  A NOVEL MUTATION (P.V228F) IN ACTIVIN RECEPTOR-LIKE KINASE 1 GENE CAUSING CHINESE FAMILY HEREDITARY HEMORRHAGIC TELANGIECTASIA
Lin Lin Jiang* (CN), Ye Ling Lu, Xue Feng Wang, Qiu Lan Ding, Jing Dai

P-TH-589  LINKS BETWEEN ANEMIA, IRON METABOLISM AND BONE DISEASES IN CHRONIC KIDNEY DISEASE-CKD
Jolanta Malyszko* (PL), Jacek Malyszko, Piotr Kozinski, Ewa Koc-Zorawska, Michal Mysliwiec

P-TH-590  IDENTIFICATION OF NOVEL ENDOTHELIAL-SPECIFIC GENES REGULATED BY TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY
Osamu Nakagawa* (JP), Satoshi Somekawa, Hisaki Hayashi, Sakabe Masahide, Tomoko Ioka, Ken Inada, Genki Satoh, Yoshihiko Saito

Tissue engineering

P-TH-591  PAR-2, BUT NOT PAR-1, IS CRITICALLY INVOLVED IN COLLATERAL FORMATION IN A MOUSE HIND LIMB ISCHEMIA MODEL
Lisa G van den Hengel* (NL), Alwine A Hellingman, Hetty C de Boer, Annemarie M van Oeveren-Rietdijk, C Arnold Spek, Anton Jan van Zonneveld, Pieter H Reitsma, Jaap F Hamming, Paul HA Quax, Henri H Versteeg

P-TH-592  CONTROLLED ACTIVATION OF MORPHOGENESIS TO GENERATE A FUNCTIONAL HUMAN MICROVASCULATURE IN A SYNTHETIC MATRIX
Sharon Gerecht (US), Donny Hanjaya-Putra*, Vivek Bose, Yu-I Shen, Jane Yee, Sudhir Khetan, Jason A Burdick

P-TH-593  VENOUS ENDOTHELIAL CELLS ARE LESS PROCOAGULANT COMPARED TO ARTERIAL ONES: IMPLICATIONS FOR VASCULAR TISSUE ENGINEERING
Henri M H Spronk* (NL), Irma Geenen, Daniel G.M. Molin, Mark J. Post, Rene van Oerle, Hugo ten Cate, Henri M.H. Spronk
POSTER PRESENTATIONS

Thursday, July 28, 2011

Experimental models

P-TH-594 THE P2Y1 RECEPTOR CONTRIBUTES TO TNFα-INDUCED VASCULAR INFLAMMATION IN MICE
Beatrice Hechler* (FR), Murielle Zerr, Stephanie Magnenat, Monique Freund, Jean-Pierre Cazenave, Catherine Leon, Christian Gachet

P-TH-595 PROTEASE ACTIVATED RECEPTOR 1 CONTRIBUTES TO ANGIOTENSIN II-INDUCED CARDIOVASCULAR REMODELING AND INFLAMMATION
Rafal Pawlinski* (US), Silvio Antoniak, Jessica C Cardenas, Nigel Mackman, Rafal Pawlinski

P-TH-596 ALPHA-2-MACROGLOBULIN AS A BIOMARKER FOR GLUCOCORTICOID-INDUCED OSTEONECROSIS OF THE FEMORAL HEAD
Chantal Seguin* (CA), Alberto Carli, Mireille Sayegh, Bouziane Azeddine, Allian Li, Ayoub Nahal, Rene Michel, Janet E. Henderson, Edward J. Harvey

P-TH-597 MICROPARTICLES (MPS) CONVEY CD14 FROM MONOCYTES TO LEUCOCYTES AND AMPLIFY LIPOPOLYSACCHARIDE (LPS)-INDUCED APOPTOSIS IN CELLULAR CROSSTALK MODELS
Xavier Delabranche* (FR), Julie Boisrame-Helms, Asael Berger, Emmanuel Haas, Fatiha Zobairi, Michel Hasselmann, Ferhat Meziani, Florence Toti

P-TH-598 VWF IS PROTECTIVE AGAINST STATUS EPILEPTICUS-INDUCED DEATH IN MICE
Georgette L Suidan* (US), Alexander Brill, Simon F. De Meyer, Jaymie R Voorhees, Denisa D Wagner

P-TH-599 INVESTIGATION OF IN VITRO MICROPARTICLE CLOTTING ACTIVITY
Nima Vaezzadeh* (CA), Peter L Gross

iPS cells and stem cells

P-TH-600 ACCELERATION OF CORD BLOOD HEMATOPOIETIC STEM CELLS PROLIFERATION BY A NEW CYTOKINE COCKTAIL IN SERUM FREE MEDIUM
Kamonnaree Chotinantakul* (TH), Seiji Okada, Wilairat Leeanansaksiri

Novel animal models

P-TH-601 NOVEL MURINE HEMOPHILIA LINGUAL VEIN BLEEDING MODEL PROVIDES LOWER VARIATION AND HIGHER SENSITIVITY IN COMPARISON TO TAIL VEIN TRANSECTION MODEL (TVT)
Maria Koelinerberger* (US), Perry Liu, Derek Sim, Jim Newgren, Cornell Mallari, Yifan Xu, John E. Murphy, Jesper Haaning

P-TH-602 A NOVEL MOUSE MODEL TO STUDY THROMBOGENESIS AND THROMBUS RESOLUTION WITH CONTINUOUS BLOOD FLOW IN THE INFERIOR VENA CAVA
Jose Antonio Diaz* (US), Christine M. Alvarado, Shirley K. Wrobelksi, Nichole Baker, Angela E. Hawley, Peter K. Henke, Benedict R. Lucchesi, Thomas W. Wakefield, Daniel D. Myers

Nanotechnology

P-TH-603 FIRST RESULTS OF THE BMBF (FEDERAL MINISTRY OF EDUCATION AND RESEARCH) FUNDED PROJECT “ON CHIP FLOW CHAMBER” TO MONITOR ANTICOAGULANT THERAPY AND COAGULATION DISEASES
Sascha Meyer dos Santos* (DE), Ute Klindhardt, Anita Zorn, Sebastian Harder
POSTER PRESENTATIONS

Thursday, July 28, 2011

P-TH-604  ASSESSMENT OF DIFFERENT METHODS STUDYING THE IMPACT OF CARBON NANOMATERIALS ON PLATELET FUNCTION
Julie Laloy* (BE), Francois Mullier, Severine Robert, Lutfiye Alpan, Jorge Mejia, Jean-Pascal Piret, Nicolas Bailly, Stephane Lucas, Bernard Chatelain, Olivier Toussaint, Bernard Masereel, Stephanie Rolin, Jean-Michel Dogne

P-TH-605  COLLAGEN NANOFIBERS ARRAYS AS A HOMOGENEOUS, REPEATABLE SUBSTRATE FOR PLATELET FLOW ASSAYS
Ryan Robert Hansen* (US), Alena A Tipnis, Jorge A Di Paola, Keith B Neeves

P-TH-606  CALIBRATED THROMBIN GENERATION TEST (CTGT) IS A POWERFUL PRECLINICAL TOXICOLOGICAL SCREENING TOOL TO ASSESS THE PROCOAGULANT ACTIVITY OF NANOMATERIALS
Severine Robert* (BE), Julie Laloy, Catherine Marbehant, Francois Mullier, Jorge Meija, Jean-Pascal Piret, Stephane Lucas, Bernard Chatelain, Jean-Michel Dogne, Olivier Toussaint, Bernard Masereel, Stephanie Rolin

P-TH-607  NEW METHOD FOR COUNTING AND SIZING CLINICALLY RELEVANT MICROPARTICLES (MPS) IN THE 0.15 TO 1 MICRON SIZE RANGE
Don A Gabriel* (US), Don A Gabriel, Richard T Stravitz, Regina Bowling, Samuel Glover, Nigel S Key

P-TH-608  EVALUATION OF THE ELASTIC PROPERTIES BY ATOMIC FORCE MICROSCOPY OF ERYTHROCYTES AND LIPID PEROXIDATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Lizaveta Drozd* (BY), Elena Konstantinova, Inna Buko

P-TH-609  Ti(N,C,O) DIFFUSIVE LAYERS DEVELOPED ON TITANIUM ALLOY AS THE BLOOD CONTACT SURFACE
Malgorzata Gonsior* (PL), Roman Kustosz, Tadeusz Wierzchon, Tomasz Borowski, Maciej Ossowski, Elzbieta Czarnowska, Marek Sanak, Bogdan Walkowiak, Wieslawa Okrój, Magdalena Walkowiak-Przybyla, Bogdan Jakiella
Special Symposia
Sunday, July 24, 2011

Special Symposium  

Room A

Made possible by generous support from Baxter Healthcare Corporation

Future Directions in the Prediction and Prevention of FVIII Inhibitors
Chairpersons: Jan Astermark (SE) and Bruce Ewenstein (US)

Welcome and introduction
Jan Astermark (SE) 12:30 – 12:45

What can we learn from and how should we interpret pup studies?
Bruce Ewenstein (US) 12:45 – 13:00

Refining how we think about the inhibitor risk based on fviii mutation type
Tom Howard (US) 13:00 – 13:15

Antibody response versus immune tolerance against fviii: How can we design future therapeutics?
Birgit Reipert (AT) 13:15 – 13:35

Evidence for the role of novel immune response genes in inhibitor development
Jan Astermark (SE) 13:35 – 13:50

EPIC: A study on the prevention of inhibitors
GÜnter Auerswald (DE) 13:50 – 14:05

Questions and answers
Panel Discussion 14:05 – 14:30

Special Symposium

Annex Hall 1

The programme supported by an unrestricted educational grant from AstraZeneca

EBAC Accredited Educational Programme organised by the Sahlgrenska Academy – Gothenburg University

Course director: K. Swedberg (Gothenburg, Sweden)

This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one hour of External CME credits. Each participant should claim only those hours of credit that
have actually been spent in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS)

**Antiplatelet therapy: Improving the care of ACS patients through evidence-based approaches**
Chairperson: Philippe Gabriel Steg (FR)

**Welcome and introduction**
Philippe Gabriel Steg (FR) 13:00 – 13:10

**Improving care with oral antiplatelet therapy: Lessons from recent large outcomes trials**
Philippe Gabriel Steg (FR) 13:10 – 13:25

**New mechanisms, new agents in antiplatelet therapy**
Marco Cattaneo (IT) 13:25 – 13:40

**Biomarkers in ACS: Prognostic indicators or meaningful endpoints?**
Robert Storey (UK) 13:40 – 13:55

**Genetic influences on platelet function: Recent insights**
Paul Gurbel (US) 13:55 – 14:10

**Panel discussion**
Chairperson and Faculty 14:10 – 14:30

---

**Special Symposium Annex Hall 2**

Made possible by generous support from Biogen Idec Hemophilia & Swedish Orphan Biovitrum

**Clinical Evaluation of Coagulation Factors with Prolonged Pharmacokinetic Activity**
Chairpersons: Glenn Pierce (US) and Alok Srivastava (IN)

**Welcome and introduction**
Glenn Pierce (US) and Alok Srivastava (IN) 12:35 – 12:40

**Bleeding risk and pharmacokinetics: Shifting paradigms?**
Alok Srivastava (IN) 12:40 – 12:55
Sunday, July 24, 2011 12:30-14:30

Coagulation factor pharmacokinetics and implications for treatment
Sven Bjorkman (SE) 12:55 – 13:10

Mechanism of action of fc fusion proteins
Robert Peters (US) 13:10 – 13:30

Preclinical models for clinical pharmacokinetics and efficacy in hemophilia
Haiyan Jiang (US) 13:30 – 13:45

Clinical trial considerations for long-lasting rFVIII-Fc fusion protein

Prolonged clinical activity of rFIX-Fc fusion protein in hemophilia b
Midori Shima (JP) 13:55 – 14:05

Summary conclusions
Alok Srivastava (IN) 14:05 – 14:10

Questions and answers
Glenn Pierce 14:10 – 14:30

Sunday, July 24, 2011 15:00-17:00

Special Symposium Room A

Made possible by generous support from The IME Group and InforMEDical Communications, Inc. (Supported by an educational grant from Baxter)

Bypass Therapy Prophylaxis for Inhibitor Management in Hemophilia A
Chairperson: Cindy A. Leissinger (US)

Doors open / Lunch served 15:00 – 15:30

Welcome and introduction
Cindy A. Leissinger (US) 15:30 – 15:35

Bypass therapy: Prophylaxis versus on-demand therapy
Alessandro Gringeri (IT) 15:35 – 16:00
Sunday, July 24, 2011 15:00-17:00

Clinical trials of prophylactic therapy in hemophilia patients with inhibitors
Cindy A. Leissinger (US) 16:00 – 16:25

Achieving consensus and developing guidelines for prophylaxis in inhibitor management
Jerome M. Teitel (CA) 16:25 – 16:50

Panel discussion and Q&A
Chair and Panel 16:50 – 17:00

Symposium close 17:00

Special Symposium Annex Hall 1

Made possible by generous support from Bayer Healthcare Pharmaceuticals

Prophylaxis: Current and Future Trends, Insights and Controversies
Chairpersons: David Lillicrap (CA) and Midori Shima (JP)

Welcome and introduction
David Lillicrap (CA) 15:00 – 15:05

Controversies in the use of prophylaxis: An interactive session
David Lillicrap (CA) 15:05 – 15:15

Prophylaxis with rFVIII in adults: New data from a prospectively designed study
Jerry Powell (US) 15:15 – 15:40

Long-term comparison of prophylaxis versus episodic treatment in a nested control study: Impact on joint health
Jørgen Ingerslev (DK) 15:40 – 16:05

New insights from preclinical research on modifying immune response and inhibitor binding
John Murphy (US) 16:05 – 16:30

Debate on the use of lifelong prophylaxis
Mike Makris (UK) and Kathelijn Fischer (NL) 16:30 – 16:55
Sunday, July 24, 2011

**Concluding remarks**
Midori Shima (JP) 16:55 – 17:00

**Special Symposium**
**Annex Hall 2**

**Made possible by generous support from Sanofi**

**Toward Better Anticoagulation Management: Experience and Evidence with Enoxaparin**
Chairpersons: Shinya Goto (JP) and Ajay Kakkar (UK)

**Welcome and introduction**
Shinya Goto (JP) 15:00 – 15:05

- **A call to action for VTE awareness**
  Ajay Kakkar (UK) 15:05 – 15:20

- **Update on VTE in Asia-Pacific**
  Ben Chong (AU) 15:20 – 15:35

- **Beyond Medenox: Reaching new horizons in non-surgical settings**
  Roger Yusen (US) 15:35 – 15:50

- **Medical oncology and thrombosis: What next?**
  Alok Khorana (USA) 15:50 – 16:05

- **Pleiotropic properties: Implications for anticoagulant differentiation**
  Ludovic Drouet (FR) 16:05 – 16:20

- **Panel discussion**
  All Facilitator, Sarah Jarvis (UK) 16:20 – 16:50

- **Concluding remarks**
  Ajay Kakkar (UK) 16:50 – 17:00
Monday, July 25, 2011 18:15-20:15

Special Symposium Sakura

Made possible by generous support from Bayer
Long-Term Oral Anticoagulation: Debating the Future
Chairpersons: the Lord Kakkar (UK) and Kenneth Bauer (US)

Welcome and introductory presentation
Ajay Kakkar (UK) 18:15 – 18:30

Atrial fibrillation: Updates on recent therapeutic advances
Gregory Lip (UK) 18:30 – 18:50

Debate-style discussion
Gregory Lip (UK), Masatsugu Hori (JP) 18:50 – 19:20

VTE Treatment: Updates on recent therapeutic advances
Harry Büller (NL) 19:20 – 19:40

Debate-style discussion
Harry Büller (NL), Alexander GG Turpie (CA), Walter Ageno (IT) 19:40 – 20:10

Closing remarks
Kenneth Bauer (US) 20:10 – 20:15

Special Symposium Room A

Supported by an educational grant provided by Novo Nordisk Health Care AG.

Challenges and Progress in the Management of Joint Health in Haemophilia Patients
Chairperson: Victor Blanchette (CA)
Co-Chair: Marilyn Manco-Johnson (US)

Welcome and introduction
Victor Blanchette (CA) 18:15 – 18:25

Pathogenesis of haemophilic arthropathy: Of mice and men
Leonard Valentino (US) 18:25 – 18:45
Monday, July 25, 2011 18:15-20:15

Tools to characterise joint condition: Imaging & functionality - The role of imaging in the detection of early haemophilic arthropathy
Michael Manco-Johnson (US) 18:45 – 19:05

Tools to characterise joint condition: The role of functional assessments in the detection of early haemophilic arthropathy
Marilyn Manco-Johnson (US) 19:05 – 19:25

Joint health in the inhibitor-positive patient: An evolving challenge
Elena Santagostino (IT) 19:25 – 19:55

Questions & concluding remarks
Victor Blanchette (CA) 19:55 – 20:15

Special Symposium Annex Hall 2
Made possible by generous support from CSL Behring
Factors for Life – Advances in Treatment of Congenital and Coagulopathic Bleeding Disorders
Chairpersons: Barbara Zieger (DE) and Steven Pipe (US)

Welcome and introduction
Steven Pipe (US) 18:15 – 18:20

CONGENITAL BLEEDING

Physiology of Von Willebrand Factor and its clinical implications for people with VWD
Reinhard Schneppenheim (DE) 18:20 – 18:45

Pioneering designs for recombinant coagulation factors
Stefan Schulte (DE) 18:45 – 19:05

Questions & answers
Barbara Zieger (DE) 19:05 – 19:15

ACQUIRED BLEEDING DISORDERS

The role of fibrinogen: A new paradigm in the treatment of coagulopathic bleeding
Benny Soerensen (UK) 19:15 – 19:35
Monday, July 25, 2011  
18:15-20:15

Fibrinogen concentrate in the treatment of severe bleeding after aortic aneurysm graft surgery. Clinical results of a prospective clinical trial
Niels Rahe-Meyer (DE) 19:35 – 20:00

Questions & answers
Steven Pipe (US) 20:00 – 20:10

Concluding remarks
Barbara Zieger (DE) 20:10 – 20:15

Special Symposium Room D

Made possible by generous support from Daiichi Sankyo, Co., Ltd.
Chronic Anticoagulation in AF: Optimization of Treatment
Chairpersons: Jeffrey Weitz (CA) and Yukihiro Koretsune (JP)

Registration and boxed dinner to be provided on first come first served basis 18:15 – 18:30

Welcome and introduction
Jeffrey Weitz (CA) 18:30 – 18:35

Focus on the guidelines
Takeshi Yamashita (JP) 18:35 – 18:55

Current perceptions of the barriers to anticoagulation
Raffaele De Caterina (IT) 18:55 – 19:15

Defining the clinical risks for bleeding in AF: Optimization of patient and treatment outcomes
Bradley C. Martin (US) 19:15 – 19:35

Next generation of anticoagulants
Jeffrey Weitz (CA) 19:35 – 19:55

Closing remarks
Yukihiro Koretsune (JP) 19:55 – 20:15
Monday, July 25, 2011 18:15-20:15

Special Symposium Room B-1

Made possible by generous support from Otsuka Pharmaceutical Co., Ltd.

Burdens on Anti-Thrombotic Therapy —How Do You Select Anti-Platelet Agents?—
Chairperson: Takenori Yamaguchi (JP) and Philippe Gabriel Steg (FR)

Welcome and introduction

Risk & benefit of anti-thrombotic therapy: Still ignore the bleeding risk?
Shinya Goto (JP)

The latest evidence on stroke treatment in asian population: Impact of CSPSII
Shinichiro Uchiyama (JP)

New trends in anti-platelet agents: Updates with the current topics
William R. Hiatt (USA)
### Satellite Symposia

Satellite Symposia take place on:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tuesday July 26</strong></td>
<td><strong>18:15 - 19:45</strong></td>
<td><strong>Daiichi Sankyo, Co., Ltd.</strong> Room D</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Stago</strong> Room E</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Boehringer Ingelheim</strong> Annex Hall 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Novo Nordisk A/S</strong> Room A</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Alexion Pharmaceuticals</strong> Room B-2</td>
</tr>
<tr>
<td><strong>Wednesday July 27</strong></td>
<td><strong>14:15 - 15:45</strong></td>
<td><strong>GlaxoSmithKline</strong> Room D</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Pfizer</strong> Sakura</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Loyola University Medical Center</strong> Room B-1</td>
</tr>
</tbody>
</table>
Tuesday July 26, 2011 18:15 - 19:45

**Novo Nordisk A/S**  
Room A

**Progress in Haemophilia Care: New Molecules on the Horizon**  
Chairperson: Tadashi Matsushita (JP)

**Welcome and introduction**  
Tadashi Matsushita (JP) 18:15 – 18:18

**Changing possibilities in haemophilia: Bringing trials to life together**  
Stephanie Seremetis (DK) 18:18 – 18:28

**Recombinant activated FVII analogue (vatreptacog alfa activated) for treatment of bleeds in haemophilia patients with inhibitors: Results from a global randomised phase 2 trial**  
Erich de Paula (BR) 18:28 – 18:53

**The historical evolution of haemophilia clinical trial programmes for product approval: A clinician's perspective**  
Roshni Kulkarni (US) 18:53 – 19:18

**Creating a paradigm shift in haemophilia B care: Results from the phase 1 trial of glycoPEGylated rFIX (N9-GP)**  
Paul Giangrande (UK) 19:18 – 19:43

**Questions & concluding remarks**  
Tadashi Matsushita (JP) 19:43 – 19:45

**Daiichi Sankyo, Co., Ltd.**  
Room D

**Chronic Anticoagulation in Prevention and Treatment of VTE**  
Chairpersons: Harry Buller (NL) and Mitsuru Murata (JP)

**Registration and Boxed Dinner to be provided on first come first served basis**  
18:15 – 18:30

**Welcome and introduction**  
Harry Buller (NL) 18:30 – 18:35

**Focus on the guidelines**  
Giancarlo Agnelli (IT) 18:35 – 18:55
Tuesday July 26, 2011 18:15 - 19:45

Next generation anticoagulants-prevention focus
Takeshi Fuji (JP) 18:55 – 19:15

Next generation anticoagulants-treatment focus
Harry Buller (NL) 19:15 – 19:35

Closing remarks
Mitsuru Murata (JP) 19:35 – 19:45

Boehringer Ingelheim Annex Hall 1
Join the revolution: Advances in Oral Anticoagulation
Chairperson: Ken Okumura (JP)

Chair’s welcome and introduction
Ken Okumura (JP) 18:15 – 18:20

Breakthroughs in the prevention and treatment of VTE
Sam Schulman (CA) 18:20 – 18:35

Current challenges in stroke prevention in patients with atrial fibrillation
Jeffrey Weitz (CA) 18:35 – 18:50

New insights from the landmark phase III RE-LY® trial – Oral anticoagulation is evolving
Gregory Lip (UK) 18:50 – 19:10

Introducing a novel oral anticoagulant – Clinical practice implications
Michael Ezekowitz (US) 19:10 – 19:30

Panel discussion: Questions and answers from the floor
All faculty 19:30 – 19:40

Conclusions and closing remarks
Ken Okumura (JA) 19:40 – 19:45
**Stago**

**Room E**

**Can We Predict Interventions in Haemostasis and Thrombosis?**

*Chairperson: Kenneth Mann (US)*

**Introductory lecture: “Thrombin generation assays”; Why should we care?**

*Kenneth Mann (US)*

18:15 – 18:30

**Evaluation of clotting function of acquired hemophilia**

*Midori Shima (JP)*

18:30 – 18:50

**Predicting and following haemostasis in patients with hemophilia and inhibitors**

*Claude Negrier (FR)*

18:50 – 19:10

**Laboratory testing of the new oral factor xa inhibitors**

*Elisabeth Perzborn (DE)*

19:10 – 19:30

**Concluding remarks**

*Kenneth Mann (US)*

19:30 – 19:45

**Alexion Pharmaceuticals**

**Room B-2**

**Atypical Hemolytic Uremic Syndrome (aHUS): New Insights and Emerging Treatment Options**

*Chairperson: Yoshihiro Fujimura (JP)*

**Welcome and opening remarks**

*Yoshihiro Fujimura (JP)*

18:15 – 18:20

**Update on aHUS and the role of complement in disease pathogenesis**

*Craig B. Langman (US)*

18:20 – 18:45

**Eculizumab and terminal complement inhibition as a therapeutic strategy in aHUS**

*Christoph Licht (CA)*

18:45 – 19:25

**New insights on thrombotic microangiopathy (TMA) in Japan**

*Masanori Matsumoto (JP)*

19:25 – 19:40
Tuesday July 26, 2011 18:15 - 19:45

Discussion and concluding remarks
Yoshihiro Fujimura (JA) 19:40 – 19:45

Wednesday July 27, 2011 14:15 - 15:45

Loyola University Medical Center Room B-1

Development of New Anticoagulant Drugs! Are Unmet Needs Met?
Chairpersons: Yasuo Ikeda (JP) and Samuel Goldhaber (US)
Moderator: M.M. Samama (FR)

Welcome and introduction
Paul Whelton (US) 14:30 – 14:40

Milestones in the development of newer anticoagulant drugs. What is achieved?
Jawed Fareed (US) 14:40 – 14:50

New oral anticoagulant drugs. The pros and cons.
Samuel Goldhaber (US) 14:50 – 15:00

Management of cancer associated thrombosis. The role of heparins.
M.M. Samama (FR) 15:00 – 15:10

Alternative anticoagulant management of heparin compromised patients. Role of anti-FXa and anti-FIIa agents.
Jeanine Walenga (US) 15:10 – 15:20

Newer parenteral anticoagulant advantages and disadvantages
John Fletcher (AU) 15:20 – 15:30

Safety issues related to newer anticoagulants
Russell Hull 15:30 – 15:40

Open discussion forum 15:40 – 16:00
**GlaxoSmithKline**  
**Room D**

**Challenges in VTE Management in East and West**  
*Chairpersons: Kazuyuki Shimada (JP) and Masato Sakon (JP)*

**Introduction**  
*Masato Sakon (JP)*  
14:15 – 14:20

**Risk and incidence of VTE in asian and western countries**  
*Walter Ageno (IT)*  
14:20 – 14:40

**Challenges in VTE prevention in north america and europe**  
*John W. Eikelboom (CA)*  
14:40 – 15:00

**Pharmacological prophylaxis of VTE in Japan**  
*Masataka Ikeda (JP)*  
15:00 – 15:20

**Update in the VTE treatment**  
*Mashio Nakamura (JP)*  
15:20 – 15:40

**Concluding remarks**  
*Kazuyuki Shimada (JP)*  
15:40 – 15:45

---

**Pfizer**  
**Sakura**

**Managing Haemophilia for Life: Treatment Trends in Haemophilia B**  
*Chairperson: Man-Chiu Poon (CA)*

**Chairperson’s introduction**  
*Man-Chiu Poon (CA)*  
14:15 – 14:20

**The global haemophilia B landscape**  
*Man-Chiu Poon (CA)*  
14:20 – 14:35

**Current trends in Asia**  
*Renchi Yang (CN)*  
14:35 – 14:55

**Global perspectives on haemophilia B treatment**  
*Paul Monahan (US)*  
14:55 – 15:30

**Panel discussion**  
*Moderated by Chairperson*  
15:30 – 15:40
Chairperson’s summary
Man-Chiu Poon (CA) 15:40 – 15:45

Close 15:45
Technical Symposia Sessions
Technical Symposia Sessions take place on:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
</table>
| Wednesday July 27, 2011 | 16:00 - 17:00 | Inspiration Biopharmaceuticals, Inc. - Room D  
Pfizer Japan, Inc. - Room B-2 |
Inhibition Biopharmaceuticals, Inc.  Room D

Inhibitors to Factor VIII: Use of a Recombinant Porcine FVIII as a Future Treatment Option
Chairperson: Amy D. Shapiro (US)

Welcome and introduction
Amy Shapiro (US) 16:00 – 16:05

Overview of Inspiration Development Programs
Ed Gomperts (US) 16:05 – 16:10

Recombinant porcine FVIII: Ex-vivo results
Johannes Oldenburg (DE) 16:10 – 16:25

Recombinant porcine FVIII: Phase 1 and 2 studies–Safety and efficacy
Johnny Mahlangu (ZA) 16:25 – 16:40

Recombinant porcine FVIII: Safety and efficacy among the first acquired inhibitor patients
Anne Greist (US) 16:40 – 16:55

Questions and answers
All 16:55 – 17:00

Concluding remarks
Amy Shapiro (US) 17:00

Pfizer Japan Inc.  Room B-2

Prevention of Stroke-What Can We Learn from the Recent Clinical Trials?-
Chairperson: Shinichiro Uchiyama (JP)

Pierre Amarenco (FR) 16:00-17:00
Exhibition and Sponsors
Sponsors

ISTH 2011 would like to thank the following

PLATINUM SPONSORS

- Baxter
- Bayer
- Daiichi-Sankyo
- Novo Nordisk

GOLD SPONSORS

- Boehringer Ingelheim
- Biogen Idec
- Sobi
- Sanofi
- Pfizer
Sponsors  ISTH 2011 would like to thank the following

**SILVER SPONSORS**

- Alexion
- AstraZeneca
- CSL Behring
- Otsuka
- Stago

**BRONZE SPONSORS**

- gsk GlaxoSmithKline
- Grifols
- Inspiration Biopharmaceuticals
- Werfen Group
- Instrumentation Laboratory
- LEO
ISTH 2011 Partners

Accumetrics
Alexion Pharmaceuticals, Inc.
American Biochemical & Pharmaceuticals Limited
Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
Astrazeneca
Baxter
Bayer Healthcare
Biogen Idec Hemophilia
Boehringer Ingelheim
Cellix Limited
Central Japan Railway Company
Chrono-log Corporation
CSL Behring Gmbh
Daiichi Sankyo Company, Limited
Diagnostica Stago S.A.S.
Elsevier B.V.
Enzyme Research Laboratories / R2 Diagnostics, Inc.
Finggal Link Co. Ltd.
Fujimori Kogyo
Gen-Probe
GlaxoSmithKline
Grifols International
Haematologic Technologies, Inc.
HYPHEN BioMed
Inspiration Biopharmaceuticals, Inc.
Instrumentation Laboratory (II)
Intelligent Imaging Innovations, Inc. (3i)
ISTH

ISTH 2013
ISTH SSC 2012
Japan Pharma Consortium
Kantar Health
Kedrion Spa
Leo Pharma
LFB France
Loyola University Chicago - Stritch School of Medicine
Medirox
Multiplate Services Gmbh
Novo Nordisk Haemophilia Foundation (Nnhf)
Otsuka Pharmaceutical Co., Ltd.
Pentapharm / Dsm
Pfizer Inc
Pfizer Japan Inc.
Precision Biologic
Provision Kinetics
Roche Diagnostics Ltd.
Rotem
Sanofi-aventis
Schattauer Publishers
Siemens
Springer Science+business Media
Sysmex Corporation
Talecris Biotherapeutics
Technoclone Gmbh
Wiley-Blackwell
World Federation of Hemophilia
ISTH 2011 Partners

Accumetrics
Alexion Pharmaceuticals, Inc.
American Biochemical & Pharmaceuticals Limited
Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
AstraZeneca
Baxter
Bayer HealthCare
Biogen Idec Hemophilia & Swedish Orphan Biovitrum
Boehringer Ingelheim
Cellix Limited
Central Japan Railway Company
Chrono-log Corporation
CSL Behring GmbH
Daiichi Sankyo Company, Limited
Elsevier B.V.
Enzyme Research Laboratories / R2 Diagnostics, Inc.
Finggal Link Co., Ltd.
FUJIMORI KOGYO CO., LTD. (ZACROS)
Gen-Probe
GlaxoSmithKline
Grifols International
aemalogic Technologies, Inc.
HYPHEN BioMed
Inspiration Biopharmaceuticals, Inc.
Instrumentation Laboratory
Intelligent Imaging Innovations, Inc.
ISTH
ISTH 2013
ISTH SSC 2012
Japan Pharma Consortium
Kantar Health
Kedrion Spa
Leo Pharma
LFB France
Loyola University Chicago - Stritch School of Medicine
Medirox
Multiplate Services GmbH
Novo Nordisk Health Care AG
Otsuka Pharmaceutical Co., Ltd.
Pentapharm / Dsm
Pfizer Inc.
Pfizer Japan Inc.
Precision BioLogic
Provision Kinetics
Roche Diagnostics Ltd.
Rotem
Sanofi
Schattauer Publishers
Siemens
Springer Science+Business Media
Stago
Sysmex Corporation
Technoclone GmbH
Wiley-Blackwell
World Federation of Hemophilia
Exhibition Area

The Exhibition is held concurrently with the ISTH 2011 Congress. The coffee break and lunch areas are located adjacent to the booths. Thanks to exhibitors from all over the world, attendees will have a complete overview of new findings in the domain of thrombosis and haemostasis.
## Exhibition List

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accumetrics</td>
<td>Exhibition Hall 2 39</td>
</tr>
<tr>
<td>American Biochemical &amp; Pharmaceuticals Limited</td>
<td>Exhibition Hall 1 34</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>Exhibition Hall 2 35</td>
</tr>
<tr>
<td>Baxter</td>
<td>Main Event Hall 3</td>
</tr>
<tr>
<td>Bayer HealthCare</td>
<td>Main Event Hall 10, 12</td>
</tr>
<tr>
<td>Biogen Idec Hemophilia &amp; Swedish Orphan Biovitrum</td>
<td>Exhibition Hall 2 42</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>Exhibition Hall 1 24</td>
</tr>
<tr>
<td>Cellix Limited</td>
<td>Exhibition Hall 1 23</td>
</tr>
<tr>
<td>Chrono-log Corporation</td>
<td>Exhibition Hall 2 41</td>
</tr>
<tr>
<td>CSL Behring Gmbh</td>
<td>Main Event Hall 11</td>
</tr>
<tr>
<td>Daiichi Sankyo Company, Limited</td>
<td>Main Event Hall 13</td>
</tr>
<tr>
<td>Enzyme Research Laboratories / R2 Diagnostics, Inc.</td>
<td>Exhibition Hall 2 37</td>
</tr>
<tr>
<td>Finggal Link Co. Ltd.</td>
<td>Exhibition Hall 2 70</td>
</tr>
<tr>
<td>Fujimori Kogyo</td>
<td>Exhibition Hall 2 40</td>
</tr>
<tr>
<td>Gen-Probe</td>
<td>Main Event Hall 19</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>Exhibition Hall 2 45</td>
</tr>
<tr>
<td>Grifols International</td>
<td>Exhibition Hall 1 20</td>
</tr>
<tr>
<td>Haematologic Technologies, Inc.</td>
<td>Main Event Hall 16</td>
</tr>
<tr>
<td>HemaCore LLC</td>
<td>Exhibition Hall 2 73</td>
</tr>
<tr>
<td>HYPHEN BioMed</td>
<td>Exhibition Hall 2 38</td>
</tr>
<tr>
<td>Instrumentation Laboratory</td>
<td>Exhibition Hall 2 50</td>
</tr>
<tr>
<td>Intelligent Imaging Innovations, Inc.</td>
<td>Exhibition Hall 1 52</td>
</tr>
<tr>
<td>ISTH</td>
<td>Main Event Hall 5</td>
</tr>
<tr>
<td>ISTH Academy</td>
<td>Hallway to Event Hall 73</td>
</tr>
</tbody>
</table>
## Exhibition List

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISTH 2013 Amsterdam</td>
<td>Main Event Hall 7</td>
</tr>
<tr>
<td>ISTH SSC 2012 Liverpool</td>
<td>Main Event Hall 6</td>
</tr>
<tr>
<td>Kantar Health</td>
<td>Exhibition Hall 2 71</td>
</tr>
<tr>
<td>Kedrion Spa</td>
<td>Exhibition Hall 1 21</td>
</tr>
<tr>
<td>Leo Pharma</td>
<td>Exhibition Hall 1 25</td>
</tr>
<tr>
<td>LFB France</td>
<td>Exhibition Hall 1 27</td>
</tr>
<tr>
<td>Medirox</td>
<td>Exhibition Hall 1 51</td>
</tr>
<tr>
<td>Multiplate Services GmbH</td>
<td>Main Event Hall 17</td>
</tr>
<tr>
<td>Novo Nordisk Health Care AG</td>
<td>Main Event Hall 9, 18</td>
</tr>
<tr>
<td>Otsuka Pharmaceutical Co., Ltd.</td>
<td>Exhibition Hall 1 26</td>
</tr>
<tr>
<td>Pentapharm / Dsm</td>
<td>Exhibition Hall 2 44</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>Exhibition Hall 2 36</td>
</tr>
<tr>
<td>Precision BioLogic</td>
<td>Main Event Hall 15</td>
</tr>
<tr>
<td>Provision Kinetics</td>
<td>Exhibition Hall 2 72</td>
</tr>
<tr>
<td>Roche Diagnostics Ltd.</td>
<td>Exhibition Hall 2 46</td>
</tr>
<tr>
<td>Rotem</td>
<td>Exhibition Hall 1 31</td>
</tr>
<tr>
<td>Stago</td>
<td>Main Event Hall 2</td>
</tr>
<tr>
<td>Sanofi</td>
<td>Main Event Hall 4</td>
</tr>
<tr>
<td>Schattauer Publishers</td>
<td>Exhibition Hall 2 47</td>
</tr>
<tr>
<td>Sysmex / Siemens</td>
<td>Exhibition Hall 1 30</td>
</tr>
<tr>
<td>Technoclone GmbH</td>
<td>Main Event Hall 14</td>
</tr>
<tr>
<td>Wiley-Blackwell</td>
<td>Exhibition Hall 1 33</td>
</tr>
<tr>
<td>World Federation of Hemophilia</td>
<td>Exhibition Hall 1 22</td>
</tr>
</tbody>
</table>
Exhibition and Sponsor Profiles
EXHIBITOR AND SPONSOR PROFILES

58TH ANNUAL MEETING OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE

BOOTH No. 6

Committee of the ISTH - SSC 2012, Liverpool
Address: ISTH Headquarters
610 Jones Ferry Road Suite 205
Carrboro, NC 27510
tel: +1 919 929-3807
fax: +1 919 929-3935
www.ssc2012.com

SSC 2012 (June 27-30, Liverpool UK) will bring together experts on practical matters related to blood coagulation, hemorrhagic disorders, and related standards and methods of research. It combines the SSC working sessions with educational programming, plenary presentations and hot topics.

ACCUMETRICS

BOOTH No. 39

Accumetrics’ family of VerifyNow® tests, which measures patient response to all major types of antiplatelet therapies (i.e. aspirin, Plavix®, EFFIENT®, Ticlid®, ReoPro® and Integrilin®), provides physicians with rapid, easy and valuable tools to help make more informed treatment decisions.

ALEXION PHARMACEUTICALS, INC.

SPONSOR

AMERICAN BIOCHEMICAL & PHARMACEUTICALS LIMITED

BOOTH No. 34

American Biochemical & Pharmaceuticals Limited (abp) is well known as the source of RISTO.abp.CETIN (Ristocetin Sulphate). abp now introduces its new range of Platelet Function Reagents, highlighted by COLLAGEN (Equine Tendon Type 1) and Lyophilized Platelets, matched to abp’s RISTO.abp.CETIN.
### Exhibitor and Sponsor Profiles

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)</strong></td>
<td></td>
</tr>
<tr>
<td>10 Circle Drive, Suite 12, North Liberty, IA 52317 USA</td>
<td></td>
</tr>
<tr>
<td>atvb.ahajournals.org</td>
<td></td>
</tr>
<tr>
<td>ATVB publishes research on the biology, prevention, and impact of vascular diseases related to arterioscleroses and thrombosis from a variety of disciplines including biochemistry, biophysics, cell and molecular biology, clinical investigation, epidemiology, genetics, lipoproteins, nutrition, metabolism, and pathology.</td>
<td></td>
</tr>
<tr>
<td><strong>AstraZeneca</strong></td>
<td>35</td>
</tr>
<tr>
<td>SE-431 83 Mölndal, Sweden</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.astrazeneca.com">www.astrazeneca.com</a></td>
<td></td>
</tr>
<tr>
<td>AstraZeneca is a global, innovation-driven, biopharmaceutical company with a primary focus on the discovery, development and commercialisation of prescription medicines that fulfil unmet medical needs in important areas of healthcare. For more information please visit: <a href="http://www.astrazeneca.com">www.astrazeneca.com</a></td>
<td></td>
</tr>
<tr>
<td><strong>Baxter</strong></td>
<td>3</td>
</tr>
<tr>
<td>One Baxter Way, Westlake Village, CA 91362 USA</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.baxter.com">www.baxter.com</a></td>
<td></td>
</tr>
<tr>
<td>Baxter’s BioScience business is a leader in recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders. Baxter continues to innovate, advancing medical science and technology to improve patient care worldwide.</td>
<td></td>
</tr>
<tr>
<td><strong>Bayer Healthcare</strong></td>
<td>10 &amp; 12</td>
</tr>
<tr>
<td>Bayer Healthcare AG</td>
<td></td>
</tr>
<tr>
<td>Leverkusen, Germany</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.bayerhealthcare.com">www.bayerhealthcare.com</a></td>
<td></td>
</tr>
<tr>
<td>Bayer Healthcare, one of the world’s leading, innovative companies in the healthcare and medical products industry, discovers and manufactures products that improve human health and enhance well-being and quality of life worldwide by diagnosing, preventing and treating diseases.</td>
<td></td>
</tr>
<tr>
<td><strong>Biogen Idec Hemophilia</strong></td>
<td>42</td>
</tr>
<tr>
<td>133 Boston Post Road, Weston, MA 02493 USA</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.BiogenIdecHemophilia.com">www.BiogenIdecHemophilia.com</a></td>
<td></td>
</tr>
<tr>
<td>We are Biogen Idec Hemophilia, and we’re exploring ways to make clotting factors last longer. Backed by more than 30 years of biotechnology leadership and break-through therapies with global impact, we are blazing a new trail of scientific discovery toward long-lasting clotting factors.</td>
<td></td>
</tr>
</tbody>
</table>
EXHIBITOR AND SPONSOR PROFILES

BOEHRINGER INGELHEIM  
Bingerstrasse 173,  
55216 Ingelheim,  
Germany  
www.boehringer-ingelheim.com

The Boehringer Ingelheim group is one of the world’s 15 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and approximately 42,000 employees.

CELLIX LIMITED  
Unit 3.81, Institute of Molecular Medicine,  
Trinity Health Centre,  
James’s St., Dublin 8,  
Ireland  
www.cellix ltd.com

Cellix produces microfluidic pumping solutions and disposable biochips capable of mimicking human capillaries for basic research in the areas of drug discovery, diagnostics and medical research. These are used to investigate cell adhesion, migration and transmigration studies in real-time under physiological conditions of flow – mimicking the same flow rates in human blood vessels.

CHRONO-LOG CORPORATION  
2 West Park Road,  
Havertown, PA 19083  
USA  
www.chronolog.com

Manufacturer of the Multi-channel WBA and the Model 700 Whole Blood-Optical Lumi-Aggregation Systems. The Impedance Aggregation mode detects platelet defects and monitors anti-platelet drugs. Lumi-Aggregometry for performing simultaneous Secretion Studies can now be tested in up to four (4) samples at a time.

CSL BEHRING GMBH  
Emil-von-Behring-Strasse 76  
35041 Marburg  
Germany  
www.cslbehring.com

CSL Behring is a global leader in the protein biotherapeutics industry. Passionate about improving the quality of patients’ lives, CSL Behring manufactures and markets a range of plasma-derived and recombinant products for the treatment of Hemophilia, von Willebrand’s disease and other bleeding disorders. For more information, visit www.cslbehring.com

DAIICHI SANKYO COMPANY, LIMITED  
3-5-1 Nihonbashi-honcho,  
Chuo-ku, Tokyo 103-8426,  
Japan  
www.daiichisankyo.com

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients worldwide. The Group is actively engaged in the development of novel treatments for thrombotic disorders.
EXHIBITOR AND SPONSOR PROFILES

ELSEVIER B.V. SPONSOR
Radarweg 29, 1043 NX Amsterdam, The Netherlands www.elsevier.com
Elsevier is a leading publisher of more than 20,000 products and services, including journals, books, electronic products, services, databases and portals serving the global scientific, technical and medical (STM) communities.

ENZYME RESEARCH LABORATORIES / R2 DIAGNOSTICS, INC. BOOTH No. 37
1801 Commerce Drive, South Bend, IN 46628 USA www.enzymeresearch.com
Enzyme Research Laboratories provides purified proteins, monoclonal and polyclonal antibodies, immunodepleted plasmas, and ELISA reagents for hemostasis research. r2 Diagnostics produces innovative reagents and diagnostic kits for the clinical hemostasis laboratory. Custom projects are also available with both companies.

FINGGAL LINK CO. LTD. BOOTH No. 70
Higashi-Komagata 2-13-13, Sumida-Ku, Tokyo 130-0005, Japan www.finggal-link.com
Finggal Link presents ROTEM® as a haemostatic monitoring system for perioperative bleeding management; Calibrated Automated Thrombogram as a physiologic function test measuring thrombin concentration in clotting plasma; and Verigene system as a fully-automated multiplex technology for SNP analysis/infectious disease testing.

FUJIMORI KOGYO CO., LTD. (ZACROS) BOOTH No. 40
Fujimori Kogyo is a Japanese manufacturer which was established in 1914. “ZACROS” is our house name. We create new value of packaging, film and equipment. We are now developing T-TAS which is expected to observe thrombogenesis with a Whole Blood.

GEN-PROBE BOOTH No. 19
20925 Crossroads Circle, Waukesha, WI. 53186 USA www.gen-probe.com
Gen-Probe is a leader in molecular diagnostics used for diagnosing infectious diseases, screening donated blood, assessing immune response for transfusion, measuring components of the coagulation pathway, helping ensure transplant compatibility, and aiding biomedical research/drug development.
EXHIBITOR AND SPONSOR PROFILES

GLAXOSMITHKLINE BOOTH No. 45

980 Great West Road, Brentford, Middlesex, TW8 9GS
United Kingdom
www.gsk.com

GlaxoSmithKline - one of the world’s leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

GRIFOLS, S.A. BOOTH No. 20 & 29

Parque Empresarial Can Sant Joan
Av. de la Generalitat 152-158
08174 Sant Cugat del Vallès, Barcelona, Spain
www.grifols.com

Grifols improves people’s lives with high quality innovative hospital products and services. Our plasma-derived therapies have outstanding records of efficacy and safety and we are also a world-leading manufacturer of medical devices, analyzers and reagents used by blood banks, transfusion centers and clinical laboratories.

GTI DIAGNOSTICS PLEASE SEE GEN-PROBE LISTING

HAEMATOLOGIC TECHNOLOGIES, INC. BOOTH No. 16

57 River Road, Unit 1021, Essex Junction, Vermont 05452
USA
www.haemtech.com

Haematologic Technologies, Inc. manufactures highly purified plasma proteins and associated research reagents involved in the regulation of blood coagulation and fibrinolysis. Our product line includes clotting factors, inhibitors and antibodies. Services include: custom protein purification, assay development, and stability testing.

HAEMONETICS CORPORATION SPONSOR

400 Wood Road
Braintree, MA 02184-9114, USA
www.haemonetics.com

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions. Our devices, consumables, IT products, and consulting services deliver a suite of business for blood and plasma component collection and hospital transfusion services. http://www.haemonetics.com/
HEMACORE LLC
34th street of 8 March, Moscow,
Russia, 123319

HemaCore LLC is focused on blood coagulation disorders diagnostics, developing analytical systems and diagnostics kits for the new medical test with tremendous predictive ability of thrombosis. The test is now going into clinical trials and will be on market within 2 years.

HYPHEN BioMed
155, Rue d’Eragny,
95000- Neuville sur Oise,
FRANCE
www.hyphen-biomed.com

Highly specialized company in the field of Thrombosis, Hemostasis, Fibrinolysis and related Auto-Immune disorders diagnostic reagents, HYPHEN BioMed is highly innovative, a major partner of pharmaceutical laboratories and offers IVDs, research reagents and customized solutions. Products are available worldwide through specialized distributors.

INSPIRATION BIOPHARMACEUTICALS, INC
28202 Cabot Road, te 300,
SuLaguna Niguel, CA 92677
www.inspirationbio.com

Inspiration Biopharmaceuticals is the only pharmaceutical company dedicated solely to developing therapies for hemophilia. Products in late-stage clinical trials are a recombinant FIX and a recombinant porcine FVIII. Inspiration’s mission: Broaden access to care and improve treatment of hemophilia patients with inhibitors.

INSTRUMENTATION LABORATORY (IL)
180 Hartwell Road
Bedford, MA 01730
www.ilww.com

IL’s exhibit features: the ACL TOP Family of Hemostasis Testing Systems, including the new ACL TOP® 300 CTS in addition to the ACL AcuStar™ system. Combined with the HemosIL® line of reagents, IL offers complete disease state management for the hemostasis lab.

INTELLIGENT IMAGING INNOVATIONS, INC. (3i)
5124 Washington St.
Denver, Colorado
USA
www.intelligent-imaging.com

3i develops multi-modal systems controlled by its SlideBook-5.0™ software for avant-garde fluorescence microscopy imaging and analysis. System options: inverted and fixed stage microscopes, spinning disk confocals, high-power solid state lasers, FLIM, FRET, FRAP, Ratio Imaging, Rapid 4D image acquisition and 2-Photon microscopy.
EXHIBITOR AND SPONSOR PROFILES

XXIV ISTH CONGRESS & 59TH ANNUAL SSC MEETING  BOOTH No. 7

Congress secretariat
MCI - Eurocongress
Jan van Goyenkade 11
1075 HP Amsterdam
The Netherlands
www.isth2013.org

Up-to-date information regarding the congress programme is available on the website www.isth.org. Starting 2nd November 2012 the site will allow participants to register and to submit abstracts.

KANTAR HEALTH  BOOTH No. 71

Kirkgate, 19-31 Church Street,
Epsom, Surrey, KT17 4PF,
UK
www.kantarhealth.com

Kantar Health, a global consultancy and marketing insights organisation, is a leading strategic decision support partner to the life sciences industry.

KARGER PUBLISHERS  SPONSOR

S. Karger AG
Medical and Scientific Publishers
Allschwilerstrasse 10
P.O. Box CH – 4009 Basel
Switzerland
www.karger.com

S. Karger AG is a leading international publisher of books and journals in the basic and medical sciences. Our Journal Acta Haematologica is a well established and internationally recognized publication featuring balanced, wide-ranging coverage of current hematology research.

KEDRION SPA  BOOTH No. 21

Loc. ai Conti - 55051
Castelvecchio Pascoli - Barga (LU)
Italy
www.kedrion.com

Kedrion is specialized in the development, production, commercialization and distribution of plasmaderivates Kedrion works in four business areas: Plasmaderivates production and commercialization Flu vaccines and synthetic pharmaceutical products distribution Plasma collection and commercialization Other activities such as technological know-how transfer

LFB  BOOTH No. 27

3 avenue des Tropiques - BP 305 Les Ulis
91940 Courtaboeuf cedex
France
www.lfb.fr

LFB is a biopharmaceutical group that develops, manufactures and markets plasma-derived medicinal products, for the treatment of serious and often rare diseases in several major therapeutic fields, namely immunology, hemostasis and intensive care.

In 2010, LFB’s turnover reached € 411.6 million; €86.5 million were dedicated to the group’s R&D activities.
LOYOLA UNIVERSITY CHICAGO - STRITCH SCHOOL OF MEDICINE

2160 South First Avenue

www.meddean.luc.edu

Loyola University Chicago Stritch School of Medicine serves a Jesuit tradition of academic excellence in education, research and clinical care that embraces social responsibility, service to those in need and respect for diversity of thought, opinion and belief.

MEDIROX

SE-611 82 Nyköping, Sweden

Phone: +46 (0)155 45 44 10

Fax: +46 (0)155 26 30 11

www.medirox.se

MediRox has produced instruments, diagnostic reagents and quality control material used in the areas of visco-elasticity and coagulation diagnostics since 1998. Our customers are located within laboratory diagnostics in healthcare. MediRox is ISO9000 certified, and all products are CE marked.

MULTIPLATE SERVICES GMBH

Reichenbachstrasse 27,

80469 Munich,

Germany

www.multiplate.net

Multiplate® is the most widely applied platelet aggregometer in Europe for the monitoring of antiplatelet therapy. The application of Multiplate® delivers superior predictivity for stent thrombosis and allows for superior stratification of major bleeding risk and transfusion requirements.

NOVO NORDISK HEALTH CARE AG

Andreasstrasse 15

CH-8050 Zurich

Switzerland

www.novonordisk.com

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, please visit our exhibit or www.novonordisk.com.

OTSUKA PHARMACEUTICAL CO., LTD.

Shinagawa Grand Central Tower 2-16-4 Konan,

Minato-ku, Tokyo 108-8242,

Japan

www.otsuka.co.jp/en

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a healthcare company with the corporate philosophy: "Otsuka-people creating new products for better health worldwide." Otsuka researches, develops, manufactures and markets innovative, original products with its focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health.
EXHIBITOR AND SPONSOR PROFILES

PENTAPHARM / DSM
Engelgasse 109, P.O.Box, CH-4002 Basel, Switzerland
www.pentapharm.com
Pentapharm develops and manufactures reagents for coagulation diagnostics. Products include test kits (APC-R FV Leiden, PiCT®UC, Reptilase®Time, TAFI, in-TDT® or OEM tests) and reagent raw materials for further manufacturing of diagnostic kits, including chromogenic and fluorogenic substrates, enzyme inhibitors and activators isolated from snake venom (e.g. Protac®, ecarin, batroxobin).

PFIZER INC.
235 E. 42nd Street
New York, NY 10017
USA
www.pfizer.com
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

PFIZER JAPAN INC.
3-22-7, Bunka Quint Bldg., Yoyogi, Shibuya-ku, Tokyo151-8589 Japan
www.pfizer.co.jp/pfizer/english/company
As the world’s leading research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world’s best-known consumer healthcare brands.

PRECISION BIOLOGIC
140 Eileen Stubbs Avenue, Dartmouth, NS B3B 0A9 Canada
www.precisionbiologic.com
Precision BioLogic develops, manufactures and sells CRYOcheck™ frozen controls, calibrators and reagents used for testing in coagulation labs around the globe. Our unique approach to serving customers is built on superior products, commitment to customer support and attention to detail.

PROVISION KINETICS
107 Skyline Drive, Arlington, Wisconsin 53911 USA
www.provisionkinetics.com
Provision Kinetics manufactures and distributes the Kinetichrome line of Anti-IIa and Anti-Xa heparin/LMW-heparin test kits. Our kits are designed and optimized for quality control and specification testing by pharmaceutical and medical device manufacturers.
EXHIBITOR AND SPONSOR PROFILES

ROCHE DIAGNOSTICS LTD.  
BOOTH No. 46
Forrenstrasse,  
6343 Rotkreuz,  
Switzerland  
www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

TEM INTERNATIONAL GMBH  
BOOTH No. 31
Martin-Kollar-Strasse 13,  
81829 Munich,  
Germany  
www.rotem.de

Tem International provides patient diagnostic devices for acute bleeding. The ROTEM® system provides rapid and clear results in whole blood. It gives a rapid overview about the coagulation status after 10 minutes allowing controlled targeted therapies and avoiding unnecessary transfusion.

SANOFI  
BOOTH No. 4
174 avenue de France  
75013 Paris  
France  
en.sanofi.com/at-a-glance/edito.asp

Sanofi is a diversified global healthcare company, focused on patients’ needs. A worldwide presence, market leadership in vaccines with the Group’s vaccine division Sanofi Pasteur, major biological products and a strong and long-established presence in emerging markets: these are the core strengths of sanofi. Company business activities also include consumer healthcare (OTC) products, generics and animal health products.

SCHATTAUER PUBLISHERS  
BOOTH No. 47
Hölderlinstr. 3  
70174 Stuttgart  
Germany  
www.thrombosis-online.com

THROMBOSIS AND HAEMOSTASIS, published since 1957, promotes standards in haematology, and is a leader at the cutting edge of basic and applied research in vascular biology. It is an invaluable resource for haematologists, clinical pharmacologists, cardiologists, surgeons, gynaecologists, internal specialists and laboratory physicians.
EXHIBITOR AND SPONSOR PROFILES

SIEMENS

Siemens Healthcare Diagnostics Products GmbH
Michael Nöh,
Head of Hemostasis Business Unit Global Marketing
Emil-von-Behring-Straße 76
35041 Marburg
Germany
www.siemens.com/healthcare

Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Our innovative portfolio of performance driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcomes.

SPRINGER SCIENCE+BUSINESS MEDIA

Dordrecht,
the Netherlands
www.springer.com

Knowledge, Information and Quality are the three things that shape Springer’s business activities. We develop, manage and disseminate knowledge – through books, journals and the Internet. We work with the world’s best academics and authors in long-standing loyal partnerships based on mutual trust and we are always open to new input.

STAGO

9 rue des Frères Chausson - 92600
Asnières sur Seine
France
www.stago.com

Stago dedicates its research and innovative skills to develop and improve the accuracy of the medical diagnostic. The firm formulates, manufactures and markets worldwide, a broad range of reagents and fully automated systems for Haemostasis & Thrombosis. Thanks to its Haemostasis expertise, Stago is recognized and is in a position to cooperate with the scientific community worldwide.

SYSMEX CORPORATION

1-5-1,Wakinohama-kaigandori,Chuo-ku,
Kobe,Hyogo 651-0073,
Japan
www.sysmex.co.jp

Sysmex has given birth to a wide spectrum of products and services that feature advanced technology in the diagnostics field. At present, Sysmex’s products and services are being used at medical institutions in over 160 countries around the world.
EXHIBITOR AND SPONSOR PROFILES

TECHNOCLONE GMBH
Brunner Str. 67,
1230 Vienna,
Austria
www.technoclone.com

TECHNOCLONE is a world leading producer of global and special coagulation tests. The new optimized Ceveron® alpha TGA offers the unique feature of fully automated thrombin generation measurement in the routine: CV <5% and assay times <20min Peak Thrombin.

WILEY-BLACKWELL
350 Main Street
Commerce Place
Malden, MA 02148
USA
www.wiley.com

Visit our booth for your copy of Journal of Thrombosis and Haemostasis, official journal of ISTH. Don’t miss the 2011 State of the Art issue alongside Wiley-Blackwell’s leading books, journals and databases bringing you the latest in hemostasis and thrombosis.

WORLD FEDERATION OF HEMOPHILIA
1425 Rene Levesque Boulevard West,
Suite 1010, Montreal,
Quebec, Canada H3G 1T7
Canada
www.wfh.org

Through training programs, educational activities, and international congress, the World Federation of Hemophilia improves and sustains treatment for all people with inherited bleeding disorders. Visit our booth to enter to win free registration to the 2012 WFH Congress in Paris.
ISTH2011 Kyoto, Japan
Floorplan

Layout of the Congress Venue
# Registration

<table>
<thead>
<tr>
<th>Registration fee</th>
<th>On-site</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISTH Member</td>
<td>JPY 80,000</td>
</tr>
<tr>
<td>ISTH Non Member in the process of acquiring membership</td>
<td>JPY 80,000</td>
</tr>
<tr>
<td>ISTH Non Member</td>
<td>JPY 100,000</td>
</tr>
<tr>
<td>Trainees and Students*1 up to the age of 38</td>
<td>JPY 25,000</td>
</tr>
<tr>
<td>Nursing Forum Attendees</td>
<td>JPY 25,000</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>JPY 50,000</td>
</tr>
<tr>
<td>Accompanying Persons*2</td>
<td>JPY 10,000</td>
</tr>
<tr>
<td>SSC Meeting attendance only Saturday July 23, Sunday July 24, 2011*3</td>
<td>free</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>free</td>
</tr>
<tr>
<td>All Congress Party*4,5</td>
<td>JPY 7,500</td>
</tr>
</tbody>
</table>

Fees payable in Japanese Yen (JPY) only.

*1 For trainees and students, a letter of confirmation from the Head of Department on departmental letterhead must be submitted. Students older than 38 can request a waiver from this age restriction, by providing a brief explanation and a letter from the Department Chair confirming their student status.

*2 Accompanying person must be a partner or a spouse of the registered participant.

*3 SSC-ONLY meeting registration is Free of Charge and good for two days.

*4 All Congress Party will be held on Wednesday 27, July 2011. On-Site Ticket Sale for All Congress Party is available only if there are still spaces.

*5 All Congress Party open only for registered participants and their registered accompanying persons.
**Registration**

**Entitlements**

<table>
<thead>
<tr>
<th>ISTH Member</th>
<th>ISTH Non Member</th>
<th>Trainee/Student</th>
<th>Nursing Attendee</th>
<th>Exhibitors</th>
<th>Special Pass</th>
<th>SSC Only (no badge)</th>
<th>Press/Media</th>
</tr>
</thead>
<tbody>
<tr>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
<td>○</td>
</tr>
</tbody>
</table>

**On-site Registration**

The Registration Desk will be open as follows:

- **Saturday:** July 23, 2011 07:00 - 18:00
- **Sunday:** July 24, 2011 07:30 - 19:30
- **Monday:** July 25, 2011 07:30 - 18:30
- **Tuesday:** July 26, 2011 07:30 - 18:30
- **Wednesday:** July 27, 2011 07:30 - 18:30
- **Thursday:** July 28, 2011 07:30 - 17:45

**Cancellation of Registration**

Cancellation must be made by informing the Registration Desk in writing either by fax or e-mail. For cancellations received after May 31, 2011, no refund are available.
Hotel and Transportation Information

Hotels
JTB Global Marketing & Travel Inc. (JTB GMT) has been appointed as the official travel agent for the ISTH 2011 and handles hotel accommodations and tours. JTB GMT has reserved a large number of rooms in different hotel categories and offers discounted room rates for Congress participants. Only reservations made through JTB GMT will benefit from these rates. All of these hotels are located in the Kyoto City Center, or near the Convention Center. Please also note that availability of hotel accommodations at the time of on-site registration may be limited.

Methods of Payment
No reservation will be confirmed in the absence of payment. Personal checks are not accepted. All payment must be in Japanese yen. If the remittance covers more than one person, please inform us the name of each participant.
Payment should be in the form of:
- One of the following credit cards:
  1. VISA 2. MasterCard 3. Diners Club 4. AMEX 5. JCB
- A bank transfer to JTB Global Marketing & Travel Inc.

Cancellation
In the event of cancellation, the following cancellation fees will be deducted before any refund is made.
Up to 10 days before the first night of stay ------- None
9 to 2 days before ------------------------------------------ 20% of daily room charge
1 day before ----------------------------------------------- 80% of daily room charge
On the day of arrival or no notice given ------------ 100% of daily room charge

If you have any inquiries please contact:
JTB Global Marketing & Travel Inc.
JTB Bldg. 14F 2-3-11 Higashishinagawa,
Shinagawa-ku, Tokyo 140-8604, Japan
Tel: +81-3-5796-5445
Fax: +81-3-5495-0685
E-mail: isth2011@gmt.jtb.jp
Hotel and Transportation Information

Map of Kyoto

Kyoto International Conference Center (ICCK)

Grand Prince Hotel Kyoto
ANA Hotel Kyoto
Kyoto Brighton Hotel
Kyoto Kokusai Hotel
Kyoto New Hankyu Hotel
Hotel Avashell Kyoto
Hotel Keihan Kyoto
Hotel Ginmond Kyoto
Kyoto Daimon Tower Hotel
Rhino Hotel Kyoto
Hotel Sunroute Kyoto
Court Hotel Kyoto Shijo
Hotel Hokke Club Kyoto
Hyatt Regency Kyoto Hotel

Westin Miyako Hotel Kyoto
Hotel Granvia Kyoto
Hotel Monterey Kyoto
Kyoto Royal Hotel & Spa
Kyoto Century Hotel
Karasuma Kyoto Hotel
Kyoto Tower Hotel
Mitsui Garden Hotel Kyoto Shijo
Kyoto Garden Hotel
Hotel Oaks Kyoto Shijo
Hotel Rich Kyoto
APA Hotel Kyoto Ekimae
Kyoto Daiichi Hotel

Kyoto Hotel Okura
Hotel Nikko Princess Kyoto
Rihga Royal Hotel Kyoto
Kyoto Tokyu Hotel
New Miyako Hotel
Mitsui Garden Hotel Kyoto Sanjo
Hearton Hotel Kyoto
Arandet Hotel Kyoto
Hotel Unizo Kyoto
Kyoto Central Inn
Hotel Alpha Kyoto
APA Hotel Kyoto Eki-Honkawa-Dori
Via Inn Kyoto Shijo Muromachi

Hotel and Transportation Information

Subway Karasuma Line
Subway Tozai Line
Hankyu Line
Keihan Line

1. Grand Prince Hotel Kyoto
2. Kyoto Brighton Hotel
3. ANA Hotel Kyoto
4. Kyoto Kokusai Hotel
5. Kyoto New Hankyu Hotel
6. Hotel Avashell Kyoto
7. Hotel Keihan Kyoto
8. Hotel Ginmond Kyoto
9. Kyoto Daimon Tower Hotel
10. Rhino Hotel Kyoto
11. Hotel Sunroute Kyoto
12. Court Hotel Kyoto Shijo
13. Hotel Hokke Club Kyoto
14. Hyatt Regency Kyoto Hotel
15. Westin Miyako Hotel Kyoto
16. Hotel Granvia Kyoto
17. Hotel Monterey Kyoto
18. Kyoto Royal Hotel & Spa
19. Kyoto Century Hotel
20. Karasuma Kyoto Hotel
21. Kyoto Tower Hotel
22. Mitsui Garden Hotel Kyoto Shijo
23. Kyoto Garden Hotel
24. Hotel Oaks Kyoto Shijo
25. Hotel Rich Kyoto
26. APA Hotel Kyoto Ekimae
27. Kyoto Daiichi Hotel
28. Kyoto Hotel Okura
29. Hotel Nikko Princess Kyoto
30. Rihga Royal Hotel Kyoto
31. Kyoto Tokyu Hotel
32. New Miyako Hotel
33. Mitsui Garden Hotel Kyoto Sanjo
34. Hearton Hotel Kyoto
35. Arandet Hotel Kyoto
36. APA Hotel Kyoto Eki-Honkawa-Dori
37. Via Inn Kyoto Shijo Muromachi
## Hotel and Transportation Information

### The Official Congress Hotels

<table>
<thead>
<tr>
<th>Room Rates (Japanese Yen / night / room)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Double or Twin (2beds) Room</strong></td>
</tr>
<tr>
<td>---------------------------------------</td>
</tr>
<tr>
<td><strong>Double Use</strong></td>
</tr>
<tr>
<td><strong>Room rates include service charge and 5% consumption tax.</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hotel Name</th>
<th>(Check-in &amp; out time)</th>
<th>Room Rate</th>
<th>Access to/from ICCK by subway</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Grand Prince Hotel Kyoto</strong></td>
<td>19,000 17,000 --- 24,000 19,500 ---</td>
<td>ICCK 5 min walk</td>
<td></td>
</tr>
<tr>
<td><strong>Wesmil Miyako Hotel Kyoto / Deluxe room</strong></td>
<td>32,000 28,500 --- 37,800 31,400 ---</td>
<td>Tozai Keage st 3 min</td>
<td></td>
</tr>
<tr>
<td><strong>Kyoto Hotel Okura</strong></td>
<td>26,000 25,000 18,000 31,000 27,500 20,500</td>
<td>Tozai Shiyakushomae sta 1 min</td>
<td></td>
</tr>
<tr>
<td><strong>Kyoto Brighton Hotel</strong></td>
<td>25,000 23,000 --- 30,600 25,800 ---</td>
<td>Imadegawa st. 15 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Granvia Kyoto</strong></td>
<td>25,000 23,000 --- 30,000 25,500 ---</td>
<td>Tozai Shiyakushomae sta 1 min</td>
<td></td>
</tr>
<tr>
<td><strong>ANA Hotel Kyoto</strong></td>
<td>17,000 14,000 11,000 21,000 16,000 13,000</td>
<td>Tozai Nijo-mae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Monterey Kyoto</strong></td>
<td>17,500 15,000 11,000 22,500 17,500 13,500</td>
<td>Tozai Nijo-mae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>RIHGA Royal Hotel Kyoto</strong></td>
<td>18,000 15,000 11,000 22,000 16,000 13,000</td>
<td>Tozai Nijo-mae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Okura Kyoto</strong></td>
<td>17,000 14,000 11,000 20,500 16,000 13,000</td>
<td>Tozai Shiyakushomae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel New Hankyu Hotel</strong></td>
<td>18,000 15,000 11,000 20,000 16,000 13,000</td>
<td>Tozai Shiyakushomae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Keihan Kyoto</strong></td>
<td>17,000 15,000 11,000 22,500 17,500 13,500</td>
<td>Tozai Shiyakushomae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Century Hotel</strong></td>
<td>17,000 15,000 11,000 22,000 16,000 13,000</td>
<td>Tozai Shiyakushomae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Kobe Shinsaibashi</strong></td>
<td>17,000 15,000 11,000 22,500 17,500 13,500</td>
<td>Tozai Shiyakushomae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Holiday Inn Kyoto</strong></td>
<td>17,000 15,000 11,000 22,000 16,000 13,000</td>
<td>Tozai Shiyakushomae sta. 5 min</td>
<td></td>
</tr>
<tr>
<td><strong>Hotel Shinagawa Kyohealth</strong></td>
<td>17,000 15,000 11,000 22,500 17,500 13,500</td>
<td>Tozai Shiyakushomae sta. 5 min</td>
<td></td>
</tr>
</tbody>
</table>

---

### Access to/from ICCK by subway

- **ICCK 5 min walk**
- **Tozai Keage st 3 min**
- **Tozai Shiyakushomae sta 1 min**
- **Imadegawa st. 15 min**
- **Kyoto st 3 min**
- **Kyoto st 20 min.**
# Hotel and Transportation Information

## Transportation

A complimentary shuttle service is available between the official Congress hotels and the congress center (ICC Kyoto) from July 23 to July 28.

Kyoto is a very convenient city with highly developed train network. If your hotel is located near a train station, we recommend you to take a train. (Please see Kyoto Hotel Map on page 9 to check the closest station to your hotel.)

## ISTH2011 Shuttle Bus Route

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hotel</td>
<td>Hotel</td>
<td>Hotel</td>
<td>Hotel</td>
<td>Hotel</td>
</tr>
<tr>
<td>1</td>
<td>New Miyako Hotel</td>
<td>Hotel Granvia Kyoto</td>
<td>Karasuma Kyoto Hotel</td>
<td>Aranvert Hotel Kyoto</td>
</tr>
<tr>
<td></td>
<td>Hotel Keihan Kyoto</td>
<td>Kyoto Century Hotel</td>
<td>Hotel Nikko Princess Kyoto</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kyoto Dai-Ichi Hotel</td>
<td>Kyoto Tower Hotel</td>
<td>Mitsu Garden Hotel</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hotel Kyoto Shijo</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Rihga Royal Hotel Kyoto</td>
<td>Kyoto Brighton Hotel</td>
<td>Hotel Monterey Kyoto</td>
<td>Kyoto Hotel Okura</td>
</tr>
<tr>
<td></td>
<td>APA Hotel Kyoto Ekimae</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Kyoto Tokyu Hotel</td>
<td>Hotel Avanshell Kyoto</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>ANA Hotel Kyoto</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kyoto Kokusai Hotel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Red/Bus Stop:** (TBC)

**Black/Neigboring Hotels:**
Hotel and Transportation Information

“How To get there”

From Kansai International Airport, you can easily get to the Conference Center by public transportation. It is 75 minutes by Airport Express, 95 minutes by Limousine Bus to Kyoto station. From there it is only a few stops by local subway line to the nearest station (Kokusai kaikan station) to the Conference Center. If you arrive at Narita Airport close to Tokyo, you could take Narita Express Train to Tokyo station, then Bullet Train to Kyoto station. Another option is Nagoya Centrair Airport which is approximately an hour away from Kyoto Station. All the signs in the stations are available in English.
Abstract CD-Rom
The Abstract CD-Rom includes all submitted abstracts as well as the abstracts of the Plenary, Presidential Symposium, State-of-the-Art and Symposia. It may be received at booth #4 in exchange for the Abstract CD-Rom ticket.

ATM (Automatic Teller Machine)
There are ATM's located at the “Kokusai Kaikan” subway station, the closest station of ICC Kyoto. Please ask the General Information Desk for further information.

Badges
Congress Name Badges are issued upon check in at the Congress site and must be visible and used at all times throughout the ICC Kyoto for access to the meetings and official social functions.

CME
AMA PRA Credits
The Congress has been reviewed by the American Medical Association and approved for a maximum of 34 AMA PRA Category 1 Credits™. Credit claim forms will be available in your congress bag. In order to receive credit you must complete the claim form, pay the $35 USD processing fee (waived for AMA members), and return the form to the AMA monitor’s desk during the Congress or fax the form to AMA headquarters after the conference. A credit certificate will be emailed to physicians within 4 weeks of receipt of the claim form. Physicians should claim only the credit commensurate with the extent of their participation in the activity. One credit may be claimed for each hour of participation in approved sessions. If you should have any questions about this process, you may contact the AMA directly (Rita LePard, rita.lepard@ama-assn.org/phone: 464-5196/fax: 312-464-5830). Further information can be obtained at www.ama-assn.org/go/internationalcme.

Congress Bag
The Congress Bag will be distributed to registered participants at the Congress bag counter beside the Registration Desk.

Congress Documents
The Congress documents should be collected on-site at the Registration Desk at the ICC Kyoto.
ISTH 2011 Congress Information

Congress News Daily
The ISTH 2011 Congress will feature a newspaper that will include scientific highlights. A new issue will be distributed each day from Monday, July 25 to Thursday, July 28.

Congress Organizer
Japan Convention Services, Inc
Daido Seimei Kasumigaseki Bldg.
1-4-2 Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
Tel: +81-3-3508-1202
Fax: +81-3-3508-0820
E-mail: isth2011@convention.jp
Website: http://www.isth2011.com/

Duplicating / Recording
Any form of duplication (recording, audio taping, digital taping, photography and video) of sessions including Poster Presentations is prohibited without the expressed written consent of the Congress Organizers.

Exhibition
Exhibition Area Information
The Congress Exhibition, featuring commercial displays of international organizations, sponsor pharmaceutical companies, media publishers and scientific societies, catering and lounge areas will be located in Event Hall and Exhibition Hall 1 & 2(tent) of ICC Kyoto.

Exhibition Area Schedule
Monday July 25, 2011 10:30 - 18:00
Tuesday July 26, 2011 10:30 - 18:00
Wednesday July 27, 2011 09:30 - 14:00
Thursday July 28, 2011 09:30 - 16:00
ISTH 2011 Congress Information

Food & Beverage
Coffee Breaks
Coffee breaks are included in the registration fee. Coffee will be served to delegates in the Exhibition Area, from Monday to Thursday during the session breaks. (For times, please see the Program at a Glance on page <p000>). Coffee breaks will be provided outside the meeting rooms during the SSC Annual Meeting and Education Program on Saturday and Sunday. It will also be possible to purchase coffee at the main lounge of ICC Kyoto.

Lunch
Lunch bags are included in the registration fee, and may be collected at the Exhibition area upon presentation of your voucher.

Future Meetings
Information about Future Meetings is available at booth #6 (ISTH SSC 2012 Liverpool) and booth #7 (ISTH 2013 Amsterdam) in the Exhibition Area.

Internet
Wifi is provided at the main lounge of ICC Kyoto. Cyber Café is situated inside the Exhibition.

ISTH General Membership Assembly
The ISTH Membership Meeting will take place on Wednesday July 27, from 11:00-11:15 in the Main Hall.

ISTH Secretariat
The International Society on Thrombosis and Haemostasis Secretariat is located in Room 157 on the first Floor of the ICC Kyoto.

Language
English is the official Congress language, and no translation services are offered by ISTH 2011.

Messages
Participants can use the message options available at the Business Center located in the main lounge.
ISTH 2011 Congress Information

Media / Press Room
The Media Room is located in Room 522 on the fifth floor of the ICC Kyoto.

Mini Program
A Mini Program will be handed out to participants.

Poster Sessions
Poster sessions will take place in Exhibition Hall 1 & 2 (tent) of ICC Kyoto. Posters should be displayed on the assigned board during the following time on the day of their presentation. (Poster number and pins will be available at the poster board). The presenting authors for posters should attend their poster and be available for discussion on the day of their poster session. Posters should be dismantled during the designated time on the day of their presentation. Any posters remaining after the designated time will be discarded by ISTH2011.

Poster Schedule

<table>
<thead>
<tr>
<th></th>
<th>Monday 25 Jul</th>
<th>Tuesday 26 Jul</th>
<th>Wednesday 27 Jul</th>
<th>Thursday July 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Set-up</td>
<td>9:00-10:30</td>
<td>9:00-10:30</td>
<td>9:00-10:00</td>
<td>9:00-10:30</td>
</tr>
<tr>
<td>Dismantle</td>
<td>17:00-18:30</td>
<td>17:00-18:30</td>
<td>14:00-15:00</td>
<td>14:00-16:00</td>
</tr>
</tbody>
</table>

Registration Schedule
The Registration Desk will be open as follows:
Saturday  July  23, 2011  07:00 - 18:00
Sunday    July  24, 2011  07:30 - 19:30
Monday    July  25, 2011  07:30 - 18:30
Tuesday   July  26, 2011  07:30 - 18:30
Wednesday July  27, 2011  07:30 - 18:30
Thursday  July  28, 2011  07:30 - 17:45
Please arrive early if you wish to register on-site.
Please also note that availability of congress party at that time may be limited.
ISTH 2011 Congress Information

Rules
Smoking Policy
The ISTH 2011 Congress is a non-smoking event. Participants are kindly requested to refrain from smoking in the ICC Kyoto, including the Exhibition Area.

Mobile Phones
Delegates are kindly requested to keep their mobile phones silenced in the rooms where scientific and educational sessions are being held, as well as during poster sessions.

Speaker’s Preview Room
Speakers are asked to bring their formatted PowerPoint presentations to the Speaker’s Preview Room (Room 104) at least two hours before their session. Files from key drives or CD-ROMs can be transferred to the Congress servers at that time. All conference rooms contain state-of-the-art technical equipment.

The Speakers’ Preview Room will be open as follows:
Friday July 22, 2011 15:00 - 18:00
Saturday July 23, 2011 07:30 - 19:00
Sunday July 24, 2011 07:30 - 19:00
Monday July 25, 2011 07:30 - 19:00
Tuesday July 26, 2011 07:30 - 19:00
Wednesday July 27, 2011 07:30 - 16:00
Thursday July 28, 2011 08:00 - 17:45

State-of-the-Art Book and CD-Rom
The State-of-the-Art Book and is inside the Congress Bag. The CD-Rom may be received at booth #9 in exchange for the SOA CD-Rom ticket.

Transportation from / to Hotels
Shuttle Service
A complimentary shuttle service between ICC Kyoto and official Congress Hotels are available to participants from Saturday, July 23 to Thursday, July 28. For shuttle bus route, please see page <p000>. The shuttle bus time table is handed out at ICC Kyoto and official Congress Hotels.

Train
Kyoto is a very convenient city with highly developed train network. If your hotel is located near a train station, we recommend you to take a train.
Website of ISTH 2011
Updated information is available on the website: www.isth2011.com.

ISTH 2011 Smart Planner
ISTH 2011 Smart Planner is an application available for iPod Touch / iPhone / iPad and android OS devices. The password for the application has been sent to all ISTH members and pre-registered participants. You may read all ISTH 2011 abstracts, check the Congress program, and make your own schedule via ISTH 2011 Smart Planner!
About Kyoto

Kyoto is special because it reigned as national capital for more than a 1000 years, which is not only the longest that any city has ruled Japan but also it was the center of activity throughout the formative years when what we now think of as Japanese culture was born, developed and refined. Kyoto is the city where today during your visit you can delve into Japanese history as well as experience the way of living that keeps Kyoto at the forefront of developing emerging technologies.

Japanese history and heritage lives on in the 1.5 million population modern Kyoto: Seventeen UNESCO World Cultural Heritage Sites are situated in a cityscape dominated by 2000 temples and shrines. The city offers you endless opportunities to gain meaningful hands-on experience of rich Kyoto culture through tea ceremony, sake brewing, kimono wearing, swordsmanship, and more.

At the same time Kyoto universities, research institutions, and pioneering companies (Nintendo, Shimadzu, Omron, Kyocera) are at the center of developing emerging technologies that will drive the world economy in the 21st century.

Japan is renowned for its safety and the compactness of Kyoto makes for wonderful strolling during free time. From the moment of arrival at Kansai International Airport - just
Kyoto Information

75 minutes from the city center - you will be pampered with everything you need from refined Kyoto service.

*For more information, please visit the following links:
VISIT JAPAN 2011-JAPAN Tourism Agency
http://www.visitjapan.jp/eng/index.html
Kyoto Tourism Federation
http://www.kyoto-kankou.or.jp/english/
Kyoto City Web
City of Kyoto and Kyoto Tourism Council
http://www.kyoto.travel/

Getting to Kyoto

Kyoto is very accessible from overseas. It only takes a little over an hour by Airport Express Train from the nearest international airports (Kansai International Airport). Many direct flights around 11 hours are available from US and Europe, even closer from Asia and Australia.

From Kansai International Airport, you can easily get to the Conference Center by public transportation. It is 75 minutes by Airport Express, 95 minutes by Limousine Bus to Kyoto station. From there it is only a few stops by local subway line to the nearest station (Kokusai-kaikan station) to the Conference Center. If you arrive at Narita Airport close to Tokyo, you could take Narita Express Train to Tokyo station, then Bullet Train to Kyoto station. Another option is Nagoya Centrair Airport which is approximately an hour away
from Kyoto Station. All the signs in the stations are available in English.

Getting Around
Kyoto is a convenient city with highly developed Train network. You usually do not need a car to move around.

Subways
Two subway lines cut Kyoto: the Karasuma line running north to south and the Tozai line running east to west. The Karasuma line is the fastest way to travel from north to south. Tickets can be purchased from the vending machines in the subway stations. Instructions for the machines are available in English. The electronic signs which show the names of the next stop in subway cars are available in English as well.

Trains
Kyoto is connected to Osaka via the Hankyu (downtown), Keihan (along east side of river) and JR (from Kyoto Stn.) lines; and to Nara by the JR and Kintetsu lines (both from Kyoto Stn.). The way to purchase tickets is essentially the same as on the subway.

*For more information, please visit the following links:
Public transport in Kyoto:
http://www.city.kyoto.jp/koho/eng/access/transport.html
Kyoto train/subway route map
Kyoto city bus travel map

Taxi
The normal fare is ¥630 for the first two kilometers, and more for additional distance. After midnight there is a 20% surcharge.

Food
Japan is famed for its regional specialties and Kyoto is no exception. Of particular note is Kaiseki ryori, an extremely refined cuisine consisting of multiple courses. It makes use of fresh seasonal ingredients, prepared in a simple manner to enhance the inherent flavor of the food, and elegantly arranged to appeal to the visual senses. There are also a lot of inexpensive food courts around Kyoto station to entertain you.
Kyoto Information

Climate
It becomes seriously hot and humid in summer, and it is hot even during nights. The average temperature of July in Kyoto is 26.8°C. (The average high temperature in July is 31.5 while the low is 23.2.)

Currency
The unit of Japanese currency is yen (JPY, ¥). Coins are available in denominations of 1, 5, 10, 50, 100 and 500 yen and bank notes in denominations of 1,000, 2,000, 5,000 and 10,000 yen.

Money Exchange
Cash or travelers checks can be exchanged at any "Authorized Foreign Exchange Bank" (signs are displayed in English) or at some of Kyoto’s larger hotels and department stores. Main post offices will also cash traveler's checks.

Credit Cards
All major hotels and most restaurants and shops accept credit cards. It is advisable to carry an identity card, passport or other form of photo identification. However, cash is recommended to go sightseeing since temples, shrines and many local stores do not accept credit cards.

Taxes
There is a 5% consumption tax on retail purchases in Japan. If you dine at higher-end restaurants and stay at first-class accommodation, you will encounter a service charge, which varies from 10% to 15%.

Tipping
Tipping is not necessary in Japan.
Kyoto Information

Business Hours

<table>
<thead>
<tr>
<th></th>
<th>Weekdays</th>
<th>Saturday</th>
<th>Sunday &amp; National Holidays</th>
</tr>
</thead>
<tbody>
<tr>
<td>Banks</td>
<td>09:00-15:00</td>
<td>closed</td>
<td>closed</td>
</tr>
<tr>
<td>Post Offices</td>
<td>09:00-17:00</td>
<td>closed</td>
<td>closed</td>
</tr>
<tr>
<td>Department Stores</td>
<td>10:00-20:00</td>
<td>10:00-20:00</td>
<td>10:00-19:30</td>
</tr>
<tr>
<td>Shops</td>
<td>10:00-20:00</td>
<td>10:00-20:00</td>
<td>10:00-20:00</td>
</tr>
<tr>
<td>Museums</td>
<td>10:00-17:00</td>
<td>10:00-17:00</td>
<td>10:00-17:00</td>
</tr>
<tr>
<td>Offices</td>
<td>09:00-17:00</td>
<td>closed</td>
<td>closed</td>
</tr>
</tbody>
</table>

*Some main post offices are open seven days a week.
*Most department stores are closed for two to three weekdays a month.
*Most museums are closed on Mondays.

Time

Japan has only one standard time zone: UTC/ GMT+9 hours. There is no Summer Time.

Travel Insurance

Although Japan is a clean and relatively safe country, it is always advisable to take out travel insurance for the duration of your stay. The meeting organizers will not be held liable for illness, accidents or thefts suffered by participants.

Electricity

The voltage in Japan is 100 Volt, which is different from North America (110V), Central Europe (220V) and most other regions of the world. Two kinds of frequencies are in use; 60Hz in the west (Kyoto), 50Hz in the east and Tokyo. Flat 2-pin plugs. (There are no columnar-shaped plugs or 3-pin plugs.)

Telephone

Mobile Phone

The Japanese mobile phones protocol is different from that in other parts of the world, so please check with your provider before you depart. Mobile phones are available for rental at the airport. It is very hard to find rental cell phones in Kyoto, so it is best to rent one at the airport.

Public Phone

A direct overseas call can be made from a public telephone displaying an International and Domestic Telephone sign. These phones are not widespread, but can be found at airports, hotels, and other key facilities.
Opening Ceremony and Welcome Reception

Sunday July 24, 2011, 17:30

Included in the registration fee

Opening Ceremony will take place at the Main Hall in ICC Kyoto, followed by the Welcome Reception, which will take place at the beautiful Japanese-style garden. From 21:00 until 21:30 shuttle bus departures are scheduled to the official ISTH 2011 Congress Hotels.
Social Events

**Presidential Dinner**
Monday July 25, 2011, 19:00
**Invitation only**
This event will take place at Kodai-ji temple (Cocktail Reception) and THE GARDEN ORIENTAL KYOTO (Dinner). The shuttle bus will leave ICC Kyoto at 18:45 for Kodai-ji temple.

**All Congress Party**
Wednesday July 27, 2011, 18:00
**Reservation fee of JPY 7,500 must be paid in advance**
This event will take place at the Grand Prince Hotel, a short walk from ICC Kyoto.
If you would still like to register for the All Congress Party onsite, please inquire at the Registration Desk.

**Accompanying Persons’ Program / Tours**
All tours depart from and return to the ICC Kyoto.
Tours will take place only if a minimum of participants is met (please see page <No.80Tours > for details of each tour).

*JTB Global Marketing & Travel Inc. (JTB GMT) is the official travel agent for the ISTH 2011 and will handle hotel accommodations and tours.*
Tours

ISTH 2011 Tours Overview

**Saturday 23**
World Cultural Heritage 1 13:00 - 16:30
Heian Shrine and Sanjusangendo 13:00 - 16:00

**Sunday 24**
World Cultural Heritage 1 13:00 - 16:30
Flower (Lotus) and Arashiyama 9:00 - 13:00
Heian Shrine and Sanjusangendo 9:00 - 12:00

**Monday 25**
World Cultural Heritage 1 9:00 - 12:30
World Cultural Heritage 3 13:00 - 16:00
Fushimi Inari and Japanese Sake Brewery 13:00 - 17:00

**Tuesday 26**
World Cultural Heritage 2 9:00 - 13:00
Rapids Shooting and World Cultural Heritage 9:00 - 17:00

**Wednesday 27 (Excursion Day)**
World Cultural Heritage 3 13:00 - 16:00
World Cultural Heritage 4 13:00 - 17:00
Flower (Lotus) and Arashiyama 9:00 - 13:00
Fushimi Inari and Japanese Sake Brewery 13:00 - 17:00
Mt. Hiei, Lake Biwa and Ohara 9:00 - 17:00

**Thursday 28**
World Cultural Heritage 2 9:00 - 13:00
Nara 1 Day 8:30 - 18:00

CANCELLATION
In the event of cancellation, the following cancellation fees will be deducted before any refund is made:
- 7 - 2 days before the departure day of one day tours: 30% of tour fare
- 1 day before: 40% of tour fare
- Prior to starting time on the departure day: 50% of tour fare
- After departure or failure to show without notice: 100% of tour fare

If you have any inquiries please contact:
JTB Global Marketing & Travel Inc. (JTBGMT)
JTB Bldg. 14F 2-3-11 Higashishinagawa, Shinagawa-ku, Tokyo 140-8604, Japan
Tel: +81-3-5796-5445 Fax: +81-3-5495-0685 E-mail: isth2011@gmt.jtb.jp
EX-1 World Cultural Heritage 1

Date & Time  
Saturday July 23, 2011, 13:00 - 16:30 / 3.5 hours  
Sunday July 24, 2011, 13:00 - 16:30 / 3.5 hours  
Monday July 25, 2011, 09:00 - 12:30 / 3.5 hours

Fare  
JPY6,500 per person

Course  
ICCK ▶ Nijo Castle ▶ Golden Pavilion (Kinkakuji-Temple) ▶ ICCK

Nijo Castle served as the residence of the Tokugawa Shoguns when they visited Kyoto. The typical style of art of the warrior class which can be observed here, is in clear contrast to that of the Court noble. The castle was built by Ieyasu Tokugawa at the beginning of the 17th century. After the Meiji Restoration, it became the detached palace of the Imperial Household, but it was given to the city of Kyoto in 1939.

Golden Pavilion was originally the villa of a Court noble named Kintsune Saionji in the precincts of the present Kinkakuji Temple. The villa was greatly improved by its second owner, Yoshimitsu Ashikaga. He laid out an extensive garden and built a beautiful pavilion toward the end of the 14th century. The pavilion became known as the “Golden Pavilion” or Kinkaku because of its gorgeous gilding. After Yoshimitsu’s death the villa was turned into a Buddhist Temple of the Zen sect under the name of Rokuonji. However, the temple is better known by its popular name Kinkakuji or the “Temple of the Golden Pavilion”.

Guide  
English-speaking guide service is included

Meals  
No meal

Minimum number of participants necessary for the tour  
30 persons per coach

Transportation  
Motor coach
EX-2 World Cultural Heritage 2

Date & Time
Tuesday July 26, 2011, 09:00 - 13:00 / 4 hours
Thursday July 28, 2011, 09:00 - 13:00 / 4 hours

Fare
JPY6,800 per person

Course
ICCK □ Nishi Honganji Temple □ Kiyomizu Temple □ ICCK

Nishi Honganji Temple is one of the finest in Kyoto, and is often referred to by art critics as the finest existing example of Buddhist architecture. Originally it was founded in 1272 at Higashiyama, and moved to the present site three centuries later in 1591, after the donation of a plot of land by Hideyoshi Toyotomi. In 1602, Ieyasu Tokugawa fearing the growing power of the Shinshu sect, sought to weaken it by giving a former abbot permission to found a new branch of the sect, known as the otani school.

Kiyomizu Temple is one of the oldest temples in Kyoto, its origin dating back to the 8th century. The temple is noted for the unique style of its architecture. Its main hall stands on a cliff with a wooden platform in front, from which a panoramic view of Kyoto can be enjoyed. Most of the present buildings were reconstructed in 1633, but they reflect the style of the original ones, suggesting the style of residences of the 8th and 9th centuries.

Guide
English-speaking guide service is included

Meals
No meal

Minimum number of participants necessary for the tour
30 persons per coach

Transportation
Motor coach

EX-3 World Cultural Heritage 3

Date & Time
Monday July 25, 2011, 13:00 - 16:00 / 4 hours
Wednesday July 27, 2011, 13:00 - 16:00 / 4 hours

Fare
JPY7,000 per person

Course
ICCK □ Golden Pavilion (Kinkakuji-Temple) □ Daisen-in Temple □ ICCK

Golden Pavilion was originally the villa of a Court noble named Kintsune
Tours

Saionji in the precincts of the present Kinkakuji Temple. The villa was greatly improved by its second owner, Yoshimitsu Ashikaga. He laid out an extensive garden and built a beautiful pavilion toward the end of the 14th century. The pavilion became known as the “Golden Pavilion” or Kinkaku because of its gorgeous gilding. After Yoshimitsu’s death the villa was turned into a Buddhist Temple of the Zen sect under the name of Rokuonji. However, the temple is better known by its popular name Kinkakuji or the “Temple of the Golden Pavilion”.

Daisen-in Temple founded in 1319 by Abbot Daito. Later, Abbot Ikkyu reconstructed it as one of the chief temple of the rinzai sect. Having been supported by tea masters, warriorsn and rich merchants, there are many subordinate temples in the precincts of this temple and almost all of them possess numerous princeless paintings and landscaped gardens dating from the 15th to the 17th centuries. The garden of Daisen-in is perhaps most remarkable. Karesansui (garden which uses white sand and ocks to symbolize water and lands) is known for its special scenic beauty.

Guide English-speaking guide service is included
Meals No meal
Minimum number of participants necessary for the tour 30 persons per coach
Transportation Motor coach

EX-4 World Cultural Heritage 4
Date & Time Wednesday July 27, 2011, 13:00 - 17:00 / 4 hours
Fare JPY7,000 per person
Course ICCK ▴ Shorei-in Temple ▴ Byodoin Temple ▴ ICCK

Shoren-in is well known for having been the residence of the head abbot of the Tendai sect, who, in pre-Restoration days, held the rank of Imperial prince. The present buildings date from 1895. The sliding screens of the Main Hall are decorated with paintings by Mitsunobu Kano, Motonobu Kano, Gukei Sumiyoshi, etc. The garden, of the best landscape gardens in Kyoto.

Byodoin Temple Designated a World Heritage site, Byodoin Temple was once the villa of Fujiwara Michinaga, the model for the hero in the Japanese classic “The Tale of Genji," was turned into a temple by Fujiwara's son in 1052 and now includes numerous national treasures. The main hall -- called Ho-oh-doh or "Phoenix Hall" -- was built in 1053 and is a national treasure. The hall enshrines a large statue of Amida Buddha sculpted by famous artist Jocho that is also a national treasure. The temple's elegant bell is considered one of the finest such bells in Japan and is another national treasure. The temple is located on the banks of the Uji River near Kyoto.

Guide English-speaking guide service is included
Meals No meal
Minimum number of participants necessary for the tour 30 persons per coach
Transportation Motor coach
EX-5 Flower (Lotus) and Arashiyama

Date & Time
Sunday July 24, 2011, 09:00 - 13:00 / 4 hours
Wednesday July 27, 2011, 09:00 - 13:00 / 4 hours

Fare
JPY6,500 per person

Course
ICCK  Ryoanji Temple  Arashiyama  Tenryuji Temple  ICCK

Ryoanji Temple was founded by Priest Giten under the patronage of Katsumoto Hosokawa in 1448. Katsumoto Hosokawa was a famous general of the Ashikaga Shogunate and was a pious devotee of Zen Buddhism. The temple suffered a conflagration toward the end of the 18th century, and the present building was reconstructed after the fire. However, its gardens have remained intact, and the temple is especially noted for its five hundred year old rock garden, which contains no trees at all. The garden was constructed around 1450, soon after the founding of the temple. As it contains no plants, it is one of the very few old gardens which can be seen exactly as the designer made them. It is generally believed that the garden is the work of Soami, the most famous garden designer of his day. Some authorities maintain that another man named Zenami was the designer of this garden. It is the supreme example of a flat rock garden, and is the best specimen of the gardens classified as Karesansui or “Dry Landscape” type.

Arashiyama is a beautiful spot where one finds within its limited area all the beauties of nature. The beauty lies in the varied vegetation of the hillside facing the river. Large pines, interspersed with innumerable cherry and maple trees in their respective seasons, lend an exquisite beauty to the area.

Tenryuji Temple is the headquarters of the Tenryuji school of the Rinzai sect. It was founded in 1339 by the first Ashikaga shogun, Takauji, in memory of Emperor Godaigo. The noted Priest Soseki, also known by the name of Muso-Kokushi, was the first superior. The temple was repeatedly ravaged by fire, the present buildings dating from 1900. The Main Hall, called Tahoden, located in the center of the grounds, contains the memorial tablet to Emperor Godaigo. In the Lecture Hall to the right of the Main Hall are statues of Sakyamuni, Monju and Fugen. A noted landscape garden designed by Muso-Kokushi is located at the rear of the abbot’s quarters.

Guide
English-speaking guide service is included

Meals
No meal

Minimum number of participants necessary for the tour
30 persons per coach

Transportation
Motor coach
EX-6 Heian shrine and Sanjusangendo

Date & Time  
Saturday July 23, 2011, 13:00 - 16:00 / 3 hours  
Sunday July 24, 2011, 09:00 - 12:00 / 3 hours

Fare  
JPY6,500 per person

Course  
ICCK □ Sanjusangendo □ Heian shrine □ ICCK

Sanjusangendo
Sanjusangendo literally means the “hall of thirty-three spaces”. It is so called because there are thirty-three spaces between the pillars in front of its extraordinarily long altar. Thirty-three is an important symbolic number in Buddhism, especially associated with the worship of Kannon. It is preached that Kannon manifests himself in thirty-three different forms to save mankind. Sanjusangendo is a temple with the longest frontage in Japan, measuring about 120m in length. The present building was reconstructed about the middle of the 13th century, and is regarded as one of the best specimens of architecture of its kind. The temple is also known as the “Temple of Thousand Images” because of its numerous Buddhist images. As well as the main image, there are one thousand carved wooden images of Kannon on the long altar.

Heian Shrine is the most representative Shinto shrine in Kyoto, and is dedicated to Emperor Kammu, the founder of the Kyoto Capital, and Emperor Komei, the last Emperor of the Kyoto Capital. Heian, which literally means “peace and tranquility”, was the ancient name of Kyoto. Patterned after the Imperial Palace which was built toward the end of the 8th century, the shrine was erected in 1895 in commemoration of Kyoto’s 1100th anniversary. The vermilion structures with their green roofs reflect the influence of Chinese palace architecture of the T’ang dynasty, which flourished in the 8th century. The garden at the rear of the shrine is well known for its weeping cherry trees, maple trees, azaleas, irises and waterlilies.

Guide  
English-speaking guide service is included

Meals  
No meal

Minimum number of participants necessary for the tour  
30 persons per coach

Transportation  
Motor coach
EX-7 Fushimi Inari and Japanese Sake Brewery

Date & Time  
Monday July 25, 2011, 13:00 - 17:00 / 4 hours  
Wednesday July 27, 2011, 13:00 - 17:00 / 4 hours

Fare  
JPY7,500 per person

Course  
ICCK □ Fushimi Inari □ Gekeikan Sake Brewery □ ICCK

**Gekeikan Sake Brewery**  
Sake is a traditional Japanese rice wine, produced strictly from moldy rice, steamed rice and water; it has an alcoholic content of 15 to 17 per cent. It is inseparable from the daily life of the Japanese, to say nothing of all ceremonial occasions. Gekkeikan has the honours of being appointed as purveyor to Imperial Household. Sake tasting will take place at the end of the tour.

**Fushimi Inari**  
Dedicated to the god of rice and sake, Fushimi Inari Shrine has a history stretching back to the early 700’s, yet is still popular with modern merchants, who come here to pray for success in business. Behind the shrine is a four-kilometer pathway lined with ten thousand orange torii-style gates that have been donated by worshippers through the ages. The path leads to the top of Mt. Inari, which is also a place of veneration for believers. There are numerous smaller shrines along the way, as well as quaint food stands where one might stop and enjoy a brief snack. The hike to the mountaintop typically takes three hours.

Guide  
English-speaking guide service is included

Meals  
1 lunch

Minimum number of participants necessary for the tour  
30 persons per coach

Transportation  
Motor coach
EX-8 Rapids Shooting and World Cultural Heritage (Full day Tour)

Date & Time  Tuesday July 26, 2011, 09:00 - 17:00 / 8 hours
Fare  JPY18,000 per person
Course  ICCK □ Kameoka (Rapids Shooting) Arashiyama □ lunch □ Tenryuji Temple □ Ryoanji Temple □ ICCK

Rapids Shooting is an exciting 16-kilometer, ninety-minute trip downstream, shooting the Hozu Rapids aboard a flat-bottomed boat from Kameoka to scenic Arashiyama. The changing beauty of the winding gorge will leave unforgettable memories.

Arashiyama is a beautiful spot where one finds within its limited area all the beauties of nature. The beauty lies in the varied vegetation of the hillside facing the river. Large pines, interspersed with innumerable cherry and maple trees in their respective seasons, lend an exquisite beauty to the area.

Tenryuji Temple is the headquarters of the Tenryuji school of the Rinzai sect. It was founded in 1339 by the first Ashikaga shogun, Takauji, in memory of Emperor Godaigo. The noted Priest Soseki, also known by the name of Muso-Kokushi, was the first superior. The temple was repeatedly ravaged by fire, the present buildings dating from 1900. The Main Hall, called Tahoden, located in the center of the grounds, contains the memorial tablet to Emperor Godaigo. In the Lecture Hall to the right of the Main Hall are statues of Sakyamuni, Monju and Fugen. A noted landscape garden designed by Muso-Kokushi is located at the rear of the abbot’s quarters.

Ryoanji Temple was founded by Priest Giten under the patronage of Katsumoto Hosokawa in 1448. Katsumoto Hosokawa was a famous general of the Ashikaga Shogunate and was a pious devotee of Zen Buddhism. The temple suffered a conflagration toward the end of the 18th century, and the present building was reconstructed after the fire. However, its gardens have remained intact, and the temple is especially noted for its five hundred year old rock garden, which contains no trees at all. The garden was constructed around 1450, soon after the founding of the temple. As it contains no plants, it is one of the very few old gardens which can be seen exactly as the designer made them. It is generally believed that the garden is the work of Soami, the most famous garden designer of his day. Some authorities maintain that another man named Zenami was the designer of this garden. It is the supreme example of a flat rock garden, and is the best specimen of the gardens classified as Karesansui or “Dry Landscape” type.

Guide  English-speaking guide service is included
Meals  1 lunch
Minimum number of participants necessary for the tour  30 persons per coach
Transportation  Motor coach
EX-9 Nara 1 day (Full day Tour)

Date & Time   Thursday July 28, 2011, 08:30 - 18:00 / 9.5 hours
Fare          JPY13,000 per person
Course        ICCK □ Kasuga Shrine □ Todaiji Temple □ lunch □ Horyuji Temple  □ Kyoto St. □ ICCK

Kasuga Shrine consists of four small shrines. The contrasting colors of bright vermilion and the green of the woods in which it nestles, the shrine presents a striking picture. It is famous for the 3,000 antique lanterns made of stone and bronze which align both sides of the street leading to the shrine. The lanterns are lighted twice a year, once in February and again in August.

Todaiji Temple boasts of two of the world’s largest work of man. One is the Daibutsu or Great Buddha, the largest bronze statue on earth. So overwhelming is its size – it weighs 450 tons and a thumb alone is 1.6 meters long – that it took four long years and about 437 tons of bronze, a large amount of charcoal, and gold, mercury, vegetable wax and other materials to complete the original statue in 749. The other is the Daibutsuden or the Hall of the Great Buddha in which the Daibutsu is enclosed. It is the largest wooden structure made by man.

Horyuji Temple (Preserving the ideals of Prince Shotoku and the treasure house of ancient culture) Established in 607 A.D. by Prince Shotoku, a vigorous supporter of Buddhism, Horyuji Temple was Various national treasures representing Japanese Buddhist art are displayed, such as the statue of Kudara Kannon in the Kudara-Kannon-Do Hall of the Dainon-in treasure house. The precinct is divided into the West Precinct and the East Precinct. In the former are structures of the Asuka period or 8th century, such as the five-storied pagoda and the Kondo Hall. “Tamamushi-no-Zushi,” a Buddhist altar of the Asuka period, Yumechigai Kannon statue, and other temple treasures are also found in this Precinct. The Tamamushi-no-Zushi, is decorated with the wings of jewel beetles laid under the metal openwork. In the East Precinct is the Yumedono, the eldest octagonal hall in Japan. “Guze Kannon” a life-sized wooden Buddha statue of Prince Shotoky is kept here.

Guide         English-speaking guide service is included
Meals         1 lunch
Minimum number of participants necessary for the tour 30 persons per coach
Transportation Motor coach
EX-10 Mt. Hiei, Lake Biwa and Ohara (Full day Tour)

Date & Time
Wednesday July 27, 2011, 09:00 - 17:00 / 8 hours

Fare
JPY17,000 per person

Course
ICCK  Enryakuji Temple  Otsu Lake Biwa Cruise Otsu
Ohara Sanzenin/Jyakkoin Temple  CCK

Enryakuji Temple is located atop Mt. Hiei in a thick grove of Japanese cypress-trees. It was established in 788 by Priest Saicho, better known as Dengyo-Daishi (767-822), founder of the Tendai sect by order of Emperor Kammu. The object of its foundation was to protect the new capital from evil spirits which were supposed to come from the northeast direction.

Lake Biwa: is the largest fresh-water lake in Japan, with a circumference of 188 kilometers and an area of 674 square kilometers. The name is derived from the fact that the lake is shaped like the musical instrument called the biwa. Geologists hold the view that the lake was formed by the subsidence of the land. Tradition has it, however, that it was formed overnight in 286 B.C. by an earthquake, which produced Mt. Fuji at the same time. Enjoy a delightful cruise on Lake Biwa aboard a large sightseeing vessel called the “Michigan”.

Sanzen-in Temple was built at Ohara as a residence for the brothers and sisters of deified emperors. The site was chosen since Ohara had been considered a holy place from ancient times by believers in Jodo, the Pure Land or Buddhist Heaven. The temple consists of a beautiful mansion and gardens set in secluded hills. Located west, Jakkoin temple is a convent built on a perfectly secluded site. It is famous as the place where the Empress Kenreimon-in, mother of the infant Emperor Antoku, became a nun in 1185. She spent the rest of her life here after her imperial son perished along with the rest of the Taira clan at Dan-no-ura (the present Shimonoseki, in western Japan). Her tomb lies on a hill behind the temple. The convent’s garden is regarded as one of the finest places for maple-viewing in Kyoto.

Guide
English-speaking guide service is included

Meals
1 lunch

Minimum number of participants necessary for the tour
30 persons per coach

Transportation
Motor coach
Recommend a subscription for your library today!

Journal of Thrombosis and Haemostasis
Journal of the International Society on Thrombosis and Haemostasis
Edited by: Mike Greaves & David Lane

Do you have access to:
- the official Journal of the ISTH?
- the number one international specialty journal in the field of thrombosis, bleeding disorders and vascular biology?
- original research reports, state-of-the art reviews, commentaries and debates on timely topics?
- highly cited articles written by internationally acclaimed experts in the field?

If not, recommend that your library subscribe to JTH! Use our convenient form online at: wileyonlinelibrary.com/libraryrecform

Don’t miss the 2011 State of the Art issue which contains the definitive collection of topical reviews in thrombosis and hemostasis written by internationally acclaimed experts in the field. These articles are freely available without a subscription. Visit the journal online to download these reviews today!

wileyonlinelibrary.com/journal/jth
BIOGEN IDEC HEMOPHILIA PRESENTS

FC FUSION
The forward-thinking long-lasting technology

We’re using unique Fc fusion technology to develop therapies that last longer.

Fc fusion is an established technology that has been shown to extend the half-life of drugs by using a well-understood, naturally occurring pathway in the body.¹

By using recombinant DNA technology, Fc fusion links a therapeutic protein to the “Fc” portion of an immunoglobulin. Fc is a fragment of an endogenous antibody, which is designed to keep therapeutic proteins in circulation longer.¹

Want to learn more?
See the Fc fusion video at booth #42 or visit us online at www.BiogenIdecHemophilia.com.
